PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kannel, WB				Kannel, WB			Blood pressure as a cardiovascular risk factor - Prevention and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION	Objective.-To examine the prevalence, incidence, predisposing factors for hypertension, its hazards as an ingredient of the cardiovascular risk profile, and the implications of this information for prevention and treatment. Methods.-Prospective longitudinal analysis of 36-year follow-up data from the Framingham Study of the relation of antecedent blood pressure to occurrence of subsequent cardiovascular morbidity and mortality depending on the metabolically linked burden of associated risk factors. Results.-Hypertension is one of the most prevalent and powerful contributors to cardiovascular diseases, the leading cause of death in the United States. There is, on average, a 20 mm Hg systolic and 10 mm Hg diastolic increment increase in blood pressure from age 30 to 65 years. Isolated systolic hypertension is the dominant variety. There is no evidence of a decline in the prevalence of hypertension over 4 decades despite improvements in its detection and treatment. Hypertension contributes to all of the major atherosclerotic cardiovascular disease outcomes increasing risk, on average, 2- to 3-fold. Coronary disease, the most lethal and common sequela, deserves highest priority. Hypertension clusters with dyslipidemia, insulin resistance, glucose intolerance, and obesity, occurring in isolation in less than 20%. The hazard depends on the number of these associated metabolically linked risk factors present. Coexistent overt cardiovascular disease also influences the hazard and choice of therapy. Conclusion.-The absence of a decline in the prevalence of hypertension indicates an urgent need for primary prevention by weight control, exercise, and reduced salt and alcohol intake. The urgency and choice of therapy of existing hypertension should be based on the multivariate cardiovascular risk profile that more appropriately targets hypertensive persons for treatment and prevention of cardiovascular sequelae.			Kannel, WB (corresponding author), BOSTON UNIV,SCH MED,FRAMINGHAM HEART STUDY,EVANS MEM RES FDN,DEPT MED,BOSTON,MA 02118, USA.				NHLBI NIH HHS [N01-HV-52971, N01-HV-92922] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; Anderson K. M., 1991, CIRCULATION, V83, P357; BELANGER A, 1988, 802970 US DEP HHS PH; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CUPPLES LA, 1987, SOME RISK FACTORS RE, P87; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V7, P676; GARRISON RJ, 1987, PREV MED, V16, P234; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; KANNEL WB, 1993, AM HEART J, V125, P1154, DOI 10.1016/0002-8703(93)90129-W; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KANNEL WB, 1991, P R COLL PHYS EDINB, V21, P273; Kannel William B., 1994, Am J Geriatr Cardiol, V3, P33; KRUMHOLZ HM, 1995, J AM COLL CARDIOL, V25, P879, DOI 10.1016/0735-1097(94)00473-4; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; *NIH, 1993, 932669 NIH NAT HEART; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WILSON PWF, 1995, HYPERTENSION PATHOPH, V1, P99; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; 1993, ARCH INTERN MED, V153, P154; 1992, JAMA-J AM MED ASSOC, V267, P1213; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	29	921	962	0	76	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1571	1576		10.1001/jama.275.20.1571	http://dx.doi.org/10.1001/jama.275.20.1571			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622248				2022-12-24	WOS:A1996UL02900029
J	Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR				Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR			Conserved left-right asymmetry of nodal expression and alterations in murine situs inversus	NATURE			English	Article							MOUSE; LATERALITY; SIDEDNESS; REVERSAL	VERTEBRATES have characteristic and conserved left-right (L-R) visceral asymmetries, for example the left-sided heart. In humans, alterations of L-R development can have serious clinical implications, including cardiac defects(1). Although little is known about how the embryonic L-R axis is established, a recent study in the chick embryo revealed L-R asymmetric expression of several previously cloned genes, including Cnr-1 (for chicken nodal-related-1), and indicated how this L-R molecular asymmetry might be important for subsequent visceral morphogenesis(2). Here we show that nodal(3) is asymmetrically expressed in mice at similar stages, as is Xnr-1 (for Xenopus nodal related-1)(4) in frogs. We also examine nodal expression in two mouse mutations that perturb L-R development, namely situs inversus viscerum (iv)(5), in which assignment of L-R asymmetry is apparently random and individuals develop either normally or are mirror-image-reverse (situs inversus), and inversion of embryonic turning (inv)(6), in which all individuals develop with situs inversus. In both, nodal expression is strikingly affected, being reversed or converted to symmetry. These results further support a key role for nodal and nodal-related genes in interpreting and relaying L-R patterning information in vertebrates. To our knowledge, our results provide the first direct evidence that iv and inv normally function well before the appearance of morphological L-R asymmetry.	NCI,EXPTL IMMUNOL BRANCH,NIH,BETHESDA,MD 20892; UNIV CINCINNATI,CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Vanderbilt University; Baylor College of Medicine			Supp, Dorothy/ABQ-7999-2022; Kuehn, Michael R/A-4573-2014	Supp, Dorothy/0000-0002-2429-6630; Kuehn, Michael R/0000-0002-7703-9160; Sampath, Karuna/0000-0002-0729-1977; Overbeek, Paul/0000-0001-9784-2084				BROWN NA, 1990, DEVELOPMENT, V109, P1; BROWN NA, 1989, DEVELOPMENT, V107, P637; BURN J, 1991, CIBA F SYMP, V162, P282; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DANOS MC, 1995, DEVELOPMENT, V121, P1467; FUJINAGA M, 1994, DEV BIOL, V162, P558, DOI 10.1006/dbio.1994.1109; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOGAN B, 1994, MANIPULATING MOUSE E, P357; JONES CM, 1995, DEVELOPMENT, V121, P3651; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; PANSERA F, 1994, MED HYPOTHESES, V42, P283, DOI 10.1016/0306-9877(94)90134-1; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	24	402	418	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					158	161		10.1038/381158a0	http://dx.doi.org/10.1038/381158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610013	Green Submitted			2022-12-24	WOS:A1996UK13900050
J	Malaviya, R; Ikeda, T; Ross, E; Abraham, SN				Malaviya, R; Ikeda, T; Ross, E; Abraham, SN			Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; KLEBSIELLA-PNEUMONIAE; MICE; INFLAMMATION; RECRUITMENT; PERITONITIS; MOUSE	ALTHOUGH mast cells have been implicated in a variety of inflammatory conditions including immediate hypersensitivity and interstitial cystitis,(1,2) their physiological role in the body is unknown. We investigated the role of mast cells in host defence against bacterial infections using a well characterized mast-cell-deficiency mouse model(3,4). We report here that mast cells, which are selectively located at portals of bacterial entry, are important to host defence. Mast-cell-deficient WBB6F1-W/W-v mice (W/W-v) were up to 20-fold less efficient in clearing enterobacteria than WBB6F1+/+ (+/+)mice or mast-cell-reconstituted W/W-v (W/W-v + MC) mice. With higher bacterial inocula, only W/W-v mice died (80%). The limited bacterial clearance in W/W-v mice directly correlated with impaired neutrophil influx. The mast-cell chemoattractant TNF-alpha was implicated in the neutrophil response because TNF-alpha was locally released only in +/+ and W/W-v + MC mice, TNF-alpha-specific antibodies blocked over 70% of the neutrophil influx, and purified mast cells released TNF-alpha upon incubation with bacteria. Additionally, the type-1 fimbrial subunit, FimH, was the necessary enterobacterial component for mast-cell activation and neutrophil influx because an isogenic FimH(-) mutant evoked a limited neutrophil response in +/+ mice compared to wild-type bacteria.	WASHINGTON UNIV,BARNES JEWISH HOSP,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; AZABU UNIV,DEPT VET MICROBIOL,KANAGAWA,JAPAN	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Azabu University								ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; ESPOSITO AL, 1987, AM REV RESPIR DIS, V135, P676; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Malaviya R, 1996, J IMMUNOL, V156, P1490; MALONE DG, 1988, ANN ALLERGY, V61, P27; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; OFEK I, 1993, INFECT IMMUN, V61, P4208, DOI 10.1128/IAI.61.10.4208-4216.1993; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUZUKI N, 1993, AM J RESP CELL MOL, V9, P475, DOI 10.1165/ajrcmb/9.5.475; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	24	909	941	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					77	80		10.1038/381077a0	http://dx.doi.org/10.1038/381077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609993				2022-12-24	WOS:A1996UJ05300060
J	Nightingale, SL				Nightingale, SL			Nicotine nasal spray approved for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-24	WOS:A1996UF47800007
J	Tosini, G; Menaker, M				Tosini, G; Menaker, M			Circadian rhythms in cultured mammalian retina	SCIENCE			English	Article							SUPRACHIASMATIC NUCLEUS; SYSTEM; MELATONIN; PINEAL; CLOCK; LESIONS; LIGHT	Many retinal functions are circadian, but in most instances the location of the clock that drives the rhythm is not known. Cultured neural retinas of the golden hamster (Mesocricetus auratus) exhibited circadian rhythms of melatonin synthesis for at least 5 days at 27 degrees C. The rhythms were entrained by light cycles applied in vitro and were free-running in constant darkness. Retinas from hamsters homozygous for the circadian mutation tau, which shortens the free-running period of the circadian activity rhythm by 4 hours, showed a shortened free-running period of melatonin synthesis. The mammalian retina contains a genetically programmed circadian oscillator that regulates its synthesis of melatonin.	UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22903 USA; UNIV VIRGINIA, NATL SCI FDN CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA	University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; tosini, gianluca/0000-0003-3645-4533	NICHD NIH HHS [HD13162] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013162] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CAHILL GM, 1991, J NEUROSCI, V11, P2959; FALCON J, 1991, CELL TISSUE RES, V265, P601, DOI 10.1007/BF00340884; JANIK DS, 1990, J COMP PHYSIOL A, V166, P811; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; MENAKER M, IN PRESS 6 SAPP S BI; OOKASOUDA S, 1993, NEUROSCI LETT, V164, P33, DOI 10.1016/0304-3940(93)90850-K; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; Straume M, 1991, TOPICS FLUORESCENCE, P177, DOI DOI 10.1007/B112907; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1982, J NEUROSCI, V2, P815; TERMAN JS, 1993, BRAIN RES, V605, P256; TERMAN M, 1985, ANN NY ACAD SCI, V453, P147, DOI 10.1111/j.1749-6632.1985.tb11807.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	18	587	596	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					419	421		10.1126/science.272.5260.419	http://dx.doi.org/10.1126/science.272.5260.419			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602533				2022-12-24	WOS:A1996UG25200050
J	Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D				Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D			In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector	SCIENCE			English	Article							VIRUS TYPE-1 RNA; RETROVIRAL VECTORS; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS; HIGH-TITER; INFECTION; DNA; EXPRESSION; PROTEIN; TROPISM	A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated neurons. The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Salk Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X	NIAID NIH HHS [AI37510] Funding Source: Medline; NIA NIH HHS [AG08514, AG10435] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG008514, R01AG008514, P01AG010435] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; BERKOWITZ RD, 1995, VIROLOGY, V212, P718, DOI 10.1006/viro.1995.1530; BUCHSCHACHER GL, 1992, J VIROL, V66, P2731, DOI 10.1128/JVI.66.5.2731-2739.1992; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BYRNES JJ, 1984, MOL CELL BIOCHEM, V62, P13; CARROLL R, 1994, J VIROL, V68, P6047, DOI 10.1128/JVI.68.9.6047-6051.1994; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN A, 1983, J BIOL CHEM, V258, P2334; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; FINER MH, 1994, BLOOD, V83, P43; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GALLAY P, UNPUB; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE JF, 1995, J VIROL, V69, P6588, DOI 10.1128/JVI.69.10.6588-6592.1995; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KNOWLES RM, 1995, NEW ENGL J MED, V333, P823; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCORMICK PJ, 1983, BIOCHIM BIOPHYS ACTA, V755, P36; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAIDINI L, UNPUB; NALDININ L, UNPUB; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDSON JH, 1995, J GEN VIROL, V76, P691, DOI 10.1099/0022-1317-76-3-691; RICHARDSON JH, 1993, J VIROL, V67, P3997, DOI 10.1128/JVI.67.7.3997-4005.1993; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VERMA IM, 1994, MOL MED, V1, P2; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILLIAMS RS, 1995, NAT MED, V1, P1137, DOI 10.1038/nm1195-1137; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	66	3771	4303	6	400	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					263	267		10.1126/science.272.5259.263	http://dx.doi.org/10.1126/science.272.5259.263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602510				2022-12-24	WOS:A1996UE72900040
J	Lu, KP; Hanes, SD; Hunter, T				Lu, KP; Hanes, SD; Hunter, T			A human peptidyl-prolyl isomerase essential for regulation of mitosis	NATURE			English	Article							PROTEIN-KINASE; ASPERGILLUS-NIDULANS; YEAST; GENE; INDUCTION; NIMA	THE NIMA kinase is essential for progression through mitosis in Aspergillus nidulans(1-6), and there is evidence for a similar pathway in other eukaryotic cells(5-8). Here we describe the human protein Pin1, a peptidyl-prolyl cis/trans isomerase (PPIase) that interacts with NIMA. PPIases are important in protein folding, assembly and/or transport(9-13), but none has so far been shown to be required for cell viability(9-11). Pin1 is nuclear PPIase containing a WW protein interaction domain, and is structurally and functionally related to Ess1/Ptf1, an essential protein in budding yeast(14,15). PPIase activity is necessary for Ess1/Pin1 function in yeast. Depletion of Pin1/Ess1 from yeast or HeLa cells induces mitotic arrest, whereas HeLa cells overexpressing Pin1 arrest in the G2 phase of the cell cycle. Pin1 is thus an essential PPIase that regulates mitosis presumably by interacting with MMA and attenuating its mitosis-promoting activity.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, LAB DEV GENET, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Lu, KP (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; FISCHER G, 1994, ANGEW CHEM INT EDIT, V63, P67; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPECTOR DL, 1993, REV CELL BIOL, V9, P265; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247	30	782	831	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					544	547						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606777				2022-12-24	WOS:A1996UE66300055
J	Muller, T; Feichtinger, H; Berger, H; Muller, W				Muller, T; Feichtinger, H; Berger, H; Muller, W			Endemic Tyrolean infantile cirrhosis: An ecogenetic disorder	LANCET			English	Article							INDIAN CHILDHOOD CIRRHOSIS; COPPER STORAGE DISEASE; LIVER	Background 138 infants and young children died from an endemic infantile liver cirrhosis in a circumscribed rural area of western Austria between 1900 and 1974. Frequency of the disease peaked between 1930 and 1960. It has disappeared from this area since 1974. Methods Clinical and genetic data on the patients was gathered; pedigrees analysed and ethnographic studies and interviews were undertaken. Findings The disease, which was clinically and pathologically indistinguishable from Indian childhood cirrhosis and hepatic copper toxicosis, was transmitted by autosomal recessive inheritance. Cow's milk, contaminated with copper from untinned copper or brass vessels, may have contributed to the development of copper toxicosis. Replacement of untinned copper cooking utensils by modern industrial vessels has eradicated the disease. Interpretation Our findings strongly suggest that the endemic Tyrolean childhood cirrhosis-and by analogy non-Wilsonian hepatic copper toxicosis occurring elsewhere-is an ecogenetic disorder requiring the involvement of both genetic and environmental factors for the disease to become manifest.	COMMUNITY HOSP, DEPT PAEDIAT, A-6600 REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PAEDIAT, REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, REUTTE, AUSTRIA	University of Innsbruck; University of Innsbruck								ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; BAKER A, 1995, J HEPATOL, V23, P538, DOI 10.1016/0168-8278(95)80059-X; BHAVE SA, 1992, ANN TROP PAEDIATR, V12, P23, DOI 10.1080/02724936.1992.11747542; BHAVE SA, 1982, ARCH DIS CHILD, V57, P922, DOI 10.1136/adc.57.12.922; Finney DJ., 1947, ANN EUGEN, V14, P319, DOI [10.1111/j.1469-1809.1947.tb02410.x, DOI 10.1111/J.1469-1809.1947.TB02410.X]; Fodisch H J, 1968, Verh Dtsch Ges Pathol, V52, P557; GOGL H, 1947, WIENER BEIRAGE KINDE, V1; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; KAELIN A., 1955, ARCH JULIUS KLAUS STIFT, V30, P263; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; SCHULER F., 1942, Arch. Kinderheilk., V126, P5; TANNER MS, 1979, LANCET, V1, P1203; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; VOGEL F, 1979, HUMAN GENETICS PROBL, P105; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152	22	120	123	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					877	880		10.1016/S0140-6736(96)91351-3	http://dx.doi.org/10.1016/S0140-6736(96)91351-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622397				2022-12-24	WOS:A1996UC45000015
J	Pellmyr, O; LeebensMack, J; Huth, CJ				Pellmyr, O; LeebensMack, J; Huth, CJ			Non-mutualistic yucca moths and their evolutionary consequences	NATURE			English	Article							SEQUENCE	Interspecific mutualisms are regarded as having evolved from antagonistic or commensalistic interactions, with most mutualisms remaining facultative but some having coevolved into obligate reciprocal dependency(1-4). Underlying mutualism is an intrinsic conflict between the parties, in that each is under selection for increased exploitation of the other(3-7). Theoretical models suggest that this conflict is a source of evolutionary instability, and that evolution of 'cheating' by one party may lead to reciprocal extinction(4,6,7). Here we present phylogenetic evidence for reversal of an obligate mutualism: within the yucca moth complex, distinct cheater species derived from obligate pollinators inflict a heavy cost on their yucca hosts by laying their eggs but not pollinating the yucca. Phylogenetic data show the cheaters to have existed for a long time. Coexisting pollinators and cheaters are not sister taxa, supporting predictions that evolution of cheating within a single pollinator is evolutionarily unstable. Several lines of evidence support a hypothesis that host shifts preceded the reversal of obligate mutualism. Host or partner shifts is a mechanism that can provide a route of evolutionary escape among obligate mutualists in general.			Pellmyr, O (corresponding author), VANDERBILT UNIV,DEPT BIOL,NASHVILLE,TN 37235, USA.		Leebens-Mack, James/AAF-6770-2019	Leebens-Mack, James/0000-0003-4811-2231				AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; BROWN JL, ANN ENTOMOL SOC AM, V87, P795; BULL JJ, 1991, J THEOR BIOL, V149, P63, DOI 10.1016/S0022-5193(05)80072-4; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; Dawkins R, 1989, SELFISH GENE; FEIST MA, 1995, THESIS U CINCINNATI; Felsenstein J., 1993, PHYLOGENETIC INFEREN; GALIL J, 1969, Tijdschrift voor Entomologie, V112, P1; GARGAS A, 1995, SCIENCE, V268, P1492, DOI 10.1126/science.7770775; KEELEY JE, 1986, AM MIDL NAT, V115, P1, DOI 10.2307/2425831; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; MAINERO JS, 1985, BIOL MUTUALISM, P192; MCKELVEY S, 1947, YUCCAS SW US; MILES N J, 1983, Journal of the Lepidopterists' Society, V37, P207; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; PELLMYR O, 1992, P NATL ACAD SCI USA, V89, P2927, DOI 10.1073/pnas.89.7.2927; POWELL JA, 1992, TRENDS ECOL EVOL, V7, P10, DOI 10.1016/0169-5347(92)90191-D; RICHTER KS, 1995, NATURE, V376, P557, DOI 10.1038/376557b0; Riley C.V., 1892, ANN REP MO BOT GARD, P99; Riley CV, 1881, P AM ASS ADV SCI, V29, P617; Swofford D, 1993, PHYLOGENETIC ANAL US; Thompson J. N., 1994, COEVOLUTIONARY PROCE, DOI 10.7208/chicago/9780226797670.001.0001; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; TYRE AJ, 1993, OECOLOGIA, V94, P173, DOI 10.1007/BF00341314; VICKERY WL, 1991, AM NAT, V137, P847, DOI 10.1086/285197; WIEBES JT, 1994, P K NED AKAD WETENSC, V97, P491; Wright S, 1969, THEORY GENE FREQUENC, V2; YAMAUCHI A, 1995, AM NAT, V145, P434, DOI 10.1086/285748; [No title captured]	30	152	158	2	109	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					155	156		10.1038/380155a0	http://dx.doi.org/10.1038/380155a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600388				2022-12-24	WOS:A1996TZ97800049
J	Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH				Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH			Epidemiology of diarrhea among expatriate residents living in a highly endemic environment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; MONOCLONAL-ANTIBODIES; CAMPYLOBACTER-JEJUNI; FOREIGN RESIDENTS; ANTIGEN-DETECTION; UNITED-STATES; MEXICO; CELLS; GASTROENTERITIS	Objective.-To determine the etiology of diarrhea among expatriate residents living in a developing country and identify risk factors for travelers' diarrhea that are difficult to evaluate in tourist populations. Design.-Clinic-based case-control study. Setting.-Primary care travel medicine clinic in Kathmandu, Nepal. Participants.-A total of 69 expatriate residents with diarrhea, compared with 120 tourists with diarrhea, and 112 asymptomatic resident and tourist controls, selected systematically during a 1-year period. Main Outcome Measures.-Risk factors for diarrhea assessed by questionnaire and pathogen prevalence assessed by microbiologic analysis of stool specimens. Results.-The dominant risk factors for diarrhea among expatriate residents included younger age (P=.003), shorter duration of stay in Nepal (P<.001), and eating out in restaurants ((=.01). Eating raw vegetables, salads, fresh fruit, or ice served in restaurants was not significantly associated with diarrhea. Longer duration of residence was linearly correlated with protection. Enteric pathogens were identified in 44 (64%) of 69 residents with diarrhea compared with 100 (83%) of 120 tourists with diarrhea, with enterotoxigenic Escherichia coli, Campylobacter, and Shigella predominant for both groups. Pathogens were also found in stools;from 32 (37%) of 87 asymptomatic resident controls and 13 (52%) of 25 tourist controls. The attack rate of diarrhea among expatriates was estimated to be 49% (95% confidence interval, 37% to 61%) per month during the first 2 years of residence. The highest-risk months were April through July. Conclusions.-Diarrhea among expatriates in a highly endemic environment is a persistent risk. The extremely high prevalence of enteric pathogens among asymptomatic persons reflects widespread exposure. The most important risk factors for travelers' diarrhea are difficult to modify, including younger age, duration of stay, eating in restaurants, and seasonality. Preventive dietary recommendations may not be fully protective, suggesting that pretravel advice should emphasize empiric treatment in addition to strategies to avoid exposure.	ARMED FORCES RES INST MED SCI,DEPT BACTERIOL IMMUNOL & MOLEC GENET,BANGKOK 10400,THAILAND; CIWEC CLIN,KATMANDU,NEPAL; UNIV MASSACHUSETTS,MED CTR,DIV INFECT DIS,WORCESTER,MA; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Massachusetts System; University of Massachusetts Worcester; Uniformed Services University of the Health Sciences - USA								BLACK RE, 1990, REV INFECT DIS, V12, pS73; CHANG TW, 1978, ANN INTERN MED, V89, P428, DOI 10.7326/0003-4819-89-3-428_2; CROSS J H, 1968, Chinese Journal of Microbiology, V1, P117; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; Dean AG, 1994, EPI INFO VERSION 6 0; DUPONT HL, 1977, AM J EPIDEMIOL, V105, P37, DOI 10.1093/oxfordjournals.aje.a112353; ECHEVERRIA P, 1991, J INFECT DIS, V164, P550, DOI 10.1093/infdis/164.3.550; ECHEVERRIA P, 1990, P95; ENG TR, 1993, MORBIDITY MORTALITY; ERICSSON CD, 1980, GASTROENTEROLOGY, V79, P812; HABERBERGER RL, 1994, AM J TROP MED HYG, V51, P870, DOI 10.4269/ajtmh.1994.51.870; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KNUTTON S, 1991, INFECT IMMUN, V59, P365, DOI 10.1128/IAI.59.1.365-371.1991; KOLLARITSCH H, 1989, EUR J EPIDEMIOL, V5, P74, DOI 10.1007/BF00145049; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; OKHUYSEN PC, 1992, MED CLIN N AM, V6, P1357; ORSKOV F, 1975, ACTA PATH MICRO IM B, V83, P595; PICKERING LK, 1977, J INFECT DIS, V135, P1003, DOI 10.1093/infdis/135.6.1003; RYDER RW, 1981, J INFECT DIS, V144, P442, DOI 10.1093/infdis/144.5.442; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; TAYLOR DN, 1986, REV INFECT DIS, V8, pS136; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; WANG WLL, 1983, J CLIN MICROBIOL, V18, P803, DOI 10.1128/JCM.18.4.803-807.1983; 1992, WKLY EPIDEMIOL REC, V67, P273	33	77	77	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					533	538		10.1001/jama.275.7.533	http://dx.doi.org/10.1001/jama.275.7.533			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606474				2022-12-24	WOS:A1996TV56900030
J	Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ				Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ			Concerns about AIDS in general practice	BRITISH MEDICAL JOURNAL			English	Article							HIV		NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS									Bartelds A I, 1993, Gesundheitswesen, V55, P3; BARTELDS AIM, 1994, CONTINUOUS MORBIDITY; MILNE RIG, 1988, BRIT MED J, V296, P533, DOI 10.1136/bmj.296.6621.533; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; 1988, J R COLL GEN PRACT, V38, P219	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					285	286						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611785	Green Published			2022-12-24	WOS:A1996TU50700023
J	Kaplan, NM; Gifford, RW				Kaplan, NM; Gifford, RW			Choice of initial therapy for hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACOLOGICAL TREATMENT; ANTIHYPERTENSIVE AGENTS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; GUIDELINES; MANAGEMENT; SOCIETY; TRIAL	Hypertension is one of the most common conditions treated by the clinician, yet accurate diagnosis and selection of the appropriate treatment can be challenging and recommendations regarding antihypertensive medications continue to evolve. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diet and exercise for the initial treatment of mild hypertension, followed by a diuretic or P-blocker if necessary, unless contraindicated. This recommendation is based on outcome studies using these drugs that demonstrate reductions in major diseases that treatment of hypertension is intended to prevent: stroke and cardiovascular morbidity and mortality. Other antihypertensive drugs, while not tested in large trials evaluating outcomes, have unique advantages for certain patients. Consideration of the patient's medical conditions and needs, including the cost of medication, is essential to ensuring optimal treatment of hypertension.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; CLEVELAND CLIN FDN,DEPT NEPHROL INTERNAL MED & HYPERTENS,CLEVELAND,OH 44195	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation	Kaplan, NM (corresponding author), UNIV TEXAS,SW MED CTR,DIV HYPERTENS,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ACKER CG, 1995, NEW ENGL J MED, V333, P1572, DOI 10.1056/NEJM199512073332316; [Anonymous], 1993, BMJ, V307, P1541; APPLEGATE WB, 1991, ARCH INTERN MED, V151, P1817, DOI 10.1001/archinte.151.9.1817; BURNIER M, 1992, J INTERN MED, V232, P381, DOI 10.1111/j.1365-2796.1992.tb00603.x; CARTER BL, 1989, J FAM PRACTICE, V29, P257; FRISHMAN WH, 1994, ARCH INTERN MED, V154, P1461, DOI 10.1001/archinte.154.13.1461; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1989, HYPERTENSION S, V2, P65; GILLENWATER JY, 1995, J UROLOGY, V154, P110, DOI 10.1016/S0022-5347(01)67243-4; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1994, CLIN HYPERTENSION, P191; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MAHEUX P, 1994, AM J HYPERTENS, V7, P416, DOI 10.1093/ajh/7.5.416; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PIERDOMENICO SD, 1995, EUR HEART J, V16, P692, DOI 10.1093/oxfordjournals.eurheartj.a060975; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; RIBACKE M, 1995, J INTERN MED, V237, P473, DOI 10.1111/j.1365-2796.1995.tb00872.x; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SILAGY CA, 1992, AM J CARDIOL, V70, P1299, DOI 10.1016/0002-9149(92)90765-Q; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WRIGHT JT, 1995, AM J HYPERTENS, V8, pA27; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, ARCH INTERN MED, V153, P154	30	59	59	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1577	1580		10.1001/jama.275.20.1577	http://dx.doi.org/10.1001/jama.275.20.1577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622249				2022-12-24	WOS:A1996UL02900030
J	Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B				Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B			Regulation by the ribosome of the GTPase of the signal-recognition particle during protein targeting	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSLOCATION; RECEPTOR; HYDROLYSIS; SEQUENCE; BINDING; POLYPEPTIDE; REQUIRES; SRP	THE signal-recognition particle (SRP) is important for the targeting of many secretory and membrane proteins to the endoplasmic reticulum (ER). Targeting is regulated by three GTPases, the 54K subunit of SRP (SRP54), and the alpha- and beta-subunits of the SRP receptor(1). When a signal sequence emerges from the ribosome, SRP interacts with it and targets the resulting complex to the ER membrane by binding to the SRP receptor. Subsequently, SRP releases the signal sequence into the translocation channel(2,3). Here we use a complex of a ribosome with a nascent peptide chain, the SRP and its receptor, to investigate GTP binding to SRP54, and GTP hydrolysis. Our findings indicate that a ribosomal component promotes GTP binding to the SRP54 subunit of SRP, GTP-bound SRP54 is essential for high-affinity interaction between SRP and its receptor in the ER membrane. This interaction induces the release of the signal sequence from SRP, the insertion of the nascent polypeptide chain into the translocation channel, and GTP hydrolysis. The contribution of the ribosome had previously escaped detection because only synthetic signal peptides were used in the analysis(4).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	Bacher, G (corresponding author), UNIV HEIDELBERG,ZMBH,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HIGH S, 1991, J CELL BIOL, V113, P54; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	26	121	122	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					248	251		10.1038/381248a0	http://dx.doi.org/10.1038/381248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622769				2022-12-24	WOS:A1996UL24900058
J	Reijo, R; Alagappan, RK; Patrizio, P; Page, DC				Reijo, R; Alagappan, RK; Patrizio, P; Page, DC			Severe oligozoospermia resulting from deletions of azoospermia factor gene on Y chromosome	LANCET			English	Article							INFERTILITY; REGION	Background About 13% of cases of non-obstructive azoospermia are caused by deletion of the azoospermia factor (AZF), a gene or gene complex normally located on the long arm of the Y chromosome. Oligozoospermia is far more common than azoospermia, but little is known about genetic causes. We investigated whether severe oligozoospermia is caused by AZF deletions and, if so, whether those deletions are present in mature spermatozoa, Methods By PCR, we tested leucocyte DNA, from 35 men who presented at infertility clinics and who had severe oligozoospermia, for the presence of 118 DNA landmarks scattered across the Y chromosome. In the two men in whom Y-chromosome deletions in leucocyte DNA were detected, we also tested leucocyte DNA from the individuals' fathers, and in one man we tested sperm DNA. Findings In two men with ejaculate sperm counts of 40 000-100 000 per mL, we detected Y-chromosome leucocyte DNA similar in location to those reported in azoospermic individuals. No Y-chromosome deletions were detected in the fathers of the two men, For one of the two men, sperm DNA was tested, and it showed the same Y-chromosome deletion seen in leucocytes. Interpretation The Y-chromosome deletions in these two men are de-novo mutations, and are therefore the cause of their severe oligozoospermia. Not only is the absence of AZF compatible with spermatogenesis, albeit at reduced rate, but also the resultant sperm bear the mutant Y chromosome. Because intracytoplasmic sperm injection is increasingly used as a means of circumventing oligozoospermia, AZF deletions could be transmitted by this practice, and would probably result in infertile sons. In cases of severe oligozoospermia, it may be appropriate to offer Y-DNA testing and genetic counselling before starting assisted reproductive procedures.	WHITEHEAD INST,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA; FERTIL CTR SAN ANTONIO,MALE INFERTIL SERV,SAN ANTONIO,TX	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Patrizio, Pasquale/AGO-0674-2022	Reijo Pera, Renee/0000-0002-6487-1329				ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BHASIN S, 1994, J CLIN ENDOCR METAB, V79, P1525, DOI 10.1210/jc.79.6.1525; BORGAONKAR DS, 1971, NATURE, V230, P52, DOI 10.1038/230052a0; CHANDLEY AC, 1994, HUM MOL GENET, V3, P1449, DOI 10.1093/hmg/3.suppl_1.1449; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GYLLENSTEN U, 1990, PCR PROTOCOLS, V1, P300; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; NAKAHORI Y, 1994, HUM MOL GENET, V3, P1709, DOI 10.1093/hmg/3.9.1709; ORD T, 1990, HUM REPROD, V5, P987, DOI 10.1093/oxfordjournals.humrep.a137233; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; SILBER SJ, 1995, HUM REPROD, V10, P148, DOI 10.1093/humrep/10.1.148; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANZYL JA, 1975, INT J FERTIL, V20, P129; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	18	437	459	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1290	1293		10.1016/S0140-6736(96)90938-1	http://dx.doi.org/10.1016/S0140-6736(96)90938-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622504				2022-12-24	WOS:A1996UK75800009
J	Watson, MA; Chaconas, G				Watson, MA; Chaconas, G			Three-site synapsis during Mu DNA transposition: A critical intermediate preceding engagement of the active site	CELL			English	Article							INTEGRATION HOST FACTOR; STRAND-TRANSFER-REACTION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; PHAGE-MU; B-PROTEIN; HIN INVERTASOME; A-PROTEIN; ENHANCER; ENDS	The chemical steps of bacteriophage Mu DNA transposition take place within a higher order nucleoprotein structure. We describe a novel intermediate that precedes the previously characterized transpososomes and directly demonstrates the interaction of a distant enhancer element with recombination regions. The transpositional enhancer interacts with the Mu left and right ends to form a three-site synaptic (LER) complex. Under normal reaction conditions, the LER complex is rapidly converted into the more stable Mu transpososomes. However, mutation of the Mu terminal nucleotides results in accumulation of the LER and a failure to form the type 0 transpososome. During the transition from LER to type 0, the Mu DNA termini and the active site of the transposase engage in a catalytically competent conformation.			Watson, MA (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON N6A 5C1, CANADA.			Watson, Mark/0000-0002-3557-101X				ALLISON RG, 1992, J BIOL CHEM, V267, P19963; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANPUTTE P, 1992, TRENDS GENET, V8, P457; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, GENE DEV, V9, P2545, DOI 10.1101/gad.9.20.2545; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; ZOU A, 1991, J BIOL CHEM, V266, P20476	51	66	66	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					435	445		10.1016/S0092-8674(00)81121-6	http://dx.doi.org/10.1016/S0092-8674(00)81121-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616898	Bronze			2022-12-24	WOS:A1996UK14000016
J	Ferris, JP; Hill, AR; Liu, RH; Orgel, LE				Ferris, JP; Hill, AR; Liu, RH; Orgel, LE			Synthesis of long prebiotic oligomers on mineral surfaces	NATURE			English	Article								MOST theories of the origin of biological organization assume that polymers with lengths in the range of 30-60 monomers are needed to make a genetic system viable(1). But it has not proved possible to synthesize plausibly prebiotic polymers this long by condensation in aqueous solution, because hydrolysis competes with polymerization. The potential of mineral surfaces to facilitate prebiotic polymerization was pointed out long ago(2). Here we describe a system that models prebiotic polymerization by the oligomerization of activated monomers-both nucleotides and amino acids. We find that whereas the reactions in solution produce only short oligomers (the longest typically being a 10-mer), the presence of mineral surfaces (montmorillonite for nucleotides, illite and hydroxylapatite for amino acids) induces the formation of oligomers up to 55 monomers long. These are formed by successive 'feedings' with the monomers; polymerization takes place on the mineral surfaces in a manner akin to solid-phase synthesis of biopolymers(3,4).	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute	Ferris, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ACEVEDO OL, 1986, NATURE, V321, P790, DOI 10.1038/321790a0; BERNAL JD, 1951, PHYSICAL BASIS LIFE; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; GIBBS D, 1980, J MOL EVOL, V15, P347, DOI 10.1007/BF01733141; HOLM NG, 1993, ORIGINS LIFE EVOL B, V23, P195, DOI 10.1007/BF01581839; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; SCHWARTZ AW, 1985, J MOL EVOL, V21, P299, DOI 10.1007/BF02102362; Szostak J.W., 1993, RNA WORLD, P511	9	612	626	6	215	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					59	61		10.1038/381059a0	http://dx.doi.org/10.1038/381059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609988	Green Submitted			2022-12-24	WOS:A1996UJ05300053
J	Gao, JM; Mammen, M; Whitesides, GM				Gao, JM; Mammen, M; Whitesides, GM			Evaluating electrostatic contributions to binding with the use of protein charge ladders	SCIENCE			English	Article								Electrostatic interactions between charges on ligands and charges on proteins that are remote from the binding interface can influence the free energy of binding (Delta G(b)). The binding affinities between charged ligands and the members of a charge ladder of bovine carbonic anhydrase (CAII) constructed by random acetylation of the amino groups on its surface were measured by affinity capillary electrophoresis (ACE). The values of Delta G(b) derived from this analysis correlated approximately linearly with the charge. Opposite charges on the ligand and the members of the charge ladder of CAII were stabilizing; like charges were destabilizing. The combination of ACE and protein charge ladders provides a tool for quantitatively examining the contributions of electrostatics to free energies of molecular recognition in biology.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM51559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON HA, 1942, ELECTROPHORESIS PROT, pCH5; BASAK SK, 1995, ANAL BIOCHEM, V226, P51, DOI 10.1006/abio.1995.1190; CHU YH, 1995, ACCOUNTS CHEM RES, V28, P461, DOI 10.1021/ar00059a004; DODGSON SJ, 1991, CARBONIC ANHYDRASES; GAO JM, 1994, P NATL ACAD SCI USA, V91, P12027, DOI 10.1073/pnas.91.25.12027; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ise N, 1996, ACCOUNTS CHEM RES, V29, P3, DOI 10.1021/ar950019k; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; Schmitz KS, 1996, ACCOUNTS CHEM RES, V29, P7, DOI 10.1021/ar950129r; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0	12	82	84	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					535	537		10.1126/science.272.5261.535	http://dx.doi.org/10.1126/science.272.5261.535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614800				2022-12-24	WOS:A1996UG82600040
J	Lehman, A; Black, R; Ecker, JR				Lehman, A; Black, R; Ecker, JR			HOOKLESS1, an ethylene response gene, is required for differential cell elongation in the Arabidopsis hypocotyl	CELL			English	Article							NUCLEOTIDE-SEQUENCE; T-DNA; PLANTS; AUXIN; ACETYLTRANSFERASE; EXPRESSION; MUTANTS; GROWTH; MUTAGENESIS; THALIANA	Bending in plant tissues results from differential cell elongation. We have characterized Arabidopsis ''hookless'' mutants that are defective in differential growth in the hypocotyl. HOOKLESS1 was cloned and its predicted protein shows similarity to a diverse group of N-acetyltransferases. HOOKLESS1 mRNA is increased by treatment with ethylene and decreased in the ethylene-insensitive mutant ein2. High level expression of HOOKLESS1 mRNA results in constitutive hook curvature. The morphology of the hookless hypocotyl is phenocopied by inhibitors of auxin transport or by high levels of endogenous or exogenous auxin. Spatial patterns of expression of two immediate early auxin-responsive genes are altered in hookless1 mutants, suggesting that the ethylene response gene HOOKLESS1 controls differential cell growth by regulating auxin activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT BIOL,MEDIA,PA 19603	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University			Ecker, Joseph R/B-9144-2008	Ecker, Joseph R/0000-0001-5799-5895				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABELES FB, 1992, IN PRESS ETHYLENE PL; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLACK RC, 1986, PLANT PHYSIOL, V80, P145, DOI 10.1104/pp.80.1.145; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; CASERO RA, 1991, J BIOL CHEM, V266, P810; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; Cleland R. E., 1987, Plant hormones and their role in plant growth and development., P132; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DARWIN C, 1896, POWER MOVEMENT PLANT, P87; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FIRN RD, 1980, ANNU REV PLANT PHYS, V31, P131, DOI 10.1146/annurev.pp.31.060180.001023; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; GIL P, 1996, IN PRESS EMBO J; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HEIM U, 1989, NUCLEIC ACIDS RES, V17, P7103, DOI 10.1093/nar/17.17.7103; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KANG BG, 1967, SCIENCE, V156, P958, DOI 10.1126/science.156.3777.958; KERK NM, 1995, DEVELOPMENT, V121, P2825; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; King JJ, 1995, PLANT CELL, V7, P2023, DOI 10.1105/tpc.7.12.2023; KRUGEL H, 1993, GENE, V127, P127, DOI 10.1016/0378-1119(93)90627-F; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LI Y, 1994, PLANT MOL BIOL, V24, P715, DOI 10.1007/BF00029853; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; Lomax Terri L., 1995, P509; MORGAN DG, 1964, NATURE, V201, P476, DOI 10.1038/201476a0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; Reinecke D. M., 1987, Plant hormones and their role in plant growth and development., P24; ROMAN G, 1995, GENETICS, V139, P1393; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHWARK A, 1993, J PLANT PHYSIOL, V142, P585, DOI 10.1016/S0176-1617(11)80403-7; SCHWARK A, 1992, J PLANT PHYSIOL, V140, P562, DOI 10.1016/S0176-1617(11)80790-X; SILK WK, 1978, AM J BOT, V65, P310, DOI 10.2307/2442271; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; Tamas I. A., 1987, Plant hormones and their role in plant growth and development., P393; TENOVER FC, 1988, J BACTERIOL, V170, P471, DOI 10.1128/jb.170.1.471-473.1988; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; WYATT RE, 1993, PLANT MOL BIOL, V22, P731, DOI 10.1007/BF00027361; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153; ZIMMER W, 1991, MOL GEN GENET, V229, P41, DOI 10.1007/BF00264211	60	330	349	7	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					183	194		10.1016/S0092-8674(00)81095-8	http://dx.doi.org/10.1016/S0092-8674(00)81095-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612271	hybrid			2022-12-24	WOS:A1996UG25500007
J	Sawle, G				Sawle, G			Visual vertigo	LANCET			English	Editorial Material											Sawle, G (corresponding author), QUEENS MED CTR,DIV CLIN NEUROL,NOTTINGHAM,ENGLAND.							BRONSTEIN AM, 1995, J NEUROL NEUROSUR PS, V59, P472, DOI 10.1136/jnnp.59.5.472; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P510; RUDGE P, 1995, J NEUROL NEUROSUR PS, V59, P568, DOI 10.1136/jnnp.59.6.568	3	2	2	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					986	987		10.1016/S0140-6736(96)90140-3	http://dx.doi.org/10.1016/S0140-6736(96)90140-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606609				2022-12-24	WOS:A1996UF38000005
J	Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S				Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S			Human parvovirus B19 infection associated with acute hepatitis	LANCET			English	Article							DISEASE	Background Human parvovirus (HPV) B19 infection produces a range manifestations including erythema infectiosum in children. Here we describe seven children who had acute hepatitis with HPV B19 infection. Methods Hepatic dysfunction was noted in three children referred to our hospital during the course of erythema infectiosum caused by HPV B19 infection diagnosed by ELISA and PCR. The role of HPV B19 in the pathogenesis of hepatic involvement was investigated retrospectively by PCR assay of stored serum samples from 773 patients admitted to our hospital. Findings 15 patients admitted to our hospital from January, 1991, to June, 1992, were HPV B19 DNA positive, of whom four had acute hepatitis of unknown origin. These four patients were aged between 7 months and 5 years. Of the seven patients, infection with hepatitis A, B, or C viruses or Epstein-Barr virus was ruled out in six by virological examinations. Interpretation Epidemiological evidence suggests that HPV B19 can be the cause of acute hepatitis.			Yoto, Y (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT PEDIAT,CHUO KU,S-1,W-16,SAPPORO,HOKKAIDO 060,JAPAN.							BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; HAAS L, 1990, J VET MED B, V37, P106, DOI 10.1111/j.1439-0450.1990.tb01033.x; JELINEK F, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P69; METZMAN R, 1989, J PEDIATR GASTR NUTR, V9, P112; MUIR K, 1992, LANCET, V339, P1139, DOI 10.1016/0140-6736(92)90735-L; OHGA S, 1993, AM J PEDIAT HEMATOL, V15, P291; SALIMANS MMM, 1989, J CLIN PATHOL, V42, P525, DOI 10.1136/jcp.42.5.525; TSUDA H, 1993, AM J GASTROENTEROL, V88, P1463; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; YOTO Y, 1993, ACTA HAEMATOL-BASEL, V90, P8	10	115	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					868	869		10.1016/S0140-6736(96)91348-3	http://dx.doi.org/10.1016/S0140-6736(96)91348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622394				2022-12-24	WOS:A1996UC45000012
J	Reichhardt, T				Reichhardt, T			Regulators face questioning on particulate rules	NATURE			English	Editorial Material																			0	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					11	12						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598893				2022-12-24	WOS:A1996TY87700017
J	Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M				Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M			Characterization of a cancer cachectic factor	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; CACHEXIA; MICE; MECHANISM; MUSCLE; CELLS; MODEL	CANCER cachexia is a syndrome of progressive wasting which has been suggested to be mediated by tumour-necrosis factor-alpha (ref. 1), interleukins 1 and 6 (ref. 2), interferon-gamma (ref. 3) and leukaemia-inhibitory factor(4). It has proved difficult to correlate levels of tumour-necrosis factor-alpha and interleukin-6 with cancer cachexia(5,6), and the weight loss induced by leukaemia-inhibitory factor may be due to toxicity(7). In the murine adenocarcinoma MAC16, cachexia is mediated by circulatory catabolic factors(8,9), which we have now isolated using an antibody cloned from splenocytes of mice transplanted with the MAC16 tumour, with a delayed cachexia(10). The material is a proteoglycan of relative molecular mass 24K which produces cachexia in vivo by inducing catabolism of skeletal muscle. The 24K material was also present in urine of cachectic cancer patients, but was absent from normal subjects, patients with weight loss due to trauma, and cancer patients with little or no weight loss. This suggests that cachexia in mice and humans may be produced by the same material.	UNIV ASTON,INST PHARMACEUT SCI,CRC,NUTR BIOCHEM RES GRP,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT BIOCHEM,CRC,MOLEC TOXICOL GRP,LONDON W1P 6D8,ENGLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Aston University; University of Birmingham; University of London; University College London; Royal Infirmary of Edinburgh; University of Edinburgh								BECK SA, 1987, CANCER RES, V47, P5919; BECK SA, 1991, CANCER RES, V51, P6089; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BIBBY MC, 1987, J NATL CANCER I, V78, P539; GARCIAMARTINEZ C, 1994, CANCER LETT, V76, P1, DOI 10.1016/0304-3835(94)90126-0; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MCDEVITT TM, 1992, BRIT J CANCER, V66, P815, DOI 10.1038/bjc.1992.366; MCDEVITT TM, 1995, J CANCER RES, V55, P1458; METCALF D, 1990, BLOOD, V76, P50; MORI M, 1991, CANCER RES, V51, P6656; PLUMB JA, 1991, CLIN NUTR, V10, P23, DOI 10.1016/0261-5614(91)90077-P; SMITH KL, 1993, BRIT J CANCER, V68, P314, DOI 10.1038/bjc.1993.334; SOCHER SH, 1988, J NATL CANCER I, V80, P595, DOI 10.1093/jnci/80.8.595; SODA K, 1994, JPN J CANCER RES, V85, P1124, DOI 10.1111/j.1349-7006.1994.tb02917.x; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; YOSHIZAWA N, 1992, J IMMUNOL, V148, P3110	17	340	361	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					739	742		10.1038/379739a0	http://dx.doi.org/10.1038/379739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602222				2022-12-24	WOS:A1996TW56700056
J	Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S				Smith, S; Robinson, J; Hollyer, J; Bhatt, R; Ash, S; Shaunak, S			Combining specialist and primary health care teams for HIV positive patients: Retrospective and prospective studies	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; FUNDING POLICIES; HOSPITAL DOCTORS; AIDS; COMMUNICATION; INFECTION	Objective-To develop and evaluate a model of health care for HIV positive patients involving specialist, hospital based teams and primary health care teams. Design-One year retrospective and 2 1/2 year prospective study. Setting-Two hospitals in west London and 88 general practitioners in 72 general practices. Subjects-209 adults with HIV infection. Intervention-General practitioners enrolled in the project were fared structured outpatient clinic summaries. When hospital inpatients were discharged, a brief discharge summary was fared. General practitioners had access to consultant physicians skilled in HIV medicine through a 24 hour mobile telephone service. An HIV/AIDS management and treatment guide containing relevant local information was produced. Quarterly discussion forums for general practitioners were held, and a regular newsletter was produced. Main outcome measures-Hospital attendance and general practitioner consultations; perceived benefits and problems of patients and general practitioners. Results-The average length of a hospital inpatient stay was halved for those patients who had participated in the project for two years, and the average number of visits to the outpatient clinic per month fell for patients with AIDS. There was a substantial increase in the number of visits to general practitioners by patients with AIDS and symptomatic HIV infection. Patients and general practitioners both felt that the standard of health care provided had improved. Conclusions-This model of health care efficiently and effectively utilised existing teams of hospital and primary health care professionals to provide care for HIV positive patients. Simple, prompt, and regular communication systems which provided information relevant to the needs of general practitioners were central to its success.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT INFECT DIS,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,MED STAT UNIT,LONDON W12 0NN,ENGLAND; GROVE MED PRACTICE,NORTHOLT,MIDDX,ENGLAND; EALING GEN HOSP,CAMERON CTR,LONDON,ENGLAND	Imperial College London; Imperial College London; Imperial College London								Butters E, 1991, Health Trends, V23, P59; COULTER A, 1995, BRIT MED J, V311, P1447, DOI 10.1136/bmj.311.7018.1447; COYLE A, 1995, BRIT MED J, V310, P1636, DOI 10.1136/bmj.310.6995.1636; GRUN L, 1994, BRIT MED J, V308, P538; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; HICKMAN M, 1994, J PUBLIC HEALTH MED, V16, P447, DOI 10.1093/oxfordjournals.pubmed.a043026; HOCHULI V, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-b; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; Main J, 1993, Qual Health Care, V2, P53, DOI 10.1136/qshc.2.1.53; MANSFIELD S, 1993, LANCET, V342, P726; MCCARTHY M, 1993, BRIT MED J, V307, P367, DOI 10.1136/bmj.307.6900.367; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; RAWAL J, 1993, BRIT MED J, V307, P1044, DOI 10.1136/bmj.307.6911.1044; REGNARD C, 1994, BRIT MED J, V308, P655, DOI 10.1136/bmj.308.6929.655d; SCHRODER F, 1995, BRIT MED J, V310, P142; SINGH S, 1994, BRIT MED J, V308, P539; SMITH S, 1993, BRIT MED J, V307, P801, DOI 10.1136/bmj.307.6907.801-c; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; VANDAMME R, 1994, BRIT J GEN PRACT, V44, P9; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; WILLIAMS H, 1993, BRIT MED J, V307, P802, DOI 10.1136/bmj.307.6907.802; 1994, BRIT MED J, V308, P559; 1994, BRIT MED J, V308, P1208	25	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					416	420						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601114	Green Published			2022-12-24	WOS:A1996TW56400024
J	Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D				Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D			Asymptomatic gonorrhoea and chlamydial infection in rural Tanzanian men	BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED DISEASES; GONOCOCCAL INFECTIONS; RISK-FACTORS; EPIDEMIOLOGY; URETHRITIS; TRANSMISSION; TRACHOMATIS	Objective-To measure the prevalence of urethritis due to Neisseria gonorrhoeae and Chlamydia trachomatis in rural Tanzanian men. Design-About 500 men aged 15-54 years were selected from each of 12 rural communities by random cluster sampling; interviewed concerning past or present symptoms of sexually transmitted diseases; and asked to provide a first catch urine specimen, which was tested for pyuria with a leucocyte esterase dipstick test. Subjects with symptoms or with a positive result on testing were examined, and urethral swabs were taken for detection of N gonorrhoeae by gram stain and of C trachomatis by antigen detection immunoassay. Setting-Mwanza region, north western Tanzania. Subjects-5876 men aged 15-54 years. Main outcome measures-Prevalence of urethral symptoms, observed urethral discharge, pyuria, urethritis (>4 pus cells per high power field on urethral smear), N gonorrhoeae infection (intracellular gram negative diplococci), and C trachomatis infection (IDEIA antigen detection assay). Results-1618 (28%) subjects reported ever having had a urethral discharge. Current discharge was reported by 149 (2.5%) and observed on examination in 207 (3.5%). Gonorrhoea was found in 128 subjects (2.2%) and chlamydial infection in 39 (0.7%). Only 24 of 158 infected subjects complained of urethral discharge at the time of interview (15%). Conclusion-Infection with N gonorrhoeae and C trachomatis is commonly asymptomatic among men in this rural African population. This has important implications for the design of control programmes for sexually transmitted disease.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NATL INST MED RES,MWANZA,TANZANIA	University of London; London School of Hygiene & Tropical Medicine; National Institute of Medical Research				Todd, Jim/0000-0001-5918-4914; MAYAUD, Philippe/0000-0001-5730-947X; Hayes, Richard/0000-0002-1729-9892; Grosskurth, Heiner/0000-0001-9960-7280				Arya O P, 1977, Trop Doct, V7, P51; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016; DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639; HANDSFIELD HH, 1974, NEW ENGL J MED, V290, P117, DOI 10.1056/NEJM197401172900301; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MAHEY DCW, 1994, GENITOURIN MED, V70, P1; MAYAUD P, 1992, GENITOURIN MED, V68, P361; MAYAUD P, 1993, 10TH P INT M ISSTDR; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MEHEUS A, 1980, INT J EPIDEMIOL, V9, P239, DOI 10.1093/ije/9.3.239; NDOYE I, 1993, 10TH P INT M ISSTDR; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RIETMEIJER CAM, 1991, SEX TRANSM DIS, V18, P28, DOI 10.1097/00007435-199101000-00007; SCHACHTER J, 1994, CHLAMYDIAL INFECTION, P293; SCHULZ K, 1987, GENITOURIN MED, V62, P320; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; VANDYCK E, 1989, WHOVDT443; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WEST B, 1995, GENITOURIN MED, V71, P9; 1993, INVESTING HLTH; 1993, WHOGPASTD931	23	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					277	280						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611782	Green Published			2022-12-24	WOS:A1996TU50700020
J	Minakami, H; Sato, I				Minakami, H; Sato, I			Reestimating date of delivery in multifetal pregnancies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIPLETS; STILLBIRTH; BIRTHS; RISK	Objective.-To clarify the optimal estimated date of delivery for multifetal pregnancies. Design, Subjects, and Setting.-A retrospective study of all 88 936 infants born of multifetal pregnancies and all 6 020 542 infants born of singleton pregnancies that occurred at 26 weeks or more of gestation between 1989 and 1993 in Japan. Main Outcome Measure.-Incidence of stillbirth and early neonatal death according to gestational age at delivery. Results.-The mean+/-SD duration of pregnancy was 37.0+/-2.7 weeks for multifetal pregnancies and 39.6+/-1.6 weeks for singleton pregnancies. In multifetal pregnancies, the incidence of stillbirth and of early neonatal death gradually declined until 37 to 38 weeks' gestation and then increased. These parameters in singleton pregnancies declined until 39 weeks' gestation before increasing. The lowest incidence of perinatal death (stillbirth plus early neonatal death) seen at 38 weeks' gestation in multifetal pregnancies corresponded to that seen at 43 weeks' gestation in singleton pregnancies (10.5 vs 9.7 per 1000 infants). The risk of perinatal death was more than 6 times as high for fetuses of multifetal pregnancies born at 37 weeks or later than for singleton fetuses born at 40 weeks or later (relative risk, 6.6; 95% confidence interval, 6.1-7.1). Conclusion.-Fetuses of multifetal pregnancies are at an increased risk of death after reaching the normative gestational age for singleton pregnancies. Limiting the estimated date of delivery to 37 to 38 weeks may be appropriate in multifetal pregnancies.			Minakami, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					AHLENIUS I, 1995, ACTA OBSTET GYN SCAN, V74, P109, DOI 10.3109/00016349509008917; CHISWICK M, 1995, BRIT MED J, V310, P141, DOI 10.1136/bmj.310.6973.141; COLLINS MS, 1990, AM J OBSTET GYNECOL, V162, P1384, DOI 10.1016/0002-9378(90)90896-F; Crowley P., 1989, EFFECTIVE CARE PREGN, P776; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; Imaizumi Y., 1994, J EPIDEMIOL, V4, P103; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MCCLUREBROWNE JC, 1963, AM J OBSTET GYNECOL, V85, P573, DOI 10.1016/0002-9378(63)90304-1; MCLENNAN A, 1990, LANCET, V335, P267; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *MIN HLTH WELF CHI, 1994, TAB INF; MINAKAMI H, 1993, LANCET, V341, P1603, DOI 10.1016/0140-6736(93)90746-4; MORRISON I, 1985, AM J OBSTET GYNECOL, V152, P975, DOI 10.1016/0002-9378(85)90542-3; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239	17	106	112	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1432	1434		10.1001/jama.275.18.1432	http://dx.doi.org/10.1001/jama.275.18.1432			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618370				2022-12-24	WOS:A1996UJ30300030
J	Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE				Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE			The cotranslational integration of membrane proteins into the phospholipid bilayer is a multistep process	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; POLYPEPTIDE TRANSLOCATION; PHOTOCROSS-LINKING; ER; SEC61P; INSERTION; ADJACENT; IDENTIFICATION; PREPROLACTIN	During the cotranslational integration of a nascent protein into the endoplasmic reticulum membrane, the transmembrane (TM) sequence moves out of an aqueous pore formed by Sec61 alpha, TRAM, and other proteins and into the nonpolar lipid bilayer. Photocross-linking reveals that this movement involves the sequential passage of the TM domain through three different proteinaceous environments: one adjacent to Sec61 alpha and TRAM and two adjacent to TRAM that place different restrictions on TM domain movement. In addition, the TM sequence is not allowed to diffuse into the bilayer from the final TRAM-proximal site until translation terminates. Cotranslational integration is therefore linked to translation and occurs via an ordered multistep pathway at an endoplasmic reticulum site that is multilayered both structurally and functionally.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University	Do, H (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JANIAK F, 1994, J BIOL CHEM, V269, P9842; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; JOHNSON AE, 1996, IN PRESS COLD SPRING, V60; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	35	213	214	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					369	378		10.1016/S0092-8674(00)81115-0	http://dx.doi.org/10.1016/S0092-8674(00)81115-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616892	Bronze			2022-12-24	WOS:A1996UK14000010
J	Dybowski, R; Weller, P; Chang, R; Gant, V				Dybowski, R; Weller, P; Chang, R; Gant, V			Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm	LANCET			English	Article							SEPSIS; SCORE	Background Decisions about which patients to admit to intensive care and how long to keep them there are difficult. A flexible computer-based mathematical model which is sensitive to the complexity of intensive care medicine, and which accurately models prognosis, seems highly desirable. Methods We have created, optimised by genetic algorithms, trained, and evaluated the performance of an artificial neural network (ANN) in the clinical setting of systemic inflammatory response syndrome and haemodynamic shock. 258 patients were selected from an intensive care database of 4484 patients al a London teaching hospital and randomised to a network training set (168) and a test set (90). The outcome evaluated was death during that hospital admission and the performance of the neural net was compared (by receiver operating characteristic [ROC] curves and by Brier scores) with that of a logistic regression model. Findings Artificial neural network performance increased with successive generations; the best-performing ANN was created after 7 generations and predicted outcome more accurately than the logistic regression model (ROC curve area 0.863 vs 0.753). Interpretation In this study, ANNs have lent themselves particularly well to modelling a complex clinical situation; we suggest that this relates to their inherently flexible nature which accommodates interactions between the clinical input fields. In addition, we have demonstrated the value of a second computational technique (genetic algorithms) in ''tuning'' ANN performance. These techniques can potentially be implemented in individual intensive care units; the outcome models which they will generate will be sensitive to local practice. Analysis of such accurate clinical outcome models may empower clinicians with a hitherto unappreciated degree of insight into those elements of their clinical practice which are most relevant to their patients' outcome.	CITY UNIV LONDON,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND; UNIV LONDON ST GEORGES HOSP,LONDON,ENGLAND	City University London; St Georges University London	Dybowski, R (corresponding author), UMDS,DIV INFECT,INFECT & IMMUN LAB,ST THOMAS HOSP CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.							ABRAHAM E, 1994, JAMA-J AM MED ASSOC, V271, P1876, DOI 10.1001/jama.271.23.1876; ATKINSON S, 1994, LANCET, V344, P1203, DOI 10.1016/S0140-6736(94)90514-2; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Breiman L, 1983, CLASSIFICATION REGRE; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Doig G S, 1993, Proc Annu Symp Comput Appl Med Care, P361; DYBOWSKI R, 1995, LANCET, V346, P1203, DOI 10.1016/S0140-6736(95)92904-5; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LONG WJ, 1993, COMPUT BIOMED RES, V26, P74, DOI 10.1006/cbmr.1993.1005; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MILLER GF, 1989, 3RD P INT C GEN ALG, P379; MONTANA DJ, 1989, P 11 INT JOINT C ART, P762; NARAYANAN MN, 1993, METHOD INFORM MED, V32, P55, DOI 10.1055/s-0038-1634888; RIPLEY BD, 1994, J R STAT SOC B, V56, P409; SAHASAKUL Y, 1990, BRIT HEART J, V64, P182; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; YATES JF, 1982, ORGAN BEHAV HUM PERF, V30, P132, DOI 10.1016/0030-5073(82)90237-9	27	161	167	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1146	1150		10.1016/S0140-6736(96)90609-1	http://dx.doi.org/10.1016/S0140-6736(96)90609-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609749				2022-12-24	WOS:A1996UG75500011
J	Morrison, PJ				Morrison, PJ			Anticipating more anticipation	LANCET			English	Editorial Material							REPEAT				Morrison, PJ (corresponding author), BELFAST CITY HOSP,NO IRELAND REG GENET CTR,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND.							Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; MORRISON PJ, 1993, LANCET, V342, P385; Morrison PJ, 1996, J MED GENET, V33, P504, DOI 10.1136/jmg.33.6.504; ODONOVAN MC, 1995, NAT GENET, V10, P379; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1132	1132		10.1016/S0140-6736(96)90605-4	http://dx.doi.org/10.1016/S0140-6736(96)90605-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609745				2022-12-24	WOS:A1996UG75500007
J	Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC				Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC			Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage	LANCET			English	Article								Background Acute upper gastrointestinal haemorrhage is a common medical emergency and hospital admission has usually been regarded as obligatory until the risk of further haemorrhage has receded. This policy means that some patients at low risk stay in hospital for longer than is necessary especially when delayed. We attempted to negligible risk of further bleeding or death and for whom early discharge or even outpatient management would be possible with no adverse effect on standards of care. Methods We used a validated risk scoring system based on age (score 0-2), presence of shock (0-2), comorbidity (0-3), diagnosis (0-2), and endoscopic stigmata of recent haemorrhage (0-2); the maximum possible score was 11. We studied patients identified through the UK National Audit of acute upper gastrointestinal haemorrhage; they had been admitted with upper gastrointestinal haemorrhage to hospitals in the UK during 4 months of 1993. This analysis was based on the 2531 patients from the national audit who underwent endoscopy after an acute admission. Findings 744 (29.4%) of the 2531 patients scored 2 or less on the risk score. Of these patients only 32 (4.3% [95% CI 3.0-6.0] rebled and only one (0.1% [0.006-0.75] died). Thus, the risk score identifies patients at low risk of rebleeding or death. The median hospital stay for these patients was 4 days; duration of hospital stay increased with risk score. Within risk score categories of 5 or less, there was a trend of increasing hospital stay as the time between admission and endoscopy increased. Interpretation Our risk score identifies a large proportion of patients with acute upper gastrointestinal haemorrhage who are at low risk of further bleeding or death. Early endoscopy and discharge of such patients could allow substantial resource savings.	QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; ST GEORGE HOSP,SCH MED,LONDON,ENGLAND	University of Nottingham; St Georges University London	Rockall, TA (corresponding author), ROYAL COLL SURGEONS ENGLAND,AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X	4	249	262	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1138	1140		10.1016/S0140-6736(96)90607-8	http://dx.doi.org/10.1016/S0140-6736(96)90607-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609747				2022-12-24	WOS:A1996UG75500009
J	Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E				Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E			Activation of medial temporal structures during episodic memory retrieval	NATURE			English	Article							HIPPOCAMPUS; AMNESIA	MEDIAL temporal lobe structures have been implicated in human episodic memory. Patients with medial temporal lesions show memory deficits(1-3), and functional neuroimaging studies have revealed activation in this region during episodic encoding and retrieval when data are averaged over a sample of subjects(4-7). The relevance of such observations for memory performance has remained unclear, however. Here we have used positron emission tomography (PET) to examine cerebral blood how related to verbal episodic retrieval. We observed strong positive correlations between retrieval and blood flow in left medial temporal structures in individual normal human subjects. In addition, multivariate analysis showed that regions in the left medial temporal lobe were dominant components of a pattern of brain regions that distinguished a high-retrieval condition from conditions of lower retrieval. These results suggest that medial temporal activity is related to retrieval success rather than retrieval attempt, possibly by reflecting reactivation of stored patterns.	UMEA UNIV,DEPT PSYCHOL,S-90187 UMEA,SWEDEN; CLARKE INST PSYCHIAT,PET CTR,TORONTO,ON M5T 1R8,CANADA; UNIV STOCKHOLM,DEPT PSYCHOL,S-10691 STOCKHOLM,SWEDEN	Umea University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Stockholm University	Nyberg, L (corresponding author), BAYCREST CTR GERIATR CARE,ROTMAN RES INST,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.		Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019; McIntosh, Anthony R/G-4955-2011	Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Houle, Sylvain/0000-0002-4231-6316; McIntosh, Anthony/0000-0002-1784-5662				AMARAL DG, 1990, DISCUSSIONS NEUROSCI; BOOKSTEIN FL, 1990, COMMUN STAT THEORY, V19, P765, DOI 10.1080/03610929008830231; Edgington E. S., 1987, RANDOMIZATION TESTS; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; HAIST F, 1992, J EXP PSYCHOL LEARN, V18, P691, DOI 10.1037/0278-7393.18.4.691; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; Kosslyn SM, 1996, J COGNITIVE NEUROSCI, V8, P78, DOI 10.1162/jocn.1996.8.1.78; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH M, 1989, HDB NEUROPSYCHOLOGY, V3; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; TALAIRACH J, 1988, STEREOTAXIC ATLAS HU; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	25	306	311	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					715	717		10.1038/380715a0	http://dx.doi.org/10.1038/380715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614466				2022-12-24	WOS:A1996UG82700052
J	Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R				Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R			The no apical meristem gene of petunia is required for pattern formation in embryos and flowers and is expressed at meristem and primordia boundaries	CELL			English	Article							ARABIDOPSIS-THALIANA; ANTIRRHINUM-MAJUS; HOMEOTIC GENES; MORPHOGENESIS; MUTAGENESIS; MUTATIONS; PROTEINS; SEQUENCE	Petunia embryos carrying the no epical meristem (nam) mutation fail to develop a shoot apical meristem. Occasional shoots on nam(-) seedlings bear flowers that develop ten instead of five primordia in the second whorl. Double mutants with the homeotic gene green petals show that nam acts independently of organ identity in whorl 2 and now also affects primordium number in whorl 3. The nam gene was isolated by transposon tagging. The encoded protein shares a conserved N-terminal domain with several other proteins of unknown function and thus represents a novel class of proteins. Strikingly, nam mRNA accumulates in cells at the boundaries of meristems and primordia. These data indicate a role for nam in determining positions of meristems and primordia.			Souer, E (corresponding author), VRIJE UNIV AMSTERDAM,BIOCENTRUM,INST MOLEC BIOL SCI,DEPT GENET,DE BOELELAAN 1087,1081 HV AMSTERDAM,NETHERLANDS.			Koes, Ronald/0000-0003-3793-5072; Souer, Erik/0000-0003-4459-2485				ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; ANGENENT GC, 1995, PLANT CELL, V7, P507, DOI 10.1105/tpc.7.5.507; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTON MK, 1993, DEVELOPMENT, V119, P823; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CANAS LA, 1994, PLANT J, V6, P597, DOI 10.1046/j.1365-313X.1994.6040597.x; CLARK SE, 1993, DEVELOPMENT, V119, P397; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DOODEMAN M, 1984, THEOR APPL GENET, V67, P357, DOI 10.1007/BF00272875; ERRAMPALLI D, 1991, PLANT CELL, V3, P149, DOI 10.1105/tpc.3.2.149; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GERATS AGM, 1990, PLANT CELL, V2, P1121, DOI 10.1105/tpc.2.11.1121; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; HAUGHN GW, 1995, CAN J BOT, V73, P959, DOI 10.1139/b95-105; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HERNANDEZ LF, 1993, PLANT CELL, V5, P1725, DOI 10.1105/tpc.5.12.1725; HERNANDEZ LF, 1991, PLANTA, V185, P139, DOI 10.1007/BF00194054; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JURGENS G, 1994, ANNU REV GENET, V28, P351, DOI 10.1146/annurev.ge.28.120194.002031; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1991, DEVELOPMENT S, V1, P27; KOES R, 1995, P NATL ACAD SCI USA, V92, P8149, DOI 10.1073/pnas.92.18.8149; KUSH A, 1993, PLANT PHYSIOL, V102, P1051, DOI 10.1104/pp.102.3.1051; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; NAGATO Y, 1989, THEOR APPL GENET, V78, P11, DOI 10.1007/BF00299746; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHERIDAN WF, 1993, PLANT J, V3, P347, DOI 10.1111/j.1365-313X.1993.tb00186.x; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SOUER E, 1995, PLANT J, V7, P677, DOI 10.1046/j.1365-313X.1995.7040677.x; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361	40	706	896	12	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					159	170		10.1016/S0092-8674(00)81093-4	http://dx.doi.org/10.1016/S0092-8674(00)81093-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612269	Bronze			2022-12-24	WOS:A1996UG25500005
J	Taunton, J; Hassig, CA; Schreiber, SL				Taunton, J; Hassig, CA; Schreiber, SL			A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ACETYLATION; NUCLEOSOME; ACTIVATION; LOCI	Trapoxin is a microbially derived cyclotetrapeptide that inhibits histone deacetylation in vivo and causes mammalian cells to arrest in the cell cycle. A trapoxin affinity matrix was used to isolate two nuclear proteins that copurified with histone deacetylase activity. Both proteins were identified by peptide microsequencing, and a complementary DNA encoding the histone deacetylase catalytic subunit (HD1) was cloned from a human Jurkat T cell library. As the predicted protein is very similar to the yeast transcriptional regulator Rpd3p, these results support a role for histone deacetylase as a key regulator of eukaryotic transcription.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; STILLMAN DJ, 1994, GENETICS, V136, P781; TAUNTON J, UNPUB; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	20	1463	1587	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					408	411		10.1126/science.272.5260.408	http://dx.doi.org/10.1126/science.272.5260.408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602529				2022-12-24	WOS:A1996UG25200046
J	Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G				Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G			Specificity of ribonucleoprotein interaction determined by RNA folding during complex formation	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; U1A PROTEIN; CRYSTAL-STRUCTURE; PREMESSENGER RNA; NMR-SPECTROSCOPY; BINDING DOMAIN; POLYADENYLATION; CONFORMATION	Many proteins involved in pre-mRNA processing contain one or more copies of a 70-90-amino-acid alpha beta module called the ribonucleoprotein domain(1-4). RNA maturation depends on the specific recognition by ribonucleoproteins of RNA elements within pre-mRNAs and small nuclear RNAs. The human U1A protein binds an RNA hairpin during splicing(5-8), and regulates its own expression by binding an internal loop(9) in the 3'-untranslated region of its pre mRNA, preventing polyadenylation3. Here we report the nuclear magnetic resonance structure of the complex between the regulatory element of the U1A 3'-untranslated region (UTR)(9-11) and the U1A protein RNA-binding domain. Specific intermolecular recognition requires the interaction of the variable loops of the ribonucleoprotein domain with the well-structured helical regions of the RNA. Formation of the complex then orders the flexible RNA single-stranded loop against the protein beta-sheet surface, and reorganizes the carboxy-terminal region of the protein to maximize surface complementarity and functional group recognition.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 1QB,ENGLAND	MRC Laboratory Molecular Biology								ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; AVIS J, 1996, J MOL BIOL; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1990, XPLOR 3 1 SYSTEM XRA; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DIAMOND R, 1995, ACTA CRYSTALLOGR D, V51, P127, DOI 10.1107/S0907444994010723; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Gubser CC, 1996, BIOCHEMISTRY-US, V35, P2253, DOI 10.1021/bi952319f; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Liljas A, 1995, CURR OPIN STRUC BIOL, V5, P721, DOI 10.1016/0959-440X(95)80003-4; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	233	237	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					646	650		10.1038/380646a0	http://dx.doi.org/10.1038/380646a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602269				2022-12-24	WOS:A1996UF74100052
J	Donnan, GA				Donnan, GA			Posterior leucoencephalopathy syndrome	LANCET			English	Editorial Material							CYCLOSPORINE				Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR,DEPT NEUROL,MELBOURNE,VIC,AUSTRALIA.			Donnan, Geoffrey/0000-0001-6324-3403				BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BYROM FB, 1954, LANCET, V2, P201; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Hughes EC., 1972, OBSTET GYNECOLOGIC T; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Oppenheimer BS, 1928, ARCH INTERN MED, V41, P264, DOI 10.1001/archinte.1928.00130140126010; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					988	988		10.1016/S0140-6736(96)90142-7	http://dx.doi.org/10.1016/S0140-6736(96)90142-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606611				2022-12-24	WOS:A1996UF38000007
J	Back, AL; Wallace, JI; Starks, HE; Pearlman, RA				Back, AL; Wallace, JI; Starks, HE; Pearlman, RA			Physician-assisted suicide and euthanasia in Washington State - Patient requests and physician responses	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH; DECISIONS; LIFE	Objectives.-To estimate how often physicians receive requests for physician-assisted suicide and euthanasia and to describe a case series of patient requests for physician-assisted suicide and euthanasia, including physician responses to these requests. Design.-A mailed, anonymous two-part questionnaire. Participants.-A total of 828 physicians returned questionnaires sent to 1453 potential respondents, for a response rate of 57%. Questionnaires were mailed to a random sample (25%) of primary care physicians and all physicians in selected medical subspecialties in Washington State. Main Outcome Measures.-The frequency of explicit patient requests for physician-assisted suicide and euthanasia reported by physicians and individual case descriptions of patient characteristics, physician perceptions of patient concerns, and physician responses to patient requests. Results.-In the past year, 12% of responding physicians received one or more explicit requests for physician-assisted suicide, and 4% received one or more requests for euthanasia. These physicians provided 207 case descriptions. The diagnoses most often associated with requests were cancer, neurological disease, and the acquired immunodeficiency syndrome (AIDS). The patient concerns most often perceived by physicians were worries about loss of control, being a burden, being dependent on others for personal care, and loss of dignity, Physicians provided assistance more often to patients with physical symptoms. Physicians infrequently sought advice from colleagues, Of 156 patients who requested physician-assisted suicide, 38 (24%) received prescriptions, and 21 of these died as a result. Of 58 patients who requested euthanasia, 14 (24%) received parenteral medication and died. Conclusions.-Patient requests for physician-assisted suicide and euthanasia are not rare, As perceived by physicians, the most common patient concerns at the time these requests are made are nonphysical, Physicians occasionally provide these practices, even though they are currently illegal in Washington State. Physicians do not consult colleagues often about these requests. These findings raise the question of how to ensure quality in the evaluation of patient requests for physician-assisted death.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED HIST & ETH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH, DEPT HLTH SERV, SEATTLE, WA 98195 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Back, AL (corresponding author), VET AFFAIRS PUGET SOUND HLTH CARE SYST, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.				NIA NIH HHS [AG00615-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1991, J PAIN SYMPTOM MANAG, V6, P298, DOI 10.1016/0885-3924(91)90053-7; BATTIN MP, 1995, ACAD MED, V70, P583; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSELL EJ, 1991, HASTINGS CENT REP, V21, P24, DOI 10.2307/3563319; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FINS JJ, 1995, J AM GERIATR SOC, V43, P563, DOI 10.1111/j.1532-5415.1995.tb06107.x; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GIRSH FJ, 1992, WESTERN J MED, V157, P188; Humphry Derek, 1991, FINAL EXIT PRACTICAL; JECKER NS, 1994, J AM GERIATR SOC, V42, P672, DOI 10.1111/j.1532-5415.1994.tb06869.x; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; PEARLMAN RA, 1993, THEOR MED, V14, P197, DOI 10.1007/BF00995162; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Pellegrino E D, 1992, J Clin Ethics, V3, P95; PELLEGRINO ED, 1995, J CLIN ETHIC, V6, P161; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; *WA STAT DEP HLTH, 1994, WASH STAT VIT STAT; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, J AM GERIATR SOC, V43, P579	37	258	258	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					919	925		10.1001/jama.275.12.919	http://dx.doi.org/10.1001/jama.275.12.919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UA563	8598619				2022-12-24	WOS:A1996UA56300031
J	Nightingale, SL				Nightingale, SL			National surveillance program for changes in antimicrobial susceptibilities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, MMWR-MORBID MORTAL W, V45, P110	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-24	WOS:A1996UA56300011
J	Bond, CM; Bradley, C				Bond, CM; Bradley, C			Over the counter drugs - The interface between the community pharmacist and patients .3.	BRITISH MEDICAL JOURNAL			English	Article								Pharmacists play an important part in primary health care, and their accessibility is a key factor. Their NHS payments relate predominantly to the dispensing of prescribed medicines; to recognise the service element of their advisory role, an NHS funded professional fee could be built into the cost structure for pharmacy medicines. The increased number of medicines available over the counter has need for training for counter assistants; it will become compulsory in July 1996, and some family health services authorities are providing this. The shift to care in the community could mean that pharmacists will have an even greater role in the primary health care team. Encouraging the public to seek advice from the community pharmacist may lead to a greater proportion of visits to doctors resulting from referrals from the pharmacist. Joint development by pharmacists and doctors of guidelines for advice on, and recommendation of, over the counter medicines is needed.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Bond, CM (corresponding author), UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN,SCOTLAND.							BLENKINSOPP A, 1994, OTCS PRESCRIPTION HE; Bond C M, 1995, Health Bull (Edinb), V53, P26; Bond CM, 1995, INT J PHARM PRACT, V3, P85; BOND CM, 1992, PHARM J, V249, pR6; *COMM INQ PHARM, 1986, REP NUFF FDN; DARRACOTT R, 1995, PHARM J, V254, P497; Eaton G, 1979, Sociol Health Illn, V1, P69, DOI 10.1111/1467-9566.ep11006781; EVANS D, 1994, PHARM J, V252, P631; FLINT JF, 1995, PHARM J, V254, P28; GOODBURN E, 1991, BMJ-BRIT MED J, V302, P440, DOI 10.1136/bmj.302.6774.440; HARGIE ODW, 1987, INT PHARM J, V1, P175; Jepson M, 1991, CONSUMER EXPECTATION; KRSKA J, 1994, PHARM J, V252, P936; National Audit Office, 1992, COMM PHARM ENGL; *ROYAL PHARM SOC, 1992, PHARM CAR FUT ROL CO; TAPSTER JV, 1994, PHARM J, V253, P112; 1987, CM249	17	35	35	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					758	760						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605465				2022-12-24	WOS:A1996UC16600039
J	Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD				Ogilvie, AD; Battersby, S; Bubb, VJ; Fink, G; Harmar, AJ; Goodwin, GM; Smith, CAD			Polymorphism in serotonin transporter gene associated with susceptibility to major depression	LANCET			English	Article							HYDROXYLASE GENE; DISORDERS	Background The serotonin transporter of the brain provides the primary target for the action of selective antidepressant drugs. We set out to identify polymorphisms of the serotonin transporter gene and to find out whether there was a relation between any such polymorphisms and the occurrence of affective disorder. Methods A comparison of a polymorphic region of the human serotonin transporter gene was carried out between two groups. The study group comprised 83 patients (39 unipolar depressive disorder, 44 bipolar disorder) with major affective disorder. The control group comprised 122 anonymous blood donors, and 71 volunteers who had been screened for psychiatric disorders. Findings We detected three novel alleles of the variable-number-tandem-repeat (VNTR) region (STin2.9, STin2.10, and STin2.12) containing nine, ten and 12 copies of the VNTR element, respectively. The frequencies of the different forms of the allele in the control group were compared with those in the affective disorder group. There was a significant difference between the control and affective disorder groups, largely explained by the excess of the STin2.9 allele in the unipolar group (chi(2)=10.05, p<0.004 [Bonferroni corrected]). The presence of the allele with nine copies of the repeat was significantly associated with risk of unipolar disorder (odds ratio=6.95 [95% CI 1.8-27.2]). Interpretation This association, for an obvious candidate gene, may provide a critical starting point for an understanding of the likely polygenic contributions towards susceptibility to affective disorder.	ROYAL EDINBURGH & ASSOCIATED HOSP,MRC,BRAIN METAB UNIT,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,CRC LABS,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh				Fink, George/0000-0002-0713-527X; Harmar, Anthony/0000-0002-3838-9264				American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; ANDERSON IM, 1994, J PSYCHOPHARMACOL, V8, P238, DOI 10.1177/026988119400800407; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BOYER WF, 1991, SEROTONIN HYPOTHESIS, P71; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; GOLTSOV AA, 1992, AM J HUM GENET, V51, P627; HUDSON JI, 1990, AM J PSYCHIAT, V147, P552; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; OWENS MJ, 1994, CLIN CHEM, V40, P288; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013	15	460	492	0	28	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					731	733		10.1016/S0140-6736(96)90079-3	http://dx.doi.org/10.1016/S0140-6736(96)90079-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602004				2022-12-24	WOS:A1996TZ98200012
J	Harada, K; Martin, SS; Frankel, AD				Harada, K; Martin, SS; Frankel, AD			Selection of RNA-binding peptides in vivo	NATURE			English	Article							BACTERIOPHAGE-LAMBDA; N-PROTEIN; RECOGNITION; ANTITERMINATION; REQUIRES; RESIDUES	Many principles of sequence-specific DNA recognition have been established over the past decade, largely from structural studies of protein-DNA and drug-DNA complexes. On the basis of these principles, it has been possible to design or select variants of known structural motifs, including zinc-fingers(1-3) and minor groove-binding drugs', that bind desired sequences. Here we describe a strategy, based on transcriptional termination in bacteria, to identify specific RNA-binding peptides using the arginine-rich RNA-binding motifs as a framework. Peptides were isolated from two combinatorial libraries that bind tightly and specifically to the Rev response element of HIV. It appears that a-helical peptides resembling Rev were selected from one library whereas new peptides that probably do not form helices were selected from the other, suggesting that the arginine-rich motif may be a particularly versatile framework for recognizing RNA structures.			Harada, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRANKLIN NC, 1989, J BACTERIOL, V171, P2513, DOI 10.1128/jb.171.5.2513-2522.1989; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JONES KA, 1994, REV BICOH, V63, P717; KJERNS J, 1992, EMBO J, V11, P1119; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Sambrook J., 1989, MOL CLONING; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9	23	110	113	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					175	179		10.1038/380175a0	http://dx.doi.org/10.1038/380175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600395				2022-12-24	WOS:A1996TZ97800056
J	Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN				Verheij, M; Bose, R; Lin, XH; Yao, B; Jarvis, WD; Grant, S; Birrer, MJ; Szabo, E; Zon, LI; Kyriakis, JM; HaimovitzFriedman, A; Fuks, Z; Kolesnick, RN			Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis	NATURE			English	Article							KINASE; DEATH	The induction of programmed cell death, or apoptosis, involves activation of a signalling system, many elements of which remain unknown(1). The sphingomyelin pathway, initiated by hydrolysis of the phospholipid sphingomyelin in the cell membrane to generate the second messenger ceramide(2,3), is thought to mediate apoptosis in response to tumour-necrosis factor (TNF)-alpha(2,3), to Fas ligand(4) and to X-rays(5). It is not known whether it plays a role in the stimulation of other forms of stress-induced apoptosis. Given that environmental stresses also stimulate a stress-activated protein kinase (SAPR/JNK)(6-12), the sphingomyelin and SAPK/ JNK signalling systems may be coordinated in induction of apoptosis. Here we report that ceramide initiates apoptosis through the SAPK cascade and provide evidence for a signalling mechanism that integrates cytokine- and stress-activated apoptosis.	MEM SLOAN KETTERING CANC CTR,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV HEMATOL ONCOL,RICHMOND,VA 23298; NCI,DIV CANC PREVENT & CONTROL,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PEDIAT,DANA FARBER CANC INST,CHILDRENS HOSP,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,MED SERV,DIABET RES LAB,BOSTON,MA 02129	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital			Verheij, Marcel/O-9652-2018	Szabo, Eva/0000-0003-3891-0942				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; BROWN PH, 1994, ONCOGENE, V9, P791; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HAM J, 1995, CELL, V14, P927; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	30	1696	1756	1	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					75	79		10.1038/380075a0	http://dx.doi.org/10.1038/380075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598911				2022-12-24	WOS:A1996TY87700060
J	Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL				Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL			Cryptosporidiosis: An outbreak associated with drinking water despite state-of-the-art water treatment	ANNALS OF INTERNAL MEDICINE			English	Article							SUPPLIES; GIARDIA	Objective: To determine the magnitude and source of an outbreak of cryptosporidiosis among persons with human immunodeficiency virus (HIV) infection and to determine whether the outbreak extended into the immunocompetent population. Design: Matched case-control study and environmental investigation. Setting: Clark County, Nevada. Participants: Adults with HIV infection (36 case-patients with laboratory-confirmed Cryptosporidium parvum infection and 107 controls), matched by physician or clinic and by CD4(+) cell count category. Measurements: Potential risk factors for infection, death rates, and data on water quality. Results: Review of surveillance and microbiology records identified 3 cases of cryptosporidiosis in 1992 (the first year that cryptosporidiosis was reportable in Nevada), 23 cases in 1993, and 78 cases in the first quarter of 1994. Of the 78 laboratory-confirmed cases in the first quarter of 1994, 61 (78.2%) were in HIV-infected adults. Of these 61 adults, 32 (52.5%) had died by 30 June 1994; at least 20 of the 32 (62.5%) had cryptosporidiosis listed on their death certificates. In the case-control study, persons who drank any unboiled tap water were four times more likely than persons who drank only bottled water to have had cryptosporidiosis (odds ratio, 4.22 [95% CI, 1.22 to 14.65]; P = 0.02). For persons with CD4(+) cell counts less than 100 cells/mm(3), the association between tap water and cryptosporidiosis was even stronger (odds ratio, 13.52 [CI, 1.78 to 102.92]; P = 0.01). Additional data indicate that this outbreak also affected persons who were not infected with HIV. No elevated turbidity values or coliform counts and no Cryptosporidium oocysts were found in testing of source (Lake Mead) or finished (treated) water during the study period, but so-called presumptive oocysts were intermittently found after the investigation in samples of source water, filter backwash, and finished water. Conclusions: A cryptosporidiosis outbreak was associated with municipal drinking water, despite state-of-the-art water treatment and water quality better than that required by current federal standards. This outbreak highlights the importance of surveillance for cryptosporidiosis and the need for guidelines for the prevention of waterborne-Cryptosporidium infection among HIV-infected persons.	CDCP, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CLARK CTY DIST HLTH DEPT, LAS VEGAS, NV 89106 USA; CDCP, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; Boyce TG, 1996, PEDIATR INFECT DIS J, V15, P87, DOI 10.1097/00006454-199601000-00019; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P661; CIESIELSKI C, 1995, 2ND NAT C HUM RETR R; CLANCY JL, 1994, J AM WATER WORKS ASS, V86, P89; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; HAAS CN, 1994, 1994 P ANN C AM WAT, P517; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JURANEK DD, 1995, CLIN INFECT DIS, V21, pS57, DOI 10.1093/clinids/21.Supplement_1.S57; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P159; LECHAVALLIER MW, 1994, PREVENTING WATERBORN, P2; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Moore Anne C., 1993, Morbidity and Mortality Weekly Report, V42, P1; MUSIAL CE, 1987, APPL ENVIRON MICROB, V53, P687, DOI 10.1128/AEM.53.4.687-692.1987; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; SORVILLO F, 1994, EPIDEMIOL INFECT, V113, P313, DOI 10.1017/S0950268800051748; SORVILLO FJ, 1994, AM J TROP MED HYG, V51, P326, DOI 10.4269/ajtmh.1994.51.326; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; 1993, 1993 BOOK ASTM STAND, P899; 1989, FED REGISTER, V54, P27486	23	168	174	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					459	+		10.7326/0003-4819-124-5-199603010-00001	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602703				2022-12-24	WOS:A1996TW77300001
J	Glanz, K; Yang, H				Glanz, K; Yang, H			Communicating about risk of infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCEPTIONS; RADON				Glanz, K (corresponding author), UNIV HAWAII,CANC RES CTR HAWAII,PREVENT & CONTROL PROGRAM,1236 LAUHALA ST,HONOLULU,HI 96813, USA.							ALLEN FW, 1987, SCI TECHNOL HUM VAL, V12, P138; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHALK R, 1987, SCI TECHNOL HUM VAL, V12, P11; DUTTON DB, 1987, SCI TECHNOL HUM VAL, V12, P48; FISCHHOFF B, 1987, SCI TECHNOL HUM VAL, V12, P13; Garrett L., 1994, COMING PLAGUE NEWLY; GLANZ K, 1990, HLTH BEHAVIOR HLTH E; GOODMAN RA, 1994, PRINCIPLES PRACTICE, P150; Hovland C. I., 1953, COMMUNICATION PERSUA; KULIK JA, 1987, HEALTH PSYCHOL, V6, P15, DOI 10.1037/0278-6133.6.1.15; Lederberg J., 1992, EMERGING INFECTIONS; McGuire W. J., 1985, HDB SOCIAL PSYCHOL, P233; MCLEROY K R, 1989, Health Education Research, V4, P169, DOI 10.1093/her/4.2.169; PLOUGH A, 1987, SCI TECHNOL HUM VAL, V12, P4; SANDMAN PM, 1993, HEALTH EDUC QUART, V20, P471, DOI 10.1177/109019819302000408; SHORT JF, 1984, AM SOCIOL REV, V49, P711, DOI 10.2307/2095526; SLOVIC P, 1993, RISK ANAL, V13, P675, DOI 10.1111/j.1539-6924.1993.tb01329.x; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Slovic P., 1981, ASSESSMENT PERCEPTIO; van der Veide F, 1992, PSYCHOL HEALTH, V6, P23, DOI DOI 10.1080/08870449208402018; WEINSTEIN ND, 1993, HEALTH PSYCHOL, V12, P324, DOI 10.1037/0278-6133.12.4.324; WEINSTEIN ND, 1993, RISK ANAL, V13, P103, DOI 10.1111/j.1539-6924.1993.tb00733.x; WEINSTEIN ND, 1988, AM J PUBLIC HEALTH, V78, P796, DOI 10.2105/AJPH.78.7.796; WEINSTEIN ND, 1992, HEALTH PSYCHOL, V11, P170, DOI 10.1037/0278-6133.11.3.170; WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431; 1989, IMPROVING RISK COMMU; 1994, MMWR-MORBID MORTAL W, V43, P1	27	23	23	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					253	256		10.1001/jama.275.3.253	http://dx.doi.org/10.1001/jama.275.3.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP282	8604182				2022-12-24	WOS:A1996TP28200037
J	Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C				Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C			A national outbreak of Salmonella enteritidis infections from ice cream	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOODBORNE OUTBREAK; UNITED-STATES; RAW-MILK; CONSUMPTION; GASTROENTERITIS; TRANSMISSION	Background. In September 1994, the Minnesota Department of Health detected an increase in the number of reports of Salmonella enteritidis infections. After a case-control study implicated a nationally distributed brand of ice cream (Schwan's) in the outbreak, the product was recalled and further epidemiologic and microbiologic investigations were conducted. Methods. We defined an outbreak-associated case of S. enteritidis infection as one in which S. enteritidis was cultured from a person who became ill in September or October 1994. We established national surveillance and surveyed customers of the implicated manufacturer, The steps involved in the manufacture of ice cream associated with cases of S. enteritidis infection were compared with those of products not known to be associated with infection matched for the date of manufacture. Cultures for bacteria were obtained from ice cream samples, the ice cream plant, and tanker trailers that had transported the ice cream base (premix) to the plant. Results. estimate that S. enteritidis gastroenteritis developed in 224,000 persons in the United States after they ate Schwan's ice cream. The attack rate for consumers was 6.6 percent. Ice cream associated with infection contained a higher percentage of premix that had been transported by tanker trailers that had carried nonpasteurized eggs immediately before (P = 0.02). S. enteritidis was isolated from 8 of 266 ice cream products (3 percent), but not from environmental samples obtained from the ice cream plant (n = 157) or tanker trailers (n = 204). Conclusions. This nationwide outbreak of salmonellosis was most likely the result of contamination of pasteurized ice cream premix during transport in tanker trailers that had previously carried nonpasteurized liquid eggs containing S. enteritidis. To prevent further outbreaks, food products not destined for repasteurization should be transported in dedicated containers.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,PUBL HLTH LAB,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,EXECUT OFF,MINNEAPOLIS,MN 55440; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30341; MINNESOTA DEPT AGR,DIV DAIRY & FOOD INSPECT,ST PAUL,MN; US FDA,MINNEAPOLIS,MN; OLMSTED CTY HLTH DEPT,ROCHESTER,MN; US FDA,CHICAGO,IL	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)				Belongia, Edward/0000-0001-7478-0415				BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BLASER MJ, 1982, REV INFECT DIS, V4, P1096; *CDCP, 1995, SALM SURV ANN TAB SU; CHALKER RB, 1988, REV INFECT DIS, V10, P111; Ewing WH, 1986, IDENTIFICATION ENTER; GRASMICK A, 1992, CLIN MICROBIOLOGY PR, V1; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3203, DOI 10.1001/jama.268.22.3203; HEDBERG CW, 1993, J INFECT DIS, V167, P107, DOI 10.1093/infdis/167.1.107; HEDBERG CW, 1991, J INFECT DIS, V164, P1135, DOI 10.1093/infdis/164.6.1135; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; HEDBERG CW, 1987, NEW ENGL J MED, V316, P993, DOI 10.1056/NEJM198704163161605; HICKMANBRENNER FW, 1991, J CLIN MICROBIOL, V29, P2817, DOI 10.1128/JCM.29.12.2817-2823.1991; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; OSTERHOLM MT, 1981, NEW ENGL J MED, V304, P24, DOI 10.1056/NEJM198101013040106; OSTERHOLM MT, 1980, AM J EPIDEMIOL, V112, P8, DOI 10.1093/oxfordjournals.aje.a112978; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; TAYLOR A, 1974, AM J EPIDEMIOL, V100, P150, DOI 10.1093/oxfordjournals.aje.a112017; *US FDA, 1992, BACT AN MAN; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; 1994, MMWR-MORBID MORTAL W, V43, P740; 1988, JAMA-J AM MED ASSOC, V259, P2103; 1994, MMWR-MORBID MORTAL W, V43, P669	26	234	241	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1281	1286		10.1056/NEJM199605163342001	http://dx.doi.org/10.1056/NEJM199605163342001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609944				2022-12-24	WOS:A1996UK88000001
J	Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T				Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T			Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2	NATURE			English	Article							RETINOIC ACID; DNA-BINDING	THE retinoic acid-inducible transcription factor AP-2 is expressed in epithelial and neural crest cell lineages during murine development(1-5). AP-2 can regulate neural and epithelial gene transcription, and is associated with overexpression of c-erbB-2 in human breast-cancer cell lines(4-6). To ascertain the importance of AP-2 for normal development, we have derived mice containing a homozygous disruption of the AP-2 gene. These AP-2-null mice have multiple congenital defects and die at birth, In particular, the AP-2 knockout mice exhibit anencephaly, craniofacial defects and thoraco-abdominoschisis. Skeletal defects occur in the head and trunk region, where many bones are deformed or absent. Analysis of these mice earlier in embryogenesis indicates a failure of cranial neural-tube closure and defects in cranial ganglia development. We have shown that AP-2 is a fundamental regulator of mammalian craniofacial development.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA; HARVARD UNIV, BIOL LABS, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University; Harvard University; Howard Hughes Medical Institute; Yale University; Yale University			McMahon, Andrew P/ABE-7520-2020					BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHEN JM, 1952, J ANAT, V86, P373; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COPP AJ, 1994, CIBA F SYMP, V181, P118; DAVIES AF, 1995, HUM MOL GENET, V4, P121; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; GUNTHER T, 1994, DEVELOPMENT, V120, P3119; Hall B. K., 1988, NEURAL CREST; HALL BK, 1986, J EMBRYOL EXP MORPH, V93, P133; KOTCH LE, 1992, AM J MED GENET, V44, P168, DOI 10.1002/ajmg.1320440210; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARK M, 1993, DEVELOPMENT, V119, P319; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY G, 1994, NEURAL TUBE DEFECTS, P55; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Warren G, 1996, GENOMICS, V31, P234, DOI 10.1006/geno.1996.0037; WEI X, 1993, AM J MED GENET, V47, P862, DOI 10.1002/ajmg.1320470613; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	30	497	515	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					238	241		10.1038/381238a0	http://dx.doi.org/10.1038/381238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622766				2022-12-24	WOS:A1996UL24900055
J	Driver, J				Driver, J			Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading	NATURE			English	Article								MECHANISMS of human attention allow selective processing of just the relevant events among the many stimuli bombarding our senses(1). Most laboratory studies examine attention within just a single sense, but in the real world many important events are specified multimodally, as in verbal communication. Speech comprises visual lip movements as well as sounds, and lip-reading contributes to speech perception. even for listeners with good hearing, by a process of audiovisual integration(2). Such examples raise the problem of how we coordinate our spatial attention across the sensory modalities, to select sights and sounds from a common source for further processing. Here we show that this problem is alleviated by allowing some cross-modal matching before attentional selection is completed. Cross modal matching can lead to an illusion, whereby sounds are mislocated at their apparent visual source(3); this crossmodal illusion can enhance selective spatial attention to speech sounds.			Driver, J (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,MALET ST,LONDON WC1E 7HX,ENGLAND.		Driver, Jon/A-4779-2010					BERTELSON P, 1976, PERCEPT PSYCHOPHYS, V19, P531, DOI 10.3758/BF03211222; Blauert J., 1983, SPATIAL HEARING; CHERRY EC, 1953, J ACOUST SOC AM, V25, P975, DOI 10.1121/1.1907229; DRIVER J, 1994, ATTENTION PERFORM, V15, P311; MASSARO DW, 1995, CURR DIR PSYCHOL SCI, V4, P104, DOI 10.1111/1467-8721.ep10772401; MASSARO DW, 1987, PERSPECTIVES PERCEPT, P273; Massaro DW, 1987, SPEECH PERCEPTION EA; MCGURK H, 1976, NATURE, V263, P747; Naatanen R., 2018, ATTENTION BRAIN FUNC; RADEAU M, 1994, CAH PSYCHOL COGN, V13, P3; REISBERG D, 1978, ACTA PSYCHOL, V42, P331, DOI 10.1016/0001-6918(78)90007-0; WITKIN HA, 1952, J EXP PSYCHOL, V43, P58, DOI 10.1037/h0055889	12	197	200	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					66	68		10.1038/381066a0	http://dx.doi.org/10.1038/381066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UJ053	8609989				2022-12-24	WOS:A1996UJ05300056
J	Fine, KD				Fine, KD			The prevalence of occult gastrointestinal bleeding in celiac sprue	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTEN-FREE DIET; IRON-DEFICIENCY; REFRACTORY SPRUE; DISEASE; DIARRHEA; CHILDREN; ANEMIA	Background. Iron deficiency complicating celiac sprue is usually attributed to the malabsorption of dietary iron or the loss of iron from the intestinal mucosa, There has been little investigation of the role of intestinal loss of blood in patients with this condition, The purpose of this study was to determine the prevalence of occult gastrointestinal bleeding in patients with celiac sprue. Methods. We tested one 48- or 72-hour stool collection from each of 8 patients with partial villous atrophy and 28 patients with total villous atrophy using a guaiac-impregnated card (Hemoccult). Serving as controls were 18 normal subjects, each studied before and during laxative-induced diarrhea; 17 patients with idiopathic chronic diarrhea; 63 patients with microscopic colitis; 23 patients with pancreatic steatorrhea; and 7 patients with treated celiac sprue who had normal intestinal histologic features, All the patients underwent a diagnostic workup that included esophagogastroduodenoscopy, colonoscopy, and barium radiography of the small bower. Results. Positive Hemoccult tests were infrequent in each of the control groups, occurring in 0 to 8 percent of the subjects, whereas 2 of the 8 patients with partial villous atrophy (25 percent) and 15 of the 28 patients with total villous atrophy (54 percent) had positive tests, When the patients with total villous atrophy were classified according to their subsequent responses to a gluten-free diet, 7 of the 17 who were responsive to gluten withdrawal (41 percent) were Hemoccult-positive, as compared with 8 of the 11 who did not respond to the diet (73 percent). Conclusions. Occult gastrointestinal bleeding can be detected in about half of patients with celiac sprue and should be added to the list of factors that can contribute to iron deficiency in patients with this disorder. (C) 1996, Massachusetts Medical Society.			Fine, KD (corresponding author), BAYLOR UNIV, MED CTR, DEPT GASTROINTESTINAL RES, 3500 GASTON AVE, DALLAS, TX 75246 USA.				NIDDK NIH HHS [5-R01-DK37172-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; BADENOCH J, 1954, BLOOD, V9, P123, DOI 10.1182/blood.V9.2.123.123; BADENOCH J, 1960, LANCET, V1, P192; BONAMICO M, 1987, J PEDIATR GASTR NUTR, V6, P702, DOI 10.1097/00005176-198709000-00007; BRADY CE, 1994, J CLIN GASTROENTEROL, V18, P130, DOI 10.1097/00004836-199403000-00010; COOKE WT, 1984, COELIAC DISEASE, P128; COOPER BT, 1987, Q J MED, V63, P269; DEPLA ACTM, 1990, HEPATO-GASTROENTEROL, V37, P90; DUBOIS RN, 1989, JAMA-J AM MED ASSOC, V262, P935, DOI 10.1001/jama.262.7.935; GIULIANI ER, 1961, J NUCL MED, V2, P297; GOSTOUT CJ, 1993, GASTROINTEST ENDOSC, V39, P76, DOI 10.1016/S0016-5107(93)70018-8; HOFFBRAND AV, 1974, CLIN GASTROENTEROL, V3, P71; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, DYN NUTR R, V2, P105; KAGNOFF MF, 1991, TXB GASTROENTEROLOGY, P1503; KILPATRICK ZM, 1969, J AMER MED ASSOC, V208, P999, DOI 10.1001/jama.208.6.999; KOSNAI I, 1979, ARCH DIS CHILD, V54, P375, DOI 10.1136/adc.54.5.375; MARSH MN, 1993, EUR J GASTROEN HEPAT, V5, P784; MCGUIGAN JE, 1964, GASTROENTEROLOGY, V47, P636; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEVENS D, 1979, ARCH DIS CHILD, V54, P648, DOI 10.1136/adc.54.8.648; SUTTON DR, 1970, LANCET, V2, P387; SYLWESTROWICZ T, 1989, AM J GASTROENTEROL, V84, P763; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; WEBB MGT, 1967, BMJ-BRIT MED J, V2, P151, DOI 10.1136/bmj.2.5545.151; WHITEHEAD R, 1965, J CLIN PATHOL, V18, P110, DOI 10.1136/jcp.18.1.110	26	100	104	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1163	1167		10.1056/NEJM199605023341804	http://dx.doi.org/10.1056/NEJM199605023341804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602182				2022-12-24	WOS:A1996UG83100004
J	Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J				Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J			Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I	NATURE			English	Article							SPLICING FACTOR; CONSERVED FAMILY; RNA; DOMAINS; REGULATORS; EXPRESSION; PARTICLES; CLONING; U1-70K	SEVERAL metazoan splicing factors are characterized by ribonucleoprotein (RNP) consensus sequences and arginine-serine repeats (RS domain)(1-8) which are essential for their function in splicing(5,9,10). These include members of the SR-protein family (SC35, SF2/ASF), the U1 small nuclear (sn)RNP protein (U1-70K) and the U2 snRNP auxiliary factor (U2AF). SR proteins are phosphorylated in vivo(11) and the phosphorylation state of U1-70K's RS domain influences its splicing activity(12). Here we report the purification of a protein kinase that is specific for SR proteins and show that it is DNA topoisomerase I. This enzyme lacks a canonical ATP-binding motif hut hinds ATP with a dissociation constant of 50 nM. Camptothecin and derivatives, known to be specific inhibitors of DNA topoisomerase I, strongly inhibit the kinase activity in the presence of DNA and affect the phosphorylation state of SR proteins. Thus, DNA topoisomerase I may well be one of the SR protein kinases operating in vivo.	CNRS,CTR RECH BIOCHIM MACROMOLEC,LP 9008,INSERM,U249,F-34033 MONTPELLIER 1,FRANCE; RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,UNITE CANCEROL,DEPT BIOL,F-94403 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Sanofi-Aventis			DIVITA, GILLES/AAV-9214-2021; Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; riou, jean-francois/0000-0002-0055-6506; Labourier, Emmanuel/0000-0001-8010-0674; Tazi, Jamal/0000-0002-1949-8748				BACH M, 1990, METHOD ENZYMOL, V181, P232; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; COTWILL K, 1996, EMBO J, V15, P265; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DIVITA G, 1993, J BIOL CHEM, V268, P13178; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; MENNO A, 1993, NATURE, V365, P227; Moore M., 1993, RNA WORLD, P303; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P133; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053; ZIEVE G, 1981, J MOL BIOL, V145, P501, DOI 10.1016/0022-2836(81)90542-8; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	30	279	281	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					80	82		10.1038/381080a0	http://dx.doi.org/10.1038/381080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609994				2022-12-24	WOS:A1996UJ05300061
J	Khunti, K				Khunti, K			A method of creating a death register for general practice	BRITISH MEDICAL JOURNAL			English	Article							AUDIT				Khunti, K (corresponding author), UNIV LEICESTER,ELI LILLY NATL CLIN AUDIT CTR,DEPT GEN PRACTICE & PRIMARY HLTH CARE,LEICESTER LE5 4PW,LEICS,ENGLAND.		/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099				BERLIN A, 1993, BRIT J GEN PRACT, V43, P70; BLACK DA, 1984, BMJ-BRIT MED J, V288, P1127, DOI 10.1136/bmj.288.6424.1127; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					952	952						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616311				2022-12-24	WOS:A1996UF65900023
J	Senard, JM; Montastruc, P; Herxheimer, A				Senard, JM; Montastruc, P; Herxheimer, A			Early warnings about drugs - From the stock market	LANCET			English	Editorial Material											Senard, JM (corresponding author), FAC MED TOULOUSE,SERV PHARMACOL MED & CLIN,TOULOUSE,FRANCE.			Senard, Jean-Michel/0000-0001-7679-1281				COSNARD D, 1993, ECHOS           1026, P12; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; NODELANGLOIS F, 1995, LIBERATION      0729, P20; 1995, SCRIP, V2048, P16; 1993, INVESTIR, V1032, P18; 1994, ECHOS           0817, P7; 1995, INVESTIR, V1095, P14	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					987	988		10.1016/S0140-6736(96)90141-5	http://dx.doi.org/10.1016/S0140-6736(96)90141-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606610				2022-12-24	WOS:A1996UF38000006
J	Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP				Rothwell, PM; Wroe, SJ; Slattery, J; Warlow, CP			Is stroke incidence related to season or temperature?	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; RATES	Background A winter excess of ischaemic stroke has been found in mortality and hospital-based studies. It is often assumed that this is due to seasonal variation in stroke incidence and several pathophysiological explanations have been proposed. We studied the incidence of stroke in relation to season and outside temperature. Methods The data came from a community-based study of first ever in a lifetime stroke in a defined population of about 105 000. 675 such strokes were registered over four years and the month of onset was analysed separately for cerebral infarction, primary intracerebral haemorrhage, and subarachnoid haemorrhage. Findings There was no significant seasonal variation. The incidence of primary intracerebral haemorrhage was increased at low temperatures, but there was no significant relation between the incidence of ischaemic stroke or subarachnoid haemorrhage and temperature. Interpretation The widely reported winter excess of ischaemic strokes may be an artifact due to referral bias in hospital-based studies and increased case fatality during the winter in mortality studies.	IPSWICH HOSP,DEPT NEUROL,IPSWICH,SUFFOLK,ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital	Rothwell, PM (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALLEN CMC, 1983, Q J MED, V52, P515; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; HABERMAN S, 1981, J NEUROL SCI, V52, P25, DOI 10.1016/0022-510X(81)90131-3; KELLYHAYES M, 1995, STROKE, V26, P1343, DOI 10.1161/01.STR.26.8.1343; PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0; RICCI S, 1992, NEUROEPIDEMIOLOGY, V11, P59, DOI 10.1159/000110913; ROTHWELL PM, 1994, LANCET, V344, P1161, DOI 10.1016/S0140-6736(94)90671-8; SOBEL E, 1987, STROKE, V18, P38, DOI 10.1161/01.STR.18.1.38; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; WALTER SD, 1975, BRIT J PREV SOC MED, V29, P18; *WHO, 1977, WHO MAN MORT AN, P212; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	14	127	130	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					934	936		10.1016/S0140-6736(96)91415-4	http://dx.doi.org/10.1016/S0140-6736(96)91415-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598757				2022-12-24	WOS:A1996UD59100010
J	AbouElela, S; Igel, H; Ares, M				AbouElela, S; Igel, H; Ares, M			RNase III cleaves eukaryotic preribosomal RNA at a U3 snoRNP-dependent site	CELL			English	Article							EXTERNAL TRANSCRIBED SPACER; PRECURSOR RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEASE-III; PROCESSING EVENT; POLYMERASE-I; S-POMBE; YEAST	A yeast gene homologous to bacterial RNase III (RNT1) encodes a double-strand-specific endoribonuclease essential for ribosome synthesis. Two rRNA processing events are blocked in cells temperature sensitive for RNT1: cleavage at the snoRNA-dependent A0 site in the 5' ETS and cleavage in the 3' ETS. Recombinant RNT1 protein accurately cleaves a synthetic 5' ETS RNA at the AO site in vitro, in the absence of snoRNA or other factors. A synthetic 3' ETS substrate is specifically cleaved at a site 21 nt downstream of the 3' end of 28S rRNA. These observations show that a protein endonuclease collaborates with snoRNAs in eukaryotic rRNA processing and exclude a catalytic role for snoRNAs at certain pre-rRNA cleavage sites.			AbouElela, S (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, DEPT BIOL, CTR MOL BIOL RNA, SANTA CRUZ, CA 95064 USA.			Ares, Manny/0000-0002-2552-9168	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BAYEV AA, 1980, NUCLEIC ACIDS RES, V8, P4919, DOI 10.1093/nar/8.21.4919; BELTRAME M, 1994, NUCLEIC ACIDS RES, V22, P4057, DOI 10.1093/nar/22.20.4057; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; COURT D, 1993, CONTROL MRNA STABILI, P70; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GOOD L, 1994, J BIOL CHEM, V269, P22169; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLEMENZ R, 1980, NUCLEIC ACIDS RES, V8, P2679, DOI 10.1093/nar/8.12.2679; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; NICHOLSON AW, 1988, NUCLEIC ACIDS RES, V16, P1577, DOI 10.1093/nar/16.4.1577; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; Perbal B., 1988, PRACTICAL GUIDE MOL; POTTER S, 1995, SCIENCE, V268, P1056, DOI 10.1126/science.7538698; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTONDO G, 1995, MOL GEN GENET, V247, P698, DOI 10.1007/BF00290401; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SHUMARD CM, 1988, J BIOL CHEM, V263, P19346; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P5179, DOI 10.1093/nar/8.22.5179; VENEMA J, 1995, EMBO J, V14, P4883, DOI 10.1002/j.1460-2075.1995.tb00169.x; Wells SE, 1996, GENE DEV, V10, P220, DOI 10.1101/gad.10.2.220; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; YEH LCC, 1992, J MOL BIOL, V228, P827, DOI 10.1016/0022-2836(92)90867-J; YIP MT, 1989, J BIOL CHEM, V264, P4045	61	203	215	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					115	124		10.1016/S0092-8674(00)81087-9	http://dx.doi.org/10.1016/S0092-8674(00)81087-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620530	Bronze, Green Submitted			2022-12-24	WOS:A1996UE55900014
J	Sengupta, P; Chou, JH; Bargmann, CI				Sengupta, P; Chou, JH; Bargmann, CI			odr-10 encodes a seven transmembrane domain olfactory receptor required for responses to the odorant diacetyl	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SENSITIVE ADENYLATE-CYCLASE; C-ELEGANS; PROTEIN; EXPRESSION; EPITHELIUM; SEQUENCE; GENOME; SYSTEM; TRANSDUCTION	Olfactory signaling is initiated by interactions between odorants and olfactory receptors. We show that the C. elegans odr-10 gene is likely to encode a receptor for the odorant diacetyl. odr-10 mutants have a specific defect in chemotaxis to diacetyl, one of several odorants detected by the AWA olfactory neurons. odr-10 encodes a predicted seven transmembrane domain receptor; a green fluorescent protein-tagged Odr-10 protein is localized to the AWA sensory cilia. odr-10 expression is regulated by odr-7, a transcription factor implicated in AWA sensory specification. Expression of odr-10 from a heterologous promoter directs behavioral responses to diacetyl, but not to another odorant detected by the AWA neurons. These results provide functional evidence for a specific interaction between an olfactory receptor protein and its odorant ligand.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,GENET PROGRAM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526; Bargmann, Cornelia/0000-0002-8484-0618; Chou, Joseph/0000-0002-3138-0777				AATSINKI JT, 1994, BIOTECHNIQUES, V16, P282; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOEKHOFF I, 1994, J NEUROSCI, V14, P3304; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1994, GENETICS, V137, P987; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVANOVA TT, 1993, J GEN PHYSIOL, V102, P1085, DOI 10.1085/jgp.102.6.1085; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KANG JS, 1995, J NEUROPHYSIOL, V73, P172, DOI 10.1152/jn.1995.73.1.172; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; SIDDIQI O, 1987, TRENDS GENET, V3, P137, DOI 10.1016/0168-9525(87)90204-6; SINGER MS, 1995, NATURE, V377, P19, DOI 10.1038/377019b0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	55	397	418	2	70	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					899	909		10.1016/S0092-8674(00)81068-5	http://dx.doi.org/10.1016/S0092-8674(00)81068-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601313	Bronze			2022-12-24	WOS:A1996UC38100011
J	[Anonymous]				[Anonymous]			Infected blood in Japan	NATURE			English	Editorial Material																		1996, NATURE, V379, P663; 1996, NATURE, V379, P760	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598891				2022-12-24	WOS:A1996TY87700002
J	Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ				Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ			Crystal structure of a yeast TFIIA/TBP/DNA complex	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TFIIA; INITIATION; SUBUNITS; IDENTIFICATION; GENES; EXPRESSION	The X-ray crystal structure of the transcription factor IIA (TFIIA) in complex with the TATA-box-binding protein (TBP) and TATA-element DNA is presented at 2.5 Angstrom resolution. TFIIA is composed of a beta-barrel and a four-helix bundle motif that together have a boot-like appearance. The beta-barrel extends the TBP beta-sheet and bridges over the DNA major groove immediately upstream of the TATE box. The four-helix bundle contributes substantially to the surface of the complex available for interaction with additional transcription factors.	ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50	50	257	262	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					127	134		10.1038/381127a0	http://dx.doi.org/10.1038/381127a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610010				2022-12-24	WOS:A1996UK13900040
J	Cleland, JGF; Swedberg, K				Cleland, JGF; Swedberg, K			Carvedilol for heart failure, with care	LANCET			English	Editorial Material							SURVIVAL		GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN; UNIV GLASGOW,CLIN RES INITIAT HEART FAILURE,GLASGOW G61 1BD,LANARK,SCOTLAND	Sahlgrenska University Hospital; University of Gothenburg; University of Glasgow			Swedberg, Karl/B-2475-2008; Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016				Bristow MR, 1995, CIRCULATION S1, V92, P142; Cohn Jay N., 1996, Journal of the American College of Cardiology, V27, p169A; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLUCCI WS, 1995, CIRCULATION, V92, P394; CUBEDDU LX, 1987, CLIN PHARMACOL THER, V41, P31, DOI 10.1038/clpt.1987.6; Fowler Michael B., 1996, Journal of the American College of Cardiology, V27, p169A; HELD P, 1993, AM J CARDIOL, V71, pC39, DOI 10.1016/0002-9149(93)90085-Q; PACKER M, 1995, CIRCULATION S1, V92, P143; PACKER M, 1995, CIRCULATION S1, V92, P142; SACKNERBERNSTEI.J, 1995, CIRCULATION S1, V92, P395; SUNG CP, 1993, J CARDIOVASC PHARM, V21, P221, DOI 10.1097/00005344-199302000-00006; SWEDBERG K, 1979, LANCET, V1, P1374; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; 1995, CIRCULATION, V92, P394; 1995, CIRCULATION, V92, P212	15	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1201		10.1016/S0140-6736(96)90729-1	http://dx.doi.org/10.1016/S0140-6736(96)90729-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622445				2022-12-24	WOS:A1996UJ59700004
J	Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ				Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ			Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SKIN; QUEENSLAND; EDUCATION; CAMPAIGN	Objective-To describe recent trends in mortality from melanoma in Australia. Design-An analysis of trends in age standardised and age and sex specific mortalities by year of death and median year of birth (cohort). Setting-Australia. Subjects-All deaths from melanoma registered in Australia between 1931 and 1994. Results-Melanoma mortality rose steadily from 1931 to 1985. From 1959 the annual rate of increase was 6.3% in men and 2.9% in women, resulting in mortalities of 4.82 and 2.51 per 100 000 person years in 1985 and 1989, respectively. Mortalities for both sexes seem to have plateaued from June 1985 onwards. In 1990-4 the rate rose by 3.7% in men to 5.00 per 100 000 and in women it fell by 5.2% to 2.38 per 100 000. The non-significant increase after 1985 in mortality in men was restricted to those aged over 70 years of age, whereas the fall in rates in women was mostly in those aged under 55 years. This pattern was generally reflected in the state trends, though with some variation: rates for women in Queensland had peaked in the late 1970s; while rates for men in New South Wales continued to rise in 1990-4, placing them above those for Queensland. Examination of mortalities specific for age, period, and cohort for Australia as a whole showed several salient features. Rates in men rose steeply in cohorts born before about 1930; were stable in cohorts born between 1930 and 1950; and fell in more recent cohorts. Rates in women showed similar changes but about five years earlier. Conclusion-Melanoma mortality in Australia peaked in about 1985 and has now plateaued. On the basis of trends in cohorts it can be expected to fall in coming years.	AUSTRALIAN INST HLTH & WELF, ACTON, ACT 2061, AUSTRALIA; UNIV NEWCASTLE, FAC MED & HLTH SCI, CALLAGHAN, NSW 2308, AUSTRALIA	University of Newcastle	Giles, GG (corresponding author), ANTICANC COUNCIL VICTORIA, CANC EPIDEMIOL CTR, CARLTON, VIC 3053, AUSTRALIA.			Giles, Graham/0000-0003-4946-9099				ARMSTRONG BK, 1994, CANCER SURV, V20, P219; ARMSTRONG BK, 1987, MED J AUSTRALIA, V147, P150; Beardmore G. L., 1972, MELANOMA SKIN CANCER, P39; BONETT A, 1989, MED J AUSTRALIA, V151, P502, DOI 10.5694/j.1326-5377.1989.tb128496.x; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; COATES M, 1994, CANC NEW S WALES INC; COOKE K, 1992, NEW ZEAL MED J, V105, P303; CRISTOFOLINI M, 1993, J DERMATOL SURG ONC, V19, P117, DOI 10.1111/j.1524-4725.1993.tb03439.x; Davis N C, 1966, Med J Aust, V1, P643; ELWOOD JM, 1989, T MENZIES F, V15, P131; GILES GG, 1994, CANC FORUM, V18, P12; GILES GG, 1994, CANSTAT SKIN CANC; Green A, 1982, Australas J Dermatol, V23, P105, DOI 10.1111/j.1440-0960.1982.tb00739.x; Hill D, 1993, Eur J Cancer Prev, V2, P447; HOLMAN CDJ, 1980, INT J CANCER, V26, P703, DOI 10.1002/ijc.2910260602; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; JELFS PL, 1994, MED J AUSTRALIA, V161, P182, DOI 10.5694/j.1326-5377.1994.tb127379.x; JONES ME, 1992, MED J AUSTRALIA, V157, P373, DOI 10.5694/j.1326-5377.1992.tb137243.x; KHLAT M, 1992, AM J EPIDEMIOL, V135, P1103, DOI 10.1093/oxfordjournals.aje.a116210; KRICKER A, 1993, 13 IARC INT AG RES C; LANCASTER H. O., 1956, MED JOUR AUSTRALIA I, V43, P1082; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCCARTHY WH, 1980, MED J AUSTRALIA, V2, P137, DOI 10.5694/j.1326-5377.1980.tb76944.x; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897; SWERDLOW AJ, 1990, ANN NY ACAD SCI, V609, P235, DOI 10.1111/j.1749-6632.1990.tb32071.x; THORN M, 1992, BRIT J CANCER, V66, P563, DOI 10.1038/bjc.1992.315; VENZON DJ, 1984, AM J EPIDEMIOL, V119, P62, DOI 10.1093/oxfordjournals.aje.a113726; [No title captured]	33	157	160	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	1996	312	7039					1121	1125						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620126				2022-12-24	WOS:A1996UK06900019
J	Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E				Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E			Nerve growth factor is an autocrine survival factor for memory B lymphocytes	CELL			English	Article							MESSENGER-RNA; REGIONAL DISTRIBUTION; TRK PROTOONCOGENE; FACTOR RECEPTORS; FACTOR FAMILY; CELL MEMORY; FACTOR NGF; BCL-2; EXPRESSION; AFFINITY	Production of nerve growth factor (NGF) was assessed in cultures of human T and B lymphocytes and macrophages. NGF was constitutively produced by B cells only, which also expressed surface p140(trk-A) and p75(NGFR) molecules and hence efficiently bound and internalized the cytokine. Neutralization of endogenous NGF caused disappearance of Bcl-2 protein and apoptotic death of resting lymphocytes bearing surface IgG or IgA, a population comprising memory cells, while surface IgM/IgD ''virgin'' B lymphocytes were not affected. In vivo administration of neutralizing anti-NGF antibodies caused strong reduction in the titer of specific lgG in mice immunized with tetanus toroid, nitrophenol, or arsonate and reduced numbers of surface IgG or IgA B lymphocytes. Thus, NGF is an autocrine survival factor for memory B lymphocytes.	UNIV ROMA TOR VERGATA,DEPT EXPTL MED,I-00133 ROME,ITALY; UNIV FLORENCE,DEPT CLIN PHYSIOPATHOL,I-50139 FLORENCE,ITALY; CNR,INST NEUROBIOL,I-00185 ROME,ITALY; NATL INST CANC RES,SERV CLIN PATHOL,I-16132 GENOA,ITALY	University of Rome Tor Vergata; University of Florence; Consiglio Nazionale delle Ricerche (CNR); University of Genoa; IRCCS AOU San Martino IST			Rubartelli, Anna/AAA-1259-2021; Nencioni, Lucia/K-5988-2016; lucibello, maria/AAI-1417-2020; Torcia, Maria Gabriella G/K-1840-2018; Bracci-Laudiero, Luisa/H-1541-2013; Bracci Laudiero, Luisa/AAC-3521-2022	Nencioni, Lucia/0000-0003-4427-4823; Torcia, Maria Gabriella G/0000-0003-4740-4646; Bracci-Laudiero, Luisa/0000-0002-1682-6371; Cozzolino, Federico/0000-0002-2800-640X				ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARBACID M, 1994, J NEUROBIOL, V25, P386; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRODIE C, 1992, J IMMUNOL, V148, P3492; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DICOU E, 1993, NEUROREPORT, V5, P321, DOI 10.1097/00001756-199312000-00036; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; EAGER KB, 1991, ONCOGENE, V6, P819; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10981; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HAWKINS CJ, 1994, IMMUNOL REV, V142, P127, DOI 10.1111/j.1600-065X.1994.tb00886.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KATAYAMA N, 1993, BLOOD, V81, P610; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MCCONKEY DJ, 1989, FASEB J, V3, P1844; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NISONOFF A, 1967, METHODS IMMUNOLOGY I, P1; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROMAGNANI S, 1982, J IMMUNOL, V129, P596; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SODERSTROM S, 1990, J NEUROSCI RES, V27, P665, DOI 10.1002/jnr.490270427; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; UEYAMA T, 1993, J HYPERTENS, V11, P1061, DOI 10.1097/00004872-199310000-00009; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2840; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	62	357	374	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					345	356		10.1016/S0092-8674(00)81113-7	http://dx.doi.org/10.1016/S0092-8674(00)81113-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616890	Green Published, Bronze			2022-12-24	WOS:A1996UK14000008
J	Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA				Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA			Evidence for a new step in telomere maintenance	CELL			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; QUADRUPLEX STRUCTURE; MACRONUCLEAR DNA; BINDING PROTEIN; YEAST TELOMERE; 3' TERMINUS; S-PHASE; REPLICATION; RECOMBINATION	The strand of telomeric DNA that runs 5'3' toward a chromosome end is typically G rich. Telomerase-generated G tails are expected at one end of individual DNA molecules. Saccharomyces telomeres acquire TG(1-3) tails late in S phase. Moreover, the telomeres of linear plasmids can interact when the TG(1-3) tails are present. Molecules that mimic the structures predicted for telomere replication intermediates were generated in vitro. These in vitro generated molecules formed telomere-telomere interactions similar to those on molecules isolated from yeast, but only if both ends that interacted had a TG(1-3) tail. Moreover, TG(1-3), tails were generated in vivo in cells lacking telomerase. These data suggest a new step in telomere maintenance, cell cycle-regulated degradation of the C(1-3)A strand, which can generate a potential substrate for telomerase and telomere-binding proteins at every telomere.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	Wellinger, RJ (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE, PQ J1H 5N4, CANADA.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEELER T, 1994, J BIOL CHEM, V269, P7279; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER XCW, 1995, TELOMERES, V29, P35; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HENIKOFF S, 1987, GENETICS, V117, P711; HOBZA P, 1987, J AM CHEM SOC, V109, P1302, DOI 10.1021/ja00239a003; HUANG KN, 1993, MOL CELL BIOL, V13, P3125, DOI 10.1128/MCB.13.6.3125; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KERR C, 1972, J BIOL CHEM, V247, P311; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SADOWSKI PD, 1985, NUCLEASES, P23; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SOMMERVILLE FW, 1987, ELECT MICROSCOPY MOL; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNDQUIST WI, 1993, CURR BIOL, V3, P893, DOI 10.1016/0960-9822(93)90229-H; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUNDQUIST WI, 1990, NUCL ACIDS MOL BIOL, V5, P1; SUTCLIFFE JG, 1978, NUCLEIC ACIDS RES, V5, P2721, DOI 10.1093/nar/5.8.2721; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1992, CHROMOSOMA, V102, pS150, DOI 10.1007/BF02451800; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WELLINGER RJ, 1993, CHROMOSOME SEGRATI H, V72, P133; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILEY EA, 1995, GENETICS, V139, P67; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	73	258	264	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					423	433		10.1016/S0092-8674(00)81120-4	http://dx.doi.org/10.1016/S0092-8674(00)81120-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616897	Bronze			2022-12-24	WOS:A1996UK14000015
J	Buckley, NA; Smith, AJ				Buckley, NA; Smith, AJ			Evidence-based medicine in toxicology: Where is the evidence?	LANCET			English	Editorial Material											Buckley, NA (corresponding author), UNIV NEWCASTLE,DISCIPLINE CLIN PHARMACOL,FAC MED,UNIV DR,CALLAGHAN,NSW 2308,AUSTRALIA.		Smith, Ashley/GZB-0298-2022; Buckley, Nicholas A/D-4030-2012	Buckley, Nicholas A/0000-0002-6326-4711				Baselt R.C., 1989, DISPOSITION TOXIC DR; BUCKLEY NA, 1995, J TOXICOL-CLIN TOXIC, V33, P199, DOI 10.3109/15563659509017984; BUCKLEY NA, 1994, LANCET, V343, P159, DOI 10.1016/S0140-6736(94)90940-7; BUCKLEY NA, 1995, BMJ-BRIT MED J, V310, P219, DOI 10.1136/bmj.310.6974.219; BUCKLEY NA, 1994, MED J AUSTRALIA, V160, P188, DOI 10.5694/j.1326-5377.1994.tb126600.x; BUCKLEY NA, 1995, MED J AUSTRALIA, V162, P190, DOI 10.5694/j.1326-5377.1995.tb126020.x; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; DEBARD ML, 1981, CLIN TOXICOL, V18, P1117, DOI 10.3109/15563658108990341; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; FISHER WL, 1993, HDB MED TOXICOLOGY; HOOPER RG, 1979, JACEP-J AM COLL EMER, V8, P98, DOI 10.1016/S0361-1124(79)80150-1; JACOBSEN D, 1984, HUM TOXICOL, V3, P93, DOI 10.1177/096032718400300203; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; KOPPEL C, 1987, HUM TOXICOL, V6, P355, DOI 10.1177/096032718700600503; MATTHEW H, 1968, BMJ-BRIT MED J, V2, P101, DOI 10.1136/bmj.2.5597.101; NORMANN S, 1992, POISINDEX R SYSTEM, V86; POND SM, 1995, MED J AUSTRALIA, V162, P174, DOI 10.5694/j.1326-5377.1995.tb126015.x; RESCH F, 1982, KLIN PADIATR, V194, P42, DOI 10.1055/s-2008-1033768; SACKETT DL, 1989, CLIN EPIDEMIOLOGY BA; von Muhlendahl K E, 1978, Monatsschr Kinderheilkd, V126, P123; WEISSMAN RS, 1994, GOLDFRANKS TOXICOLOG; WINEK CL, 1977, CLIN TOXICOL, V11, P287, DOI 10.3109/15563657708989842; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001	23	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1167	1169		10.1016/S0140-6736(96)90615-7	http://dx.doi.org/10.1016/S0140-6736(96)90615-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609755				2022-12-24	WOS:A1996UG75500017
J	Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM				Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM			Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; IMMUNE-RESPONSE; FACTOR-ALPHA; MYOCARDITIS; RNA	Background Two important features of dilated cardiomyopathy (DCM) are low myocardial contractility and risk of thromboembolism. Nitric oxide (NO) exerts a negative inotropic effect on the myocardium and is produced by NO-synthase, an inducible form of which (iNOS) is stimulated by tumour necrosis factor (TNF-alpha). Accordingly, we hypothesised that locally produced TNF-alpha might contribute to the pathogenesis and complications of DCM by inducing iNOS in the heart. Methods iNOS and TNF-alpha were quantified by histochemistry and computerised image analysis in explanted heart tissues or myocardial biopsy material from patients with DCM (n=21) or ischaemic heart disease (IHD; n=10) and from normal donor hearts (n=9). Findings Immunoreactivity for iNOS was strong in myocytes of DCM hearts, particularly in areas adjacent to the endocardium, and moderately intense in blood vessels of DCM and IHD hearts, The median optical density of the immunostaining for iNOS was greater in cardiac myocytes of patients with DCM (0.86, range 0.21 to 1.29) than in those from patients with IHD (0.20, range 0.095 to 0.26) (p<0.01) or controls (0.01, range 0.001 to 0.02) (p<0.001). Staining for TNF-alpha was observed in the vascular endothelium and smooth muscle cells of patients with DCM but not in IHD or control tissues. Interpretation The localisation of iNOS and TNF-alpha within cardiac tissues in DCM suggests that TNF-alpha contributes to both the low contractility and the tendency to thromboembolism in these patients.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIOL,LONDON,ENGLAND; HAREFIELD HOSP,HEART SCI CTR,HAREFIELD UB9 6JH,MIDDX,ENGLAND	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital								ARBUSTINI E, 1989, AM J CARDIOL, V64, P991, DOI 10.1016/0002-9149(89)90796-0; BOWLES NE, 1989, CIRCULATION, V80, P1128, DOI 10.1161/01.CIR.80.5.1128; BOWLES NE, 1986, LANCET, V1, P1120; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1993, AM HEART J, V126, P761, DOI 10.1016/0002-8703(93)90926-Z; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; HABIB F, 1994, LANCET, V344, P371, DOI 10.1016/S0140-6736(94)91402-8; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; KATZ SD, 1993, CIRCULATION, V88, P55, DOI 10.1161/01.CIR.88.1.55; KIRCHHOFER D, 1994, J CLIN INVEST, V93, P2073, DOI 10.1172/JCI117202; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; LATIF N, 1993, J AM COLL CARDIOL, V22, P1378, DOI 10.1016/0735-1097(93)90546-D; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MATSUMORI A, 1994, CIRCULATION, V89, P955, DOI 10.1161/01.CIR.89.3.955; MCBRIDE JT, 1995, IMAGE ANAL HISTOLOGY; MCMURRAY J, 1991, BRIT HEART J, V66, P356; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNKVAD S, 1991, LYMPHOKINE CYTOK RES, V10, P325; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WALLEY KR, 1994, J APPL PHYSIOL, V76, P1060, DOI 10.1152/jappl.1994.76.3.1060; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	30	293	303	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1151	1155		10.1016/S0140-6736(96)90610-8	http://dx.doi.org/10.1016/S0140-6736(96)90610-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609750				2022-12-24	WOS:A1996UG75500012
J	Normandeau, M; Taylor, AP; Dewdney, PE				Normandeau, M; Taylor, AP; Dewdney, PE			A galactic chimney in the Perseus arm of the Milky Way	NATURE			English	Article							H-I SHELLS; O-STARS; TERMINAL VELOCITIES; INTERSTELLAR-MEDIUM; MOLECULAR CLOUD; STELLAR WINDS; MASS-LOSS; EVOLUTION; SUPERSHELLS; COMPLEX	GALAXIES are surrounded by large haloes of hot gas(1) which must be replenished as the gas cools, This has led to the concept(2) of galactic 'chimneys'-cavities in the interstellar medium, created by multiple supernova explosions, that can act as conduits for the efficient transport of hot gas from a galaxy's disk to its halo. Here we present a high-resolution map of atomic hydrogen in the Perseus arm of our Galaxy, which shows clear evidence for the existence of such a chimney, This chimney appears to have been formed by the energetic winds from a cluster of young massive stars, and may currently have reached the stage of blowing out into the halo.	NATL RES COUNCIL CANADA,DOMINION RADIO ASTROPHYS OBSERV,OTTAWA,ON,CANADA	National Research Council Canada	Normandeau, M (corresponding author), UNIV CALGARY,DEPT PHYS & ASTRON,2500 UNIV DR NW,CALGARY,AB T2N 3E7,CANADA.							Alter G., 1970, CATALOGUE STAR CLUST; BURKI G, 1979, ASTRON ASTROPHYS, V79, P613; CHIOSI C, 1978, ASTRON ASTROPHYS, V63, P103; DEANDRES FL, 1982, ASTRON ASTROPHYS, V107, P43; DICKEL HR, 1980, ASTROPHYS J, V238, P829, DOI 10.1086/158044; DIGEL SW, IN PRESS ASTROPHYS; GOUDIS C, 1979, ASTROPHYS SPACE SCI, V61, P417, DOI 10.1007/BF00640542; GROENEWEGEN MAT, 1989, ASTRON ASTROPHYS, V221, P78; HARRIS GLH, 1976, ASTROPHYS J SUPPL S, V30, P451, DOI 10.1086/190368; HEILES C, 1987, ASTROPHYS J, V315, P555, DOI 10.1086/165158; Heiles C., 1974, Astronomy and Astrophysics Supplement Series, V14, P1; HEILES C, 1979, ASTROPHYS J, V229, P533, DOI 10.1086/156986; HEILES C, 1984, ASTROPHYS J SUPPL S, V55, P585, DOI 10.1086/190970; HOWARTH ID, 1989, ASTROPHYS J SUPPL S, V69, P527, DOI 10.1086/191321; JOSHI UC, 1983, J ROY ASTRON SOC CAN, V77, P40; LADA CJ, 1978, ASTROPHYS J, V226, pL39, DOI 10.1086/182826; LAMERS HJGLM, 1993, ASTROPHYS J, V412, P771, DOI 10.1086/172960; MACLOW M, 1988, ASTROPHYS J, V337, P776; MATHYS G, 1987, ASTRON ASTROPHYS SUP, V71, P201; NORMAN CA, 1989, ASTROPHYS J, V345, P372, DOI 10.1086/167912; PRINJA RK, 1990, ASTROPHYS J, V361, P607, DOI 10.1086/169224; TENORIOTAGLE G, 1988, ANNU REV ASTRON ASTR, V26, P145; THRONSON HA, 1985, ASTROPHYS J, V297, P662, DOI 10.1086/163565; TOMISAKA K, 1986, PUBL ASTRON SOC JPN, V38, P697; Vogler A, 1996, ASTRON ASTROPHYS, V305, P74; Weaver H., 1973, Astronomy and Astrophysics Supplement Series, V8, P1; WEAVER R, 1977, ASTROPHYS J, V218, P377, DOI 10.1086/155692	27	117	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					687	689		10.1038/380687a0	http://dx.doi.org/10.1038/380687a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614462				2022-12-24	WOS:A1996UG82700041
J	Glazewski, S; Chen, CM; Silva, A; Fox, K				Glazewski, S; Chen, CM; Silva, A; Fox, K			Requirement for alpha-CaMKII in experience-dependent plasticity of the barrel cortex	SCIENCE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; PROTEIN-KINASE; GENE-EXPRESSION; STRIATE CORTEX; CALMODULIN; HISTOCHEMISTRY; SYSTEM; BRAIN	The mammalian sensory neocortex exhibits experience-dependent plasticity such that neurons modify their response properties according to changes in sensory experience. The synaptic plasticity mechanism of long-term potentiation requiring calcium-calmodulin-dependent kinase type II (CaMKII) could underlie experience-dependent plasticity. Plasticity in adult mice can be induced by changes in the patterns of tactile input to the barrel cortex. This response is strongly depressed in adult mice that lack the gene encoding alpha-CaMKII, although adolescent animals are unaffected. Thus, alpha-CaMKII is necessary either for the induction or for the expression of plasticity in adult mice.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Minnesota System; University of Minnesota Twin Cities; Cold Spring Harbor Laboratory			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X	PHS HHS [27759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BENSON DL, 1992, NEUROSCIENCE, V46, P825, DOI 10.1016/0306-4522(92)90188-8; BURGIN KE, 1990, J NEUROSCI, V10, P1788; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; FOX K, 1994, J NEUROSCI, V14, P7665; FOX K, 1992, J NEUROSCI, V12, P1286; GLAZEWSKI S, 1996, J NEUROPHYSIOL, V74, P1714; Gordon J. A., 1994, Society for Neuroscience Abstracts, V20, P465; Hand PJ, 1982, CHANGING CONCEPTS NE, P49; HENDRY SHC, 1986, P NATL ACAD SCI USA, V83, P1536, DOI 10.1073/pnas.83.5.1536; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOSSUT M, 1992, PROG NEUROBIOL, V39, P389, DOI 10.1016/0301-0082(92)90013-5; LI XR, 1995, J COMP NEUROL, V357, P465, DOI 10.1002/cne.903570310; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; NEVE RL, 1989, P NATL ACAD SCI USA, V86, P4781, DOI 10.1073/pnas.86.12.4781; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; VIDEEN TO, 1986, BRAIN RES, V371, P1, DOI 10.1016/0006-8993(86)90803-6; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105	31	126	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					421	423		10.1126/science.272.5260.421	http://dx.doi.org/10.1126/science.272.5260.421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602534				2022-12-24	WOS:A1996UG25200051
J	Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T				Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T			Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted Prp gene	NATURE			English	Article							PROTEIN; SCRAPIE; BRAIN	PRION protein (PrP) is a glycoprotein constitutively expressed on the neuronal cell surface. A protease-resistant isoform of prion protein is implicated in the pathogenesis of a series of transmissible spongiform encephalopathies(1). We have developed a line of mice homozygous for a disrupted PrP gene in which the whole PrP-coding sequence is replaced by a drug-resistant gene(2). In keeping with pre,ious results(3-8), we find that homozygous loss of the PrP gene has no deleterious effect on the development of these mice and renders them resistant to prion(2). The PrP-null mice grew normally after birth, but at about 70 weeks of age all began to show progressive symptoms of ataxia. Impaired motor coordination in these ataxic mice was evident in a rotorod test. Pathological examination revealed an extensive loss of Purkinje cells in the vast majority of cerebellar folia, suggesting that PrP plays a role in the long-term survival of Purkinje neurons.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PATHOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; KANSAI MED UNIV,DEPT ANAT,MORIGUCHI,OSAKA 570,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOKYO 170,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Kansai Medical University; Japanese Foundation for Cancer Research			Noda, Tetsuo/B-1667-2016; hasegawa, sumitaka/A-4020-2012					BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197	15	400	408	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					528	531		10.1038/380528a0	http://dx.doi.org/10.1038/380528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606772				2022-12-24	WOS:A1996UE66300050
J	Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ				Hurt, RD; Offord, KP; Croghan, IT; GomezDahl, L; Kottke, TE; Morse, RM; Melton, LJ			Mortality following inpatient addictions treatment - Role of tobacco use in a community-based cohort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING; ALCOHOLICS; ABUSE; DEPENDENCE; DRINKING; SUICIDE	Objective.-To determine the impact of tobacco- and alcohol-related deaths on overall mortality following inpatient treatment for alcoholism and other nonnicotine drugs of dependence. Design.-Population-based retrospective cohort study. Setting.-Olmsted County, Minnesota (the Rochester Epidemiology Project), and the Inpatient Addiction Program (IAP) at Mayo Clinic, Rochester. Patients.-All 845 Olmsted County residents admitted to an inpatient addiction program for treatment of alcoholism and other nonnicotine drugs of dependence during the period 1972 through 1983. Methods.-Patients were followed up through the medical record linkage system of the Rochester Epidemiology Project through December 1994 to obtain vital status, and death certificates were obtained for those who died. The underlying cause of death was classified as alcohol related, tobacco related, both, or neither based on the classification from the Centers for Disease Control and Prevention. The observed number of deaths by underlying cause was compared with the expected number using cause-specific 1987 death rates for the white population of the United States. All-cause mortality was also compared with that expected for persons in the West North Central Region of the United States of like age, sex, and year of birth. Univariate and multivariate assessments were made to identify predictors of all-cause mortality from baseline demographic information. Results.-At admission, the mean (SD) age of the 845 patients was 41.4 (14.5) years, and 35% were women. Altogether, 78% had alcohol as their only nonnicotine drug of dependence and 18% had alcohol and other nonnicotine drugs of dependence, while 4% were classified as having a nonalcohol, nonnicotine drug dependence alone. At admission, 75% were current and 8% former cigarette smokers, 3% were current cigar or pipe smokers, and 2% were current users of smokeless tobacco. Follow-up after the index IAP admission totaled 8913 person-years (mean [SD] of 10.5 [5.6] years per patient). Death certificates were obtained for 96% (214) of the 222 patients who died. Of these 214 deaths, 50.9% (109) had a tobacco-related and 34.1% (73) had an alcohol-related underlying cause (P<.001). The cumulative mortality significantly exceeded that expected (P<.001); at 20 years, the observed mortality was 48.1% vs an expected 18.5%. Multivariate predictors of mortality, even after adjusting for expected mortality, were older age at admission (P<.001) and male sex (P<.001). Conclusions.-Patients previously treated for alcoholism and/or other nonnicotine drug dependence had an increased cumulative mortality that was due more to tobacco-related than to alcohol-related causes. Nicotine dependence treatment is imperative in such high-risk patients.	MAYO CLIN & MAYO FDN, BIOSTAT SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PSYCHIAT & PSYCHOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Hurt, RD (corresponding author), MAYO CLIN & MAYO FDN, NICOTINE DEPENDENCE CTR, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NIAMS NIH HHS [AR30582] Funding Source: Medline; NIDA NIH HHS [DA 08039] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008039] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARR HC, 1994, J STUD ALCOHOL, V45, P440; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; Bergstralh E, 1986, TECHNICAL REPORT SER, V31; BERGSTRALH EJ, 1988, TECHNICAL SUPPORT SE, V37; BULLOCK KD, 1992, JAMA-J AM MED ASSOC, V267, P668, DOI 10.1001/jama.267.5.668; BURLING TA, 1988, ADDICT BEHAV, V13, P185, DOI 10.1016/0306-4603(88)90010-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAIG TJ, 1977, J STUD ALCOHOL, V38, P1434, DOI 10.15288/jsa.1977.38.1434; Delaney G O, 1988, N J Med, V85, P131; DIETVORST TF, 1978, J CLIN PSYCHOL, V34, P244, DOI 10.1002/1097-4679(197801)34:1<244::AID-JCLP2270340150>3.0.CO;2-V; DIFRANZA JR, 1990, J STUD ALCOHOL, V51, P130, DOI 10.15288/jsa.1990.51.130; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; EDWARDS G, 1983, LANCET, V2, P269; FEUERLEIN W, 1994, ADDICTION, V89, P841, DOI 10.1111/j.1360-0443.1994.tb00987.x; FINNEY JW, 1992, J STUD ALCOHOL, V53, P142, DOI 10.15288/jsa.1992.53.142; FISHMAN ML, 1993, J SUBST ABUSE TREAT, V10, P133, DOI 10.1016/0740-5472(93)90037-3; FLEMING TR, 1981, COMMUN STAT A-THEOR, V10, P763, DOI 10.1080/03610928108828073; GILLIS L S, 1969, South African Medical Journal, V43, P230; GOLDSMITH JR, 1991, J ADDICT DIS, V11, P67; HOFFMAN AL, 1993, J SUBST ABUSE TREAT, V10, P153, DOI 10.1016/0740-5472(93)90040-9; HURT RD, 1994, ALCOHOL CLIN EXP RES, V18, P867, DOI 10.1111/j.1530-0277.1994.tb00052.x; JOSEPH AM, 1990, JAMA-J AM MED ASSOC, V263, P3043; KARAN LD, 1993, J SUBST ABUSE TREAT, V10, P101, DOI 10.1016/0740-5472(93)90032-W; KOZLOWSKI LT, 1989, ADDICT BEHAV, V14, P273, DOI 10.1016/0306-4603(89)90058-0; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; LAMBIE DG, 1982, NZ MED J, V96, P199; LEWIS CE, 1995, ALCOHOL CLIN EXP RES, V19, P984, DOI 10.1111/j.1530-0277.1995.tb00978.x; MALETZKY BM, 1974, AM J PSYCHIAT, V131, P445; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARSHALL EJ, 1994, ADDICTION, V89, P1293, DOI 10.1111/j.1360-0443.1994.tb03308.x; MCALPINE DE, 1990, MAYO CLIN PROC, V65, P13, DOI 10.1016/S0025-6196(12)62105-3; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MOOS RH, 1994, ALCOHOL CLIN EXP RES, V18, P187, DOI 10.1111/j.1530-0277.1994.tb00902.x; MORSE RM, 1991, PROFESSIONAL COU AUG, P33; National Center for Health Statistics, 1993, DHHS PUBL, V41; OCONNOR A, 1985, BRIT J PSYCHIAT, V146, P645, DOI 10.1192/bjp.146.6.645; OHARA K, 1989, BRIT J ADDICT, V84, P287; ORLEANS CT, 1993, J SUBST ABUSE TREAT, V10, P197, DOI 10.1016/0740-5472(93)90045-4; PUCKET CD, 1994, ED ANNOTATION ICD9CM; RAVENHOLT RT, 1984, POPUL DEV REV, V10, P697, DOI 10.2307/1973289; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROSENGREN A, 1988, ACTA MED SCAND, V223, P111; SCHMIDT W, 1981, CANCER-AM CANCER SOC, V47, P1031, DOI 10.1002/1097-0142(19810301)47:5<1031::AID-CNCR2820470534>3.0.CO;2-C; TAYLOR JR, 1983, J STUD ALCOHOL, V44, P17, DOI 10.15288/jsa.1983.44.17; U. S. Department of Health and Human Services, 1990, DHHS PUBL; VAILLANT GE, 1991, J GEN INTERN MED, V6, P299, DOI 10.1007/BF02597425; 1995, MINN CANC SURVEI MAR, P2; 1993, MMWR-MORBID MORTAL W, V42, P645; 1990, MMWR-MORBID MORTAL W, V11, P172	51	514	517	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1097	1103		10.1001/jama.275.14.1097	http://dx.doi.org/10.1001/jama.275.14.1097			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD027	8601929				2022-12-24	WOS:A1996UD02700026
J	Nader, S				Nader, S			Female judoists: Their hormones, muscles, and bones	LANCET			English	Editorial Material							EXERCISE; RUNNERS				Nader, S (corresponding author), UNIV TEXAS,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,HOUSTON,TX 77025, USA.							BARROW GW, 1988, AM J SPORT MED, V16, P209, DOI 10.1177/036354658801600302; BULLEN BA, 1985, NEW ENGL J MED, V312, P1349, DOI 10.1056/NEJM198505233122103; DE CREE C, 1995, J CLIN ENDOCR METAB, V80, P3639, DOI 10.1210/jc.80.12.3639; KEIZER HA, 1990, SPORTS MED, V10, P218, DOI 10.2165/00007256-199010040-00002; ROGOL AD, 1992, ENDOCRIN METAB CLIN, V21, P817, DOI 10.1016/S0889-8529(18)30190-7; SANBORN CF, 1982, AM J OBSTET GYNECOL, V143, P859, DOI 10.1016/0002-9378(82)90463-X; SCHACHTER M, 1994, FERTIL STERIL, V62, P1; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8	8	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					919	920		10.1016/S0140-6736(96)91411-7	http://dx.doi.org/10.1016/S0140-6736(96)91411-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598753				2022-12-24	WOS:A1996UD59100006
J	Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG				Will, RG; Ironside, JW; Zeidler, M; Cousens, SN; Estibeiro, K; Alperovitch, A; Poser, S; Pocchiari, M; Hofman, A; Smith, PG			A new variant of Creutzfeldt-Jakob disease in the UK	LANCET			English	Article								Background Epidemiological surveillance of Creutzfeldt-Jakob disease (CJD) was reinstituted in the UK in 1990 to identify any changes in the occurrence of this disease after the epidemic of bovine spongiform encephalopathy (BSE) in cattle. Methods Case ascertainment of CJD was mostly by direct referral from neurologists and neuropathologists. Death certificates on which CJD was mentioned were also obtained. Clinical details were obtained for all referred cases, and information on potential risk factors for CJD was obtained by a standard questionnaire administered to patients' relatives. Neuropathological examination was carried out on approximately 70% of suspect cases. Epidemiological studies of CJD using similar methodology to the UK study have been carried out in France, Germany, Italy, and the Netherlands between 1993 and 1995. Findings Ten cases of CJD have been identified in the UK in recent months with a new neuropathological profile. Other consistent features that are unusual include the young age of the cases, clinical findings, and the absence of the electroencephalogram features typical for CJD. Similar cases have not been identified in other countries in the European surveillance system. Interpretation These cases appear to represent a new variant of CJD, which may be unique to the UK. This raises the possibility that they are causally linked to BSE. Although this may be the most plausible explanation for this cluster of cases, a link with BSE cannot be confirmed on the basis of this evidence alone. It is essential to obtain further information on the current and past clinical and neuropathological profiles of CJD in the UK and elsewhere.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1,ENGLAND; HOP LA PITIE SALPETRIERE,INSERM,PARIS,FRANCE; UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,W-3400 GOTTINGEN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY; ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS	University of London; London School of Hygiene & Tropical Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Istituto Superiore di Sanita (ISS); Erasmus University Rotterdam	Will, RG (corresponding author), WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486; Ironside, James/0000-0001-5869-2108; Smith, Peter/0000-0003-0080-7560				BATEMAN D, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91828-0; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BRITTON TC, 1995, LANCET, V346, P1155, DOI 10.1016/S0140-6736(95)91827-2; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DELASNERIELAUPRETRE N, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92735-2; Fraser H., 1979, Aspects of slow and persistent virus infections, P30; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; HOWARD RS, 1996, LANCET, V347, P945; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; *NAT CJD SURV UN D, 1995, 4 LOND SCH HYG TROP; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; WELLER RO, 1986, NEUROPATH APPL NEURO, V12, P117, DOI 10.1111/j.1365-2990.1986.tb00045.x	18	2040	2102	0	150	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					921	925		10.1016/S0140-6736(96)91412-9	http://dx.doi.org/10.1016/S0140-6736(96)91412-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598754				2022-12-24	WOS:A1996UD59100007
J	Landi, G				Landi, G			No to DNR orders in acute stroke	LANCET			English	Editorial Material											Landi, G (corresponding author), OSPED MAGGIORE POLICLIN,MILAN,ITALY.							Alexandrov AV, 1996, STROKE, V27, P232, DOI 10.1161/01.STR.27.2.232; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					848	848		10.1016/S0140-6736(96)91342-2	http://dx.doi.org/10.1016/S0140-6736(96)91342-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622388				2022-12-24	WOS:A1996UC45000006
J	Levy, A				Levy, A			Perioperative steroid cover	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BROMBERG JS, 1991, TRANSPLANTATION, V51, P385, DOI 10.1097/00007890-199102000-00023; FRASER CG, 1952, JAMA-J AM MED ASSOC, V149, P1542, DOI 10.1001/jama.1952.72930340001009; Friedman RJ, 1995, J BONE JOINT SURG AM, V77A, P1801, DOI 10.2106/00004623-199512000-00002; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; LEWIS L, 1953, ANN INTERN MED, V39, P116, DOI 10.7326/0003-4819-39-1-116	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					846	847		10.1016/S0140-6736(96)91340-9	http://dx.doi.org/10.1016/S0140-6736(96)91340-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622386				2022-12-24	WOS:A1996UC45000004
J	Nagar, B; Overduin, M; Ikura, M; Rini, JM				Nagar, B; Overduin, M; Ikura, M; Rini, JM			Structural basis of calcium-induced E-cadherin rigidification and dimerization	NATURE			English	Article							CELL-ADHESION; PROTEIN	THE cadherins mediate cell adhesion and play a fundamental role in normal development(1). They participate in the maintenance of proper cell-cell contacts: for example, reduced levels of epithelial cadherin (E-cadherin) correlate with increased invasiveness in many human tumour cell types(2,3). The cadherins typically consist of five tandemly repeated extracellular domains, a single membrane-spanning segment and a cytoplasmic region(4-6). The N-terminal extracellular domains mediate cell-cell contact(7) while the cytoplasmic region interacts with the cytoskeleton through the catenins(8). Cadherins depend on calcium for their function: removal of calcium abolishes adhesive activity, renders cadherins vulnerable to proteases (reviewed in ref, 4) and, in E-cadherin, induces a dramatic reversible conformational change in the entire extracellular region(9). We report here the X-ray crystal structure at 2.0 Angstrom resolution of the two N-terminal extracellular domains of E-cadherin in the presence of calcium. The structure reveals a two-fold symmetric dimer, each molecule of which binds a contiguous array of three bridged calcium ions. Not only do the bound calcium ions linearize and rigidify the molecule, they promote dimerization. Although the N-terminal domain of each molecule in the dimer is aligned in a parallel orientation, the interactions between them differ significantly from those found in the neural cadherin (N-cadherin) N-terminal domain (NCD1) structure(10). The E-cadherin dual-domain structure reported here defines the role played by calcium in the cadherin-mediated formation and maintenance of solid tissues.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Tsukuba; University of Tsukuba			Overduin, Michael/AAG-3632-2020; Nagar, Bhushan/C-1297-2010	Overduin, Michael/0000-0002-3114-6585; Ikura, Mitsuhiko/0000-0002-9524-1303				BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; Blaschuk O W, 1994, Can J Oncol, V4, P291; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; BRUNGER AT, 1992, XPLOR V 3 1 SYSTEM X; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, IN PRESS METH ENZYM; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAREEL M, 1994, MOL BIOL REP, V19, P45, DOI 10.1007/BF00987321; NOSE A, 1990, CELL, V61, P17; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OVERDUIN M, IN PRESS J BIOMOL NM; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RINGWALD M, 1987, EMBO J, V6, P3547; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TESMER JJG, 1994, PROTEINS, V18, P394, DOI 10.1002/prot.340180410; TONG KI, 1994, FEBS LETT, V352, P318; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832	28	547	561	1	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					360	364		10.1038/380360a0	http://dx.doi.org/10.1038/380360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598933				2022-12-24	WOS:A1996UC37900064
J	Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC				Ernster, VL; Barclay, J; Kerlikowske, K; Grady, D; Henderson, IC			Incidence of and treatment for ductal carcinoma in situ of the breast	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRADUCTAL CARCINOMA; SCREENING MAMMOGRAPHY; FEMALE BREAST; INSITU; CANCER; WOMEN; LESIONS; DCIS; PREVALENCE; MANAGEMENT	Objective.-To describe trends in incidence and treatment for ductal carcinoma in situ (DCIS) of the breast in the United States between 1973 and 1992 and to estimate total numbers of in situ cases diagnosed and numbers treated by mastectomy since 1983, when screening mammography for breast cancer began to become widespread. Design.-Analysis of population-based breast cancer incidence data collected by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program since 1973 and treatment data collected by the SEER program since 1983. Study Population.-All women in the geographic areas of the United States included in the SEER program. Main Outcome Measures.-Annual age-adjusted and age-specific incidence rates for DCIS; time trends in distribution of cases by type of treatment; percentage of cases treated by mastectomy by geographic area; and estimated numbers for the entire United States of DCIS cases, mastectomies for DCIS, and cases attributable to mammography. Results.-There was a marked increase in DCIS incidence beginning in the early 1980s. Average annual increases in rates between 1973 and 1983 and between 1983 and 1992 changed from 0.3% to 12.0% among women aged 30 to 39 years, from 0.4% to 17.4% among women aged 40 to 49 years, and from 5.2% to 18.1% among women aged 50 years or older. The total estimated number of DCIS cases in the United States in 1992 (23 368) was 200% higher than expected based on 1983 rates and trends between 1973 and 1983, Between 1983 and 1992, there was a marked decline in the proportion of DCIS cases treated by mastectomy (from 71% to 43.8%) and an increase in those treated by lumpectomy (from 25.6% to 53.3%). In 1992, 23.3% of cases were treated by lumpectomy and radiation, 30.2% by lumpectomy alone, and 2.6% with no surgery, Treatment patterns varied substantially by geographic area, with 57.7% of cases in New Mexico treated by mastectomy in 1992 compared with 28.8% in Connecticut, Despite the decline in the proportion of cases treated by mastectomy, the increased DCIS incidence rates resulted in an increase in the absolute number of cases treated by mastectomy until 1990 (n=10 657); in 1992, there were an estimated 10 242 DCIS cases treated by mastectomy. Conclusions-Incidence rates of DCIS of the breast have increased dramatically since 1983. This increase correlates with the widespread adoption of modern mammographic screening. While early detection of invasive breast cancer is beneficial, the value of DCIS detection is currently unknown. There is cause for concern about the large number of DCIS cases that are being diagnosed as a consequence of screening mammography, most of which are treated; by some form of surgery. In addition, the proportion of cases treated by mastectomy may be inappropriately high, particularly in some areas of the United States.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; VET ADM MED CTR,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94121; SEQUUS PHARMACEUT INC,MENLO PK,CA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ernster, VL (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOSTAT & EPIDEMIOL,BOX 0560,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58207-03, U01 CA 63740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTH A, 1995, WESTERN J MED, V163, P360; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; BASSETT LW, 1992, RADIOL CLIN N AM, V30, P93; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BERG JW, 1995, CANCER, V75, P257, DOI 10.1002/1097-0142(19950101)75:1+<257::AID-CNCR2820751311>3.0.CO;2-Y; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; CARPENTER R, 1989, BRIT J SURG, V76, P564, DOI 10.1002/bjs.1800760612; COLEMAN EA, 1992, AM J SURG, V164, P74, DOI 10.1016/S0002-9610(05)80652-X; FAGGIANO F, 1994, J EPIDEMIOL COMMUN H, V48, P447, DOI 10.1136/jech.48.5.447; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER ER, 1991, J SURG ONCOL, V47, P139, DOI 10.1002/jso.2930470302; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; GUMP FE, 1987, SURGERY, V102, P790; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LYNDE JL, 1993, SOUTHERN MED J, V86, P338, DOI 10.1097/00007611-199303000-00018; MILLIKAN R, 1995, BREAST CANCER RES TR, V35, P65, DOI 10.1007/BF00694747; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; *NCI, 1995, SURV EP END RES SEER; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; OSTEEN RT, 1994, CANCER, V73, P1994, DOI 10.1002/1097-0142(19940401)73:7<1994::AID-CNCR2820730735>3.0.CO;2-O; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Page DL, 1987, DIAGNOSTIC HISTOPATH, P157; POPE TL, 1988, RADIOLOGY, V168, P63, DOI 10.1148/radiology.168.1.3380984; REBNER M, 1994, RADIOLOGY, V190, P623, DOI 10.1148/radiology.190.3.8115600; Ries L, 1994, NIH PUBLICATION, V94-2789; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; SONNENFIELD M, 1991, RADIOLOGY, V181, P623; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; VANDONGEN JA, 1992, EUR J CANCER, V28A, P626, DOI 10.1016/S0959-8049(05)80113-3; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208; 1990, MMWR-MORBID MORTAL W, V39, P621; 1990, MMWR-MORBID MORTAL W, V39, P627	48	440	452	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					913	918		10.1001/jama.275.12.913	http://dx.doi.org/10.1001/jama.275.12.913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598618				2022-12-24	WOS:A1996UA56300030
J	Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA				Bourne, Y; Watson, MH; Hickey, MJ; Holmes, W; Rocque, W; Reed, SI; Tainer, JA			Crystal structure and mutational analysis the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1	CELL			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SCHIZOSACCHAROMYCES-POMBE; DIVISION CYCLE; CDC2; GENE; PHOSPHORYLATION; P34(CDC2); BINDING	The 2.6 Angstrom crystal structure for human cyclin-dependent kinase 2 (CDK2) in complex with CksHs1, a human homolog of essential yeast cell cycle-regulatory proteins suc1 and Cks1, reveals that CksHs1 binds via all four beta strands to the kinase C-terminal robe. This interface is biologically critical, based upon mutational analysis, but far from the CDK2 N-terminal lobe, cyclin, and regulatory phosphorylation sites. CDK2 binds the Cks single domain conformation and interacts with conserved hydrophobic residues plus His-60 and Glu-63 in their closed beta-hinge motif conformation. The beta hinge opening to form the Cks beta-interchanged dimer sterically precludes CDK2 binding, providing a possible mechanism regulating CDK2-Cks interactions. One face of the complex exposes the sequence-conserved phosphate-binding region on Cks and the ATP-binding site on CDK2, suggesting that Cks may target CDK2 to other phosphoproteins during the cell cycle.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; GLAXO WELLCOME, RES TRIANGLE PK, NC 27709 USA	Scripps Research Institute; GlaxoSmithKline			Bourne, Yves/AAC-4635-2022; Tainer, John/GWQ-4878-2022	Bourne, Yves/0000-0003-3850-0548; Tainer, John/0000-0003-1659-2429				ARVAI AS, 1995, PROTEINS, V21, P70, DOI 10.1002/prot.340210109; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; AZZI L, 1994, J BIOL CHEM, V269, P13279; Boume Y., 1995, P NATL ACAD SCI USA, V92, P10232; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENDICOTT JA, 1995, STRUCTURE, V3, P321, DOI 10.1016/S0969-2126(01)00162-9; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KHATIB ZA, 1993, CANCER RES, V53, P5535; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	59	209	213	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					863	874		10.1016/S0092-8674(00)81065-X	http://dx.doi.org/10.1016/S0092-8674(00)81065-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601310	Bronze			2022-12-24	WOS:A1996UC38100008
J	Foucar, E				Foucar, E			Carcinoma-in-situ of the breast: Have pathologists run amok?	LANCET			English	Editorial Material							LESIONS				Foucar, E (corresponding author), PRESBYTERIAN HOSP,DEPT PATHOL,POB 26666,ALBUQUERQUE,NM 87125, USA.							Foote FW, 1941, AM J PATHOL, V17, P491; HAYAKAWA SI, 1990, LANGUAGE THOUGHT ACT, P111; HETELEKIDIS S, 1995, CA-CANCER J CLIN, V45, P244, DOI 10.3322/canjclin.45.4.244; MORROW M, 1994, ARCH SURG-CHICAGO, V129, P1091; Morrow M, 1996, JAMA-J AM MED ASSOC, V275, P61; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSAI J, 1996, BREAST ACKERMANS SUR, P1596; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SILVERSTEIN MJ, 1991, AM J CLIN ONCOL-CANC, V14, P534, DOI 10.1097/00000421-199112000-00014; SIMPSON JF, 1994, CANCER, V73, P2352, DOI 10.1002/1097-0142(19940501)73:9<2352::AID-CNCR2820730918>3.0.CO;2-X; STEWART FW, 1950, ATLAS TUMOUR PATHOL, P18; TAVASSOLI FA, 1994, MODERN PATHOL, V7, P813; WALT AJ, 1992, ARCH SURG-CHICAGO, V127, P904; WINCHESTER DP, 1995, ANN SURG ONCOL, V2, P207, DOI 10.1007/BF02307025	15	26	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					707	708		10.1016/S0140-6736(96)90073-2	http://dx.doi.org/10.1016/S0140-6736(96)90073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601998				2022-12-24	WOS:A1996TZ98200006
J	Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML				Yu, SF; Baldwin, DN; Gwynn, SR; Yendapalli, S; Linial, ML			Human foamy virus replication: A pathway distinct from that of retroviruses and hepadnaviruses	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; HUMAN-IMMUNODEFICIENCY; GENE-PRODUCTS; GAG PROTEINS; IDENTIFICATION; EXPRESSION; VIRIONS; BINDING; GENOME; BEL	Human foamy virus (HFV) is the prototype of the Spumavirus genus of Retroviridae. In all other retroviruses, the pol gene products, including reverse transcriptase, are synthesized as Gag-Pol fusion proteins and are cleaved to functional enzymes during viral budding or release, In contrast, the Pol protein of HFV is translated from a spliced messenger RNA and lacks Gag domains, Infectious HFV particles contain double-stranded DNA similar in size to full-length provirus, suggesting that reverse transcription has taken place in viral particles before new rounds of infection, reminiscent of hepadnaviruses. These data suggest that foamy viruses possess a replication pathway containing features of both retroviruses and hepadnaviruses but distinct from both.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,INTERDISCIPLINARY PROGRAM MOLEC & CELLULAR BIOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA18282, F32 CA60357] Funding Source: Medline; NHLBI NIH HHS [HL53762] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018282, F32CA060357] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053762] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN D, UNPUB; BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; BARTHOLOMA A, 1992, VIRUS RES, V23, P27, DOI 10.1016/0168-1702(92)90065-H; Coffin J. M., 1990, VIROLOGY, P1437; FELSENSTEIN KM, 1988, J VIROL, V62, P2179, DOI 10.1128/JVI.62.6.2179-2182.1988; GANEM D, 1994, INFECT AGENT DIS, V3, P85; HAHN H, 1994, J GEN VIROL, V75, P2635, DOI 10.1099/0022-1317-75-10-2635; HATTON T, 1992, J VIROL, V66, P5232, DOI 10.1128/JVI.66.9.5232-5241.1992; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; KOGEL D, 1995, VIROLOGY, V213, P97, DOI 10.1006/viro.1995.1550; KONVALINKA J, 1995, J VIROL, V69, P7264, DOI 10.1128/JVI.69.11.7264-7268.1995; LOCHELT M, 1991, VIROLOGY, V184, P43, DOI 10.1016/0042-6822(91)90820-2; Lochelt M, 1996, J VIROL, V70, P1033; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MAURER B, 1988, J VIROL, V62, P1590, DOI 10.1128/JVI.62.5.1590-1597.1988; MURANYI W, 1991, J VIROL, V65, P727, DOI 10.1128/JVI.65.2.727-735.1991; Nassal M, 1993, Trends Microbiol, V1, P221, DOI 10.1016/0966-842X(93)90136-F; NETZER KO, 1990, J GEN VIROL, V71, P1237, DOI 10.1099/0022-1317-71-5-1237; NETZER KO, 1993, VIROLOGY, V192, P336, DOI 10.1006/viro.1993.1039; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; SCHLIEPHAKE AW, 1994, J VIROL, V68, P4946, DOI 10.1128/JVI.68.8.4946-4954.1994; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; Vogt P. K., 1990, CURR TOP MICROBIOL, V157, P93; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yu SF, 1996, J VIROL, V70, P1250, DOI 10.1128/JVI.70.2.1250-1254.1996; YU SF, 1993, J VIROL, V67, P6618, DOI 10.1128/JVI.67.11.6618-6624.1993; [No title captured]	31	230	238	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1579	1582		10.1126/science.271.5255.1579	http://dx.doi.org/10.1126/science.271.5255.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599113				2022-12-24	WOS:A1996TZ98300040
J	TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC				TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC			Cyclophosphamide-induced cystitis and bladder cancer in patients with wegener granulomatosis	ANNALS OF INTERNAL MEDICINE			English	Article							ULCERATIVE-COLITIS; RHEUMATOID-ARTHRITIS; TOXICITY	Objective: To describe the incidence of, clinical manifestations of, and risk factors for cyclophosphamide-induced urinary bladder toxicity in patients treated for nonmalignant disease. Design: Retrospective analysis of patients followed at the National Institutes of Allergy and Infectious Diseases from 1967 to 1993. Setting: The Warren G. Magnuson Clinical Center of the National Institutes of Health (NIH). Patients: 145 patients who received cyclophosphamide for the treatment of Wegener granulomatosis and were followed for 0.5 to 27 years (median, 8.5 years), for a total of 1333 patient-years. Measurements: Clinical characteristics, cystoscopic findings, results of cytologic examination of urine, surgical pathology. and total dose and duration of cyclophosphamide therapy were recorded and analyzed using a computer-based information retrieval system. Results: Nonglomerular hematuria occurred in 73 of 145 patients treated with cyclophosphamide (50%). Sixty of the 73 patients with nonglomerular hematuria (82%) had cystoscopy at the NIH. Forty-two of the 60 patients (70%) who had cystoscopy had macroscopic changes consistent with cyclophosphamide-induced bladder injury. Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder. In 6 of these 7 patients, the total cumulative cyclophosphamide dose exceeded 100 g, and the cumulative duration of cyclophosphamide therapy exceeded 2.7 years. Before they were given a diagnosis of bladder cancer, all 7 patients had had one or more episodes of microscopic or gross nonglomerular hematuria. In contrast, none of the 72 patients who had never had nonglomerular hematuria developed bladder cancer. Cox proportional hazards regression analysis showed that only microscopic nonglomerular hematuria was a significant risk factor for the development of bladder cancer (P < 0.01). Conclusion: Long-term oral cyclophosphamide therapy is associated with substantial urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder. In this cohort of patients, the estimated incidence of bladder cancer after the first exposure to cyclophosphamide was 5% at 10 years and 16% at 15 years. Nonglomerular hematuria was a frequent manifestation of cyclophosphamide-induced cystitis, and it identified a subgroup of patients at high risk for the development of bladder cancer.	NIAID,NIH,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAKER GL, 1987, AM J MED, V83, P1, DOI 10.1016/0002-9343(87)90490-6; COLEMAN DV, 1975, ACTA CYTOL, V19, P93; COX DR, 1972, J R STAT SOC B, V34, P187; COX PJ, 1979, BIOCHEM PHARMACOL, V28, P2045, DOI 10.1016/0006-2952(79)90222-3; CROWLEY J, 1977, J AM STAT ASSOC, V72, P27, DOI 10.2307/2286902; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FORNI AM, 1964, CANCER, V17, P1348, DOI 10.1002/1097-0142(196410)17:10<1348::AID-CNCR2820171017>3.0.CO;2-0; FRAISER LH, 1991, DRUGS, V42, P781, DOI 10.2165/00003495-199142050-00005; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; JEWELL DP, 1993, GASTROINTESTINAL DIS, P105; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORELITZ BI, 1995, BOCKUS GASTROENTEROL, P1364; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; PEDERSENBJERGAARD J, 1988, NEW ENGL J MED, V318, P1028, DOI 10.1056/NEJM198804213181604; PLOTZ PH, 1979, ANN INTERN MED, V91, P221, DOI 10.7326/0003-4819-91-2-221; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; RIES LAG, 1994, NIH942789 PUB; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; STILLWELL TJ, 1988, ARTHRITIS RHEUM, V31, P465, DOI 10.1002/art.1780310402; WEISS MA, 1989, PATHOLOGY URINARY BL, P245	24	379	393	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					477	&		10.7326/0003-4819-124-5-199603010-00003	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602705				2022-12-24	WOS:A1996TW77300003
J	Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T				Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T			Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with graves disease	ANNALS OF INTERNAL MEDICINE			English	Article							PROPYLTHIOURACIL-INDUCED AGRANULOCYTOSIS; INSULIN AUTOIMMUNE SYNDROME; COLONY-STIMULATING FACTOR; LUPUS-LIKE SYNDROME; MHC CLASS-II; ANTITHYROID DRUGS; IMMUNE-RESPONSE; HLA; SUSCEPTIBILITY; GENES	Objective: To determine the association between HLA class II genes and methimazole-induced agranulocytosis in patients with Graves disease. Design: Case-control study. Setting: Kuma Hospital, which specializes in thyroid diseases, in Kobe, Japan. Subjects: 24 patients with Graves disease who had methimazole-induced agranulocytosis diagnosed by peripheral granulocyte counts of less than 0.5 x 10(9)/L, and 68 patients with Graves disease treated with methimazole, who were free from agranulocytosis. Controls were 525 healthy, unrelated Japanese student volunteers at Kyushu University in Japan. Measurements: All HLA class II genes were analyzed for polymorphisms at the DNA level by using the polymerase chain reaction sequence-specific oligonucleotide probes method. The allele frequencies in the agranulocytotic Graves disease group were compared with those in the nonagranulocytotic Graves disease and control groups. Results: A strong positive association was seen in DRB1*08032 between the agranulocytotic group and both the control and nonagranulocytotic Graves disease groups. Conclusion: The HLA DRB1*08032 allele was strongly associated with susceptibility to methimazole-induced agranulocytosis, suggesting that cellular autoimmunity may be involved in its development.	KYUSHU UNIV, MED INST BIOREGULAT, DEPT GENET, HIGASHI KU, FUKUOKA 812, JAPAN; TOKYO MED & DENT UNIV, MED RES INST,DEPT TISSUE PHYSIOL,DIV ADULT DIS, CHIYODA KU, TOKYO 101, JAPAN; KUMA HOSP, CHUOU KU, KOBE, HYOGO 650, JAPAN; NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, NAGASAKI 852, JAPAN	Kyushu University; Tokyo Medical & Dental University (TMDU); Kuma Hospital; Nagasaki University	Tamai, H (corresponding author), KYUSHU UNIV, FAC MED, DEPT PSYCHOSOMAT MED, HIGASHI KU, 3-1-1 MAIDASHI, FUKUOKA 812, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AMRHEIN JA, 1970, J PEDIATR-US, V76, P54, DOI 10.1016/S0022-3476(70)80130-5; BERKMAN EM, 1983, TRANSFUSION, V23, P135, DOI 10.1046/j.1537-2995.1983.23283172851.x; BILEZIKIAN SB, 1976, JOHNS HOPKINS MED J, V138, P124; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; COOPER DS, 1983, ANN INTERN MED, V98, P26, DOI 10.7326/0003-4819-98-1-26; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; DONG RP, 1992, HUM IMMUNOL, V35, P165, DOI 10.1016/0198-8859(92)90101-R; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; FU XT, 1995, J EXP MED, V181, P915, DOI 10.1084/jem.181.3.915; GEORGE AJT, 1995, IMMUNOL TODAY, V16, P209, DOI 10.1016/0167-5699(95)80158-8; GUFFY MM, 1984, ARCH INTERN MED, V144, P1687, DOI 10.1001/archinte.144.8.1687; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HEINRICH B, 1989, ANN INTERN MED, V111, P621, DOI 10.7326/0003-4819-111-7-621_2; Imanish T, 1992, HLA 1991, V1, P1065; KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; MARSHALL KW, 1994, J IMMUNOL, V152, P4946; MATSUSHITA S, 1994, J EXP MED, V180, P873, DOI 10.1084/jem.180.3.873; MCDEVITT HO, 1980, NEW ENGL J MED, V303, P1514, DOI 10.1056/NEJM198012253032606; MCGAVACK TH, 1954, AM J MED, V17, P36, DOI 10.1016/0002-9343(54)90141-2; McIntyre P A, 1971, Trans Assoc Am Physicians, V84, P217; MOORE FD, 1946, JAMA-J AM MED ASSOC, V130, P315, DOI 10.1001/jama.1946.02870060001001; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RENOUX G, 1980, DRUGS, V20, P89, DOI 10.2165/00003495-198020020-00001; ROSOVE MH, 1977, WESTERN J MED, V126, P339; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SATO K, 1985, J ENDOCRINOL INVEST, V8, P551, DOI 10.1007/BF03348560; TAKAYAMAHASUMI S, 1990, DIABETES RES CLIN PR, V10, P211, DOI 10.1016/0168-8227(90)90063-Y; TAMAI H, 1994, J CLIN ENDOCR METAB, V78, P94, DOI 10.1210/jc.78.1.94; TAMAI H, 1989, CLIN ENDOCRINOL, V30, P525, DOI 10.1111/j.1365-2265.1989.tb01424.x; TAMAI H, 1993, J CLIN ENDOCR METAB, V77, P1356, DOI 10.1210/jc.77.5.1356; TIWARI JL, HLA DISEASE ASS, P214; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TOTH EL, 1988, AM J MED, V85, P725; TROTTER W. R., 1962, JOUR NEW DRUGS, V2, P333, DOI 10.1177/009127006200200603; UCHIGATA Y, 1992, LANCET, V340, P1467, DOI 10.1016/0140-6736(92)92654-X; UNO H, 1981, NATURE, V292, P768, DOI 10.1038/292768a0; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; WALL JR, 1984, J CLIN ENDOCR METAB, V58, P868, DOI 10.1210/jcem-58-5-868; WALZER RA, 1963, JAMA-J AM MED ASSOC, V184, P743, DOI 10.1001/jama.1963.03700230043006; WEITZMAN SA, 1978, LANCET, V1, P1068	44	53	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					490	494		10.7326/0003-4819-124-5-199603010-00005	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602707				2022-12-24	WOS:A1996TW77300005
J	Jain, RK				Jain, RK			Delivery of molecular medicine to solid tumors	SCIENCE			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Harvard Medical School	Jain, RK (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,EDWIN L STEELE LAB,BOSTON,MA 02114, USA.		Berk, David A/A-4863-2012; Jain, Rakesh K/I-1384-2017; Swartz, Melody A./F-9563-2011	Berk, David A/0000-0002-3855-6886; Jain, Rakesh K/0000-0001-7571-3548; 				[Anonymous], 1996, B MED ETHICS; BAXTER LT, 1995, CANCER RES, V55, P4611; Beardsley T, 1994, SCI AM, V270, P118; DEDRICK RL, 1973, J PHARMACOKINET BIOP, V1, P435, DOI 10.1007/BF01059667; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HALL SS, 1995, SCIENCE, V270, P915, DOI 10.1126/science.270.5238.915; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; JAIN RK, IN PRESS ANN BIOMED; Jobe P C, 1994, Physiologist, V37, P79; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; REESE DM, 1995, NATURE, V378, P532, DOI 10.1038/378532c0; WADMAN M, 1995, NATURE, V378, P655, DOI 10.1038/378655a0; WURTMAN RJ, 1995, NAT MED, V1, P1122, DOI 10.1038/nm1195-1122	14	270	315	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1079	1080		10.1126/science.271.5252.1079	http://dx.doi.org/10.1126/science.271.5252.1079			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599082				2022-12-24	WOS:A1996TW70100027
J	Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES				Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES			Disruption of the nuclear hormone receptor ROR alpha in staggerer mice	NATURE			English	Article							MUTANT MICE; PURKINJE-CELLS; MULTIPLE INNERVATION; CEREBELLAR CORTEX; CLIMBING FIBERS; MOUSE; ABNORMALITIES	HOMOZYGOUS staggerer (sg) mice show a characteristic severe cerebellar ataxia due to a cell-autonomous defect in the development of Purkinje cells(1,2). These cells show immature morphology, synaptic arrangement, biochemical properties and gene expression, and are reduced in numbers(3-12). In addition, sg heterozygotes show accelerated dendritic atrophy and cell loss(13), suggesting that sg has a role in mature Purkinje cells. Effects of this mutation on cerebellar development have been studied for 25 years, but its molecular basis has remained unknown, We have genetically mapped staggerer to an interval of 160 kilobases on mouse chromosome 9 which was found to contain the gene encoding ROR alpha, a member of the nuclear hormone-receptor superfamily. Staggerer mice were found to carry a deletion within the ROR alpha gene that prevents translation of the ligand-binding homology domain. We propose a model based on these results, in which ROR alpha interacts with the thyroid hormone signalling pathway to induce Purkinje-cell maturation.	JACKSON LAB, BAR HARBOR, ME 04609 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	Jackson Laboratory; Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Oak Ridge National Laboratory	Hamilton, BA (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012; van Berkel, Victor/AAC-1956-2021	Kusumi, Kenro/0000-0002-1458-4540; Hamilton, Bruce/0000-0001-5599-9139				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; HATTEN ME, 1978, NATURE, V276, P504, DOI 10.1038/276504a0; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HERRUP K, 1979, BRAIN RES, V172, P1, DOI 10.1016/0006-8993(79)90891-6; HERRUP K, 1979, BRAIN RES, V178, P443, DOI 10.1016/0006-8993(79)90705-4; Herrup K, 1983, Brain Res, V313, P267; HERRUP K, 1981, DEV BRAIN RES, V1, P475, DOI 10.1016/0165-3806(81)90002-X; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDIS DMD, 1978, J COMP NEUROL, V179, P831, DOI 10.1002/cne.901790408; LEGRAND J, 1979, TRENDS NEUROSCI, V2, P234, DOI 10.1016/0166-2236(79)90091-2; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MESSER A, 1988, J NEUROCHEM, V51, P888, DOI 10.1111/j.1471-4159.1988.tb01825.x; Sambrook J., 1989, MOL CLONING LAB MANU; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SOTELO C, 1975, ADV NEUROL, V12, P335; SOTELO C, 1974, BRAIN RES, V67, P519, DOI 10.1016/0006-8993(74)90499-5; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TRENKNER E, 1979, NATURE, V277, P566, DOI 10.1038/277566a0; TRENKNER E, 1986, J NEUROSCI, V6, P1733; ZANJANI HS, 1992, DEV BRAIN RES, V67, P153, DOI 10.1016/0165-3806(92)90216-J; ZHOU L, 1994, J BIOL CHEM, V269, P13346	30	411	424	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					736	739		10.1038/379736a0	http://dx.doi.org/10.1038/379736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602221				2022-12-24	WOS:A1996TW56700055
J	Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE				Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE			Targeted disruption of the mouse STAT1 results in compromised innate immunity to viral disease	CELL			English	Article							GAMMA SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; MUTANT-CELL LINE; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; GENE; INDUCTION; IRF-1	The STAT1 transcription factor is activated in response to many cytokines and growth factors. To study the requirement for STAT1 in vivo, we disrupted the Stat1 gene in embryonic stem (ES) cells and in mice. Stat1(-/-) ES cells were unresponsive to interferon (IFN), but retained responsiveness to leukemia inhibitory factor (LIF) and remained LIF dependent for undifferentiated growth. Stat1(-/-) animals were born at normal frequencies and displayed no gross developmental defects. However, these animals failed to thrive and were extremely susceptible to viral disease. Cells and tissues from Stat1(-/-) mice were unresponsive to IFN, but remained responsive to all other cytokines tested. Thus, STAT1 appears to be specific for IFN pathways that are essential for viability in the face of otherwise innocuous pathogens.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	New York University; New York University; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022; Simon, Celeste/AAG-3941-2021	Levy, David/0000-0002-7320-7788; 				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COMPTON SR, 1993, LAB ANIM SCI, V43, P15; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HAVELL EA, 1972, ANTIMICROB AGENTS CH, V2, P476, DOI 10.1128/AAC.2.6.476; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUME DA, 1995, J INTERF CYTOK RES, V15, P279, DOI 10.1089/jir.1995.15.279; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; LORD KA, 1990, ONCOGENE, V5, P387; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIJNS VECJ, 1994, J IMMUNOL, V153, P2029; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P7828; Wurst W., 1993, Gene targeting: a practical approach., P33; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	62	1280	1321	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					443	450		10.1016/S0092-8674(00)81289-1	http://dx.doi.org/10.1016/S0092-8674(00)81289-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608598	hybrid			2022-12-24	WOS:A1996TV70800013
J	Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL				Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL			Characterization of the active intermediate of a GroEL-GroES-mediated protein folding reaction	CELL			English	Article							RHODANESE; CYCLE	Recent studies of GroE-mediated protein folding indicate that substrate proteins are productively released from a cis ternary complex in which the nonnative substrate is sequestered within the GroEL channel underneath GroES. Here, we examine whether protein folding can occur in this space. Stopped-flow fluorescence anisotropy of a pyrene-rhodanese-GroEL complex indicates that addition of GroES and ATP (but not ADP) leads to a rapid change in substrate flexibility at GroEL. Strikingly, when GroES release is blocked by the use of either a nonhydrolyzable ATP analog or a single-ring GroEL mutant, substrates complete folding while remaining associated with chaperonin. We conclude that the cis ternary complex, in the presence of ATP, is the active state intermediate in the GroE-mediated folding reaction: folding is initiated in this state and for some substrates may be completed prior to the timed release of GroES triggered by ATP hydrolysis.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Vanderbilt University	Weissman, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.			Rye, Hays/0000-0002-9420-3137; Weissman, Jonathan/0000-0003-2445-670X				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; ELLIS RJ, 1994, CURR BIOL, V4, P633; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; ROUSSEAU DL, 1995, BIOCHEMISTRY-US, V34, P14508, DOI 10.1021/bi00044a029; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TANDON S, 1989, J BIOL CHEM, V264, P9859; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YEE DP, 1994, J MOL BIOL, V241, P557, DOI 10.1006/jmbi.1994.1531; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	42	344	347	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					481	490		10.1016/S0092-8674(00)81293-3	http://dx.doi.org/10.1016/S0092-8674(00)81293-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608602	hybrid			2022-12-24	WOS:A1996TV70800017
J	Hilleman, MR				Hilleman, MR			Cooperation between government and industry in combating a perceived emerging pandemic - The 1976 swine influenza vaccination program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Hilleman, MR (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,MERCK INST THERAPEUT RES,WP53C-350,W POINT,PA 19486, USA.							HILLEMAN M R, 1958, Mil Med, V123, P23; LANGMUIR AD, 1979, J ROY SOC MED, V72, P660, DOI 10.1177/014107687907200908; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, DOI [10.17226/12660, DOI 10.17226/12660]; OSBORN JE, 1977, HIST SCI POLITICS IN; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P1005; Silverstein ArthurM., 1981, PURE POLITICS IMPURE; SOFRANOK TJ, 1991, AM J EPIDEMIOL, V133, P940; WEBSTER RG, 1994, SEMIN VIROL, V5, P103, DOI 10.1006/smvy.1994.1011; 1976, L94380 PUB; 1976, L94266 PUB, P890	10	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					241	243		10.1001/jama.275.3.241	http://dx.doi.org/10.1001/jama.275.3.241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604179				2022-12-24	WOS:A1996TP28200034
J	Tytler, D; Fan, XM; Burles, S				Tytler, D; Fan, XM; Burles, S			Cosmological baryon density derived from the deuterium abundance at redshift z=3.57	NATURE			English	Article								THE primordial ratio of deuterium to hydrogen nuclei (D/H), created as a result of the Big Bang, provides the most sensitive measure of the cosmological density of baryons(1-5). Measurements of the D/H ratio in the interstellar medium of our Galaxy place a strict lower limit on the primordial ratio(6), because processing of gas by stars reduces the abundance of deuterium relative to hydrogen. Absorption of radiation from distant quasars by intervening clouds of gas offers a means of probing D/H ratios at large redshifts, where the effects of stellar processing should be negligible. Measurements(7,8) on one absorption system have indicated an extremely high primordial abundance ratio of 24 x 10(-5). Here we report a measurement of the D/H ratio in another high-redshift absorption system, and obtain a value that is an order of magnitude lower than that reported previously(7,8). The measured ratio of 2.3 x 10(-5) is consistent with that in the interstellar medium (after allowing for Galactic chemical evolution(9,10)), and indicates that the absorption spectra on which the earlier estimates are based may have been subject to strong contamination. We calculate a baryon density that is 5% of the critical density required to close the Universe.	UNIV CALIF SAN DIEGO, CTR ASTROPHYS & SPACE SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Tytler, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHYS, C0111, LA JOLLA, CA 92093 USA.							Carswell RF, 1996, MON NOT R ASTRON SOC, V278, P506, DOI 10.1093/mnras/278.2.506; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1; CHARBONNEL C, 1995, ASTROPHYS J, V453, pL41; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; DONAHUE M, 1991, ASTROPHYS J, V383, P511, DOI 10.1086/170809; EDMUNDS MG, 1994, MON NOT R ASTRON SOC, V270, pL37; GAIL HP, 1974, ASTRON ASTROPHYS, V32, P65; GALLI D, 1995, ASTROPHYS J, V443, P536, DOI 10.1086/175546; GEISS J, 1994, ORIGIN EVOLUTION ELE, V89; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; KRAUSS LM, 1995, PHYS LETT B, V347, P347, DOI 10.1016/0370-2693(95)00082-V; Levshakov SA, 1996, MON NOT R ASTRON SOC, V278, P497, DOI 10.1093/mnras/278.2.497; LINSKY JL, 1995, ASTROPHYS J, V451, P335, DOI 10.1086/176223; MATHEWS WG, 1987, ASTROPHYS J, V323, P456, DOI 10.1086/165843; MCCULLOUGH PR, 1992, ASTROPHYS J, V390, P213, DOI 10.1086/171271; MORTON DC, 1991, ASTROPHYS J SUPPL S, V77, P119, DOI 10.1086/191601; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PAGEL BEJ, 1994, ESO EIPC WORKSH LIGH, P155; PERSIC M, 1992, MON NOT R ASTRON SOC, V258, pP14, DOI 10.1093/mnras/258.1.14P; PETITJEAN P, 1990, ASTRON ASTROPHYS, V231, P309; PRATT M, 1996, WORKSHOP DARK MATTER; Ryan SG, 1996, ASTROPHYS J, V458, P543, DOI 10.1086/176838; SARKAR S, UNPUB REP PROG PHYS; SASSELOV D, 1995, ASTROPHYS J, V444, pL5; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; STEIGMAN G, 1992, ASTROPHYS J, V401, P150, DOI 10.1086/172048; STEIGMAN G, 1995, ASTROPHYS J, V453, P173, DOI 10.1086/176378; THUAN TX, 1996, INTERPLAY MASSIVE ST; VAUCLAIR S, 1995, ASTRON ASTROPHYS, V295, P715; VOGT S, 1994, P SOC PHOTO-OPT INS, V2198, P362, DOI 10.1117/12.176725; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WAMPLER EJ, UNPUB	34	287	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					207	209		10.1038/381207a0	http://dx.doi.org/10.1038/381207a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622761	Green Submitted			2022-12-24	WOS:A1996UL24900044
J	Levy, EM; Viscoli, CM; Horwitz, RI				Levy, EM; Viscoli, CM; Horwitz, RI			The effect of acute renal failure on mortality - A cohort analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; RISK-FACTORS; APACHE-II; PREDICTION; SURVIVAL; INSUFFICIENCY; HEMODIALYSIS; PROGNOSIS; VARIABLES; PATTERNS	Objective.-To determine if the high mortality in acute renal failure is explained by underlying illnesses (comorbidity). Design.-Cohort analytic study. Setting.-An 826-bed general hospital providing primary, secondary, and tertiary care. Patients.-From 16248 inpatients undergoing radiocontrast procedures between 1987 and 1989, we identified 183 index subjects who developed contrast media-associated renal failure (defined as an increase in serum creatinine level of at least 25%, to at least 177 mu mol/L [2 mg/dL], within 2 days of receiving contrast material) and 174 paired subjects, matched for age and baseline serum creatinine level, who underwent similar contrast procedures without developing renal failure. Main Outcome Measure.-Death during hospitalization. Results.-The mortality rate in subjects without renal failure was 7%, compared with 34% in the corresponding index subjects with renal failure (odds ratio, 6.5; P<.001). After adjusting for differences in comorbidity, renal failure was associated with an odds ratio of dying of 5.5. Subjects who died after developing renal failure had complicated clinical courses characterized by sepsis, bleeding, delirium, and respiratory failure; most of these complications developed after the onset of renal failure. Deaths from renal causes were rare. Conclusions.-The high mortality rate in acute renal failure is not explained by the underlying conditions alone, Renal failure appears to increase the risk of developing severe nonrenal complications that lead to death and should not be regarded as a treatable complication of serious illness.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University	Levy, EM (corresponding author), BRIGHAM & WOMENS HOSP,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABREO K, 1986, ARCH INTERN MED, V146, P1338, DOI 10.1001/archinte.146.7.1338; ANDERSON RJ, 1977, NEW ENGL J MED, V296, P1134, DOI 10.1056/NEJM197705192962002; BOULTONJONES M, 1994, LANCET, V344, P559, DOI 10.1016/S0140-6736(94)91958-5; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; CAMERON JS, 1986, Q J MED, V59, P337; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CIOFFI WG, 1984, ANN SURG, V200, P205, DOI 10.1097/00000658-198408000-00015; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DOUMA CE, 1994, J AM SOC NEPHROL, V5, P391; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; FLEISS JL, 1981, STATISTICAL METHODS, P143; FROST L, 1993, SCAND J UROL NEPHROL, V27, P453, DOI 10.3109/00365599309182277; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GROENEVELD ABJ, 1991, NEPHRON, V59, P602, DOI 10.1159/000186651; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Halstenberg W., 1993, Journal of the American Society of Nephrology, V4, P317; HOSMER DW, 1989, APPL LOGISTIC REGRES, V1, P10; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVY EM, 1994, J AM SOC NEPHROL, V4, P319; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; MAHER ER, 1989, Q J MED, V72, P857; MCMURRAY SD, 1978, ARCH INTERN MED, V138, P950, DOI 10.1001/archinte.138.6.950; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; RASMUSSEN HH, 1985, ARCH INTERN MED, V145, P2015, DOI 10.1001/archinte.145.11.2015; RASMUSSEN HH, 1982, AM J MED, V73, P211, DOI 10.1016/0002-9343(82)90181-4; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROUTH GS, 1980, POSTGRAD MED J, V56, P244, DOI 10.1136/pgmj.56.654.244; SCHAEFER JH, 1991, INTENS CARE MED, V17, P19, DOI 10.1007/BF01708404; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; WERB R, 1979, RESUSCITATION, V7, P95, DOI 10.1016/0300-9572(79)90003-0; WHEELER DC, 1986, Q J MED, V61, P977; WILKINS RG, 1983, ANAESTHESIA, V38, P628, DOI 10.1111/j.1365-2044.1983.tb12153.x	35	1063	1127	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1489	1494		10.1001/jama.275.19.1489	http://dx.doi.org/10.1001/jama.275.19.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622223				2022-12-24	WOS:A1996UJ93700032
J	Garner, DW				Garner, DW			Banning tobacco billboards - The case for municipal action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1994, Baltimore, Md, became the first city to generally prohibit billboards from displaying alcohol and tobacco advertisements. The owner of most of Baltimore's billboards, Penn Advertising, sued, but the federal district court rejected the billboard company's complaint and ruled that the First Amendment had not been violated and that the federal cigarette labeling acts had not preempted the ability of Baltimore to regulate and prohibit billboard cigarette advertising. In the fall of 1995, the federal district court's judgment was unanimously affirmed by the Fourth Circuit Court of Appeals in Richmond, Va. This article analyzes the constitutional and preemption issues and concludes that states and municipalities are on firm legal ground when they restrict the location or placement of publicly visible cigarette advertisements without attempting to regulate the advertisement's content or message. States and municipalities command broad authority to protect children and to shield the public from intrusive forms of advertisement that inflict their messages on a captive audience. A billboard ban thus offers local communities a legal avenue to help curb the rising tide of juvenile smoking without raising taxes, creating bureaucracy, or angering smokers.			Garner, DW (corresponding author), SO ILLINOIS UNIV,SCH LAW,CARBONDALE,IL 62901, USA.							AGUS C, 1990, NEWSDAY         0613, P4; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; KIRBY J, 1990, NEWSDAY         0304, P4; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; ROEMER R, 1986, UNPUB NATL LEGISLATI, P66; RONSON J, 1992, WORLD SMOKING HLTH, V2, P25; RONSON J, 1992, WORLD SMOKING HLTH, V2, P24; ROTHSTEIN L, 1995, HLTH LAW NEWS    SEP, P4; *SMOK CONTR ADV RE, 1994, ISS STUD CORR ADV IN; *US DEPT HHS, 1989, HLTH CONS SMOK NIC A, P9; *US DEPT HHS, 1994, PREV TOB US YOUNG PE, P192; 1995, TOBOCCO FREE YOU FAL, P17; 1965, PUB L, V8992; 1994, MILFORD DAILY N 1118, P1; 1993, FED REGISTER, V58, P45156; 1995, FED REGISTER, V60, P41314; 1993, SCENIC AM, P16; 1995, FED REGISTER, V60, P41315; 1970, 91222 PUB L; 1993, FED REGISTER, V58, P45158	21	6	6	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1263	1269						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601959				2022-12-24	WOS:A1996UF47800031
J	Choi, OH; Kim, JH; Kinet, JP				Choi, OH; Kim, JH; Kinet, JP			Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor	NATURE			English	Article							CELL; TRANSDUCTION; PLATELETS	Calcium mobilization through antigen receptors, including high-affinity IgE receptors (Fc epsilon RI), is thought to be mediated by inositol-1,4,5-trisphosphate production (InsP(3))(1-4). Here we show that antigen clustering of Fc epsilon RI on the rat mast-cell line (RBC 2H3) activates a sphingosine kinase (SK) and produces sphingosine-l-phosphate (S1P), an alternative second messenger for intracellular calcium mobilization, The sphingosine analogue, D-L-threo-dihydrosphingosine (DHS), inhibits the SK enzyme competitively with a dissociation constant, K-i, of 5 to 18 mu M. This inhibition substantially suppresses the Fc epsilon RI-mediated calcium signal, but leaves intact the syk tyrosine kinase activation and the small InsP(3) production. The entire InsP(3)-dependent pathway activated by a transfected G-protein coupled receptor, used here as a positive control, also remained intact. Thus Fc epsilon RI principally utilizes a SK pathway to mobilize calcium.	BETH ISRAEL HOSP,LAB ALLERGY & IMMUNOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Choi, OH (corresponding author), NIAID,LAB ALLERG DIS,NIH,ROCKVILLE,MD 20852, USA.							BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CHOI OH, 1993, J IMMUNOL, V151, P5586; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MATTIE M, 1994, J BIOL CHEM, V269, P3181; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x	17	372	385	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					634	636						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602265				2022-12-24	WOS:A1996UF74100048
J	Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN				Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN			Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene	NATURE			English	Article							IL-4; GENERATION; INVIVO; CELLS	Signal transducers and activators of transcription (Stats) are activated by tyrosine phosphorylation in response to cytokines, and are thought to mediate many of their functional responses(1-4) Stat6 is activated in response to interleukin (IL)-4 (refs 5,6) and may contribute to various functions including mitogenesis, T-helper cell differentiation and immunoglobulin isotype switching(7). To evaluate the role of Stat6, we generated Stat6-null mice (Stat6(-/-)) by gene disruption in embryonic stem cells. The mice were viable, indicating the lack of a non-redundant function in normal development. Although naive lymphoid cell development was normal, Stat6(-/-) mice were deficient in IL-4-mediated functions including Th2 helper T-cell differentiation, expression of cell surface markers, and immunoglobulin class switching to IgE. In contrast, IL-4-mediated proliferation was only partly affected.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NIAID, IMMUNOL LAB, NIH, BETHESDA, MD 20892 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Quelle, Frederick/0000-0002-1184-6170; Doherty, Peter Charles/0000-0002-5028-3489; Sangster, Mark/0000-0002-1599-5894				COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COVFFMAN RL, 1996, J IMMUNOL, V136, P4538; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; HOUR J, 1994, SCIENCE, V265, P1701; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KATONA IM, 1991, J IMMUNOL, V146, P4215; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRETSOVALI A, 1995, NUCLEIC ACIDS RES, V23, P2919, DOI 10.1093/nar/23.15.2919; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RICHARDSML, 1994, J IMMUNOL, V22, P3453; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SNAPPER CM, 1988, P NATL ACAD SCI USA, V85, P6107, DOI 10.1073/pnas.85.16.6107; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7	29	1072	1096	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	1996	380	6575					630	633		10.1038/380630a0	http://dx.doi.org/10.1038/380630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602264				2022-12-24	WOS:A1996UF74100047
J	Sugita, Y				Sugita, Y			Global plasticity in adult visual cortex following reversal of visual input	NATURE			English	Article							CONNECTIONS; MOTION	THE reversal or displacement of the retinal image by prism spectacles leads to extreme disruption of visually guided behaviour, but after an extended period of visual transformation normal behaviour is gradually restored. It is unclear whether this adaptation involves a change in visual perception(1-5), the learning of new motor responses(6), a modification of the sensorimotor control system(7) or a proprioceptive change in the perceived positions of the body parts(8). Here I describe the effects of visual field reversal on neuronal activity in the monkey visual cortex After a few months of wearing reversing spectacles, some cells in the primary visual cortex began to respond to stimuli presented not only in the contralateral visual field but also in the ipsilateral field. These cells were not selective for orientation or direction of motion, but responded well to a light flash. This result suggests that adaptation to visual field reversal is mediated, at least in part, by a large-scale functional reorganization at an early stage the visual processing pathway.			Sugita, Y (corresponding author), TOYOHASHI UNIV TECHNOL,LAB NEURAL SYST,TOYOHASHI,AICHI 441,JAPAN.							BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P466, DOI 10.1113/jphysiol.1962.sp006990; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DAY RH, 1967, PSYCHOL BULL, V67, P307, DOI 10.1037/h0024482; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HARRIS CS, 1963, SCIENCE, V140, P812, DOI 10.1126/science.140.3568.812; HELD R, 1963, SCIENCE, V142, P455, DOI 10.1126/science.142.3591.455; Kohler I, 1964, PSYCHOL ISSUES, V3, P1; SHIMOJO S, 1981, PERCEPTION, V10, P391, DOI 10.1068/p100391; SPATZ WB, 1984, NEUROSCI LETT, V48, P49, DOI 10.1016/0304-3940(84)90287-8; Stratton G. M., 1897, PSYCHOL REV, V4, P463, DOI [10.1037/h0075482, DOI 10.1037/H0071173]; Stratton G.M., 1897, PSYCHOL REV, V4, P341, DOI [DOI 10.1037/H0075482, 10.1037/h0075482]; SUGITA Y, 1994, PERCEPT MOTOR SKILL, V79, P1047, DOI 10.2466/pms.1994.79.2.1047; SUGITA Y, 1991, NEUROREPORT, V2, P751, DOI 10.1097/00001756-199112000-00005; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; Taylor J. g., 1962, BEHAV BASIS PERCEPTI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4	16	60	60	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					523	526		10.1038/380523a0	http://dx.doi.org/10.1038/380523a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE663	8606770				2022-12-24	WOS:A1996UE66300048
J	Gerstein, HC; Yusuf, S				Gerstein, HC; Yusuf, S			Dysglycaemia and risk of cardiovascular disease	LANCET			English	Article							CORONARY-HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; MORTALITY; HYPERGLYCEMIA; ASSOCIATION; WHITEHALL; NIDDM; DEATH; MEN		MCMASTER UNIV, CHEDOKE MCMASTER HOSP, DEPT MED, DIABET CARE & RES CTR, HAMILTON, ON L8N 3Z5, CANADA; HAMILTON CIV HOSP, RES CTR, PREVENT CARDIOL & THERAPEUT PROGRAMME, HAMILTON, ON, CANADA	McMaster University; McMaster University			Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1994, STROKE, V25, P951, DOI 10.1161/01.STR.25.5.951; CURB JD, 1995, CIRCULATION, V91, P2591, DOI 10.1161/01.CIR.91.10.2591; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; DONAHUE RP, 1992, DIABETES CARE, V15, P1141, DOI 10.2337/diacare.15.9.1141; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; FULLER JH, 1980, LANCET, V1, P1373; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HERMAN JB, 1977, DIABETOLOGIA, V13, P229, DOI 10.1007/BF01219704; JARRETT RJ, 1984, DIABETOLOGIA, V26, P99; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; Kenny S.J., 1995, NIH PUBLICATION, P47; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LEONETTI F, 1993, J ENDOCRINOL INVEST, V16, P875, DOI 10.1007/BF03348949; MALBERG K, 1995, J AM COLL CARDIOL, V26, P57; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; REWERS M, 1995, NIH PUBLICATION, P179; SCHEIDTNAVE C, 1991, AM J EPIDEMIOL, V133, P565, DOI 10.1093/oxfordjournals.aje.a115928; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; VIBERTI G, 1995, NEW ENGL J MED, V332, P1293, DOI 10.1056/NEJM199505113321909; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; 1992, JAMA-J AM MED ASSOC, V266, P1292	29	138	143	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					949	950		10.1016/S0140-6736(96)91420-8	http://dx.doi.org/10.1016/S0140-6736(96)91420-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598762				2022-12-24	WOS:A1996UD59100015
J	Francino, MP; Chao, L; Riley, MA; Ochman, H				Francino, MP; Chao, L; Riley, MA; Ochman, H			Asymmetries generated by transcription-coupled repair in enterobacterial genes	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTATION-RATES; DNA-REPLICATION; LAGGING-STRAND; CODON USAGE; POPULATIONS; DEAMINATION; SALMONELLA; REGION; OPERON	Although certain replication errors occur at different frequencies on each of the complementary strands of DNA, it remains unclear whether this bias is prevalent enough during chromosome replication to affect sequence evolution. Here, nucleotide substitutions in enteric bacteria were examined, and no difference in mutation rates was detected between the leading and lagging strands, but in comparing the coding and noncoding strands, an excess of C-->T changes was observed on the coding strand. This asymmetry is best explained by transcription-coupled repair on the noncoding strand. Although the vast majority of mutations are thought to arise from spontaneous errors during replication, this result implicates DNA damage as a substantial source of mutations in the wild.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; UNIV MARYLAND, DEPT ZOOL, COLLEGE PK, MD 20742 USA; YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA	University of Rochester; University System of Maryland; University of Maryland College Park; Yale University			Francino, M.Pilar/H-9090-2015; Riley, Margaret Ann/AAB-9743-2022	Francino, M.Pilar/0000-0002-4510-5653; 				BERG OG, 1995, J MOL EVOL, V41, P449, DOI 10.1007/BF00160316; BOYD EF, 1994, P NATL ACAD SCI USA, V91, P1280, DOI 10.1073/pnas.91.4.1280; BULMER M, 1991, J MOL EVOL, V33, P305, DOI 10.1007/BF02102861; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DOWNES CS, 1993, BIOESSAYS, V15, P209, DOI 10.1002/bies.950150311; DUBOSE RF, 1988, P NATL ACAD SCI USA, V85, P7036, DOI 10.1073/pnas.85.18.7036; EYREWALKER A, 1995, GENETICS, V140, P1407; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FREDERICO LA, 1993, BIOCHEMISTRY-US, V32, P6523, DOI 10.1021/bi00077a005; HALL BG, 1992, MOL BIOL EVOL, V9, P654; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; Kornberg A., 1992, DNA REPLICATION; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MADDISON WP, 1992, MACCLADE V 3 0 ANAL; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NELSON K, 1994, P NATL ACAD SCI USA, V91, P10227, DOI 10.1073/pnas.91.21.10227; NELSON K, 1991, P NATL ACAD SCI USA, V88, P6667, DOI 10.1073/pnas.88.15.6667; NELSON K, 1992, J BACTERIOL, V174, P6886, DOI 10.1128/JB.174.21.6886-6895.1992; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; ROBERTS JD, 1994, J BIOL CHEM, V269, P1711; SELANDER RK, 1994, FEMS SYMP, P17; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SKANDALIS A, 1994, MUTAT RES, V314, P21, DOI 10.1016/0921-8777(94)90057-4; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WU CI, 1991, NATURE, V352, P114, DOI 10.1038/352114b0; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; [No title captured]	31	109	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					107	109		10.1126/science.272.5258.107	http://dx.doi.org/10.1126/science.272.5258.107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600517				2022-12-24	WOS:A1996UD59700049
J	Nehrbass, U; Blobel, G				Nehrbass, U; Blobel, G			Role of the nuclear transport factor p10 in nuclear import	SCIENCE			English	Article							PROTEIN RAN/TC4	The nuclear import factor p10 was cloned from Saccharomyces cerevisiae and found to be essential. The protein p10 can bind directly to several peptide repeat-containing nucleoporins. It also binds to the guanosine triphosphatase (GTPase) Ran in its guanosine diphosphate (GDP)-bound form and to karyopherin beta. Assembly of the karyopherin heterodimer on immobilized nucleoporin yielded cooperative binding of p10 and Ran-GDP. Addition of GTP to this pentameric complex led to dissociation of karyopherin alpha, presumably via in situ formation of Ran-GTP from Ran-GDP. Thus, p10 appears to coordinate the Ran-dependent association and dissociation reactions underlying nuclear import.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University				Vallar, Laurent/0000-0002-4404-1010; Nehrbass, Ulf/0000-0002-7028-8076				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DECASTILLIA CS, 1995, J CELL BIOL, V131, P19; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	27	155	157	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					120	122		10.1126/science.272.5258.120	http://dx.doi.org/10.1126/science.272.5258.120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600522				2022-12-24	WOS:A1996UD59700054
J	Nowak, MA; Bangham, CRM				Nowak, MA; Bangham, CRM			Population dynamics of immune responses to persistent viruses	SCIENCE			English	Review							CYTOTOXIC LYMPHOCYTES-T; CENTRAL-NERVOUS-SYSTEM; EPSTEIN-BARR-VIRUS; GENETIC-VARIATION; CELL RECOGNITION; HIV-INFECTION; TYPE-1; INVIVO; INFLUENZA; CLEARANCE	Mathematical models, which are based on a firm understanding of biological interactions, can provide nonintuitive insights into the dynamics of host responses to infectious agents and can suggest new avenues for experimentation. Here, a simple mathematical approach is developed to explore the relation between antiviral immune responses, virus load, and virus diversity. The model results are compared to data on cytotoxic Tell responses and viral diversity in infections with the human T cell leukemia virus (HTLV-1) and the human immunodeficiency virus (HIV-1).	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, LONDON W2 1PG, ENGLAND	Imperial College London	Nowak, MA (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008	Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUR Z, 1991, EXP HEMATOL, V19, P364; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ANDERSON R M, 1991; ANDERSON RM, 1994, SCIENCE, V264, P1884, DOI 10.1126/science.8009218; ANDERSON RM, 1989, CELL TO CELL SIGNALLING : FROM EXPERIMENTS TO THEORETICAL MODELS, P335; Antia R, 1996, P NATL ACAD SCI USA, V93, P985, DOI 10.1073/pnas.93.3.985; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; ASJO B, 1990, AIDS RES HUM RETROV, V6, P1177, DOI 10.1089/aid.1990.6.1177; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Bangham C R, 1993, Curr Opin Neurobiol, V3, P773, DOI 10.1016/0959-4388(93)90152-O; Bangham CRM, 1996, SEMIN VIROL, V7, P41, DOI 10.1006/smvy.1996.0006; BERTOLETTI A, 1994, J EXP MED, V180, P933, DOI 10.1084/jem.180.3.933; BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0; BONHOEFFER S, 1995, IMMUNOL TODAY, V16, P131, DOI 10.1016/0167-5699(95)80129-4; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BUREAU JF, 1993, NAT GENET, V5, P87, DOI 10.1038/ng0993-87; BURK RD, 1994, J INFECT DIS, V170, P1418, DOI 10.1093/infdis/170.6.1418; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CANNON MJ, 1987, IMMUNOLOGY, V62, P133; CHEYNIER R, 1995, ADV EXP MED BIOL, V374, P173; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Daenke S, 1996, VIROLOGY, V217, P139, DOI 10.1006/viro.1996.0101; DEBOER RJ, 1994, P NATL ACAD SCI USA, V91, P544, DOI 10.1073/pnas.91.2.544; DEBOER RJ, 1995, J THEOR BIOL, V175, P567, DOI 10.1006/jtbi.1995.0165; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DIEHL LJ, 1995, J VIROL, V69, P2328, DOI 10.1128/JVI.69.4.2328-2332.1995; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; Ferrari C, 1996, SEMIN VIROL, V7, P23, DOI 10.1006/smvy.1996.0004; FONG TL, 1994, J MED VIROL, V43, P155, DOI 10.1002/jmv.1890430210; FOX JC, 1995, J GEN VIROL, V76, P309, DOI 10.1099/0022-1317-76-2-309; FROST SDW, 1994, AIDS, V8, P323, DOI 10.1097/00002030-199403000-00005; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HERZ AVM, IN PRESS P NATL ACAD; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HIRSCH VM, 1995, J VIROL, V69, P955, DOI 10.1128/JVI.69.2.955-967.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; KHANNA R, 1993, J IMMUNOL, V150, P5154; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCELRATH MJ, 1994, J VIROL, V68, P5074, DOI 10.1128/JVI.68.8.5074-5083.1994; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MCLEAN AR, 1992, J THEOR BIOL, V155, P69, DOI 10.1016/S0022-5193(05)80549-1; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MITTLER JE, J ACQUIRED IMMUNE DE; MOSKOPHIDIS D, 1994, J IMMUNOL, V152, P4976; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; NIEWIESK S, IN PRESS J MOL EVOL; NOWAK MA, 1995, J THEOR BIOL, V175, P325, DOI 10.1006/jtbi.1995.0146; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, IN PRESS P NATL ACAD; OLDSTONE MB, 1973, J EXP MED, V137, P1201, DOI 10.1084/jem.137.5.1201; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PLATAK M, 1993, SCIENCE, V259, P1749; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; REHERMANN B, 1995, J CLIN INVEST, V96, P1527, DOI 10.1172/JCI118191; RICKINSON AB, 1986, EPSTEINBARR VIRUS RE, P75; RIDDELL SR, 1992, SCIENCE, V257, P238; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SASAKI A, 1994, J THEOR BIOL, V168, P291, DOI 10.1006/jtbi.1994.1110; SHANLEY JD, 1993, J INFECT DIS, V167, P264, DOI 10.1093/infdis/167.2.264; STEINHAUER DA, 1987, ANNU REV MICROBIOL, V41, P409, DOI 10.1146/annurev.mi.41.100187.002205; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZINKERNAGEL RM, 1985, NATURE, V316, P814, DOI 10.1038/316814a0; Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173	102	890	937	6	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					74	79		10.1126/science.272.5258.74	http://dx.doi.org/10.1126/science.272.5258.74			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600540				2022-12-24	WOS:A1996UD59700039
J	Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA				Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA			Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children	LANCET			English	Article								Background High hepatic copper concentrations have been reported in several liver disorders. We report six Native Canadian children with severe chronic cholestatic liver disease, who had excess hepatic copper and zinc. Methods The children, aged 22 months to 8 years, dame from northern Ontario, Canada. All were referred for possible liver transplantation because of end-stage liver disease. We examined explanted liver samples (or liver biopsy material in one case) by scanning transmission electronmicroscopic (STEM) X-ray elemental microanalysis and atomic absorption spectrophotometry. Samples from four controls (two with no liver pathology, one with biliary atresia, and one with Wilson's disease) were also analysed by atomic absorption spectrophotometry. Findings The explanted livers showed similar distinctive signs of advanced biliary cirrhosis, and on electronmicroscopy there were dense deposits in enlarged lyosomes and in cytoplasm. Hepatic copper concentrations were many times higher in the five patients with measurements (47.6-56.9 mu g/g dry weight) than in two samples of normal control liver tissue (2.3 and 2.9 mu g/g). Similarly, hepatic zinc concentrations were many times higher in the patients than in controls (104-128 vs 1.9-3.2 mu g/g dry weight). Interpretation The excess copper may be due to chronic cholestasis but the excess zinc is unexplained. Since three of the patients are related (shared grandparents), a genetic disorder of metal metabolism is possible, but we cannot exclude environmental factors.	HOSP SICK CHILDREN,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT SURG,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PAEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto								ADAMS PC, 1994, HEPATOLOGY, V19, P101, DOI 10.1016/0270-9139(94)90059-0; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; VONMUHLENDAHL KE, 1994, LANCET, V344, P1515; WEBER AM, 1981, GASTROENTEROLOGY, V81, P653	6	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					866	868		10.1016/S0140-6736(96)91347-1	http://dx.doi.org/10.1016/S0140-6736(96)91347-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622393				2022-12-24	WOS:A1996UC45000011
J	Raffle, AE				Raffle, AE			Trust me, I'm a scientist: Will urologists set a lead for geneticists to follow?	LANCET			English	Editorial Material											Raffle, AE (corresponding author), AVON HLTH AUTHOR,KING SQ HOUSE,KING SQ,BRISTOL BS2 8EE,AVON,ENGLAND.							Harper PS, 1995, LANCET, V346, P1645, DOI 10.1016/S0140-6736(95)92835-9; KNOX EG, 1982, CANC UTERINE CERVIX; KNOX G, 1991, PUBLIC HEALTH, V105, P55, DOI 10.1016/S0033-3506(05)80317-8; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MILLER AB, 1986, IARC SCI PUBLICATION, V76; MURPHY SB, 1991, LANCET, V337, P344, DOI 10.1016/0140-6736(91)90957-Q; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, LANCET, V341, P100; STROUD E, 1990, BLOOD CHOLESTEROL TE; Wilson JM, 1968, PUBLIC HLTH PAPERS W, V34; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1995, NATURE, V337, P273	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					883	884		10.1016/S0140-6736(96)91353-7	http://dx.doi.org/10.1016/S0140-6736(96)91353-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622399				2022-12-24	WOS:A1996UC45000017
J	Pasqualini, R; Ruoslahti, E				Pasqualini, R; Ruoslahti, E			Organ targeting in vivo using phage display peptide libraries	NATURE			English	Article							RECEPTOR; PROTEINS	PREFERENTIAL homing of tumour cells(1,2) and leukocytes(3,4) to specific organs indicates that tissues carry unique marker molecules accessible to circulating cells. Organ-selective address molecules on endothelial surfaces have been identified for lymphocyte homing to various lymphoid organs and to tissues undergoing inflammation(5-8), and an endothelial marker responsible for tumour homing to the lungs has also been identified(9). Here we report a new approach to studying organ-selective targeting based on in vivo screening of random peptide sequences. Peptides capable of mediating selective localization of phage to brain and kidney blood vessels were identified, and showed up to 13-fold selectivity for these organs. One of the peptides displayed by the brain-localizing phage mas synthesized and shown to specifically inhibit the localization of the homologous phage into the brain. When coated onto glutaraldehyde-fixed red blood cells, the peptide caused selective localization of intravenously injected cells into the brain, These peptide sequences represent the first step towards identifying selective endothelial markers, which may be useful in targeting cells, drugs and genes into selected tissues.	LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SALMI M, 1992, P NATL ACAD SCI USA, V89, P11436, DOI 10.1073/pnas.89.23.11436; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	15	972	1156	2	170	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					364	366		10.1038/380364a0	http://dx.doi.org/10.1038/380364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598934				2022-12-24	WOS:A1996UC37900065
J	Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL				Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL			Should there be a trial of home versus hospital delivery in the United Kingdom? Measuring outcomes other than safety is feasible	BRITISH MEDICAL JOURNAL			English	Article											Dowswell, T (corresponding author), UNIV LEEDS,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				CAMPBELL R, 1986, BRIT J OBSTET GYNAEC, V93, P675, DOI 10.1111/j.1471-0528.1986.tb07965.x; CUNNINGHAM JD, 1993, SOC SCI MED, V36, P475, DOI 10.1016/0277-9536(93)90409-W; *DEP HLTH EXP MAT, 1993, REP 1; *HOUS COMM HLTH CO, 1992, WINT REP; *ROY COLL OBST GYN, 1992, RESP REP HOUS COMM H	5	38	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					753	753						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605464				2022-12-24	WOS:A1996UC16600032
J	Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD				Brownell, JE; Zhou, JX; Ranalli, T; Kobayashi, R; Edmondson, DG; Roth, SY; Allis, CD			Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation	CELL			English	Article							TRANSCRIPTION; NUCLEOSOME; DNA; CHROMATIN; SNF2/SWI2; PROTEINS; SNF5; SWI1	We report the cloning of a transcription-associated histone acetyltransferase type A (HAT A). This Tetrahymena enzyme is strikingly homologous to the yeast protein Gcn5, a putative transcriptional adaptor, and we demonstrate that recombinant Gcn5p possesses HAT activity. Both the ciliate enzyme and Gcn5p contain potential active site residues found in other acetyltransferases and a highly conserved bromodomain. The presence of this domain in nuclear A-type HATs, but not in cytoplasmic B-type HATs, suggests a mechanism whereby HAT A is directed to chromatin to facilitate transcriptional activation. These findings shed light on the biochemical function of the evolutionarily conserved Gcn5p-Ada complex, directly linking histone acetylation to gene activation, and indicate that histone acetylation is a targeted phenomenon.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Rochester; Cold Spring Harbor Laboratory; University of Texas System; UTMD Anderson Cancer Center				Dent, Sharon/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715	NCI NIH HHS [F32CA65098] Funding Source: Medline; NIGMS NIH HHS [GM51189, GM53512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA065098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053512, R37GM053512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; JOHNSON LM, 1990, P NATL ACAD SCI USA, V369, P245; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; KURIHARA T, 1992, EUR J BIOCHEM, V210, P999, DOI 10.1111/j.1432-1033.1992.tb17505.x; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1994, CHROMOSOMA, V103, P441; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAVERNARAKIS N, 1995, MOL GEN GENET, V247, P571, DOI 10.1007/BF00290348; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WINSTON F, 1992, TRENDS GENET, V8, P337; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	59	1247	1303	6	102	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					843	851		10.1016/S0092-8674(00)81063-6	http://dx.doi.org/10.1016/S0092-8674(00)81063-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601308	hybrid			2022-12-24	WOS:A1996UC38100006
J	Lansdown, ABG				Lansdown, ABG			Zinc in the healing wound	LANCET			English	Editorial Material							VENOUS LEG ULCERS; TISSUE				Lansdown, ABG (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT COMPARAT BIOL,LONDON,ENGLAND.							AGREN MS, 1993, BRIT J DERMATOL, V129, P221, DOI 10.1111/j.1365-2133.1993.tb03533.x; BARCIA PJ, 1970, ANN SURG, V172, P1048, DOI 10.1097/00000658-197012000-00019; ERIKSSON G, 1986, BRIT J DERMATOL, V114, P227, DOI 10.1111/j.1365-2133.1986.tb02801.x; HALLBOOK T, 1972, LANCET, V2, P780; HENG MK, 1993, BRIT J DERMATOL, V129, P280, DOI 10.1111/j.1365-2133.1993.tb11847.x; HENZEL JH, 1970, ARCH SURG-CHICAGO, V100, P349; Lansdown A. B. G., 1993, International Journal of Cosmetic Science, V15, P83, DOI 10.1111/j.1467-2494.1993.tb00072.x; LANSDOWN ABG, 1995, CRC CRIT R TOXICOL, V12, P397; OCCLESTON NL, 1995, 5 ANN M EUR TISS REP; PARISI AF, 1969, AM J CLIN NUTR, V22, P1222; PORIES WJ, 1967, ANN SURG, V165, P432; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93	12	64	65	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					706	707		10.1016/S0140-6736(96)90072-0	http://dx.doi.org/10.1016/S0140-6736(96)90072-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601997	Bronze			2022-12-24	WOS:A1996TZ98200005
J	Coupland, RM				Coupland, RM			The effect of weapons on health	LANCET			English	Editorial Material							RED-CROSS				Coupland, RM (corresponding author), RED CROSS,INT COMM,DIV MED,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; BECK LD, 1993, BLINDING WEAPONS; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; GILLOW JT, 1995, J ROY SOC MED, V88, pP347; 1994, LANCET, V344, P1649	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					450	451		10.1016/S0140-6736(96)90017-3	http://dx.doi.org/10.1016/S0140-6736(96)90017-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618490				2022-12-24	WOS:A1996TV72200016
J	Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V				Godfrey, K; Robinson, S; Barker, DJP; Osmond, C; Cox, V			Maternal nutrition in early and late pregnancy in relation to placental and fetal growth	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; SIZE	Objective-To assess how nutrient intakes of mothers in early and late pregnancy influence placental and fetal growth. Design-Prospective observational study. Setting-Princess Anne Maternity Hospital, Southampton. Subjects-538 mothers who delivered at term. Main outcome measures-Placental and birth weights adjusted for the infant's sex and duration of gestation. Results-Mothers who had high carbohydrate intakes in early pregnancy had babies with lower placental and birth weights. Low maternal intakes of dairy and meat protein in late pregnancy were also associated with lower placental and birth weights. Placental weight fell by 49 g (95% confidence interval 16 g to 81 g; P=0.002) for each log g increase in intake of carbohydrate in early pregnancy and by 1.4 g (0.4 g to 2.4 g; P=0.005) for each g decrease in intake of dairy protein in late pregnancy. Birth weight fell by 165 g (49 g to 282 g; P=0.005) for each log g increase in carbohydrate intake in early pregnancy and by 3.1 g (0.3 g to 6.0 g; P=0.03) for each g decrease in meat protein intake in late pregnancy. These associations were independent of the mother's height and body mass index and of strong relations between the mother's birth weight and the placental and birth weights of her offspring. Conclusion-These findings suggest that a high carbohydrate intake in early pregnancy suppresses placental growth, especially if combined with a low dairy protein intake in late pregnancy. Such an effect could have long term consequences for the offspring's risk of cardiovascular disease.			Godfrey, K (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Godfrey, Keith/0000-0002-4643-0618; Robinson, Sian/0000-0003-1766-7269				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; BOTTING B, 1993, POPULATION TRENDS, V74, P27; CAMPBELL D, IN PRESS BR J OBSTET; CRAWLEY H, 1988, FOOD PORTION SIZES; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; HEAP FC, 1967, J REPROD FERTIL, V13, P269, DOI 10.1530/jrf.0.0130269; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; Holland B., 1991, MCCANCE WIDDOWSONS C, V5; Holland B, 1991, MCCANCE WIDDOWSONS S; Holland B., 1989, MCCANCE WIDDOWSONS S; Holland B., 1988, MCCANCE WIDDOWSONS S; HOWE D, 1995, BRIT MED J, V310, P1601, DOI 10.1136/bmj.310.6994.1601b; HOWE DT, 1995, BRIT J OBSTET GYNAEC, V102, P213, DOI 10.1111/j.1471-0528.1995.tb09096.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MAHOMED K, 1989, EFFECTIVE CARE PREGN, V1, P301; MARGETTS BM, 1989, INT J EPIDEMIOL, V18, P868, DOI 10.1093/ije/18.4.868; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; MCKEIGUE P, 1995, LANCET, V345, P269, DOI 10.1016/S0140-6736(95)90269-4; MCKEOWN T, 1953, J ENDOCRINOL, V10, P73, DOI 10.1677/joe.0.0100073; OUNSTED M, 1966, NATURE, V212, P687; OWENS JA, 1988, FETAL NEONATAL GROWT, P49; PRENTICE A, IN PRESS EUR J CLIN; Robinson JS, 1994, EARLY FETAL GROWTH D, P317; ROBINSON SM, IN PRESS EUR J CLIN; ROSSO P, 1990, NUTR METABOLISM PREG, P175; RUSH D, 1989, EFFECTIVE CARE PREGN, V1, P301; SLEN SB, 1969, NUTR ANIMALS AGR I 2, P827; THOMAS WJK, 1970, LOWLAND SHEEP PRODUC; WILLETT WC, 1994, AM J CLIN NUTR S, V59, P171	34	442	447	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					410	414						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601112	Green Published			2022-12-24	WOS:A1996TW56400021
J	Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA				Lithell, HO; McKeigue, PM; Berglund, L; Mohsen, R; Lithell, UB; Leon, DA			Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; FETAL GROWTH; RISK-FACTORS; FOLLOW-UP; HYPERTENSION; RESISTANCE; MELLITUS; UPPSALA; DISEASE	Objective-To establish whether the relation between size at birth and non-insulin dependent diabetes is mediated through impaired beta cell function or insulin resistance. Design-Cohort study. Setting-Uppsala, Sweden. Subjects-1333 men whose birth records were traced from a cohort of 2322 men born during 1920-4 and resident in Uppsala in 1970. Main outcome measures-Intravenous glucose tolerance test at age 50 years and non-insulin dependent diabetes at age 60 years. Results-There was a weak inverse correlation (r=-0.07, P=0.03) between ponderal index at birth and 60 minute insulin concentrations in the intravenous glucose tolerance test at age 50 years. This association was stronger (r=-0.19, P=0.001) in the highest third of the distribution of body mass index than in the other two thirds (P=0.01 for the interaction between ponderal index and body mass index). Prevalence of diabetes at age 60 years was 8% in men whose birth weight was less than 3250 g compared with 5% in men with birth weight 3250 g or more (P=0.08; 95% confidence interval for difference -0.3% to 6.8%). There was a stronger association between diabetes and ponderal index: prevalence of diabetes was 12% in the lowest fifth of ponderal index compared with 4% in the other four fifths (P=0.001; 3.0% to 12.6%). Conclusion-These results confirm that reduced fetal growth is associated with increased risk of diabetes and suggest a specific association with thinness at birth, This relation seems to be mediated through insulin resistance rather than through impaired beta cell function and to depend on an interaction with obesity in adult life.	UNIV LONDON LONDON SCH HYG & TROP MED, EPIDEMIOL UNIT, LONDON WC1E 7HT, ENGLAND; UNIV UPPSALA, DEPT GERIATR, S-75125 UPPSALA, SWEDEN	University of London; London School of Hygiene & Tropical Medicine; Uppsala University			Berglund, Lars/AAA-3188-2019; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010	Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762				BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DRAPER NR, 1966, APPL REGRESSION ANAL, P149; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS M, 1979, DIABETES, V28, P1039; LITHELL H, 1984, ACTA MED SCAND, V215, P403; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MILLER HC, 1973, PEDIATRICS, V52, P504; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SJOLIN S, 1975, HLTH CARE MOTHERS CH, P229; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	22	560	577	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	1996	312	7028					406	410						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601111				2022-12-24	WOS:A1996TW56400020
J	Paterson, CR; Ogston, SA; Henry, RM				Paterson, CR; Ogston, SA; Henry, RM			Life expectancy in osteogenesis imperfecta	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV STRATHCLYDE,DEPT MANAGEMENT SCI,GLASGOW G1 1XH,LANARK,SCOTLAND	University of Dundee; University of Strathclyde	Paterson, CR (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND.							BAKER RJ, 1978, GLIM SYSTEM; MATTEI JP, 1994, CLIN RHEUMATOL, V13, P447; PATERSON CR, 1987, ACTA PAEDIATR SCAND, V76, P548, DOI 10.1111/j.1651-2227.1987.tb10519.x; SILLENCE D, 1981, CLIN ORTHOPAEDICS, V159, P11; 1983, MORTALITY STATISTICS	5	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611834				2022-12-24	WOS:A1996TV69800026
J	deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG				deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG			A cortical neuropeptide with neuronal depressant and sleep-modulating properties	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; METABOLITES; INHIBITION; BRAIN; CA1	ACETYLCHOLINE (ACh) plays a key role in the transitions between the different phases of sleep(1): Slow-wave sleep requires low ACh concentrations in the brain, whereas rapid-eye-movement (REM) sleep is associated with high levels of ACh, Also, these phases of sleep are differentially sensitive to a number of endogenous neuropeptides and cytokines, including somatostatin, which has been shown to increase REM sleep without significantly affecting other phases(2). Here we report the cloning and initial characterization of cortistatin, a neuropeptide that exhibits strong structural similarity to somatostatin, although it is the product of a different gene. Administration of cortistatin depresses neuronal electrical activity but, unlike somatostatin, induces low-frequency waves in the cerebral cortex and antagonizes the effects of acetylcholine on hippocampal and cortical measures of excitability. This suggests a mechanism for cortical synchronization related to sleep.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			de Lecea, Luis/ABE-4005-2021; de Lecea, Luis/B-3171-2009	de Lecea, Luis/0000-0002-8921-5942; de Lecea, Luis/0000-0002-8921-5942	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058543] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH058543] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	308	317	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					242	245		10.1038/381242a0	http://dx.doi.org/10.1038/381242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622767				2022-12-24	WOS:A1996UL24900056
J	Triolo, T; Sternglanz, R				Triolo, T; Sternglanz, R			Role of interactions between the origin recognition complex and SIR1 in transcriptional silencing	NATURE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; PROTEIN; STATES; LOCI	TRANSCRIPTIONAL silencing of the HM mating-type loci in the yeast Saccharomyces cerevisiae is caused by the localized formation of an altered chromatin structure, analogous to heterochromatin in higher eukaryotes. Silencing depends on cis-acting sequences, termed silencers, as well as several trans-acting factors, including histones H4 and H3, proteins RAP1 and ABF1, and the four SIR proteins (SIR1-4)(1). Each of the four HM silencers contains an autonomously replicating sequence (ARS) to which the origin replication complex (ORC)(2) binds. This six-protein complex is required for initiation of DNA replication, as well as for silencing(3-7). Efficient establishment of the silenced state requires both passage through the S phase of the cell cycle(8) and SIR1 protein(9,10). Previous experiments suggested that SIR1 might be localized to the silencers by binding to ORC and/or RAP1 (ref. 11). Here we report that SIR1 can bind directly to ORC1, the largest of the ORC subunits, and that targeting of SIR1 to ORC1 at a silencer is sufficient to establish a silenced state.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STUDIER W, 1990, METHOD ENZYMOL, V185, P5	18	234	240	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					251	253		10.1038/381251a0	http://dx.doi.org/10.1038/381251a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622770				2022-12-24	WOS:A1996UL24900059
J	Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT				Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT			Cerebellum implicated in sensory acquisition and discrimination rather than motor control	SCIENCE			English	Article							CORTICOPONTINE PROJECTION; ORGANIZATION; MOVEMENT; MONKEY; CORTEX	Recent evidence that the cerebellum is involved in perception and cognition challenges the prevailing view that its primary function is fine motor control. A new alternative hypothesis is that the lateral cerebellum is not activated by the control of movement per se, but is strongly engaged during the acquisition and discrimination of sensory information. Magnetic resonance imaging of the lateral cerebellar output (dentate) nucleus during passive and active sensory tasks confirmed this hypothesis. These findings suggest that the lateral cerebellum may be active during motor, perceptual, and cognitive performances specifically because of the requirement to process sensory data.	UNIV TEXAS, HLTH SCI CTR, SCH MED, RES IMAGING CTR, SAN ANTONIO, TX 78284 USA; CALTECH, PASADENA, CA 91125 USA	University of Texas System; University of Texas Health San Antonio; California Institute of Technology			Bower, James/F-8343-2010; Fox, Peter/B-4725-2010; Li, Jinqi/F-7778-2010	Fox, Peter/0000-0002-0465-2028; Parsons, Lawrence/0000-0001-7498-8742; Xiong, Jinhu/0000-0001-5262-5756	NIDA NIH HHS [P20 DA52176-01] Funding Source: Medline; NIMH NIH HHS [MH/DA52145] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baddeley A, 1986, WORKING MEMORY; BOWEN J, 1995, HUMAN BRAIN MAPPING, V2, P255, DOI DOI 10.1002/HBM.460020407; BOWER JM, 1990, J COMP NEUROL, V302, P768, DOI 10.1002/cne.903020409; BOWER JM, 1992, BEHAV BRAIN SCI, V15, P714; BOWER JM, IN PRESS BEHAV BRAIN; BOWER JM, IN PRESS PROG BRAIN; Brodal A, 1981, NEUROLOGICAL ANATOMY; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; ELLERMAN JM, 1994, NMR BIOMED, V7, P63, DOI 10.1002/nbm.1940070110; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FOX PT, 1985, P NATL ACAD SCI USA, V82, P7462, DOI 10.1073/pnas.82.21.7462; Gao J.-H., 1995, Society for Neuroscience Abstracts, V21, P270; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; Ito M, 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; LEINER HC, 1995, HUMAN BRAIN MAPPING, V2, P244; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Parsons L. M., 1995, Society for Neuroscience Abstracts, V21, P272; PARSONS LM, 1995, NATURE, V375, P54, DOI 10.1038/375054a0; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; SABATINI U, 1993, J CEREBR BLOOD F MET, V13, P639, DOI 10.1038/jcbfm.1993.82; SCHMAHMANN JD, 1990, J COMP NEUROL, V295, P299, DOI 10.1002/cne.902950212; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SCHMAHMANN JD, IN PRESS; SEITZ RJ, 1990, NEUROREPORT, V1, P17; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Welker W, 1987, NEW CONCEPTS CEREBEL, P239; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	37	533	547	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					545	547		10.1126/science.272.5261.545	http://dx.doi.org/10.1126/science.272.5261.545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614803				2022-12-24	WOS:A1996UG82600043
J	Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL				Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL			Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta	NATURE			English	Article							BACILLUS-CEREUS; BOVINE BRAIN; PHOSPHATIDYLINOSITOL; REFINEMENT; C-DELTA-1; PROGRAM	Mammalian phosphoinositide-specific phospholipase C enzymes (PI-PLC) act as signal transducers that generate two second messengers, inositol-1,4,5-trisphosphate and diacylglycerol. The 2.4-Angstrom structure of phospholipase C delta 1 reveals a multidomain protein incorporating modules shared by many signalling proteins. The structure suggests a mechanism for membrane attachment and Ca2+-dependent hydrolysis of second-messenger precursors. The regulation and reversible membrane association of PI-PLC may serve as a model for understanding other multidomain enzymes involved in phospholipid signalling.	UNIV CAMBRIDGE, CTR MRC, CTR PROT RES, CAMBRIDGE CB2 2QH, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Williams, Roger/0000-0001-7754-4207; Perisic, Olga/0000-0002-3842-2896	Medical Research Council [MC_U105184308] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; BURKHARD R, 1993, J MOL BIOL, V232, P584; CCP4, 1979, CCP4 SUITE PROGRAMS; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIN GL, 1990, BIOCHEMISTRY-US, V29, P277; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; Nicholls A., 1992, GRASP GRAPHICAL REPR; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; QUIOCHO FA, 1989, T AM CRYST ASS, V25, P23; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHEDLER DJA, 1992, DISS ABSTR INT B, V53, P4118; SEITZ SP, 1992, BIOORG MED CHEM LETT, V2, P171, DOI 10.1016/S0960-894X(01)80444-3; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; SIMOES AP, 1995, FEBS LETT, V365, P155; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	50	505	516	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					595	602		10.1038/380595a0	http://dx.doi.org/10.1038/380595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602259				2022-12-24	WOS:A1996UF74100036
J	Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH				Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH			Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP	NATURE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; PROTEIN; BINDING; ELEMENT; GENE; SEQUENCES	The Tax protein of human T-lymphotrophic virus (HTLV)-1 activates expression of the HTLV-1 long terminal repeat through a DNA element that resembles the cellular cyclic AMP-regulated enhancer (CRE)(1,2). Tax contains a transcriptional activation domain(3), but its ability to activate gene expression depends on interactions with cellular CRE-binding proteins such as CREB. Whether Tax can activate the expression of cellular CRE-containing genes has been controversial. Here we show that Tax can activate both the HTLV-1 and consensus cellular CREs, and propose that this activation may occur through mechanisms that are differentially dependent on CREB phosphorylation. Tax not only increases the binding of CREB to the viral CRE but also recruits the transcriptional co-activator CBP4,5 in a manner independent of CREB phosphorylation. In contrast, association of Tax with the cellular CRE occurs through CBP which, in turn, is recruited only in the presence of phosphorylated CREB.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Oregon Health & Science University; Baylor College of Medicine			Shih, Hsiu-Ming/S-7023-2018					BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FELBER BK, 1985, SCIENCE, V229, P54; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Langton B., 1988, MED VIROL, V8, P295; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	24	300	302	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					642	646		10.1038/380642a0	http://dx.doi.org/10.1038/380642a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602268				2022-12-24	WOS:A1996UF74100051
J	Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N				Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N			Inhibition of an inwardly rectifying K+ channel by G-protein alpha-subunits	NATURE			English	Article							BETA-GAMMA; RECEPTORS; EXPRESSION	Cholinergic muscarinic, serotonergic, opioid and several other G-protein-coupled neurotransmitter receptors activate inwardly rectifying K+ channels of the GIRK family, slowing the heartbeat and decreasing the excitability of neuronal cells'. Inhibitory modulation of GIRKs by G-protein-coupled receptors may have important implications in cardiac and brain physiology, Previously G alpha and G beta gamma subunits of heterotrimeric G proteins have both been implicated in channel opening(2,3), but recent studies attribute this role primarily to the G beta gamma dimer that activates GIRKs in a membrane-delimited fashion, probably by direct binding to the channel protein(4-8). We report here that free GTP gamma S-activated G(alpha i1), but not G(alpha i2) or G(alpha i3), potently inhibits G(beta 1 gamma 2)-induced GIRK activity in excised membrane patches of Xenopus oocytes expressing GIRK1. High-affinity but partial inhibition is produced by G(alpha s)-GTP gamma S. G(alpha i1)-GTP gamma S also inhibits G(beta 1 gamma 2)-activated GIRK in atrial myocytes. Antagonistic interactions between G(alpha) and G(beta gamma) may be among the mechanisms determining specificity of G protein coupling to GIRKs.	GRAZ UNIV,INST MED PHYS & BIOPHYS,A-8010 GRAZ,AUSTRIA; UNIV TEXAS,SW MED SCH,DEPT PHARMACOL,DALLAS,TX 75235; TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; CALTECH,DIV BIOL,PASADENA,CA 91125	University of Graz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tel Aviv University; Sackler Faculty of Medicine; California Institute of Technology			Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Schreibmayer, Wolfgang/0000-0002-4631-7922				ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEDIN KE, IN PRESS NEURON; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INABOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; PFAFFINGER PJ, 1985, NATURE, V317, P538; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TRAUTWEIN W, 1990, REV PHYSL, V52, P257; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	30	97	99	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					624	627		10.1038/380624a0	http://dx.doi.org/10.1038/380624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602262				2022-12-24	WOS:A1996UF74100045
J	Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A				Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A			The relationship of bone and blood lead to hypertension - The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; PRESSURE RELATIONS; ALCOHOL INTAKE; CONFOUNDERS; HEMOGLOBIN; EXPOSURE; BURDEN	Objective.-To test the hypothesis that long-term lead accumulation, as reflected by levels of lead in bone (as opposed to blood, which reflects recent lead exposure), is associated with an increased odds of developing hypertension. Design.-Case-control study of participants in the Veterans Administration (now Department of Veterans Affairs) Normative Aging Study, a 30-year longitudinal study of men. Participants.-Of 1171 active subjects who were seen between August 1991 and December 1994, 590 (50%) participated in this investigation and had data on all variables of interest. Main Outcome Measures.-Hypertension was defined as taking daily medication for the treatment of hypertension or systolic blood pressure higher than 160 mm Hg or diastolic blood pressure of 96 mm Hg or higher during the time of examination. Levels of lead in the tibia (representing cortical bone) and the patella (representing trabecular bone) were measured in vivo with a K x-ray fluorescence (KXRF) instrument. Levels of lead in blood were measured by graphite furnace atomic absorption spectroscopy. Results.-Blood lead levels were low, ranging from less than 0.05 to 1.35 mu mol/L (<1 to 28 mu g/dL), with a mean (SD) of 0.30 (0.20) mu mol/L (6.3 [4.1] mu g/dL). Bone lead levels were similar to those described in other general populations. In comparison to nonhypertensives, mean levels of lead in blood and both tibia and patella bone lead levels were significantly higher in hypertensive subjects. In a logistic regression model of hypertensive status that began with age, race, body mass index, family history of hypertension, history of ethanol ingestion, pack-years of smoking, dietary sodium intake, dietary calcium intake, blood lead, tibia lead, and patella lead, the variables that remained after backward elimination were body mass index, family history of hypertension, and level of lead in the tibia. An increase from the midpoint of the lowest quintile to the midpoint of the highest quintile of tibia lead from 8 to 37 mu g per gram of bone mineral was associated with an increased odds ratio of hypertension of 1.5. Conclusion.-Our findings suggest that long-term lead accumulation, as reflected by levels of lead in bone, may be an independent risk factor for developing hypertension in men in the general population.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DEPT VET AFFAIRS,NORMAT AGING STUDY,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Hu, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [NIEHS ES 05257-01A1, NIEHS 2 P30 ES 00002, NIEHS P42-ES05947] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005947, P30ES000002, R01ES005257] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARRY PSI, 1970, BRIT J IND MED, V27, P339; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; Bell B, 1972, AGING HUM DEVELOP, V3, P4; Burger D E, 1990, Basic Life Sci, V55, P287; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; COCHRAN WG, 1968, TECHNOMETRICS, V10, P637, DOI 10.2307/1267450; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FINE BP, 1988, TOXICOL APPL PHARM, V93, P388, DOI 10.1016/0041-008X(88)90041-5; GORDON CL, 1993, BRIT J IND MED, V50, P637; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HENSE HW, 1994, EPIDEMIOLOGY, V5, P120, DOI 10.1097/00001648-199401000-00018; HERTZPICCIOTTO I, 1993, EPIDEMIOL REV, V15, P352, DOI 10.1093/oxfordjournals.epirev.a036125; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; HU H, 1994, JAMA-J AM MED ASSOC, V272, P1512, DOI 10.1001/jama.272.19.1512; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; JONES KW, 1987, INVITRO BOD COMPOSIT, V363, P373; KIM R, 1995, PHYS MED BIOL, V40, P1475, DOI 10.1088/0031-9155/40/9/007; KOPP SJ, 1988, ENVIRON HEALTH PERSP, V78, P91, DOI 10.2307/3430507; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LANDRIGAN PJ, 1991, ENVIRON HEALTH PERSP, V91, P81, DOI 10.2307/3430987; MANTON WI, 1985, BRIT J IND MED, V42, P168; PERRY HM, 1988, ENVIRON HEALTH PERSP, V78, P107, DOI 10.2307/3430509; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1995, ARCH ENVIRON HEALTH, V50, P31, DOI 10.1080/00039896.1995.9955010; SHARP DS, 1990, AM J EPIDEMIOL, V131, P1098, DOI 10.1093/oxfordjournals.aje.a115603; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1990, AM J EPIDEMIOL, V131, P845, DOI 10.1093/oxfordjournals.aje.a115575; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; TYROLER HA, 1988, ENVIRON HEALTH PERSP, V78, P3, DOI 10.2307/3430491; WARD KD, 1994, INT J OBESITY, V18, P137; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780	37	242	252	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1171	1176		10.1001/jama.275.15.1171	http://dx.doi.org/10.1001/jama.275.15.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609684				2022-12-24	WOS:A1996UE62500028
J	Lasic, DD				Lasic, DD			Doxorubicin in sterically stabilized liposomes	NATURE			English	Article							LONG-CIRCULATING LIPOSOMES; CLEARANCE											BANGHAM AD, 1995, BIOESSAYS, V17, P1081, DOI 10.1002/bies.950171213; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016; DAEMEN T, 1995, INT J CANCER, V61, P716, DOI 10.1002/ijc.2910610520; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; GABIZON A, 1994, CANCER RES, V54, P987; GABIZON A, 1994, ACTA ONCOL, V33, P779, DOI 10.3109/02841869409083948; GREGORIADIS G, 1980, FEBS LETT, V119, P43, DOI 10.1016/0014-5793(80)80994-X; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; ISRAELACHVILI JN, 1985, SURFACE INTERPARTICL; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KUHL TL, 1994, BIOPHYS J, V66, P1479, DOI 10.1016/S0006-3495(94)80938-5; LASIC DD, 1992, FEBS LETT, V312, P255, DOI 10.1016/0014-5793(92)80947-F; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1994, ANGEW CHEM INT EDIT, V33, P1685, DOI 10.1002/anie.199416851; LASIC DD, 1995, BBA-BIOMEMBRANES, V1239, P145, DOI 10.1016/0005-2736(95)00159-Z; LASIC DD, 1993, LIPOSOMES PHYSICS AP; LASIC DD, 1995, CHEM REV, V96, P1601; Lasic DD, 1995, STEALTH LIPOSOMES; MAYHEW EG, 1992, INT J CANCER, V51, P302, DOI 10.1002/ijc.2910510221; Needham D., 1992, J LIPOSOME RES, V2, P411, DOI [10.3109/08982109209010218, DOI 10.3109/08982109209010218]; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11640; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; VAAGE J, 1992, INT J CANCER, V51, P942, DOI 10.1002/ijc.2910510618; WILLIAMS SS, 1993, CANCER RES, V53, P3964; Zheng S., 2008, LIPOSOME ENCAPSULATE, V3, P575, DOI [proxy.lib.ohio-state.edu/10.3109/08982109309150740, DOI 10.3109/08982109309150740]	28	253	265	3	49	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					561	562		10.1038/380561a0	http://dx.doi.org/10.1038/380561a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606781				2022-12-24	WOS:A1996UE66300061
J	Mayer, A; Wickner, W; Haas, A				Mayer, A; Wickner, W; Haas, A			Sec18p (NSF)-driven release of sec17p (alpha-SNAP) can precede docking and fusion of yeast vacuoles	CELL			English	Article							VESICULAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; VESICLE FUSION; GOLGI STACK; MEMBRANE-PROTEINS; SEGREGATION; ATTACHMENT; PATHWAY; PURIFICATION; INHERITANCE	S. cerevisiae inherits its vacuole by projecting vacuole-derived membrane vesicles and tubules into the bud, where they fuse to establish the daughter vacuole. This homotypic fusion event can be assayed in vitro. It requires Sec17p and Sec18p, the homologs of the mammalian alpha-SNAP and NSF, which cooperate in multiple steps of membrane trafficking. We now report that Sec17p, Sec18p, and ATP are only needed for an early stage of the reaction that results in Sec17p release. Sec17p and Sec18p actions precede, and are needed for, the step employing the Ras-like GTPase Ypt7p. Sec18p-driven release of Sec17p can even precede vacuole docking, as it can occur prior to mixing of vacuoles and is insensitive to vacuole concentration. Sec17p and Sec18p thus may function in a predocking stage of the reaction, rather than in bilayer fusion per se.			Mayer, A (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HAAS A, IN PRESS EMBO J; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XU Z, 1996, IN PRESS J CELL BIOL	63	496	501	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					83	94		10.1016/S0092-8674(00)81084-3	http://dx.doi.org/10.1016/S0092-8674(00)81084-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620540	hybrid			2022-12-24	WOS:A1996UE55900011
J	Nishiyama, KI; Suzuki, T; Tokuda, H				Nishiyama, KI; Suzuki, T; Tokuda, H			Inversion of the membrane topology of SecG coupled with SecA-dependent preprotein translocation	CELL			English	Article							PROTON MOTIVE FORCE; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; INVITRO TRANSLOCATION; ALKALINE-PHOSPHATASE; SECRETORY PROTEINS; RECONSTITUTION	E. coli preprotein translocase comprises SecA and a SecY/E/G complex. SecA delivers the preprotein to the putative protein-conducting channel formed by SecY/E by undergoing ATP-driven cycles of membrane insertion and deinsertion. SecG renders the translocase highly efficient. An antibody raised against the C-terminal region of SecG inhibits preprotein translocation into everted membrane vesicles despite the exposure of this region to the inside of membrane vesicles in the absence of preprotein translocation. When preprotein translocation was started with ATP and then blocked by the inhibition of ATP hydrolysis, the C-terminal region was exposed to the outside of membrane vesicles. Another region of SecG showed a change in membrane sidedness upon preprotein translocation, indicating that SecG undergoes topology inversion. This topology inversion was tightly coupled to the SecG function and linked with the insertion-deinsertion cycle of SecA.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1994, FEBS LETT, V346, P65, DOI 10.1016/0014-5793(94)00317-3; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	44	187	189	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					71	81		10.1016/S0092-8674(00)81083-1	http://dx.doi.org/10.1016/S0092-8674(00)81083-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620539	Bronze			2022-12-24	WOS:A1996UE55900010
J	Guttman, A				Guttman, A			High-resolution carbohydrate profiling by capillary gel electrophoresis	NATURE			English	Article								Capillary gel electrophoresis with laser-induced fluorescent detection has been found to be a powerful separation and characterization tool for fluorescently labelled carbohydrates.			Guttman, A (corresponding author), BECKMAN INSTRUMENTS INC,2500 HARBOUR BLVD,FULLERTON,CA 92634, USA.		Guttman, András/GLT-9077-2022					CHIESA C, 1993, J CHROMATOGR, V645, P337, DOI 10.1016/0021-9673(93)83394-8; EVANGELISTA RA, 1995, ANAL CHEM, V67, P2239, DOI 10.1021/ac00109a051; GUTTMAN A, 1995, ELECTROPHORESIS, V16, P1906, DOI 10.1002/elps.11501601314; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; Guttman A, 1996, ELECTROPHORESIS, V17, P412, DOI 10.1002/elps.1150170221; JACKSON P, 1994, ANAL BIOCHEM, V216, P243, DOI 10.1006/abio.1994.1038; TOWNSEND RR, 1995, CARBOHYDRATE ANAL; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	8	111	113	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					461	462		10.1038/380461a0	http://dx.doi.org/10.1038/380461a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602248				2022-12-24	WOS:A1996UD59000069
J	Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL				Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL			Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources	ANNALS OF INTERNAL MEDICINE			English	Article							KALA-AZAR; SODIUM STIBOGLUCONATE; PARASITIC DISEASE; MALNUTRITION; RISK; POPULATION; INFECTION; ADULTS	Objectives: 1) To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes. Design: Cohort study. Setting: Medicins sans Frontieres-Holland's treatment center in Duar, Western Upper Nile province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis. Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate. Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]). Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77 g/L) and malnourished (median body mass index of adults [greater than or equal to 18 years of age], 15.2 kg/m(2)); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (<5 or greater than or equal to 45 years of age), long duration of illness (greater than or equal to 5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% CI, 1.4 to 3.6) for those with a long duration of illness, 3.6 (CI, 2.1 to 5.9) for those 45 years of age or older, 4.6 (CI, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (CI, 3.2 to 47.2) for those with a body mass index less than 12 kg/m(2). Conclusion: Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.	CTR DIS CONTROL & PREVENT, DIV PARASIT DIS, ATLANTA, GA 30341 USA; MED SANS FRONTIERES HOLLAND, AMSTERDAM, NETHERLANDS	Centers for Disease Control & Prevention - USA								ASHFORD RW, 1992, T ROY SOC TROP MED H, V86, P379, DOI 10.1016/0035-9203(92)90229-6; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639; BAKER RJ, 1978, GLIM MANUAL RELEASE; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; DEBEER P, 1990, LANCET, V335, P224, DOI 10.1016/0140-6736(90)90313-T; DEBEER P, 1991, AM J TROP MED HYG, V44, P283, DOI 10.4269/ajtmh.1991.44.283; DYE C, 1993, P ROY SOC B-BIOL SCI, V254, P33, DOI 10.1098/rspb.1993.0123; GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83; GOLDEN MHN, 1993, LANCET, V342, P360, DOI 10.1016/0140-6736(93)91491-4; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; HARRISON LH, 1986, REV INFECT DIS, V8, P447; HENRY CJK, 1990, EUR J CLIN NUTR, V44, P329; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; LIGHTNER LK, 1983, AM J TROP MED HYG, V32, P296, DOI 10.4269/ajtmh.1983.32.296; MANSONBAHR PE, 1987, MANSONS TROPICAL DIS, P43; MENGESHA B, 1978, TROP GEOGR MED, V30, P199; PEARSON RD, 1992, AM J TROP MED HYG, V47, P8, DOI 10.4269/ajtmh.1992.47.8; PEREA WA, 1991, T ROY SOC TROP MED H, V85, P48, DOI 10.1016/0035-9203(91)90152-O; SEAMAN J, 1993, J INFECT DIS, V168, P715, DOI 10.1093/infdis/168.3.715; SEAMAN J, 1995, CLIN INFECT DIS, V21, P188, DOI 10.1093/clinids/21.1.188; SEAMAN J, 1992, ANN TROP MED PARASIT, V86, P481, DOI 10.1080/00034983.1992.11812697; SEAMAN J, IN PRESS INT J EPIDE; THAKUR CP, 1991, AM J TROP MED HYG, V45, P435, DOI 10.4269/ajtmh.1991.45.435; THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7; *UN, 1985, WORLD POP PROSP EST; ZIJLSTRA EE, 1992, J TROP PEDIATRICS, V38, P17, DOI 10.1093/tropej/38.1.17; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P365, DOI 10.1016/0035-9203(91)90293-8; 1991, TROPICALDIS RES NEWS, V37, P1; 1991, TROPICAL DIS RES NEW, V37, P1	34	88	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					664	672		10.7326/0003-4819-124-7-199604010-00007	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607595				2022-12-24	WOS:A1996UB51300007
J	Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG				Patten, PA; Gray, NS; Yang, PL; Marks, CB; Wedemayer, GJ; Boniface, JJ; Stevens, RC; Schultz, PG			The immunological evolution of catalysis	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; IMMUNE-RESPONSE; HYPERVARIABLE REGIONS; ANTIBODY DIVERSITY; SOMATIC MUTATION; MATURATION; BINDING; GENERATION; EXPRESSION; FRAGMENT	The germline genes used by the mouse to generate the esterolytic antibody 48G7 were cloned and expressed in an effort to increase our understanding of the detailed molecular mechanisms by which the immune system evolves catalytic function. The nine replacement mutations that were fixed during affinity maturation increased affinity for the transition state analogue by a factor of 10(4), primarily the result of a decrease in the dissociation rate of the hapten-antibody complex. There was a corresponding increase in the rate of reaction of antibody with substrate, k(cat)/K-m, from 1.7 x 10(2) M(-1) min(-1) to 1.4 x 10(4) M(-1) min-l The three-dimensional crystal structure of the 48G7-transition state analogue complex at 2.0 angstroms resolution indicates that none of the nine residues in which somatic mutations have been fixed directly contact the hapten. Thus, in the case of 48G7, affinity maturation appears to play a conformational role, either in reorganizing the active site geometry or limiting side-chain and backbone flexibility of the germline antibody. The crystal structure and analysis of somatic and directed active site mutants underscore the role of transition state stabilization in the evolution of this catalytic antibody.	UNIV CALIF BERKELEY,DEPT CHEM,HOWARD HUGHES MED INST,BERKELEY,CA 94720; STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; Stanford University			Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725; Yang, Priscilla/0000-0001-7456-2557; Gray, Nathanael/0000-0001-5354-7403	PHS HHS [R01 AL24695] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHEN C, 1995, EMBO J, V14, P2784, DOI 10.1002/j.1460-2075.1995.tb07278.x; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COCHRAN AG, 1990, SCIENCE, V249, P781, DOI 10.1126/science.2389144; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLINELLIPIMPAN.B, 1994, CURR BIOL, V2, P175; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Haldane JBS, 1930, ENZYMES; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JACOBS JW, 1989, THESIS U CALIFORNIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JESKE DJ, 1984, J IMMUNOL, V133, P1090; JONES TA, O COMPUTER GRAPHICS; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KAUFFMAN SA, 1988, MATURATION IMMUNE RE, V2, P349; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; MALMBORG AC, 1992, SCAND J IMMUNOL, V35, P643, DOI 10.1111/j.1365-3083.1992.tb02970.x; PADLAN EA, 1985, ANN INST PASTEUR IMM, VC136, P271, DOI 10.1016/S0769-2625(85)80058-1; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCHIFF C, 1986, J EXP MED, V163, P573, DOI 10.1084/jem.163.3.573; SCHULTZ PG, 1995, SCIENCE, V269, P835; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; STEINER LA, 1967, J EXP MED, V126, P1143, DOI 10.1084/jem.126.6.1143; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; THERIAULT TP, 1991, J MOL BIOL, V221, P257; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; VANVRANKEN DL, 1994, TETRAHEDRON LETT, V35, P3873, DOI 10.1016/S0040-4039(00)76689-5; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; [No title captured]	47	198	205	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1086	1091		10.1126/science.271.5252.1086	http://dx.doi.org/10.1126/science.271.5252.1086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599084	Green Submitted			2022-12-24	WOS:A1996TW70100029
J	Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH				Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH			Inhibition of C-protein-mediated MAP kinase activation by a new mammalian gene family	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; G1 ARREST; A-FACTOR; DESENSITIZATION; PHOSPHORYLATION; RECEPTOR	A GENERAL property of signal transduction pathways is that prolonged stimulation decreases responsiveness, a phenomenon termed desensitization. Yeast cells stimulated with mating pheromone activate a heterotrimeric G-protein-linked, MAP-kinase-dependent signalling pathway that induces G1-phase cell-cycle arrest and morphological differentiation (reviewed in refs 1, 2). Eventually the cells desensitize to pheromone and resume growth(3). Genetic studies have demonstrated the relative importance of a desensitization mechanism that uses the SST2 gene product, Sst2p(4-7). Here we identify a mammalian gene family termed RGS (for regulator of G-protein signalling) that encodes structural and functional homologues of Sst2p. Introduction of RGS family members into yeast blunts signal transduction through the pheromone-response pathway. Like SST2 (refs 8-10), they negatively regulate this pathway at a point upstream or at the level of the G protein. The RGS family members also markedly impair MAP kinase activation by mammalian G-protein-linked receptors, indicating the existence and importance of an SST2-like desensitization mechanism in mammalian cells.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL)			Blumer, Kendall J/C-5268-2012; Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ADAMS TH, 1992, MOL CELL BIOL, V12, P3827, DOI 10.1128/MCB.12.9.3827; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HONG JX, 1993, J IMMUNOL, V150, P3895; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1993, ANNU REV GENET, V27, P147; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MAZER BD, 1992, J CLIN INVEST, V90, P759, DOI 10.1172/JCI115948; MOORE SA, 1984, J BIOL CHEM, V259, P1004; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, PHEROMONE RESPONSE S, P657; STEVEN BJ, 1989, MOL GEN GENET, V219, P421, DOI 10.1007/BF00259615; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	28	414	432	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					742	746		10.1038/379742a0	http://dx.doi.org/10.1038/379742a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602223	Green Submitted			2022-12-24	WOS:A1996TW56700057
J	Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ				Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ			Transcription factor AP-2 essential for cranial closure and craniofacial development	NATURE			English	Article							NEURAL CREST; VERTEBRATES; DISRUPTION; BINDING; ORIGIN; CELLS; TUBE	DURING closure of the neural tube in the mouse, transcription factor AP-2 (refs 1-4) is expressed in ectoderm and in neural-crest cells migrating from the cranial neural folds(5). Cranial neural crest cells provide patterning information for craniofacial morphogenesis, generate most of the skull bones, and, together with placodal ectoderm, form the cranial ganglia(6-8). To study the role of AP-2 during embryogenesis, we undertook a targeted mutagenesis of the AP-2 gene in the mouse. Here we report that AP-2(-/-) mice died perinatally with cranio-abdominoschisis and severe dismorphogenesis of the face, skull, sensory organs and cranial ganglia. Failure of cranial closure between 9 and 9.5 days postcoitum coincided with increased apoptosis in the midbrain, anterior hindbrain and proximal mesenchyme of the first branchial arch, but did not involve loss of expression of twist or Pax-3, two other regulatory genes known to be required for cranial closure.	MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA; UNIV ZURICH, INST MOLEC BIOL, CH-8057 ZURICH, SWITZERLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); University of Zurich; Massachusetts Institute of Technology (MIT); Whitehead Institute			Schorle, Hubert/M-5001-2016; Buchert, Michael/Z-1777-2019; Schorle, Hubert/S-1713-2019	Schorle, Hubert/0000-0001-8272-0076; Buchert, Michael/0000-0003-2672-0148; Meier, Pascal/0000-0003-2760-6523				CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; EMFORS P, 1995, NATURE, V368, P147; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON R, 1985, J EMBRYOL EXP MORPH, V89, P229; Hogan B, 1994, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaufman M.H., 1992, ATLAS MOUSE DEV; Le Douarin N.M., 1982, NEURAL CREST; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Richman J, 1996, CURR BIOL, V6, P364, DOI 10.1016/S0960-9822(02)00496-7; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; WILKINSON DG, 1992, IN SITU HYDRIDIZATIO; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMADA G, 1995, DEVELOPMENT, V121, P2917	30	492	501	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					235	238		10.1038/381235a0	http://dx.doi.org/10.1038/381235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622765				2022-12-24	WOS:A1996UL24900054
J	Heynen, AJ; Abraham, WC; Bear, MF				Heynen, AJ; Abraham, WC; Bear, MF			Bidirectional modification of CA1 synapses in the adult hippocampus in vivo	NATURE			English	Article							LONG-TERM POTENTIATION; AREA CA1; DEPRESSION	MEMORIES are believed to be stored by synaptic modifications. One type of activity-dependent synaptic modification, long-term potentiation (LTP), has received considerable attention as a possible memory mechanism, particularly in hippocampus(1). However, use-dependent decreases in synaptic strength can store information as well. A form of homosynaptic long-term depression (LTD) has been described and widely studied in the CA1 region of the developing hippocampus in vitro(2-4). However, the relevance of this model of LTD to memory has been questioned because of failures to replicate it in the adult brain in vitro(5) and, more recently, in vivo(6). Here we re-examine this important issue and find that homosynaptic LTD can in fact be elicited in the adult hippocampus in vivo, that it has all the properties described in immature CA1 in vitro, and that LTD and LTP are reversible modifications of the same Schaffer collateral synapses. Thus homosynaptic LTD is not peculiar to brain slices, nor is it only of developmental significance. Rather, our data suggest that the mechanisms of LTP and LTD may be equal partners in the mnemonic operations of hippocampal neural networks.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912; UNIV OTAGO,DEPT PSYCHOL,DUNEDIN,NEW ZEALAND; UNIV OTAGO,NEUROSCI RES CTR,DUNEDIN,NEW ZEALAND	Brown University; Brown University; Howard Hughes Medical Institute; University of Otago; University of Otago				Bear, Mark/0000-0002-9903-2541				ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREESE CR, 1989, J NEUROSCI, V9, P1097; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; KERR DS, 1995, P NATL ACAD SCI USA, V92, P11637, DOI 10.1073/pnas.92.25.11637; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; THIELS E, 1994, J NEUROPHYSIOL, V71, P3009; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	12	149	152	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					163	166		10.1038/381163a0	http://dx.doi.org/10.1038/381163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610015				2022-12-24	WOS:A1996UK13900052
J	Bentham, G				Bentham, G			Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; TIME TRENDS; EXPOSURE; EPIDEMIOLOGY; CANCER; RISK	Objectives-To examine whether the incidence of non-Hodgkin's lymphoma in different areas of England and Wales is associated with levels of solar ultraviolet radiation. Design-Geographically based study examining the association between incidence of non-Hodgkin's lymphoma and estimated levels of solar ultraviolet radiation, controlling for social class and employment in agriculture. Setting-59 counties in England and Wales. Subjects-All registered cases of non-Hodgkin's lymphoma during the period 1968-85. Main outcome measure-Age and sex adjusted odds ratio for non-Hodgkin's lymphoma in each county. Results-Incidence of non-Hodgkin's lymphoma was significantly associated with solar ultraviolet radiation levels (P<0.001), even after social class and employment in agriculture were controlled for (P=0.004). In a comparison of counties in the highest and lowest quarters of solar ultraviolet radiation, the relative risk of non-Hodgkin's lymphoma was 1.27 (95% confidence interval 1.24 to 1.29), rising to 1.34 (1.32 to 1.37) after adjustment for social class and employment in agriculture. Conclusions-The incidence of non-Hodgkin's lymphoma in different areas of England and Wales is positively associated with levels of solar ultraviolet radiation. These results are consistent with the hypothesis that exposure to solar ultraviolet radiation increases the risk of non-Hodgkin's lymphoma.			Bentham, G (corresponding author), UNIV E ANGLIA,SCH ENVIRONM SCI,CTR SOCIAL & ECON RES GLOBAL ENVIRONM,NORWICH NR4 7TJ,NORFOLK,ENGLAND.							ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ADAMI J, 1995, BMJ-BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750b; BARROW EM, 1993, 1961 90 BASELINE CLI; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; DEVESA SS, 1992, CANCER RES, V52, pS5432; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOETTSCH W, 1993, THYMUS, V21, P93; GREINER TC, 1994, DIAGN ONCOL, V4, P26; Hartge P., 1992, CANC RES S, V52, p5466s; HOLFORD TR, 1992, CANCER RES, V52, pS5443; KINLEN L, 1992, CANCER RES, V52, pS5474; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEVINE AM, 1992, CANCER RES, V52, pS5482; MADRONICH S, 1995, AMBIO, V24, P143; MCKINNEY PA, 1991, LEUKEMIA LYMPHOMA, V4, P123, DOI 10.3109/10428199109068055; MO T, 1974, PHOTOCHEM PHOTOBIOL, V20, P483, DOI 10.1111/j.1751-1097.1974.tb06607.x; MUELLER NE, 1992, CANCER RES, V52, pS5479; NEWTON R, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750a; *OFF POP CENS SURV, 1975, CENS 1971 ENGL WAL E; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PEARCE N, 1992, CANCER RES, V52, pS5496; SASIENI P, 1995, BRIT MED J, V311, P749, DOI 10.1136/bmj.311.7007.749a; SCHERR PA, 1992, CANCER RES, V52, pS5503; SWERDLOW A, 1993, ATLAS CANC INCIDENCE; VICKERS M, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WHO World Health Organization, 1994, ENV HLTH CRIT, V160; ZAHM SH, 1992, CANCER RES, V52, pS5485; 1990, ARCH INTERN MED, V150, P2473	34	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1128	1131						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620128				2022-12-24	WOS:A1996UK06900021
J	Borel, AC; Simon, SM				Borel, AC; Simon, SM			Biogenesis of polytopic membrane proteins: Membrane segments assemble within translocation channels prior to membrane integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN; SECRETORY PROTEINS; TRANSMEMBRANE GLYCOPROTEIN; MULTIDRUG RESISTANCE; TRANSLATION PRODUCTS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INSERTION	The initial steps in the biogenesis of membrane proteins parallel that of secretory proteins. The translocation of membrane proteins, however, must be interrupted prior to the complete traversal of the membrane. This is followed by their folding and integrating into the lipid bilayer. We have previously shown that as each latent transmembrane segment (TMS) in a polytopic membrane protein emerges from the ribosome, it sequentially translocates across the membrane. Here we demonstrate that these translocated TMSs can be extracted from the membrane with urea. This suggests that nascent TMSs do not integrate into the bilayer as they achieve a transmembrane topography. The integration is delayed until after the protein is synthesized and released from the ribosome. Prior to insertion into the bilayer, these TMSs appear to be stabilized by salt-sensitive electrostatic bonds within an aqueous-accessible compartment.	ROCKEFELLER UNIV,LAB CELLULAR BIOPHYS,NEW YORK,NY 10021	Rockefeller University				Simon, Sanford/0000-0002-8615-4224				ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1967, J MOL BIOL, V26, P293, DOI 10.1016/0022-2836(67)90298-7; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KAWAHARA K, 1965, BIOCHEMISTRY-US, V4, P1203, DOI 10.1021/bi00883a001; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1981, P NATL ACAD SCI-BIOL, V78, P5127, DOI 10.1073/pnas.78.8.5127; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; REDMAN CM, 1966, J BIOL CHEM, V241, P1150; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	53	115	115	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					379	389		10.1016/S0092-8674(00)81116-2	http://dx.doi.org/10.1016/S0092-8674(00)81116-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616893	Bronze			2022-12-24	WOS:A1996UK14000011
J	Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ				Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ			Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients - Results from the Cooperative Cardiovascular Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; DISEASE; RISK; CARE	Objective.-To develop a prediction model of death within 30 days of hospital admission for Medicare patients with acute myocardial infarction that would permit use of risk-adjusted mortality rates as hospital quality measures. Design.-Retrospective cohort study using data created from medical charts and administrative flies. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, or Wisconsin. Patients.-A cohort of 14 581 patients with acute myocardial infarction covered by Medicare in 1993. Results.-The unadjusted 30-day mortality rate was 21%, ranging from 18% in Connecticut to 23% in Alabama. The 4 largest contributors to variability in mortality rates were mean arterial pressure, age, respiratory rate, and serum urea nitrogen level. The area under the receiver operator characteristic curve was 0.79 in a developmental sample of 10 936 patients and 0.78 in a validation sample of 3645 patients. Based on admission variables, we were able to explain 27% of the variability in 30-day mortality rates. During the index admission, aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and thrombolytic agents were used in 72%, 39%, 32%, and 15% of patients, respectively. Explained variation increased by 6 percentage points to 33% when drug therapies and revascularization procedures performed during the index admission were added to the model predictors, Conclusions.-Short-term mortality remains high for elderly patients with acute myocardial infarction, and a large percentage of variation remains unexplained after controlling for admission severity. Part of the unexplained variability can be explained by the location of the admitting hospital; some of the remaining unexplained variation may reflect differences in quality of care or unmeasured differences in disease severity. Researchers should develop quality indicators based on process measures for acute myocardial infarction and should incorporate these measures into mortality models to determine whether quality accounts for variation in 30-day mortality rates beyond that explained by clinical status at admission.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; DEPT VET AFFAIRS MED CTR,DIV CARDIOL,BROCKTON,MA; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Brigham & Women's Hospital	Normand, SLT (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,PARCEL B,1ST FLOOR,25 SHATTUCK ST,BOSTON,MA 02115, USA.			Glickman, Mark/0000-0003-3993-2801	AHRQ HHS [R01-HS08071, R01-HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BERGER CJ, 1992, JAMA-J AM MED ASSOC, V268, P1545, DOI 10.1001/jama.268.12.1545; Codman EA, 1916, SURG GYNECOL OBSTET, V22, P119; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; CRAWFORD SL, 1995, J CLIN EPIDEMIOL, V48, P209, DOI 10.1016/0895-4356(94)00124-9; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FIRSHEIN J, 1993, F GRAYS MED HLTH, V47, P3; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LITTLE RJ, 1987, STAT ANAL MISSING DA, P9; LITTLE RJA, 1985, BIOMETRIKA, V72, P497, DOI 10.2307/2336722; NAGELKERKE NJ, 1991, BIOMETRIKA, V3, P691; NORMAND SLT, 1995, J CLIN EPIDEMIOL, V48, P229, DOI 10.1016/0895-4356(94)00126-B; PARSONNET V, 1989, CIRCULATION, V79, P3; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; *SAS I INC, 1990, SAS STAT US GUID VER, P2; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HLTH HUM S, 1992, MED HOSP INF 1992; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122	24	116	120	3	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1322	1328		10.1001/jama.275.17.1322	http://dx.doi.org/10.1001/jama.275.17.1322			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614117				2022-12-24	WOS:A1996UG61200028
J	Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ				Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ			Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old	LANCET			English	Article							PLATELET-AGGREGATION; CLINICAL-TRIAL; DIHYDROPYRIDINES; HEMORRHAGE	Background Calcium antagonists are used frequently in management of hypertension, In addition to their cardiovascular effects, these drugs inhibit platelet aggregation. Therefore we examined whether the use of calcium antagonists was associated with an increased risk of gastrointestinal haemorrhage (GIH). Methods A prospective cohort study was conducted from 1985 through 1992 on 1636 hypertensive persons aged greater than or equal to 68 years living in three communities. The participants were taking beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, or calcium antagonists; those taking combinations of these drugs were excluded, The incidence of GIH was assessed by surveying hospital discharge deaths. Age, gender, disability, arterial pressure, other drugs, and comorbid conditions were examined as confounders. Findings Compared with beta-blockers (4819 person-years, 65 events), after adjustment for confounders the relative risk for GIH associated with ACE inhibitors (772 person-years, 13 events) was 1 . 23 (95% CI 0 . 66-2 . 28) and with calcium antagonists (1510 person-years, 42 events) it was 1 . 86 (1 . 22-2 . 82). The risks for verapamil, diltiazem, and nifedipine did not differ significantly. The results were unchanged when the analyses were restricted to severe events (GIH in conjunction with blood transfusion or death). Interpretation Calcium antagonists were associated with an increased risk of GIH in this population. Therefore caution is needed in prescription of these agents to old patients who have other risk factors for gastrointestinal bleeding.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Wake Forest University; Wake Forest Baptist Medical Center	Pahor, M (corresponding author), UNIV CATTOLICA SACRO CUORE,IST MED INTERNA & GERIATRIA,LARGO F VITO 1,I-00168 ROME,ITALY.							BERKELS R, 1994, THROMB HAEMOSTASIS, V72, P309; BLACHE D, 1992, PHARMACOLOGY, V45, P250, DOI 10.1159/000139008; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAVIS BR, IN PRESS AM J HYPERT; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUDSON N, 1995, GUT, V37, P177, DOI 10.1136/gut.37.2.177; KARIO K, 1995, J HUM HYPERTENS, V9, P206; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P94, DOI DOI 10.1001/JAMA.1963.03060120024016; KONRADDALHOFF I, 1991, EUR J CLIN PHARMACOL, V41, P313, DOI 10.1007/BF00314958; LANDRY JA, 1988, GERONTOLOGIST, V28, P672, DOI 10.1093/geront/28.5.672; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; PAHOR M, 1994, J AM GERIATR SOC, V42, P816, DOI 10.1111/j.1532-5415.1994.tb06552.x; PAHOR M, 1994, JAMA-J AM MED ASSOC, V272, P595, DOI 10.1001/jama.272.8.595; PALES J, 1991, BIOCHIM BIOPHYS ACTA, V1064, P169, DOI 10.1016/0005-2736(91)90298-M; *PHS HLTH CAR FIN, 1980, INT CLASS DIS; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; *SPSS, 1993, SPSS ADV STAT REF GU; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; WALLEN NH, 1995, AM J CARDIOL, V75, P1, DOI 10.1016/S0002-9149(99)80516-5; ZUCKER ML, 1993, THROMB HAEMOSTASIS, V70, P332; 1977, JAMA-J AM MED ASSOC, V237, P2385	30	215	217	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1061	1065		10.1016/S0140-6736(96)90276-7	http://dx.doi.org/10.1016/S0140-6736(96)90276-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602055				2022-12-24	WOS:A1996UG04200009
J	Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ				Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ			Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT GEN PRACTICE,SECT DUTCH NURSING HOME MED,2301 RC LEIDEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,WHO NATL INFLUENZA CTR NETHERLANDS,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	Remarque, EJ (corresponding author), UNIV LEIDEN HOSP,DEPT PATHOL,SECT GERONTOL,BLDG 1 P3-Q,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Remarque, Edmond J/B-2217-2010; Remarque, Ed/AAE-8643-2020					BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; REMARQUE EJ, 1993, VACCINE, V11, P649, DOI 10.1016/0264-410X(93)90311-K	5	32	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1015	1015						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616350				2022-12-24	WOS:A1996UG61000028
J	Mebatsion, T; Konig, M; Conzelmann, KK				Mebatsion, T; Konig, M; Conzelmann, KK			Budding of rabies virus particles in the absence of the spike glycoprotein	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; MATRIX PROTEIN; INSECT CELLS; MEMBRANE; GENE; PRECURSOR; SEQUENCES; RNA	Budding of enveloped viruses from cellular membranes is believed to depend on the presence of transmembrane spike proteins interacting with cytoplasmic virus components. To address the mechanism of rhabdovirus budding, we generated rabies virus mutants deficient for the glycoprotein G or the G cytoplasmic tail. We found that spikeless rhabdovirus particles were released from cells infected with the G-deficient mutant, demonstrating that a viral surface protein is not required to drive the budding process. However, particle production is enhanced approximately B-fold and 30-fold in the presence of tailless G or G, respectively. This reveals that G also possesses an intrinsic and independent exocytosis activity. We propose a model according to which efficient budding of rhabdoviruses is achieved by a concerted action of both core and spike proteins.	UNIV GIESSEN,INST VIROL,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen	Mebatsion, T (corresponding author), FED RES CTR VIRUS DIS ANIM,INST CLIN VIROL,PAUL EHRLICH STR 28,D-72076 TUBINGEN,GERMANY.		Conzelmann, Karl-Klaus/L-7239-2013	Conzelmann, Karl-Klaus/0000-0002-8614-3656				ANILIONIS A, 1981, NATURE, V294, P275, DOI 10.1038/294275a0; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHONG LD, 1994, J VIROL, V68, P441, DOI 10.1128/JVI.68.1.441-447.1994; CHONG LD, 1993, J VIROL, V67, P407, DOI 10.1128/JVI.67.1.407-414.1993; CONZELMANN KK, 1991, VIROLOGY, V184, P655, DOI 10.1016/0042-6822(91)90435-E; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1991, VIROLOGY, V184, P441, DOI 10.1016/0042-6822(91)90866-A; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; JIN H, 1994, EMBO J, V13, P5504, DOI 10.1002/j.1460-2075.1994.tb06885.x; JUSTICE PA, 1995, J VIROL, V69, P3156, DOI 10.1128/JVI.69.5.3156-3160.1995; Kessler S W, 1981, Methods Enzymol, V73, P442; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; LI Y, 1993, J VIROL, V67, P4415, DOI 10.1128/JVI.67.7.4415-4420.1993; MEBATSION T, 1995, J VIROL, V69, P1444, DOI 10.1128/JVI.69.3.1444-1451.1995; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; OWENS RJ, 1993, J VIROL, V67, P360, DOI 10.1128/JVI.67.1.360-365.1993; RHEE SS, 1990, J VIROL, V64, P3844, DOI 10.1128/JVI.64.8.3844-3852.1990; ROLLS MM, 1994, CELL, V79, P497, DOI 10.1016/0092-8674(94)90258-5; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SCHNEIDER LG, 1981, REPLICATION NEGATIVE, P947; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; SOKOL F, 1968, J VIROL, V2, P836, DOI 10.1128/JVI.2.8.836-849.1968; SUOMALAINEN M, 1992, J VIROL, V66, P4737, DOI 10.1128/JVI.66.8.4737-4747.1992; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WUNNER WH, 1985, ANN INST PASTEUR VIR, V136E, P353, DOI 10.1016/S0769-2617(85)80127-1; ZAVADA J, 1982, J GEN VIROL, V63, P15, DOI 10.1099/0022-1317-63-1-15; ZHAO HX, 1994, EMBO J, V13, P4204, DOI 10.1002/j.1460-2075.1994.tb06740.x	37	216	249	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					941	951		10.1016/S0092-8674(00)81072-7	http://dx.doi.org/10.1016/S0092-8674(00)81072-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601317	Bronze			2022-12-24	WOS:A1996UC38100015
J	Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ				Self, DW; Barnhart, WJ; Lehman, DA; Nestler, EJ			Opposite modulation of cocaine-seeking behavior by D-1- and D-2-like dopamine receptor agonists	SCIENCE			English	Article							SELF-ADMINISTRATION BEHAVIOR; VENTRAL TEGMENTAL AREA; RHESUS-MONKEYS; RAT; REINSTATEMENT; BROMOCRIPTINE; HEROIN; AMPHETAMINE; INVOLVEMENT; INJECTIONS	Activation of the mesolimbic dopamine system is known to trigger relapse in animal models of cocaine-seeking behavior. We found that this ''priming'' effect was selectively induced by D-2-like, and not by D-1-like, dopamine receptor agonists in rats. Moreover, D-1-like receptor agonists prevented cocaine-seeking behavior induced by cocaine itself, whereas D-1-like receptor agonists enhanced this behavior, These results demonstrate an important dissociation between D-1- and D-2-like receptor processes in cocaine-seeking behavior and support further evaluation of D-1-like receptor agonists as a possible pharmacotherapy for cocaine addiction.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PHARMACOL, NEW HAVEN, CT 06508 USA	Yale University	Self, DW (corresponding author), YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, LAB MOLEC PSYCHIAT, NEW HAVEN, CT 06508 USA.							ANDERSEN PH, 1990, EUR J PHARM-MOLEC PH, V188, P335, DOI 10.1016/0922-4106(90)90194-3; BELMAKER RH, 1977, BRIT J PSYCHIAT, V131, P222, DOI 10.1192/bjp.131.2.222b; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; CHILDRESS AR, 1988, NIDA RES MONOGR, P137; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; FREEDMAN JE, 1995, TRENDS PHARMACOL SCI, V272, pR1; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; HUBNER CB, 1990, NEUROPSYCHOPHARMACOL, V3, P101; JAFFE JH, 1989, PSYCHOPHARMACOLOGY, V97, P59, DOI 10.1007/BF00443414; JOHANSON C, 1995, PSYCHOPHARMACOLOGY 4; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KLEVEN MS, 1990, PSYCHOPHARMACOLOGY, V101, P208, DOI 10.1007/BF02244128; LARGE CH, 1994, TRENDS PHARMACOL SCI, V15, P46, DOI 10.1016/0165-6147(94)90108-2; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; PRESTON KL, 1992, J PHARMACOL EXP THER, V262, P279; ROBERTS DCS, 1977, PHARMACOL BIOCHEM BE, V6, P615, DOI 10.1016/0091-3057(77)90084-3; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; SATEL S, 1992, CLIN GUIDE COCAINE A, P172; SELF DW, 1995, SYNAPSE, V21, P312, DOI 10.1002/syn.890210405; SELF DW, 1992, BRAIN RES, V582, P349, DOI 10.1016/0006-8993(92)90155-3; SHIPPENBERG TS, 1991, PSYCHOPHARMACOLOGY, V103, P209, DOI 10.1007/BF02244205; SHIPPENBERG TS, 1987, BRAIN RES, V436; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIRIS SG, 1991, SCHIZOPHRENIA BULL, V17, P75, DOI 10.1093/schbul/17.1.75; SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260; SPEALMAN RD, 1991, J PHARMACOL EXP THER, V258, P945; STEWART J, 1988, BRAIN RES, V457, P287, DOI 10.1016/0006-8993(88)90698-1; STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0; TSURUTA K, 1981, NATURE, V292, P463, DOI 10.1038/292463a0; WEED MR, 1993, PSYCHOPHARMACOLOGY, V113, P51, DOI 10.1007/BF02244333; WISE RA, 1990, PSYCHOPHARMACOLOGY, V100, P355, DOI 10.1007/BF02244606; WITKIN JM, 1991, J PHARMACOL EXP THER, V257, P706	37	418	424	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1586	1589		10.1126/science.271.5255.1586	http://dx.doi.org/10.1126/science.271.5255.1586			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599115				2022-12-24	WOS:A1996TZ98300042
J	Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J				Dib, C; Faure, S; Fizames, C; Samson, D; Drouot, N; Vignal, A; Millasseau, P; Marc, S; Hazan, J; Seboun, E; Lathrop, M; Gyapay, G; Morissette, J; Weissenbach, J			A comprehensive genetic map of the human genome based on 5,264 microsatellites	NATURE			English	Article								The great increase in successful linkage studies in a number of higher eukaryotes during recent years has essentially resulted from major improvements in reference genetic linkage maps(1-6), which at present consist of short tandem repeat polymorphisms of simple sequences or microsatellites(7,8). We report here the last version of the Genethon human linkage map(6). This map consists of 5,264 short tandem (AC/TG)(n) repeat polymorphisms with a mean heterozygosity of 70%. The map spans a sex-averaged genetic distance of 3,699 cM and comprises 2,335 positions, of which 2,032 could be ordered with an odds ratio of at least 1,000:1 against alternative orders. The average interval size is 1.6 cM; 59% of the map is covered by intervals of 2 cM at most and 1% remains in intervals above 10 cM.	GENETHON SA,F-91000 EVRY,FRANCE; CNRS,URA 1922,F-91000 EVRY,FRANCE; HOP ST LOUIS,INSERM,U358,PARIS,FRANCE; CHU LAVAL,CTR RECH,QUEBEC CITY,PQ G1V 4G2,CANADA	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Laval University			Vignal, Alain/I-6253-2017	Vignal, Alain/0000-0002-6797-2125; Hazan, Jamile/0000-0001-8119-0325; Fizames, Cecile/0000-0002-0551-8250; Steinbach, Delphine/0000-0001-7144-7908				BARENDSE W, 1994, NAT GENET, V6, P227, DOI 10.1038/ng0394-227; CHUMAKOV IM, 1995, NATURE, V377, P175; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ELSNER TI, 1995, AM J HUM GENET, V56, P500; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; PLAETKE R, 1995, AM J HUM GENET, V56, P508; Spurr N. K., 1994, European Journal of Human Genetics, V2, P193; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1995, AM J HUM GENET, V57, P619	21	2675	2781	1	51	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					152	154		10.1038/380152a0	http://dx.doi.org/10.1038/380152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600387				2022-12-24	WOS:A1996TZ97800048
J	Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD				Nakai, J; Dirksen, RT; Nguyen, HT; Pessah, IN; Beam, KG; Allen, PD			Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; STEM-CELL LINES; COMPLEMENTARY-DNA; RELEASE CHANNEL; CALCIUM CURRENT; PERCHLORATE; EXPRESSION	Excitation-contraction coupling in skeletal muscle involves a voltage sensor in the plasma membrane which, in response to depolarization, causes an intracellular calcium-release channel to open. The skeletal isoform of the ryanodine receptor (RyR-1) functions as the Ca2+-release channel(1-3) and the dihydropyridine receptor (DHPR) functions as the voltage sensor and also as an L-type Ca2+ channel(4,5). Here we examine the possibility that there is a retrograde signal from RyR-1 to the DHPR, using myotubes from mice homozygous for a disrupted RyR-1 gene (dyspedic mice)(3). As expected, we find that there is no excitation-contraction coupling in dyspedic myotubes, but we also find that they have a roughly 30-fold reduction in L-type Ca2+-current density. Injection of dyspedic myotubes with RyR-1 complementary DNA restores excitation-contraction coupling and causes the density of L-type Ca2+ current to rise towards normal. Despite the differences in Ca2+-current magnitude, measurements of charge movement indicate that the density of DHPRs is similar in dyspedic and RyR-1-expressing myotubes. Our results support the possibility of a retrograde signal hy which RyR-1 enhances the function of DHPRs as Ca2+ channels.	CHILDRENS HOSP,DEPT CARDIOL,MOLEC CARDIOL LAB,BOSTON,MA 02115; KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 60601,JAPAN; COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT ANAT & NEUROBIOL,FT COLLINS,CO 80523; UNIV CALIF DAVIS,SCH VET MED,DEPT MOLEC BIOSCI,DAVIS,CA 95616; BRIGHAM & WOMENS HOSP,DEPT ANESTHESIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Kyoto University; Colorado State University; University of California System; University of California Davis; Harvard University; Brigham & Women's Hospital			Nakai, Junichi/GQZ-6415-2022; Tuluc, Petronel/C-2527-2011; Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				ADAMS BA, 1989, J GEN PHYSIOL, V94, P429, DOI 10.1085/jgp.94.3.429; ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; BUCK R, 1992, J BIOL CHEM, V287, P23560; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; DIRKSEN RT, 1995, J GEN PHYSIOL, V105, P227, DOI 10.1085/jgp.105.2.227; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FELDMEYER D, 1993, PFLUG ARCH EUR J PHY, V425, P54, DOI 10.1007/BF00374503; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; GARCIA J, 1994, J GEN PHYSIOL, V103, P107, DOI 10.1085/jgp.103.1.107; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P373, DOI 10.1085/jgp.102.3.373; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; MA J, 1991, Biophysical Journal, V59, p201A; MA JJ, 1988, BIOPHYS J, V53, P387, DOI 10.1016/S0006-3495(88)83115-1; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEJIAALVAREZ R, 1991, J GEN PHYSIOL, V97, P393, DOI 10.1085/jgp.97.2.393; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; WINGER DB, 1990, J PHYSIOL-LONDON, V425, P563; YATANI A, 1988, J BIOL CHEM, V263, P9887	30	386	389	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					72	75		10.1038/380072a0	http://dx.doi.org/10.1038/380072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598910				2022-12-24	WOS:A1996TY87700059
J	Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV				Zimmerman, SC; Zeng, FW; Reichert, DEC; Kolotuchin, SV			Self-assembling dendrimers	SCIENCE			English	Article							CASCADE	Hydrogen bond-mediated self-assembly is a powerful strategy for generating large structures from smaller subunits. The synthesis of molecules containing two isophthalic acid units covalently attached to a rigid aromatic spacer is described. By normal pairing of carboxylic acids into hydrogen-bonded dimers, these molecules self-assemble in organic solvents to form either a series of linear aggregates or a cyclic hexamer. These molecules were linked to the core of a family of polyether dendrimers, which caused the hexamer to be formed preferentially. The stability of the hexamer depended on the generation number of the dendrimer. The largest of these hydrogen-bonded macromolecular assemblies is roughly disk-shaped with a 9-nanometer diameter and a 2-nanometer thickness. Its size and molecular mass (34,000 daltons) are comparable to that of small proteins.			Zimmerman, SC (corresponding author), UNIV ILLINOIS,DEPT CHEM,600 S MATHEWS AVE,URBANA,IL 61801, USA.		Reichert, David/B-3281-2009; Reichert, David/AAS-4442-2020; Zimmerman, Steven C. C/E-4244-2010	Reichert, David/0000-0003-3432-8998; Reichert, David/0000-0003-3432-8998; Zimmerman, Steven C. C/0000-0002-5333-3437	NIGMS NIH HHS [GM39782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONSEN MW, 1994, CARBOHYD POLYM, V25, P13, DOI 10.1016/0144-8617(94)90157-0; BARTH HG, 1994, ANAL CHEM, V66, pR595, DOI 10.1021/ac00084a022; CHAPMAN TM, 1994, J AM CHEM SOC, V116, P11195, DOI 10.1021/ja00103a060; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; HAWKER CJ, 1993, J CHEM SOC PERK T 1, P1287, DOI 10.1039/p19930001287; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1994, PURE APPL CHEM, V66, P1961, DOI 10.1351/pac199466101961; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MATHIAS JP, 1994, J AM CHEM SOC, V116, P1725, DOI 10.1021/ja00084a013; MHATRE R, 1994, CHROMATOGRAPHIA, V38, P349, DOI 10.1007/BF02269779; NEWKOME GR, 1993, J ORG CHEM, V58, P3123, DOI 10.1021/jo00063a036; NEWKOME GR, 1995, POLYM PREPRINTS, V36, P609; NEWKOME GR, 1992, ALDRICHIM ACTA, V25, P31; ROGER P, 1993, CARBOHYD POLYM, V21, P83, DOI 10.1016/0144-8617(93)90002-L; TOMALIA DA, 1993, TOP CURR CHEM, V165, P193; VANHEST JCM, 1995, SCIENCE, V268, P1592, DOI 10.1126/science.268.5217.1592; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; XU ZF, 1994, ADV DENDR MACROMOL, V1, P69; ZERKOWSKI JA, 1992, J AM CHEM SOC, V114, P5473, DOI 10.1021/ja00039a096; ZIMMERMAN SC, 1993, P NATL ACAD SCI USA, V90, P1190, DOI 10.1073/pnas.90.4.1190	20	567	591	1	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1095	1098		10.1126/science.271.5252.1095	http://dx.doi.org/10.1126/science.271.5252.1095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599085				2022-12-24	WOS:A1996TW70100031
J	Neuenschwander, S; Singer, W				Neuenschwander, S; Singer, W			Long-range synchronization of oscillatory light responses in the cat retina and lateral geniculate nucleus	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; GANGLION-CELLS; VISUAL-CORTEX; DISCHARGE; NEURONS	VISUAL responses in the retina and the lateral geniculate nucleus (LGN) exhibit oscillatory patterning within a broad range of frequencies(1-9). Oscillatory activity is often associated with the synchronization of spatially distributed responses(10). Here we demonstrate, with simultaneous multi-electrode recordings from the retina and the LGN, that stationary and moving light stimuli evoke in retinal ganglion cells oscillatory responses in the frequency range of 61 to 114 Hz that become synchronized over distances larger than 20 degrees of visual angle across the nasal and temporal halves of the retina. This temporal patterning of retinal responses is transmitted reliably by LGN neurons, such that stimuli crossing the vertical meridian evoke synchronous responses in the LGNs of both hemispheres. The oscillatory responses are not phase-locked to the stimulus onset, indicating that synchronization results from horizontal interactions in the retina, The occurrence of synchronization depends on global stimulus properties such as size and continuity, suggesting that temporal correlation among responses of spatially segregated ganglion cells can be exploited to convey information relevant for perceptual grouping.	MAX PLANCK INST HIRNFORSCH, D-60528 FRANKFURT, GERMANY	Max Planck Society			Singer, Wolf/D-6874-2012	NEUENSCHWANDER, Sergio/0000-0001-7493-121X				ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; ARNETT DW, 1975, EXP BRAIN RES, V24, P111; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; COOK JE, 1995, MICROSC RES TECHNIQ, V31, P408, DOI 10.1002/jemt.1070310510; DEVRIES SH, 1993, CELL S, V10, P1390; DOTY RW, 1963, J PHYSIOL-LONDON, V168, P205, DOI 10.1113/jphysiol.1963.sp007187; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; GERSTEIN GL, 1972, BIOPHYS J, V12, P453, DOI 10.1016/S0006-3495(72)86097-1; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; ITO H, 1994, SOC NEUR ABSTR, V20; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; MASTRONARDE DN, 1989, TRENDS NEUROSCI, V12, P75, DOI 10.1016/0166-2236(89)90140-9; NUNEZ A, 1992, NEUROSCIENCE, V51, P269, DOI 10.1016/0306-4522(92)90314-R; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; ROBSON JG, 1987, J OPT SOC AM A, V4, P2301, DOI 10.1364/JOSAA.4.002301; RODIECK RW, 1967, J NEUROPHYSIOL, V30, P1043, DOI 10.1152/jn.1967.30.5.1043; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; STEVENS JK, 1976, J NEUROPHYSIOL, V39, P239, DOI 10.1152/jn.1976.39.2.239; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WORGOTTER F, 1995, VISUAL NEUROSCI, V12, P469, DOI 10.1017/S0952523800008373	26	240	246	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					728	733		10.1038/379728a0	http://dx.doi.org/10.1038/379728a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602219				2022-12-24	WOS:A1996TW56700053
J	Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE				Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE			Prospective assessment of breastfeeding and breast cancer incidence among 89887 women	LANCET			English	Article							RISK-FACTORS; LACTATION; POPULATION; AGE; ASSOCIATION; PREGNANCY; DURATION; 1ST	Background The relation between breastfeeding and breast-cancer risk has been examined in many studies; some have reported no association, and others a reduced risk, particularly among premenopausal women. In the only prospective cohort study, no association was found. We have assessed prospectively the association between breastfeeding and incidence of breast cancer among 89 887 women in the US Nurses' Health Study. Methods In 1986, participants were asked about the number of months they breastfed for all their children combined. Parous women with no history of cancer were included in this analysis. During 6 years of follow-up (513 015 person-years), 1459 invasive breast cancer cases were diagnosed. Findings Relative to women who had never breastfed, no significant overall association was found-after adjusting for established risk factors for breast cancer-between a history of having breastfed and subsequent development of breast cancer (relative risk [RR] 0.93, 95% CI 0.83-1.03). No inverse trend was observed with duration of breastfeeding; women who breastfed for 2 years or longer had a RR of 1.11 (0.90-1.38). Among women who had given birth only once, women who had breastfed their child experienced a lower incidence of breast cancer (RR 0.68, 0.46-1.00). Among premenopausal women, who tended to be near menopause due to the age structure of the cohort, the RR of breast cancer for those who had lactated was 1.16 (0.89-1.50). Premenopausal women who had lactated for 1 year or more had a RR of 1.10 (0.78-1.57). Interpretation These data suggest that there is no important overall association between breast-feeding and the occurrence of breast cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; BRIGNONE G, 1987, INT J EPIDEMIOL, V16, P356, DOI 10.1093/ije/16.3.356; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CHILVERS CED, 1993, BRIT MED J, V307, P17, DOI 10.1136/bmj.307.6895.17; DEWAILLY E, 1994, J NATL CANCER I, V86, P803, DOI 10.1093/jnci/86.10.803-a; Haring M H, 1992, Ned Tijdschr Geneeskd, V136, P743; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HENDERSHOT GE, 1984, PEDIATRICS, V74, P591; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; ING R, 1977, LANCET, V2, P124; Jensen A.A., 1991, CHEM CONTAMINANTS HU; KALACHE A, 1980, BRIT MED J, V280, P223, DOI 10.1136/bmj.280.6209.223-a; KELSEY JL, 1994, NEW ENGL J MED, V330, P136, DOI 10.1056/NEJM199401133300210; KURINIJ N, 1989, AM J PUBLIC HEALTH, V79, P1247, DOI 10.2105/AJPH.79.9.1247; KVALE G, 1988, J EPIDEMIOL COMMUN H, V42, P30, DOI 10.1136/jech.42.1.30; LAING AE, 1993, J NATL MED ASSOC, V85, P931; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LANECLAYPON JE, 1926, 32 HM STAT OFF REP; LAWRENCE RA, 1994, BREASTFEEDING GUIDE; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1994, NEW ENGL J MED, V330, P1682, DOI 10.1056/NEJM199406093302311; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V42, P185; MACMAHON B, 1993, JNCI-J NATL CANCER I, V71, P3183; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Romieu I., 1994, American Journal of Epidemiology, V139, pS68; ROSEROBIXBY L, 1987, INT J CANCER, V40, P747, DOI 10.1002/ijc.2910400606; Rosner B., 2011, FUNDAMENTALS BIOSTAT, P352; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Segi M, 1957, GANN               S, V48, P1; SIMOPOULOS AP, 1984, PEDIATRICS, V74, P603; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; TAO SC, 1988, INT J CANCER, V42, P495, DOI 10.1002/ijc.2910420404; THOMAS DB, 1993, INT J EPIDEMIOL, V22, P619, DOI 10.1093/ije/22.4.619; Wainwright JM, 1931, AM J CANCER, V15, P10; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOO KY, 1992, AM J EPIDEMIOL, V135, P726, DOI 10.1093/oxfordjournals.aje.a116359	42	75	78	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					431	436		10.1016/S0140-6736(96)90010-0	http://dx.doi.org/10.1016/S0140-6736(96)90010-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618484				2022-12-24	WOS:A1996TV72200010
J	Aoufouchi, S; Yelamos, J; Milstein, C				Aoufouchi, S; Yelamos, J; Milstein, C			Nonsense mutations inhibit RNA splicing in a cell-free system: Recognition of mutant codon is independent of protein synthesis	CELL			English	Article							MESSENGER-RNA; SITE SELECTION; GENE; MATURATION; EXON; TRANSLATION; STABILITY; SEQUENCES; PRODUCT; OCCURS	Mutations resulting in premature termination codons reduce the corresponding mRNA levels. We describe a cell-free system in which depletion of the mutant immunoglobulin kappa mRNA pool correlates with inefficient splicing and not with RNA decay. Splicing deficiency does not depend on the sequence surrounding the in-frame nonsense codon and can be partially corrected by mutating the methionine initiation codon. Despite the apparent link between translation and low mutant mRNA levels, inefficient splicing is not dependent on protein synthesis. Abnormal splicing of mutant immunoglobulin RNA is observed with B-cell but not with HeLa or T-cell extracts. A nonsense mutant beta-globin RNA is normally spliced by B-cell extract. We propose that the phenomenon exhibits tissue and gene specificity.			Aoufouchi, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Yelamos, Jose/N-2842-2016; Aoufouchi, Said/I-2985-2016; AOUFOUCHI, Said/P-9926-2019	AOUFOUCHI, Said/0000-0001-6547-2664; Yelamos, Jose/0000-0003-1195-1496				BARKER GF, 1991, MOL CELL BIOL, V11, P2760, DOI 10.1128/MCB.11.5.2760; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; COOK GP, 1995, INT IMMUNOL, V7, P89, DOI 10.1093/intimm/7.1.89; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MAQUAT LE, 1995, RNA, V1, P453; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURALIDHAR S, 1994, J VIROL, V68, P170, DOI 10.1128/JVI.68.1.170-176.1994; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; QIAN L, 1993, J IMMUNOL, V151, P6801; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	127	130	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					415	422		10.1016/S0092-8674(00)81119-8	http://dx.doi.org/10.1016/S0092-8674(00)81119-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616896	Bronze			2022-12-24	WOS:A1996UK14000014
J	Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD				Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD			Diet and risk of non-Hodgkin lymphoma in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PEYER PATCHES; CANCER; MICE; FAT; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; REPRODUCIBILITY; CARCINOGENESIS	Objective.-To test whether high dietary intakes of fat, protein, and milk are associated with the development of non-Hodgkin lymphoma in older women. Design.-Prospective cohort study with a 7-year follow-up period. Setting.-General community. Participants.-Sample of 35 156 Iowa women aged 55 to 69 years with no prior history of cancer who returned the 1986 baseline questionnaire. Main Outcome Measure.-Non-Hodgkin lymphoma (104 incident cases). Main Results.-After controlling for age, marital status, residence, total energy intake, and transfusion history, the relative risks (RRs) for the highest tertile of intake compared with the lowest were 2.00 (95% confidence interval [CI], 1.21-3.30; P for trend=.01) for animal fat, 1.69 (95% CI, 1.07-2.67; P for trend=.02) for saturated fat, and 1.90 (95% CI, 1.18-3.04; P for trend=.01) for monounsaturated fat, and there was no association with vegetable fat or polyunsaturated fat. Greater intake of animal protein (RR=1.52; 95% CI, 0.94-2.44; P for trend=.08), but not vegetable protein, was associated with elevated risk, and this was mainly explained by greater consumption of red meat (RR=1.98; 95% CI, 1.13-3.47; P for trend=.02) and hamburger in particular (RR=2.35; 95% CI, 1.23-4.48; P for trend=.02). Milk and dairy product consumption were not associated with elevated risk. There was also a decreased risk of non-Hodgkin lymphoma with greater consumption of fruits (RR=0.64; 95% CI, 0.40-1.05; P for trend=.07). Conclusions.-A high-meat diet and a high intake of fat from animal sources is associated with an increased risk of non-Hodgkin lymphoma in older women.	UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center			Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Cerhan, James/0000-0002-7482-178X; Potter, John/0000-0001-5439-1500; Kushi, Lawrence/0000-0001-9136-1175	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER OF, 1993, J AM GERIATR SOC, V41, P1245, DOI 10.1111/j.1532-5415.1993.tb07310.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BOST KL, 1986, CARCINOGENESIS, V7, P1257, DOI 10.1093/carcin/7.8.1257; BOST KL, 1986, CARCINOGENESIS, V7, P1251, DOI 10.1093/carcin/7.8.1251; CANTOR KP, 1988, AM J PUBLIC HEALTH, V78, P570, DOI 10.2105/AJPH.78.5.570; CARROLL KK, 1986, CANCER, V58, P1818, DOI 10.1002/1097-0142(19861015)58:8+<1818::AID-CNCR2820581406>3.0.CO;2-4; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; CINADER B, 1983, IMMUNOL LETT, V6, P331, DOI 10.1016/0165-2478(83)90077-9; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DAVIS DAP, 1994, FUND APPL TOXICOL, V23, P81, DOI 10.1006/faat.1994.1082; DAVIS S, 1992, CANCER RES, V52, pS5492; ERICKSON KL, 1986, INT J IMMUNOPHARMACO, V8, P529, DOI 10.1016/0192-0561(86)90023-8; ESUMI H, 1989, JPN J CANCER RES, V80, P1176, DOI 10.1111/j.1349-7006.1989.tb01651.x; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, IN PRESS J OCCUP ENV; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; FRIEDMAN A, 1994, CHEM IMMUNOL, V58, P259; LYNCH CF, 1994, AM J PUBLIC HEALTH, V84, P469, DOI 10.2105/AJPH.84.3.469; MALVY DJM, 1993, INT J EPIDEMIOL, V22, P761, DOI 10.1093/ije/22.5.761; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NIGG HN, 1990, EFFECTS PESTICIDES H, P35; OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665; PEARCE N, 1992, CANCER RES, V52, pS5496; RABKIN CS, 1993, SEMIN HEMATOL, V30, P286; Ries L, 1994, NIH PUBLICATION, V94-2789; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; TURTELTAUB KW, 1992, CANCER RES, V52, P4682; URSIN G, 1990, BRIT J CANCER, V61, P454, DOI 10.1038/bjc.1990.100; VITALE JJ, 1981, CANCER RES, V41, P3706; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1976, INT CLASS DIS; YESS NJ, 1991, J ASSOC OFF ANA CHEM, V74, P273; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725	38	115	115	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1315	1321		10.1001/jama.275.17.1315	http://dx.doi.org/10.1001/jama.275.17.1315			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614116				2022-12-24	WOS:A1996UG61200027
J	Goodman, R; Graham, P				Goodman, R; Graham, P			Psychiatric problems in children with hemiplegia: Cross sectional epidemiological survey	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; PREVALENCE	Objective-To examine the prevalence and predictors of psychiatric problems in children with hemiplegia. Design-Cross sectional questionnaire survey of an epidemiological sample with individual assessments of a representative subgroup, The questionnaire survey was repeated on school age subjects four years later. Subjects-428 hemiplegic children aged 2 1/2-16 years, of whom 149 (aged 6-10 years) were individually assessed. Main outcome measures-Psychiatric symptom scores and the occurrence of psychiatric disorder. Results-Psychiatric disorders affected 61% (95% confidence interval 53% to 69%) of subjects as judged by individual assessments and 54% (49% to 59%) and 42% (37% to 47%) as judged from parent and teacher questionnaires, respectively, Few affected children had been in contact with child mental health services, The strongest consistent predictor of psychiatric problems was intelligence quotient (IQ), which was highly correlated with an index of neurological severity; age, sex, and laterality of lesion had little or no predictive power. Conclusion-Though most hemiplegic children have considerable emotional or behavioural difficulties, these psychological complications commonly go unrecognised or untreated, Comprehensive health provision for children with chronic neurodevelopmental disorders such as hemiplegia should be psychologically as well as physically oriented.	INST CHILD HLTH,BEHAV SCI UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Goodman, R (corresponding author), INST PSYCHIAT,DEPT CHILD & ADOLESCENT PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; BRANDENBURG NA, 1990, J AM ACAD CHILD PSY, V29, P76, DOI 10.1097/00004583-199001000-00013; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; GOODMAN R, 1994, J CHILD PSYCHOL PSYC, V35, P1483, DOI 10.1111/j.1469-7610.1994.tb01289.x; GOODMAN R, 1995, J CHILD PSYCHOL PSYC, V36, P409, DOI 10.1111/j.1469-7610.1995.tb01299.x; Goodman R, 1996, J CHILD PSYCHOL PSYC, V37, P369, DOI 10.1111/j.1469-7610.1996.tb01418.x; Goodman R, 1996, DEV MED CHILD NEUROL, V38, P156; GOODMAN R, 1995, EUR CHILD ADOLES PSY, V4, P187, DOI 10.1007/BF01980457; GOODMAN R, 1994, CHILD ADOLESCENT PSY, P49; GOODMAN R, IN PRESS DEV MED CHI; KORNHUBER HH, 1985, EUR ARCH PSY CLIN N, V235, P129, DOI 10.1007/BF00380981; MCGUIRE J, 1986, J CHILD PSYCHOL PSYC, V27, P7, DOI 10.1111/j.1469-7610.1986.tb00618.x; Richman N., 1977, EPIDEMIOLOGICAL APPR, P125; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1968, BRIT J PSYCHIAT, V114, P563, DOI 10.1192/bjp.114.510.563; RUTTER M, 1970, ED HLTH BEHAVIOR; Rutter M., 1970, CLIN DEV MED, V35; SEIDEL UP, 1975, DEV MED CHILD NEUROL, V17, P563; TAYLOR E, 1986, BRIT J PSYCHIAT, V149, P760, DOI 10.1192/bjp.149.6.760; Wechsler DW., 1999, INTELLIGENCE SCALE C; WHO, 2012, ICD 10 CLASS MENT BE	23	100	100	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1065	1069						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616413				2022-12-24	WOS:A1996UH81600024
J	Schneider, BL; Yang, QH; Futcher, AB				Schneider, BL; Yang, QH; Futcher, AB			Linkage of replication to start by the Cdk inhibitor Sic1	SCIENCE			English	Article							PROTEIN-KINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; YEAST; CYCLINS; CLB5; DNA	In Saccharomyces cerevisiae, three G(1) cyclins (Clns) are important for Start, the event committing cells to division. Sic1, an inhibitor of Clb-Cdc28 kinases, became phosphorylated at Start, and this phosphorylation depended on the activity of Clns. Sic1 was subsequently lost, which depended on the activity of Clns and the ubiquitin-conjugating enzyme Cdc34. Inactivation of Sic1 was the only nonredundant essential function of Clns, because a sic1 deletion rescued the inviability of the cln1 cln2 cln3 triple mutant. In sic1 mutants, DNA replication became uncoupled from budding. Thus, Sic1 may be a substrate of Cln-Cdc28 complexes, and phosphorylation and proteolysis of Sic1 may regulate commitment to replication at Start.	SUNY STONY BROOK, GRAD PROGRAM GENET, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schneider, BL (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS F, UNPUB COMMUNICATION; CROSS FR, COMMUNICATION; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GARRELS J, UNPUB; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; SCHNEIDER BL, UNPUB; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	21	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					560	562		10.1126/science.272.5261.560	http://dx.doi.org/10.1126/science.272.5261.560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614808				2022-12-24	WOS:A1996UG82600048
J	Miles, MM; Shaw, RJ				Miles, MM; Shaw, RJ			Effect of inadvertent intradermal administration of high dose percutaneous BCG vaccine	BRITISH MEDICAL JOURNAL			English	Article									PARKSIDE HLTH COMMUNITY TRUST,LONDON W9 3XZ,ENGLAND; ST MARYS HOSP,CHEST & ALLERGY CLIN,LONDON W2 1NY,ENGLAND	Imperial College London								*DEP HLTH, 1992, IMM INF DIS, P76; HALL C, 1994, INDEPENDENT     1125, P4; 1990, BRIT MED J, V30, P995	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1014	1014						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616349				2022-12-24	WOS:A1996UG61000027
J	Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J				Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J			A role for brassinosteroids in light-dependent development of Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; PLANT-GROWTH; GENE	Although steroid hormones are important for animal development, the physiological role of plant steroids is unknown. The Arabidopsis DET2 gene encodes a protein that shares significant sequence identity with mammalian steroid 5 alpha-reductases. A mutation of glutamate 204, which is absolutely required for the activity of human steroid reductase, abolishes the in vivo activity of DET2 and leads to defects in light-regulated development that can be ameliorated by application of a plant steroid, brassinolide. Thus, DET2 may encode a reductase in the brassinolide biosynthetic pathway, and brassinosteroids may constitute a distinct dass of phytohormones with an important role in light-regulated development of higher plants.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92037 USA	Salk Institute; University of California System; University of California San Diego			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778; Vitart, Veronique/0000-0002-4991-3797; Nagpal, Punita/0000-0003-2257-9183				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arteca Richard N., 1995, P206; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; Davies Peter J., 1995, P1; DEGREEF JA, 1983, PHOTOMORPHOGENESIS, P401; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; GEUNS JMC, 1978, PHYTOCHEMISTRY, V17, P1, DOI 10.1016/S0031-9422(00)89671-5; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Li J. P. H., UNPUB; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577	27	671	722	13	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					398	401		10.1126/science.272.5260.398	http://dx.doi.org/10.1126/science.272.5260.398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602526				2022-12-24	WOS:A1996UG25200043
J	Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC				Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC			Altered circadian activity rhythms and sleep in mice devoid of prion protein	NATURE			English	Article							FATAL FAMILIAL INSOMNIA; GENE; SCRAPIE; NUCLEI; RATS; EEG	There is a wealth of data supporting a central role for the prion protein (PrP) in the neurodegenerative prion diseases of both humans and other species(1), yet the normal function of PrP, which is expressed at the cell surface of neurons and glial cells(2,3), is unknown. It has been speculated that neuropathology may be due to loss of normal function of PrP (ref. 4). Here we show that in mice devoid of PrP there is an alteration in both circadian activity rhythms and sleep patterns. To our knowledge, this is the first null mutation that has been shown to affect sleep regulation and our results indicate that the pathology of at least one of the inherited prion diseases, fatal familial insomnia(5), where there is a profound alteration in sleep and the daily rhythms of many hormones(6-10), may be related to the normal function of the prion protein.	UNIV ZURICH,DEPT 1,INST MOLEC BIOL,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,CENT BIOL LAB,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; BBSRC,INST ANIM HLTH,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND; MRC,NEUROPATHOGENESIS UNIT,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND	University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Roslin Institute; University of Edinburgh	Tobler, I (corresponding author), UNIV ZURICH,INST PHARMACOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.		Achermann, Peter/N-1215-2014	Achermann, Peter/0000-0002-0208-3511				Borbely AA, 1994, PRINCIPLES PRACTICE, P309; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BULT A, 1993, BRAIN RES BULL, V32, P623, DOI 10.1016/0361-9230(93)90164-7; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEBOER T, 1994, J COMP PHYSIOL A, V174, P145; DEBOER T, 1995, BRAIN RES, V670, P153, DOI 10.1016/0006-8993(94)01299-W; FISCHER M, IN PRESS EMBO J; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198, DOI 10.1152/ajpregu.1991.261.1.R198; FRIEDMAN.JK, 1974, PHYSIOL BEHAV, V12, P169, DOI 10.1016/0031-9384(74)90169-3; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; Manson J., 1992, Neurodegeneration, V1, P45; MANSON JC, 1995, NEURODEGENERATION, V4, P113; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONTAGNA P, 1995, ADV NEUROIMMUNOL, V5, P13, DOI 10.1016/0960-5428(94)00042-M; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; PORTALUPPI F, 1994, J CLIN ENDOCR METAB, V78, P1075, DOI 10.1210/jc.78.5.1075; POSSIDENTE B, 1988, BEHAV GENET, V18, P109, DOI 10.1007/BF01067080; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; TOBLER I, 1986, ELECTROEN CLIN NEURO, V64, P74, DOI 10.1016/0013-4694(86)90044-1; VALATX JL, 1974, BRAIN RES, V69, P315, DOI 10.1016/0006-8993(74)90009-2; VALATX JL, 1972, NATURE, V238, P226, DOI 10.1038/238226a0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035; YAMADA N, 1988, PHYSIOL BEHAV, V42, P87, DOI 10.1016/0031-9384(88)90265-X	28	508	523	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					639	642		10.1038/380639a0	http://dx.doi.org/10.1038/380639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602267				2022-12-24	WOS:A1996UF74100050
J	Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C				Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C			Control of root growth and development by cyclin expression	NATURE			English	Article							ARABIDOPSIS-THALIANA; CELL-PROLIFERATION; GENE; FIBROBLASTS; ONCOGENE; G(1)	ROOT development is plastic, with post-embryonic organogenesis being mediated by meristems(1), Although cell division is intrinsic to meristem initiation, maintenance and proliferative growth, the role of the cell cycle in regulating growth and development is unclear, To address this question, we examined the expression of cdc2 and eye genes, which encode the catalytic and regulatory subunits, respectively, of cyclin-dependent protein kinases that control progression through the cell cycle(2). Unlike cdc2, which is expressed not only in apical meristems but also before lateral root initiation(3) in quiescent, pericycle cells arrested in the G2 phase of the cell cycle(4), cyc1At transcripts accumulate specifically in dividing cells immediately before cytokinesis. Ectopic expression of cyc1At under the control of the cdc2aAt promoter in Arabidopsis plants markedly accelerates growth without altering the pattern of lateral root development or inducing neoplasia. Thus cyclin expression is a limiting factor for growth, which in turn drives indeterminate development of the root system.			Doerner, P (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Doerner, Peter/0000-0001-7218-8469				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BLAKELY LM, 1979, PLANT SCI LETT, V14, P79, DOI 10.1016/0304-4211(79)90158-5; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; DOLAN L, 1993, DEVELOPMENT, V119, P71; DREW MC, 1975, NEW PHYTOL, V75, P479, DOI 10.1111/j.1469-8137.1975.tb01409.x; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FERREIRA PCG, 1994, PLANT CELL, V6, P1763, DOI 10.1105/tpc.6.12.1763; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEMERLY A, 1992, P NATL ACAD SCI USA, V89, P3295, DOI 10.1073/pnas.89.8.3295; HEMERLY A, 1995, EMBO J, V14, P3295; HEMERLY AS, 1993, PLANT CELL, V5, P1711, DOI 10.1105/tpc.5.12.1711; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURRAY A, 1993, CELL CYCLE; NORRIS SR, 1993, PLANT MOL BIOL, V21, P895, DOI 10.1007/BF00027120; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEVES TA, 1989, PATTERNS PLANT DEV, P1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846	30	308	335	1	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					520	523		10.1038/380520a0	http://dx.doi.org/10.1038/380520a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606769				2022-12-24	WOS:A1996UE66300047
J	Shan, SO; Loh, S; Herschlag, D				Shan, SO; Loh, S; Herschlag, D			The energetics of hydrogen bonds in model systems: Implications for enzymatic catalysis	SCIENCE			English	Article							DIMETHYL-SULFOXIDE SOLUTION; PROTON-TRANSFER REACTIONS; GENERAL ACID CATALYSIS; CARBON ACIDS; GAS-PHASE; EQUILIBRIUM ACIDITIES; EXCHANGE EQUILIBRIA; ION SOLVATION; ANIONS; SOLVENT	Low-barrier or short, strong hydrogen bonds have been proposed to contribute 10 to 20 kilocalories per mole to transition-state stabilization in enzymatic catalysis. The proposal invokes a large increase in hydrogen bond energy when the pK(a) values of the donor and acceptor (where K-a is the acid constant) become matched in the transition state (Delta pK(a) = 0). This hypothesis was tested by investigating the energetics of hydrogen bonds as a function of Delta pK(a) for homologous series of compounds under nonaqueous conditions that are conducive to the formation of low-barrier hydrogen bonds. In all cases, there was a linear correlation between the increase in hydrogen-bond energy and the decrease in Delta pK(a), as expected from simple electrostatic effects. However, no additional energetic contribution to the hydrogen bond was observed at Delta pK(a) = 0. These results and those of other model studies suggest alternative mechanisms by which hydrogen bonds can contribute to enzymatic catalysis, in accord with conventional electrcstatic considerations.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; ALBRECHT G, 1983, J CHEM SOC F1, V80, P553; ALLERHAND A, 1963, J AM CHEM SOC, V85, P371, DOI 10.1021/ja00887a001; ALTMAN LJ, 1978, J AM CHEM SOC, V100, P8264, DOI 10.1021/ja00494a040; BARTL H, 1980, Z KRISTALLOGR, V152, P161, DOI 10.1524/zkri.1980.152.3-4.161; BEESON C, 1993, J AM CHEM SOC, V115, P10275, DOI 10.1021/ja00075a049; BIAGINICINGI M, 1977, ACTA CRYSTALLOGR B, V33, P3772; BORDWELL FG, 1988, ACCOUNTS CHEM RES, V21, P456, DOI 10.1021/ar00156a004; BORDWELL FG, 1984, J ORG CHEM, V49, P1424, DOI 10.1021/jo00182a020; BORDWELL FG, 1980, J ORG CHEM, V45, P3305, DOI 10.1021/jo01304a034; BORS DA, 1985, J AM CHEM SOC, V107, P6975, DOI 10.1021/ja00310a038; CALDWELL G, 1984, J AM CHEM SOC, V106, P4660, DOI 10.1021/ja00329a002; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DIXON HP, 1972, J CHEM PHYS, V57, P4388, DOI 10.1063/1.1678079; EXNER O, 1988, CORRELATION ANAL CHE, P439; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUNDERBURK LH, 1978, J AM CHEM SOC, V100, P6708, DOI 10.1021/ja00489a026; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1524, DOI 10.1073/pnas.86.5.1524; GORDON JE, 1961, J ORG CHEM, V26, P738, DOI 10.1021/jo01062a024; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HINE J, 1972, J AM CHEM SOC, V94, P5766, DOI 10.1021/ja00771a038; HINE J, 1962, PHYSICAL ORGANIC CHE, pCH4; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, pCH6; KASENDE O, 1984, J PHYS CHEM-US, V88, P2636, DOI 10.1021/j150656a042; KOLTHOFF IM, 1971, J AM CHEM SOC, V93, P3843, DOI 10.1021/ja00745a001; Kortum G., 1961, DISSOCIATION CONSTAN; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KRYGOWSKI TM, 1975, J AM CHEM SOC, V97, P2143, DOI 10.1021/ja00841a026; LARSON JW, 1983, J AM CHEM SOC, V105, P2944, DOI 10.1021/ja00348a003; MATTHEWS WS, 1975, J AM CHEM SOC, V97, P7006, DOI 10.1021/ja00857a010; MEOTNER M, 1984, J AM CHEM SOC, V106, P1257, DOI 10.1021/ja00317a015; MEOTNER M, 1986, J PHYS CHEM-US, V90, P6687, DOI 10.1021/j100283a019; MEOTNER M, 1986, J AM CHEM SOC, V108, P7525, DOI 10.1021/ja00284a014; MIHALICK JE, UNPUB; NADLER EB, 1989, J AM CHEM SOC, V111, P213, DOI 10.1021/ja00183a033; PAWLAK Z, 1984, ELECTROCHIM ACTA, V29, P391, DOI 10.1016/0013-4686(84)87080-2; PERRIN CL, 1989, J AM CHEM SOC, V111, P8010, DOI 10.1021/ja00202a050; PERRIN CL, 1992, J AM CHEM SOC, V114, P8559, DOI 10.1021/ja00048a031; PERRIN CL, 1994, SCIENCE, V266, P1665, DOI 10.1126/science.266.5191.1665; RAO SN, 1987, NATURE, V328, P551, DOI 10.1038/328551a0; ROTHENBERG ME, 1985, J AM CHEM SOC, V107, P1340, DOI 10.1021/ja00291a038; RUBIN J, 1965, J PHYS CHEM-US, V69, P3089, DOI 10.1021/j100893a045; SAUNDERS M, 1984, J AM CHEM SOC, V106, P3098, DOI 10.1021/ja00323a005; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; SCHMIDEDER H, 1987, J MOL STRUCT, V161, P87, DOI 10.1016/0022-2860(87)85064-0; SCHWARTZ B, 1995, J AM CHEM SOC, V117, P11902, DOI 10.1021/ja00153a011; SCHWARTZ B, 1995, BIOCHEMISTRY-US, V34, P15459, DOI 10.1021/bi00047a010; SHAN S, UNPUB; SHERRY AD, 1970, J PHYS CHEM-US, V74, P3535, DOI 10.1021/j100713a017; STAHL N, 1986, J AM CHEM SOC, V108, P4196, DOI 10.1021/ja00274a058; TAFT RW, 1969, J AM CHEM SOC, V91, P4801, DOI 10.1021/ja01045a038; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; USHER KC, 1994, BIOCHEMISTRY-US, V33, P7753, DOI 10.1021/bi00191a002; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WARSHEL A, 1981, BIOCHEMISTRY-US, V20, P3167, DOI 10.1021/bi00514a028; WILCOX CS, 1995, TETRAHEDRON, V51, P621, DOI 10.1016/0040-4020(94)00921-G; YAMDAGNI R, 1971, J AM CHEM SOC, V93, P7139, DOI 10.1021/ja00755a003	67	252	254	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					97	101		10.1126/science.272.5258.97	http://dx.doi.org/10.1126/science.272.5258.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600542				2022-12-24	WOS:A1996UD59700046
J	Polson, AG; Bass, BL; Casey, JL				Polson, AG; Bass, BL; Casey, JL			RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase	NATURE			English	Article							UNWINDING ACTIVITY; MAMMALIAN-CELLS; GENOME; REPLICATION; EXPRESSION; MECHANISM	HEPATITIS delta virus (HDV) is a subviral human pathogen that requires hepatitis B virus (HBV) for packaging(1,2). Concurrent infection by HBV and HDV increases the risk of severe liver disease compared to infection with HBV alone(3). The HDV genome is a closed circular RNA of about 1,700 bases which is replicated through an RNA intermediate, the antigenome(4). Both RNAs cars be folded into highly base-paired, rod-shaped structures, similar to the plant viroid RNAs(5). Two forms of the sole HDV protein, hepatitis delta antigen, are derived from a single open reading frame by RNA editing; the enzymes responsible for the editing have not been characterized, Here we report that the purified enzyme dsRAD (for double-stranded-RNA-adenosine deaminase) can edit HDV antigenomic RNA in vitro. Most important, we observe that mutations in critical sequences of the antigenome have identical effects on in vitro and in vivo editing, suggesting that dsRAD, or a closely related enzyme, is responsible for editing HDV RNA in vivo.	UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; GEORGETOWN UNIV,MED CTR,DIV MOL VIROL & IMMUNOL,ROCKVILLE,MD 20852	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Georgetown University	Polson, AG (corresponding author), UNIV UTAH,DEPT BIOCHEM,6110A EIHG,BLDG 533,SALT LAKE CITY,UT 84112, USA.			Casey, John/0000-0003-0396-9856				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CASEY JL, 1992, P NATL ACAD SCI USA, V89, P7149, DOI 10.1073/pnas.89.15.7149; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hurst SR, 1995, RNA, V1, P1051; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NETTER HJ, 1995, J VIROL, V69, P1687, DOI 10.1128/JVI.69.3.1687-1692.1995; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; TANG JR, 1994, J MED VIROL, V42, P1, DOI 10.1002/jmv.1890420102; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; ZHENG HQ, 1992, J VIROL, V66, P4693, DOI 10.1128/JVI.66.8.4693-4697.1992	27	256	264	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					454	456						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602246				2022-12-24	WOS:A1996UD59000066
J	Lanker, S; Valdivieso, MH; Wittenberg, C				Lanker, S; Valdivieso, MH; Wittenberg, C			Rapid degradation of the G(1) cyclin Cln2 induced by CDK-dependent phosphorylation	SCIENCE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; G1 CYCLINS; GENE; CDC28; ASSOCIATION; ACTIVATOR; DIVISION; COMPLEX	Cyclins regulate the major cell cycle transitions in eukaryotes through association with cyclin-dependent protein kinases (CDKs). In yeast, G(1) cyclins are essential, rate-limiting activators of cell cycle initiation. G(1)-specific accumulation of one G(1) cyclin, Cln2, results from periodic gene expression coupled with rapid protein turnover. Site-directed mutagenesis of CLN2 revealed that its phosphorylation provides a signal that promotes rapid degradation. Cln2 phosphorylation is dependent on the Cdc28 protein kinase, the CDK that it activates, These findings suggest that Cln2 is rendered self-limiting by virtue of its ability to activate its cognate CDK subunit.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; EDIFICIO DEPT MICROBIOL BIOL, E-37007 SALAMANCA, SPAIN	Scripps Research Institute; Scripps Research Institute			Valdivieso, M.-Henar/B-5199-2017	Valdivieso, M.-Henar/0000-0002-6857-7493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; LANKER S, UNPUB; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LITTLEFIELD R, UNPUB; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VALDIVIESO M, UNPUB; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WITTENBERG C, 1987, J CELL BIOL, V105, P1527, DOI 10.1083/jcb.105.4.1527; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WITTENBERG C, UNPUB; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	32	195	196	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1597	1601		10.1126/science.271.5255.1597	http://dx.doi.org/10.1126/science.271.5255.1597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599119				2022-12-24	WOS:A1996TZ98300046
J	Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R				Hirsch, E; Iglesias, A; Potocnik, AJ; Hartmann, U; Fassler, R			Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta(1) integrins	NATURE			English	Article							GENE REARRANGEMENT; FETAL LIVER; ADHESION; HEMATOPOIESIS; TRANSCRIPTION; PRECURSORS; ACTIVATION; RECEPTOR; CHAIN	Adhesive interactions mediated by integrins of the beta(1) subfamily(1) are thought to be critical in controlling differentiation and migration of blood cell precursors(2-7). Here we report that chimaeric mice generated with beta(1)-integrin-deficient embryonic stem (ES) cells(8,9) lack beta(1)(-/-) cells in blood and in haematopoietic organs such as spleen, thymus and bone marrow. Chimaeric embryos contain beta(1)-null haematopoietic cells in the yolk sac and in fetal blood but not in fetal liver. We show that such beta(1)(-/-) haematopoietic stem cells derived from yolk sac of 10.5-day-old chimaeric embryos readily generate erythroid and myeloid colonies and that beta(1)(-/-) ES cells can differentiate into mature B lymphocytes in vitro. Our results indicate that haematopoietic stem cells lacking beta(1) integrins can form and differentiate into different lineages but cannot colonize the fetal liver.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	Max Planck Society; Max Planck Society; Max Planck Society			Hirsch, Emilio/F-4848-2013	Hirsch, Emilio/0000-0002-9073-6024; Potocnik, Alexandre/0000-0002-4730-8593				ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; GIANCOTTI FG, 1986, J CELL BIOL, V103, P429, DOI 10.1083/jcb.103.2.429; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGLESIAS A, 1992, EUR J IMMUNOL, V22, P335, DOI 10.1002/eji.1830220208; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEPTIN M, 1984, EUR J IMMUNOL, V14, P534, DOI 10.1002/eji.1830140610; Moore K. A., 1993, Gene targeting: a practical approach., P63; PAPAYANNOPOULOU T, 1992, BLOOD, V79, P1686; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; PEVNY L, 1995, DEVELOPMENT, V121, P163; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; RUIZ P, 1995, EUR J IMMUNOL, V25, P2034, DOI 10.1002/eji.1830250735; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUBRAMANIAM M, 1995, J EXP MED, V181, P2277, DOI 10.1084/jem.181.6.2277; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WILT FH, 1965, SCIENCE, V147, P1588, DOI 10.1126/science.147.3665.1588; YANG JT, 1995, DEVELOPMENT, V121, P549	28	291	301	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					171	175		10.1038/380171a0	http://dx.doi.org/10.1038/380171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600394				2022-12-24	WOS:A1996TZ97800055
J	Dias, R; Robbins, TW; Roberts, AC				Dias, R; Robbins, TW; Roberts, AC			Dissociation in prefrontal cortex of affective and attentional shifts	NATURE			English	Article							FRONTAL-CORTEX; LOBE	The prefrontal cortex is implicated in such human characteristics as volition, planning, abstract reasoning and affect(1-6). Frontal-lobe damage can cause disinhibition such that the behaviour of a subject is guided by previously acquired responses that are inappropriate to the current situation(7-9). Here we demonstrate that disinhibition, or a loss of inhibitory control, can be selective for particular cognitive functions and that different regions of the prefrontal cortex provide inhibitory control in different aspects of cognitive processing. Thus, whereas damage to the lateral prefrontal cortex (Brodmann's area 9) in monkeys causes a loss of inhibitory control in attentional selection, damage to the orbito-frontal cortex in monkeys causes a loss of inhibitory control in 'affective' processing, thereby impairing the ability to alter behaviour in response to fluctuations in the emotional significance of stimuli. These findings not only support the view that the prefrontal cortex has multiple functions, but also provide evidence for the distribution of different cognitive functions within specific regions of prefrontal cortex.	UNIV CAMBRIDGE,DEPT EXPTL PSYCHOL,CAMBRIDGE CB2 3EB,ENGLAND	University of Cambridge			Roberts, Angela C/C-1313-2012; Robbins, Trevor W/A-7551-2008	Roberts, Angela C/0000-0003-2873-157X; Robbins, Trevor/0000-0003-0642-5977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARAL DG, 1993, AMYGDALA NEUROBIOLOG, P1; Brodmann, 1909, VERGLEICHENDE LOKALI; Damasio A. R., 1994, DESCARTES ERROR EMOT; Fuster J.M., 1989, PREFRONTAL CORTEX; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Mishkin M., 1964, FRONTAL GRANULAR COR, P219; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PREUSS TM, 1991, J COMP NEUROL, V310, P429, DOI 10.1002/cne.903100402; ROBERTS AC, 1994, J NEUROSCI, V14, P2531; ROBERTS AC, 1988, Q J EXP PSYCHOL-B, V40, P321; Shallice T, 1988, NEUROPSYCHOLOGY MENT, P328; SUTHERLAND NS, 1971, MECHANISMS ANIMAL DI; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	18	1196	1209	0	99	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					69	72		10.1038/380069a0	http://dx.doi.org/10.1038/380069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598908				2022-12-24	WOS:A1996TY87700058
J	Klingelhutz, AJ; Foster, SA; McDougall, JK				Klingelhutz, AJ; Foster, SA; McDougall, JK			Telomerase activation by the E6 gene product of human papillomavirus type 16	NATURE			English	Article							TERMINAL TRANSFERASE; HUMAN FIBROBLASTS; RIBONUCLEOPROTEIN; ONCOPROTEIN; REPEATS; ENZYME; CELLS; P53	Activation of telomerase, a ribonucleoprotein complex that synthesizes telomere repeat sequences(1-4), is linked to cell immortalization and is characteristic of most cell lines and tumours(4,5-8) Here we show that expression of the human papillomavirus type 16 (HPV-16) E6 protein activates telomerase in early-passage human keratinocytes and mammary epithelial cells. This activation was observed in cells pre-crisis, that is, before they became immortal, and occurred within one passage of retroviral infection with vectors expressing HPV-16 E6. Studies using HPV-16 E6 mutants showed that there was no correlation between the ability of the mutants to activate telomerase and their ability to target p53 for degradation, suggesting that telomerase activation by HPV-16 E6 is p53 independent. Keratinocytes expressing wild-type HPV-16 E6 have an extended lifespan, but do not become immortal(9), indicating that telomerase activation and E6-mediated degradation of p53 are insufficient for their immortalization. These results show that telomerase activation is an intrinsic, but insufficient, component of transformation by HPV.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Klingelhutz, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM CANC BIOL,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; MILLER AD, 1988, J VIROL, V62, P4337, DOI 10.1128/JVI.62.11.4337-4345.1988; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	21	649	677	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					79	82		10.1038/380079a0	http://dx.doi.org/10.1038/380079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598912				2022-12-24	WOS:A1996TY87700061
J	RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H				RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H			RNA binding and translational suppression by bicoid	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYOS; BODY PATTERN; GRADIENT; PROTEIN; TRANSCRIPTION; EXPRESSION; KRUPPEL; LOCALIZATION; ANTERIOR	THE anterior determinant bicoid (bcd) of Drosophila is a homeodomain protein. It forms an anterior-to-posterior gradient in the embryo and activates, in a concentration-dependent manner, several zygotic segmentation genes during blastoderm formation(1-4). Its posterior counterpart, the homeodomain transcription factor caudal (cad)(5-7), forms a concentration gradient in the opposite direction, emanating from evenly distributed messenger RNA in the egg. In embryos lacking bcd activity as a result of mutation, the cad gradient fails to form and cad becomes evenly distributed throughout the embryo(8). This suggests that bcd may act in the region-specific control of cad mRNA translation. Here we report that bcd binds through its homeodomain to cad mRNA in vitro, and exerts translational control through a bcd-binding region of cad mRNA.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	RiveraPomar, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,ABT MOLEK ENTWICKLUNGSBIOL,FASSBERG,D-37077 GOTTINGEN,GERMANY.		Niessing, Dierk/AAE-4936-2022; Niessing, Dierk/M-4619-2014	Niessing, Dierk/0000-0002-5589-369X; Niessing, Dierk/0000-0002-5589-369X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1989, THESIS EBERHARD KARL; HESS MA, 1994, J BIOL CHEM, V269, P10913; HUISKAMP M, 1988, NATURE, V338, P629; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Pankratz Michael J., 1993, P467; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STJOHNSTON RD, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	250	254	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					746	749		10.1038/379746a0	http://dx.doi.org/10.1038/379746a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602224				2022-12-24	WOS:A1996TW56700058
J	Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB				Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB			Association of the auscultatory gap with vascular disease in hypertensive patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; vascular diseases; blood pressure; auscultation; atherosclerosis	CAROTID-ARTERY ATHEROSCLEROSIS; BLOOD-PRESSURE; MEDIAL THICKNESS; ULTRASOUND; STIFFNESS; PULSE; POPULATIONS; VALIDATION; PREVALENCE; URBAN	Objective: To assess the relation of the auscultatory gap during blood pressure measurement to cardiovascular structure and function. Design: Cross-sectional study. Setting: A hypertension center in a university hospital. Patients: 168 persons with hypertension who were otherwise healthy and were not receiving medication. Measurements: Wideband external pulse recordings and ultrasonographic examination of the left ventricle and extracranial carotid arteries. Vascular stiffness was evaluated using simultaneous carotid pressure waveforms obtained by applanation tonometry of the contralateral carotid artery. Results: Classic auscultatory gaps were present in 21% of patients and were associated with older age (mean age +/- SD, 64 +/- 11 years for patients with gaps and 55 +/- 13 years for patients without gaps; P < 0.001), female sex (67% of patients with gaps and 44% of patients without gaps were female; P < 0.05), and increased arterial stiffness (arterial stiffness index, 8.5 +/- 4.6 in patients with gaps and 5.8 +/- 3.2 in patients without gaps; P < 0.005). The prevalence of atherosclerotic plaques was increased more than twofold among patients with gaps compared with patients without gaps (50% compared with 22%; P < 0.002). Patients with and without auscultatory gaps had similar blood pressures, left ventricular structure and function, serum cholesterol levels, and smoking history. Logistic regression analysis indicated that only female sex (P < 0.02), arterial stiffness (P < 0.002), and atherosclerotic plaque (P < 0.02) were independently associated with the presence of an auscultatory gap. Conclusions: This study provides strong evidence that auscultatory gaps are related to carotid atherosclerosis and to increased arterial stiffness in hypertensive patients, independent of age. Although these observations need to be confirmed prospectively, they suggest that auscultatory gaps may have prognostic relevance.	CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV CARDIOL, NEW YORK, NY 10021 USA; UNIV FLORENCE, IST GERONTOL & GERIATR, I-50141 FLORENCE, ITALY; CORNELL UNIV, MED CTR, NEW YORK HOSP, HYPERTENS CTR, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; University of Florence; Cornell University; NewYork-Presbyterian Hospital				Pini, Riccardo/0000-0002-7940-7908	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323, P01HL047540] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL047540, HL 18323, HL 47540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOLIO AP, 1985, CIRCULATION, V71, P202, DOI 10.1161/01.CIR.71.2.202; AVOLIO AP, 1983, CIRCULATION, V68, P50, DOI 10.1161/01.CIR.68.1.50; BLANK SG, 1991, HYPERTENSION, V17, P225, DOI 10.1161/01.HYP.17.2.225; BLANK SG, 1988, CIRCULATION, V77, P1297, DOI 10.1161/01.CIR.77.6.1297; Cook JE, 1917, J AMER MED ASSOC, V68, P1088; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FLORAS JS, 1988, HYPERTENSION, V11, P273, DOI 10.1161/01.HYP.11.3.273; Hamilton WF, 1939, AM J PHYSIOL, V125, P48, DOI 10.1152/ajplegacy.1938.125.1.48; HANDA N, 1990, STROKE, V21, P1567, DOI 10.1161/01.STR.21.11.1567; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; KELLY R, 1992, J AM COLL CARDIOL, V20, P952, DOI 10.1016/0735-1097(92)90198-V; Kelly R, 1989, J VASC MED BIOL, V3, P142; Kelly R, 1989, J VASC MED BIOL, V1, P241; KOCHAR MS, 1992, POSTGRAD MED, V91, P393; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P221; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P319; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P113; LONDON G, 1992, HYPERTENSION, V20, P10, DOI 10.1161/01.HYP.20.1.10; Mudd SG, 1928, ARCH INTERN MED, V41, P249, DOI 10.1001/archinte.1928.00130140111008; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; PETERSON LH, 1960, CIRC RES, V8, P622, DOI 10.1161/01.RES.8.3.622; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; Ragan C, 1941, B JOHNS HOPKINS HOSP, V69, P504; RODBARD S, 1957, CIRCULATION, V15, P850, DOI 10.1161/01.CIR.15.6.850; ROMAN MJ, 1992, J HYPERTENS, V10, pS115; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROMAN MJ, 1992, CIRCULATION, V86, P1909, DOI 10.1161/01.CIR.86.6.1909; SABA PS, 1993, J AM COLL CARDIOL, V22, P1873, DOI 10.1016/0735-1097(93)90772-S; SAFAR ME, 1989, J HYPERTENS, V7, P769, DOI 10.1097/00004872-198910000-00001; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNABEL TG, 1952, CIRCULATION, V5, P257, DOI 10.1161/01.CIR.5.2.257; SESSLER GM, 1966, J ACOUST SOC AM, V40, P1433, DOI 10.1121/1.1910245; TAVEL ME, 1969, CIRCULATION, V39, P465, DOI 10.1161/01.CIR.39.4.465; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; WEST JE, 1983, J ACOUST SOC AM, V74, P680, DOI 10.1121/1.389852	44	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					877	+		10.7326/0003-4819-124-10-199605150-00003	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610916				2022-12-24	WOS:A1996UJ80100003
J	Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS				Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS			Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; LYMPHOCYTES; AIDS; DISEASE; CELLS; VIREMIA; AGENTS; MODEL	Background. Activation of the immune system is a normal response to antigenic stimulation, and such activation enhances the replication of human immunodeficiency virus type 1 (HIV-1). We studied the effect of immunization with a common recall antigen on viral expression in HIV-1-infected patients, on the ability to isolate virus, and on the susceptibility to HIV-1 infection of peripheral-blood mononuclear cells (PBMCs) from control subjects not infected with HIV-1. Methods. Thirteen HIV-1-infected patients and 10 uninfected adults were given a 0.5-ml booster dose of tetanus toroid. Studies were performed to evaluate changes in the degree of plasma viremia, proviral burden, the ability to isolate HIV-1, and the susceptibility of PBMCs to acute infection in vitro. Two patients underwent sequential lymph-node biopsies for the assessment of viral burden in these tissues. Results. All 13 HIV-1-infected patients had transient increases in plasma viremia after immunization, and the proviral burden increased in 11. These changes did not correlate with the base-line CD4+ T-cell counts. The lymph-node tissue also had increases in the proviral burden and viral RNA after immunization. The virus was more easily isolated from PBMCs from nine of the patients after immunization than before immunization. Despite considerable variability in the results, PBMCs from 7 of the 10 normal subjects were more easily infected in vitro with HIV-1 after immunization than before immunization. Conclusions. Activation of the immune system by an ongoing antigen-specific immune response to an exogenous stimulus transiently increases the expression of HIV-1 and may enhance the susceptibility of uninfected subjects to HIV-1. (C) 1996, Massachusetts Medical Society.	NCI,DEPT NURSING,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,BETHESDA,MD 20892; MOL HISTOL INC,GAITHERSBURG,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stanley, SK (corresponding author), NIAID,IMMUNOREGULAT LAB,NIH,BLDG 30,RM 7A03,31 CTR DR,MSC-2520,BETHESDA,MD 20892, USA.			Hedayati, S Susan/0000-0001-8850-4729				BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; BRICHACEK B, 1995, 2 NAT C HUM RETR REL, P98; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BURKE AP, 1994, HUM PATHOL, V25, P248, DOI 10.1016/0046-8177(94)90196-1; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; COLEBUNDERS RL, 1991, AIDS, V5, pS103; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOLKS T, 1986, J IMMUNOL, V136, P4049; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; JANOFF EN, 1991, J IMMUNOL, V147, P2130; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; NAGELKERKE NJD, 1990, AIDS, V4, P743, DOI 10.1097/00002030-199008000-00005; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POPOV J, 1992, J ACQ IMMUN DEF SYND, V5, P391; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; SCHWIEBERT R, 1994, J VIROL, V68, P5538, DOI 10.1128/JVI.68.9.5538-5547.1994; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; WACHTER H, 1986, LANCET, V2, P1216; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	31	320	324	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1222	1230		10.1056/NEJM199605093341903	http://dx.doi.org/10.1056/NEJM199605093341903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606717				2022-12-24	WOS:A1996UJ05400003
J	Nellen, D; Burke, R; Struhl, G; Basler, K				Nellen, D; Burke, R; Struhl, G; Basler, K			Direct and long-range action of a DPP morphogen gradient	CELL			English	Article							DEVELOPING DROSOPHILA EYE; GENE-EXPRESSION; BETA FAMILY; PATTERN; PROTEIN; RECEPTOR; EMBRYO; CELLS; ACTS	During development of the Drosophila wing, the decapentaplegic (dpp) gene is expressed in a stripe of cells along the anteroposterior compartment boundary and gives rise to a secreted protein that exerts a long-range organizing influence on both compartments. Using clones of cells that express DPP, or in which DPP receptor activity has been constitutively activated or abolished, we show that DPP acts directly and at long range on responding cells, rather than by proxy through the short-range induction of other signaling molecules. Further, we show that two genes, optomotor-blind and spalt are transcriptionally activated at different distances from DPP-secreting cells and provide evidence that these genes respond to different threshold concentrations of DPP protein. We propose that DPP acts as a gradient morphogen during wing development.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	Nellen, D (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Burke, Richard/0000-0003-0086-0767				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; Boveri T, 1903, VERHANDLUNGEN PHYSIK, V35, P67; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1994, CURR BIOL, V4, P374; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KOHNLEIN RP, 1994, EMBO J, V13, P168; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1972, J CELL SCI, V11, P815; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H., 1938, EMBRYONIC DEV INDUCT; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STUMPF HF, 1966, NATURE, V212, P430, DOI 10.1038/212430a0; SUN YH, 1995, GENETICS, V141, P1075; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINCENT JP, 1994, TRENDS GENET, V10, P383, DOI 10.1016/0168-9525(94)90040-X; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT S, P3; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	62	795	804	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					357	368		10.1016/S0092-8674(00)81114-9	http://dx.doi.org/10.1016/S0092-8674(00)81114-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616891	hybrid, Green Accepted			2022-12-24	WOS:A1996UK14000009
J	Echtenacher, B; Mannel, DN; Hultner, L				Echtenacher, B; Mannel, DN; Hultner, L			Critical protective role of mast cells in a model of acute septic peritonitis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CONNECTIVE-TISSUE-TYPE; FACTOR-ALPHA; TNF-ALPHA; GRANULOCYTE INFILTRATION; DEFICIENT W/WV; MICE; MOUSE; CACHECTIN; RECRUITMENT	MAST cells play a detrimental role in IgE dependent allergic reactions, In contrast, a protective function for mast cells has been proposed on the basis of some worm infection models. No reports exist on the in vivo significance of these cells in bacterial infections(1,2). Here we use congenitally mast-cell-deficient W/W-v mice and normal +/+ littermates(3,4) to analyse the role of mast cells in a model of acute septic peritonitis (caecum ligation and puncture (CLP)), Following CLP, W/W-v mice showed a significantly increased mortality compared to +/+ mice, The selective reconstitution of W/W-v mice with cultured +/+ mast cells substantially protected them from the lethal effects of CLP, whereas an anti-tumour-necrosis-factor (TNF) antibody injected immediately after CLP completely suppressed this protection, Our results reveal a previously unrecognized protective role of mast cells and mast-cell-derived TNF in acute bacterial peritonitis.	GSF MUNICH,INST EXPT HAMATOL,D-81377 MUNICH,GERMANY; UNIV REGENSBURG,INST PATHOL TUMORIMMUNOL,D-93042 REGENSBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Regensburg								ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; ANSEL JC, 1993, J IMMUNOL, V150, P4478; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Echtenacher B, 1993, HOST DEFENSE DYSFUNC, P755; EGGER D, 1995, J IMMUNOL, V154, P1830; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HOLZHEIMER RG, 1991, INFECTION, V19, P447, DOI 10.1007/BF01726463; HULTNER L, 1989, J IMMUNOL, V142, P3440; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MATSUDA H, 1989, J IMMUNOL, V142, P927; MCCLEAN KL, 1994, CLIN INFECT DIS, V19, P100, DOI 10.1093/clinids/19.1.100; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKANO T, 1987, J IMMUNOL, V138, P544; OTANI I, 1982, J IMMUNOL, V129, P2109; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; SCHWARTZ LB, 1994, CURR OPIN IMMUNOL, V6, P91, DOI 10.1016/0952-7915(94)90039-6; SHER A, 1979, LAB INVEST, V41, P490; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1994, ADV EXP MED BIOL, V347, P39; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	30	755	783	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					75	77		10.1038/381075a0	http://dx.doi.org/10.1038/381075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609992				2022-12-24	WOS:A1996UJ05300059
J	Aldaz, H; Schuster, E; Baker, TA				Aldaz, H; Schuster, E; Baker, TA			The interwoven architecture of the Mu transposase couples DNA synapsis to catalysis	CELL			English	Article							BACTERIOPHAGE-MU; TRANSPOSITIONAL ENHANCER; INVITRO TRANSPOSITION; STRAND TRANSFER; B-PROTEIN; A-PROTEIN; MINI-MU; SITE; RECOMBINATION; ENDS	Mu transposition occurs exclusively using a pair of recombination sites found at the ends of the phage genome. To address the mechanistic basis of this specificity, we have determined both where the individual subunits of the tetrameric transposase bind on the DNA and where they catalyze DNA joining. We demonstrate that subunits do not catalyze recombination at the site adjacent to where they are bound, but rather on the opposite end of the phage genome. Furthermore, subunits bound to two different sites contribute to catalysis of one reaction step. This interwoven subunit arrangement suggests a molecular explanation for the precision with which recombination occurs using a pair of DNA signals and provides an example of the way in which the architecture of a protein-DNA complex can define the reaction products.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Aldaz, H (corresponding author), MIT,DEPT BIOL,68-523,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Schuster, Eugene/0000-0001-5076-2810	NIGMS NIH HHS [GM499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; Berg D. E., 1989, MOBILE DNA; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; GROENEN MAM, 1986, EMBO J, V5, P3687, DOI 10.1002/j.1460-2075.1986.tb04700.x; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG SH, 1994, J BIOL CHEM, V269, P12789; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZOU A, 1991, J BIOL CHEM, V266, P20476; ZOU AH, 1991, EMBO J, V10, P1585	66	79	82	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					257	269		10.1016/S0092-8674(00)81102-2	http://dx.doi.org/10.1016/S0092-8674(00)81102-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612278	Bronze			2022-12-24	WOS:A1996UG25500014
J	Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A				Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A			Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome	CELL			English	Article							FMR-1 GENE; PROTEIN; RECOGNITION; SEQUENCE	The KH module is a sequence motif found in a number of proteins that are known to be in close association with RNA. Experimental evidence suggests a direct involvement of KH in RNA binding. The human FMR1 protein, which has two KH domains, is associated with fragile X syndrome, the most common inherited cause of mental retardation. Here we present the three-dimensional solution structure of the KH module. The domain consists of a stable beta alpha alpha beta beta alpha fold. On the basis of our results, we suggest a potential surface for RNA binding centered on the loop between the first two helices. Substitution of a well-conserved hydrophobic residue located on the second helix destroys the KH fold; a mutation of this position in FMR1 leads to an aggravated fragile X phenotype.	UNIV BASILICATA, I-85100 POTENZA, ITALY	University of Basilicata	Musco, G (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Nilges, Michael/E-4803-2011; Musco, Giovanna/Q-2756-2019; musco, giovanna/I-7122-2012	Nilges, Michael/0000-0002-1451-8092; musco, giovanna/0000-0002-0469-2994; Gibson, Toby James/0000-0003-0657-5166; Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117				BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EBERSOLE TA, 1995, IN PRESS NATURE GENE; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GUENTERT P, 1991, Journal of Molecular Biology, V217, P517; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KHARRAT A, 1995, EMBO J, V14, P3563; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; LUYEBEEL KA, 1995, NAT GENET, V10, P483; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Mandel JL, 1992, CURR OPIN GENET DEV, V2, P422, DOI 10.1016/S0959-437X(05)80153-4; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; NUSSBAUM RL, 1995, METABOLIC BASIS INHE, P795; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; REGNIER P, 1987, J BIOL CHEM, V262, P63; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	43	255	260	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 19	1996	85	2					237	245		10.1016/S0092-8674(00)81100-9	http://dx.doi.org/10.1016/S0092-8674(00)81100-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612276	Bronze			2022-12-24	WOS:A1996UG25500012
J	ORiain, MJ; Jarvis, JUM; Faulkes, CG				ORiain, MJ; Jarvis, JUM; Faulkes, CG			A dispersive morph in the naked mole-rat	NATURE			English	Article							BEHAVIOR; COLONIES	Close inbreeding is known for a variety of small mammal species(1-4) for which a high probability of mortality during dispersal makes helping and delayed maturation a relatively secure fitness option(5). Prolonged inbreeding, however, is usually associated with lowered fitness(6,7), and it has been shown that most highly inbred small mammals(8) and social insects(9) have inbreeding-avoidance mechanisms that promote some degree of outbreeding. However, previous field and laboratory research on the naked mole-rat (Heterocephalus glaber) suggested that this cooperatively breeding rodent is highly inbred(10-12), with new colonies forming by fission(13). Here we report the discovery of a dispersal phenotype that may occasionally promote outbreeding in naked mole-rats. These dispersers are morphologically, physiologically and behaviourally distinct from other colony members. They are laden with fat, exhibit elevated levels of luteinizing hormone, have a strong urge to disperse, and only solicit matings with non-colony members. These findings suggest that, although rare, a dispersive morph exists within naked mole-rat colonies.	ZOOL SOC LONDON,INST ZOOL,CONSERVAT GENET GRP,LONDON NW1 4RY,ENGLAND	Zoological Society of London	ORiain, MJ (corresponding author), UNIV CAPE TOWN,DEPT ZOOL,RONDEBOSCH 7700,SOUTH AFRICA.		Faulkes, Chris/B-8377-2008; Faulkes, Chris/O-8101-2019	O'Riain, M. Justin/0000-0001-5233-8327				[Anonymous], 1991, BIOL NAKED MOLE RAT; ARMITAGE KB, 1986, ECOLOGY, V67, P1186, DOI 10.2307/1938674; BENGTSSON BO, 1978, J THEOR BIOL, V73, P439, DOI 10.1016/0022-5193(78)90151-0; BLOUIN SF, 1988, TRENDS ECOL EVOL, V3, P230, DOI 10.1016/0169-5347(88)90164-4; Brett R.A., 1991, P97; CLARKE KR, 1994, USER GUIDE PRIMER VE; Dobzhansky Th., 1971, GENETICS EVOLUTIONAR; FAULKES CG, 1990, J ZOOL, V221, P87, DOI 10.1111/j.1469-7998.1990.tb03778.x; Hamilton William D., 1993, P429; HOECK HN, 1982, Z TIERPSYCHOL, V59, P177; JARVIS JUM, 1994, TRENDS ECOL EVOL, V9, P47, DOI 10.1016/0169-5347(94)90267-4; Lacey E.A., 1991, P275; LOVEGROVE BG, 1991, BEHAV ECOL SOCIOBIOL, V28, P37; MYLES TG, 1978, Q REV BIOL, V63, P1; ORIAIN MJ, IN PRESS ANIM BEHAV; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; SELANDER RK, 1970, AM ZOOL, V10, P53; Smith Andrew T., 1993, P329; SMITH AT, 1987, BEHAV ECOL SOCIOBIOL, V13, P37; STENSETH NC, 1984, ECOLOGY ANIMAL MOVEM, P63	20	225	230	0	81	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					619	621		10.1038/380619a0	http://dx.doi.org/10.1038/380619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602260				2022-12-24	WOS:A1996UF74100043
J	Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H				Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H			Longitudinal study of low-level lead exposure and impairment of renal function The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; SERUM CREATININE; SMELTER WORKERS; HYPERTENSION; NEPHROPATHY; POPULATION; PARAMETERS; EXCRETION; FAILURE; PLASMA	Objective.-To determine whether low-level lead exposure is associated with impaired renal function. Design.-Retrospective cohort study. Setting and Participants.-Subjects were 459 men randomly selected from the participants of the Normative Aging Study who were originally recruited from healthy veterans in the greater Boston area in 1961 and were periodically examined at the Department of Veterans Affairs Outpatient Clinic every 3 to 5 years. We reconstructed blood lead concentrations for the period between 1979 and 1994 using samples of either archived red blood cells or fresh whole blood. Main Outcome Measures.-Serum creatinine concentration. Results.-After adjustment for age, body mass index, smoking, alcohol consumption, educational level, and hypertension, blood lead concentration was positively and significantly associated with concurrent concentration of serum creatinine (P=.005). A 10-fold increase in blood lead level predicted an increase of 7 mu mol/L (0.08 mg/dL) in serum creatinine concentration, which is roughly equivalent to the increase predicted by 20 years of aging. The association was also significant among subjects whose blood lead concentrations had never exceeded 0.48 mu mol/L (10 mu g/dL) throughout the study period. The age-related increase in serum creatinine level was earlier and faster in the group with the highest-quartile levels of long-term lead exposure than in the group with the lowest-quartile levels. Conclusions.-Low-level exposure to lead may impair renal function in middle-aged and older men. Longitudinal data suggest an acceleration of age-related impairment of renal function in association with long-term low-level lead exposure.	HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; DEPT VET AFFAIRS, OUTPATIENT CLIN, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kim, R (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005257, P42ES005947] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES05947, ES05257] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BELL B, 1972, AGING HUM DEVELOP, V3, P5, DOI 10.2190/GGVP-XLB5-PC3N-EF0G; BENNETT WM, 1985, KIDNEY INT, V28, P212, DOI 10.1038/ki.1985.143; BERNARD A, 1989, TOXICOL LETT, V46, P293, DOI 10.1016/0378-4274(89)90137-9; BROCHNERMORTENSEN J, 1977, SCAND J UROL NEPHROL, V11, P263, DOI 10.3109/00365597709179963; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; *CDC, 1985, PUBL CDC; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLEONI N, 1986, NEPHRON, V44, P32, DOI 10.1159/000183908; CRAMER K, 1974, BRIT J IND MED, V31, P113; DESILVA PE, 1981, BRIT J IND MED, V38, P209; DOSSANTOS AC, 1994, AM J IND MED, V26, P635; ERJJUKA J, 1992, BR J IND MED, V49, P631; FOWLER BA, 1991, ENVIRON HEALTH PERSP, V91, P77, DOI 10.2307/3430986; FRIEDMAN SA, 1972, ANN INTERN MED, V76, P41, DOI 10.7326/0003-4819-76-1-41; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; Goyer R A, 1971, Curr Top Pathol, V55, P147; GOYER RA, 1970, ARCH ENVIRON HEALTH, V20, P705, DOI 10.1080/00039896.1970.10665647; GOYER RA, 1985, DIETARY ENV LEAD HUM; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HENDERSON D. A., 1958, MED JOUR AUSTRALIA I, V45, P377; Jaffe M., 1886, J PHYS CHEM-US, V10, P391, DOI [DOI 10.1515/BCHM1.1886.10.5.391, 10.1515/bchm1.1886.10.5.391]; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LILIS R, 1968, BRIT J IND MED, V25, P196; LILIS R, 1979, J ENVIRON PATHOL TOX, V2, P1447; LIN JL, 1994, J RHEUMATOL, V21, P705; MANTON WI, 1984, BRIT J IND MED, V41, P313; MEYER BR, 1984, AM J MED, V76, P989, DOI 10.1016/0002-9343(84)90847-7; MULDOON SB, 1994, AM J EPIDEMIOL, V139, P599, DOI 10.1093/oxfordjournals.aje.a117049; *OCC SAF HLTH ADM, 1978, 29CFR19101025 OCC SA; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROELS H, 1994, OCCUP ENVIRON MED, V51, P505, DOI 10.1136/oem.51.8.505; ROSE CL, 1976, GERONTOLOGIST, V16, P508, DOI 10.1093/geront/16.6.508; ROWE JW, 1979, J GERONTOL, V81, P155; SAUDIE E, 1984, J CHRON DIS, V37, P617; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH DR, 1992, ENVIRON RES, V57, P190, DOI 10.1016/S0013-9351(05)80079-9; SPARROW D, 1986, AM J CARDIOL, V57, P218, DOI 10.1016/0002-9149(86)90894-5; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; *TECHN, 1983, SG40011988 TECHN; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; VERSCHOOR M, 1987, AM J IND MED, V12, P341, DOI 10.1002/ajim.4700120402; VICTERY W, 1982, J LAB CLIN MED, V99, P354; WEDEEN RP, 1986, AM J KIDNEY DIS, V8, P380, DOI 10.1016/S0272-6386(86)80113-5; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; *WHO, 1980, WHO, V647	56	155	159	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1177	1181		10.1001/jama.275.15.1177	http://dx.doi.org/10.1001/jama.275.15.1177			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609685				2022-12-24	WOS:A1996UE62500029
J	Armstrong, D; Reyburn, H; Jones, R				Armstrong, D; Reyburn, H; Jones, R			A study of general practitioners' reasons for changing their prescribing behaviour	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To explore general practitioners' reasons for recent changes in their prescribing behaviour. Design - Qualitative analysis of semistructured interviews. Setting - General practice in south east London. Subjects - A heterogeneous sample of 18 general practitioners. Results - Interviewees were able to identify between two and five specific changes that had occurred in their prescribing in the preceding six months. The most frequently mentioned changes related to fluoxetine, angiotensin converting enzyme inhibitors, and the antibiotic treatment of Helicobacter pylori. Three models of change were identified: an accumulation model, in which the volume and authority of evidence were important; a challenge model, in which behaviour change followed a dramatic or conflictual clinical event; and a continuity model, in which change took place against a background of willingness to change, modulated by other factors such as cost pressures and the comprehensible therapeutic action of a drug. Behaviour change was reinforced and sustained by experiences with individual patients. Conclusions - Multiple factors are involved in general practitioners) decisions to change their prescribing habits. Three models of change can be identified which have important implications for the design and evaluation of interventions aimed at behaviour change.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London			Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				[Anonymous], 1995, LANCET, V346, P785; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; SMITH R, 1995, BRIT MED J, V311, P961; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244	7	120	122	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					949	952						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616310				2022-12-24	WOS:A1996UF65900022
J	Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y				Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y			Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENES	1,3-beta-D-Glucan synthase [also known as beta(1-->3)glucan synthase] is a multi-enzyme complex that catalyzes the synthesis of 1,8-beta-linked glucan, a major structural component of the yeast cell wall. Temperature-sensitive mutants in the essential Rho-type guanosine triphosphatase (GTPase), Rho1p, displayed thermolabile glucan synthase activity, which was restored by the addition of recombinant Rho1p. Glucan synthase from mutants expressing constitutively active Rho1p did not require exogenous guanosine triphosphate for activity. Rho1p copurified with beta(1-->3)glucan synthase and associated with the Fks1p subunit of this complex in vivo. Both proteins were localized predominantly at sites of cell wall remodeling. Therefore, it appears that Rho1p is a regulatory subunit of beta(1-->3)glucan synthase.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN; JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA; NIPPON ROCHE RES CTR, DEPT MYCOL, KAMAKURA, KANAGAWA 247, JAPAN; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tokyo; Johns Hopkins University; Roche Holding; University of Tennessee System; University of Tennessee Health Science Center			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; Levin, David/0000-0003-0696-2860	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOUGLAS CM, 1994, P NATL ACAD SCI USA, V91, P12907, DOI 10.1073/pnas.91.26.12907; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Inoue S., UNPUB; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MOL PC, 1994, J BIOL CHEM, V269, P31267; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, IN PRESS YEAST; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SZANISZLO PJ, 1985, J BACTERIOL, V161, P1188, DOI 10.1128/JB.161.3.1188-1194.1985; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	22	376	394	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					279	281		10.1126/science.272.5259.279	http://dx.doi.org/10.1126/science.272.5259.279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602515				2022-12-24	WOS:A1996UE72900045
J	Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM				Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM			The FHIT gene at 3p14.2 is abnormal in lung cancer	CELL			English	Article							CHROMOSOMAL REGION 3P21; SMALL-CELL CARCINOMA; SHORT ARM; HOMOZYGOUS DELETION; P53 GENE; ADENOCARCINOMA; MUTATIONS; HETEROZYGOSITY; EXPRESSION; FREQUENT	To determine the role of the FHIT gene, which encompasses the fragile site at 3p14.2, we analyzed 59 tumors of the small cell and non-small cell type by reverse transcription of FHIT mRNA, followed by PCR amplification and sequencing of products. Allelic losses affecting the gene were evaluated by microsatellite polymorphism analysis and genomic alterations by hybridization using cDNA and genomic probes. Small cell lung tumors (80%) and non-small cell lung cancers (40%) showed abnormalities in RNA transcripts of FHIT, and 76% of the tumors exhibited loss of FHIT alleles. Abnormal lung tumor transcripts lack two or more exons of the FHIT gene. Small cell lung cancer tumors and cell lines were analyzed by Southern blotting and showed rearranged BamHI fragments. These data suggest a critical role of the FHIT gene in lung carcinogenesis.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107, USA.		Young, Richard A/F-6495-2012; sozzi, gabriella/G-8259-2011; Negrini, Massimo/J-2377-2016; Pastorino, Ugo/C-2712-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Negrini, Massimo/0000-0002-0007-1920; Pastorino, Ugo/0000-0001-9974-7902; Pierotti, Marco Alessandro/0000-0002-7431-8332	NATIONAL CANCER INSTITUTE [R35CA039860, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA56336, CA39860, P01CA21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BARSKY SH, 1994, MODERN PATHOL, V7, P633; BAXI MD, 1994, BIOCHEMISTRY-US, V33, P14601, DOI 10.1021/bi00252a028; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHIBA I, 1990, ONCOGENE, V5, P1603; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DRUCK T, 1995, CANCER RES, V55, P5348; EBINA M, 1994, CANCER RES, V54, P2496; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1993, CANCER RES, V53, P1; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; *INT UN CANC, 1987, TNM CLASS MAL TUM; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KIM SY, 1993, AM J PATHOL, V142, P307; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOK K, 1994, CANCER RES, V54, P4183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURATA M, 1992, JPN J HUM GENET, V37, P205, DOI 10.1007/BF01900714; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SOZZI G, 1991, CANCER RES, V51, P400; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; World Health Organization, 1981, HIST TYP LUNG TUM; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	40	538	573	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					17	26		10.1016/S0092-8674(00)81078-8	http://dx.doi.org/10.1016/S0092-8674(00)81078-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620533	Bronze			2022-12-24	WOS:A1996UE55900005
J	Bradley, C; Blenkinsopp, A				Bradley, C; Blenkinsopp, A			Over the counter drugs - The future for self medication	BRITISH MEDICAL JOURNAL			English	Article								The increasing trend towards deregulation of more medicines to over the counter status has implications for the primary health care team as well as for consumers and patients. Better information for patients could improve the safety of over the counter medicines, but better systems need to be devised for reporting adverse reactions. ''Collaborative care'' could bring financial benefits. Doctors, nurses, and pharmacists need to discuss how they will respond to self medication practices, and ways of rewarding pharmacists for advising patients need to be found. Improved communication between doctors and pharmacists and the involvement of nurses could bring health care professionals into a new and more constructive interaction with each other and with the patient-or the changes required could split the professions as they each try to keep control of medicines.	UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Bradley, C (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				Blenkinsopp A, 1996, BRIT MED J, V312, P629; BRADLEY C, 1995, PRESCRIBER      0305, P75; DRIFE JO, 1993, BRIT MED J, V307, P695, DOI 10.1136/bmj.307.6906.695; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; *MED CONTR AG, 1992, CHANG LEG CLASS PRES; 1995, PHARM J, V254, P433; 1993, LANCET, V342, P565; 1992, OFFICIAL J EUROPEA L, P113	9	65	67	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					835	837						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608296				2022-12-24	WOS:A1996UD37800032
J	Brown, DR; Schmidt, B; Kretzschmar, HA				Brown, DR; Schmidt, B; Kretzschmar, HA			Role of microglia and host prion protein in neurotoxicity of a prion protein fragment	NATURE			English	Article							SCRAPIE PRION; NITRIC-OXIDE; BRAIN; PRP; SUPEROXIDE; RESISTANT	THE prion protein PrPc is a glycoprotein of unknown function(1) normally found in neurons(2) and glia(3). It is involved in diseases such as bovine spongiform encephalopathy (BSE), scrapie and Creutzfeldt-Jakob disease(4). PrPSc, an altered isoform of PrPc that is associated with disease, shows greater protease resistance and is part of the infectious agent, the prion(5,6). Prion diseases are characterized by neuronal degeneration, gliosis and accumulation of PrPSc (ref. 7). Mice devoid of PrPc are resistant to scrapie(8). A fragment of human PrP consisting of amino acids 106-126 that forms fibrils in vitro is toxic to cultured neurons(9-11). Here we show that this toxic effect requires the presence of microglia which respond to PrP106-126 by increasing their oxygen radical production, The combined direct and microglia-mediated effects of PrP106-126 are toxic to normal neurons but are insufficient to destroy neurons from mice not expressing PrPc.	UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Gottingen			Brown, David/A-4083-2008					BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x	22	485	497	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					345	347		10.1038/380345a0	http://dx.doi.org/10.1038/380345a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598929				2022-12-24	WOS:A1996UC37900060
J	Dobrowolski, JM; Sibley, LD				Dobrowolski, JM; Sibley, LD			Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite	CELL			English	Article							CYTOCHALASIN-B; COCCIDIAN SPOROZOITES; MALARIAL PARASITES; GONDII; MOTILITY; EXPRESSION; RESISTANT; JUNCTION; VACUOLES; FUSION	Toxoplasma gondii is an obligate intracellular parasite that invades a wide range of vertebrate host cells. We demonstrate that invasion is critically dependent on actin filaments in the parasite, but not the host cell. Invasion into cytochalasin D (CD)-resistant host cells was blocked by CD, while parasite mutants invaded wild-type host cells in the presence of drug. CD resistance in Toxoplasma was mediated by a point mutation in the single-copy actin gene ACT1. Transfection of the mutant act1 allele into wild-type Toxoplasma conferred motility and invasion in the presence of CD. We conclude that host cell invasion by Toxoplasma, and likely by related Apicomplexans, is actively powered by an actin-based contractile system in the parasite.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Sibley, L. David/C-4616-2008		NIAID NIH HHS [AI07172, AI34036, R01 AI034036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036, T32AI007172] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; MORISAKI JH, 1995, J CELL SCI, V108, P2457; NICHOLS BA, 1981, LAB INVEST, V44, P324; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; PFEFFERKORN ER, 1977, J PROTOZOOL, V24, P449, DOI 10.1111/j.1550-7408.1977.tb04774.x; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RUSSELL DG, 1984, J CELL SCI, V65, P193; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; SCHWARTZMAN JD, 1983, J PROTOZOOL, V30, P657, DOI 10.1111/j.1550-7408.1983.tb05339.x; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1995, TRENDS CELL BIOL, V5, P129, DOI 10.1016/S0962-8924(00)88964-3; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; TOYAMA S, 1988, J CELL BIOL, V107, P1499, DOI 10.1083/jcb.107.4.1499; WANG FW, 1990, GENE, V100, P195	31	504	527	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					933	939		10.1016/S0092-8674(00)81071-5	http://dx.doi.org/10.1016/S0092-8674(00)81071-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601316	Bronze			2022-12-24	WOS:A1996UC38100014
J	Hamblin, TJ				Hamblin, TJ			From dendritic cells to tumour vaccines	LANCET			English	Editorial Material							ANTI-IDIOTYPE ANTIBODY; LYMPHOMA				Hamblin, TJ (corresponding author), ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL & ONCOL,BOURNEMOUTH,DORSET,ENGLAND.							CHEN TT, 1994, J IMMUNOL, V153, P4775; FLAMAND V, 1994, EUR J IMMUNOL, V24, P605, DOI 10.1002/eji.1830240317; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; HAMBLIN TJ, 1987, BLOOD, V69, P790; HAWKINS RE, 1994, BLOOD, V83, P3279; HSU FJ, 1993, ANN NY ACAD SCI, V690, P385; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; KOTERA Y, 1994, CANCER RES, V54, P2856; MARCHAND M, 1993, DERMATOLOGY, V186, P278, DOI 10.1159/000247375; MCCABE BJ, 1995, CANCER RES, V55, P1741; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAKAMIZAWA M, 1995, J CLIN INVEST, V95, P296, DOI 10.1172/JCI117654; TAO MH, 1993, NATURE, V362, P755, DOI 10.1038/362755a0	15	11	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	706		10.1016/S0140-6736(96)90071-9	http://dx.doi.org/10.1016/S0140-6736(96)90071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601996				2022-12-24	WOS:A1996TZ98200004
J	Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD				Klauck, TM; Faux, MC; Labudda, K; Langeberg, LK; Jaken, S; Scott, JD			Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein	SCIENCE			English	Article							KINASE-C; POSTSYNAPTIC DENSITIES; REGULATORY SUBUNIT; PHOSPHATIDYLSERINE	Multivalent binding proteins, such as the yeast scaffold protein Sterile-5, coordinate the location of kinases by serving as platforms for the assembly of signaling units. Similarly, in mammalian cells the cyclic adenosine 3',5'-monophosphate-dependent protein kinase (PKA) and phosphatase 2B [calcineurin (CaN)] are complexed by an A kinase anchoring protein, AKAP79. Deletion analysis and binding studies demonstrate that a third enzyme, protein kinase C (PKC), binds AKAP79 at a site distinct from those bound by PKA or CaN. The subcellular distributions of PKC and AKAP79 were similar in neurons. Thus, AKAP79 appears to function as a scaffold protein for three multifunctional enzymes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946	Oregon Health & Science University					NCI NIH HHS [CA538841] Funding Source: Medline; NIGMS NIH HHS [GM50152, GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARR DW, 1992, J BIOL CHEM, V267, P16816; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COGHLAN VM, 1995, ADV PROTEIN PHOSPHAT, V8, P51; Corbin J D, 1974, Methods Enzymol, V38, P287; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FAUX MC, UNPUB; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLAUCK T, UNPUB; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LEACH KL, 1988, J BIOL CHEM, V263, P13223; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIEBERMAN DN, 1994, SCIENCE, V369, P235; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; ORR JW, 1992, J BIOL CHEM, V267, P15263; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POTTER RL, 1978, ARCH BIOCHEM BIOPHYS, V190, P174, DOI 10.1016/0003-9861(78)90265-5; PRINTEN JA, 1994, GENETICS, V138, P609; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SARKAR D, 1984, J BIOL CHEM, V259, P9840; Scott J. I., UNPUB; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WOLF M, 1986, J BIOL CHEM, V261, P3327; WOLF M, 1986, BIOCHEM BIOPH RES CO, V140, P691, DOI 10.1016/0006-291X(86)90787-4	33	469	485	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1589	1592		10.1126/science.271.5255.1589	http://dx.doi.org/10.1126/science.271.5255.1589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599116				2022-12-24	WOS:A1996TZ98300043
J	Pickering, WG				Pickering, WG			Does medical treatment mean patient benefit?	LANCET			English	Article																		BERN JL, 1988, BR J CLIN PHARM, V26, P679; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MEDAWAR C, 1992, POWER DEPENDENCE; PICKERING W, 1992, BRIT MED J, V304, P1516; Pickering W G, 1993, J Med Ethics, V19, P121, DOI 10.1136/jme.19.2.121-a; 1995, BRIT NATIONAL FORMUL, P219; 1994, PRESCRIPTION IMPROVE	8	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					379	380		10.1016/S0140-6736(96)90544-9	http://dx.doi.org/10.1016/S0140-6736(96)90544-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598708				2022-12-24	WOS:A1996TU69500016
J	Taylor, FC; Ramsay, ME; Renton, A; Cohen, H				Taylor, FC; Ramsay, ME; Renton, A; Cohen, H			Methods for managing the increased workload in anticoagulant clinic	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,SCH MED,DEPT PUBL HLTH,HLTH CARE DEV UNIT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT HAEMATOL,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	Taylor, FC (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.							DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; Taylor F., 1994, British Journal of Haematology, V86, P68; VANDENBESSELAAR AMHP, 1990, THROMB HAEMOSTASIS, V63, P316	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611786				2022-12-24	WOS:A1996TU50700024
J	Hedges, SB; Parker, PH; Sibley, CG; Kumar, S				Hedges, SB; Parker, PH; Sibley, CG; Kumar, S			Continental breakup and the ordinal diversification of birds and mammals	NATURE			English	Article							EVOLUTION; PHYLOGENY	THE classical hypothesis for the diversification of birds and mammals proposes that most of the orders diverged rapidly in adaptive radiations after the Cretaceous/Tertiary (K/T) extinction event 65 million years ago (1-3). Evidence is provided by the near-absence of fossils representing modern orders before the K/T boundary(4,5). However, fossil-based estimates of divergence time are known to be conservative because of sampling biases(6), and some molecular/time estimates point to earlier divergences among orders(7-10). In an attempt to resolve this controversy, we have estimated times of divergence among avian and mammalian orders with a comprehensive set of genes that exhibit a constant rate of substitution. Here we report molecular estimates of divergence times that average about 50-90% earlier than those predicted by the classical hypothesis, and show that the timing of these divergences coincides with the Mesozoic fragmentation of emergent land areas. This suggests that continental breakup may have been an important mechanism in the ordinal diversification of birds and mammals.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,208 MUELLER LAB,UNIVERSITY PK,PA 16802, USA.		Kumar, Sudhir/F-1411-2011	Kumar, Sudhir/0000-0002-9918-8212				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; HAY JM, 1995, MOL BIOL EVOL, V12, P928; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P9861, DOI 10.1073/pnas.91.21.9861; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JANKE A, 1994, GENETICS, V137, P243; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OTA T, 1994, J MOL EVOL, V38, P642; Padian K., 1985, P41; PRAGER EM, 1974, J MOL EVOL, V3, P243, DOI 10.1007/BF01796041; RAMIREZ V, 1993, J MOL EVOL, V37, P296, DOI 10.1007/BF00175506; Russell Dale E., 1995, Historical Biology, V10, P3; SMITHSON TR, 1989, NATURE, V342, P676, DOI 10.1038/342676a0; TAJIMA F, 1993, GENETICS, V135, P599; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	20	378	385	2	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					226	229		10.1038/381226a0	http://dx.doi.org/10.1038/381226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622763				2022-12-24	WOS:A1996UL24900051
J	Lange, P; Ulrik, CS; Vestbo, J				Lange, P; Ulrik, CS; Vestbo, J			Mortality in adults with self-reported asthma	LANCET			English	Article							AIR-FLOW OBSTRUCTION; GENERAL-POPULATION; FOLLOW-UP; BRONCHIAL-ASTHMA; SAMPLE; QUESTIONNAIRES; PROGNOSIS; SYMPTOMS; DISEASE	Background On the question of whether asthma shortens survival the published work gives no clear answer. We have prospectively analysed overall and cause-specific mortality in persons with self-reported asthma. Methods A sample of 13 540 individuals (6104 men) 20 years of age or older, randomly selected from the general population of the city of Copenhagen, was followed for 17 years. Findings Survival in participants with self-reported asthma was significantly poorer than in non-asthmatics, the excess mortality being limited to pulmonary mortality. After statistical adjustment for age, length of school education, and smoking, women with asthma had a 1.7 higher risk of dying than women without asthma (95% confidence interval 1.3-2.2). Although the relative risk (RR) of dying with asthma was sightly lower in men (RR=1.5, 95% CI 1.2-1.9) the difference between sexes was not significant. The results were similar within smoking groups and the highest risk of death associated with asthma was seen among never-smokers (RR=2.1, 95% CI 1.6-2.3). Inclusion of one-second forced expiratory volume, in % predicted, in the mortality analyses showed that the increased risk of death associated with asthma was mediated mainly through reduced lung function. Interpretation We conclude that, in the general population, self-reported asthma is associated with a slight excess of mortality, mainly from respiratory diseases.	BISPEBJERG HOSP,DEPT PULM MED,DK-2400 COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,COPENHAGEN CTR PROSPECT POPULAT STUDIES,COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital	Lange, P (corresponding author), RIGSHOSP,COPENHAGEN CITY HEART STUDY,EPIDEMIOL RES UNIT,DEPT 7121,DK-2200 COPENHAGEN N,DENMARK.		Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362				ALDERSON M, 1977, BRIT J DIS CHEST, V71, P198, DOI 10.1016/0007-0971(77)90110-3; ALDERSON M, 1974, LANCET, V2, P1475; ALMIND M, 1992, DAN MED BULL, V39, P561; [Anonymous], 1984, Acta Med Scand Suppl, V682, P1; BEATY TH, 1985, J CHRON DIS, V38, P703, DOI 10.1016/0021-9681(85)90024-4; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BUIST AS, 1994, NEW ENGL J MED, V331, P1584, DOI 10.1056/NEJM199412083312309; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; COX DR, 1972, J R STAT SOC B, V34, P187; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; OPENSHAW PJM, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80056-3; ROBINETTE CD, 1978, J CHRON DIS, V31, P619, DOI 10.1016/0021-9681(78)90022-X; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K., 1994, European Respiratory Journal, V7, p253S; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; VESTBO J, 1988, AM REV RESPIR DIS, V137, P1114, DOI 10.1164/ajrccm/137.5.1114; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366	30	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1285	1289		10.1016/S0140-6736(96)90937-X	http://dx.doi.org/10.1016/S0140-6736(96)90937-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622503				2022-12-24	WOS:A1996UK75800008
J	Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T				Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T			Natural evolution of late whiplash syndrome outside the medicolegal context	LANCET			English	Article							SOFT-TISSUE INJURIES; CERVICAL-SPINE; NECK	Background In Lithuania, few car drivers and passengers are covered by insurance and there is little awareness among the general public about the potentially disabling consequences of a whiplash injury. We took this opportunity to study the natural course of head and neck symptoms after rear-end car collisions. Methods In a retrospective questionnaire-based cohort study, 202 individuals (157 men; 45 women) were identified from the records of the traffic police department in Kaunas, Lithuania. These individuals were interviewed 1-3 years after experiencing a rear-end car collision. Neck pain, headache, subjective cognitive dysfunction, psychological disorders, and low back pain in this group were compared with the same complaints in a sex-matched and age-matched control group of uninjured individuals selected randomly from the population register of the same geographic area. Findings Neck pain was reported by 71 (35% [95% CI 29-42]) accident victims and 67 (33% [27-40]) controls. Headache was reported by 107 (53% [46-60]) accident victims and 100 (50% [42-57]) controls. Chronic neck pain and chronic headache (more than 7 days per month) were also reported in similar proportions (17 [8 . 4%; 5-13] vs 14 [6 . 9%; 4-12] and 19 [9 . 4%; 6-15] vs 12 [5 . 9%; 3-10]) by the two groups, Of those who reported chronic neck pain or daily headache after the accident, substantial proportions had had similar symptoms before the accident (7/17 for chronic neck pain; 10/12 for daily headache). There was no significant difference found. No one in the study group had disabling or persistent symptoms as a result of the car accident. There was no relation between the impact severity and degree of pain. A family history of neck pain was the most important risk factor for current neck symptoms in logistic regression analyses. Interpretation Our results suggest that chronic symptoms were not usually caused by the car accident. Expectation of disability, a family history, and attribution of pre-existing symptoms to the trauma may be more important for the evolution of the late whiplash syndrome.	KAUNAS MED ACAD,DEPT NEUROL,KAUNAS,LITHUANIA; KAUNAS MED ACAD,DEPT PREVENT MED,KAUNAS,LITHUANIA	Lithuanian University of Health Sciences; Lithuanian University of Health Sciences	Schrader, H (corresponding author), UNIV TRONDHEIM HOSP,DEPT NEUROL,N-7006 TRONDHEIM,NORWAY.			Schrader, Harald/0000-0001-9975-1960; Obelieniene, Diana/0000-0002-7356-7150				AWERBUCH MS, 1992, MED J AUSTRALIA, V156, P193; Balla J, 1987, Clin Exp Neurol, V23, P179; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BORCHGREVINK GE, 1995, ACTA RADIOL, V36, P425; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; CARETTE S, 1994, NEW ENGL J MED, V330, P1083, DOI 10.1056/NEJM199404143301512; CROWE H, 1928, ANN M W ORTH ASS SAN; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; ELLERTSEN AB, 1978, ACTA NEUROL SCAND  S, V67, P269; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; GOTTEN N, 1956, JAMA-J AM MED ASSOC, V162, P856; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; HOHL M, 1974, J BONE JOINT SURG AM, VA 56, P1675, DOI 10.2106/00004623-197456080-00018; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MAKELA M, 1991, AM J EPIDEMIOL, V134, P1356; MARSHALL PD, 1995, INJURY, V20, P17; Michler Ralf-Peter, 1993, Tidsskrift for den Norske Laegeforening, V113, P1104; MILES KA, 1988, SKELETAL RADIOL, V17, P493, DOI 10.1007/BF00364043; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; WATKINSON A, 1991, INJURY, V22, P307, DOI 10.1016/0020-1383(91)90012-4; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	29	278	282	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1207	1211		10.1016/S0140-6736(96)90733-3	http://dx.doi.org/10.1016/S0140-6736(96)90733-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622449				2022-12-24	WOS:A1996UJ59700008
J	Fiscella, K; Franks, P				Fiscella, K; Franks, P			Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENERAL-PRACTITIONERS ADVICE; CHEWING-GUM; CONTROLLED TRIAL; CIGARETTE-SMOKING; SMOKERS; EXPENDITURES; WITHDRAWAL; IMPACT	Objective.-To determine the incremental cost-effectiveness of the transdermal nicotine patch. Design.-Decision analytic model that evaluated the incremental cost-effectiveness of the addition of the nicotine patch to smoking cessation counseling. Costs were based on physician time and the retail cost of the nicotine patch, and benefits were based on quality-adjusted life years (QALYs) saved. Patients.-Male and female smokers aged 25 to 69 years receiving primary care. Intervention.-Addition of the nicotine patch to physician-based smoking cessation counseling. Main Outcome Measure.-Costs (1995 dollars) per QALYs saved discounted by 3% annually. Results.-The use of the patch produced 1 additional lifetime quitter at a cost of $7332. The incremental cost-effectiveness of the nicotine patch by age group ranged from $4390 to $10943 per QALY for men and $4955 to $6983 per QALY for women. A clinical strategy involving limiting prescription renewals to patients successfully abstaining for the first 2 weeks improved the cost-effectiveness of the patch by 25%. Conclusions.-The findings provide support both for the routine use of the nicotine patch as an adjunct to physicians' smoking cessation counseling and for health insurance coverage of nicotine patch therapy.			Fiscella, K (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT FAMILY MED,HIGHLAND HOSP,PRIMARY CARE INST,ROCHESTER,NY 14642, USA.							ABELIN T, 1989, METHOD FIND EXP CLIN, V11, P205; ABELIN T, 1989, LANCET, V1, P7; ADAMS PF, 1992, VIT HLTH STAT, V184; BENITOCEPEDA A, 1993, J CONSULT CLIN PSYCH, V61, P822; BLONDAL T, 1989, ARCH INTERN MED, V149, P1818, DOI 10.1001/archinte.149.8.1818; BUCHKREMER G, 1989, ADDICT BEHAV, V14, P229, DOI 10.1016/0306-4603(89)90054-3; *CDC, 1989, CDC PUBL; Cummings K M, 1994, Arch Fam Med, V3, P682, DOI 10.1001/archfami.3.8.682; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; FAGERSTROM KO, 1982, J BEHAV MED, V5, P343, DOI 10.1007/BF00846161; FEE WM, 1982, PRACTITIONER, V226, P148; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; Gold MR, 1996, COST EFFECTIVENESS H; GOLD MR, 1994, MED DECIS MAKING, V14, P431; GOURLAY SG, 1994, BRIT MED J, V309, P842, DOI 10.1136/bmj.309.6958.842; HJALMARSON AIM, 1984, JAMA-J AM MED ASSOC, V252, P2835, DOI 10.1001/jama.252.20.2835; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; HUGHES JR, 1991, PREV MED, V20, P486, DOI 10.1016/0091-7435(91)90046-7; HURT RD, 1994, JAMA-J AM MED ASSOC, V271, P595, DOI 10.1001/jama.271.8.595; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; JARVIK ME, 1984, AM J PSYCHIAT, V141, P790; JARVIS MJ, 1982, BRIT MED J, V285, P537, DOI 10.1136/bmj.285.6341.537; JOHNSON RE, 1992, J FAM PRACTICE, V34, P61; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; LAM W, 1987, LANCET, V2, P27; LAW M, 1995, ARCH INTERN MED, V155, P1933, DOI 10.1001/archinte.155.18.1933; LEU RE, 1983, SOC SCI MED, V17, P1907, DOI 10.1016/0277-9536(83)90168-5; LEU RE, 1985, SOC SCI MED, V21, P825, DOI 10.1016/0277-9536(85)90131-5; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MANNING W, 1991, COSTS POOR HLTH HABI; NORREGAARD J, 1993, PREV MED, V22, P261, DOI 10.1006/pmed.1993.1021; ORLEANS CT, 1994, JAMA-J AM MED ASSOC, V271, P601, DOI 10.1001/jama.271.8.601; OSTER G, 1984, PREV MED, V13, P377, DOI 10.1016/0091-7435(84)90029-X; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PIERCE JP, 1995, J NATL CANCER I, V87, P87, DOI 10.1093/jnci/87.2.87; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; RUSSELL MAH, 1983, BRIT MED J, V287, P1782, DOI 10.1136/bmj.287.6407.1782; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SACHS DPL, 1993, ARCH INTERN MED, V153, P1881, DOI 10.1001/archinte.153.16.1881; SACHS DPL, 1995, ARCH INTERN MED, V155, P1973, DOI 10.1001/archinte.155.18.1973; SCHAUFFLER HH, 1993, HEALTH EDUC QUART, V20, P185, DOI 10.1177/109019819302000211; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; STEWART PJ, 1982, CAN MED ASSOC J, V126, P1051; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Torrance GW, 1987, METHODS EC EVALUATIO; *TREEAG SOFTW INC, 1995, DATA VERS 2 6; 1995, MED LETT DRUGS THER, V37, P6; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P504; 1995, STAT NOTES, V7, P1	53	160	161	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1247	1251		10.1001/jama.275.16.1247	http://dx.doi.org/10.1001/jama.275.16.1247			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601956				2022-12-24	WOS:A1996UF47800028
J	Toburen, LH				Toburen, LH			Electromagnetic fields, radon, and cancer	LANCET			English	Editorial Material									NATL RES COUNCIL,BOARD RADIAT EFFECTS RES,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	Toburen, LH (corresponding author), E CAROLINA UNIV,DEPT PHYS,GREENVILLE,NC 27858, USA.							Henshaw DL, 1996, INT J RADIAT BIOL, V69, P25, DOI 10.1080/095530096146156; *NAT RES COUNC COM, 1988, HLTH RISK RAD OTH IN; *NAT RES COUNC COM, 1994, HLTH EFFECTS EXPOSUR	3	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1059	1060		10.1016/S0140-6736(96)90274-3	http://dx.doi.org/10.1016/S0140-6736(96)90274-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602054				2022-12-24	WOS:A1996UG04200007
J	Savilahti, H; Mizuuchi, K				Savilahti, H; Mizuuchi, K			Mu transpositional recombination: Donor DNA cleavage and strand transfer in trans by the Mu transposase	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYNUCLEOTIDYL TRANSFER; INTEGRASE PROTEIN; INVITRO PROCEEDS; BACTERIOPHAGE-MU; SITE; MECHANISM; DOMAINS; IDENTIFICATION; COMPLEX	Central to the Mu transpositional recombination are the two chemical steps; donor DNA cleavage and strand transfer. These reactions occur within the Mu transpososome that contains two Mu DNA end segments bound to a tetramer of MuA, the transposase. To investigate which MuA-monomer catalyzes which chemical reaction, we made transpososomes containing wild-type and active site mutant MuA. By preloading the MuA variants onto Mu end DNA fragments of different length prior to transpososome assembly, we could track the catalysis by MuA bound to each Mu end segment. The donor DNA end that underwent the chemical reaction was identified. Both the donor DNA cleavage and strand transfer were catalyzed in trans by the MuA monomers bound to the partner Mu end. This arrangement explains why the transpososome assembly is a prerequisite for the chemical steps.	NIDDKD, MOLEC BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Savilahti, Harri/0000-0002-6246-2572				ARCISZEWSKA LK, 1991, NUCLEIC ACIDS RES, V19, P5021, DOI 10.1093/nar/19.18.5021; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; Berg D. E., 1989, MOBILE DNA; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JOHNSON R, 1996, DNA PROTEIN STRUCTUR, P141; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; MIZUCHI M, 1996, CELL, V83, P375; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook JFE, 1989, MOL CLONING LAB MANU; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VANGENT DC, 1996, IN PRESS SCIENCE; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOU AH, 1991, J BIOL CHEM, V266, P20478	59	81	89	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					271	280		10.1016/S0092-8674(00)81103-4	http://dx.doi.org/10.1016/S0092-8674(00)81103-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612279	Bronze			2022-12-24	WOS:A1996UG25500015
J	Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ				Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ			Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid	CELL			English	Article							ELECTROLYTE TRANSPORT; LUNG-DISEASE; CELLS; EXPRESSION; CULTURES; SITE	Despite an increased understanding of the cellular and molecular biology of the CFTR Cl- channel, it is not known how defective Cl- transport across airway epithelia causes chronic bacterial infections in cystic fibrosis (CF) airways. Here, we show that common CF pathogens were killed when added to the apical surface of normal airway epithelia. In contrast, these bacteria multiplied on CF epithelia. We found that bactericidal activity was present in airway surface fluid of both normal and CF epithelia. However, because bacterial killing required a low NaCl concentration and because CF surface fluid has a high NaCl concentration, CF epithelia failed to kill bacteria. This defect was corrected by reducing the NaCl concentration on CF epithelia. These data explain how the loss of CFTR Cl- channels may lead to lung disease and suggest new approaches to therapy.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Smith, JJ (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.			Greenberg, Everett/0000-0001-9474-8041; Welsh, Michael/0000-0002-1646-6206	NHLBI NIH HHS [HL42385] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BOUCHER RC, 1983, LUNG, V161, P1, DOI 10.1007/BF02713837; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DAVIS PB, 1993, CYSTIC FIBROSIS, P193; DEKOSTER JA, 1995, AM IND HYG ASSOC J, V56, P573, DOI 10.1202/0002-8894(1995)056<0573:BCINCA>2.0.CO;2; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FICK RB, 1981, J CLIN INVEST, V68, P899, DOI 10.1172/JCI110345; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; GOLDSTEIN IM, 1994, TXB RESPIRATORY MED, P402; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Konstan M.W., 1993, CYSTIC FIBROSIS, V64, P219; LARIVEE P, 1994, AIRWAY SECRETION PHY, P469; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Pilewski J M, 1995, Curr Opin Pulm Med, V1, P435, DOI 10.1097/00063198-199511000-00002; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SANCHIS J, 1973, NEW ENGL J MED, V288, P651, DOI 10.1056/NEJM197303292881304; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; Taussig LM, 1984, CYSTIC FIBROSIS, P338; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; Wine JJ, 1995, CURR BIOL, V5, P1357, DOI 10.1016/S0960-9822(95)00269-7; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; YEATES DB, 1976, ARCH DIS CHILD, V51, P28, DOI 10.1136/adc.51.1.28; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585	42	790	817	1	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					229	236		10.1016/S0092-8674(00)81099-5	http://dx.doi.org/10.1016/S0092-8674(00)81099-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612275	Bronze			2022-12-24	WOS:A1996UG25500011
J	Lichtenstein, P; Olausson, PO; Kallen, AJB				Lichtenstein, P; Olausson, PO; Kallen, AJB			Twin births to mothers who are twins: A registry based study	BRITISH MEDICAL JOURNAL			English	Article							GENE	Objectives-To estimate the risk of having twin infants for mothers who are twins; to investigate the genetic influence on twinning. Design-Retrospective study of multiple births in two nationwide registries. Setting-Sweden. Subjects-Multiple births among 31586 deliveries between 1973 and 1991 to women who were twins. Main outcome measures-Numbers of monozygotic and dizygotic twin births expected and estimated. Results-Women who are dizygotic twins have a moderately increased risk of having twins (relative risk 1.30, 95% confidence interval 1.14 to 1.49) which seems to be completely the result of dizygotic twinning. When a mother is a monozygotic twin, her risk of having twins of the same sex is significantly increased (1.47; 1.10 to 1.97). This is the result of an excess of monozygotic twins (39 pairs estimated, 18 expected). Conclusion-Women who are twins have an increased risk of giving birth to twins. Genetic components of monozygotic and dizygotic twinning seem to be independent.	NATL BOARD HLTH & WELF,CTR EPIDEMIOL,S-10630 STOCKHOLM,SWEDEN; LUND UNIV,TORNBALD INST,S-22362 LUND,SWEDEN	National Board of Health & Welfare; Lund University	Lichtenstein, P (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,BOX 210,S-17177 STOCKHOLM,SWEDEN.			lichtenstein, paul/0000-0003-3037-5287				Bulmer M. G., 1970, BIOL TWINNING MAN; CARMELLI D, 1978, TWIN RES, V3, P81; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; CEDERLOF R, 1978, TWIN RES, V3, P189; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; CRUMPACKER DW, 1979, ACTA GENET MED GEMEL, V28, P173, DOI 10.1017/S0001566000009041; DAVIS GH, 1991, BIOL REPROD, V44, P620, DOI 10.1095/biolreprod44.4.620; Derom R, 1995, MULTIPLE PREGNANCY E, P145; JAMES WH, 1992, ACTA GENET MED GEMEL, V41, P33, DOI 10.1017/S0001566000002488; Medlund P, 1976, Acta Med Scand Suppl, V600, P1; MILLHAM S, 1964, LANCET, V2, P566; MONTGOMERY GW, 1993, NAT GENET, V4, P410, DOI 10.1038/ng0893-410; NYLANDER PP, 1970, ACTA GENET MED GEMEL, V19, P36, DOI 10.1017/S1120962300024951; PARAZZINI F, 1993, ACTA OBSTET GYN SCAN, V72, P177, DOI 10.3109/00016349309013368; PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0; PHILIPPE P, 1985, AM J MED GENET, V20, P97, DOI 10.1002/ajmg.1320200112; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; WEINBERG W, 1902, PFLUGERS ARCH GES PH, V88, P346; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P322; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P470; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P609; WYSHAK G, 1965, AM J PUBLIC HEALTH N, V55, P1586, DOI 10.2105/AJPH.55.10.1586	22	30	30	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					879	881						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611875				2022-12-24	WOS:A1996UE37100020
J	Moore, MS				Moore, MS			Generation of GTP-Ran for nuclear protein import	SCIENCE			English	Editorial Material											Moore, MS (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120	2	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					47	47		10.1126/science.272.5258.47	http://dx.doi.org/10.1126/science.272.5258.47			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600534				2022-12-24	WOS:A1996UD59700033
J	Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA				Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA			Role of the INK4a locus in tumor suppression and cell mortality	CELL			English	Article							ONCOGENES; MICE; CYCLINS; RAS; TRANSFORMATION; EXPRESSION; REQUIRES; KINASES	The cell cycle inhibitor p16(INK4a) is inactivated in many human tumors and in families with hereditary melanoma and pancreatic cancer. Tumor-associated alterations in the INK4a locus may also affect the overlapping gene encoding p19(ARF) and the adjacent gene encoding p15(INK4b), both negative regulators of cell proliferation. We report the phenotype of mice carrying a targeted deletion of the INK4a locus that eliminates both p-16(INK4a) and p19(ARF). The mice are viable but develop spontaneous tumors at an early age and are highly sensitive to carcinogenic treatments. INK4a-deficient primary fibroblasts proliferate rapidly and have a high colony-formation efficiency. in contrast with normal cells, the introduction of activated Ha-ras into INK4a-deficient fibroblasts can result in neoplastic transformation. These findings directly demonstrate that the INK4a locus functions to suppress neoplastic growth.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	Serrano, M (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA09173] Funding Source: Medline; NEI NIH HHS [EY09300] Funding Source: Medline; NICHD NIH HHS [HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BATES S, 1994, ONCOGENE, V9, P71; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Conzen SD, 1995, ONCOGENE, V11, P2295; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DURO D, 1995, ONCOGENE, V11, P21; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; KRIPKE ML, 1994, CANCER RES, V54, P6102; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MAO L, 1995, CANCER RES, V55, P2995; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PALMIERI S, 1989, CURR TOP MICROBIOL, V148, P43; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Silver W. K., 1979, COAT COLORS MICE MOD; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ueki K, 1996, CANCER RES, V56, P150; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIDA S, 1995, CANCER RES, V55, P2756; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	76	1353	1402	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					27	37		10.1016/S0092-8674(00)81079-X	http://dx.doi.org/10.1016/S0092-8674(00)81079-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620534	Bronze			2022-12-24	WOS:A1996UE55900006
J	Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF				Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF			Ownership of the human genome	NATURE			English	Editorial Material									UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND	University of Sussex	Thomas, SM (corresponding author), UNIV SUSSEX,SCI POLICY RES UNIT,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND.							COLETURNER R, 1995, SCIENCE, V270, P52, DOI 10.1126/science.270.5233.52; DIXON D, 1995, NATURE, V378, P425; DIXON D, 1996, NATURE, V379, P574; *EUR COMM, 1994, EUR15897 EUR COMM; *OFF TECHN ASS, 1992, BIOT GLOB EC; SWINBANKS D, 1994, NATURE, V371, P731; THOMAS SM, 1995, RES POLICY, V24, P645, DOI 10.1016/S0048-7333(98)80001-2	7	28	28	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					387	388		10.1038/380387a0	http://dx.doi.org/10.1038/380387a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602236				2022-12-24	WOS:A1996UD59000035
J	Bernhard, JD				Bernhard, JD			Mastocytosis: For better and worse	LANCET			English	Editorial Material							SYSTEMIC MASTOCYTOSIS				Bernhard, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							AUSTEN KF, 1992, NEW ENGL J MED, V326, P639, DOI 10.1056/NEJM199202273260912; BERNHARD JD, 1994, ITCH MECHANISMS MANA, P251; DUFFY TP, 1993, NEW ENGL J MED, V328, P1333, DOI 10.1056/NEJM199305063281809; FRIEDMAN BS, 1994, J ALLERGY CLIN IMMUN, V93, P53, DOI 10.1016/0091-6749(94)90232-1; KENDALL ME, 1984, J AM ACAD DERMATOL, V10, P903, DOI 10.1016/S0190-9622(84)80443-0; Kors JW, 1996, J INTERN MED, V239, P157, DOI 10.1046/j.1365-2796.1996.440787000.x; KUTER I, 1992, NEW ENGL J MED, V326, P472; LEGRAIN V, 1994, ANN DERMATOL VENER, V121, P561; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; MAHOOD JM, 1982, ACTA DERM-VENEREOL, V62, P264; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; TUR E, 1990, DERMATOLOGICA, V181, P5, DOI 10.1159/000247849	13	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					705	705		10.1016/S0140-6736(96)90070-7	http://dx.doi.org/10.1016/S0140-6736(96)90070-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8601995	Bronze			2022-12-24	WOS:A1996TZ98200003
J	Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A				Stearman, R; Yuan, DS; YamaguchiIwai, Y; Klausner, RD; Dancis, A			A permease-oxidase complex involved in high-affinity iron uptake in yeast	SCIENCE			English	Article							WILSON DISEASE GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FERRIC REDUCTASE; PROTEIN; ATPASE	Iron must cross biological membranes to reach essential intracellular enzymes. Two proteins in the plasma membrane of yeast-a multicopper oxidase, encoded by the FET3 gene, and a permease, encoded by the FTR1 gene-were shown to mediate high-affinity iron uptake. FET3 expression was required for FTR1 protein to be transported to the plasma membrane. FTR1 expression was required for apo-FET3 protein to be loaded with copper and thus acquire oxidase activity. FTR1 protein also played a direct role in iron transport. Mutations in a conserved sequence motif of FTR1 specifically blocked iron transport.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BOMFORD A, 1976, Q J MED, V45, P611; BOTHWELL TH, 1995, METABOLIC MOL BASES, P2237; Brittenham Gary M., 1995, P492; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Cammack R, 1990, IRON TRANSPORT STORA, P17; CHANEY RL, 1988, J PLANT NUTR, V11, P1033, DOI 10.1080/01904168809363867; CONRAD ME, 1993, BLOOD, V81, P517; CRICHTON RR, 1991, INORGANIC BIOCH IRON, P144; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; DOOLING EC, 1974, ARCH NEUROL-CHICAGO, V30, P770; DOOLING EC, 1995, NEUROLOGY, V45, P1138; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; *GEN COMP GROUP, 1994, PROGRMA MANUAL WISCO; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; HALLERVORDENSPA.EC, 1980, NEUROLOGY, V30, P1128; Halliwell B., 1991, FREE RADICALS BIOL M; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hofmann K., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LI CY, 1994, J BIOL CHEM, V269, P10242; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P125; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; NIELANDS JB, 1981, ANNU REV NUTR, V1, P27; OREILLY S, 1968, NEUROLOGY, V18, P634, DOI 10.1212/WNL.18.7.634; OSAKI S, 1966, J BIOL CHEM, V241, P2746; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; WANG X, 1995, J NEUROCHEM, V74, P1868; WEINBERG ED, 1985, J PHARMACOL-PARIS, V16, P358; WILLIAMS RJP, 1990, IRON TRANSPORT STORA, P2; Winkelmann G, 1987, IRON TRANSPORT MICRO; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YAMAGUCHIIWAI Y, UNPUB; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; YUAN DS, UNPUB	57	561	575	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1552	1557		10.1126/science.271.5255.1552	http://dx.doi.org/10.1126/science.271.5255.1552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599111				2022-12-24	WOS:A1996TZ98300032
J	Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G				Blendy, JA; Kaestner, KH; Weinbauer, GF; Nieschlag, E; Schutz, G			Severe impairment of spermatogenesis in mice lacking the CREM gene	NATURE			English	Article							MAJOR CHROMOSOMAL PROTEIN; CDNA CLONE; MITOCHONDRIAL CAPSULE; MAMMALIAN SPERMATIDS; TRANSITION PROTEIN-1; NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; MESSENGER-RNAS; SELENO-PROTEIN; EXPRESSION	Spermatogenesis is a complex developmental process that occurs in several phases. A large number of genes have been identified that are expressed during spermatogenesis(1,2), but the biological significance of many of these is not yet known. We have used gene targeting to selectively eliminate the transcription factor CREM (cyclic AMP-responsive element modulator), which is thought to be important for mammalian spermatogenesis(3-5). Male mice deficient for all CREM proteins are sterile, as their developing spermatids fail to differentiate into sperm, and postmeiotic gene expression in the testis declines dramatically. The cessation of sperm development is not accompanied by decreases in the levels of follicle-stimulating hormone or testosterone. Our findings indicate that the CREM gene is essential for spermatogenesis, and mice deficient for this transcription factor could serve as a model system for the study of idiopathic infertility in men.	GERMAN CANC RES CTR,MOL BIOL CELL DIV 1,D-69120 HEIDELBERG,GERMANY; UNIV MUNSTER,INST REPROD MED,D-48149 MUNSTER,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munster								ADHAM IM, IN PRESS DNA CELL BI; ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANDOLIA RK, 1991, ACTA ENDOCRINOL-COP, V125, P547, DOI 10.1530/acta.0.1250547; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; ERIKSON RP, 1990, TRENDS GENET, V6, P264; ESCALIER D, 1991, DEVELOPMENT, V1133, P779; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HEIDARAN MA, 1987, GENE, V54, P281, DOI 10.1016/0378-1119(87)90498-7; HEIDARAN MA, 1988, J CELL BIOL, V106, P1427, DOI 10.1083/jcb.106.5.1427; HURST HC, 1995, PROTEIN PROFILE, V2, P105; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KISTLE RMK, 1994, BIOL REPROD, V51, P1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1989, DEVELOPMENT, V106, P367; KLEENE KC, 1990, DEV BIOL, V137, P395, DOI 10.1016/0012-1606(90)90263-I; KLEMM U, 1990, DIFFERENTIATION, V42, P160, DOI 10.1111/j.1432-0436.1990.tb00757.x; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; NIESCHLAG E, 1993, CLIN ENDOCRINOL, V38, P123, DOI 10.1111/j.1365-2265.1993.tb00983.x; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P119; SHIH DM, 1992, MOL REPROD DEV, V33, P222, DOI 10.1002/mrd.1080330216; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; VANDERHOORN FA, 1992, P NATL ACAD SCI USA, V89, P703, DOI 10.1073/pnas.89.2.703; WEINBAUER GF, 1993, MOL BIOL MALE REPROD, P99; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	31	422	447	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					162	165		10.1038/380162a0	http://dx.doi.org/10.1038/380162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600391				2022-12-24	WOS:A1996TZ97800052
J	Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP				Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP			Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B-12 deficiency after gastric surgery	ANNALS OF INTERNAL MEDICINE			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; COBALAMIN DEFICIENCY; FOLATE-DEFICIENCY; NORMAL SERUM; MALABSORPTION; URINE; QUANTITATION; PLASMA; RISK	Objective: To determine the prevalence of vitamin B-12 deficiency in patients who have had gastric surgery. Design: Cross-sectional study. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 61 patients who had had gastric surgery and 107 controls. Measurements: Serum levels of vitamin B-12 folate, methylmalonic acid, and total homocysteine measured before and after treatment in participants with vitamin B-12 deficiency. Vitamin B-12 deficiency was defined as one of the following: 1) a serum vitamin B-12 level less than 221 pmol/L and an elevated methylmalonic acid level; 2) a serum vitamin B-12 level less than 221 pmol/L and an elevated total homocysteine level that decreased with vitamin B-12 treatment; or 3) in patients unavailable for treatment, a serum vitamin B-12 level less than 221 pmol/L, a folate level greater than 9 nmol/L, and an elevated total homocysteine level. Results: Study patients and controls were similar in age, sex, and racial distribution. Nineteen patients (31%) and 2 controls (2%) had vitamin B-12 deficiency (P < 0.001). Twelve (63%) of the 19 vitamin B-12-deficient patients had elevated total homocysteine levels. In all participants with vitamin B-12 deficiency who received treatment (15 of 21). methylmalonic acid and total homocysteine levels decreased substantially, confirming the deficiency before treatment. Conclusion: Patients who have had gastric surgery have a high prevalence of vitamin B-12 deficiency. Prompt recognition and treatment of the deficiency with resultant normalization of elevated total homocysteine and methylmalonic acid levels may prevent the development of cardiovascular, hematologic, and neurologic abnormalities. Our data support both frequent screening and vitamin B-12 replacement therapy in patients who have had gastric surgery and have serum vitamin B-12 levels less than 221 pmol/L.	HAHNEMANN UNIV, PHILADELPHIA COLL PHARM & SCI, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV BIOCHEM DEV & MOLEC DIS, PHILADELPHIA, PA 19104 USA; UNIV COLORADO, HLTH SCI CTR, DIV HEMATOL, DENVER, CO 80262 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sumner, AE (corresponding author), MED COLL PENN, PHILADELPHIA VET AFFAIRS MED CTR, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA.		Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223; Berry, Gerard/0000-0001-5299-3313	NIA NIH HHS [AG00532, AG0983] Funding Source: Medline; NIDDK NIH HHS [DK-21365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021365] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; BADENOCH J, 1955, BRIT J HAEMATOL, V1, P339, DOI 10.1111/j.1365-2141.1955.tb05518.x; BAKER H, 1979, J AM GERIATR SOC, V27, P444, DOI 10.1111/j.1532-5415.1979.tb01724.x; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DELER DJ, 1963, LANCET, V2, P162; DOSCHERHOLMEN A, 1973, GASTROENTEROLOGY, V64, P913; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HINES JD, 1967, AM J MED, V43, P555, DOI 10.1016/0002-9343(67)90179-9; KARNAZE DS, 1990, ARCH NEUROL-CHICAGO, V47, P1008, DOI 10.1001/archneur.1990.00530090082017; KLIPSTEIN FA, 1962, ANN INTERN MED, V57, P133, DOI 10.7326/0003-4819-57-1-133; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MACLEAN LD, 1957, NEW ENGL J MED, V257, P262, DOI 10.1056/NEJM195708082570603; MAHMUD MB, 1971, J AMER MED ASSOC, V216, P1167; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MARCELL PD, 1985, ANAL BIOCHEM, V150, P58, DOI 10.1016/0003-2697(85)90440-3; MARCUARD SP, 1994, ANN INTERN MED, V120, P211, DOI 10.7326/0003-4819-120-3-199402010-00006; MARTIN DC, 1992, J AM GERIATR SOC, V40, P168, DOI 10.1111/j.1532-5415.1992.tb01939.x; MOLINOFF PB, 1990, PEPTIC ULCER DISEASE; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; Rowlands RA, 1932, LANCET, V2, P1202; RYGVOLD O, 1974, SCAND J GASTROENTERO, V9, P57; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; SCHADE SG, 1967, AM J CLIN NUTR, V20, P636, DOI 10.1093/ajcn/20.6.636; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STABLER SP, 1993, BLOOD, V81, P3404; STABLER SP, 1986, J CLIN INVEST, V77, P1606, DOI 10.1172/JCI112476; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG WM, 1980, DIGEST DIS SCI, V25, P188, DOI 10.1007/BF01308137; STREETER AM, 1974, AM J SURG, V128, P340, DOI 10.1016/0002-9610(74)90169-X; TALSTAD I, 1975, SCAND J GASTROENTERO, V10, P1; YALE CE, 1993, AM J HEMATOL, V42, P63, DOI 10.1002/ajh.2830420113	36	83	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					469	+		10.7326/0003-4819-124-5-199603010-00002	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602704				2022-12-24	WOS:A1996TW77300002
J	Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM				Leon, DA; Koupilova, I; Lithell, HO; Berglund, L; Mohsen, R; Vagero, D; Lithell, UB; McKeigue, PM			Failure to realise growth potential in utero and adult obesity in relation to blood pressure in 50 year old Swedish men	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL BIRTH COHORT; HYPERTENSION; FETAL; RISK; LIFE; ENVIRONMENT; CHILDHOOD; INUTERO; AGE	Objectives-To clarify the type of fetal growth impairment associated with increased blood pressure in adult life, and to establish whether this association is influenced by obesity and is mediated through impairment of insulin action. Design-Cross sectional survey with retrospective ascertainment of size at birth from obstetric archives. Subjects-1333 men resident in Uppsala, Sweden, who took part in a 1970 study of coronary risk factors at age 50 and for whom birth weight was traced. Main outcome measures-Systolic and diastolic blood pressure at age 50. Results-In the full study population for a 1000 g increase in birth weight there was a small change in systolic blood pressure of -2.2 mm Hg (95% confidence interval -4.2 to -0.3 mm Hg) and in diastolic blood pressure of -1.0 mm Hg (-2.2 to 0.1 mm Hg). Much stronger effects were observed among men who were born at term and were in the top third of body mass index at age 50, for whom a 1000 g increase in birth weight was associated with a change of -9.1 mm Hg (-16.4 to -1.9 mm Hg) systolic and -4.2 mm Hg (-8.3 to -0.1 mm Hg) diastolic blood pressure. Men who were light at birth (< 3250 g) but were of above median adult height had particularly high blood pressure. Adjustment for insulin concentrations reduced the associations of birth weight with systolic and diastolic blood pressure. Conclusions-A failure to realise growth potential in utero (as indicated by being light at birth but tall as an adult) is associated with raised adult blood pressure. Impaired fetal growth may lead to substantial increases in adult blood pressure among only those who become obese. Metabolic disturbances, possibly related to insulin resistance, may provide a pathway through which fetal growth affects blood pressure.	UNIV UPPSALA,INST GERIATR,S-75125 UPPSALA,SWEDEN; UNIV STOCKHOLM,SWEDISH INST SOCIAL RES,S-10691 STOCKHOLM,SWEDEN	Uppsala University; Stockholm University	Leon, DA (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Koupil, Ilona/AAC-9067-2020; Berglund, Lars/AAD-3856-2019; Leon, David A/G-2195-2010; Berglund, Lars/AAA-3188-2019	Koupil, Ilona/0000-0002-7034-1922; Berglund, Lars/0000-0002-7437-9047; Leon, David A/0000-0001-9747-1762; 				ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; BAKKETEIG L, 1989, EFFECTIVE CARE PREGN, P765; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; COHEN MP, 1988, DIABETES, V37, P824, DOI 10.2337/diabetes.37.6.824; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Gruenwald P, 1974, CIBA F S, V27, P3; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, SCI AM           JUL, P54; HEDSTRAND H, 1976, ACTA MED SCAND, V199, P281; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARTYN CN, 1995, BRIT HEART J, V73, P116; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; SEIDMAN DS, 1993, ISRAEL J MED SCI, V29, P772; SKARFORS ET, 1991, J HYPERTENS, V9, P217, DOI 10.1097/00004872-199103000-00004; Stein Z., 1975, FAMINE HUM DEV DUTCH; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; 1993, STATA REFERENCE MANU	29	332	340	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					401	406						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601110	Green Published			2022-12-24	WOS:A1996TW56400019
J	Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ				Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ			A DEAD-box RNA helicase in the Escherichia coli RNA degradosome	NATURE			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; PROTEIN; DEGRADATION; DECAY; GENE; INVITRO; MUTANT; INVIVO; ATPASE	THE Escherichia coli RNA degradosome is a multi-enzyme complex that contains the exoribonuclease polynucleotide phosphorylase (PNPase) and the endoribonuclease RNase E(1,2). Both enzymes are important in RNA processing and messenger RNA degradation(3-14). Here we report that enolase and RhlB are two other major components of the degradosome. Enolase is a glycolytic enzyme with an unknown role in RNA metabolism. RhlB is a member of the DEAD-box family of ATP-dependent RNA helicases, which are found in both prokaryotes and eukaryote(15-26). We show that the degradosome has an ATP-dependent activity that aids the degradation of structured RNA by PNPase. Incubation of the degradosome with affinity-purified antibody against RhlB inhibited the ATP-stimulated RNA degradation. These results suggest that RhlB acts by unwinding RNA structures that impede the processive activity of PNPase. RhlB is thus an important enzyme in mRNA turnover.	UNIV OXFORD, NUFFIELD DEPT CLIN BIOCHEM, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND; CNRS, LAB MICROBIOL & GENET MOLEC, UPR 9007, F-31062 TOULOUSE, FRANCE	University of Oxford; Cancer Research UK; University of Oxford; Centre National de la Recherche Scientifique (CNRS)			Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KALMAN M, 1991, NEW BIOL, V3, P886; KLEIN M, 1994, EMBL DATA BANK; LIANG L, 1994, DEVELOPMENT, V120, P1201; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)80206-A; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SPRING TG, 1975, METHOD ENZYMOL, V62, P323; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0	30	454	457	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					169	172		10.1038/381169a0	http://dx.doi.org/10.1038/381169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610017				2022-12-24	WOS:A1996UK13900054
J	Duthie, DJR				Duthie, DJR			Aminoacid infusions to prevent postoperative hypothermia	LANCET			English	Editorial Material							ACID INFUSION				Duthie, DJR (corresponding author), PAPWORTH HOSP,DEPT ANAESTHESIA,CAMBRIDGE,ENGLAND.							CARLSON GL, 1994, AM J PHYSIOL, V266, pE848; GIOVANNINI I, 1988, CRIT CARE MED, V16, P667, DOI 10.1097/00003246-198807000-00004; HALL GM, 1978, ANAESTHESIA, V33, P924; HERSIO K, 1991, CRIT CARE MED, V19, P503, DOI 10.1097/00003246-199104000-00008; JEQUIER E, 1986, CLIN NUTR, V5, P181, DOI 10.1016/0261-5614(86)90022-1; SELIDEN E, 1994, CLIN SCI, V86, P611; SELLDEN E, 1996, BRIT J ANAESTH, V96, P227; SESSLER DI, 1993, FASEB J, V7, P638, DOI 10.1096/fasebj.7.8.8500688	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1199		10.1016/S0140-6736(96)90728-X	http://dx.doi.org/10.1016/S0140-6736(96)90728-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622444				2022-12-24	WOS:A1996UJ59700003
J	Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG				Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG			A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors	CELL			English	Article							THYROID-HORMONE RECEPTORS; RETINOID X-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FACTOR CREB; RXR-BETA; C-JUN; ACID; PROTEIN; FOS	Nuclear receptors regulate gene expression by direct activation of target genes and inhibition of AP-1. Here we report that, unexpectedly, activation by nuclear receptors requires the actions of CREB-binding protein (CBP) and that inhibition of AP-1 activity is the apparent result of competition for limiting amounts of CBP/p300 in cells. Utilizing distinct domains, CBP directly interacts with the ligand-binding domain of multiple nuclear receptors and with the p160 nuclear receptor coactivators, which upon cloning have proven to be variants of the SRC-1 protein. Because CBP represents a common factor, required in addition to distinct coactivators for function of nuclear receptors, CREB, and AP-1, we suggest that CBP/p300 serves as an integrator of multiple signal transduction pathways within the nucleus.	UNIV CALIF SAN DIEGO,SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,WHITTIER DIABET ASSOC DEPT,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Ligand Pharmaceuticals	Kamei, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Lin, SC/G-4666-2010; Glass, Christopher/AAI-3933-2021; Heinzel, Thorsten/B-1013-2015	Glass, Christopher/0000-0003-4344-3592; 				Abate C, 1990, Semin Cancer Biol, V1, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ONATE SA, 1995, SCIENCE, V270, P1354; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	62	1889	1948	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					403	414		10.1016/S0092-8674(00)81118-6	http://dx.doi.org/10.1016/S0092-8674(00)81118-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616895	Green Published, Bronze			2022-12-24	WOS:A1996UK14000013
J	Nakano, T; Kodama, H; Honjo, T				Nakano, T; Kodama, H; Honjo, T			In vitro development of primitive and definitive erythrocytes from different precursors	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; C-KIT; DEVELOPING MOUSE; STEM-CELLS; YOLK-SAC; EXPRESSION; INVITRO; BLOOD; CULTURE; EMBRYO	During mouse embryogenesis the production of ''primitive'' erythrocytes (EryP) precedes the production of ''definitive'' erythrocytes (EryD) in parallel with the transition of the hematopoietic site from the yolk sac to the fetal liver. On a macrophage colony-stimulating factor-deficient stromal cell line OP9, mouse embryonic stem cells were shown to give rise to EryP and EryD sequentially with a time course similar to that seen in murine ontogeny. Studies of the different growth factor requirements and limiting dilution analysis of precursor frequencies indicate that most EryP and EryD probably developed from different precursors by way of distinct differentiation pathways.	KYOTO UNIV,FAC ENGN,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN; OHU UNIV,SCH DENT,DEPT ANAT,KORIYAMA,FUKUSHIMA 963,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					BREIVIK H, 1971, J CELL PHYSIOL, V78, P73, DOI 10.1002/jcp.1040780111; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; INGRAM VM, 1972, NATURE, V235, P338, DOI 10.1038/235338a0; JOYNER AL, 1993, GENE TARGETING; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KODAMA H, 1994, EXP HEMATOL, V22, P979; LEDER A, 1992, DEVELOPMENT, V116, P1041; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MIWA Y, 1991, DEVELOPMENT, V111, P543; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; NAKANO T, UNPUB; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; RUGH R, 1968, MOUSE; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1983, BLOOD, V62, P1280; WONG PMC, 1986, BLOOD, V67, P716; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	30	185	194	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					722	724		10.1126/science.272.5262.722	http://dx.doi.org/10.1126/science.272.5262.722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614833				2022-12-24	WOS:A1996UJ05100051
J	Yang, JY; Jayaram, M; Harshey, RM				Yang, JY; Jayaram, M; Harshey, RM			Positional information within the Mu transposase tetramer: Catalytic contributions of individual monomers	CELL			English	Article							PHAGE-MU; STRAND TRANSFER; DNA ENDS; SITE; PROTEIN; RECOMBINATION; DOMAINS; MECHANISM; COMPLEXES; CLEAVAGE	The strand cleavage and strand transfer reactions of Mu DNA transposition require structural/catalytic contributions from separate polypeptide domains of individual transposase (MuA) monomers within the functional MuA tetramer. Based on catalytic complementation between two inactive MuA variants, we have derived certain rules by which the physical location of a MuA monomer within the transposition complex specifies its role in DNA breakage and transfer. During strand transfer, MuA monomers contributing domain II to the reaction occupy R1 (the subsite proximal to the strand-transferred nucleotide), while those contributing domain III alpha occupy R2. The positions of the monomers contributing these two domains appear to be reversed during DNA cleavage.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ALDAZ H, 1996, IN PRESS CELL, V85; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE D, 1995, CURR TOP MICROBIOL, V204, P83; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1996, IN PRESS J MOL BIOL; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NAMGOONG S, 1994, J MOL BIOL, V238, P514, DOI 10.1006/jmbi.1994.1311; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SAVILAHTI H, 1996, IN PRESS CELL, V85; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANGJY, 1995, GENE DEV, V9, P2545; ZOU A, 1991, J BIOL CHEM, V266, P20476	40	34	35	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					447	455		10.1016/S0092-8674(00)81122-8	http://dx.doi.org/10.1016/S0092-8674(00)81122-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616899	Bronze			2022-12-24	WOS:A1996UK14000017
J	Durand, GM; Kovalchuk, Y; Konnerth, A				Durand, GM; Kovalchuk, Y; Konnerth, A			Long-term potentiation and functional synapse induction in developing hippocampus	NATURE			English	Article							EXCITATORY SYNAPSES; DENTATE GYRUS; RAT; SLICES; RECEPTORS; REGION	LONG-TERM potentiation (LTP) is a cellular mechanism that potentially underlies learning and memory(1). To test the hypothesis that LTP is involved in activity-dependent synapse formation, we combined whole-cell recordings and confocal microscopy to investigate hippocampal glutamatergic synapses at their earliest stages of development. Here we report that, during the first postnatal week, the hippocampal glutamatergic network becomes gradually functional owing to the transformation of precursor, pure NMDA (N-methyl-D-aspartate)-receptor-based synaptic contacts into conducting AMPA (alpha-amino-3-hydroxyd-methylisoxazole-4-proprionate)/NMDA-receptor-type synapses. This functional synapse induction is caused by an associative form of LTP, so it is input-specific and easily triggered experimentally by pairing presynaptic stimulation with postsynaptic depolarization. Our results challenge previous views that LTP occurs in the hippocampus only at later stages of development(2-6) and that its induction requires dendritic spines(7). They also provide direct evidence that LTP is important for the activity-dependent formation of conducting glutamatergic synapses in the developing mammalian brain.	UNIV SAARLAND, INST PHYSIOL, D-66421 HOMBURG, GERMANY	Saarland University								BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BEKENSTEIN JW, 1991, DEV BRAIN RES, V63, P245, DOI 10.1016/0165-3806(91)90084-V; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; EILERS J, 1995, P NATL ACAD SCI USA, V92, P10272, DOI 10.1073/pnas.92.22.10272; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARNS KM, 1984, J PHYSIOL-LONDON, V346, P27; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KONNERTH A, 1990, PFLUG ARCH EUR J PHY, V417, P285, DOI 10.1007/BF00370994; KONNERTH A, 1990, TRENDS NEUROSCI, V13, P321, DOI 10.1016/0166-2236(90)90137-Y; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WONG LA, 1993, MOL PHARMACOL, V44, P504; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	644	663	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					71	75		10.1038/381071a0	http://dx.doi.org/10.1038/381071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609991				2022-12-24	WOS:A1996UJ05300058
J	Newburger, JW				Newburger, JW			Treatment of Kawasaki disease	LANCET			English	Editorial Material							INTRAVENOUS GAMMA-GLOBULIN				Newburger, JW (corresponding author), CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA.		Nakashima, Lynne/I-1708-2019	Nakashima, Lynne/0000-0002-0712-7958				Burns JC, 1995, INT CONGR SER, V1093, P296; DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; FURUSHO K, 1984, LANCET, V2, P1055; HARADA K, 1993, P 4 INT S KAW DIS DA, P459; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KLASSEN TP, 1993, J PEDIATR-US, V122, P538, DOI 10.1016/S0022-3476(05)83532-2; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Rosenfeld EA, 1995, INT CONGR SER, V1093, P291; SCHNEIDER L, 1994, MMWR-MORBID MORTAL W, V43, P505; Silverman ED, 1995, INT CONGR SER, V1093, P301; TAUBERT KA, 1991, J PEDIATR-US, V119, P279, DOI 10.1016/S0022-3476(05)80742-5	12	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1128	1128		10.1016/S0140-6736(96)90600-5	http://dx.doi.org/10.1016/S0140-6736(96)90600-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609740				2022-12-24	WOS:A1996UG75500002
J	Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR				Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR			Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13	SCIENCE			English	Article							GENE; LIMB; EXPRESSION; REPRESSION; PROTEINS; HOXD-13; LOCUS	Hox genes regulate patterning during limb development. It is believed that they function in the determination of the timing and extent of local growth rates. Here, it is demonstrated that synpolydactyly, an inherited human abnormality of the hands and feet, is caused by expansions of a polyalanine stretch in the amino-terminal region of HOXD13. The homozygous phenotype includes the transformation of metacarpal and metatarsal bones to short carpal- and tarsal-like bones. The mutations identify the polyalanine stretch outside of the DNA binding domain of HOXD13 as a region necessary for proper protein function.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT SURG,DIV PLAST SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Muragaki, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Mundlos, Stefan/ABH-9585-2020		NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036820, R37AR036819, R01AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, DEVELOPMENT, P181; MURAGAKI Y, UNPUB; Polymeropoulos M. H., 1995, American Journal of Human Genetics, V57, pA200; ROBERTS DJ, 1994, AM J HUM GENET, V55, P1; ROGINA B, 1993, NUCLEIC ACIDS RES, V21, P1316, DOI 10.1093/nar/21.5.1316; ROSEN DR, 1993, HUM MOL GENET, V2, P617, DOI 10.1093/hmg/2.5.617; SARFARAZI M, 1995, HUM MOL GENET, V4, P1453, DOI 10.1093/hmg/4.8.1453; SAYLI BS, 1994, J MED GENET, V32, P421; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	26	457	479	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					548	551		10.1126/science.272.5261.548	http://dx.doi.org/10.1126/science.272.5261.548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614804				2022-12-24	WOS:A1996UG82600044
J	Minor, DL; Kim, PS				Minor, DL; Kim, PS			Context-dependent secondary structure formation of a designed protein sequence	NATURE			English	Article							DIFFERENT CONFORMATIONS; PENTAPEPTIDES	PROTEIN secondary structures have been viewed as fundamental building blocks for protein folding, structure and design. Previous studies indicate that the propensities of individual amino acids to form particular secondary structures are the result of a combination of local conformational preferences(1,2) and non-local factors(3-7). To examine the extent to which non-local factors influence the formation of secondary structural elements, we have designed an 11-amino-acid sequence (dubbed the 'chameleon' sequence) that folds as an alpha-helix when in one position but as a beta-sheet when in another position of the primary sequence of the IgG-binding domain of protein G (GB1). Both proteins, chameleon-alpha and chameleon-beta, are folded into structures similar to native GB1, as judged hy several biophysical criteria. Our results demonstrate that non-local interactions can determine the secondary structure of peptide sequences of substantial length. They also support views of protein folding that favour tertiary interactions as dominant determinants of structure (for example, see refs 8,9).	MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute								ACHARI A, 1992, BIOCHEMISTRY-US, V31, P10449, DOI 10.1021/bi00158a006; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DILL KA, 1995, PROTEIN SCI, V4, P561; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; GARRATT RC, 1985, FEBS LETT, V188, P59, DOI 10.1016/0014-5793(85)80874-7; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GRONENBOM AM, 1993, J MOL BIOL, V223, P331; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; Laue T. M., 1994, MODERN ANAL ULTRACEN; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; ORBAN J, 1995, BIOCHEMISTRY-US, V34, P15291, DOI 10.1021/bi00046a038; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Woody R., 1985, PEPTIDES; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349	31	341	349	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					730	734		10.1038/380730a0	http://dx.doi.org/10.1038/380730a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614471				2022-12-24	WOS:A1996UG82700057
J	Kononen, M; Waltimo, A; Nystrom, M				Kononen, M; Waltimo, A; Nystrom, M			Does clicking in adolescence lead to painful temporomandibular joint locking?	LANCET			English	Article							DYSFUNCTION	Background It has been assumed that clicking of the temporomandibular joint (TMJ) may predispose to closed locking. Although jaw clicking is a common complaint, locking of the TMJ is rare. Methods To assess whether clicking is a reliable predictor of locking, we examined longitudinally over 9 years the variation of reported and recorded TMJ clicking in 128 young Finnish adults. Subjects were interviewed and examined at the ages of 14, 15, 18, and 23 years. Findings Reported and recorded TMJ clicking both increased significantly with age, varying from 11% to 31% and from 11% to 34%, respectively. However, clicking showed no predictable pattern, and only a few subjects consistently reported clicking (2%) or had it recorded (2%). None developed locking. Interpretation Because none of the young adults developed locking of the TMJ, we suggest treatment for clicking should be conservative.	UNIV HELSINKI,DEPT PEDODONT & ORTHODONT,HELSINKI,FINLAND	University of Helsinki	Kononen, M (corresponding author), UNIV HELSINKI,DEPT PROSTH DENT,POB 41,SF-00014 HELSINKI,FINLAND.							Annandale T, 1887, LANCET, V129, P411; BROOKE RI, 1988, ORAL SURG ORAL MED O, V65, P668, DOI 10.1016/0030-4220(88)90005-9; DOLWICK MF, 1983, J PROSTHET DENT, V49, P415, DOI 10.1016/0022-3913(83)90287-1; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; GREENE CS, 1988, J AM DENT ASSOC, V117, P461, DOI 10.1016/S0002-8177(88)73018-4; GROSS A, 1983, J AM DENT ASSOC, V107, P932, DOI 10.14219/jada.archive.1983.0354; Kononen Mauno, 1993, Journal of Orofacial Pain, V7, P329; RANDOLPH CS, 1990, AM J ORTHOD DENTOFAC, V77, P77; WANMAN A, 1990, ORAL SURG ORAL MED O, V69, P2, DOI 10.1016/0030-4220(90)90259-U	9	72	73	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1080	1081		10.1016/S0140-6736(96)90280-9	http://dx.doi.org/10.1016/S0140-6736(96)90280-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602059				2022-12-24	WOS:A1996UG04200013
J	Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S				Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S			Essential role of Stat6 in IL-4 signalling	NATURE			English	Article							RESTING B-CELLS; INTERLEUKIN-4; EXPRESSION; LIPOPOLYSACCHARIDE; LYMPHOKINE; RECEPTOR	Interleukin-4(IL-4) is a pleiotropic lymphokine which plays an important role in the immune system(1). IL-4 activates two distinct signalling pathways through tyrosine phosphorylation of Stat6, a signal transducer and activator of transcription, and of a 170K protein called 4PS(2-7). To investigate the functional role of Stat6 in IL-4 signalling, we generated mice deficient in Stat6 by gene targeting. We report here that in the mutant mice, expression of CD23 and major histocompatibility complex (MHC) class II in resting B cells was not enhanced in response to IL-4. IL-4-induced B-cell proliferation costimulated by anti-IgM antibody was abolished. The T-cell proliferative response was also notably reduced. Furthermore, production of Th2 cytokines from T cells as well as IgE and IgG1 responses after nematode infection were profoundly reduced. These findings agreed with those obtained in IL4-deficient mice(8,9) or using antibodies to IL-4(10) and the IL-4 receptor(11). We conclude that Stat6 plays a central role in exerting IL-4-mediated biological responses.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN; HYOGO MED UNIV, DEPT IMMUNOL & MED ZOOL, NISHINOMIYA, HYOGO 663, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, IZUMI, OSAKA 59002, JAPAN	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo			Kishimoto, Tadamitsu/C-8470-2009; Tanaka, Takashi/O-8254-2015; Takeda, Kiyoshi/C-9331-2009; Akira, Shizuo/C-3134-2009					CONRAD DH, 1988, J IMMUNOL, V141, P1091; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1987, J EXP MED, V165, P157, DOI 10.1084/jem.165.1.157; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; PAUL WE, 1991, BLOOD, V77, P1859; PEMIS A, 1995, P NATL ACAD SCI USA, V92, P7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; RABIN EM, 1986, J EXP MED, V164, P517, DOI 10.1084/jem.164.2.517; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROTHMAN P, 1993, RES IMMUNOL, V144, P579, DOI 10.1016/S0923-2494(05)80006-9; STREET NE, 1990, J IMMUNOL, V144, P1629; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	28	1235	1266	2	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					627	630		10.1038/380627a0	http://dx.doi.org/10.1038/380627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602263				2022-12-24	WOS:A1996UF74100046
J	Jeevaratnam, DR; Menon, DK				Jeevaratnam, DR; Menon, DK			Survey of intensive care of severely head injured patients in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL PERFUSION-PRESSURE; RANDOMIZED CLINICAL-TRIAL; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; BRAIN INJURY; BLOOD-FLOW; MANAGEMENT; HYPERVENTILATION; STEROIDS	Objectives-To study practice in intensive care of patients with severe head injury in neurosurgical referral centres in United Kingdom. Design-Structured telephone interview of senior nursing staff in intensive care unit of adult neurosurgical referral centre. Setting-39 intensive care units in hospitals that accepted acute head injuries for specialist neurosurgical management, identified from Medical Directory and information from professional bodies. Main outcome measures-Details of organisation and administration of intensive care and patterns of monitoring and treatment for patients admitted with severe head injury. Results-Patients were managed in specialist neurosurgical intensive care units in 21 of the centres and in general intensive care units in 18. Their intensive care was coordinated by an anaesthetist in 25 units and by a neurosurgeon in 12. Annual caseload varied between units: 20 received >100 patients, 12 received 50-100, and seven received 25-49. Monitoring and treatment varied considerably between centres. Invasive arterial pressure monitoring was used routinely in 36 units, but central venous pressure monitoring was routinely used in 24 and intracranial pressure was routinely monitored in only 19. Corticosteroids were used to treat intracranial hypertension in 19 units. Seventeen units routinely aimed for arterial carbon dioxide pressure of 3.3-4.0 kPa, and one unit still used severe hyperventilation to a pressure of <3.3 kPa. Conclusion-The intensive care of patients with acute head injuries varied widely between the centres surveyed. Rationalisation of the intensive care of severe head injury with the production of widely accepted guidelines ought to improve the quality of care.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT ANAESTHESIA,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Jennett B., 1981, MANAGEMENT HEAD INJU; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Young B, 1991, Neurosurg Clin N Am, V2, P301	29	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					944	947						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616307				2022-12-24	WOS:A1996UF65900019
J	Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M				Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M			Activation of the primary visual cortex by Braille reading in blind subjects	NATURE			English	Article							MONKEY; MACAQUE	PRIMARY visual cortex receives visual input from the eyes through the lateral geniculate nuclei, but is not known to receive input from other sensory modalities'. Its level of activity, both at rest and during auditory or tactile tasks, is higher in blind subjects than in normal controls(2), suggesting that it can subserve nonvisual functions; however, a direct effect of non-visual tasks on activation has not been demonstrated(2-4). To determine whether the visual cortex receives input from the somatosensory system(5-8), we used positron emission tomography (PET) to measure activation during tactile discrimination tasks in normal subjects and in Braille readers blinded in early life. Blind subjects showed activation of primary and secondary visual cortical areas during tactile tasks, whereas normal controls showed deactivation, A simple tactile stimulus that did not require discrimination produced no activation of visual areas in either group. Thus, in blind subjects, cortical areas normally reserved for vision may be activated by other sensory modalities.	NINCDS, HUMAN MOTOR CONTROL SECT, NIH, BETHESDA, MD 20892 USA; NINCDS, COGNIT NEUROSCI SECT, MED NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; FUKUI MED SCH, BIOMED IMAGING RES CTR, MATUOKA, FUKUI 91011, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Fukui			Pascual-Leone, Alvaro/AAC-5101-2019; Deiber, Marie-Pierre/ABF-9026-2020; Deiber, Marie-Pierre/M-5949-2014; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Grafman, Jordan H./0000-0001-8645-4457; Deiber, Marie-Pierre/0000-0002-4984-7363; Sadato, Norihiro/0000-0002-9786-3907				BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Heller Morton, 1991, PSYCHOL TOUCH; Hollins M., 1989, UNDERSTANDING BLINDN; HYVARINEN J, 1981, NEUROSCI LETT, V26, P239, DOI 10.1016/0304-3940(81)90139-7; Kennedy John., 1993, DRAWING BLIND PICTUR; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; MEYER E, 1991, ANN NEUROL, V29, P440, DOI 10.1002/ana.410290418; Millar Susanna, 1994, UNDERSTANDING REPRES, DOI 10.1093/acprof:oso/9780198521426.001.0001; Morgan MichaelJ., 1977, MOLYNEUXS QUESTION V; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; ROLAND PE, 1989, EUR J NEUROSCI, V1, P3, DOI 10.1111/j.1460-9568.1989.tb00769.x; SADATO N, 1995, NEUROLOGY, V45, pA426; SHIPP S, 1989, EUR J NEUROSCI, V1, P309, DOI 10.1111/j.1460-9568.1989.tb00798.x; Talairach J., 1988, APPROACH CEREBRAL IM; UHL F, 1994, ELECTROEN CLIN NEURO, V91, P249, DOI 10.1016/0013-4694(94)90188-0; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	24	790	801	0	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					526	528		10.1038/380526a0	http://dx.doi.org/10.1038/380526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606771				2022-12-24	WOS:A1996UE66300049
J	Werler, MM; Louik, C; Shapiro, S; Mitchell, AA				Werler, MM; Louik, C; Shapiro, S; Mitchell, AA			Prepregnant weight in relation to risk of neural tube defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the relation between prepregnant weight and the risk of neural tube defects (NTDs). Design.-Data were collected from 1988 to 1994 in a case-control surveillance program of birth defects. Setting.-Study subjects were ascertained at tertiary care centers and birth hospitals in the greater metropolitan areas of Boston, Mass, and Philadelphia, Pa, and in southeastern Ontario. Participants.-Cases were 604 fetuses or infants with an NTD identified within 6 months of delivery. Controls were 1658 fetuses or infants with other major malformations identified within 6 months of delivery. For 1992 to 1994, there were 93 control infants without major malformations. Main Outcome Measure.-Relative risk of NTDs in infants or fetuses for different maternal weights. Results.-Relative to women who weighed 50 to 59 kg, risk of NTDs increased from 1.9 (95% confidence interval [CI], 1.2 to 2.9) for women weighing 80 to 89 kg to 4.0 (95% CI, 1.6 to 9.9) for women weighing 110 kg or more. When women were classified according to daily intake above or below the recommended level of 400 mu g of folate, approximate threefold increases in risk were estimated for the heaviest weights in both groups. Intakes of 400 mu g of folate or more reduced risk of NTDs by 40% among women weighing less than 70 kg, but no risk reduction was observed among heavier women. Conclusion.-The risk of NTDs increased with increasing prepregnant weight, independent of the effects of folate intake.			Werler, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	NICHD NIH HHS [R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMITAGE P, 1971, STAT ASPECTS MED RES; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; GOLDENBERG RL, 1995, JAMA-J AM MED ASSOC, V274, P463, DOI 10.1001/jama.274.6.463; HADDOW JE, 1995, AM J OBSTET GYNECOL, V172, P245, DOI 10.1016/0002-9378(95)90139-6; HADDOW JE, 1981, CLIN CHEM, V27, P133; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEMIRE RJ, 1988, JAMA-J AM MED ASSOC, V259, P558, DOI 10.1001/jama.259.4.558; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; *NAT AC SCI, 1990, NUTR PREGN, P5; Shaw G. M., 1995, Teratology, V51, P196; SHAW GM, 1995, LANCET, V345, P393; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339; 1992, MMWR-MORBID MORTAL W, V41, P1	17	249	250	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1089	1092		10.1001/jama.275.14.1089	http://dx.doi.org/10.1001/jama.275.14.1089			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601927				2022-12-24	WOS:A1996UD02700024
J	Grant, GF				Grant, GF			My brain stem stroke	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					917	917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611912				2022-12-24	WOS:A1996UE37100072
J	GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J				GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J			araucan and caupolican, two members of the novel iroquois complex, encode homeoproteins that control proneural and vein-forming genes	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; DROSOPHILA-MELANOGASTER; SUBSTRATE RECOGNITION; EXPRESSION; PROTEIN; SEGMENTATION; SEQUENCE; EXTRAMACROCHAETAE; SEARCH	In Drosophila imaginal wing discs, the achaete-scute (ac-sc) proneural genes and rhomboid (veinlet) are expressed in highly resolved patterns that prefigure the positions of sensory organs and wing veins, respectively. It is thought that these patterns are generated by a combination of factors (a prepattern) regulating these genes. We provide evidence for the existence of this prepattern by identifying two of its factors, Araucan and Caupolican. They are members of a novel family of homeoproteins, with homologs in vertebrates. Araucan and Caupolican, present in domains of the imaginal discs larger than those expressing as-sc and rhomboid, are necessary for expression of these genes in the overlapping domains. Araucan and Caupolican appear to be positive, direct regulators of ac-sc.			GomezSkarmeta, JL (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL SEVERO OCHOA, CANTOBLANCO, E-28049 MADRID, SPAIN.		Ferres-Marco, Maria/G-8364-2015; Gomez-Skarmeta, Jose Luis/B-5268-2014; DIEZ DEL CORRAL, RUTH/K-7974-2014	Ferres-Marco, Maria/0000-0002-0596-4891; Gomez-Skarmeta, Jose Luis/0000-0001-5125-4332; DIEZ DEL CORRAL, RUTH/0000-0003-2649-7214; de la Calle-Mustienes, Elisa/0000-0002-8975-6503				ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHEN SM, 1993, DEV DROSOPHILA MELAN, P747; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1992, INT J DEV BIOL, V36, P85; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; GOMEZSKARMETA JL, 1995, THESIS U AUTONOMA MA; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; LEYNS L, 1991, THESIS U LIBRE BRUXE; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook JFE, 1989, MOL CLONING LAB MANU; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN CURT, 1954, AMER SCI, V42, P213; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; XU T, 1993, DEVELOPMENT, V117, P1223	51	268	272	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					95	105		10.1016/S0092-8674(00)81085-5	http://dx.doi.org/10.1016/S0092-8674(00)81085-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620542	Bronze			2022-12-24	WOS:A1996UE55900012
J	Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E				Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E			Integrin activation by R-ras	CELL			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-5-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; SURFACE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; CELL-ADHESION; AFFINITY; PROTEIN	Expression of a constitutively active R-ras converted two cell lines that grow in suspension into highly adherent cells. There was little change in cell surface expression of integrins, but attachment to surfaces coated with the integrin ligands was greatly enhanced. Cells transfected with activated R-ras bound integrin ligands from solution with higher affinities and assembled severalfold more fibronectin matrix than control transfectants. Introduction of a dominant negative R-ras into adherent cells reduced the adhesiveness of the cells, indicating that endogenous R-ras can control the ligand-binding activity of integrins. These results provide a mechanism for the modulation of integrin ligand-binding activity as well as a novel function for R-ras.	UNIV CALIF SAN DIEGO, SCH MED, MOL PATHOL PROGRAM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Zhang, ZH (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA62042, CA67224, CA28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R01CA067224, R01CA062042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COX AD, 1994, ONCOGENE, V9, P3281; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1990, BLOOD, V76, P2017; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIERSCHBACHER MD, 1981, CELL, V56, P281; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAEZ R, 1994, ONCOGENE, V9, P2977; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SYMONS MH, 1992, J CELL BIOL, V118, P1235, DOI 10.1083/jcb.118.5.1235; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YANG JT, 1993, DEVELOPMENT, V119, P1093; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	56	365	368	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					61	69		10.1016/S0092-8674(00)81082-X	http://dx.doi.org/10.1016/S0092-8674(00)81082-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620538	Bronze			2022-12-24	WOS:A1996UE55900009
J	Joossens, L; Raw, M				Joossens, L; Raw, M			Are tobacco subsidies a misuse of public funds?	BRITISH MEDICAL JOURNAL			English	Article								The European Union spends about 1000m ecu (pound 800m, $1240m) a year subsidising tobacco production but only about 1.55m ecu (pound 1.2m, $1.85m) on smoking prevention. The subsidies, part of the common agriculutral policy, were originally intended to encourage farmers to grow commercially valued varieties of tobacco and thus reduce imports. But they also aimed to guarantee farmers' income, a goal in direct conflict with the first. The policy has failed to adapt production to demand or reduce imports, Since most tobacco grown in the union has little commercial value. Reforms introduced in 1992 have had a limited impact on expenditure, and data produced as a result of the reforms show that it would be much cheaper to give farmers direct income support than to subsidise them growing tobacco. Tobacco subsidies should be abolished and more should be spent on smoking prevention.	UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5,ENGLAND		Joossens, L (corresponding author), INT UNION AGAINST CANC,EUROPEAN UNION OFF,RUE PASCAL 33,B-1000 BRUSSELS,BELGIUM.							*COMM EUR COMM, 1993, 9371 COMM EUR COMM; JOOSSENS L, 1991, BRIT J ADDICT, V86, P1191, DOI 10.1111/j.1360-0443.1991.tb01699.x; SLAMA K, 1995, TOBACCO HLTH; 1994, OFFICIAL J EUROPEAN, V37; 1992, OFFICIAL J EUROPEA L, V215, P70; 1992, OFFICIAL J EUROPEA L, V351, P17	6	8	8	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					832	835						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608295	Green Published			2022-12-24	WOS:A1996UD37800031
J	Gems, D; Riddle, DL				Gems, D; Riddle, DL			Longevity in Caenorhabditis elegans reduced by mating but not gamete production	NATURE			English	Article							FERTILIZATION-DEFECTIVE MUTANTS; FEMALE DROSOPHILA-MELANOGASTER; LIFE-SPAN; WILD-TYPE; SPERM; EVOLUTION; MALES; GENE	THEORIES Of life-history evolution propose that trade-offs occur between fitness components, including longevity and maximal reproduction(1-3). In Drosophila, female lifespan is shortened by increased egg production(4), receipt of male accessory fluid(5) and courting(6), Male lifespan is also reduced by courting and/or mating(7). Here we show that in the nematode Caenorhabditis elegans, mating with males reduces the lifespan of hermaphrodites by a mechanism independent of egg production or receipt of sperm, Conversely, males appear unaffected by mating, Thus, in C. elegans there is no apparent trade-off between longevity and increased egg or sperm production, but there is a substantial cost to hermaphrodites associated with copulation.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Gems, D (corresponding author), UNIV MISSOURI, PROGRAM MOLEC BIOL, COLUMBIA, MO 65211 USA.			Gems, David/0000-0002-6653-4676				ARGON Y, 1980, GENETICS, V96, P413; BRENNER S, 1974, GENETICS, V77, P71; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HODGKIN J, 1983, GENETICS, V103, P43; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LHEMAULT SW, 1988, GENETICS, V120, P435; PARTRIDGE L, 1988, SCIENCE, V241, P1449, DOI 10.1126/science.241.4872.1449; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; PARTRIDGE L, 1981, NATURE, V294, P580, DOI 10.1038/294580a0; SCHEDL T, 1988, GENETICS, V119, P43; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WARD S, 1978, GENETICS, V88, P285; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WILKINSON L, 1989, SYSTAT SYSTEMS STATI; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	24	152	158	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					723	725		10.1038/379723a0	http://dx.doi.org/10.1038/379723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602217				2022-12-24	WOS:A1996TW56700051
J	Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR				Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR			Linguistic ability in early life and cognitive function and Alzheimer's disease in late life - Findings from the Nun Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; ADULTS; SENTENCES; AGE; POPULATION; PREVALENCE; DEMENTIA; SPAN	Objective.-To determine if linguistic ability in early life is associated with cognitive function and Alzheimer's disease in late life. Design.- Two measures of linguistic ability in early life, idea density and grammatical complexity, were derived from autobiographies written at a mean age of 22 yearr. Approximately 58 years later, the women who wrote these autobiographies participated in an assessment of cognitive function, and those who subsequently died were evaluated neuropathologically, Setting.-Convents in the United States participating in the Nun Study; primarily convents in the Milwaukee, Wis, area. Participants.-Cognitive function was investigated in 93 participants who were aged 75 to 95 years at the time of their assessments, and Alzheimer's disease was investigated in the 14 participants who died at 79 to 96 years of age. Main Outcome Measures.-Seven neuropsychological tests and neuropathologically confirmed Alzheimer's disease. Results.-Low idea density and low grammatical complexity in autobiographies written in early life were associated with low cognitive test scores in late life, Low idea density in early life had stronger and more consistent associations with poor cognitive function than did low grammatical complexity. Among the 14 sisters who died, neuropathologically confirmed Alzheimer's disease was present in all of those with low idea density in early life and in none of those with high idea density. Conclusions.-Low linguistic ability in early life was a strong predictor of poor cognitive function and Alzheimer's disease in late life.	UNIV KENTUCKY, DEPT PREVENT MED, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PHYSIOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT NEUROL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PATHOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KANSAS, DEPT PSYCHOL, LAWRENCE, KS USA; UNIV MINNESOTA, VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT EPIDEMIOL, MINNEAPOLIS, MN 55455 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kansas; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Snowdon, DA (corresponding author), UNIV KENTUCKY, SANDERS BROWN CTR AGING, COLL MED, 101 SANDERS BROWN BLDG, LEXINGTON, KY 40536 USA.				NATIONAL INSTITUTE ON AGING [K04AG000553, K04AG000443, R01AG009862] Funding Source: NIH RePORTER; NIA NIH HHS [K04AG00443, K04AG00553, R01AG09862] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; CHEUNG H, 1992, APPL PSYCHOLINGUIST, V13, P53, DOI 10.1017/S0142716400005427; CROPLEY AJ, 1977, LIFELONG ED PSYCHOL; DARCY C, 1994, NEUROBIOL AGING, V15, pS40; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; GATZ M, 1994, GERONTOLOGIST, V34, P251, DOI 10.1093/geront/34.2.251; KEMPER S, 1993, ARCH NEUROL-CHICAGO, V50, P81, DOI 10.1001/archneur.1993.00540010075021; KEMPER S, 1989, APPL PSYCHOLINGUIST, V10, P49, DOI 10.1017/S0142716400008419; KEMPER S, 1990, DISCOURSE PROCESS, V13, P207, DOI 10.1080/01638539009544754; Kemper S., 1990, EUR J COGN PSYCHOL, V2, P205, DOI [10.1080/09541449008406205, DOI 10.1080/09541449008406205, https://doi.org/10.1080/09541449008406205]; Kemper S., 1992, EVERYDAY MEMORY AGIN, P138, DOI [10.1007/978-1-4613-9151-7_9, DOI 10.1007/978-1-4613-9151-7_9]; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KINTSCH W, 1973, COGNITIVE PSYCHOL, V5, P257, DOI 10.1016/0010-0285(73)90036-4; KURIANSKY J, 1976, INT J AGING HUM DEV, V7, P343, DOI 10.2190/X45L-TWW7-WXXY-KA6K; LAZAR I, 1982, LASTING EFFECTS EARL; LYONS K, 1993, AGING COGNITION, V50, P81; MCKEOWN MG, 1987, NATURE VOCABULARY AC; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mortimer J. A., 1988, ETIOLOGY DEMENTIA AL, P39; MORTIMER JA, 1993, NEUROLOGY, V43, pS39; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P476; ROSENBERG S, 1987, APPL PSYCHOLINGUIST, V8, P19, DOI 10.1017/S0142716400000047; ROTH M, 1986, BRIT MED BULL, V42, P42, DOI 10.1093/oxfordjournals.bmb.a072097; Snedecor G.W., 1980, STAT METHODS, V7; SNOWDON DA, 1989, AM J EPIDEMIOL, V130, P999, DOI 10.1093/oxfordjournals.aje.a115433; SNOWDON DA, 1989, J CLIN EPIDEMIOL, V42, P1055, DOI 10.1016/0895-4356(89)90047-4; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; STERNBERG RJ, 1983, AM PSYCHOL, V38, P878, DOI 10.1037/0003-066X.38.8.878; Turner A., 1977, CONSTRUCTION USE PRO; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1985, SAS USERS GUIDE STAT	37	703	714	1	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					528	532		10.1001/jama.275.7.528	http://dx.doi.org/10.1001/jama.275.7.528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV569	8606473				2022-12-24	WOS:A1996TV56900029
J	Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL				Zhao, FZ; Murray, C; Spinaci, S; Styblo, K; Broekmans, J; Zou, JQ; Dai, YS; Chi, YH; Du, X; Cao, JP; Chen, YL; Li, LM; Li, NW; Liu, CJ; Liu, HQ; Lu, Q; Tang, DR; Wang, PF; Wang, ZH; Wu, PE; Zhang, FD; Zhang, FS; Zhu, GL			Results of directly observed short-course chemotherapy in 112842 Chinese patients with smear-positive tuberculosis	LANCET			English	Article							PROGRAM	Background Tuberculosis remains a substantial public health burden in China. The cure rate in treatment programmes has been about 50%. In 1991, a new project based on directly observed short-course chemotherapy was introduced. We report the results of the first 112 842 patients treated. Methods Patients with symptoms suggesting tuberculosis are referred by general health services to the tuberculosis county dispensary for physical examination and fluoroscopy. Those with suspicious findings submit three sputum samples for smear examination. Village doctors deliver free, directly observed therapy to ail smear-positive patients on an outpatient basis. New cases are treated with streptomycin (750 mg), isoniazid (600 mg), pyrazinamide (2000 mg), and rifampicin (600 mg) every other day for 2 months, followed by 4 months of alternate-day isoniazid plus rifampicin. Previously treated patients receive streptomycin, isoniazid, pyrazinamide, rifampicin, and ethambutol (1250 mg) every other day for 2 months, followed by 6 months of isoniazid, rifampicin. and ethambutol. Patients are re-examined and smears are repeated at 2 months (then 3 months if still positive) and at 5 and 6 months (new cases) or 5 and 8 months (previously treated cases). Findings Nearly 1.6 million patients with suspected tuberculosis were referred for fluoroscopy between 1991 and 1994. 48% had suspicious findings on fluoroscopy and underwent sputum examination. 104 444 new smear positive cases and 95616 previously treated smear positive cases have been diagnosed. Results of treatment for those enrolled up to the first quarter of 1994 show cure rates of 89.7% among new cases (55 213) and 81.1% among those previously treated (57 629). The failure rate in previously treated cases, an indicator of drug resistance, fell from 17.6% among 437 patients enrolled in 1991 to 62% among 7822 patients enrolled in the first quarter of 1994. Interpretation Our experience shows that high rates of compliance and cure can be achieved on a mass scale and in a short time by means of directly observed short-course chemotherapy and the WHO technical strategy for effective tuberculosis control.	HARVARD UNIV,CTR POPULAT & DEV STUDIES,CAMBRIDGE,MA 02138	Harvard University								BELL J, 1988, S AFR MED J, V73, P31; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BROEKMANS JF, 1994, TUBERCULOSIS BACK FU, P171; CHEUNG R, 1988, EUR J CLIN PHARMACOL, V35, P401, DOI 10.1007/BF00561372; Farmer P, 1991, Semin Respir Infect, V6, P254; MANOLO F, 1990, AM REV RESPIR DIS, V142, P1301; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MORISKY DE, 1990, HEALTH EDUC QUART, V17, P253, DOI 10.1177/109019819001700303; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447; MURRAY CJL, 1990, B INT UNION TUBERC, V65, P2; VALEZA FS, 1990, LANCET, V335, P473, DOI 10.1016/0140-6736(90)90705-A; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; 1990, 1989 NAT TUB I ANN R; WHOTB9417; 1988, NATIONWIDE RANDOM SU; 1981, NATIONWIDE RANDOM SU; 1995, WHOGTBCARG959 MIN PU; 1992, NATIONWIDE RANDOM SU	19	129	133	2	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					358	362						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598701				2022-12-24	WOS:A1996TU69500009
J	Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M				Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M			Infection with hepatitis GB virus C in patients on maintenance hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULMINANT-HEPATITIS; NON-A; PREVALENCE; REGION; RNA	Background. A recently discovered non-AE hepatitis virus has been designated hepatitis GB virus C (HGBV-C), but little is known about its mode of transmission and its clinical manifestations. We studied 519 patients on maintenance hemodialysis to determine whether they were infected with HGBV-C. Methods. HGBV-C RNA was identified in serum by a reverse-transcription-polymerase-chain-reaction assay with nested primers deduced from a nonstructural region. A nucleotide sequence of 100 bp in the nonstructural region was determined on HGBV-C clones. Results. HGBV-C RNA was detected in 3.1 percent of the patients on hemodialysis (16 of 519), as compared with 0.9 percent of healthy blood donors (4 of 448, P<0.03). None of the 16 patients had evidence of active liver disease, although 7 were also infected with hepatitis C virus. Eight patients with HGBV-C infection were followed for 7 to 16 years. In two patients the virus was present at the start of hemodialysis. One had a history of transfusion, and HGBV-C RNA persisted over a period of 16 years; the other became free of HGBV-C after 10 years. In five patients, HGBV-C RNA was first detected 3 to 20 weeks after blood transfusion and persisted for up to 13 years. One patient with no history of transfusion was infected with an HGBV-C variant with the same sequence as in two of the patients with post-transfusion HGBV-C infections. Conclusions. Patients on maintenance hemodialysis are at increased risk for HGBV-C infection. This virus produces persistent infections, which may be transmitted by transfusions but may also be transmitted by other means. (C) 1996, Massachusetts Medical Society.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; MASUKO HOSP, NAGOYA, AICHI, JAPAN; MASUKO INST MED RES, NAGOYA, AICHI, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO, JAPAN; MIYAKAWA MED RES FDN, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi; Toshiba Corporation			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1016/0270-9139(93)90183-N; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LONDON WT, 1969, NEW ENGL J MED, V281, P571, DOI 10.1056/NEJM196909112811101; Masuko K, 1994, J Viral Hepat, V1, P65, DOI 10.1111/j.1365-2893.1994.tb00063.x; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1016/0270-9139(94)90747-1; SATO S, 1995, ANN INTERN MED, V122, P241, DOI 10.7326/0003-4819-122-4-199502150-00001; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SZMUNESS W, 1974, JAMA-J AM MED ASSOC, V227, P901, DOI 10.1001/jama.227.8.901; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	27	449	454	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1485	1490		10.1056/NEJM199606063342301	http://dx.doi.org/10.1056/NEJM199606063342301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618602				2022-12-24	WOS:A1996UN79900001
J	Li, LM; Cohen, SN				Li, LM; Cohen, SN			tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells	CELL			English	Article							ANTI-SENSE RNA; ANCHORAGE-INDEPENDENT GROWTH; MULTIPLE SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; SEQUENCES COMPLEMENTARY; RETROVIRAL VECTORS; SUPPRESSOR GENES; LEUCINE ZIPPER; LAC REPRESSOR; STEM-CELLS	Using a novel strategy that enables the isolation of previously unknown genes encoding selectable recessive phenotypes, we identified a gene (tsg101) whose homozygous functional disruption produces cell transformation. Antisense RNA from a transactivated promoter introduced randomly into transcribed genes throughout the genome of mouse 3T3 fibroblasts was used to knock out alleles of chromosomal genes adjacent to promoter inserts, generating clones that grew in 0.5% agar and formed metastatic tumors in nude mice. Removal of the transactivator restored normal growth. The protein encoded by tsg101 cDNA encodes a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated previously in tumorigenesis. Overexpression of tsg101 antisense transcripts in naive 3T3 cells resulted in cell transformation and increased stathmin-specific mRNA.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BOOTH PM, 1994, GENE, V146, P303, DOI 10.1016/0378-1119(94)90310-7; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1990, J BIOL CHEM, V265, P11650; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIGUCHI S, 1994, J BIOCHEM-TOKYO, V116, P128, DOI 10.1093/oxfordjournals.jbchem.a124485; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; ROOS G, 1993, LEUKEMIA, V7, P1538; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TEMSAMANI J, 1991, J BIOL CHEM, V266, P468; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1593, DOI 10.1016/0006-291X(91)91756-3; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1600, DOI 10.1016/0006-291X(91)91757-4; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819	63	296	344	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					319	329		10.1016/S0092-8674(00)81111-3	http://dx.doi.org/10.1016/S0092-8674(00)81111-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616888	Bronze			2022-12-24	WOS:A1996UK14000006
J	Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G				Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G			The cytolytic P-2Z receptor for extracellular ATP identified as a P-2X receptor (P2X(7))	SCIENCE			English	Article								The P-2Z receptor is responsible for adenosine triphosphate (ATP)-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Other ATP-gated channels, the P-2X receptors, are permeable only to small cations. Here, an ATP receptor, the P2X(7) receptor, was cloned from rat brain and exhibited both these properties. This protein is homologous to other P-2X receptors but has a unique carboxyl-terminal domain that was required for the lytic actions of ATP. Thus, the P2X(7) (or P-2Z) receptor is a bifunctional molecule that could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells.			Surprenant, A (corresponding author), GLAXO INST MOLEC BIOL SA,PLAN LES OUATES,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Collo G, 1996, J NEUROSCI, V16, P2495; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; EVANS RJ, 1995, J PHYSIOL-LONDON, V487P, pP193; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; HICKMAN SE, 1994, BLOOD, V84, P2452; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; SURPRENANT A, UNPUB; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WILEY JS, 1994, BRIT J PHARMACOL, V112, P946, DOI 10.1111/j.1476-5381.1994.tb13172.x; ZAMBON A, 1994, CELL IMMUNOL, V156, P458, DOI 10.1006/cimm.1994.1190	24	1388	1452	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					735	738		10.1126/science.272.5262.735	http://dx.doi.org/10.1126/science.272.5262.735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614837				2022-12-24	WOS:A1996UJ05100055
J	Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A				Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A			15-year longitudinal study of blood pressure and dementia	LANCET			English	Article							WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; CLINICAL-DIAGNOSIS; POPULATION; CT; ENCEPHALOPATHY; DISORDER; AGE	Background Vascular causes of dementia may be more common than supposed. Vascular factors may also have a role in late-onset Alzheimer's disease, but the role of hypertension in the development of dementia is unclear. Methods As part of the Longitudinal Population Study of 70-year-olds in Goteborg, Sweden, we analysed the relation between blood pressure and the development of dementia in the age intervals 70-75, 75-79, and 79-85 years in those non-demented at age 70 (n=382). The sample was followed up for 15 years and examined repeatedly with a comprehensive investigation, including a psychiatric and physical examination. Findings Participants who developed dementia at age 79-85 had higher systolic blood pressure at age 70 (mean 178 vs 164 mm Hg, p=0.034) and higher diastolic blood pressure at ages 70 (101 vs 92, p=0.004) and 75 (97 vs 90, p=0.022) than those who did not develop dementia, For subtypes of dementia, higher diastolic blood pressure was recorded at age 70 (101, p=0.019) for those developing Alzheimer's disease and at age 75 (101, p=0.015) for those developing vascular dementia than for those who did not develop dementia. Participants with white-matter lesions on computed tomography at age 85 had higher blood pressure at age 70 than those without such lesions. Blood pressure declined in the years before dementia onset and was then similar to or lower than that in non-demented individuals. Interpretation Previously increased blood pressure may increase the risk for dementia by inducing small-vessel disease and white-matter lesions. To what extent the decline in blood pressure before dementia onset is a consequence or a cause of the brain disease remains to be elucidated.	SAHLGRENS UNIV HOSP,SECT PSYCHIAT,DEPT CLIN NEUROSCI,GOTHENBURG,SWEDEN; OSTRA HOSP,DEPT RADIOL,GOTHENBURG,SWEDEN; VASA HOSP,DEPT GERIATR MED,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT MATH,S-41124 GOTHENBURG,SWEDEN; UNIV ILLINOIS,DEPT MED,GERIATR MED SECT,CHICAGO,IL	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BLENNOW K, 1991, ACTA NEUROL SCAND, V83, P187, DOI 10.1111/j.1600-0404.1991.tb04675.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; DELAMONTE SM, 1989, ANN NEUROL, V25, P450, DOI 10.1002/ana.410250506; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V75, P262, DOI 10.1111/j.1600-0404.1987.tb07931.x; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; FARMER ME, 1990, J CLIN EPIDEMIOL, V43, P475, DOI 10.1016/0895-4356(90)90136-D; FERRER I, 1990, J NEUROL SCI, V98, P37, DOI 10.1016/0022-510X(90)90180-U; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; HACHINSKI V, 1992, LANCET, V340, P645; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; LARSON EB, 1993, NEW ENGL J MED, V328, P203, DOI 10.1056/NEJM199301213280308; LOTZ PR, 1986, AM J NEURORADIOL, V7, P817; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; PERSSON G, 1980, ACTA PSYCHIAT SCAND, V62, P119, DOI 10.1111/j.1600-0447.1980.tb00600.x; REIS DJ, 1988, ARCH NEUROL-CHICAGO, V45, P180, DOI 10.1001/archneur.1988.00520260066022; RINDER L, 1975, ACTA MED SCAND, V198, P397, DOI 10.1111/j.0954-6820.1975.tb19563.x; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SKOOG I, 1994, DEMENTIA, V5, P137, DOI 10.1159/000106711; SKOOG I, 1994, J GERIATR PSYCH NEUR, V7, P169, DOI 10.1177/089198879400700308; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STARR JM, 1992, J HYPERTENS, V10, pS31; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; TALMAN WT, 1985, ANN NEUROL, V18, P1, DOI 10.1002/ana.410180102	30	1324	1357	1	70	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1141	1145		10.1016/S0140-6736(96)90608-X	http://dx.doi.org/10.1016/S0140-6736(96)90608-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609748				2022-12-24	WOS:A1996UG75500010
J	Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ				Weiss, EJ; Bray, PF; Tayback, M; Schulman, SP; Kickler, TS; Becker, LC; Weiss, JL; Gerstenblith, G; GoldschmidtClermont, PJ			A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE ASPIRIN; ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; GPIIB-IIIA; TRIAL; REINFARCTION; PREVENTION; DISEASE; THERAPY; PECTORIS	Background. Platelet glycoprotein IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor, and it has an important role in platelet aggregation, It is known to be involved in the pathogenesis of acute coronary syndromes, Previously, we found a high frequency of a particular polymorphism, Pl(A2), of the gene encoding glycoprotein IIIa in kindreds with a high prevalence of premature myocardial infarction. Methods. To investigate the relation between the Pl(A2) polymorphism and acute coronary syndromes, we conducted a case-control study of 71 case patients with myocardial infarction or unstable angina and 68 inpatient controls without known heart disease, The groups were matched for age, race, and sex, We used two methods to determine the Pl(A2) genotype, reverse dot blot hybridization and allele-specific restriction digestion. Results. The prevalence of Pl(A2) was 2.1 times higher among the case patients than among the controls (39.4 percent vs, 19.1 percent, P=0.01), In a subgroup of patients whose disease began before the age of 60 years, the prevalence of Pl(A2) was 50 percent, a value that was 3.6 times that among control subjects under 60 years of age (13.9 percent, P=0.002), Among subjects with the Pl(A2) polymorphism, the odds ratio for having a coronary event was 2.8 (95 percent confidence interval, 1.2 to 6.4). In the patients less than 60 years of age at the onset of disease, the odds ratio was 6.2 (95 percent confidence interval, 1.8 to 22.4). Conclusions. We observed a strong association between the Pl(A2) polymorphism of the glycoprotein IIIa gene and acute coronary thrombosis, and this association was strongest in patients who had had coronary events before the age of 60 years. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BERNARD LAB, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV HEMATOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL49762] Funding Source: Medline; NINR NIH HHS [NR02241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR002241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1980, CIRCULATION, V62, P449; BORNE AEGV, 1990, TRANSFUSION, V30, P477, DOI 10.1046/j.1537-2995.1990.30590296385.x; BRAY PF, 1994, BLOOD, V84, P4361, DOI 10.1182/blood.V84.12.4361.bloodjournal84124361; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Chandler A B, 1974, Am J Cardiol, V34, P823; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEWOOD MA, 1986, NEW ENGL J MED, V315, P417, DOI 10.1056/NEJM198608143150703; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOLD HK, 1990, J CLIN INVEST, V86, P651, DOI 10.1172/JCI114757; HOFFMAN W, 1991, PROSTAG LEUKOTR ESS, V44, P159, DOI 10.1016/0952-3278(91)90051-6; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; JIN Y, 1993, BLOOD, V82, P2281; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; KICKLER TS, 1994, SCI BASIS TRANSFUSIO, P304; KIM HO, 1995, TRANSFUSION, V35, P863, DOI 10.1046/j.1537-2995.1995.351096026369.x; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; KUNICKI TJ, 1979, MOL IMMUNOL, V16, P353, DOI 10.1016/0161-5890(79)90100-7; LAM JYT, 1986, J AM COLL CARDIOL, V8, P1380, DOI 10.1016/S0735-1097(86)80311-4; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MICKELSON JK, 1989, J MOL CELL CARDIOL, V21, P393, DOI 10.1016/0022-2828(89)90650-0; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NEWMAN PJ, 1994, THROMBOSIS HEMORRHAG, P529; NYMAN I, 1992, LANCET, V340, P497, DOI 10.1016/0140-6736(92)91706-E; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; RAMSEY G, 1986, TRANSFUSION, V26, P531, DOI 10.1046/j.1537-2995.1986.26687043619.x; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RIDKER PM, 1991, CIRCULATION, V84, P708, DOI 10.1161/01.CIR.84.2.708; SHULMAN NR, 1961, J CLIN INVEST, V40, P1597, DOI 10.1172/JCI104383; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; VAN LOGHEM JJ J, 1959, Vox Sang, V4, P161; VERHEUGT FWA, 1990, AM J CARDIOL, V66, P267, DOI 10.1016/0002-9149(90)90833-M; WALLENTIN L, 1990, LANCET, V336, P827; Weiss EJ, 1995, TISSUE ANTIGENS, V46, P374, DOI 10.1111/j.1399-0039.1995.tb03129.x; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	41	624	650	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1090	1094		10.1056/NEJM199604253341703	http://dx.doi.org/10.1056/NEJM199604253341703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598867	Green Published			2022-12-24	WOS:A1996UG45700003
J	Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D				Lindpaintner, K; Lee, MA; Larson, MG; Rao, VS; Pfeffer, MA; Ordovas, JM; Schaefer, EJ; Wilson, AF; Wilson, PWF; Vasan, RS; Myers, RH; Levy, D			Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-FAILURE; HYPERTROPHY; TWINS; CELLS; CAPTOPRIL; RATS; POLYMORPHISM; HYPERTENSION; DYSFUNCTION; EXPRESSION	Background. Homozygous carriers of the D allele of the angiotensin-converting-enzyme (ACE) gene have been reported to be at increased risk for various cardiovascular disorders, including left ventricular hypertrophy. We investigated the potential role of the ACE gene in influencing left ventricular mass. Methods. Quantitative echocardiographic data and DNA samples were available for 2439 subjects from the Framingham Heart Study. ACE genotypes were determined by an assay based on the polymerase chain reaction. (The D allele of the ACE gene contains a deletion, whereas the I [insertion] allele does not.) Left ventricular mass and the prevalence of left ventricular hypertrophy, adjusted for clinical covariates, were analyzed according to genotype, Genetic linkage between the ACE locus and left ventricular mass was evaluated by quantitative analysis of pairs of siblings. Results. The ACE genotype was associated neither with left ventricular mass nor with the prevalence of left ventricular hypertrophy. Mean (+/-SE) left ventricular mass (adjusted for sex) among subjects carrying the DD, DI, and II genotypes was 165+/-1.6, 165+/-1.3, and 166+/-2.0 g, respectively (P=0.90). The prevalence of left ventricular hypertrophy among the three genotype groups was 15.6 percent, 13.6 percent, and 15.6 percent, respectively (P=0.36), and the adjusted relative risk of left ventricular hypertrophy associated with the DD genotype was 1.10 (95 percent confidence interval, 0.86 to 1.19). Linkage analysis in 759 pairs of siblings using both the ACE D/I marker and a microsatellite polymorphism at the neighboring locus for the human growth hormone gene failed to support any role of ACE in influencing left ventricular mass. Conclusions. The ACE genotype showed no association with echocardiographically determined left ventricular mass, nor did it confer an increased risk of left ventricular hypertrophy. We found no appreciable role of the ACE gene in influencing left ventricular mass.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV CARDIOL, BOSTON, MA USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02118 USA; TUFTS UNIV, SCH MED,HUMAN NUTR RES CTR AGING,USDA, LIPID METAB LAB, BOSTON, MA USA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & GENET, NEW ORLEANS, LA 70112 USA; NHLBI, BETHESDA, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Boston University; Boston University; Tufts University; United States Department of Agriculture (USDA); Framingham Heart Study; Louisiana State University System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lindpaintner, K (corresponding author), HARVARD UNIV, DIV CARDIOVASC DIS,DEPT MED,BRIGHAM & WOMENS HOSP, SCH MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021; Wilson, Alexander F./Q-6910-2019; Levy, Daniel/ABB-2752-2021; Wilson, Peter W.F./J-2455-2016; Wilson, Alexander/C-2320-2009; Lee-Kirsch, Min Ae/C-5769-2018; Ordovas, Jose/B-8727-2013	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Myers, Richard/0000-0002-8365-2674; Ordovas, Jose/0000-0002-7581-5680; Larson, Martin/0000-0002-9631-1254	NCRR NIH HHS [RR03655] Funding Source: Medline; NHLBI NIH HHS [K04-HL03138-01] Funding Source: Medline; PHS HHS [N01-38038] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL003138] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; AMOS CI, 1989, GENET EPIDEMIOL, V6, P435, DOI 10.1002/gepi.1370060306; AMOS CL, 1989, GENET EPIDEMIOL, V6, P727; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BIELEN E, 1990, EUR HEART J, V11, P7, DOI 10.1093/oxfordjournals.eurheartj.a059595; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FABRIS B, 1990, CLIN EXP PHARMACOL P, V17, P309, DOI 10.1111/j.1440-1681.1990.tb01326.x; FAGARD R, 1987, AM J CARDIOL, V60, P1362, DOI 10.1016/0002-9149(87)90620-5; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HARSHFIELD GA, 1990, AM J HYPERTENS, V3, P538, DOI 10.1093/ajh/3.7.538; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; IWAI N, 1994, CIRCULATION, V90, P2622, DOI 10.1161/01.CIR.90.6.2622; IWAI N, 1992, J HYPERTENS, V10, P1155, DOI 10.1097/00004872-199210000-00007; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JULIEN J, 1990, J AM COLL CARDIOL, V16, P137, DOI 10.1016/0735-1097(90)90470-A; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KUPARI M, 1994, AM J PHYSIOL, V267, pH1107, DOI 10.1152/ajpheart.1994.267.3.H1107; LANDRY F, 1985, JAMA-J AM MED ASSOC, V254, P77, DOI 10.1001/jama.254.1.77; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LAUER MS, 1994, AM J CARDIOL, V74, P487, DOI 10.1016/0002-9149(94)90909-1; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDPAINTNER K, 1993, J MOL CELL CARDIOL, V25, P133, DOI 10.1006/jmcc.1993.1017; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; *LOU STAT U CTR, 1991, SAGE STAT AN GEN EP; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POST WS, IN PRESS J AM COLL C; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; *SAS I, 1979, SAS STAT US GUID VER, P891; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHWARTZ K, 1995, CIRCULATION, V91, P532, DOI 10.1161/01.CIR.91.2.532; SHURTLEFF D, 1974, NIH PUBLICATION; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; TIRET L, 1992, AM J HUM GENET, V51, P197; VERHAAREN HA, 1991, AM J CARDIOL, V68, P661, DOI 10.1016/0002-9149(91)90361-N; 1992, NEW ENGL J MED, V327, P1768	52	228	234	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	1996	334	16					1023	1028		10.1056/NEJM199604183341604	http://dx.doi.org/10.1056/NEJM199604183341604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE733	8598840	Bronze			2022-12-24	WOS:A1996UE73300004
J	Grammer, LC				Grammer, LC			Cefaclor serum sickness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Grammer, LC (corresponding author), NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014				ACKLEY AM, 1981, SOUTHERN MED J, V74, P1550; HEBERT AA, 1991, J AM ACAD DERMATOL, V25, P805, DOI 10.1016/S0190-9622(08)80973-5; KEARNS GL, 1994, J PEDIATR-US, V125, P805, DOI 10.1016/S0022-3476(94)70112-1; LAWLEY TJ, 1993, ALLERGY PRINCIPLES P, P990; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3	5	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1152	1153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609672				2022-12-24	WOS:A1996UE62500009
J	Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ				Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ			Crystal structure of the motor domain of the kinesin-related motor ncd	NATURE			English	Article							PROTEIN; DROSOPHILA; MOVEMENT	MICROTUBULE-BASED ATPases of the kinesin superfamily(1,2) provide the motile force for many animated features of living cells. Kinesin motors differ in their direction of movement along microtubules. Kinesin(3) and ncd(4,5), a kinesin-related motor involved in formation and maintenance of mitotic and meiotic spindles, move in opposite directions along microtubules, even though their motor domains are 40% identical in amino-acid sequence. Here we report the crystal structure of the MgADP complex of the Drosophila ncd motor domain determined to 2.5 Angstrom by X-ray crystallography, and compare it to the kinesin structure. The ncd and kinesin motor domains are remarkably similar in structure, and the locations of conserved surface amino acids suggest these motors share a common microtubule-binding site, Moreover, structural and functional comparisons of ncd, kinesin, myosin and G proteins indicate that these NTPases may have a similar strategy of changing conformation between NTP and NDP states. We propose a general model for converting a common gamma-phosphate-sensing mechanism into opposite polarities of movement for kinesin and ncd.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BOUME HR, 1990, NATURE, V348, P125; BOUME HR, 1991, NATURE, V349, P117; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hoenger A., 1995, Molecular Biology of the Cell, V6, p157A; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	28	318	324	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					555	559		10.1038/380555a0	http://dx.doi.org/10.1038/380555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606780				2022-12-24	WOS:A1996UE66300058
J	Shaw, GM; Velie, EM; Schaffer, D				Shaw, GM; Velie, EM; Schaffer, D			Risk of neural tube defect-affected pregnancies among obese women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALPHA-FETOPROTEIN LEVELS; MATERNAL WEIGHT	Objective.-To investigate the risk for neural tube defect (NTD)-affected pregnancies among obese women (ie, women with a body mass index [BMI] >29 kg/m(2)) compared with women of average prepregnancy weight. Design.-Population-based case-control study. Setting.-All hospitals in 55 of 58 counties in California. Participants.-In-person interviews were conducted with mothers of 538 (88% of eligible) NTD cases (including fetuses and infants electively terminated, stillborn, or born alive) and with mothers of 539 nonmalformed controls (88%) within an average of 5 months from the term delivery date. Main Outcome Measures.-The risk of an NTD-affected pregnancy among obese women. Results.-Compared with women whose BMI was less than or equal to 29 kg/m(2), an increased risk for NTD-affected pregnancy was observed among obese women (odds ratio, 1.9; 95% confidence interval, 1.3 to 2.9). The increased risk was not attributable to maternal nonuse of a vitamin containing folic acid, diabetes, use of diet pills, lower dietary folate intake, or an NTD-pregnancy history. Adjustment for maternal age, education, gravidity, use of vitamins, and use of alcohol did not change the odds ratio. The risk associated with maternal obesity was greater for spina bifida and for other less prevalent NTDs than for anencephaly. Conclusion.-Because as many as 10% of women maybe obese periconceptionally, the observed twofold increased risk is relevant to the population burden of NTDs.	KAISER PERMANENTE,DIV RES,OAKLAND,CA	Kaiser Permanente	Shaw, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.		Velie, Ellen/AAF-3493-2020	Shaw, Gary/0000-0001-7438-4914				BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; CAVDAR AO, 1980, TERATOLOGY, V22, P141, DOI 10.1002/tera.1420220116; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; EANDERSON WJF, 1958, LANCET, V1, P1305; Elwood JM, 1992, EPIDEMIOLOGY CONTROL, P521; FRIEL JK, 1995, AM J MED GENET, V55, P195, DOI 10.1002/ajmg.1320550209; HADDOW JE, 1982, BRIT J OBSTET GYNAEC, V89, P93, DOI 10.1111/j.1471-0528.1982.tb04646.x; JOHNSON AM, 1990, AM J OBSTET GYNECOL, V163, P9, DOI 10.1016/S0002-9378(11)90655-3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MARTIN L, 1988, LANCET, V1, P640; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; *NAT AC SCI, 1990, NUTR PREGN, P5; PERRY GS, 1995, EPIDEMIOLOGY, V6, P61, DOI 10.1097/00001648-199501000-00012; RICHARDS ID, 1969, BRIT J PREV SOC MED, V23, P218; ROBERT E, 1995, REPROD TOXICOL, V9, P57, DOI 10.1016/0890-6238(94)00056-3; Ruge S, 1985, Obstet Gynecol Surv, V40, P57, DOI 10.1097/00006254-198502000-00001; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; *STAT EP RES CORP, 1991, EGRET VERS 0256; WALD N, 1981, BRIT J OBSTET GYNAEC, V88, P1094, DOI 10.1111/j.1471-0528.1981.tb01759.x; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; WALLER DK, 1995, AM J OBSTET GYNECOL, V172, P246, DOI 10.1016/0002-9378(95)90140-X; WATKINS M, 1994, AM J EPIDEMIOL, V139, pS11; WOLFE HM, 1990, OBSTET GYNECOL, V76, P339	23	273	274	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1093	1096		10.1001/jama.275.14.1093	http://dx.doi.org/10.1001/jama.275.14.1093			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601928				2022-12-24	WOS:A1996UD02700025
J	Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J				Szarewski, A; Jarvis, MJ; Sasieni, P; Anderson, M; Edwards, R; Steele, SJ; Guillebaud, J; Cuzick, J			Effect of smoking cessation on cervical lesion size	LANCET			English	Article							COTININE; NONSMOKERS; NICOTINE; SMOKERS; NEOPLASIA; CANCER; FLUIDS; MUCUS	Background Cigarette smoking has been postulated as a cofactor in the aetiology of cervical cancer, but a causal role is difficult to establish because of potential confounding by sexual behaviour. We have investigated the effect of cessation or reduction in cigarette smoking on the course of minor-grade cervical lesions. Methods In this intervention study 82 women volunteers with minor-grade lesions on colposcopy (cervical intraepithelial neoplasia grade 1 or less) attempted to give up smoking for 6 months. Smoking histories were taken at 3-monthly clinic visits and verified by measurement of salivary cotinine concentrations. At each clinic visit, a photograph of the cervix was taken; the image was digitised and computer-aided image analysis was used to assess lesion size, by investigators unaware of smoking status. Findings Of the 82 women, 17 stopped smoking completely for at least 6 months and 11 others reduced their smoking consumption by more than 75%. Of these 28 women, 23 (82%) showed a reduction in lesion size of at least 20% or 4 mm(2) compared with 13 (28%) of the 47 non-quitters (odds ratio 12.0 [95% CI 3.9-32.7]). The remaining seven women had unconfirmed smoking histories. There was a significant correlation between the extent of smoking reduction and the change in lesion size (chi(2) for trend=31.55, p<0.0001). Adjustment for social class, method of contraception, and stage of menstrual cycle did not affect the results. Interpretation Our findings support a link between smoking and cervical disease and suggest that smoking cessation could have a beneficial effect on early cervical abnormalities.	IMPERIAL CANC RES FUND, HLTH BEHAV UNIT, LONDON WC2A 3PX, ENGLAND; UNIV HOSP, DEPT HISTOPATHOL, NOTTINGHAM, ENGLAND; UCL HOSP TRUST, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR RES & TRAINING FAMILY PLANNING, LONDON, ENGLAND	Cancer Research UK; Nottingham University Hospital NHS Trust; University of Nottingham; University College London Hospitals NHS Foundation Trust; University of London; University College London	Szarewski, A (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Ruiz, Emilia Sanchez/K-3013-2013; Jarvis, Martin J/B-1034-2008	Ruiz, Emilia Sanchez/0000-0003-0522-8007; Jarvis, Martin J/0000-0001-9238-8038; Sasieni, Peter/0000-0003-1509-8744				BARTON SE, 1988, LANCET, V2, P652; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; FAIRLEY CK, 1995, AUST NZ J OBSTET GYN, V35, P181, DOI 10.1111/j.1479-828X.1995.tb01865.x; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; IARC, 1995, IARC MON EV CARC RIS, P64; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; LUESLEY D, 1994, BRIT J OBSTET GYNAEC, V101, P49, DOI 10.1111/j.1471-0528.1994.tb13009.x; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; POPPE WAJ, 1995, GYNECOL OBSTET INVES, V39, P34, DOI 10.1159/000292372; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; SHAFI MI, 1994, BRIT J OBSTET GYNAEC, V101, P234, DOI 10.1111/j.1471-0528.1994.tb13116.x; STAFL A, 1981, AM J OBSTET GYNECOL, V139, P815, DOI 10.1016/0002-9378(81)90549-4; TERRY G, 1994, LANCET, V344, P1096, DOI 10.1016/S0140-6736(94)91757-4; WINKELSTEIN W, 1977, AM J EPIDEMIOL, V106, P257, DOI 10.1093/oxfordjournals.aje.a112460; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	20	80	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	1996	347	9006					941	943		10.1016/S0140-6736(96)91417-8	http://dx.doi.org/10.1016/S0140-6736(96)91417-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598759				2022-12-24	WOS:A1996UD59100012
J	Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG				Hoffmann, A; Chiang, CM; Oelgeschlager, T; Xie, XL; Burley, SK; Nakatani, Y; Roeder, RG			A histone octamer-like structure within TFIID	NATURE			English	Article							IMMEDIATE EARLY PROTEIN; RNA POLYMERASE-II; TATA BOX; PROMOTER INTERACTIONS; PREINITIATION COMPLEX; TRANSCRIPTION FACTOR; INITIATION; BINDING	THE general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding(1,2), commits promoters within chromatin to transcription(3), and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment(4-7) or conformational changes in TFIID-promoter complexes(8,9). Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP)(2), TBP-associated factors (TAFs) that interact with and mediate the function of activators(2,7,10,11) and intersubunit interactions(2) but have yielded relatively little insight into the structural organization of the complete or the actual mechanism of transcriptional activation. Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15. Together with analyses of native TFIID complexes and accompanying crystallographic studies(12), the results suggest that there is a histone octamer-like TAF complex within TFIID.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,LABS MOL BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NINCDS,NIH,BETHESDA,MD 20892; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Oelgeschlager, Thomas/0000-0002-4086-719X; Burley, Stephen K./0000-0002-2487-9713				ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BURLEY SK, IN PRESS REV BIOCH; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P1; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	30	159	162	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					356	359		10.1038/380356a0	http://dx.doi.org/10.1038/380356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598932				2022-12-24	WOS:A1996UC37900063
J	Brahams, D				Brahams, D			Unnatural death, AIDS, and coroners	LANCET			English	Editorial Material											Brahams, D (corresponding author), OLD SQ CHAMBERS,LONDON WC1,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					777	777		10.1016/S0140-6736(96)90862-4	http://dx.doi.org/10.1016/S0140-6736(96)90862-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622328				2022-12-24	WOS:A1996UB15300003
J	Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I				Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I			North of England evidence based guidelines development project: Methods of guideline development .1.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUPUNCTURE; METAANALYSIS; TRIALS; PAIN		UNIV ABERDEEN, HLTH SERV RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND; ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; FREEMAN RD HOSP, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT PRIMARY HLTH CARE, SOWERBY UNIT PRIMARY CARE INFORMAT, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV YORK, DEPT HLTH SCI & CLIN EVALUAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Aberdeen; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND.		Eccles, Martin P/AAD-4029-2020; Russell, Ian T/H-1181-2012; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				[Anonymous], 1993, THORAX, V48, pS1; [Anonymous], 1979, J CANADIAN MED ASS, V121, P1193; *CLIN RES AUD GROU, 1993, CLIN GUID REP WORK P; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Institute of Medicine, 1992, GUID CLIN PRACT DEV; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; *N ENGL STAB ANG G, IN PRESS BMJ; *ROYAL COLL GEN PR, 1995, 26 ROYAL COLL GEN PR; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; *U LEEDS, 1994, B U LEEDS, V8; 1996, BRIT MED J, V312, P762	20	129	144	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	1996	312	7033					760	762						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605466				2022-12-24	WOS:A1996UC16600040
J	Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P				Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P			Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi	LANCET			English	Article							INFECTION; CHEMOTHERAPY; MORTALITY; NAIROBI; KENYA	Malawi is one of the poorest countries in the world. Despite the lack of resources, the country has a good tuberculosis (TB) recording and reporting system, developed in 1984 by the International Union against Tuberculosis and Lung Disease. Since 1985, Malawi has experienced an upsurge in TB notifications, mainly because of the HIV epidemic. The number of notified TB cases rose from 5334 in 1985 to 19 496 in 1994, according to the Malawi national TB programme. The national cure rate decreased from 80% in 1988 to 63% in 1992, as the TB programme struggled to cope with increasing numbers of patients while the economic situation worsened. The deterioration in treatment outcomes was more pronounced in the large cities of Blantyre and Lilongwe than elsewhere. This feature causes concern because Queen Elizabeth Central Hospital, Blantyre, and Kamuzu Central Hospital, Lilongwe, diagnose and treat 30-40% of all registered TB cases in Malawi. We have assessed the rates of TB notifications and treatment outcomes in Queen Elizabeth Central Hospital and the measures introduced to improve treatment outcomes.	MINIST HLTH,NATL TB PROGRAMME,LILONGWE,MALAWI; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Harries, AD (corresponding author), QUEEN ELIZABETH CENT HOSP,DEPT MED,COLL MED,POB 95,BLANTYRE,MALAWI.							ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; KOOL HEJ, 1990, TROP GEOGR MED, V42, P128; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; World Health Organization, 1993, TREATM TUB GUID NAT	9	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					807	809		10.1016/S0140-6736(96)90874-0	http://dx.doi.org/10.1016/S0140-6736(96)90874-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622340				2022-12-24	WOS:A1996UB15300015
J	Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG				Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG			Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome	LANCET			English	Article							BONNET,CHARLES SYNDROME; RELIABILITY; INTERVIEW	Background Bonnet's Syndrome (CBS) characterised by the presence of complex visual hallucinations in psychologically normal people, was considered for a long time to be rare. Systematic research on CBS has been limited. However, it has been realised that CBS occurs frequently in elderly, visually handicapped patients, and we have been able to study the syndrome in a large number of patients. Methods After screening 505 visually handicapped patients, 60 were found to meet proposed diagnostic criteria for CBS (generally, the existence of hallucinations without delusions or loss of insightful cognition.) Psychopathological characteristics, personal meaning, and the emotional impact of hallucinations, as well as factors influencing the hallucinations, were analysed. Findings Although diagnostic criteria demand merely ''partial insight'', all patients had full insight into the unreal nature of their hallucinations. Other characteristics varied. In 46 (77%) patients, hallucinations lacked a personal meaning. Sensory deprivation and a low level of arousal seemed to favour the occurrence of hallucinations. CBS caused considerable distress in only 17 (28%) patients. However, all patients were glad to be told that their hallucinations were not due to mental disease. The proper diagnosis had been made in only one of the 16 patients who had consulted a doctor. Interpretation Although largely unrecognised in clinical practice, CBS should be considered as a diagnosis in patients who complain of hallucinations and who meet defined diagnostic criteria. There is no proven treatment, but many patients will benefit from reassurance that their hallucinations do not imply mental illness.	UNIV NIJMEGEN HOSP, DEPT OPHTHALMOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT GERIATR MED, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT EPIDEMIOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Teunisse, RJ (corresponding author), UNIV NIJMEGEN HOSP, DEPT PSYCHIAT, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Zitman, Frans G./E-7705-2010; Verbeek, A.L.M./H-8103-2014; Cruysberg, Johannes R. M./D-4313-2009	Verbeek, A.L.M./0000-0002-2319-5002; Cruysberg, Johannes R. M./0000-0002-5330-0774				*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P398; BONNER C, 1760, ESSAI ANAL FACULTES; COLE MG, 1992, CAN J PSYCHIAT, V37, P267, DOI 10.1177/070674379203700411; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584; de Morsier G, 1967, ANN MED PSYCHOL, V125, P677; FUCHS T, 1992, DELUSIONS HALLUCINAT, P187; GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3; HOOIJER C, 1991, INT J GERIATR PSYCH, V6, P71, DOI 10.1002/gps.930060205; OLBRICH HM, 1987, GRAEF ARCH CLIN EXP, V225, P217, DOI 10.1007/BF02175452; PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744; SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809; SIATKOWSKI RM, 1990, J CLIN NEURO-OPHTHAL, V10, P215; TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254; TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4; WHITE NJ, 1980, BRIT J PSYCHIAT, V136, P284, DOI 10.1192/bjp.136.3.284	16	283	286	0	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					794	797		10.1016/S0140-6736(96)90869-7	http://dx.doi.org/10.1016/S0140-6736(96)90869-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UB153	8622335	Green Submitted			2022-12-24	WOS:A1996UB15300010
J	Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R				Zwicker, J; Liu, NS; Engeland, K; Lucibello, FC; Muller, R			Cell cycle regulation of E2F site occupation in vivo	SCIENCE			English	Article							TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE; BINDING PROTEIN; EXPRESSION; PRODUCT; CDNA; CLONING	DNA-binding E2F complexes have been identified throughout the mammalian cell cycle, including the transcriptionally inactive complexes with pocket proteins, which occur early in the prereplicative G(1) phase of the cycle, and the transactivating free E2F, which increases in late G(1). Here, a regulatory B-myb promoter site was shown to bind with high affinity to free E2F and to E2F-pocket protein complexes in an indistinguishable way in vitro. In contrast, in vivo footprinting with NIH 3T3 cells demonstrated E2F site occupation specifically in early G(1), when the B-myb promoter is inactive. These observations indicate that a novel mechanism governs E2F-DNA interactions during the cell cycle and emphasize the relevance of E2F site-directed transcriptional repression.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35033 MARBURG,GERMANY	Philipps University Marburg			Engeland, Kurt/AAW-9965-2020; Müller, Rolf/L-4997-2016	Engeland, Kurt/0000-0003-3525-0440; Müller, Rolf/0000-0003-3339-4248				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; ENGELAND K, UNPUB; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIU N, UNPUB; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, UNPUB	29	149	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1595	1597		10.1126/science.271.5255.1595	http://dx.doi.org/10.1126/science.271.5255.1595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599118				2022-12-24	WOS:A1996TZ98300045
J	Eastman, QM; Leu, TMJ; Schatz, DG				Eastman, QM; Leu, TMJ; Schatz, DG			Initiation of V(D)J recombination in vitro obeying the 12/23 rule	NATURE			English	Article							MOUSE THYMOCYTES; DNA-SYNTHESIS; SIGNALS; INVITRO; BREAKS	V(D)J recombination the process that assembles antigen-receptor genes, is directed by signal sequences flanking the DNA segments to be joined. Signals consist of a conserved heptamer and nonamer separated by a spacer of either 12 or 23 base pairs. Recombination occurs almost exclusively between two signals with spacers of different lengths. This restriction, called the '12/ 23 rule', governs the organization and pattern of rearrangement of antigen-receptor loci(1,2). In vitro work demonstrating the direct roles of the Rag proteins in the initiation of V(D)J recombination did not recreate the 12/23 rule(3,4). Instead, double-strand breaks were formed efficiently at isolated signals. Here we show that extracts made from a lymphoid cell line that expresses truncated forms of the Rag1 and Rag2 proteins have a signal-cutting activity that obeys the 12/23 rule. Cleavage at the two signals is concerted and requires their synapsis, and mutations of one signal prevent cleavage at both.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; UNIV ZURICH IRCHEL,CH-8057 ZURICH,SWITZERLAND	Howard Hughes Medical Institute; Yale University; Yale University; University of Zurich			Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; KULKOSKY J, 1990, J ACQ IMMUN DEF SYND, V3, P852; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P5644; SHEEHAN KM, 1993, MOL CELL BIOL, V13, P1363, DOI 10.1128/MCB.13.3.1363; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VORA AC, 1990, J VIROL, V64, P5656, DOI 10.1128/JVI.64.11.5656-5659.1990; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	20	202	204	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					85	88		10.1038/380085a0	http://dx.doi.org/10.1038/380085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598914				2022-12-24	WOS:A1996TY87700063
J	Cao, ZD; Henzel, WJ; Gao, XO				Cao, ZD; Henzel, WJ; Gao, XO			IRAK: A kinase associated with the interleukin-1 receptor	SCIENCE			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; DROSOPHILA EMBRYO; TRANSMEMBRANE PROTEIN; DORSOVENTRAL POLARITY; ARABIDOPSIS-THALIANA; GENE; TOLL; ACTIVATION	The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI). When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B). A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned. When human embryonic kidney cells (cell line 293) overexpressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated. The primary amino acid sequence of IRAK shares similarity with that of Pelle, a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.	GENENTECH INC, DEPT PROT CHEM, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech	Cao, ZD (corresponding author), TULARIK INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HIRAYAMA T, 1992, PLANT MOL BIOL, V20, P653, DOI 10.1007/BF00046450; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ING YL, 1994, ONCOGENE, V9, P1745; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MORAN TV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P9, DOI 10.1016/0167-4781(93)90031-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; STJOHNSTON D, 1992, CELL, V68, P201; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5	33	757	826	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1128	1131		10.1126/science.271.5252.1128	http://dx.doi.org/10.1126/science.271.5252.1128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599092				2022-12-24	WOS:A1996TW70100042
J	Dubnau, J; Struhl, G				Dubnau, J; Struhl, G			RNA recognition and translational regulation by a homeodomain protein	NATURE			English	Article							HOMEOTIC GENE ANTENNAPEDIA; DROSOPHILA EMBRYO; BICOID PROTEIN; MESSENGER-RNA; ANTERIOR PATTERN; POLY(A) TAIL; BINDING-SITE; MAJOR GROOVE; FUSHI-TARAZU; EXPRESSION	In Drosophila, the primary determinant of anterior pattern is the gradient morphogen bicoid (bcd), a homeodomain protein that binds DNA and transcriptionally activates target genes at different threshold concentrations. Here we present evidence that bcd also binds RNA and acts as a translational repressor to generate an opposing gradient of the homeodomain protein caudal (cad). RNA binding by bcd seems to involve direct interactions between the bcd homeodomain and discrete target sequences within the 3' untranslated region of the cad messenger RNA and to block the initiation of cad translation.			Dubnau, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,701 W 168 ST,NEW YORK,NY 10032, USA.			Dubnau, Josh/0000-0002-9285-7444				ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUBNAU J, 1995, THESIS COLUMBIA U; FISCHER JA, 1985, NUCLEIC ACIDS RES, V13, P6899, DOI 10.1093/nar/13.19.6899; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	42	286	290	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					694	699		10.1038/379694a0	http://dx.doi.org/10.1038/379694a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602214				2022-12-24	WOS:A1996TW56700042
J	Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS				Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS			Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome	LANCET			English	Article							FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; HYPOTHERMIA; BRAIN; DAMAGE	Background In laboratory animals, cerebral ischaemia is worsened by hyperthermia and improved by hypothermia. Whether these observations apply to human beings with stroke is unknown. We therefore examined the relation between body temperature on admission with acute stroke and various indices of stroke severity and outcome. Methods In a prospective and consecutive study 390 stroke patients were admitted to hospital within 6 h after stroke (median 2.4 h). We determined body temperature on admission, initial stroke severity, infarct size, mortality, and outcome in survivors. Stroke severity was measured on admission, weekly, and at discharge on the Scandinavian Stroke Scale (SSS). Infarct size was determined by computed tomography. Multiple logistic and linear regression outcome analyses included relevant confounders and potential predictors such as age, gender, stroke severity on admission, body temperature, infections, leucocytosis, diabetes, hypertension, atrial fibrillation, ischaemic heart disease, smoking, previous stroke, and comorbidity. Findings Mortality was lower and outcome better in patients with mild hypothermia on admission; both were worse in patients with hyperthermia. Body temperature was independently related to initial stroke severity (p<0.009), infarct size (p<0.0001), mortality (p<0.02), and outcome in survivors (SSS at discharge) (p<0.003). For each 1 degrees C increase in body temperature the relative risk of poor outcome (death or SSS score on discharge <30 points) rose by 2.2 (95% CI 1.4-3.5) (p<0.002). Interpretation We have shown that, in acute human stroke, an association exists between body temperature and initial stroke severity, infarct size, mortality, and outcome. Only intervention trials of hypothermic treatment can prove whether this relation is causal.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	Reith, J (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; BOISVERT DP, 1991, J CEREB BLOOD FLOW M, V11, pS637; BUCHAN A, 1992, NEUROL CLIN, V10, P49, DOI 10.1016/S0733-8619(18)30233-0; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CASTILLO J, 1994, CEREBROVASC DIS, V4, P66, DOI 10.1159/000108454; CHAMBERLAIN JM, 1991, CLIN PEDIATR, V30, P24, DOI 10.1177/0009922891030004S08; CHOPP M, 1992, STROKE, V23, P104, DOI 10.1161/01.STR.23.1.104; CHYATTE D, 1989, J NEUROSURG, V70, P489, DOI 10.3171/jns.1989.70.3.0489; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; HEISS WD, 1990, STROKE S1, V21, P2; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; JORGENSEN HS, 1994, LANCET, V344, P156; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; NORUSIS MJ, 1992, LOGISTIC REGRESSION; NURSE S, 1994, J NEUROSCI, V14, P7726; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SACCANI S, 1992, J CARDIOVASC SURG, V33, P311; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; 1992, STATISTCAL PACKAGE S; 1985, WHO TECH REP SER, V727	32	633	654	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					422	425		10.1016/S0140-6736(96)90008-2	http://dx.doi.org/10.1016/S0140-6736(96)90008-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618482				2022-12-24	WOS:A1996TV72200008
J	Beare, S; Steward, WP				Beare, S; Steward, WP			Plasma free iron and chemotherapy toxicity	LANCET			English	Editorial Material							DEFEROXAMINE				Beare, S (corresponding author), QUEENS UNIV,NATL CANC INST CANADA,CLIN TRIALS GRP,KINGSTON,ON,CANADA.							AISEN P, 1992, ANN NEUROL, V32, pS62, DOI 10.1002/ana.410320711; BUSS JL, 1993, AGENTS ACTIONS, V40, P86, DOI 10.1007/BF01976756; CARMINE TC, 1995, CANCER LETT, V94, P219, DOI 10.1016/0304-3835(95)03852-N; DONFRANCESCO A, 1992, AM J CLIN ONCOL-CANC, V15, P319, DOI 10.1097/00000421-199208000-00009; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; GORDEUK VR, 1992, FEBS LETT, V308, P4, DOI 10.1016/0014-5793(92)81037-M; HAY J, 1991, ARCH TOXICOL, V65, P81, DOI 10.1007/BF02034932; KONTOGHIORGHES GJ, 1995, ANALYST, V120, P845, DOI 10.1039/an9952000845; MALISZA KL, 1995, ARCH BIOCHEM BIOPHYS, V316, P680, DOI 10.1006/abbi.1995.1091; MARCIANI MG, 1991, HAEMATOLOGICA, V76, P131; SOBEL MM, 1991, MOL PHARMACOL, V41, P8; SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117	12	19	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					342	343		10.1016/S0140-6736(96)90530-9	http://dx.doi.org/10.1016/S0140-6736(96)90530-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598694				2022-12-24	WOS:A1996TU69500002
J	Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD				Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD			Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway	CELL			English	Article							INTERFERON-GAMMA RECEPTOR; PROTEIN-TYROSINE KINASE; TRANSCRIPTION; TRANSDUCTION; BINDING; ALPHA; IRF-1; IFN; PHOSPHORYLATION; COMPLEMENTATION	The JAK-STAT signaling pathway has been implicated in mediating biologic responses induced by many cytokines. However, cytokines that promote distinct cellular responses often activate identical STAT proteins, thereby raising the question of how specificity is manifest within this signaling pathway. Here we report the generation and characterization of mice deficient in STAT1. STAT1-deficient mice show no overt developmental abnormalities, but display a complete lack of responsiveness to either IFN alpha or IFN gamma and are highly sensitive to infection by microbial pathogens and viruses. In contrast, these mice respond normally to several other cytokines that activate STAT1 in vitro. These observations document that STAT1 plays an obligate and dedicated role in mediating IFN-dependent biologic responses and reveal an unexpected level of physiologic specificity for STAT1 action.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 92080	Washington University (WUSTL); University of Zurich; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech			Schreiber, Robert D/A-1276-2013; Kaplan, Daniel H/N-2779-2013; Schreiber, Robert/Q-7550-2019; DuBois, Raymond N./AAX-8869-2020; MERAZ RIOS, MARCO ANTONIO/F-4194-2016; Rodig, Scott/Y-3889-2019; Dighe, Anand/AAP-9640-2020	Schreiber, Robert D/0000-0001-6311-0432; Kaplan, Daniel H/0000-0002-7851-7320; MERAZ RIOS, MARCO ANTONIO/0000-0001-6748-8117; Bach, Erika/0000-0002-5997-4489; White, James Michael/0000-0001-5110-6567; Dighe, Anand/0000-0003-4130-0758; Schreiber, Robert/0000-0003-1590-2341				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, J IMMUNOL, V2, P689; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	52	1357	1401	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					431	442		10.1016/S0092-8674(00)81288-X	http://dx.doi.org/10.1016/S0092-8674(00)81288-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608597	Bronze			2022-12-24	WOS:A1996TV70800012
J	Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW				Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW			The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE PROTEIN; ZIDOVUDINE AZT; INFECTION; TYPE-1; AIDS; TRANSMISSION; SEQUENCE; RISK; RETROVIRUS	The discovery of highly divergent strains of human immunodeficiency virus (HIV) not reliably detected by a number of commonly used diagnostic tests has underscored the need for effective surveillance to track HIV variants and to direct research and prevention activities. Pathogens such as HIV that mutate extensively present significant challenges to effective monitoring of pathogens and to disease control, To date, relatively few systematic large-scale attempts have been made to characterize and sequence HIV isolates. For most of the world, including the United States, information an the distribution of HIV strains among different population groups Is limited. We describe herein the implications resulting from the rapid evolution of HIV and the need for systematic surveillance integrated with laboratory science and applied research. General surveillance guidelines are provided to assist in Identifying population groups for screening, in applying descriptive epidemiology and systematic sampling, and in developing and evaluating efficient laboratory testing algorithms. Timely reporting and dissemination of data is also an important element of surveillance efforts, Ultimately, the success of a global surveillance network depends on collaboration and on coordination of clinical laboratory, and epidemiologic efforts.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV AIDS STD & TB LAB RES, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	Hu, DJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, MAILSTOP E-50, ATLANTA, GA 30333 USA.			Hu, Dale/0000-0002-0519-1032; Weniger, Bruce/0000-0002-5450-5464				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOBKOV A, 1994, AIDS, V8, P1649, DOI 10.1097/00002030-199412000-00002; BOBKOV A, 1994, AIDS, V8, P619, DOI 10.1097/00002030-199405000-00007; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CHEINGSONGPOPOV R, 1994, AIDS RES HUM RETROV, V10, P1379, DOI 10.1089/aid.1994.10.1379; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COURPOTIN C, 1994, PEDIATR INFECT DIS J, V13, P502; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DELAPORTE E, 1988, AIDS, V2, P136, DOI 10.1097/00002030-198804000-00013; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DOOLITTLE RF, 1989, NATURE, V339, P338, DOI 10.1038/339338a0; DUMITRESCU O, 1994, J INFECT DIS, V169, P281, DOI 10.1093/infdis/169.2.281; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ESSEX M, 1995, 3RD INT C AIDS AS PA; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FENYO EM, 1988, J VIROL, V62, P4414; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GURTLER LG, 1994, J VIROL, V68, P1581; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KALISH ML, 1994, AIDS RES HUM RETROV, V10, P1573, DOI 10.1089/aid.1994.10.1573; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KOSTRIKIS LG, 1995, J VIROL, V69, P6122, DOI 10.1128/JVI.69.10.6122-6130.1995; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUIKEN CL, 1993, P NATL ACAD SCI USA, V90, P9061, DOI 10.1073/pnas.90.19.9061; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; Lederberg J., 1992, EMERGING INFECTIONS; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LI WH, 1988, MOL BIOL EVOL, V5, P313; LI WH, 1989, MOL BIOL EVOL, V6, P424; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561; LOUWAGIE J, 1992, AIDS RES HUM RETROV, V8, P1467, DOI 10.1089/aid.1992.8.1467; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; LUKASHOV VV, 1995, AIDS, V9, P435, DOI 10.1097/00002030-199509050-00004; LUO CC, 1995, LANCET, V345, P1051, DOI 10.1016/S0140-6736(95)90792-0; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; Myers G, 1994, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; OBRIEN TR, 1991, AIDS, V5, P85, DOI 10.1097/00002030-199101000-00012; OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PIENIAZEK D, 1995, EMERG INFECT DIS, V1, P86, DOI 10.3201/eid0103.950303; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; RUBSAMENWAIGMANN H, 1994, AIDS RES HUM RETROV, V10, P1401, DOI 10.1089/aid.1994.10.1401; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Schochetman G., 1994, AIDS TESTING COMPREH; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Sharp P.M., 1994, AIDS S1, V8, pS27; SHPAER EG, 1993, J MOL EVOL, V37, P57; SIEGRIST CA, 1994, LANCET, V344, P1771, DOI 10.1016/S0140-6736(94)92911-4; SMITH JD, 1994, AIDS RES HUM RETROV, V10, P577, DOI 10.1089/aid.1994.10.577; TSUCHIE H, 1995, INT J STD AIDS, V6, P117, DOI 10.1177/095646249500600211; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENIGER BG, 1994, AIDS, V8, pS13; WENIGER BG, 1994, 10TH INT C AIDS YOK; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015; WIKE CM, 1992, AIDS RES HUM RETROV, V8, P1297, DOI 10.1089/aid.1992.8.1297; WILLIAMSON C, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91543-5; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZEKENG L, 1994, AIDS, V8, P1626, DOI 10.1097/00002030-199411000-00020; ZHONG P, 1995, AIDS RES HUM RETROV, V11, P239, DOI 10.1089/aid.1995.11.239; 1993, MMWR-MORBID MORTAL W, V42, P948; 1995, MMWR-MORBID MORTAL W, V44, P603; 1981, MMWR-MORBID MORTAL W, V30, P305; 1993, MMWR-MORBID MORTAL W, V42, P329; 1990, MMWR-MORBID MORTAL W, V39, P489	119	224	227	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					210	216		10.1001/jama.275.3.210	http://dx.doi.org/10.1001/jama.275.3.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604174				2022-12-24	WOS:A1996TP28200029
J	Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L				Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L			Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective:-To evaluate whether zidovudine treatment was accepted and used by pregnant women subsequent to the release of the results of a multicenter, randomized, placebo-controlled trial (AIDS Clinical Trial Group [ACTG] Protocol 076) that showed that zidovudine significantly reduced maternal-infant human immunodeficiency virus (HIV) type 1 transmission. Design.-Prospective study. Setting:-A community hospital with an integrated, multidisciplinary HIV-dedicated program located in an impoverished, HIV-endemic urban setting. Participants.-All HIV-infected pregnant women identified after the release of the ACTG 076 results who were offered zidovudine therapy to reduce maternal-infant transmission. Results.-Only 49 of the 125 HIV-infected pregnant women delivering at our site during this study period were identified prenatally. Perinatal zidovudine therapy was chosen by 37 (75%) of 49 women. Women refusing zidovudine were more likely to report injection drug use as their HIV risk factor and to continue to use drugs during their pregnancy. Of women choosing zidovudine and delivering, 24 of 36 received all components of their elected therapy. The intrapartum dose was missed by 12 women, 4 of whom also missed their prescribed prenatal oral therapy. Lack of adherence to chosen therapy was associated with continued cocaine use during pregnancy. Conclusions.-Zidovudine therapy to interrupt vertical transmission of HIV was not widely used by these HIV-infected pregnant women. Further studies evaluating factors affecting the acceptance and use of recently published public health recommendations are needed.	BRONX LEBANON HOSP CTR,DEPT OBSTET GYNECOL,BRONX,NY 10457; ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT OBSTET GYNECOL,BRONX,NY 10467	BronxCare Health System; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Wiznia, AA (corresponding author), BRONX LEBANON HOSP CTR,DIV PEDIAT INFECT DIS,1650 SELWYN AVE,APT 2C,BRONX,NY 10457, USA.				NIAID NIH HHS [AI32914-03] Funding Source: Medline; PHS HHS [U64/CCU206826-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYER R, 1994, NEW ENGL J MED, V331, P1223, DOI 10.1056/NEJM199411033311811; BURKETT G, 1994, AM J OBSTET GYNECOL, V171, P372, DOI 10.1016/S0002-9378(94)70037-0; CDCP, 1994, EP INF VERS 6 WORD P; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PLESSINGER MA, 1993, CLIN OBSTET GYNECOL, V36, P267, DOI 10.1097/00003081-199306000-00008; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; ROGERS MF, 1994, NEW ENGL J MED, V331, P1223; *STAT NY DEP HLTH, 1994, CLIN GUID US ZID THE; *US DEP HHS, 1995, EX SUMM ACTG 152 RAN; *US DEP HHS, 1995, EX SUMM ACTG 175 RAN; WEHBEH H, 1995, AM J OBSTET GYNECOL, V172, P1014; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	17	55	55	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1504	1506		10.1001/jama.275.19.1504	http://dx.doi.org/10.1001/jama.275.19.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622226				2022-12-24	WOS:A1996UJ93700035
J	Reidenberg, MM				Reidenberg, MM			Barriers to controlling pain in patients with cancer	LANCET			English	Editorial Material							MANAGEMENT				Reidenberg, MM (corresponding author), CORNELL UNIV,COLL MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.							[Anonymous], [No title captured]; BRANDT EN, 1984, JAMA-J AM MED ASSOC, V251, P1191; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Drayer RA, 1996, J INVEST MED, V44, pA311; HILL CS, 1993, SEMIN ONCOL, V20, P1; Lee LE, 1941, J AMER MED ASSOC, V116, P216, DOI 10.1001/jama.1941.02820030038009; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *WHO EXP COMM, 1990, TECHN REP SERIES WHO, V804; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1983, ANN INTERN MED, V99, P870; 1996, BRIT MED J, V312, P823	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1278	1278		10.1016/S0140-6736(96)90935-6	http://dx.doi.org/10.1016/S0140-6736(96)90935-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622501	hybrid			2022-12-24	WOS:A1996UK75800006
J	Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM				Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM			A role for the proteasome regulator PA28 alpha in antigen presentation	NATURE			English	Article							MURINE CYTOMEGALO-VIRUS; PEPTIDES	CYTOTOXIC T cells recognize viral proteins as peptide fragments which are produced in the cytosol and transported on major histocompatibility complex (MHC) class I proteins to the cell surface(1). Viral peptides that meet the stringent binding characteristics of class I proteins are generated by the 20S proteasome(2,3), The interferon (IFN)-gamma-inducible activator of the 20S proteasome, PA28 (refs 4-6), strongly influences the proteasomal cleavage pattern in vitro(7), This led us to investigate whether changes in cellular levels of PA28 affect the efficiency of viral antigen processing, A mouse fibroblast line expressing the murine cytomegalovirus pp89 protein was transfected with either the human or murine gene encoding the PA28 alpha subunit, which is sufficient to activate the peptide-hydrolysing activity of the 20S proteasome in vitro. Here we report that enhanced expression of PA28 alpha at a level similar to that obtained after IFN-gamma induction resulted in a marked enhancement of recognition by pp89-specific cytotoxic T cells; the presentation of influenza nucleoprotein was also significantly improved, These results demonstrate a fundamental in vivo function for PA28 alpha in antigen processing.	HUMBOLDT UNIV BERLIN,FAC MED CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY; GERMAN CANC RES CTR,D-69009 HEIDELBERG,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)				Eggers, Maren/0000-0001-8485-9485; Soza, Andrea/0000-0003-3783-5231				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; KEIL GM, 1985, J VIROL, V54, P422, DOI 10.1128/JVI.54.2.422-428.1985; KOSZINOWSKI UH, 1986, J VIROL, V58, P59, DOI 10.1128/JVI.58.1.59-66.1986; MOTT JD, 1994, J BIOL CHEM, V269, P31466; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SEELIG A, 1993, ENZYME PROTEIN, V47, P330, DOI 10.1159/000468691; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O	21	302	319	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					166	168		10.1038/381166a0	http://dx.doi.org/10.1038/381166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610016				2022-12-24	WOS:A1996UK13900053
J	MacKie, RM; Hole, DJ				MacKie, RM; Hole, DJ			Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To study incidence of and survival from cutaneous malignant melanoma in relation to socioeconomic status. Design-Application of Carstairs deprivation score to all malignant melanoma patients diagnosed in a geographically defined area over a 15 year period. Setting-West of Scotland (area population 2 716 900). Subjects-3142 patients first diagnosed with malignant melanoma in the period 1979-93. Interventions-Surgical excision of primary malignant melanoma with additional treatment as appropriate and follow up until December 1994. Main outcome measures-Malignant melanoma incidence, primary tumour thickness and five year survival by socioeconomic status Results-From 1979 to 1993, the age standardised incidence rate for cutaneous malignant melanoma was 9.1/100 000 for the most affluent men and 2.4/100 000 for the least affluent men and 16.1/100 000 and 5.0/100 000 respectively for most and least affluent women (P<0.001 for trend in both). The incidence increased steadily over time in both sexes in all socioeconomic groups. Good prognosis tumours (<1.5 mm thick) were most common in the most affluent men and women, and over the study period the proportion of such tumours increased most in the intermediate affluence group (both sexes) and in the least affluent women. Five year disease free survival from melanoma for the sexes combined was 81% for most affluent, 77% for intermediate, and 73% for least affluent groups. Even after adjustment for known prognostic factors of tumour thickness, ulceration, age, and body site of primary melanoma, the more affluent the group, the better the survival. Conclusion-Although the incidence of cutaneous malignant melanoma is higher among more affluent people, the prognosis is better in this group than for less affluent individuals. Early diagnosis campaigns should be targeted particularly to less affluent men and primary prevention campaigns should emphasise the greater risk in more affluent women.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GREATER GLASGOW HLTH BOARD,GLASGOW,LANARK,SCOTLAND	University of Glasgow	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,LANARK,SCOTLAND.							BRESLOW A, 1975, ANN SURG, V182, P572, DOI 10.1097/00000658-197511000-00007; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Carstairs V., 1991, DEPRIVATION HLTH SCO; COX DR, 1972, J R STAT SOC B, V34, P187; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; NELEMANS PJ, 1993, ENVIRON HEALTH PERSP, V101, P252, DOI 10.2307/3431552; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317	9	74	78	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1125	1128						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620127				2022-12-24	WOS:A1996UK06900020
J	Hensch, TK; Stryker, MP				Hensch, TK; Stryker, MP			Ocular dominance plasticity under metabotropic glutamate receptor blockade	SCIENCE			English	Article							CATS VISUAL-CORTEX; KITTEN STRIATE CORTEX; LONG-TERM DEPRESSION; MONOCULAR DEPRIVATION; HIPPOCAMPAL-NEURONS; ANTAGONISM; INDUCTION; NEOCORTEX; ARBORS	Occluding vision through one eye during a critical period in early life nearly abolishes responses to that eye in visual cortex. This phenomenon is mimicked by long-term depression of synaptic transmission in vitro, which may require metabotropic glutamate receptors (mGluRs) and is age-dependent. Peaks in mGluR expression and glutamate stimulated phosphoinositide turnover during visual cortical development have been proposed as biochemical bases for the critical period. Pharmacological blockade of mGluRs specifically prevented synapse weakening in mouse visual cortical slices but did not alter kitten ocular dominance plasticity in vivo. Thus, a heightened mGluR response does not account for the critical period in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CTR INTEGRATED NEUROSCI,WM KECK FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Hensch, Takao/L-4182-2019	Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R37EY002874, R01EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [EY02874, R01 EY002874] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANTONINI A, 1993, J NEUROSCI, V13, P3549; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ANTONINI A, IN PRESS J COMP NEUR; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; BASKYS A, 1992, TRENDS NEUROSCI, V15, P92, DOI 10.1016/0166-2236(92)90018-4; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P489, DOI 10.1113/jphysiol.1982.sp014244; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; BRABETI, 1995, NEUROPHARMACOLOGY, V34, P895; CAHUSAC PMB, 1994, EUR J NEUROSCI, V6, P1505, DOI 10.1111/j.1460-9568.1994.tb01012.x; CATANIA MV, 1994, NEUROSCIENCE, V61, P481, DOI 10.1016/0306-4522(94)90428-6; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DRAGER UC, 1978, J NEUROPHYSIOL, V41, P28, DOI 10.1152/jn.1978.41.1.28; DUDEK SM, 1989, SCIENCE, V246, P673, DOI 10.1126/science.2573152; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUDEK SM, 1994, SOC NEUR ABSTR, V20; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; GEREAU RW, 1995, J NEUROPHYSIOL, V74, P122, DOI 10.1152/jn.1995.74.1.122; GORDON JA, IN PRESS J NEUROSCI; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARUTA H, 1994, NEUROREPORT, V5, P1829, DOI 10.1097/00001756-199409080-00036; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HENSCH TK, 1995, SOC NEUR ABSTR, V21; HSIA AY, 1995, NEUROPHARMACOLOGY, V34, P1567, DOI 10.1016/0028-3908(95)00115-M; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; JIA WWG, 1995, DEV BRAIN RES, V85, P109, DOI 10.1016/0165-3806(94)00181-X; JOLY C, 1995, J NEUROSCI, V15, P3970; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LINGENHOHL K, 1993, NEUROSCI RES, V18, P229, DOI 10.1016/0168-0102(93)90058-X; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; OMARA SM, 1995, NEUROPHARMACOLOGY, V34, P983, DOI 10.1016/0028-3908(95)00062-B; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; REID SNM, 1995, SOC NEUR ABSTR, V21; REITER HO, 1986, EXP BRAIN RES, V65, P182; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIEDEL G, 1995, J NEUROSCI, V15, P87; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; SAUGSTAD JA, 1995, EUR J PHARM-MOLEC PH, V289, P395, DOI 10.1016/0922-4106(95)90120-5; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; THOMSEN C, 1994, EUR J PHARM-MOLEC PH, V267, P77, DOI 10.1016/0922-4106(94)90227-5; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; YANG XD, 1994, J NEUROPHYSIOL, V71, P1586, DOI 10.1152/jn.1994.71.4.1586; YI PL, 1995, NEUROSCI LETT, V185, P207, DOI 10.1016/0304-3940(95)11264-W	66	50	51	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					554	557		10.1126/science.272.5261.554	http://dx.doi.org/10.1126/science.272.5261.554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614806				2022-12-24	WOS:A1996UG82600046
J	Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ				Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ			Identification and characterization of the mouse obesity gene tubby: A member of a novel gene family	CELL			English	Article							NEUROPEPTIDE-Y; FOOD-INTAKE; WEIGHT; MICE	The mutated gene responsible for the tubby obesity phenotype has been identified by positional cloning. A single base change within a splice donor site results in the incorrect retention of a single intron in the mature tub mRNA transcript. The consequence of this mutation is the substitution of the carboxy-terminal 44 amino acids with 24 intron-encoded amino acids. The normal transcript appears to be abundantly expressed in the hypothalamus, a region of the brain involved in body weight regulation. Variation in the relative abundance of alternative splice products is observed between inbred mouse strains and appears to correlate with an intron length polymorphism. This allele of tub is a candidate for a previously reported diet-induced obesity quantitative trait locus on mouse chromosome 7.	MCLAUGHLIN RES INST BIOMED SCI,GREAT FALLS,MT 59405	McLaughlin Research Institute for Biomedical Sciences, Inc.	Kleyn, PW (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEMORIAL DR,CAMBRIDGE,MA 02139, USA.							ALLISON DB, 1994, HEALTH PSYCHOL, V13, P362, DOI 10.1037/0278-6133.13.4.362; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1995, CELL, V81, P289; BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAY GA, 1984, INT J OBES S8, V1, P119; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; GOLD RM, 1977, PHYSIOL BEHAV, V18, P1111, DOI 10.1016/0031-9384(77)90019-1; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HEWITT JK, 1991, ACTA GENET MED GEMEL, V40, P133, DOI 10.1017/S0001566000002567; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KNOLL JHM, 1993, AM J MED GENET, V46, P2, DOI 10.1002/ajmg.1320460103; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; MAYER J, 1955, AM J PHYSIOL, V182, P75, DOI 10.1152/ajplegacy.1955.182.1.75; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NISHINA PM, 1994, METABOLISM, V43, P554, DOI 10.1016/0026-0495(94)90195-3; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PRICE RA, 1987, AM J PSYCHIAT, V144, P1003; PRICE RA, 1990, INT J OBESITY, V14, P185; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SELDIN MF, 1994, J CLIN INVEST, V94, P269, DOI 10.1172/JCI117317; SHORPOSNER G, 1985, PHYSIOL BEHAV, V35, P883, DOI 10.1016/0031-9384(85)90255-0; STANLEY BG, 1985, LIFE SCI, V33, P2635; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; XU Y, 1994, ISMB, V2, P376; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1994, HUM MOL GENET, V3, P621	44	273	292	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					281	290		10.1016/S0092-8674(00)81104-6	http://dx.doi.org/10.1016/S0092-8674(00)81104-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612280	Bronze			2022-12-24	WOS:A1996UG25500016
J	Lewis, MJ; Pelham, HRB				Lewis, MJ; Pelham, HRB			SNARE-mediated retrograde traffic from the Golgi complex to the endoplasmic reticulum	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; LUMINAL ER PROTEINS; SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SHUTTLE VECTORS; YEAST GENES; ENCODES; FUSION; RETRIEVAL	Operation of the secretory pathway in eukaryotic cells requires the selective docking and fusion of transport vesicles with the appropriate target organelle. This is mediated in part by integral membrane proteins termed v-SNAREs (on vesicles) and t-SNAREs (on the target membranes). We describe a novel yeast t-SNARE that resides on the endoplasmic reticulum and mediates retrograde traffic from the Golgi complex. Mutation of this protein prevents both the HDEL receptor and a membrane protein bearing a dibasic retrieval signal from recycling to the endoplasmic reticulum. Forward traffic is also blocked, but only indirectly. Comparison with other yeast mutants indicates that Sec21p (gamma-COP) and Sec20p (an endoplasmic reticulum membrane protein) are also involved primarily, if not exclusively, in retrograde transport.			Lewis, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECHERER KA, 1994, GUIDEBOOK SECRETORY, P253; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HILL J, 1991, NUCLEIC ACIDS RES, V19, P529; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	52	178	179	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					205	215		10.1016/S0092-8674(00)81097-1	http://dx.doi.org/10.1016/S0092-8674(00)81097-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612273	Bronze			2022-12-24	WOS:A1996UG25500009
J	Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD				Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD			Crystal structure of the kinesin motor domain reveals a structural similarity to myosin	NATURE			English	Article							ACTIVE-SITE; MICROTUBULES; MOLECULES; MOVEMENT; RELEASE; COMPLEX	KINESIN is the founding member of a superfamily of microtubule-based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation(1,2). It has two identical similar to 960-amino-acid chains containing an amino-terminal globular motor domain, a central alpha-helical region that enables dimer formation through a coiled coil, and a carboxy-terminal tail domain that binds light chains and possibly an organelle receptor(1). The kinesin motor domain of similar to 340 amino acids, which can produce movement in vitro(3), is much smaller than that of myosin (similar to 850 amino acids) and dynein (1,000 amino acids), and is the smallest known molecular motor. Here, we report the crystal structure of the human kinesin motor domain with bound ADP determined to 1.8-Angstrom resolution by X-ray crystallography. The motor consists primarily of a single alpha/beta arrowhead-shaped domain with dimensions of 70x45x45 Angstrom. Unexpectedly, it has a striking structural similarity to the core of the catalytic domain of the actin-based motor myosin. Although kinesin and myosin have virtually no amino-acid sequence identity, and exhibit distinct enzymatic(4-6) and motile(7-10) properties, our results suggest that these two classes of mechanochemical enzymes evolved from a common ancestor and share a similar force-generating strategy.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895-040005, P01 AR042895] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COPPIN CM, IN PRESS P NATL ACAD; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAMMAR JC, 1993, BIOCHEMISTRY-US, V32, P5752; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PESKIN CS, 1995, BIOPHYS J, V68, pS202; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	34	564	577	1	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					550	555		10.1038/380550a0	http://dx.doi.org/10.1038/380550a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606779	Green Accepted			2022-12-24	WOS:A1996UE66300057
J	vanGent, DC; Mizuuchi, K; Gellert, M				vanGent, DC; Mizuuchi, K; Gellert, M			Similarities between initiation of V(D)J recombination and retroviral integration	SCIENCE			English	Article							DNA STRAND TRANSFER; MECHANISM; SITE; PROTEIN	In the first step of V(D)J recombination, the RAG1 and RAG2 proteins cleave DNA between a signal sequence and the adjacent coding sequence, generating a blunt signal end and a coding end with a closed hairpin structure. These hairpins are intermediates leading to the formation of assembled antigen receptor genes. It is shown here that the hairpins are formed by a chemical mechanism of direct trans-esterification, very similar to the early steps of transpositional recombination and retroviral integration. A minor variation in the reaction is sufficient to divert the process from transposition to hairpin formation.	NIDDKD,NIH,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MAY EW, IN PRESS SCIENCE; MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P1037, DOI 10.1093/nar/22.6.1037; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RICE PR, UNPUB; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S	23	224	228	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1592	1594		10.1126/science.271.5255.1592	http://dx.doi.org/10.1126/science.271.5255.1592			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599117				2022-12-24	WOS:A1996TZ98300044
J	DeLeo, GA; Dobson, AP				DeLeo, GA; Dobson, AP			Allometry and simple epidemic models for microparasites	NATURE			English	Article							POPULATION-DYNAMICS; TRANSMISSION; DENSITY	SIMPLE mathematical models for microparasites offer a useful way to examine the population dynamics of different viral and bacterial pathogens, One constraint in applying these models in free-living host populations is the paucity of data with which to estimate transmission rates. Here we recast a standard epidemiological model by setting the birth and death rates of the host population and its density as simple allometric functions of host body weight. We then use standard threshold theorems for the model in order to estimate the minimum rate of transmission for the parasite to establish itself in a mammalian host population, Transmission rates that produce different comparable values of the parasites' basic reproductive number, R(o), are themselves allometric functions of host body size. We have extended the model to show that hosts having different body sizes suffer epidemic outbreaks whose frequency scales,vith body size. The expected epidemic periods for pathogens in different mammalian populations correspond to cycles observed in free-living populations.			DeLeo, GA (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08544 USA.		De Leo, Giulio/AAC-5098-2019	De Leo, Giulio/0000-0002-4186-3369; Dobson, Andy/0000-0002-9678-1694				ANDERSON R M, 1991; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; ANTONOVICS J, 1995, AM NAT, V145, P661, DOI 10.1086/285761; Calder WA., 1984, SIZE FUNCTION LIFE H; Chamov E. L., 1993, LIFE HIST INVARIANTS; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; GRENFELL BT, 1995, INFECT DIS; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SILVA M, 1995, AM NAT, V145, P704, DOI 10.1086/285764; THRALL PH, 1995, AM NAT, V145, P43, DOI 10.1086/285727	15	68	69	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					720	722		10.1038/379720a0	http://dx.doi.org/10.1038/379720a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602216				2022-12-24	WOS:A1996TW56700050
J	Phull, PS; Halliday, D; Price, AB; Jacyna, MR				Phull, PS; Halliday, D; Price, AB; Jacyna, MR			Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication	BRITISH MEDICAL JOURNAL			English	Article											Phull, PS (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.							ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915; PHULL PS, 1995, POSTGRAD MED J, V71, P413, DOI 10.1136/pgmj.71.837.413; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					349	350						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611832	Green Published			2022-12-24	WOS:A1996TV69800024
J	Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL				Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL			Trends in infectious diseases mortality in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY	Objective.-To evaluate recent trends in infectious diseases mortality in the United States. Design.-Descriptive study of infectious disease mortality, classifying International Classification of Diseases, Ninth Revision codes as infectious diseases, consequence of infectious diseases, or not infectious diseases. Multiple cause-of-death tapes from the National Center for Health Statistics for the years 1980 through 1992 were used, with a focus on underlying cause-of-death data and on codes that exclusively represent infectious diseases. Setting.-United States. Subjects.-All persons who died between 1980 and 1992. Main Outcome Measure.-Death. Results.-Between 1980 and 1992, the death rate due to infectious diseases as the underlying cause of death increased 58%, from 41 to 65 deaths per 100 000 population in the United States. Age-adjusted mortality from infectious diseases increased 39% during the same period. Infectious diseases mortality increased 25% among those aged 65 years and older (from 271 to 338 per 100 000), and 6.3 times among 25- to 44-year-olds (from six to 38 deaths per 100 000). Mortality due to respiratory tract infections increased 20%, from 25 to 30 deaths per 100 000, deaths attributed to human immunodeficiency virus increased from virtually none to 13 per 100 000 in 1992, and the rate of death due to septicemia increased 83% from 4.2 to 7.7 per 100 000. Conclusions.-Despite historical predictions that infectious diseases would wane in the United States, these data show that infectious diseases mortality in the United States has been increasing in recent years.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; TRANDES CORP,ATLANTA,GA; KLEMM ANAL GRP,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Simonsen, Lone/K-4531-2014	Simonsen, Lone/0000-0003-1535-8526				Bennett J. V., 1987, CLOSING GAP BURDEN U, P102; BONNEZ W, 1995, MANDELL DOUGLAS BENN, P1387; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Desenclos Jean-Claude A., 1992, Morbidity and Mortality Weekly Report, V41, P13; EWBANK D, 1986, MARCY ROSENAU PUBLIC, P75; FOHLMAN J, 1993, ANN MED, V25, P569; HADDIX A, 1996, PREVENTIVE EFFECTIVE; HELFAND RF, 1995, J INFECT DIS, V172, P1206, DOI 10.1093/infdis/172.5.1206; HERRINGTON CS, 1994, J CLIN PATHOL, V47, P1066, DOI 10.1136/jcp.47.12.1066; KOCHANEK KD, 1995, MONTHLY VITAL STATIS, V43, P70; Levins R., 1995, ECOSYST HEALTH, V1, P47; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MORRISON EA, 1995, CLIN INFECT DIS, V18, P172; REEVES WC, 1989, REV INFECT DIS, V11, P426; SOLL AH, 1993, GASTROINTESTINAL DIS, P580; WISE RP, 1988, AM J PREV MED, V4, P268, DOI 10.1016/S0749-3797(18)31160-7; 1994, MONTHLY VITAL STAT R, V42; 1992, EMERGING INFECTIONS; 1995, MMWR-MORBID MORTAL W, V44, P468; [No title captured]; 1992, VITAL STATISTICS MOR; 1995, WORLD DEV REPORT 199; 1995, MMWR-MORBID MORTAL W, V44, P381; 1995, MMWR-MORBID MORTAL W, V44, P535; 1995, MMWR-MORBID MORTAL W, V44, P475; 1993, MMWR-MORBID MORTAL W, V42, P869	29	401	414	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					189	193		10.1001/jama.275.3.189	http://dx.doi.org/10.1001/jama.275.3.189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604170				2022-12-24	WOS:A1996TP28200025
J	Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF				Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF			Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN NEURO-BLASTOMA; N-MYC AMPLIFICATION; ALPHA-SATELLITE DNA; GROWTH-FACTOR; INSITU HYBRIDIZATION; PARAFFIN SECTIONS; X-CHROMOSOME; FACTOR-BETA; SHORT ARM; SEQUENCE	Background. Neuroblastoma is a heterogeneous disease, with manifestations ranging from spontaneous regression to lethal spread. Sometimes the tumor spontaneously differentiates toward a benign ganglioneuroma (maturing neuroblastoma). The prognosis is frequently related to ploidy, deletions in the short arm of chromosome 1, and amplifications of the N-myc oncogene. Maturing neuroblastomas consist of both neuronal cells and Schwann cells. We investigated the genetic composition of both cell types in maturing neuroblastomas, to determine the relation between genetic abnormalities and maturation. Methods. We studied 20 maturing and mature neuroblastomas by in situ hybridization to count the chromosomes and evaluate possible deletions in the short arm of chromosome 1 in neuronal and Schwann cells. The DNA content of the cells was measured by flow cytometry. Results. Neuroblastic and ganglionic cells showed aberrations in the number of chromosomes. In situ hybridization and flow cytometry demonstrated near-triploidy in 18 of 19 tumors and pentaploidy in the remaining tumor. The Schwann cells in all 20 neuroblastomas contained normal numbers of chromosomes. In 18 tumors studied, there were no chromosome 1 deletions in either type of cell. Conclusions. The Schwann cells in maturing neuroblastomas differ genetically from the neuronal cells. The normal number of chromosomes in Schwann cells and the abnormal number in neuroblastic and ganglionic cells suggest that Schwann cells are a reactive population of normal cells that invade the neuroblastoma. Near-triploidy of neuroblastoma cells and intact chromosome 1 are presumably genetic prerequisites for spontaneous organoid maturation, because we found no diploidy or chromosome 1 deletions in the neuronal cells of spontaneously maturing neuroblastormas. (C) 1996, Massachusetts Medical Society.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN PATHOL,VIENNA,AUSTRIA; ULLEVAL UNIV HOSP,DEPT PATHOL,OSLO,NORWAY	Saint Anna Children's Hospital; University of Vienna; University of Oslo			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BRESSLER JP, 1985, BRAIN RES, V344, P249, DOI 10.1016/0006-8993(85)90802-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; DANGIO GJ, 1971, LANCET, V1, P1046; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEVILEE P, 1988, Genomics, V3, P1, DOI 10.1016/0888-7543(88)90151-6; EVANS AE, 1980, CANCER, V45, P833, DOI 10.1002/1097-0142(19800301)45:5<833::AID-CNCR2820450502>3.0.CO;2-U; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GIANNAKUDIS J, 1987, CYTOGENET CELL GENET, V46, P619; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; HAAS D, 1988, CANCER, V62, P818, DOI 10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO;2-K; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HEIDEN T, 1991, CYTOMETRY, V12, P614, DOI 10.1002/cyto.990120705; HOPMAN AHN, 1991, MODERN PATHOL, V4, P503; JABS EW, 1984, P NATL ACAD SCI-BIOL, V81, P4884, DOI 10.1073/pnas.81.15.4884; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KANEKO Y, 1987, CANCER RES, V47, P311; KOGNER P, 1993, CANCER RES, V53, P2044; Kushner BH, 1996, J CLIN ONCOL, V14, P373, DOI 10.1200/JCO.1996.14.2.373; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LIM R, 1990, DEV BIOL, V137, P444, DOI 10.1016/0012-1606(90)90269-O; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MATTHAY KK, 1989, J CLIN ONCOL, V7, P236, DOI 10.1200/JCO.1989.7.2.236; MITELMAN F, 1994, CATALOG CHROMOSOME A; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1986, EXP CELL BIOL, V54, P287; STOCK C, 1993, GENE CHROMOSOME CANC, V6, P1, DOI 10.1002/gcc.2870060103; STOCK C, 1994, GENE CHROMOSOME CANC, V11, P40, DOI 10.1002/gcc.2870110107; STREHL S, 1993, CYTOGENET CELL GENET, V63, P24, DOI 10.1159/000133494; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TSOKOS M, 1987, AM J PATHOL, V128, P484; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0	53	177	179	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1505	1511		10.1056/NEJM199606063342304	http://dx.doi.org/10.1056/NEJM199606063342304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618605				2022-12-24	WOS:A1996UN79900004
J	Rizzoli, R; Bonjour, JP				Rizzoli, R; Bonjour, JP			Pregnancy-associated osteoporosis	LANCET			English	Editorial Material							BONE MASS ACCUMULATION; LACTATION; DENSITY; WOMEN				Rizzoli, R (corresponding author), UNIV HOSP GENEVA,DIV CLIN PATHOPHYSIOL,WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,GENEVA,SWITZERLAND.							BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; COURTNEY AC, 1994, CALCIFIED TISSUE INT, V55, P55; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; DUNNE F, 1993, CLIN ENDOCRINOL, V39, P487, DOI 10.1111/j.1365-2265.1993.tb02398.x; GALLACHER SJ, 1994, EUR J ENDOCRINOL, V131, P369, DOI 10.1530/eje.0.1310369; KRITZSILVERSTEIN D, 1992, AM J EPIDEMIOL, V136, P1052, DOI 10.1093/oxfordjournals.aje.a116570; LAKHANPAL S, 1987, ANN INTERN MED, V106, P444, DOI 10.7326/0003-4819-106-3-444; MAILIS A, 1992, J RHEUMATOL, V19, P758; PECK WA, 1993, AM J MED, V94, P646; Smith R, 1995, QJM-MON J ASSOC PHYS, V88, P865; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	12	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1274	1276		10.1016/S0140-6736(96)90932-0	http://dx.doi.org/10.1016/S0140-6736(96)90932-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622498				2022-12-24	WOS:A1996UK75800003
J	Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H				Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H			Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos	NATURE			English	Article							REVERSAL; GENE	EXAMPLES Of lateral asymmetry are often found in vertebrates, such as the heart being on the left side, but the molecular mechanism governing the establishment of this left-right (LR) handedness is unknown(1). A diffusible morphogen may determine L-R polarity(2), but a likely molecule has not so far been identified. Here we report on the gene lefty, a member of the transforming growth factor-beta family, which may encode a morphogen for L-R determination. Lefty protein contains the cysteine-knot motif(3) characteristic of this superfamily(4,5) and is secreted as a processed form of relative molecular mass 25K-32K. Surprisingly, lefty is expressed in the left half of gastrulating mouse embryos. This asymmetric expression is very transient and occurs just before the first sign of lateral asymmetry appears. In the mouse mutants iv and inv, which cause situs inversus, the sites of lefty expression are inverted, indicating that lefty is downstream of iv and inv. These results suggest that lefty may be involved in setting up L-R asymmetry in the organ systems of mammals.	TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; MBL CO LTD, INA LAB, INA, NAGANO 396, JAPAN; TOKYO WOMENS MED COLL, DEPT ANAT & DEV BIOL, SHINJUKU KU, TOKYO 162, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Tokyo Metropolitan Institute of Medical Science; Osaka University; Tokyo Women's Medical University; University of Tokyo			Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; Saijoh, Yukio/0000-0002-7548-4789				BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1993, NATURE, V363, P303, DOI 10.1038/363303a0; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; HOGAN BLM, 1994, DEVELOPMENT, P53; Hummel K. P., 1959, Journal of Heredity, V50, P9; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SAIJOH Y, IN PRESS GENES CELLS; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	18	366	378	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					151	155		10.1038/381151a0	http://dx.doi.org/10.1038/381151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610011				2022-12-24	WOS:A1996UK13900048
J	Kolde, G; Bachus, R; Ludolph, AC				Kolde, G; Bachus, R; Ludolph, AC			Skin involvement in amyotrophic lateral sclerosis	LANCET			English	Article								Background Patients with sporadic amyotrophic lateral sclerosis (ALS) show disorganised collagen and elastin of the dermis. We looked for inflammatory alterations to cutaneous blood vessels. Patients and findings Seven patients with sporadic ALS were investigated; five were confined to bed, but none had bedsores. Light and electron microscopy of skin showed an oedematous dermis with collagen fibrils of irregular diameter. Small blood vessels were characterised by duplicated basement membranes and deposition of beta-amyloid protein, the main component of the neuronal and non-neuronal amyloid deposits in Alzheimer's disease. These skin changes were seen in all degrees of disability, but none was found in age-matched and sex-matched controls. Interpretation The skin in ALS is characterised by a distinctive pattern of alterations of connective tissue and blood vessels. Examination of skin is an additional and easily accessible investigation which may help elucidate the pathogenesis of ALS.	HUMBOLDT UNIV BERLIN,DEPT NEUROL,D-10117 BERLIN,GERMANY	Humboldt University of Berlin	Kolde, G (corresponding author), HUMBOLDT UNIV BERLIN,DEPT DERMATOL,VIRCHOW CLIN,DEPT DERMATOL,D-13353 BERLIN,GERMANY.							CHARCOT JM, 1880, LECON MALADIES SYSTE, V2; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DANIEL RK, 1981, ARCH PHYS MED REHAB, V62, P492; FURUKAWA T, 1976, LANCET, V1, P862; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KNIFFEN JC, 1969, NEUROLOGY, V19, P312; LUDOLPH AC, 1987, BRAIN, V110, P149, DOI 10.1093/brain/110.1.149; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; NORRIS FH, 1974, NEUROLOGY, V24, P721, DOI 10.1212/WNL.24.8.721; ONO S, 1994, J NEUROL NEUROSUR PS, V57, P94, DOI 10.1136/jnnp.57.1.94; ROY DN, 1990, TOXICANTS PLANT ORIG, P170; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6	12	48	48	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1226	1227		10.1016/S0140-6736(96)90737-0	http://dx.doi.org/10.1016/S0140-6736(96)90737-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622453				2022-12-24	WOS:A1996UJ59700012
J	Murphy, JJ				Murphy, JJ			Current practice and complications of temporary transvenous cardiac pacing	BRITISH MEDICAL JOURNAL			English	Article											Murphy, JJ (corresponding author), DARLINGTON MEM HOSP,DEPT MED,DARLINGTON DL3 6HX,DURHAM,ENGLAND.							ANDREWS R, 1992, BRIT HEART J, V68, P91; MURPHY JJ, 1995, BRIT J CLIN PRACT, V49, P126; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161	4	66	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1134	1134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620131				2022-12-24	WOS:A1996UK06900025
J	Brennick, J; Mattia, A				Brennick, J; Mattia, A			Strongyloides stercoralis Infestation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Brennick, J (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1173	1173		10.1056/NEJM199605023341806	http://dx.doi.org/10.1056/NEJM199605023341806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602184				2022-12-24	WOS:A1996UG83100006
J	Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS				Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS			Necessity of routine chest roentgenography after thoracentesis	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; THORACOCENTESIS	Objective: To determine the necessity of posteroanterior chest roentgenography for the identification of pneumothorax and other complications after thoracentesis. Design: Prospective cohort study. Setting: Tertiary care teaching hospital. Patients: 67 men and 43 women (mean age +/- SD, 62.4 +/- 13.2 years). Exclusion criteria included age younger than 18 years, concurrent pleural biopsy, ultrasound guidance, and use of mechanical ventilation. Measurements: 174 thoracenteses done between March 1991 and June 1993. Results: 2 hemothoraces (1.2%) occurred, and 8 patients had a total of 9 pneumothoraces (5.2%). The roentgenograms obtained immediately after the procedures identified 8 pneumothoraces; the other pneumothorax was seen incidentally on a delayed roentgenogram obtained 3 days later. Pneumothorax was suspected in 5 of the 8 cases, and tube thoracostomy was done in 4 of these 5 cases. Patients with unsuspected pneumothorax identified on the roentgenogram obtained immediately after the procedure did not receive treatment for their pneumothoraces. Univariate analysis showed that the variables that correlated significantly with pneumothorax were aspiration of air during the procedure (relative risk ratio, 12.3; 95% CI, 3.7 to 41.4), number of passes with the thoracentesis needle (relative risk ratio, 6.1; CI, 1.6 to 23.3), history of thoracic radiation therapy (relative risk ratio, 10.5; CI, 2.5 to 44.4), and operator suspicion of pneumothorax (relative risk ratio, 25.9; CI, 8.6 to 78.5). Conclusion: Among hospitalized patients with pleural effusions, we identified a subgroup of patients in whom the risk for pneumothorax is low enough (approximately 1%) with sufficiently minimal clinical consequences to justify the avoidance of about 60% of chest roentgenograms obtained after thoracentesis. These patients are clinically stable, have not previously received chest irradiation, had only one pass at thoracentesis attempted without the aspiration of any air, and give no other indication of pneumothorax.	WALTER REED ARMY MED CTR, PULM & CRIT CARE MED SERV, WASHINGTON, DC 20307 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA								BARTTER T, 1993, CHEST, V103, P1873, DOI 10.1378/chest.103.6.1873; BRANDSTETTER RD, 1994, HEART LUNG, V23, P67; COLLINS TR, 1987, CHEST, V91, P817, DOI 10.1378/chest.91.6.817; Gerardi D., 1994, Chest, V106, p83S; GROGAN DR, 1990, ARCH INTERN MED, V150, P873, DOI 10.1001/archinte.150.4.873; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; RAPTOPOULOS V, 1991, AM J ROENTGENOL, V156, P917, DOI 10.2214/ajr.156.5.2017951; ROTH BJ, 1991, ARCH INTERN MED, V151, P2095; SENEFF MG, 1986, CHEST, V90, P97, DOI 10.1378/chest.90.1.97; SOKOLOWSKI JW, 1989, AM REV RESPIR DIS, V140, P257, DOI 10.1164/ajrccm/140.1.257; SWINBURNE AJ, 1991, ARCH INTERN MED, V151, P2095, DOI 10.1001/archinte.1991.00400100147025; WALSHE ADP, 1992, THORAX, V47, P734, DOI 10.1136/thx.47.9.734	12	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					816	820		10.7326/0003-4819-124-9-199605010-00005	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610950				2022-12-24	WOS:A1996UG25400005
J	Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA				Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA			Structure of the UmuD' protein and its regulation in response to DNA damage	NATURE			English	Article							RECA-MEDIATED CLEAVAGE; MUTANT LEXA PROTEINS; ANOMALOUS DIFFRACTION; DEPENDENT CLEAVAGE; ESCHERICHIA-COLI; SOS MUTAGENESIS; AUTODIGESTION; POLYMERASE	FOR life to be sustained, mistakes in DNA repair must be tolerated when damage obscures the genetic information. In bacteria such as Escherichia coli, DNA damage elicits the well regulated 'SOS response' (reviewed in ref. 1). For the extreme case of damage that cannot be repaired by conventional enzymes, there are proteins that allow the replication of DNA through such lesions, but with a reduction in the fidelity of replication(2). Essential proteins in this mutagenic process are RecA, DNA polymerase III, UmuD, UmuD' and UmuC (umu: UV mutagenesis)(1-3). Regulation of this response involves a RecA-mediated self-cleavage of UmuD to produce UmuD'. To understand this system in more detail, we have determined the crystal structure of the E. coli UmuD' mutagenesis protein at 2.5 Angstrom resolution. Globular heads folded in an unusual beta-structure associate to form molecular dimers, and extended amino-terminal tails associate to produce crystallized filaments. The structure provides insight into the mechanism of the self-cleavage reaction that UmuD-like proteins undergo as part of the global SOS response(4-8).	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892	Columbia University; Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Peat, Thomas S/F-9817-2010	Peat, Thomas S/0000-0002-6488-0831; Woodgate, Roger/0000-0001-5581-4616				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; DEBAERDEMAEKER T, 1988, ACTA CRYSTALLOGR A, V44, P353, DOI 10.1107/S0108767388000017; EVANS R, 1990, VIA, V11, P134; FRIEDBERG EC, 1995, DNA REPAIR; GIMBLE FS, 1986, J MOL BIOL, V192, P39, DOI 10.1016/0022-2836(86)90462-6; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1993, J BACTERIOL, V175, P4939; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PEAT TS, IN PRESS PROTEINS; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROLAND KL, 1992, J MOL BIOL, V228, P395, DOI 10.1016/0022-2836(92)90829-9; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x	30	140	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					727	730		10.1038/380727a0	http://dx.doi.org/10.1038/380727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614470				2022-12-24	WOS:A1996UG82700056
J	DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC				DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC			Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium	SCIENCE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CLONING VEHICLES; THRA GENE; CONSTRUCTION; DERIVATIVES; ACTIVATION; NITROGEN; DISEASE	Nitric oxide (NO) is associated with broad-spectrum antimicrobial activity of particular importance in infections caused by intracellular pathogens. An insertion mutation in the metL gene of Salmonella typhimurium conferred specific hypersusceptibility to S-nitrosothiol NO-donor compounds and attenuated virulence of the organism in mice. The metL gene product catalyzes two proximal metabolic steps required for homocysteine biosynthesis. S-Nitrosothiol resistance was restored by exogenous homocysteine or introduction of the metL gene on a plasmid. Measurement of expression of the homocysteine-sensitive metH gene indicated that S-nitrosothiols may directly deplete intracellular homocysteine. Homocysteine may act as an endogenous NO antagonist in diverse processes including infection, atherosclerosis, and neurologic disease.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Iowa			Testerman, Traci L/AAI-1506-2020	Testerman, Traci L/0000-0002-3883-6407; Fang, Ferric/0000-0002-3243-110X	NIAID NIH HHS [AI32463] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032463] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; BYERLY KA, 1991, J BACTERIOL, V173, P3547, DOI 10.1128/jb.173.11.3547-3553.1991; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DEGROOTE MA, UNPUB; EVANS TG, 1993, J IMMUNOL, V151, P907; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FORMICA S, 1994, IMMUNOLOGY, V82, P42; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; KATINKA M, 1980, P NATL ACAD SCI-BIOL, V77, P5730, DOI 10.1073/pnas.77.10.5730; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Miller J.H., 1972, EXPT MOL GENETICS; MULLIGAN JT, 1982, J BACTERIOL, V151, P609, DOI 10.1128/JB.151.2.609-619.1982; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NAUCIEL C, 1992, INFECT IMMUN, V60, P450, DOI 10.1128/IAI.60.2.450-454.1992; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; SAINTGIRONS I, 1984, J BIOL CHEM, V259, P4282; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; URBANOWSKI ML, 1989, J BACTERIOL, V171, P3277, DOI 10.1128/jb.171.6.3277-3281.1989; ZAKIN MM, 1983, J BIOL CHEM, V258, P3028	30	153	167	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					414	417		10.1126/science.272.5260.414	http://dx.doi.org/10.1126/science.272.5260.414			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602531				2022-12-24	WOS:A1996UG25200048
J	Hegde, RS; Lingappa, VR				Hegde, RS; Lingappa, VR			Sequence-specific alteration of the ribosome-membrane junction exposes nascent secretory proteins to the cytosol	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; APOLIPOPROTEIN-B; ER MEMBRANE; TRANSLOCATION; POLYPEPTIDE; PROTEOLIPOSOMES; ENVIRONMENT; COMPLEX	Tight docking of the ribosome at the translocation channel ensures that nascent secretory proteins are shielded from the cytoplasm during transfer into the endoplasmic reticulum. Discrete pause transfer sequences mediate the transient stopping of translocation in certain proteins. Here we show that during a translocational pause, the junction between the ribosome and translocation channel is opened, exposing the nascent chain to the cytosol. While transient, this opening is sufficient to demonstrate macromolecular interactions between the translocating chain and molecules added to the cytosol, such as antibodies and site-specific proteases. Moreover, this opening is accompanied by alterations in the proteins that neighbor the nascent chain. These results demonstrate that specific sequences within a translocating nascent chain can elicit dramatic and reversible structural changes in the translocation machinery. Thus, the translocon is dynamic and can be regulated.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Hegde, RS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline; NIGMS NIH HHS [GM 07618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Harlow E, 1988, ANTIBODIES LAB MANUA; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SIEGEL V, 1995, CELL, V82, P167, DOI 10.1016/0092-8674(95)90301-1; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	30	66	66	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					217	228		10.1016/S0092-8674(00)81098-3	http://dx.doi.org/10.1016/S0092-8674(00)81098-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612274	Bronze			2022-12-24	WOS:A1996UG25500010
J	Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J				Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J			Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; EMPLOYMENT GRADE; CLOTTING FACTORS; WHITEHALL-II; ADULT LIFE; MORTALITY	Background High plasma fibrinogen concentration is associated with an increased risk of coronary heart disease. We have investigated associations between plasma fibrinogen and factors operating in childhood and in adulthood, including the psychosocial characteristics of work. Methods In a cross-sectional study of Civil Servants in London, UK, 2095 men and 1202 women aged 45-55 years provided blood samples for fibrinogen measurement at the time of the Whitehall II study baseline. The participants completed a questionnaire on demographic characteristics, education, employment grade, parents' occupation, health behaviours, and work characteristics. Findings Measures of childhood environment (adult height, father's social class, and participant's education) were inversely associated with adult plasma fibrinogen concentration in both sexes. Lower socioeconomic status (as shown by employment grade) was associated with higher fibrinogen concentrations, with differences from top to bottom grade of 0.22 g/L (95% CI 0.13-0.31) in men and 0.37 g/L (0.18-0.56) in women (p<0.0001, both sexes). This association was not accounted for by measures of childhood circumstances. Control over work, assessed by personnel managers, was inversely related to fibrinogen in both sexes, and a similar relation was seen for self-rated control over work among men but not women. Men in the bottom third of the distribution for self-rated and externally assessed control over work had higher fibrinogen concentrations than those in the top third for both measures (difference 0.16 g/L [0.07-0.26]; p<0.001). There was no difference between these extremes among women (0.02 g/L [-0.16 to 0.19]). Current smokers had higher fibrinogen concentrations than non-smokers, and moderate alcohol consumers had lower concentrations than those who drank occasionally or never. Interpretation Although our study was cross-sectional, it provides evidence that adult fibrinogen concentration is determined by factors operating throughout life. Fibrinogen may be a marker of the biological pathways that mediate the inverse socioeconomic gradient in coronary disease.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL, AVON, ENGLAND; ST MARYS HOSP, PORTSMOUTH PO3 6AQ, HANTS, ENGLAND	University of Bristol	Brunner, E (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Brunner, Eric/H-2114-2011; Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Brunner, Eric/0000-0002-0595-4474; Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; BAKER IA, 1988, INT J EPIDEMIOL, V17, P759, DOI 10.1093/ije/17.4.759; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1986, LANCET, V1, P1077; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRUNNER EJ, 1993, ATHEROSCLEROSIS, V102, P195, DOI 10.1016/0021-9150(93)90162-N; BULLERS S, 1994, WOMEN HEALTH, V22, P11; ELIASSON M, 1994, J CLIN EPIDEMIOL, V47, P513, DOI 10.1016/0895-4356(94)90298-4; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FERRARA A, 1994, AM J EPIDEMIOL, V140, P857, DOI 10.1093/oxfordjournals.aje.a117174; FOLSOM AR, 1993, AM J EPIDEMIOL, V138, P1023, DOI 10.1093/oxfordjournals.aje.a116821; FOLSOM AR, 1991, ATHEROSCLEROSIS, V191, P205; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1987, HAEMOSTASIS THROMBOS, P697; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PECK MN, 1995, SOC SCI MED, V41, P733, DOI 10.1016/0277-9536(94)00379-8; Power C., 1991, HLTH CLASS EARLY YEA; RABBANI LE, 1994, ATHEROSCLEROSIS, V105, P1, DOI 10.1016/0021-9150(94)90002-7; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	36	205	210	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1996	347	9007					1008	1013		10.1016/S0140-6736(96)90147-6	http://dx.doi.org/10.1016/S0140-6736(96)90147-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606563				2022-12-24	WOS:A1996UF38000012
J	Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR				Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR			A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex	NATURE			English	Article							CRYSTAL-STRUCTURE; ONCOGENE; BINDING; MOTIF	THE Ets family of transcription factors, of which there are now about 35 members(1,2), regulate gene expression during growth and development. They share a conserved domain of around 85 amino acids(3) which binds as a monomer to the DNA sequence 5'-C/ AGGAA/T-3'. We have determined the crystal structure of an ETS domain complexed with DNA, at 2.3-Angstrom resolution. The domain is similar to alpha + beta (winged) 'helix-turn-helix' proteins and interacts with a ten-base-pair region of duplex DNA which takes up a uniform curve of 8 degrees. The domain contacts the DNA by a novel loop-helix-loop architecture, Four of the amino acids that directly interact with the DNA are highly conserved: two arginines from the recognition helix lying in the major groove, one lysine from the 'wing' that binds upstream of the core GGAA sequence, and another lysine, from the 'turn' of the 'helix-turn-helix' motif, which binds downstream and on the opposite strand.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; NEUROCRINE BIOSCI,SAN DIEGO,CA 92121	Sanford Burnham Prebys Medical Discovery Institute; University of Naples Federico II; Neurocrine Biosciences				Piccialli, Gennaro/0000-0002-1313-2091; pio, frederic/0000-0003-2050-847X				BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEMER MH, 1995, CELL, V83, P761; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3	27	266	270	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					456	460		10.1038/380456a0	http://dx.doi.org/10.1038/380456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602247				2022-12-24	WOS:A1996UD59000067
J	Cochran, AG; Kim, PS				Cochran, AG; Kim, PS			Imitation of Escherichia coli aspartate receptor signaling in engineered dimers of the cytoplasmic domain	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; BACTERIAL CHEMOTAXIS; LEUCINE ZIPPER; COVALENT MODIFICATION; COILED-COILS; CRYSTAL-STRUCTURE; SENSORY RECEPTOR; KINASE CHEA; TRANSDUCTION; COMPLEX	Transmembrane signaling by bacterial chemotaxis receptors appears to require a conformational change within a receptor dimer. Dimers were engineered of the cytoplasmic domain of the Escherichia coli aspartate receptor that stimulated the kinase CheA in vitro. The folding free energy of the leucine-zipper dimerization domain was harnessed to twist the dimer interface of the receptor, which markedly affected the extent of CheA activation. Response to this twist was attenuated by modification of receptor regulatory sites, in the same manner as adaptation resets sensitivity to ligand in vivo. These results suggest that the normal allosteric activation of the chemotaxis receptor has been mimicked in a system that lacks both ligand-binding and transmembrane domains. The most stimulatory receptor dimer formed a species of tetrameric size.			Cochran, AG (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Cochran, Andrea/0000-0001-6469-795X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07348-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1991, METHOD ENZYMOL, V200, P205; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOWIE JU, 1995, ACTA CRYSTALLOGR D, V51, P145, DOI 10.1107/S0907444994010498; CARR CM, 1995, THESIS MIT; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COLLINS LA, 1992, J BACTERIOL, V174, P3667, DOI 10.1128/JB.174.11.3667-3675.1992; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOERING D, 1992, THESIS MIT; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JIN T, 1994, J MOL BIOL, V244, P477, DOI 10.1006/jmbi.1994.1746; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAPLAN N, 1988, J BACTERIOL, V170, P5134, DOI 10.1128/jb.170.11.5134-5140.1988; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; Laue MT, 1992, ANAL ULTRACENTRIFUGA, P90; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARK CY, 1990, J BACTERIOL, V172, P7179, DOI 10.1128/jb.172.12.7179-7187.1990; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SCOTT WG, 1994, STRUCTURE, V2, P877, DOI 10.1016/S0969-2126(94)00088-3; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1992, J BIOL CHEM, V267, P19753; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; YEH JI, 1993, J BIOL CHEM, V268, P8789; ZITZEWITZ JA, 1995, BIOCHEMISTRY-US, V34, P12812, DOI 10.1021/bi00039a042	62	99	100	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1113	1116		10.1126/science.271.5252.1113	http://dx.doi.org/10.1126/science.271.5252.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599087				2022-12-24	WOS:A1996TW70100037
J	Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO				Paulusma, CC; Bosma, PJ; Zaman, GJR; Bakker, CTM; Otter, M; Scheffer, GL; Scheper, RJ; Borst, P; Elferink, RPJO			Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene	SCIENCE			English	Article							HEREDITARY-CONJUGATED HYPERBILIRUBINEMIA; ATP-DEPENDENT TRANSPORT; MUTANT RATS; CANALICULAR TRANSPORT; MEMBRANE-VESICLES; ORGANIC-ANIONS; EXCRETION; LIVER; TR	The human Dubin-Johnson syndrome and its animal model, the TR(-) rat, are characterized by a chronic conjugated hyperbilirubinemia. TR(-) rats are defective in the canalicular multispecific organic anion transporter (cMOAT), which mediates hepatobiliary excretion of numerous organic anions. The complementary DNA for rat cmoat, a homolog of the human multidrug resistance gene (hMRP1), was isolated and shown to be expressed in the canalicular membrane of hepatocytes. In the TR(-) rat, a single-nucleotide deletion in this gene resulted in a reduced messenger RNA level and absence of the protein. It is likely that this mutation accounts for the TR(-) phenotype.	NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1080 HV AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Paulusma, CC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR FO116,DEPT GASTROINTESTINAL & LIVER DIS,CTR LIVER & INTESTINAL RES,1105 AZ AMSTERDAM,NETHERLANDS.		Paulusma, Coen/AAR-7943-2021	Paulusma, Coen/0000-0001-7284-1974				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; CRAWFORD JM, 1993, DISEASE LIVER, V1, P42; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES MH, 1989, N-S ARCH PHARMACOL, V340, P588, DOI 10.1007/BF00260615; ELFERINK RPJO, 1987, HEPATOLOGY, V7, P1109; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; EVERS R, IN PRESS J CLIN INVE; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KUIPERS F, 1989, J LIPID RES, V30, P1835; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; Otter M, 1995, BIOCHEM MOL BIOL INT, V37, P563; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SMIT JJM, 1994, LAB INVEST, V71, P638; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZAMAN GJR, 1993, CANCER RES, V53, P1747	36	755	765	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1126	1128		10.1126/science.271.5252.1126	http://dx.doi.org/10.1126/science.271.5252.1126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599091				2022-12-24	WOS:A1996TW70100041
J	Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS				Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS			Clinical and laboratory characteristics of human granulocytic ehrlichiosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To characterize the clinical and laboratory features observed in patients with human granulocytic ehrlichiosis (HGE) and evaluate the utility of the diagnostic tools used to confirm the diagnosis. Design.-Retrospective case study of 41 patients with laboratory-diagnosed HGE. Setting.-A total of 228 patients from Minnesota and Wisconsin were evaluated between June 1990 and May 1995. Methods.-Cases were presumptively identified by a history of an influenzalike illness acquired in an area known to be endemic for ticks. Diagnostic laboratory testing included microscopic examination of Wright-stained peripheral blood smears for presence of neutrophilic morulae, polymerase chain reaction (PCR) analysis of acute-phase blood samples for the Ehrlichia phagocytophila/Ehrlichia equi group DNA, and evaluation of serological responses by indirect immunofluorescent antibody assay (IFA), using E equi as antigen. Results.-All patients presented with a temperature of at least 37.6 degrees C, and most had headache, myalgias, chills, and varying combinations of leukopenia, anemia, and thrombocytopenia. Eighty percent of the patients tested demonstrated morulae in the cytoplasm of peripheral blood neutrophils. Only 16 of 37 patients tested by PCR were positive for HGE, whereas serum IFA assays of acute or convalescent blood samples detected antibodies against E equi in 38 of 40 patients tested. Two patients died, and the calculated case fatality rate was 4.9%. Conclusions.-Human granulocytic ehrlichiosis is being increasingly recognized in Wisconsin and Minnesota. A more severe illness is associated with increased age, anemia, increased percentage of neutrophils and decreased percentage of lymphocytes in peripheral blood, and presence of morulae in neutrophils. The differential diagnosis for patients who develop an influenzalike illness following a tick bite should include HGE. Microscopic examination of the acute-phase blood smear to detect neutrophilic morulae is currently the quickest and most practical screening method for diagnosing HGE in the upper Midwest.	DULUTH CLIN LTD, DIV LAB MED, DULUTH, MN 55805 USA; DULUTH CLIN LTD, DIV EDUC & RES, DULUTH, MN 55805 USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Bakken, JS (corresponding author), DULUTH CLIN LTD, INFECT DIS SECT, 400 E 3RD ST, DULUTH, MN 55805 USA.							ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BAKKEN JS, 1995, 33RD ANN M INF DIS S; BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P593; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; DUMLER JS, 1995, 35TH INT C ANT CHEM; DUMLER JS, 1995, NOV ASS MOL PATH ANN; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISH D, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80038-2; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FOGGIE A, 1951, J PATHOL BACTERIOL, V63, P1, DOI 10.1002/path.1700630103; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; MADIGAN JE, 1995, J INFECT DIS, V172, P1141, DOI 10.1093/infdis/172.4.1141; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MAGNARELLI LA, 1995, J CLIN MICROBIOL, V33, P2710, DOI 10.1128/JCM.33.10.2710-2714.1995; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PANCHOLI P, 1995, 33RD ANN M INF DIS S; REED K, 1995, MARSHFIELD LAB NEWS, V18, P1; REED KD, 1995, JAMA-J AM MED ASSOC, V273, P23, DOI 10.1001/jama.273.1.23b; RICHTER PJ, IN PRESS J MED ENTOM; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, 1995, 35TH INT C ANT CHEM; 1993, US 1990 CENSUS W E N	28	366	385	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					199	205		10.1001/jama.275.3.199	http://dx.doi.org/10.1001/jama.275.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604172				2022-12-24	WOS:A1996TP28200027
J	Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ				Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ			Manganese toxicity in children receiving long-term parenteral nutrition	LANCET			English	Article							CHOLESTASIS	Background In patients receiving long-term parenteral nutrition (PN), cholestatic disease acid nervous system disorders have been associated with high blood concentrations of manganese. In such patients, the normal homoeostatic mechanisms of the liver and gut ate bypassed and the requirement for this trace element is not known; nor has it been certain whether hypermanganesaemia causes the cholestasis or vice versa. We explored the direction of effect by serial tests of liver function after withdrawal of manganese supplements from children receiving long-term PN. We also examined the relation between blood manganese concentrations and brain lesions, as indicated by clinical examination and magnetic resonance imaging (MRI). Methods From a combined group of 57 children receiving PN we identified 11 with the combination of hypermanganesaemia and cholestasis; one also had a movement disorder. Manganese supplements were reduced in the first three and withdrawn in the remainder. MRI was done in two of these children. We also looked at manganese concentrations and MRI scans in six children who had received PN for more than 2 years without developing liver disease. Findings In the hypermanganesaemia/cholestasis group, four of the 11 patients died. In the seven survivors baseline whole-blood manganese was 615-1840 nmol/L, and after 4 months it had declined by a median of 643 nmol/L (p<0 . 01). Over the same interval total bilirubin declined by a median of 70 mu mol/L (p<0 . 05). Two of these children had movement disorders, one of whom survived to have an MRI scan; this showed, with T1 weighted images, bilateral symmetrically increased signal intensity in the globus pallidus and subthalamic nuclei. Such changes were also seen in five other children-one from the hypermanganesaemia/cholestasis group and four of six in the long-term PN group without liver disease (in all of whom blood manganese was above normal). Interpretation The cholestasis complicating PN is multifactorial, but these results add to the evidence that manganese contributes. In view of the additional hazard of basal ganglia damage from high manganese levels in children receiving long-term PN, we recommend a low dose regimen of not more than 0 . 018 mu mol/kg per 24 h together with regular examination of the nervous system.	GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT GASTROENTEROL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT CHEM PATHOL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT NEURORADIOL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Lalpour, Abdollah/0000-0002-7134-9395				AYOTTE P, 1985, BIOCHEM PHARMACOL, V34, P3857, DOI 10.1016/0006-2952(85)90435-6; BALL PA, 1994, PAEDIAT PARENTERAL N; DEVENYI AG, 1994, GASTROENTEROLOGY, V106, P1068, DOI 10.1016/0016-5085(94)90769-2; EJAMA A, 1992, LANCET, V339, P426; GRAEF JW, 1982, LEAD ABSORPTION CHIL, P153; HAMBIDGE KM, 1989, JPEN-PARENTER ENTER, V13, P168, DOI 10.1177/0148607189013002168; HUANG CC, 1989, ARCH NEUROL-CHICAGO, V46, P1104, DOI 10.1001/archneur.1989.00520460090018; KRIEGER D, 1995, LANCET, V346, P270, DOI 10.1016/S0140-6736(95)92164-8; LUSTIG S, 1982, ARCH INTERN MED, V142, P405, DOI 10.1001/archinte.142.2.405; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; NELSON K, 1993, BRIT J IND MED, V50, P510; PLAA GL, 1982, BIOCHEM PHARMACOL, V31, P3698, DOI 10.1016/0006-2952(82)90602-5; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; REYNOLDS AP, 1994, ARCH DIS CHILD, V71, P527, DOI 10.1136/adc.71.6.527; SINGH J, 1974, ENVIRON PHYSIOL BIOC, V4, P16; UNDERWOOD EJ, 1977, TRACE ELEMENTS HUMAN, P170; 1988, AM J CLIN NUTR, V48, P1324; 1979, JAMA-J AM MED ASSOC, V241, P2051	19	227	230	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1218	1221		10.1016/S0140-6736(96)90735-7	http://dx.doi.org/10.1016/S0140-6736(96)90735-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622451				2022-12-24	WOS:A1996UJ59700010
J	Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA				Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA			Fluorescent hydroxyl emissions from Saturn's ring atmosphere	SCIENCE			English	Article							IRRADIANCE COMPARISON EXPERIMENT-1; MICROMETEORITE EROSION; PLASMA TRANSPORT; MAGNETOSPHERE; TORUS; MODEL; HYDROGEN; ORIGIN; CLOUD; WATER	Just before Earth passed through Saturn's ring plane on 10 August 1995, the Hubble Space Telescope Faint Object Spectrograph detected ultraviolet fluorescent emissions from a tenuous atmosphere of OH molecules enveloping the rings. Brightnesses decrease with increasing distance above the rings, implying a scale height of about 0.45 Saturn radii (R(S)). A spatial scan 0.28R(S) above the A and B rings indicates OH column densities of about 10(13) cm(-2) and number densities of up to 700 cm(-3). Saturn's rings must produce roughly 10(25) to 10(29) OH molecules per second to maintain the observed OH distribution.	UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85716; SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	University of Arizona; Space Telescope Science Institute	Hall, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,DEPT PHYS & ASTRON,BALTIMORE,MD 21218, USA.							BLAMONT J, 1974, NASA SP, P125; BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; CHENG AF, 1982, J GEOPHYS RES-SPACE, V87, P4567, DOI 10.1029/JA087iA06p04567; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1986, GEOPHYS RES LETT, V13, P773, DOI 10.1029/GL013i008p00773; Cuzzi J.N., 1984, PLANETARY RINGS, V75, P73; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; DENNEFELD M, 1974, IAU S, V65, P471; DONES L, 1991, ICARUS, V92, P194, DOI 10.1016/0019-1035(91)90045-U; EVIATAR A, 1990, ANN GEOPHYS, V8, P725; GANBARUCH Z, 1994, J GEOPHYS RES-SPACE, V99, P11063, DOI 10.1029/93JA03143; HAFF PK, 1986, ICARUS, V66, P258, DOI 10.1016/0019-1035(86)90156-9; HAMILTON DP, 1993, NATURE, V365, P498, DOI 10.1038/365498c0; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HILTON DA, 1988, ICARUS, V73, P248, DOI 10.1016/0019-1035(88)90096-6; IP WH, 1995, ICARUS, V115, P295, DOI 10.1006/icar.1995.1098; IP WH, 1983, J GEOPHYS RES-SPACE, V88, P819, DOI 10.1029/JA088iA02p00819; IP WH, 1984, J GEOPHYS RES-SPACE, V89, P8843, DOI 10.1029/JA089iA10p08843; Ip WH, 1996, ASTROPHYS J, V457, P922, DOI 10.1086/176785; JOHNSON RE, 1989, ICARUS, V77, P311, DOI 10.1016/0019-1035(89)90092-4; JOHNSON RE, 1993, EOS, V74, P569; JUDGE DL, 1980, SCIENCE, V207, P431, DOI 10.1126/science.207.4429.431; LAZARUS AJ, 1983, J GEOPHYS RES-SPACE, V88, P8831, DOI 10.1029/JA088iA11p08831; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NORTHROP TG, 1982, J GEOPHYS RES-SPACE, V87, P6045, DOI 10.1029/JA087iA08p06045; NORTHROP TG, 1987, ICARUS, V70, P124, DOI 10.1016/0019-1035(87)90079-0; PILCHER CB, 1970, SCIENCE, V167, P1372, DOI 10.1126/science.167.3923.1372; POSPIESZALSKA MK, 1991, ICARUS, V93, P45, DOI 10.1016/0019-1035(91)90162-M; RICHARDSON JD, 1986, J GEOPHYS RES, V91, P8749, DOI 10.1029/JA091iA08p08749; RICHARDSON JD, 1992, J GEOPHYS RES-SPACE, V97, P13705, DOI 10.1029/92JA00920; ROTTMAN GJ, 1993, J GEOPHYS RES-ATMOS, V98, P10667, DOI 10.1029/93JD00462; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; SCHLEICHER DG, 1983, THESIS U MARYLAND CO; SHEMANSKY DE, 1992, J GEOPHYS RES-SPACE, V97, P4143, DOI 10.1029/91JA02805; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SHEMANSKY DE, 1995, CALIBRATING HUBBLE S, P88; Shi M, 1995, J GEOPHYS RES-PLANET, V100, P26387, DOI 10.1029/95JE03099; SMYTH WH, 1993, ICARUS, V101, P18, DOI 10.1006/icar.1993.1002; WEISER H, 1977, SCIENCE, V197, P755, DOI 10.1126/science.197.4305.755-a; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	45	36	36	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					516	518		10.1126/science.272.5261.516	http://dx.doi.org/10.1126/science.272.5261.516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614798				2022-12-24	WOS:A1996UG82600033
J	Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD				Barker, FG; Jannetta, PJ; Bissonette, DJ; Larkins, MV; Jho, HD			The long-term outcome of microvascular decompression for trigeminal neuralgia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETROGASSERIAN GLYCEROL RHIZOTOMY; PARTIAL SENSORY RHIZOTOMY; HEMIFACIAL SPASM; MANAGEMENT; EXPERIENCE; INJECTION; GANGLION	Background. Several surgical procedures to treat trigeminal neuralgia (tic douloureux) are available, but most reports provide only short-term follow-up information. Methods. We describe the long-term results of surgery in 1185 patients who underwent microvascular decompression of the trigeminal nerve for medically intractable trigeminal neuralgia, The outcome of the procedure was assessed prospectively with annual questionnaires. Results. Of the 1185 patients who underwent microvascular decompression during the 20-year study period, 1155 were followed for 1 year or more after the operation, The median follow-up period was 6.2 years, Most postoperative recurrences of tic took place in the first two years after surgery, Thirty percent of the patients had recurrences of tie during the study period, and 11 percent underwent second operations for the recurrences. Ten years after surgery, 70 percent of the patients (as determined by Kaplan-Meier analysis) had excellent final results - that is, they were free of pain without medication for tie. An additional 4 percent had occasional pain that did not require long-term medication, Ten years after the procedure, the annual rate of the recurrence of tic was less than 1 percent, Female sex, symptoms lasting more than eight years, venous compression of the trigeminal-root entry zone, and the lack of immediate postoperative cessation of tic were significant predictors of eventual recurrence, Having undergone a previous ablative procedure did not lessen a patient's likelihood of having a cessation of tic after microvascular decompression, but the rates of burning and aching facial pain, as reported on the last follow-up questionnaire, were higher if a trigeminal-ganglion lesion had been created with radiofrequency current before microvascular decompression. Major complications included two deaths shortly after the operation (0.2 percent) and one brain-stem infarction (0.1 percent), Sixteen patients (1 percent) had ipsilateral hearing loss. Conclusions. Microvascular decompression is a safe and effective treatment for trigeminal neuralgia, with a high rate of long-term success. (C) 1996, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, NEUROL SERV, BOSTON, MA 02114 USA; UNIV PITTSBURGH, DEPT NEUROL SURG, PITTSBURGH, PA 15260 USA; SW OHIO NEUROSURG, PIQUA, OH USA	Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Apfelbaum R I, 1983, Clin Neurosurg, V31, P351; BARBA D, 1984, J NEUROSURG, V60, P104, DOI 10.3171/jns.1984.60.1.0104; BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201; BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359; BERGENHEIM AT, 1991, ACTA NEUROCHIR, V111, P114, DOI 10.1007/BF01400498; BRISMAN R, 1987, J NEUROSURG, V67, P44, DOI 10.3171/jns.1987.67.1.0044; BROGGI G, 1990, NEUROSURGERY, V26, P783, DOI 10.1227/00006123-199005000-00008; BURCHIEL KJ, 1988, J NEUROSURG, V69, P35, DOI 10.3171/jns.1988.69.1.0035; BURCHIEL KJ, 1988, J NEUROSURG, V69, P361, DOI 10.3171/jns.1988.69.3.0361; CUTBUSH K, 1964, AUST N Z J SURG, V64, P173; FUJIMAKI T, 1990, J NEUROSURG, V73, P212, DOI 10.3171/jns.1990.73.2.0212; GEHAN EA, 1969, J CHRON DIS, V21, P629, DOI 10.1016/0021-9681(69)90035-6; HAKANSON S, 1981, NEUROSURGERY, V9, P638, DOI 10.1227/00006123-198112000-00005; HAMLYN PJ, 1992, J NEUROSURG, V76, P948, DOI 10.3171/jns.1992.76.6.0948; Jannetta P J, 1979, Clin Neurosurg, V26, P607; JANNETTA PJ, 1977, NEUROCHIRURGIA, V20, P145; JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159; Jannetta PJ, 1990, TRIGEMINAL NEURALGIA, P201; KATUSIC S, 1990, ANN NEUROL, V27, P89, DOI 10.1002/ana.410270114; KLUN B, 1992, NEUROSURGERY, V30, P49, DOI 10.1227/00006123-199201000-00009; KOLLURI S, 1984, SURG NEUROL, V22, P235, DOI 10.1016/0090-3019(84)90005-3; Lee E.T., 1992, STATISTICAL METHODS; LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001; MENDOZA N, 1995, BRIT J NEUROSURG, V9, P13, DOI 10.1080/02688699550041692; MULLAN S, 1983, J NEUROSURG, V59, P1007, DOI 10.3171/jns.1983.59.6.1007; *NAT CTR HLTH STAT, 1989, VIT STAT US, V2; PIATT JH, 1984, NEUROSURGERY, V14, P462, DOI 10.1227/00006123-198404000-00012; POLLACK IF, 1988, J NEUROSURG, V68, P559, DOI 10.3171/jns.1988.68.4.0559; PUCA A, 1993, ACTA NEUROCHIR, P165; SLETTEBO H, 1993, ACTA NEUROCHIR, V122, P231, DOI 10.1007/BF01405534; SUN T, 1994, ACTA NEUROCHIR, V126, P144, DOI 10.1007/BF01476425; SWEET WH, 1974, J NEUROSURG, V40, P143, DOI 10.3171/jns.1974.40.2.0143; Sweet WH, 1993, BRAIN SURG COMPLICAT, V2, P2053; SZAPIRO J, 1985, NEUROSURGERY, V17, P920, DOI 10.1227/00006123-198512000-00009; TAARNHOJ P, 1952, J NEUROSURG, V9, P288, DOI 10.3171/jns.1952.9.3.0288; TAHA JM, 1995, J NEUROSURG, V83, P989, DOI 10.3171/jns.1995.83.6.0989; TAYLOR JC, 1981, POSTGRAD MED J, V57, P16, DOI 10.1136/pgmj.57.663.16; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; ZAKRZEWSKA JM, 1993, ACTA NEUROCHIR, V122, P225, DOI 10.1007/BF01405533	39	913	970	3	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	1996	334	17					1077	1083		10.1056/NEJM199604253341701	http://dx.doi.org/10.1056/NEJM199604253341701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG457	8598865				2022-12-24	WOS:A1996UG45700001
J	Gong, SC; Nussenzweig, MC				Gong, SC; Nussenzweig, MC			Regulation of an early developmental checkpoint in the B cell pathway by Ig beta	SCIENCE			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; ANTIGEN RECEPTOR; ALLELIC EXCLUSION; TRANSGENIC MICE; LYMPHOCYTES-B; BONE-MARROW; LIGHT-CHAIN; PRE-B; HEAVY; MU	Many of the cell fate decisions in precursor B cells and more mature B cells are controlled by membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta signal transducers. The role of Ig beta in regulating early B cell development was examined in mice that lack Ig beta (Ig beta(-/-)). These mice had a complete block in B cell development at the immature CD43(+)B220(+) stage. Immunoglobulin heavy chain diversity (D-H) and joining (J(H)) segments rearranged, but variable (V-H) to DJ(H) recombination and Immunoglobulin messenger RNA expression were compromised. These experiments define an unexpected, early requirement for Ig beta to produce B cells that can complete VDJ(H) recombination.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019					ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; LOFFERT D, 1994, IMMUNOL REV, V137, P135, DOI 10.1111/j.1600-065X.1994.tb00662.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PAPAVASILIOU F, 1995, J EXP MED, V182, P1389, DOI 10.1084/jem.182.5.1389; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	47	232	236	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					411	414		10.1126/science.272.5260.411	http://dx.doi.org/10.1126/science.272.5260.411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602530				2022-12-24	WOS:A1996UG25200047
J	Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA				Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA			The 1.85 angstrom structure of vaccinia protein VP39: A bifunctional enzyme that participates in the modification of both mRNA ends	CELL			English	Article							TRANSFER RNA-SYNTHETASE; VIRUS POLY(A) POLYMERASE; HNRNP-C-PROTEINS; CRYSTAL-STRUCTURE; BINDING DOMAIN; CATALYTIC SUBUNIT; RESOLUTION; POLYADENYLATION; PURIFICATION; PROGRAM	VP39 is a bifunctional vaccinia virus protein that acts as both an mRNA cap-specific RNA 2'-O-methyltransferase and a poly(A) polymerase processivity factor. Here, we report the 1.85 Angstrom crystal structure of a VP39 variant complexed with its AdoMet cofactor. VP39 comprises a single core domain with structural similarity to the catalytic domains of other methyltransferases. Surface features and mutagenesis data suggest two possible RNA-binding sites with novel underlying architecture, one of which forms a cleft spanning the region adjacent to the methyltransferase active site. This report provides a prototypic structure for an RNA methyltransferase, a protein that interacts with the mRNA 5' cap, and an intact poxvirus protein.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System	Hodel, AE (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [1 RO1 GM51953-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, 1992, XPLOR VERSION 3 1; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; FUREY W, 1990, AM CRYST ASS M SUMM; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LEIJONMARCK M, 1980, NATURE, V286, P824, DOI 10.1038/286824a0; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHI X, 1996, RNA, V2, P80; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; WU JC, 1987, J BIOL CHEM, V262, P4778	54	144	146	3	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					247	256		10.1016/S0092-8674(00)81101-0	http://dx.doi.org/10.1016/S0092-8674(00)81101-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612277	Bronze			2022-12-24	WOS:A1996UG25500013
J	Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD				Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD			Positional cloning of the Warner's syndrome gene	SCIENCE			English	Article							VARIEGATED TRANSLOCATION MOSAICISM; WERNERS SYNDROME; XERODERMA-PIGMENTOSUM; FIBROBLAST-CULTURES; PUTATIVE HELICASES; DNA HELICASE; REPAIR; RECOMBINATION; CHROMOSOME-8; LYMPHOCYTES	Werner's syndrome (WS) is an inherited disease with clinical symptoms resembling premature aging. Early susceptibility to a number of major age-related diseases is a key feature of this disorder. The gene responsible for WS (known as WRN) was identified by positional cloning. The predicted protein is 1432 amino acids in length and shows significant similarity to DNA helicases. Four mutations in WS patients were identified. Two of the mutations are splice-junction mutations, with the predicted result being the exclusion of exons from the final messenger RNA. One of these mutations, which results in a frameshift and a predicted truncated protein, was found in the homozygous state in 60 percent of Japanese WS patients examined. The other two mutations are nonsense mutations. The identification of a mutated putative helicase as the gene product of the WS gene suggests that defective DNA metabolism is involved in the complex process of aging in WS patients.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT NEUROL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DIV MED GENET, DEPT MED, SEATTLE, WA 98195 USA; DARWIN MOLEC CORP, BOTHELL, WA 98021 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA; DAMASCUS CITY HOSP, ENDOCRINOL SECT, DAMASCUS, SYRIA; OSAKA UNIV, SCH MED, DEPT GERIATR MED, SUITA, OSAKA 565, JAPAN	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University; Osaka University			Hisama, Fuki M./I-7323-2019	Hisama, Fuki M./0000-0001-7772-7855	NATIONAL INSTITUTE ON AGING [R01AG012019, P01AG001751, T32AG000057] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG01751, T32 AG00057, R01 AG12019] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHANG M, 1994, AM J PATHOL, V144, P1; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUKUCHI K, 1985, SOMAT CELL MOLEC GEN, V11, P303, DOI 10.1007/BF01534688; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GODDARD KAB, IN PRESS AM J HUM GE; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1978, J AM GERIATR SOC, V26, P341, DOI 10.1111/j.1532-5415.1978.tb03681.x; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GOTO M, 1981, CLIN GENET, V19, P8; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIHARA K, 1994, JPN J HUM GENET, V39, P403, DOI 10.1007/BF01892385; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; MULLIGAN J, UNPUB; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; NAKURA J, 1994, GENOMICS, V23, P600, DOI 10.1006/geno.1994.1548; NAKURA J, 1993, GERONTOLOGY, V39, P11; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; SCHULZ VP, IN PRESS HUM GENET; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; TOLLEFSBOL TO, 1984, AGE, V7, P75, DOI 10.1007/BF02432205; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINSTON W, 1993, GENOMICS, V16, P685; YE L, 1995, GENOMICS, V28, P566, DOI 10.1006/geno.1995.1189; YU CE, 1994, AM J HUM GENET, V55, P356; YU CH, UNPUB	58	1388	1441	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					258	262		10.1126/science.272.5259.258	http://dx.doi.org/10.1126/science.272.5259.258			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602509				2022-12-24	WOS:A1996UE72900039
J	Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E				Stone, PH; Thompson, B; Anderson, V; Kronenberg, MW; Gibson, RS; Rogers, WJ; Diver, DJ; Theroux, P; Warnica, JW; Nasmith, JB; Kells, C; Kleiman, N; McCabe, CH; Schactman, M; Knatterud, GL; Braunwald, E			Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction - The TIMI III Registry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BYPASS-SURGERY; HEART-DISEASE; INTERVENTION-REGISTRY; ADVERSE PROGNOSIS; MORTALITY-RATES; WOMEN; GENDER; PATTERNS; BLACK	Objective.-To investigate the natural history and response to treatment of patients with unstable angina or non-Q-wave myocardial infarction (MI). Design.-Inception cohort. Setting.-Patients in general community, primary care, or referral hospitals. Patients.-All patients with an episode of unstable exertional chest pain or chest pain at rest presumed to be ischemic in origin lasting 5 minutes or more but without persisting ST-segment elevation greater than 30 minutes or the development of Q-waves were identified and enumerated in 18 participating hospitals. A subset of enumerated patients was selected to be followed prospectively using specific sampling strategies that would provide adequate numbers of black, women, and elderly (aged greater than or equal to 75 years) patients for comparison with their respective counterparts. Main Outcome Measures.-The primary analysis compared the incidence of death or MI at 42 days after entry into the prospective study according to race, sex, and age. Other outcomes considered were recurrent ischemia and the combined outcomes of death, MI, or recurrent ischemia by 42 days after entry. Results.-A total of 8676 admissions with unstable angina or non-Q-wave MI were enumerated and, of these, 3318 patients were selected for the prospective study. The direct adjusted mean age of the 3318 patients was 63.8 years. There were 943 blacks and 2375 nonblacks. Compared with nonblacks, blacks were less likely to be treated with intensive anti-ischemic therapy for their qualifying anginal episode and less likely to undergo invasive procedures (risk ratio [RR], 0.65; 95% confidence interval [CI], 0.58 to 0.72; P<.001). However, of those who underwent angiography (45% of blacks and 61% of nonblacks), blacks had less extensive and severe coronary stenoses than nonblacks. The incidence of death and MI was similar for blacks and nonblacks, but blacks had a lower incidence of recurrent ischemia. There were 1678 men and 1640 women. Women were less likely than men to receive intensive anti-ischemic therapy and less likely to undergo coronary angiography (RR, 0.71; 95% CI, 0.65 to 0.78; P<.001). Women had less severe and extensive coronary disease and were less likely to undergo revascularization, yet had a similar risk of experiencing an adverse cardiac event by 6 weeks. There were 2490 patients aged 75 years or less and 828 patients aged more than 75 years. Elderly patients received less aggressive anti-ischemic therapy and were less likely to undergo coronary angiography than their younger counterparts. Elderly patients had more severe and extensive coronary disease but fewer revascularization procedures than younger patients and experienced a much higher incidence of adverse cardiac events both in hospital and by 6 weeks. Conclusions.-Among patients presenting with acute ischemic chest pain without persistent ST-segment elevation, blacks appeared to have less severe coronary disease, received revascularization less frequently, and had less recurrent ischemia compared with nonblacks. Women also were found to have less severe coronary disease and were treated less intensely than men, but experienced similar outcomes. Elderly patients had more severe coronary disease than younger patients on coronary angiography, but were more likely to be treated medically, and they experienced far more adverse outcomes. These data suggest that more aggressive strategies should be directed to those patients with the greatest likelihood of adverse outcomes.	MARYLAND MED RES INST, TIMI III REGISTRY DATA COORDINATING CTR, BALTIMORE, MD 21210 USA; BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, TIMI III REGISTRY STUDY CHAIRMANS OFF, BOSTON, MA 02115 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; HARVARD UNIV, BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HOP SACRE COEUR, DEPT MED, MONTREAL, PQ H4J 1C5, CANADA; INST CARDIOL, DEPT MED, MONTREAL, PQ, CANADA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV CALGARY, FOOTHILLS PROV GEN HOSP, DEPT MED, CALGARY, AB, CANADA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, HOUSTON, TX USA; UNIV TEXAS, MED BRANCH, DEPT MED, GALVESTON, TX 77550 USA; UNIV VIRGINIA, DEPT MED, CHARLOTTESVILLE, VA USA; VICTORIA GEN HOSP, DEPT MED, HALIFAX, NS B3H 2Y9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Baylor College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; Universite de Montreal; Universite de Montreal; Institut de Cardiologie de Montreal; University of Alabama System; University of Alabama Birmingham; University of Calgary; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Medical Branch Galveston; University of Virginia; Dalhousie University; University of Victoria					NHLBI NIH HHS [R01-HL-42428, R01-HL-42311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042311, R01HL042428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY MJ, 1985, CIRCULATION, V71, P90; DIVER DJ, 1994, AM J CARDIOL, V74, P531, DOI 10.1016/0002-9149(94)90739-0; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GRAYBILL FA, 1976, THEORY APPLICATION L; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; JECKER NS, 1991, JAMA-J AM MED ASSOC, V266, P3012, DOI 10.1001/jama.266.21.3012; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; Scheffe H., 1959, ANAL VARIANCE; SHRYOCK HS, 1975, METHODS MAT DEMOGRAP, P419; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; Snedecor GW, 1967, STATISTICAL METHODS, P199; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; TAYLOR HA, 1993, CIRCULATION, V88, P1484, DOI 10.1161/01.CIR.88.4.1484; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1988, AM J CARDIOL, V62, P860, DOI 10.1016/0002-9149(88)90882-X; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557	42	285	298	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	1996	275	14					1104	1112		10.1001/jama.275.14.1104	http://dx.doi.org/10.1001/jama.275.14.1104			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD027	8601930				2022-12-24	WOS:A1996UD02700027
J	Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM				Guerette, PA; Ginzinger, DG; Weber, BHF; Gosline, JM			Silk properties determined by gland-specific expression of a spider fibroin gene family	SCIENCE			English	Article								Spiders produce a variety of silks that range from Lycra-like elastic fibers to Kevlar-like superfibers. A gene family from the spider Araneus diadematus was found to encode silk-forming proteins (fibroins) with different proportions of amorphous glycine-rich domains and crystal domains built from poly(alanine) and poly(glycine-alanine) repeat motifs. Spiders produce silks of different composition by gland-specific expression of this gene family, which allows for a range of mechanical properties according to the crystal-forming potential of the constituent fibroins. These principles of fiber property control may be important in the development of genetically engineered structural proteins.	UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER,BC V6T 1Z4,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z4,CANADA	University of British Columbia; University of British Columbia				Weber, Bernhard H.F./0000-0002-8808-7723				ANDERSEN SO, 1970, COMP BIOCHEM PHYSIOL, V35, P705, DOI 10.1016/0010-406X(70)90988-6; BECKWITT R, 1994, J BIOL CHEM, V269, P6661; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNY M, 1980, MECHANICAL PROPERTIE, P475; FRASER RDB, 1972, CONFORMATION FIBROUS; GOSLINE J, 1995, BIOMIMETICS DESIGN P, P237; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; GOSLINE JM, 1994, MAT SCI BIOTECHNOLOG, P328; HINMAN MB, 1994, MAT SCI BIOTECHNOLOG, P222; JACKSON C, 1995, MACROMOLECULES, V28, P5975, DOI 10.1021/ma00121a042; KERKAM K, 1991, NATURE, V349, P596, DOI 10.1038/349596a0; LEWIS RV, 1992, ACCOUNTS CHEM RES, V25, P392, DOI 10.1021/ar00021a002; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70	16	343	387	2	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					112	115		10.1126/science.272.5258.112	http://dx.doi.org/10.1126/science.272.5258.112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600519				2022-12-24	WOS:A1996UD59700051
J	Sieweke, MH; Tekotte, H; Frampton, J; Graf, T				Sieweke, MH; Tekotte, H; Frampton, J; Graf, T			MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation	CELL			English	Article							TRANSCRIPTION FACTOR NF-E2; TRANSFERRIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; V-ETS; SACCHAROMYCES-CEREVISIAE; ERYTHROLEUKEMIC CELLS; ESCHERICHIA-COLI; TS MUTANTS; C-JUN; EXPRESSION	Using a yeast one-hybrid screen with a DNA-bound Ets-1 protein, we have identified MafB, an AP-1 like protein, as a direct interaction partner. MafB is specifically expressed in myelomonocytic cells and binds to the DNA-binding domain of Ets-1 via its basic region or leucine-zipper domain. Furthermore, it represses Ets-1 transactivation of synthetic promoters containing Ets binding sites and inhibits Ets-1-mediated transactivation of the transferrin receptor, which is known to be essential for erythroid differentiation, Accordingly, overexpression of MafB in an erythroblast cell line down-regulates the endogenous transferrin receptor gene and inhibits differentiation without affecting cell proliferation. These results highlight the importance of inhibitory interactions between transcription factors in regulating lineage-specific gene expression.			Sieweke, MH (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTRASSEL 69117, HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015; Sieweke, Michael/AAR-7515-2020	Graf, Thomas/0000-0003-2774-4117; Sieweke, Michael/0000-0002-3228-9537; Tekotte, Hille/0000-0003-2164-7412				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAN LNL, 1989, NUCLEIC ACIDS RES, V17, P3763, DOI 10.1093/nar/17.10.3763; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Harlow E, 1988, ANTIBODIES LAB MANUA; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORTON MA, 1983, EXP CELL RES, V144, P361, DOI 10.1016/0014-4827(83)90415-9; HU HYY, 1977, SCIENCE, V197, P559, DOI 10.1126/science.267327; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; IOTH K, 1995, MOL CELL BIOL, V15, P4184; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KILLISCH I, 1992, J CELL SCI, V103, P211; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NERLOV C, 1991, ONCOGENE, V6, P1583; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OMARY MB, 1980, NATURE, V286, P888, DOI 10.1038/286888a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; QUEVA C, 1993, ONCOGENE, V8, P2511; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1993, ONCOGENE, V8, P1783; SIEFF C, 1982, BLOOD, V60, P703; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	79	245	252	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					49	60		10.1016/S0092-8674(00)81081-8	http://dx.doi.org/10.1016/S0092-8674(00)81081-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620536	Bronze			2022-12-24	WOS:A1996UE55900008
J	Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW				Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW			Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ES CELLS; ANGIOGENESIS; DIFFERENTIATION; EXPRESSION; RECEPTOR; VASCULOGENESIS; DISRUPTION; SUGGESTS; ONCOGENE	ANGIOGENESIS is required for a wide variety of physiological and pathological processes(1). The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF)(2,3) is a major mediator of pathological angiogenesis(4-6). Also, the expression of VEGF and its two receptors, Flt-1 and Flk-1/KDR, is related to the formation of blood vessels in mouse and rat embryos(7-10). Mice homozygous for mutations that inactivate either receptor die in utero between days 8.5 and 9.5 (refs 11,12). However, ligand(s) other than VEGF might activate such receptors(13,14). To assess the role of VEGF directly, we disrupted the VEGF gene in embryonic stem cells. Here we report the unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12. Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	Roche Holding; Genentech; Roche Holding; Genentech; University of Michigan System; University of Michigan	Ferrara, N (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,4600 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BREIER G, 1992, DEVELOPMENT, V114, P521; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HILBERG F, 1992, ONCOGENE, V7, P2371; Hogan B, 1994, MANIPULATING MOUSE E; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LU LH, 1994, CELL VISION, V1, P169; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBRIDE WG, 1961, LANCET, V2, P1358; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Pugh RCB, 1976, PATHOLOGY TESTIS; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; THEILER K, 1989, HOUSE MOUSE; Tisher E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640	30	2792	2929	5	89	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					439	442		10.1038/380439a0	http://dx.doi.org/10.1038/380439a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602242	Green Submitted			2022-12-24	WOS:A1996UD59000062
J	Moore, RD; Chaisson, RE				Moore, RD; Chaisson, RE			Natural history of opportunistic disease in an HIV-infected urban clinical cohort	ANNALS OF INTERNAL MEDICINE			English	Article						AIDS-related opportunistic infections; human immunodeficiency virus infection; urban health services; pneumonia, Pneumocystis carinii; acquired immunodeficiency syndrome	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; SAN-FRANCISCO; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; CONTROLLED TRIAL; UNITED-STATES; AIDS; PROPHYLAXIS	Objective: To determine the effect of contemporary clinical care on the natural history of opportunistic disease in an urban population infected with the human immunodeficiency virus (HIV). Setting: Urban university HIV clinic. Design: Retrospective and prospective observational study. Patients: 1246 HIV-infected patients with CD4(+) counts of 300 cells/mm(3) or less. Measurements: Incidence rates and Kaplan-Meier estimates of the probability of developing opportunistic disease with time, distribution of the CD4(+) counts at which opportunistic disease develops, survival after the development of opportunistic disease, and the association between preventive drug therapies and the occurrence of opportunistic infection. Results: The most common opportunistic disease was Candida esophagitis, which had an incidence of 13.3 events per 100 person-years and a 3-year Kaplan-Meier probability of 0.30. Pneumocystis carinii pneumonia, Mycobacterium avium complex bacteremia, cytomegalovirus, and the acquired immunodeficiency syndrome dementia complex occurred at rates of 5 to 9 events per 100 person-years and 3-year Kaplan-Meier probabilities of 0.15 to 0.22. Toxoplasmosis, cryptococcal meningitis, herpes zoster, the wasting syndrome, and Kaposi sarcoma occurred at rates of about 2 to 4 events per 100 person-years and with 3-year Kaplan-Meier probabilities of 0.05 to 0.10. Non-Hodgkin lymphoma, M. tuberculosis infection, progressive multifocal leukoencephalopathy, and cryptosporidiosis were the least common disorders, with an incidence of about 1 to 2 events per 100 person-years and a 3-year Kaplan-Meier probability less than 0.05. Only the incidences of cryptococcal meningitis, secondary P. carinii pneumonia, and herpes tester decreased (P < 0.05) between 1989-1992 and 1993-1995. Fluconazole use was associated with a decreased relative rate of 0.49 (P = 0.06) for cryptococcal meningitis and a decreased relative rate of 0.61 (P = 0.005) for esophageal candidiasis. Rifabutin use was associated with a decreased relative rate of 0.37 (P = 0.002) for M. avium complex bacteremia, and trimethoprim-sulfamethoxazole use was associated with decreased relative rates of 0.33 (P = 0.02) for secondary P. carinii pneumonia and 0.55 (P = 0.08) for primary P. carinii pneumonia. Candidiasis, herpes tester, and M. tuberculosis infection first occurred at a median CD4(+) count greater than 100 cells/mm(3), but all other opportunistic diseases first occurred at a median CD4(+) count less than 50 cells/mm(3). Median survival after diagnosis varied from 35 days for non-Hodgkin lymphoma to 680 days for herpes zoster. Conclusions: In the patients studied, the-incidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes tester have declined in the past 5 years. The incidences of primary P. carinii pneumonia and Kaposi sarcoma appear to be declining compared with historical estimates. However, although these and other opportunistic diseases continue to be relatively frequent complications of HIV infection, they are first occurring at more advanced immunosuppression than in the past. Continued efforts are needed to develop effective strategies for preventing opportunistic disease in very advanced HIV infection.			Moore, RD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, 1830 E MONUMENT ST, ROOM 8059, BALTIMORE, MD 21205 USA.				AHRQ HHS [R01 HS07809] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARTLETT JG, 1994, MED MANAGEMENT HIV I; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P507; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GILLESPIE SM, 1991, ANN NEUROL, V30, P597, DOI 10.1002/ana.410300413; GLESBY MJ, 1995, CLIN INFECT DIS, V21, P370, DOI 10.1093/clinids/21.2.370; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOLMBERG SD, 1995, AM J EPIDEMIOL, V141, P395, DOI 10.1093/oxfordjournals.aje.a117441; JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P336; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1992, AIDS, V6, P671, DOI 10.1097/00002030-199207000-00009; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELIK RM, 1984, AM J MED, V76, P493, DOI 10.1016/0002-9343(84)90669-7; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SPECTOR SA, 1995, 2 NAT C HUM RETR WAS; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, NEW ENGL J MED, V44, P81	50	229	239	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					633	+		10.7326/0003-4819-124-7-199604010-00003	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607591				2022-12-24	WOS:A1996UB51300003
J	Mason, JK; Mulligan, D				Mason, JK; Mulligan, D			Euthanasia by stages	LANCET			English	Article									VOLUNTARY EUTHANASIA SOC SCOTLAND,EDINBURGH,MIDLOTHIAN,SCOTLAND		Mason, JK (corresponding author), UNIV EDINBURGH,FAC LAW,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; CRANFORD RE, 1995, BRIT MED J, V311, P464, DOI 10.1136/bmj.311.7003.464; HARRIGAN P, 1995, LANCET, V346, P494, DOI 10.1016/S0140-6736(95)91332-7; *HM STAT OFF, 1994, GOV RESP REP SEL COM; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; WALL M, 1995, LANCET, V346, P368, DOI 10.1016/S0140-6736(95)92243-1; 1995, LANCET, V346, P259; [No title captured]	9	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					810	811		10.1016/S0140-6736(96)90875-2	http://dx.doi.org/10.1016/S0140-6736(96)90875-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622341				2022-12-24	WOS:A1996UB15300016
J	Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, SS; Dallmann, HG; McHenry, CS; Marians, KJ			Coupling of a replicative polymerase and helicase: A tau-DnaB interaction mediates rapid replication fork movement	CELL			English	Article							COORDINATED LEADING-STRAND; ESCHERICHIA-COLI; III HOLOENZYME; PROTEIN; PURIFICATION; IDENTIFICATION; MECHANISM; SUBUNITS; TEMPLATE; SIZE	The E. coli replication fork synthesizes DNA at the rate of nearly 1000 nt/s. We show here that an interaction between the tau subunit of the replicative polymerase (the DNA polymerase III holoenzyme) and the replication fork DNA helicase (DnaB) is required to mediate this high rate of replication fork movement. In the absence of this interaction, the polymerase follows behind the helicase at a rate equal to the slow (similar to 35 nt/s) unwinding rate of the helicase alone, whereas upon establishing a tau-DnaB contact, DnaB becomes a more effective helicase, increasing its translocation rate by more than 10-fold. This finding establishes the existence of both a physical and communications link between the two major replication machines in the replisome: the DNA polymerase and the primosome.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOL BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, SS (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557, R01GM036255] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, GM36255] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; Kim S, 1996, J BIOL CHEM, V271, P4315; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; REEMS JA, 1995, J BIOL CHEM, V270, P5606, DOI 10.1074/jbc.270.10.5606; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOUGU K, 1994, J BIOL CHEM, V269, P4675; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	35	294	295	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 23	1996	84	4					643	650		10.1016/S0092-8674(00)81039-9	http://dx.doi.org/10.1016/S0092-8674(00)81039-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TX176	8598050	hybrid			2022-12-24	WOS:A1996TX17600016
J	Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM				Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM			Disease in children infected with HIV in Abidjan, Cote d'Ivoire	BRITISH MEDICAL JOURNAL			English	Article							VIRUS; DIAGNOSIS; MORTALITY; UTILITY; INFANTS	Objective-To document the range of disease in African children infected with HIV. Design-Necropsy results in consecutive children aged 1 month or more who were HIV positive and in children who were HIV negative for comparison; IgA western blots on serum samples from children under 2 years of age who were positive for HIV-1 to test the validity of routine HIV serology. Setting-Largest hospital in Abidjan, Cote d'Ivoire. Subjects-78 children who were HIV positive and 77 children who were HIV negative on whom a necropsy was performed; their median ages at death were 18 and 21 months respectively. 36 HIV positive children and 29 HIV negative children mere 1-14 months old; 42 HIV positive and 48 HIV negative children were greater than or equal to 15 months old. Main outcome measures-Cause of death and prevalence of diseases confirmed pathologically. Results-Respiratory tract infections were more common in HIV positive than in HIV negative children (73 (94%) v 52 (68%); P<0.05), and were aetiologically heterogeneous. Pneumocystis carinii pneumonia was found in 11 out of 36 (31%) HIV positive children aged <15 months, but in no HIV negative children. Among older children measles was more common in HIV positive children (8/42 (19%) v 2/48 (4%); P < 0.06). Pyogenic meningitis was present in similar proportions of HIV positive and HIV negative children aged < 15 months (7/36 (19%) and 7/29 (24%)). In HIV positive children tuberculosis (1/78), lymphocytic interstitial pneumonitis (1/78), and HIV encephalitis (2/78) were rare. Conclusions-There is greater overlap between diseases associated with HIV infection and other common health problems in African children than there is in adults. Compared with adults, HIV positive children had a high prevalence of P carinii pneumonia and a low prevalence of tuberculosis. Measles, but not malaria, was associated with HIV infection.	UNIV LONDON UNIV COLL,LONDON MED SCH,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP,ABIDJAN,COTE IVOIRE; UNIV EDINBURGH,SCH MED,DEPT PATHOL,DEPT NEUROPATHOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of London; University College London; University of Edinburgh			Peacock, Christopher/A-4052-2012					BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Chin J, 1991, AIDS, V5 Suppl 2, pS57, DOI 10.1097/00002030-199101001-00009; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DOWELL SF, 1993, AIDS, V7, P1255, DOI 10.1097/00002030-199309000-00016; EMBREE JE, 1992, J INFECT DIS, V165, P262, DOI 10.1093/infdis/165.2.262; GIBB D, 1994, AIDS S1, V8, pS275; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Kozlowski PB, 1995, PEDIAT NEUROPATHOLOG, P435; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LEPAGE P, 1991, AIDS, V5, pS117; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MGONE CS, 1991, J ACQ IMMUN DEF SYND, V4, P910; MIOTTI PG, 1992, INT J EPIDEMIOL, V21, P792; MULLER O, 1990, J TROP PEDIATRICS, V36, P283, DOI 10.1093/tropej/36.6.283; Nelson A M, 1992, Prog AIDS Pathol, V3, P1; NICOLL A, 1994, AIDS, V8, P995, DOI 10.1097/00002030-199407000-00019; PAN LX, 1993, J PATHOL, V170, P137, DOI 10.1002/path.1711700207; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; SCHULZ DM, 1962, ARCH PATHOL, V74, P244; SENSION MG, 1988, AM J DIS CHILD, V142, P1271, DOI 10.1001/archpedi.1988.02150120025021; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WILLIAMS A. O., 1970, Ghana Medical Journal, V9, P23; 1987, MMWR-MORBID MORTAL W, V36, P1	25	140	140	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					335	338						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611829	Green Published			2022-12-24	WOS:A1996TV69800020
J	Plouffe, JF; Breiman, RF; Facklam, RR				Plouffe, JF; Breiman, RF; Facklam, RR			Bacteremia with Streptococcus pneumoniae - Implications for therapy and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL BACTEREMIA; INFECTIONS; RESISTANCE; COUNTY	Objective.-To determine the incidence and mortality rates of patients with bacteremic infections with Streptococcus pneumoniae, and to determine the serotypes and antimicrobial susceptibilities of the pneumococcal isolates. Design.-Prospective case ascertainment and procurement of S pneumoniae isolates between January 1991 and April 1994, Setting.-Ten adult care hospitals in Franklin County, Ohio. Patients.-Patients (N=590) in whom S pneumoniae was isolated from blood cultures. Measurements.-Demographic data from patients with pneumococcal bacteremia were obtained by chart review. Pneumococcal serotyping and antimicrobial susceptibility testing were performed on 499 bacteremic isolates. Results.-Among residents of Franklin County, the annual incidence of pneumococcal bacteremia was higher in patients at least 65 years old (83.0 per 100 000 population) compared with younger adults (9.6 per 100 000 population) (odds ratio [OR], 8.74; 95% confidence interval [CI], 7.19 to 10.62) and more common among African Americans than whites (OR, 1.36; 954;, CI, 1.05 to 1.75), The relative risk of pneumococcal bacteremia among persons infected with the human immunodeficiency virus was 41.8 times (CI, 19.0 to 92.0) that of county residents 18 to 64 years of age. The overall mortality rate was 19% and was age-dependent, reaching 38% in patients at least 85 years old, The distribution of pneumococcal serotypes causing bacteremia was remarkably consistent over time. The incidence of drug-resistant strains increased during the study period; by 1994 14% were resistant to penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole. The resistant strains included several serotypes of S pneumoniae. Most serotypes (89.8%) of S pneumoniae causing bacteremia are contained in the pneumococcal vaccine. Conclusions.-Increased use of pneumococcal vaccine and recognition of antimicrobial resistance patterns may assist physicians in treating patients with S pneumoniae bacteremia. Educational programs to discourage unnecessary antimicrobial drug use should be developed for patients and physicians.	CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	Plouffe, JF (corresponding author), OHIO STATE UNIV,MED CTR,DEPT INTERNAL MED,N-1135 DOAN HALL,COLUMBUS,OH 43210, USA.							APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; DOUGLAS RM, 1975, MED J AUSTRALIA, V1, P82, DOI 10.5694/j.1326-5377.1975.tb111243.x; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; MARSTON BJ, 1993, LEGIONELLA, P36; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; PLOUFFE JF, 1994, 94TH GEN M AM SOC MI; SCHAPPERT SM, 1992, ADV DATA US DEP HLTH, V214; WOODHEAD MA, 1987, LANCET, V1, P671; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1994, M7A3 NAT COMM LAB ST; 1989, MMWR-MORBID MORTAL W, V38, P64; 1993, MMWR-MORBID MORTAL W, V44, P33; 1984, MMWR-MORBID MORTAL W, V33, P281; 1987, Q J MED, V62, P195; 1995, MMWR-MORBID MORTAL W, V44, P24; 1994, MMWR-MORBID MORTAL W, V43, P23; 1984, MMWR-MORBID MORTAL W, V33, P273; 1993, AM REV RESPIR DIS, V148, P1418; 1994, MMWR-MORBID MORTAL W, V43, P223	35	244	249	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					194	198		10.1001/jama.275.3.194	http://dx.doi.org/10.1001/jama.275.3.194			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604171				2022-12-24	WOS:A1996TP28200026
J	Bayer, R				Bayer, R			AIDS prevention - Sexual ethics and responsibility	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIV; INFECTION; PARTNERS				Bayer, R (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10032, USA.				NIMH NIH HHS [K05 MH01376-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001376] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; BAYER R, 1993, AM J PUBLIC HEALTH, V83, P1471, DOI 10.2105/AJPH.83.10.1471; CHAMBERS DL, 1994, HARVARD CIVIL RIGHTS, V29, P353; COCHRAN SD, 1990, NEW ENGL J MED, V322, P774, DOI 10.1056/NEJM199003153221111; EKSTRAND M, 1993, AIDS, V7, P281, DOI 10.1097/00002030-199302000-00020; ILLINGWORTH P, 1990, AIDS GOOD SOC; KEGELES SM, 1988, JAMA-J AM MED ASSOC, V259, P216, DOI 10.1001/jama.259.2.216; MARKS G, 1992, PUBLIC HEALTH REP, V107, P100; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; MASS L, 1995, NATION          0417, P540; MOHR RD, 1986, RARITAN, V6, P38; PERRY SW, 1994, AIDS EDUC PREV, V6, P403; PILKINGTON CJ, 1994, J SEX RES, V31, P203, DOI 10.1080/00224499409551753; ROTELLO G, 1995, NATION          0417, P510; SIGNORILE M, 1995, NY TIMES        0226, V4, P15; SIMONI JM, 1995, J CONSULT CLIN PSYCH, V63, P474, DOI 10.1037/0022-006X.63.3.474; SOBO EJ, 1995, CHOOSING UNSAFE SEX; WILLIG C, 1995, J COMMUNITY APPL PSY, V4, P74; YEO M, 1991, PERSPECTIVES AIDS ET, P75	20	55	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1540	1542		10.1056/NEJM199606063342312	http://dx.doi.org/10.1056/NEJM199606063342312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN799	8618613	Green Published			2022-12-24	WOS:A1996UN79900012
J	Vega, KJ; Pina, I; Krevsky, B				Vega, KJ; Pina, I; Krevsky, B			Heart transplantation is associated with an increased risk for pancreaticobiliary disease	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL SURGICAL COMPLICATIONS; CARDIAC TRANSPLANTATION; CYCLOSPORINE THERAPY; CHOLELITHIASIS; RECIPIENTS; CHOLESTASIS; MANAGEMENT; BILE	Objective: To determine the risk factors for and the incidence, morbidity, mortality, and outcome of pancreaticobiliary disease in patients who have had orthotopic heart transplantation. Design: Retrospective case-control analysis. Setting: University hospital-based heart transplantation center. Patients: 20 case-patients with pancreaticobiliary disease and 40 controls; all patients received heart transplants between 1985 and 1994. Controls were matched to case-patients by time of transplantation and length of survival. Measurements: Charts were reviewed and data were extracted using a structured data abstraction protocol. Risk factors assessed before transplantation were cause of heart disease, history of diabetes, reproductive history, and sex. Risk factors assessed at presentation of pancreaticobiliary disease were weight change after transplantation, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent rejection episode, cyclosporine level, complete blood count, time between transplantation and onset of symptoms, body mass index, calcium level, liver function test results before and at symptom onset, and lipid profile. Results: Pancreaticobiliary disease occurred in 20 of 255 transplant recipients (7.8%). The incidence of disease in these patients within 1 year after transplantation was 3.9% compared with an expected rate of 0.2% per year (P < 0.01). A decreased serum calcium level was the only risk factor found to differ significantly between the two groups (mean +/- SD, 2.19 +/- 0.17 mmol/L in case-patients and 2.31 +/- 0.14 mmol/L in controls; P = 0.005). The duration of hospitalization for the treatment of pancreaticobiliary disease was longer for patients who received transplants than for patients who did not receive transplants and were treated at Temple University Hospital during a similar period (17.1 days compared with 7.2 days; P < 0.001). However, the outcome was excellent in most patients. Conclusions: Pancreaticobiliary disease occurs 17.4 times (95% CI, 9.2 to 32.7 times) more frequently in patients receiving transplants than in the general population. It is a seldom recognized but apparently common complication of orthotopic heart transplantation that results in substantial morbidity and health care resource use. Further study is needed to ascertain why this condition occurs and how the risk for developing it can be reduced.	TEMPLE UNIV HOSP & MED SCH, GASTROENTEROL SECT, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV HOSP & MED SCH, CARDIOL SECT, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BORTNICHAK EA, 1985, AM J EPIDEMIOL, V121, P19, DOI 10.1093/oxfordjournals.aje.a113978; BURCKART GJ, 1988, TRANSPLANT P, V20, P190; COLON R, 1988, SURGERY, V103, P32; CSENDES A, 1978, ACTA CHIR SCAND, V144, P289; DISESA VJ, 1989, ARCH SURG-CHICAGO, V124, P539; EVERHART JE, 1994, DIGESTIVE DIS US EPI, P647; GIRARDET RE, 1989, J HEART TRANSPLANT, V8, P391; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; LORBER MI, 1987, TRANSPLANT P, V19, P1808; MERRELL SW, 1989, ARCH SURG-CHICAGO, V124, P889; PARASCANDOLA SA, 1989, J HEART TRANSPLANT, V8, P400; ROTOLO FS, 1986, AM J SURG, V151, P35, DOI 10.1016/0002-9610(86)90008-5; SAPALA MA, 1979, SURG GYNECOL OBSTET, V148, P36; SCHADE RR, 1983, TRANSPLANT P, V15, P2757; SPES CH, 1990, J HEART TRANSPLANT, V9, P404; STECK TB, 1991, J HEART LUNG TRANSPL, V10, P1029; STEED DL, 1985, SURGERY, V98, P739; STONE B, 1988, TRANSPLANT P, V20, P841; *UN NETW ORG SHAR, 1995, 1994 UN NETW ORG SHA; VOGELBERG KH, 1984, DEUT MED WOCHENSCHR, V109, P1712, DOI 10.1055/s-2008-1069440	20	16	16	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					980	983		10.7326/0003-4819-124-11-199606010-00005	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624065				2022-12-24	WOS:A1996UL90500005
J	Zou, HY; Niswander, L				Zou, HY; Niswander, L			Requirement for BMP signaling in interdigital apoptosis and scale formation	SCIENCE			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; PROGRAMMED CELL-DEATH; MOUSE; MORPHOGENESIS; EXPRESSION	Interdigital cell death leads to regression of soft tissue between embryonic digits in many vertebrates. Although the signals that regulate interdigital apoptosis are not known, BMPs-signaling molecules of the transforming growth factor-beta superfamily-are expressed interdigitally. A dominant negative type I BMP receptor (dnBMPR-IB) was used here to block BMP signaling. Expression of dnBMPR in chicken embryonic hind limbs greatly reduced interdigital apoptosis and resulted in webbed feet. In addition, scales were transformed into feathers. The similarity of the webbing to webbed duck feet led to studies that indicate that BMPs are not expressed in the duck interdigit. These results indicate BMP signaling actively mediates cell death in the embryonic limb.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; Zou, Hongyan/0000-0003-4216-5607				CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DHOUAILLY D, 1980, J EMBRYOL EXP MORPH, V58, P63; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FRANCISWEST PH, 1995, DEV DYNAM, V203, P187, DOI 10.1002/aja.1002030207; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; PAULOU MP, 1975, J EMBRYOL EXP MORPH, V34, P511; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROS MA, 1994, ANAT EMBRYOL, V190, P375; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WILKINSON DG, 1993, IN SITU HYBRIDIZATIO, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZAKERI ZF, 1993, FASEB J, V7, P470, DOI 10.1096/fasebj.7.5.8462789; ZOU H, UNPUB	35	488	499	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					738	741		10.1126/science.272.5262.738	http://dx.doi.org/10.1126/science.272.5262.738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614838				2022-12-24	WOS:A1996UJ05100056
J	Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH				Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH			Central reorganization of sensory pathways following peripheral nerve regeneration in fetal monkeys	NATURE			English	Article							MACAQUE; CORTEX; MECHANISM	TRANSECTION Of a sensory nerve in adults results in profound abnormalities in sensory perception, even if the severed nerve is surgically repaired to facilitate accurate nerve regeneration, In marked contrast, fewer perceptual errors follow nerve transection and surgical repair in children(1-3), The basis for this superior recovery in children was unknown. Here rye show that there is little or no topographic order in the median nerve to the hand after median nerve section and surgical repair in immature macaque monkeys, Remarkably, however, in the same animals the representation of the reinnervated hand in primary somatosensory cortex (area 3b) is quite orderly, This indicates that there are mechanisms in the developing brain that can create cortical topography, despite disordered sensory inputs. Presumably the superior recovery of perceptual abilities after peripheral nerve transection in children depends on this restoration of somatotopy in the central sensory maps.	VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37240	Vanderbilt University	Florence, SL (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.		Jain, Neeraj/B-2882-2010	Jain, Neeraj/0000-0002-3672-5850				BUCHTHAL F, 1979, J NEUROL NEUROSUR PS, V42, P436, DOI 10.1136/jnnp.42.5.436; BUNNELL S, 1956, SURG HAND; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1991, VISION VISUAL DYSFUN, V11; DARIANSMITH C, 1990, J COMP NEUROL, V299, P47, DOI 10.1002/cne.902990104; Dellon AL, 2015, EVALUATION SENSIBILI, V4th; FITZGERALD M, 1985, J COMP NEUROL, V240, P407, DOI 10.1002/cne.902400408; FLORENCE SL, 1994, CEREB CORTEX, V4, P391, DOI 10.1093/cercor/4.4.391; HALLIN RG, 1981, EXP NEUROL, V73, P90, DOI 10.1016/0014-4886(81)90047-9; HEBB DO, 1949, ORG BEHAVIOR; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; Jain N, 1995, DEV BRAIN RES, V90, P24, DOI 10.1016/0165-3806(96)83483-3; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KILLACKEY HP, 1995, TRENDS NEUROSCI, V18, P402, DOI 10.1016/0166-2236(95)93937-S; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; SHATZ CJ, 1986, ANNU REV NEUROSCI, V9, P171, DOI 10.1146/annurev.ne.09.030186.001131; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Woolsey TA, 1990, DEV SENSORY SYSTEMS	19	75	77	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					69	71		10.1038/381069a0	http://dx.doi.org/10.1038/381069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609990				2022-12-24	WOS:A1996UJ05300057
J	Ewan, PW				Ewan, PW			Clinical study of peanut and nut allergy in 62 consecutive patients: New features and associations	BRITISH MEDICAL JOURNAL			English	Article							FOOD HYPERSENSITIVITY; NATURAL-HISTORY; ANAPHYLAXIS; PATTERNS; OIL	Objective-To investigate clinical features of acute allergic reactions to peanuts and other nuts. Design-Analysis of data from consecutive patients seen by one doctor over one year in an allergy clinic at a regional referral centre. Subjects-62 patients aged 11 months to 53 years seen between October 1993 and September 1994. Main outcome measures-Type and severity of allergic reactions, age at onset of symptoms, type of nut causing allergy, results of skin prick tests, and incidence of other allergic diseases and associated allergies. Results-Peanuts were the commonest cause of allergy (47) followed by Brazil nut (18), almond (14), and hazelnut (13). Onset of allergic symptoms occurred by the age of 2 years in 33/60 and by the age of 7 in 55/60. Peanuts accounted for all allergies in children sensitised in the first year of life and for 82% (27/33) of allergies in children sensitised by the third year of life. Multiple allergies appeared progressively with age. The commonest symptom was facial angioedema, and the major feature accounting for life threatening reactions was laryngeal oedema. Hypotension was uncommon. Of 55 patients, 53 were atopic-that is, had positive skin results of tests to common inhaled allergens-and all 53 had other allergic disorders (asthma, rhinitis, eczema) due to several inhaled allergens and other foods. Conclusions-Sensitisation, mainly to peanuts, is occurring in very young children, and multiple peanut/nut allergies appear progressively. Peanut and nut allergy is becoming common and can cause life threatening reactions. The main danger is laryngeal oedema. Young atopic children should avoid peanuts and nuts to prevent the development of this allergy.			Ewan, PW (corresponding author), UNIV CAMBRIDGE,SCH CLIN,ADDENBROOKES HOSP NHS TRUST,ALLERGY CLIN,CAMBRIDGE CB2 2QH,ENGLAND.							ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; ASSEM ESK, 1990, BRIT MED J, V300, P1377, DOI 10.1136/bmj.300.6736.1377; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1989, ALLERGY PROC, V10, P256; DONOVAN KL, 1990, BRIT MED J, V300, P1378, DOI 10.1136/bmj.300.6736.1378; FRIES JH, 1982, ANN ALLERGY, V48, P220; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOL, P570; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SMITH T, 1990, BRIT MED J, V300, P1354, DOI 10.1136/bmj.300.6736.1354; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; WARREN JB, 1986, CLIN PHARMACOL THER, V40, P673, DOI 10.1038/clpt.1986.243; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	16	260	268	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616415				2022-12-24	WOS:A1996UH81600026
J	Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN				Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN			Transcription-coupled repair deficiency and mutations in human mismatch repair genes	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI; COCKAYNE-SYNDROME; DNA DAMAGE; PREFERENTIAL REPAIR; SELECTIVE REPAIR; STRAND; YEAST; MECHANISM	Deficiencies in mismatch repair have been linked to a common cancer predisposition syndrome in humans, hereditary nonpolyposis colorectal cancer (HNPCC), and a subset of sporadic cancers. Here, several mismatch repair-deficient tumor cell lines and HNPCC-derived lymphoblastoid cell lines were found to be deficient in an additional DNA repair process termed transcription-coupled repair (TCR). The TCR defect was corrected in a mutant cell line whose mismatch repair deficiency had been corrected by chromosome transfer. Thus, the connection between excision repair and mismatch repair previously described in Escherichia coli extends to humans. These results imply that deficiencies in TCR and exposure to carcinogens present in the environment may contribute to the etiology of tumors associated with genetic defects in mismatch repair.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27706; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego	Mellon, I (corresponding author), UNIV KENTUCKY,MARKEY CANC CTR,TOXICOL PROGRAM,DEPT PATHOL,LEXINGTON,KY 40536, USA.		Koi, Minoru/C-3489-2012; Koi, Minoru/G-9197-2014		NIGMS NIH HHS [GM45535-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAYNE LV, 1992, CANCER RES, V42, P1493; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MELLON I, UNPUB; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWEDER KS, IN PRESS GENETICS; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; UMAR A, 1994, J BIOL CHEM, V269, P14367; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; XIAO W, 1995, CARCINOGENESIS, V16, P1933, DOI 10.1093/carcin/16.8.1933	46	252	252	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					557	560		10.1126/science.272.5261.557	http://dx.doi.org/10.1126/science.272.5261.557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614807	Green Submitted			2022-12-24	WOS:A1996UG82600047
J	Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C				Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C			Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de-etiolation in arabidopsis	CELL			English	Article							GENES; SEQUENCES; THALIANA	The cpd mutation localized by T-DNA tagging on Arabidopsis chromosome 5-14.3 inhibits cell elongation controlled by the ecdysone-like brassinosteroid hormone brassinolide. The cpd mutant displays de-etiolation and derepression of light-induced genes in the dark, as well as dwarfism, male sterility, and activation of stress-regulated genes in the light. The CPD gene encodes a cytochrome P450 (CYP90) sharing homologous domains with steroid hydroxylases. The phenotype of the cpd mutant is restored to wild type both by feeding with C23-hydroxylated brassinolide precursors and by ectopic overexpression of the CPD cDNA. Brassinosteroids also compensate for different cell elongation defects of Arabidopsis dot, cop, fus, and axr2 mutants, indicating that these steroids play an essential role in the regulation of plant development.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST PLANT BIOL, H-6701 SZEGED, HUNGARY; MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY; MAX PLANCK INST MOLEK PFLANZENPHYSIOL, D-14476 GOLM, GERMANY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Max Planck Society; Max Planck Society			Nagy, Ferenc/D-3532-2015	Nagy, Ferenc/0000-0002-6157-9269; Koncz, Csaba/0000-0003-4422-9993; Szekeres, Miklos/0000-0002-6354-1790; Altmann, Thomas/0000-0002-3759-360X				ADAM G, 1986, PHYTOCHEMISTRY, V25, P1787, DOI 10.1016/S0031-9422(00)81151-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMER EE, 1994, PLANT MOL BIOL, V26, P1423; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHORY J, 1994, ARABIDOPSIS, P579; CRANE FL, 1993, OXIDOREDUCTION PLASM, V2; Davies P. J., 1987, PLANT HORMONES THEIR; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; ESTELLE M, 1994, ARABIDOPSIS, P555; FEDER N, 1968, AM J BOT, V55, P123, DOI 10.2307/2440500; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1543, DOI 10.1271/bbb.59.1543; GOTOH O, 1992, J BIOL CHEM, V267, P83; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KONCZ C, 1989, P NATL ACAD SCI USA, V86, P8467, DOI 10.1073/pnas.86.21.8467; Koncz C., 1992, METHODS ARABIDOPSIS; KONCZ C, 1994, PLANT MOL BIOL MAN B, V2, P1; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sambrook JFE, 1989, MOL CLONING LAB MANU; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WINKLER RG, 1995, PLANT CELL, V7, P1307, DOI 10.1105/tpc.7.8.1307	42	779	851	11	142	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					171	182		10.1016/S0092-8674(00)81094-6	http://dx.doi.org/10.1016/S0092-8674(00)81094-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612270	Bronze			2022-12-24	WOS:A1996UG25500006
J	Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A				Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A			Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years	BRITISH MEDICAL JOURNAL			English	Article							POSTPRANDIAL LIPOPROTEIN METABOLISM; HIGH-DENSITY LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CHOLESTEROL-FED RABBITS; APOLIPOPROTEIN-E; PLASMA; RECEPTOR; CANINE; HYPERTRIGLYCERIDEMIA; ATHEROSCLEROSIS	Objective-To test the hypothesis that subjects who clear chylomicron remnants slowly from plasma may be at higher risk of coronary artery disease than indicated by their fasting plasma lipid concentrations. Design-Case control study over three years. Setting-An 800 bed general municipal hospital. Subjects-85 normolipidaemic patients with coronary artery disease selected prospectively and matched with 85 normolipidaemic subjects with normal coronary arteries on angiography. Interventions-All subjects were given a vitamin A fat loading test which specifically labels intestinal lipoproteins with retinyl palmitate. Main outcome measure-Postprandial lipoprotein metabolism. Results-The area below the chylomicron remnant retinyl palmitate curve was significantly increased in the coronary artery disease group as compared with the controls (mean 23.4 (SD 15.0) v 15.3 (8.9) mu mol/l.h; 95% confidence interval of difference 4.37 to 11.82). Conclusions-Normolipidaemic patients with coronary artery disease had significantly higher concentrations of chylomicron remnants in plasma than normolipidaemic subjects with normal coronary vessels. This may explain the mechanism underlying the susceptibility to atherosclerosis of coronary artery disease patients with normal fasting lipid values. As diet and drugs can ameliorate the accumulation of postprandial lipoproteins in plasma, the concentration of chylomicron remnants should be measured in patients at high risk of coronary artery disease.	TEL AVIV SOURASKY MED CTR,DEPT MED C,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT MED E,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,CORONARY CATHETERISAT UNIT,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,UNIT LIPID METAB,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT NEPHROL,TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Weintraub, MS (corresponding author), TEL AVIV SOURASKY MED CTR,DEPT INTERNAL MED C,TEL AVIV,ISRAEL.							BERR F, 1985, J LIPID RES, V26, P852; BERR F, 1984, J LIPID RES, V25, P805; BERR F, 1986, J LIPID RES, V27, P645; BLANCHET.EJ, 1971, J CELL BIOL, V51, P1, DOI 10.1083/jcb.51.1.1; CORTNER JA, 1987, J LIPID RES, V28, P195; DALE VP, 1962, PHYSIOL REV, V42, P674; DEMACKER PNM, 1991, EUR J CLIN INVEST, V21, P197, DOI 10.1111/j.1365-2362.1991.tb01809.x; EISENBERG S, 1984, J LIPID RES, V25, P1017; FLOREN CH, 1981, BIOCHIM BIOPHYS ACTA, V663, P336, DOI 10.1016/0005-2760(81)90219-8; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOODMAN DS, 1962, J CLIN INVEST, V41, P1886, DOI 10.1172/JCI104645; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; GRUNDY SM, 1976, METABOLISM, V25, P1225, DOI 10.1016/S0026-0495(76)80006-6; HAZARD WR, 1976, METABOLISM, V25, P777; HOLLANDER D, 1981, J LAB CLIN MED, V97, P449; HUI DY, 1986, J BIOL CHEM, V261, P4256; HUI DY, 1981, J BIOL CHEM, V256, P5646; KANE JP, 1983, ARTERIOSCLEROSIS, V3, P47, DOI 10.1161/01.ATV.3.1.47; KARPE F, 1995, ARTERIOSCL THROM VAS, V15, P199, DOI 10.1161/01.ATV.15.2.199; KORN ED, 1955, J BIOL CHEM, V215, P1; KRAINSKI SD, 1990, METABOLISM, V39, P357; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LIPPEL K, 1981, ARTERIOSCLEROSIS, V1, P406, DOI 10.1161/01.ATV.1.6.406; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; NESTEL PJ, 1982, NEW ENGL J MED, V307, P327; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; SCHOEFL GI, 1968, PROC R SOC SER B-BIO, V169, P153, DOI 10.1098/rspb.1968.0003; STENDER S, 1982, ARTERIOSCLEROSIS, V2, P493, DOI 10.1161/01.ATV.2.6.493; STENDER S, 1981, ATHEROSCLEROSIS, V39, P97; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; WEINTRAUB M, 1992, J GERONTOL, V47, pB209, DOI 10.1093/geronj/47.6.B209; WEINTRAUB MS, 1989, CIRCULATION, V79, P1007, DOI 10.1161/01.CIR.79.5.1007; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; WILSON DE, 1985, METABOLISM, V34, P551, DOI 10.1016/0026-0495(85)90193-3; WILSON DE, 1983, METABOLISM, V32, P514, DOI 10.1016/0026-0495(83)90016-1; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1984, JAMA-J AM MED ASSOC, V251, P365	44	161	161	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					935	939						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616304	Green Published			2022-12-24	WOS:A1996UF65900016
J	Richardson, A; Parsons, JT				Richardson, A; Parsons, JT			A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125(FAK)	NATURE			English	Article							FOCAL ADHESIONS; EXPRESSION; PP125FAK	FOCAL adhesion kinase(1,2) (pp125(FAK)) is a member of a growing family of structurally distinct protein tyrosine kinases that includes the recently identified FakB(3) and PYK2/CAK beta/RAFTK(4,6). Activation of pp125(FAK) has been functionally linked to the formation of focal adhesions, integrin-mediated sites of contact between the cell and the extracellular matrix(7,8). The carboxy-terminal domain of pp125(FAK) is also expressed as a separate protein called pp41/43(FRNK) (where FRNK represents pp125(FAK)-related non-kinase)(9). Here we show that pp41/43(FRNK) acts as an inhibitor of pp125(FAK) by transiently blocking the formation of focal adhesions on fibronectin and constitutively reducing tyrosine phosphorylation of both pp125(FAK) and of two focal adhesion proteins, tensin and paxillin. These inhibitory effects of pp41/43(FRNK) are reversed by co-expression of pp125(FAK), suggesting that pp125(FAK) and pp41/43(FRNK) compete for a common binding protein(s) whose association with pp125(FAK) is necessary for signalling by pp125(FAK). We propose that pp41/43F RNK functions as an endogenous regulator of pp125(FAK), thus providing an unusual means to regulate both tyrosine kinase activity and cellular adhesion to the extracellular matrix.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia			Richardson, Alan/I-4631-2015; Richardson, Alan/E-7615-2010	Richardson, Alan/0000-0003-1825-3375; 				ABRAHAM S, 1995, J BIOL CHEM, V270, P27742; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; COLINGE M, 1992, MOL CELL BIOL, V12, P2359; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOSSELMAN S, 1994, CANCER RES, V54, P220; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561	22	442	454	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					538	540		10.1038/380538a0	http://dx.doi.org/10.1038/380538a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606775				2022-12-24	WOS:A1996UE66300053
J	RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L				RamirezLatorre, J; Yu, CR; Qu, X; Perin, F; Karlin, A; Role, L			Functional contributions of alpha 5 subunit to neuronal acetylcholine receptor channels	NATURE			English	Article							ANTISENSE OLIGONUCLEOTIDES; GENE FAMILY; EXPRESSION; SUBTYPES; LIGAND	LIGAND-GATED ion channels are multi-subunit complexes where each subunit-type is encoded by several related genes. Heterologous expression of any one of the neuronal nicotinic acetylcholine receptors (nAChR) alpha-type subunits, either alone or with any beta-type subunit, typically yields functional nAChR channels(1-5). A striking exception is the nAChR alpha 5 subunit: although apparently complexed with beta 2 and beta 4 nAChR subunits in neurons(6-8), and expressed in a subset of neurons within the central and peripheral nervous systems(9,10), heterologous expression of alpha 5, either alone or with any beta-type subunit has failed to yield functional channels(1.11). We demonstrate here that alpha 5 does participate in nAChRs expressed in heterologous systems and in primary neurons, and further that alpha 5 contributes to the lining of functionally unique nAChR channels, but only if coexpressed with both another alpha- and beta-type subunit. Furthermore, channels containing the alpha 5 subunit are potently activated and desensitized by nanomolar concentrations of nicotine.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,ECOLE NORMALE SUPER,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR MOL RECOGNIT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University			Role, LW/Q-7371-2018	Role, LW/0000-0001-5851-212X; KARLIN, ARTHUR/0000-0002-4813-752X				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; BRUSSAARD AB, 1994, PFLUG ARCH EUR J PHY, V429, P27, DOI 10.1007/BF02584027; CHEN J, 1995, BIOPHYS J, V69, P849, DOI 10.1016/S0006-3495(95)79959-3; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN S, 1991, CLIN NEUROPHARMACOL, V14, pS45, DOI 10.1097/00002826-199114001-00007; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; VILLARROEL A, 1992, BIOPHYS J, V62, P196, DOI 10.1016/S0006-3495(92)81805-2; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; YU C, 1993, DEV GENET, V14, P296, DOI 10.1002/dvg.1020140407	28	319	320	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					347	351		10.1038/380347a0	http://dx.doi.org/10.1038/380347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598930				2022-12-24	WOS:A1996UC37900061
J	Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I				Campbell, KHS; McWhir, J; Ritchie, WA; Wilmut, I			Sheep cloned by nuclear transfer from a cultured cell line	NATURE			English	Article							EMBRYOS; TRANSPLANTATION	Nuclear transfer has been used in mammals as both a valuable tool in embryological studies(1) and as a method for the multiplication of 'elite' embryos(2-4). Offspring have only been reported when early embryos, or embryo-derived cells during primary culture, were used as nuclear donors(5,6). Here we provide the first report, to our knowledge, of live mammalian offspring following nuclear transfer from an established cell line. Lambs were born after cells derived from sheep embryos, which had been cultured for 6 to 13 passages, were induced to quiesce by serum starvation before transfer of their nuclei into enucleated oocytes. Induction of quiescence in the donor cells may modify the donor chromatin structure to help nuclear reprogramming and allow development. This approach will provide the same powerful opportunities for analysis and modification of gene function in livestock species that are available in the mouse through the use of embryonic stem cells(7).			Campbell, KHS (corresponding author), ROSLIN INST EDINBURGH, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND.							BONDIOLI KR, 1990, THERIOGENOLOGY, V33, P165, DOI 10.1016/0093-691X(90)90607-U; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BUCHANAN FC, 1994, ANIM GENET, V25, P60, DOI 10.1111/j.1365-2052.1994.tb00069.x; CAMPBELL KHS, 1994, BIOL REPROD, V50, P1385, DOI 10.1095/biolreprod50.6.1385; CAMPBELL KHS, 1993, BIOL REPROD, V49, P933, DOI 10.1095/biolreprod49.5.933; CHESNE P, 1993, CR ACAD SCI III-VIE, V316, P487; COLLAS P, 1994, MOL REPROD DEV, V38, P264, DOI 10.1002/mrd.1080380306; Galli C., 1994, Zygote, V2, P385; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; HOOPER ML, 1992, EMBRYONAL STEM CELLS; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; PIEDRAHITA JA, 1990, THERIOGENOLOGY, V34, P879, DOI 10.1016/0093-691X(90)90559-C; PRATHER RS, 1990, INT REV CYTOL, V120, P169; SIMS M, 1994, P NATL ACAD SCI USA, V91, P6143, DOI 10.1073/pnas.91.13.6143; SZOLLOSI D, 1988, J CELL SCI, V91, P603; WHITFIELD JF, 1985, CONTROL ANIMAL CELL, V1, P331; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0	18	1254	1466	4	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					64	66		10.1038/380064a0	http://dx.doi.org/10.1038/380064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598906				2022-12-24	WOS:A1996TY87700056
J	Jewitt, D; Senay, M; Matthews, H				Jewitt, D; Senay, M; Matthews, H			Observations of carbon monoxide in comet Hale-Bopp	SCIENCE			English	Article							P/HALLEY	The recently discovered comet Hale-Bopp (C/1995 O1) sports a bright dust coma even though it is still far from the sun (presently 6 astronomical units). This feature has attracted considerable interest in the public and scientific arenas. The comet is headed toward perihelion at 0.92 astronomical unit in April 1997 and is widely expected to then become a spectacular naked-eye comet. With millimeter-wave observations, carbon monoxide (CO) has been identified as the driver for the early activity observed in Hale-Bopp.	JOINT ASTRON CTR,HILO,HI 96720; NATL RES COUNCIL CANADA,HERZBERG INST ASTROPHYS,OTTAWA,ON K1A 0R6,CANADA	National Research Council Canada	Jewitt, D (corresponding author), UNIV HAWAII,INST ASTRON,2680 WOODLAWN DR,HONOLULU,HI 96822, USA.							AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; BAILEY M, UNPUB; BOICE DC, 1993, P DISTANT COMET ACTI, P134; Brown G. N.  Jr., 1980, Advances in Cryogenic Engineering. Vol.25. Proceedings of the 1979 Cryogenic Engineering Conference, P662; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1995, 27 ANN M AM ASTR SOC; CROVISIER J, 1983, ASTRON ASTROPHYS, V1223, P61; DAVIES J, 1995, 6225 INT ASTR UN; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; HICKS M, 1995, 6200 INT ASTR UN; HUEBNER WF, 1992, SOLAR PHOTO RATES PL, P273; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; JEWITT DC, 1991, COMETS POST HALLEY E, P19; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; LUU JX, 1990, ASTRON J, V100, P913, DOI 10.1086/115571; MATTHEWS H, 1995, 6234 INT ASTR UN; MCNAUGHT RH, 1995, 6198 INT ASTR UN; PRIALNIK D, 1989, ADV SPACE RES, V9, P25; RAUER H, 1995, 6236 INT ASTR UN; SAMARASINHA NH, 1994, ICARUS, V108, P103, DOI 10.1006/icar.1994.1044; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WHIPPLE FL, 1950, ASTROPHYS J, V111, P375, DOI 10.1086/145272; WOMACK M, 1995, 6276 INT ASTRON UNIO	24	61	61	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1110	1113		10.1126/science.271.5252.1110	http://dx.doi.org/10.1126/science.271.5252.1110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599086				2022-12-24	WOS:A1996TW70100036
J	Endress, M; Zinner, E; Bischoff, A				Endress, M; Zinner, E; Bischoff, A			Early aqueous activity on primitive meteorite parent bodies	NATURE			English	Article							EARLY SOLAR-SYSTEM; INTERSTELLAR GRAINS; ISOTOPE SYSTEMATICS	THE interstellar material from which the Solar System formed has been modified by many processes(1): evaporation and condensation in the solar nebula, accretion into protoplanetary bodies and post-accretion processes within these bodies, Meteorites provide a record of these events and their chronology(2), Carbonaceous CI chondrites are among the most primitive, undifferentiated meteorites(3-6), but nevertheless show evidence of post-accretion alteration(7); they contain carbonates that are believed to have formed by reactions between anhydrous CI precursor materials and circulating fluids in the meteorite parent body (or bodies), yet little is known about the nature of these reactions or the timescale on which they occurred, Here we report measurements of excess Cr-53-formed by the decay of short-lived Mn-53-in five carbonate fragments from the CI chondrites Orgueil and Ivuna. Our results show that aqueous alteration on small protoplanetary bodies must have begun less than 20 Myr after the time of formation of the oldest known solar-nebula condensates(2) (Allende refractory inclusions). This upper limit is much shorter than that of 50 Myr inferred from previous studies(8), and clearly establishes aqueous alteration as one of the earliest processes in the chemical evolution of the Solar System.	WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130; UNIV MUNSTER,INST PLANETOL,D-48149 MUNSTER,GERMANY	Washington University (WUSTL); University of Munster								ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; ENDRESS M, 1994, METEORITICS, V29, P463; Endress M, 1996, GEOCHIM COSMOCHIM AC, V60, P489, DOI 10.1016/0016-7037(95)00399-1; FREDRIKSSON K, 1988, METEORITICS, V23, P35, DOI 10.1111/j.1945-5100.1988.tb00894.x; Kerridge JF., 1988, METEORITES EARLY SOL; Lugmair G. W., 1992, LUNAR PLANET SCI, VXXIII, P823; LUGMAIR GW, 1994, LPS, V25, P813; MACDOUGALL JD, 1984, NATURE, V307, P249, DOI 10.1038/307249a0; MACDOUGALL JD, 1989, METEORITICS, V24, P297; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MANHES G, 1988, COMPTES RENDUS ATP P, P323; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; Richardson S. M., 1978, Meteoritics, V13, P141, DOI 10.1111/j.1945-5100.1978.tb00803.x; SCATENAWACHEL DE, 1984, LUNAR PLANET SCI, V15, P718; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; Tilton G. G., 1988, METEORITES EARLY SOL, P259; Zinner E., 1988, METEORITES EARLY SOL; [No title captured]; [No title captured]	21	128	132	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					701	703		10.1038/379701a0	http://dx.doi.org/10.1038/379701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602215				2022-12-24	WOS:A1996TW56700043
J	Koo, D; Maloney, K; Tauxe, R				Koo, D; Maloney, K; Tauxe, R			Epidemiology of diarrheal disease outbreaks on cruise ships, 1986 through 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHIGELLOSIS; ABOARD	Objective.-To describe the epidemiology of cruise-associated diarrheal disease outbreaks from 1986 through 1993, to determine if the incidence had changed since 1985, and to determine the preventability of outbreaks that continue to occur. Design.-The numerator data were collated from Centers for Disease Control and Prevention (CDC) outbreak investigation reports from 1986 through 1993. The denominator data were summations of cruise ship data on the number of passengers and length of cruises collected during routine diarrheal illness surveillance, available only for the period 1989 through 1993. Setting.-Cruise ships with outbreaks of diarrheal disease. Participants.-Cruise ship passengers and crew or staff who participated in the original investigations. Main Outcome Measures.-The incidence of outbreaks during the study period, pathogens isolated, and vehicles of transmission implicated in investigations. Results.-Among cruises of 3 to 15 days, CDC staff investigated 1.4 outbreaks per 1000 cruises, or 2.3 outbreaks per 10 million passenger-days. An etiologic agent was implicated in 21 (68%) of 31 investigated outbreaks: bacterial in 12, viral in nine. A specific vehicle of transmission was identified in 16. The most common vehicles of transmission were undercooked scallops (three outbreaks caused by enterotoxigenic Escherichia coli), eggs (two outbreaks caused by Salmonella serotype Enteritidis, one by Norwalk-like virus), and food items provided by caterers during onshore excursions (three outbreaks, one caused by Shigella sonnei). Conclusions.-Observance of two simple precautions could have prevented almost one third (5/16, or 31%) of the investigated outbreaks on cruise ships. Cruise lines have been reminded to cook seafoods thoroughly and to use pasteurized eggs for menu items calling for pooled eggs. Preventing food handlers from working while ill and riot using onshore caterers for offship excursions might have prevented at least an additional one third (5/16) of these outbreaks.	CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADDISS DG, 1989, EPIDEMIOL INFECT, V103, P63, DOI 10.1017/S0950268800030363; DAVIES JW, 1977, CAN MED ASSOC J, V106, P877; LEW JF, 1991, AM J EPIDEMIOL, V134, P413, DOI 10.1093/oxfordjournals.aje.a116103; MERSON MH, 1975, JAMA-J AM MED ASSOC, V231, P723, DOI 10.1001/jama.231.7.723; MERSON MH, 1976, J MILK FOOD TECHNOL, V39, P285, DOI 10.4315/0022-2747-39.4.285; MERSON MH, 1975, AM J EPIDEMIOL, V101, P165, DOI 10.1093/oxfordjournals.aje.a112081; 1980, VESSEL SANITATION PR	7	45	47	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					545	547		10.1001/jama.275.7.545	http://dx.doi.org/10.1001/jama.275.7.545			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606476				2022-12-24	WOS:A1996TV56900032
J	Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP				Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP			Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice	CELL			English	Article							OBESE	OB-R is a high affinity receptor for leptin, an important circulating signal for the regulation of body weight. We identified an alternatively spliced transcript that encodes a form of mouse OB-R with a long intracellular domain, db/db mice also produce this alternatively spliced transcript, but with a 106 nt insertion that prematurely terminates the intracellular domain. We further identified a G-->T point mutation in the genomic OB-R sequence in db/db mice. This mutation generates a donor splice site that converts the 106 nt region to a novel exon retained in the OB-R transcript. We predict that the long intracellular domain form of OB-R is crucial for initiating intracellular signal transduction, and as a corollary, the inability to produce this form of OB-R leads to the severe obese phenotype found in db/db mice.			Chen, H (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEM DR,CAMBRIDGE,MA 02139, USA.							BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VALCARCEL J, 1995, PREMRNA PROCESSING, P97; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	18	1821	1922	1	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					491	495		10.1016/S0092-8674(00)81294-5	http://dx.doi.org/10.1016/S0092-8674(00)81294-5			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608603	Bronze			2022-12-24	WOS:A1996TV70800018
J	Asch, DA				Asch, DA			The role of critical care nurses in euthanasia and assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTARY EUTHANASIA; ATTITUDES	Background. Euthanasia and assisted suicide have received considerable attention recently in medical literature, public discussion, and proposed state legislation. Almost all the discussion in this area has focused on the role of physicians. However, nurses - especially critical care nurses - may be in a special position to understand the wishes of patients and to act on this understanding. Methods. I mailed a survey to 1600 critical care nurses in the United States, asking them to describe anonymously any requests from patients, family members or others acting for patients (surrogates), or physicians to perform euthanasia or assisted suicide, as well as their own practices. Results. Of the 1139 nurses who responded (71 percent), 852 said they practiced exclusively in intensive care units for adults in the United States. Of these 852 nurses, 141 (17 percent) reported that they had received requests from patients or family members to perform euthanasia or assist in suicide; 129 (16 percent of those for whom data were available) reported that they had engaged in such practices; and an additional 35 (4 percent) reported that they had hastened a patient's death by only pretending to provide life-sustaining treatment ordered by a physician. Some nurses reported engaging in these practices without the request or advance knowledge of physicians or others. The method of euthanasia most commonly described was the administration of a high dose of an opiate to a terminally ill patient. Conclusions. As public debate continues about euthanasia and assisted suicide, some critical care nurses in the United States are engaging in such practices. (C) 1995, Massachusetts Medical Society.	VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,CTR BIOETH,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania				Asch, David/0000-0002-7970-286X				*AM NURS ASS, 1994, POS STAT ACT EUTH; ANDERSON JG, 1993, SOC SCI MED, V37, P105, DOI 10.1016/0277-9536(93)90323-V; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ASCH DA, 1995, CRIT CARE MED, V151, P288; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLACKSHER EA, 1995, HASTINGS CENT REP, V25, P47; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; KUHSE H, 1993, INT J NURS STUD, V30, P311, DOI 10.1016/0020-7489(93)90103-2; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Kuhse H, 1992, Aust Nurses J, V21, P21; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Stevens C A, 1994, Med Law, V13, P541; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; Young A, 1993, Oncol Nurs Forum, V20, P445; 1988, JAMA-J AM MED ASSOC, V259, P272; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	174	178	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1374	1379		10.1056/NEJM199605233342106	http://dx.doi.org/10.1056/NEJM199605233342106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL251	8614424				2022-12-24	WOS:A1996UL25100006
J	Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P				Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P			Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; CYTOMEGALO-VIRUS; CELLS; EXPRESSION; DNA; ACTIVATION; SEQUENCES; PROTEINS; AIDS; GENE	Background. The recent identification in patients with Kaposi's sarcoma of DNA sequences with homology to gammaherpesviruses has led to the hypothesis that a newly identified virus, Kaposi's sarcoma-associated herpeslike virus (KSHV), has a role in the pathogenesis of Kaposi's sarcoma. We developed serologic markers for KSHV infection. Methods. KSHV antigens were prepared from a cell line (BC-1) that contains the genomes of both KSHV and the Epstein-Barr virus (EBV). We used immunoblot and immunofluorescence assays to examine serum samples from 102 patients with human immunodeficiency virus type 1 (HIV-1) infection for antibodies to KSHV-associated proteins and to distinguish these antibodies from antibodies to EBV antigens. A positive serologic response was defined by the recognition of an antigenic polypeptide, p40, in n-butyrate-treated BC-1 cells and by the absence of p40 recognition in untreated BC-1 cells or EBV-infected, KSHV-negative cells. The detection by the immunofluorescence assay of 10 to 20 times more antigen-positive cells in n-butyrate-treated BC-1 cells than in untreated cells was considered a positive response. Results. Antibodies to the p40 antigen expressed by chemically treated BC-1 cells were identified in 32 of 48 HIV-1-infected patients with Kaposi's sarcoma (67 percent), as compared with only 7 of 54 HIV-1-infected patients without Kaposi's sarcoma (13 percent). These results were confirmed by an immunofluorescence assay. The positive predictive value of the serologic tests for Kaposi's sarcoma was 82 percent, and the negative predictive value 75 percent. Conclusions. The presence of antibodies to a KSHV antigenic peptide correlates with the presence of Kaposi's sarcoma in a high-risk population and provides further evidence of an etiologic role for KSHV.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, NEW YORK, NY USA	Yale University; Yale University; Yale University; Yale University; Mount Sinai St. Luke's; Mount Sinai West; University of California System; University of California San Francisco; Columbia University; Columbia University	Miller, G (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, RM 420 LSOG, NEW HAVEN, CT 06520 USA.		Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011; Gao, Shou-Jiang/B-8641-2012; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA070036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70036] Funding Source: Medline; NIAID NIH HHS [AI 22959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1991, CANCER SURV, V10, P5; BERAL V, 1992, CANCER SURV, V12, pA225; BOSHOFF C, 1995, LANCET, V345, P1043; BURNS LJ, 1988, BLOOD, V72, P1536; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; GORDON JA, 1972, CENT AFR J MED, V19, P1; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; KNOWLES DM, 1989, BLOOD, V73, P792; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOETHE F, 1963, ACTA PATHOL MIC SC, V161, P1; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; SAFAI B, 1980, CLIN BULL, V10, P62; SCHALLING M, 1995, NAT MED, V1, P705; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRUNSVEN WMJ, 1993, J VIROL, V67, P3908, DOI 10.1128/JVI.67.7.3908-3916.1993; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; ZURHAUSEN H, 1978, NATURE, V272, P373; 1981, MMWR-MORBID MORTAL W, V30, P305	39	222	234	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1292	1297		10.1056/NEJM199605163342003	http://dx.doi.org/10.1056/NEJM199605163342003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609946				2022-12-24	WOS:A1996UK88000003
J	Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP				Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP			Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						practice guidelines; antibiotics; outcome and process assessment (health care); decision making, computer-assisted; cost-benefit analysis	EDUCATIONAL ORDER FORM; ANTIMICROBIAL AGENTS; PRESCRIBING PATTERNS; SURVEILLANCE; INFECTIONS; QUALITY; SYSTEM; REMINDERS; MISUSE; CARE	Objective: To determine the clinical and financial outcomes of antibiotic practice guidelines implemented through computer-assisted decision support. Design: Descriptive epidemiologic study and financial analysis. Setting: 520-bed community teaching hospital in Salt Lake City, Utah. Patients: All 162 196 patients discharged from LDS Hospital between 1 January 1988 and 31 December 1994. Intervention: An antibiotic management program that used local clinician-derived consensus guidelines embedded in computer-assisted decision support programs. Prescribing guidelines were developed for inpatient prophylactic, empiric, and therapeutic uses of antibiotics. Measurements: Measures of antibiotic use included timing of preoperative antibiotic administration and duration of postoperative antibiotic use. Clinical outcomes included rates of adverse drug events, patterns of antimicrobial resistance, mortality, and length of hospital stay. Financial and use outcomes were expressed as yearly expenditures for antibiotics and defined daily doses per 100 occupied bed-days. Results: During the 7-year study period, 63 759 hospitalized patients (39.3%) received antibiotics. The proportion of the hospitalized patients who received antibiotics increased each year, from 31.8% in 1988 to 53.1% in 1994. Use of broad-spectrum antibiotics increased from 24% of all antibiotic use in 1988 to 47% in 1994. The annual Medicare case-mix index increased from 1.7481 in 1988 to 2.0520 in 1993. Total acquisition costs of antibiotics (adjusted for inflation) decreased from 24.8% ($987 547) of the pharmacy drug expenditure budget in 1988 to 12.9% ($612 500) in 1994. Antibiotic costs per treated patient (adjusted for inflation) decreased from $122.66 per patient in 1988 to $51.90 per patient in 1994. Analysis using a standardized method (defined daily doses) to compare antibiotic use showed that antibiotic use decreased by 22.8% overall. Measures of antibiotic use and clinical outcomes improved during the study period. The percentage of patients having surgery who received appropriately timed preoperative antibiotics increased from 40% in 1988 to 99.1% in 1994. The average number of antibiotic doses administered for surgical prophylaxis was reduced from 19 doses in the base year to 5.3 doses in 1994. Antibiotic-associated adverse drug events decreased by 30%. During the study, antimicrobial resistance patterns were stable, and length of stay remained the same. Mortality rates decreased from 3.65% in 1988 to 2.65% in 1994 (P < 0.001). Conclusions: Computer-assisted decision support programs that use local clinician-derived practice guidelines can improve antibiotic use, reduce associated costs, and stabilize the emergence of antibiotic-resistant pathogens.	LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, SALT LAKE CITY, UT 84143 USA				Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BERMAN JR, 1992, AM J HOSP PHARM, V49, P1701, DOI 10.1093/ajhp/49.7.1701; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BURKE JP, 1991, J HOSP INFECT, V18, P424, DOI 10.1016/0195-6701(91)90052-A; BURKE JP, 1995, CURR OPIN INFECT DIS, V8, P269, DOI 10.1097/00001432-199508000-00009; BURKE JP, 1992, ASSESSING QUALITY HL, P509; CLASSEN D, 1993, THESIS U UTAH SALT L; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COL NF, 1987, REV INFECT DIS, V9, pS232; DUNAGAN WC, 1991, REV INFECT DIS, V13, P405; DUNAGAN WC, 1993, DIAGN MICR INFEC DIS, V16, P265, DOI 10.1016/0732-8893(93)90120-V; EAST TD, 1991, INT J CLIN MONIT COM, V8, P263, DOI 10.1007/BF01739127; ECHOLS RM, 1984, J INFECT DIS, V150, P803, DOI 10.1093/infdis/150.6.803; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1990, DICP ANN PHARMAC, V24, P351, DOI 10.1177/106002809002400401; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GROSSKOPF S, 1993, MED CARE, V31, P525, DOI 10.1097/00005650-199306000-00006; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; HUTH TS, 1991, INFECT CONT HOSP EP, V12, P525; James B C, 1993, Front Health Serv Manage, V10, P3; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KUNIN CM, 1990, REV INFECT DIS, V12, P12; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LEE KR, 1994, INFECT CONT HOSP EP, V15, P710, DOI 10.2307/30148337; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; McDonald CJ, 1996, ANN INTERN MED, V124, P170, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00018; MCGOWAN JE, 1994, INFECT CONT HOSP EP, V15, P478; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P993; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P989; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P983; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; PESTOTNIK SL, 1993, THESIS U UTAH SALT L; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; PRYOR TA, 1990, INT J CLIN MONIT COM, V7, P137, DOI 10.1007/BF02915578; RILEY DK, 1994, 4 ANN M SOC HOSP EP; RYAN BA, 1993, AM J HOSP PHARM, V50, pS3, DOI 10.1093/ajhp/50.8_Suppl_4.S3; SANTELL JP, 1995, AM J HEALTH-SYST PH, V52, P151, DOI 10.1093/ajhp/52.2.151; SHULKIN DJ, 1993, AM J HOSP PHARM, V50, pS8, DOI 10.1093/ajhp/50.8_Suppl_4.S8; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; SOUMERAI SB, 1993, MED CARE, V31, P552, DOI 10.1097/00005650-199306000-00009; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; Volpp K G, 1994, JAMA, V271, P1370, DOI 10.1001/jama.271.17.1370; WALKER RD, 1994, WESTERN J MED, V161, P39; Wilson C N, 1994, Hosp Pharm, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P964	65	457	462	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					884	+		10.7326/0003-4819-124-10-199605150-00004	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610917				2022-12-24	WOS:A1996UJ80100004
J	Collignon, J; Varlet, I; Robertson, EJ				Collignon, J; Varlet, I; Robertson, EJ			Relationship between asymmetric nodal expression and the direction of embryonic turning	NATURE			English	Article							MOUSE EMBRYO; AUTORADIOGRAPHIC ANALYSIS; GASTRULATION; MUTATION; ECTODERM; POTENCY; FATE	GROWTH factors related to TGF-beta provide important signals for patterning the vertebrate body plan(1-3), One such family member, nodal, is required for formation of the primitive streak during mouse gastrulation(4-6), Here we have used a nodal-lacZ reporter allele to demonstrate asymmetric nodal expression in the mouse node, a structure thought to be the functional equivalent of the frog and chick 'organizer'(7), and in lateral plate mesoderm cells, We have also identified two additional genes acting with nodal in a pathway determining the left-right body axis. Thus we observe in inv mutant embryos(8) that the sidedness of nodal expression correlates with the direction of heart looping and embryonic turning, In contrast, HNF3-beta(+/-) nodal(lacZ/+) double-heterozygous embryos display LacZ staining on both left and right sides, and frequently exhibit defects in body situs, Taken together, these experiments, along with similar findings in chick(9), demonstrate that elements of the genetic pathway that establish the left-right body axis are conserved in vertebrates.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			collignon, jerome/K-8148-2017	Collignon, Jerome/0000-0002-1212-4006				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Hogan B, 1994, MANIPULATING MOUSE E; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MARTI E, 1995, DEVELOPMENT, V121, P2537; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEITO MA, 1992, DEVELOPMENT, V116, P227; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; POIRIER F, 1993, DEVELOPMENT, V119, P1229; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SMITH JL, 1994, DEV DYNAM, V201, P279, DOI 10.1002/aja.1002010310; TAM PPL, 1987, DEVELOPMENT, V99, P109; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	478	496	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					155	158		10.1038/381155a0	http://dx.doi.org/10.1038/381155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610012				2022-12-24	WOS:A1996UK13900049
J	Lucas, A; Morley, R; Fewtrell, MS				Lucas, A; Morley, R; Fewtrell, MS			Low triiodothyronine concentration in preterm infants and subsequent intelligence quotient (IQ) at 8 year follow up	BRITISH MEDICAL JOURNAL			English	Article											Lucas, A (corresponding author), MRC,DUNN NUTR UNIT,INFANT & CHILD NUTR GRP,CAMBRIDGE CB4 1XJ,ENGLAND.							BAKER BA, 1988, ARCH DIS CHILD, V63, P1198, DOI 10.1136/adc.63.10.1198; BRASEL JA, 1975, PERINATAL THYROID PH, P59; LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288; LUCAS A, 1990, ARCH DIS CHILD, V65, P977, DOI 10.1136/adc.65.9.977; LUCAS A, 1988, ARCH DIS CHILD, V63, P1202	5	90	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1132	1133						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620130				2022-12-24	WOS:A1996UK06900023
J	Pell, J; Gruer, L; Christie, P; Goldberg, D				Pell, J; Gruer, L; Christie, P; Goldberg, D			Management of HIV infected health care workers: Lessons from three cases	BRITISH MEDICAL JOURNAL			English	Article								Three cases in which doctors in Glasgow were diagnosed as having HIV infection were all handled differently in relation to telling patients and the media. In the first patients were not told because the doctor had been doing administrative work and there was thought to be no risk to patients; although the media did report the case, it accepted the assurances given. In the second case, where a doctor had done many jobs in different specialities and places, the media identified the doctor before most patients had been informed: most calls to the helpline subsequently set up by the health authority were fi om patients who had not been treated bg this doctor. This episode, however, allowed the incident team to be prepared for the next case, enabling the helpline to be established swiftly. In this case the doctor voluntarily identified himself, and this served to allay public fears and reduce the number of inappropriate calls to the helpline.	RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW J20 9NB,LANARK,SCOTLAND		Pell, J (corresponding author), GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BEIL DM, 1991, 7 INT C AIDS FLOR I; CHRISTIE P, 1994, HIV INFECTED HEALTHC; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Heptonstall J, 1995, OCCUPATIONAL TRANSMI; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PELL J, 1995, LANCET, V346, P1425, DOI 10.1016/S0140-6736(95)92439-6; PELL JP, 1994, HIV INFECTED HLTH CA; STARK C, 1994, BRIT MED J, V309, P44, DOI 10.1136/bmj.309.6946.44; *UK DEP HLTH, 1993, AIDS HIV INF HLTH CA; 1990, MMWR-MORBID MORTAL W, V39, P489	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1150	1152						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620136	Green Published			2022-12-24	WOS:A1996UK06900031
J	Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY				Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY			Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; INTERFERON-ALPHA; TRANSCRIPTION FACTOR; C-FOS; STIMULATED TRANSCRIPTION; ACTIVATION; ISGF3; PHOSPHORYLATION; EGF	Signal transducers and activators of transcription (STAT) proteins can be conditionally activated in response to epidermal growth factor (EGF) and interferon (IFN)-gamma. STAT activation was correlated with cell growth inhibition in response to EGF and IFN-gamma. Activated STAT proteins' specifically recognized the conserved STAT-responsive elements in the promoter of the gene encoding the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1) and regulated the induction of p21 messenger RNA. IFN-gamma did not inhibit the growth of U3A cells, which are deficient in STAT1, but did inhibit the growth of U3A cells into which STAT1 alpha was reintroduced. Thus, STAT1 protein is essential for cell growth suppression in response to IFN-gamma. The STAT signaling pathway appears to negatively regulate the cell cycle by inducing CDK inhibitors in response to cytokines.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520	Yale University			You, Zhu-Hong/AAI-6862-2020; Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Su, Wu-Chou/0000-0003-2953-4105	NIAID NIH HHS [R01 AI34522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FU XY, 1995, INDUCIBLE GENE EXPRE, V2, P99; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KITAGAWA M, UNPUB; KWOK TT, 1994, CANCER RES, V54, P2834; LAMER AC, 1993, SCIENCE, V261, P1730; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOU Z, UNPUB; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; [No title captured]	44	712	740	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					719	722		10.1126/science.272.5262.719	http://dx.doi.org/10.1126/science.272.5262.719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614832				2022-12-24	WOS:A1996UJ05100050
J	LaSalle, JM; Lalande, M				LaSalle, JM; Lalande, M			Homologous association of oppositely imprinted chromosomal domains	SCIENCE			English	Article							INSITU HYBRIDIZATION; NUCLEI; TRANSVECTION; REPLICATION; DROSOPHILA	Human chromosome 15q11-q13 encompasses the Prader-Willi syndrome (PWS) and the Angelman syndrome (AS) loci, which are subject to parental imprinting, a process that marks the parental origin of certain chromosomal subregions. A temporal and spatial association between maternal and paternal chromosomes 15 was observed in human T lymphocytes by three-dimensional fluorescence in situ hybridization. This association occurred specifically at the imprinted 15q11-q13 regions only during the late S phase of the cell-cycle. Cells from PWS and AS patients were deficient in association, which suggests that normal imprinting involves mutual recognition and preferential association of maternal and paternal chromosomes 15.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,GENET DIV,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			LaSalle, Janine M./A-4643-2008	LaSalle, Janine M./0000-0002-3480-2031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030628] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS30628] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOTTANI A, 1994, AM J MED GENET, V51, P35, DOI 10.1002/ajmg.1320510109; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CROUSE HV, 1960, GENETICS, V45, P1429; EMMERICH P, 1989, EXP CELL RES, V181, P126, DOI 10.1016/0014-4827(89)90188-2; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LALANDE M, 1994, NAT GENET, V8, P5, DOI 10.1038/ng0994-5; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LASALLE JM, UNPUB; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LESKO SA, 1995, EXP CELL RES, V219, P499, DOI 10.1006/excr.1995.1258; LEWIS JP, 1993, HUM GENET, V92, P577, DOI 10.1007/BF00420942; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robinson W. P., 1993, European Journal of Human Genetics, V1, P280; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TSAI JY, 1991, GENETICS, V129, P1159; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	32	209	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					725	728		10.1126/science.272.5262.725	http://dx.doi.org/10.1126/science.272.5262.725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614834				2022-12-24	WOS:A1996UJ05100052
J	Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF				Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF			Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: Parallels between pathogen accommodation and mitochondrial endosymbiosis	CELL			English	Article							OUTER-MEMBRANE PROTEINS; DEPENDENT ANION CHANNEL; HUMAN EPITHELIAL-CELLS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; LIPID BILAYERS; GONOCOCCAL-INFECTION; SELECTIVE CHANNELS; RECEPTOR PROTEIN; BACTERIAL PORIN	PorB of the pathogenic Neisseria species belongs to the large family of pore-forming proteins (porins) produced by gram-negative bacteria. PorB is exceptional in that it is capable of translocating vectorially into membranes of infected target cells and functions in the infection process. Here we report on an unexpected similarity between Neisserial PorB and mitochondrial porins. Both porin classes interact with purine nucleoside triphosphates, which down-regulate pore size and cause a shift in voltage dependence and ion selectivity. Patch-clamp analyses indicate that PorB channel activity is tightly regulated in intact epithelial cells. In light of recent findings on the pivotal role of PorB in virulence and the prevention of phagosome lysosome fusion, these data provide important mechanistic clues on the intracellular pathogen accommodation reminiscent of mitochondrial endosymbiosis.	MAX PLANCK INST BIOL, INFEKT BIOL ABT, D-72076 TUBINGEN, GERMANY; MAX PLANCK INST INFEKT BIOL, MOLEK BIOL ABT, D-10117 BERLIN, GERMANY; UNIV WURZBURG, THEODOR BOVERI INST BIOZENTRUM, LEHRSTUHL BIOTECHNOL, D-97074 WURZBURG, GERMANY; UNIV TUBINGEN, INST PHYSIOL 1, D-72076 TUBINGEN, GERMANY	Max Planck Society; Max Planck Society; University of Wurzburg; Eberhard Karls University of Tubingen			Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Benz, Roland/0000-0002-9510-9265				BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BENZ R, 1992, BIOL CHEM H-S, V373, P295, DOI 10.1515/bchm3.1992.373.1.295; Benz R., 1994, BACTERIAL CELL WALL, P397; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Blake M.S., 1985, PATHOGENESIS BACTERI, P51; BLAKE MS, 1987, BACTERIAL OUTER MEMB, P377; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; GRAY PTA, 1984, PROC R SOC SER B-BIO, V221, P395, DOI 10.1098/rspb.1984.0041; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HAINES KA, 1988, J BIOL CHEM, V263, P945; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANCOCK REW, 1982, J BACTERIOL, V150, P730, DOI 10.1128/JB.150.2.730-738.1982; HANCOCK REW, 1992, J BACTERIOL, V174, P471, DOI 10.1128/jb.174.2.471-476.1992; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; JALONEN T, 1989, ACTA PHYSIOL SCAND, V136, P611, DOI 10.1111/j.1748-1716.1989.tb08709.x; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOLB HA, 1991, REV PHYSIOL BIOCH P, V118, P1; KOLB HA, 1987, BIOCHIM BIOPHYS ACTA, V899, P239, DOI 10.1016/0005-2736(87)90405-6; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; KRIEGERBRAUER HJ, 1980, ARCH MICROBIOL, V124, P233, DOI 10.1007/BF00427732; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MAIER C, 1988, J BIOL CHEM, V263, P2493; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MARRERO H, 1991, EUR J NEUROSCI, V3, P813, DOI 10.1111/j.1460-9568.1991.tb01677.x; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MCGEE ZA, 1981, J INFECT DIS, V143, P413, DOI 10.1093/infdis/143.3.413; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; NEWHALL WJ, 1980, INFECT IMMUN, V28, P785; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SANDSTROM EG, 1984, SEX TRANSM DIS, V11, P77, DOI 10.1097/00007435-198404000-00005; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SCHWARZE W, 1984, PFLUG ARCH EUR J PHY, V402, P281, DOI 10.1007/BF00585511; SHAFER WM, 1989, ANNU REV MICROBIOL, V43, P121; SIEHNEL RJ, 1988, MOL MICROBIOL, V2, P347, DOI 10.1111/j.1365-2958.1988.tb00038.x; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOKUNAGA H, 1981, J BIOL CHEM, V256, P8024; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1988, BIOCHIM BIOPHYS ACTA, V938, P493, DOI 10.1016/0005-2736(88)90148-4; TROLL H, 1992, J BIOL CHEM, V267, P21072; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VIRJI M, 1992, MOL MICROBIOL, V6, P2785, DOI 10.1111/j.1365-2958.1992.tb01458.x; WARD MJ, 1992, FEMS MICROBIOL LETT, V94, P283, DOI 10.1111/j.1574-6968.1992.tb05332.x; WEEL JFL, 1991, RES MICROBIOL, V142, P985, DOI 10.1016/0923-2508(91)90009-Y; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WHITIN JC, 1980, J BIOL CHEM, V255, P1874; ZIZI M, 1994, J BIOL CHEM, V269, P1614	81	95	99	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					391	402		10.1016/S0092-8674(00)81117-4	http://dx.doi.org/10.1016/S0092-8674(00)81117-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616894	Bronze, Green Published			2022-12-24	WOS:A1996UK14000012
J	Condos, R; McClune, A; Rom, WN; Schluger, NW				Condos, R; McClune, A; Rom, WN; Schluger, NW			Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; DIAGNOSIS; STRAINS	Background There is a need for rapid diagnosis of pulmonary tuberculosis. We have previously used a PCR to detect circulating Mycobacterium tuberculosis DNA in blood samples from patients (mostly HIV-infected) with pulmonary tuberculosis. We have now prospectively investigated the role of this blood-based PCR assay for diagnosis of this disease in a clinical setting. Methods Our PCR assay is specific for the IS6110 insertion element of the M tuberculosis complex of organisms. We used it to test peripheral blood from 88 consecutive patients admitted to a chest ward with suspected pulmonary tuberculosis. Personnel who carried out the assay did not know the results of any clinical investigations and ultimate diagnosis, and clinicians did not know the PCR results. Results of the PCR assay were compared with the final clinical diagnosis. A subgroup of 15 patients had blood samples assayed serially to track the PCR signal over time. Findings 41 patients had a final clinical diagnosis of tuberculosis, and the cases were typical of those seen at our hospital: HIV infection was common, and most cases were not sputum-smear positive for acid-fast bacilli. The PCR assay correctly identified 39 of 41 patients with proven pulmonary tuberculosis, 26 (63%) of whom were sputum-smear negative. There were five patients in whom a positive PCR result did not accord with the final clinical diagnosis, and two of the 44 negative PCR results were classified as false negatives. The overall sensitivity and specificity of the PCR assay for a diagnosis of tuberculosis was 95% and 89%, respectively. In 15 patients with pulmonary tuberculosis and a positive blood assay, the PCR result remained positive after 1 month of therapy, but had reverted to negative in 13 of the 15 by 4 months of therapy. Interpretation We conclude that peripheral-blood-based PCR detection for the diagnosis of tuberculosis is a technically feasible approach that has a potentially important role in the diagnosis of pulmonary tuberculosis.	NYU,MED CTR & SCH MED,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR & SCH MED,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003030] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03030] Funding Source: Medline; PHS HHS [M01 00096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALUOCH JA, 1985, TUBERCLE, V66, P237, DOI 10.1016/0041-3879(85)90061-3; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; GODFREYFAUSSETT P, 1995, THORAX, V50, P709, DOI 10.1136/thx.50.7.709; GORDIN FM, 1983, AM REV RESPIR DIS, V139, P1090; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; KENNEDY N, 1994, J INFECT DIS, V170, P713, DOI 10.1093/infdis/170.3.713; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; SCHLUGER NW, 1994, LANCET, V344, P232, DOI 10.1016/S0140-6736(94)92999-8; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SCHLUGER NW, 1994, AM J RESP CRIT CARE, V149, P264, DOI 10.1164/ajrccm.149.1.8111591; SCHLUGERNW, 1995, AM J RESP CRIT CARE, V152, P11; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SMITH E, 1992, SCAND J INFECT DIS, V24, P109, DOI 10.3109/00365549209048409; WILSON SM, 1993, T ROY SOC TROP MED H, V87, P177, DOI 10.1016/0035-9203(93)90478-9; YAJKO DM, 1994, CLIN INFECT DIS, V19, P334, DOI 10.1093/clinids/19.2.334; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993	20	80	83	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1082	1085		10.1016/S0140-6736(96)90281-0	http://dx.doi.org/10.1016/S0140-6736(96)90281-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602060	hybrid			2022-12-24	WOS:A1996UG04200014
J	Zheng, C; Heintz, N; Hatten, ME				Zheng, C; Heintz, N; Hatten, ME			CNS gene encoding astrotactin, which supports neuronal migration along glial fibers	SCIENCE			English	Article							FETAL MONKEY NEOCORTEX; CEREBELLAR CORTEX; CELL MIGRATION; DIFFERENTIATION; SYSTEM; TIME	Vertebrate central nervous system (CNS) histogenesis depends on glia-guided migration of postmitotic neurons to form neuronal laminae. Previous studies have established that the neuronal protein astrotactin functions in murine cerebellar granule cell migration in vitro. The gene encoding astrotactin predicts a protein with three epidermal growth factor repeats and two fibronectin type III repeats. Astrotactin messenger RNA is expressed in postmitotic neuronal precursors in the cerebellum, hippocampus, cerebrum, and olfactory bulb, where migration establishes laminar structures. Fab fragments of antibodies to a recombinant astrotactin peptide blocked migration of cerebellar granule neurons in vitro along astroglial fibers. Transfection of astrotactin complementary DNA into 3T3 cells indicated that astrotactin acts as a ligand for neuron-glia binding during neuronal migration.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15429] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1994, CURRENT PROTOCOL S27, V2; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FISHELL G, 1991, DEVELOPMENT, V113, P755; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1993, SCIENCE, V260, P367, DOI 10.1126/science.8469990; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KUHAR S, 1993, DEVELOPMENT, V112, P97; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5	19	192	195	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					417	419		10.1126/science.272.5260.417	http://dx.doi.org/10.1126/science.272.5260.417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602532				2022-12-24	WOS:A1996UG25200049
J	Naylor, CD; Sermer, M; Chen, EL; Sykora, K				Naylor, CD; Sermer, M; Chen, EL; Sykora, K			Cesarean delivery in relation to birth weight and gestational glucose tolerance - Pathophysiology or practice style?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; SHOULDER DYSTOCIA; SCREENING-TESTS; PREGNANCY; COMPLICATIONS; CRITERIA; SECTION; REPRESENT; ONTARIO	Objectives.-To examine the relationship between birth weight and mode of delivery among women with untreated borderline gestational diabetes mellitus (GDM), treated overt GDM, and normoglycemia. Design.-Prospective cohort study. Setting.-Three Toronto, Ontario, teaching hospitals. Patients.-A total of 3778 volunteers aged 24 years or older. Interventions.-Subjects underwent a 3-hour, 100-g oral glucose tolerance test at 28 weeks' gestation, regardless of screening test results. Usual care was provided to 143 women who met the National Diabetes Data Group criteria for GDM, Physicians were blinded to glucose test results for all others, including 115 untreated women with borderline GDM by the broader criteria of Carpenter and Coustan. Main Outcome Measures.-Crude and adjusted rates of cesarean delivery and neonatal macrosomia (birth weight >4000 g). Results.-Compared with normoglycemic controls, the untreated borderline GDM group had increased rates of macrosomia (28.7% vs 13.7%, P<.001) and cesarean delivery (29.6% vs 20.2%, P=.02). Cesarean delivery in this subgroup was associated with macrosomia (45.5% vs 23.5%, P=.03). Usual care of known GDM normalized birth weights, but the cesarean delivery rate was about 33% whether macrosomia was present or absent. A clearly increased risk of cesarean delivery among treated patients compared with normoglycemic controls persisted after adjustment for multiple maternal risk factors (adjusted odds ratio, 2.1; 95% confidence interval, 1.3 to 3.6). Conclusions.-Infant macrosomia was a mediating factor in high cesarean delivery rates for women with untreated borderline GDM, While detection and treatment of GDM normalized birth weights, rates of cesarean delivery remained inexplicably high. Recognition of GDM may lead to a lower threshold for surgical delivery that mitigates the potential benefits of treatment.	UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,SUNNYBROOK UNIT,TORONTO,ON M5S 1A1,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto								ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; ANDERSON GM, 1989, CAN MED ASSOC J, V141, P1049; BUCHANAN TA, 1994, DIABETES CARE, V17, P275, DOI 10.2337/diacare.17.4.275; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1986, AM J OBSTET GYNECOL, V155, P1255, DOI 10.1016/0002-9378(86)90155-9; Freinkel N, 1985, Diabetes, V34 Suppl 2, P1; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GOLDMAN M, 1991, DIABETES, V40, P79, DOI 10.2337/diab.40.2.S79; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; HUNTER DS, 1991, EFFECTIVE CARE PREGN, P403; JACOBSON JD, 1989, AM J OBSTET GYNECOL, V161, P981, DOI 10.1016/0002-9378(89)90767-9; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4; LEIKIN EL, 1987, OBSTET GYNECOL, V69, P570; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUCAS MJ, 1993, OBSTET GYNECOL, V82, P260; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Metzger B E, 1985, Diabetes, V34 Suppl 2, P111; MODANLOU HD, 1982, OBSTET GYNECOL, V60, P417; NAYLOR CD, 1989, DIABETES CARE, V12, P565, DOI 10.2337/diacare.12.8.565; O'Sullivan JB, 1979, CARBOHYD METABOL, P425; OSULLIVAN JB, 1964, DIABETES, V13, P278; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; SAS Institute Inc, 1990, SAS STAT US GUID VER, P1; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; WALKINSHAW SA, 1993, PREGNANCY CHILDBIRTH; 1985, DIABETES S2, V34, P123; 1979, DIABETES, V28, P1039	34	262	269	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1165	1170		10.1001/jama.275.15.1165	http://dx.doi.org/10.1001/jama.275.15.1165			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609683				2022-12-24	WOS:A1996UE62500027
J	Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN				Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN			Is there a role for benefit-cost analysis in environmental, health, and safety regulation?	SCIENCE			English	Editorial Material									WORLD BANK,WASHINGTON,DC 20433; CHARLES RIVER ASSOCIATES INC,WASHINGTON,DC 20004; AMER ENTERPRISE INST PUBL POLICY RES,WASHINGTON,DC 20036; CARNEGIE MELLON UNIV,GRAD SCH IND ORG,PITTSBURGH,PA 15213; RESOURCES FUTURE INC,WASHINGTON,DC 20036; UNIV TENNESSEE,DEPT ECON,KNOXVILLE,TN 37996; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; DUKE UNIV,DURHAM,NC 27708; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	The World Bank; Charles River Associates; American Enterprise Institute for Public Policy Research; Carnegie Mellon University; Resources for the Future; University of Tennessee System; University of Tennessee Knoxville; Massachusetts Institute of Technology (MIT); Duke University; Harvard University	Arrow, KJ (corresponding author), STANFORD UNIV,DEPT ECON,STANFORD,CA 94305, USA.							Arrow KJ, 1996, BENEFIT COST ANAL EN; CHRISTIANSEN GB, 1985, HDB NATURAL RESOURCE, V1, P345; CROPPER ML, 1992, J ECON LIT, V30, P675; FRAAS A, 1991, LAW CONTEMP PROBL, V54, P113, DOI 10.2307/1191875; Freeman A.M., 1993, RESOURCES FUTURE, V1st ed.; Grubb W.Norton., 1984, ENV POLICY REAGANS E, P121; HAHN RW, IN PRESS RISKS COSTS; Hopkins T. D., 1992, COST REGULATION FILL; JAFFE AB, 1995, J ECON LIT, V33, P132; MORRALL JF, 1986, REGULATION, V10, P25; *OFF MAN BUDG, 1993, REG PROGR US GOV APR; *OFF MAN BUDG, 1995, BUDG US GOV FISC YEA; Schmalensee R, 1994, BALANCING EC GROWTH, P55	13	325	329	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					221	222		10.1126/science.272.5259.221	http://dx.doi.org/10.1126/science.272.5259.221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE729	8602504				2022-12-24	WOS:A1996UE72900028
J	Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC				Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC			Characterization and Inhibition of a cholecystokinin-inactivating serine peptidase	NATURE			English	Article							SYNAPTIC-MEMBRANES; BRAIN-SLICES; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENDOGENOUS CHOLECYSTOKININ; TETRAPEPTIDE DEGRADATION; ENKEPHALINASE INHIBITOR; SUBSTRATE-SPECIFICITY; OCTAPEPTIDE CCK-8; PROTEINS; AMINOPEPTIDASE	A cholecystokinin (CCK)-inactivating peptidase was purified and identified as a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4. 14. 10), a cytosolic subtilisin-like peptidase of previously unknown functions. The peptidase was found in neurons responding to cholecystokinin, as well as in non-neuronal cells. Butabindide, a potent and specific inhibitor, was designed and shown to protect endogenous cholecystokinin from inactivation and to display pro-satiating effects mediated by the CCKA receptor.	UNIV LONDON UNIV COLL, CHRISTOPHER INGOLD LABS, DEPT CHEM, LONDON WC1H 0AJ, ENGLAND; UNIV PARIS 05, FAC PHARM, F-75006 PARIS, FRANCE	University of London; University College London; UDICE-French Research Universities; Universite Paris Cite	Rose, C (corresponding author), CTR PAUL BROCA, INSERM, U109, UNITE NEUROBIOL & PHARMACOL, 2TER RUE ALESIA, F-75014 PARIS, FRANCE.							BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BAUMER P, 1992, GUT, V33, P753, DOI 10.1136/gut.33.6.753; CAMUS A, 1989, NEUROSCIENCE, V29, P595, DOI 10.1016/0306-4522(89)90133-4; CHARIOT J, 1990, AM J PHYSIOL, V259, pG198, DOI 10.1152/ajpgi.1990.259.2.G198; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIELSEN EM, 1977, BIOCHIM BIOPHYS ACTA, V494, P332, DOI 10.1016/0005-2795(77)90163-5; DESCHODTLANCKMAN M, 1984, PEPTIDES, V5, P649, DOI 10.1016/0196-9781(84)90098-6; DESCHODTLANCKMAN M, 1983, PEPTIDES, V4, P71, DOI 10.1016/0196-9781(83)90169-9; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; Dockray GJ, 1990, GASTROINTEST ENDOSC, P321; DURIEUX C, 1986, NEUROPEPTIDES, V7, P1, DOI 10.1016/0143-4179(86)90072-7; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GIROS B, 1987, J PHARMACOL EXP THER, V243, P666; HOKFELT T, 1980, NATURE, V285, P476, DOI 10.1038/285476a0; HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728; HUGHES J, 1989, NEUROPEPTIDE CHOLECY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLORENS C, 1980, BIOCHEM BIOPH RES CO, V96, P1710, DOI 10.1016/0006-291X(80)91371-6; LLORENSCORTES C, 1986, P NATL ACAD SCI USA, V83, P6226, DOI 10.1073/pnas.83.16.6226; LOTTI VJ, 1987, J PHARMACOL EXP THER, V241, P103; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATSAS R, 1984, FEBS LETT, V175, P124, DOI 10.1016/0014-5793(84)80583-9; MCDERMOTT JR, 1983, NEUROCHEM INT, V5, P641, DOI 10.1016/0197-0186(83)90058-X; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROSE C, 1988, P NATL ACAD SCI USA, V85, P8326, DOI 10.1073/pnas.85.21.8326; ROSE C, 1989, NEUROSCIENCE, V29, P583, DOI 10.1016/0306-4522(89)90132-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; SMITH GP, 1994, ANN NY ACAD SCI, V713, P236, DOI 10.1111/j.1749-6632.1994.tb44071.x; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEARDO L, 1985, J NEUROCHEM, V45, P784, DOI 10.1111/j.1471-4159.1985.tb04061.x; TARR GE, 1986, MICROCHARACTERIZATIO, P155; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; VANDERHAEGEN JJ, 1984, ANN NY ACAD SCI, V448, P1; Vanderhaeghen J.J., 1985, Handbook of Chemical Neuroanatomy, V4, P406; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; WHITTAKE.VP, 1966, ANN NY ACAD SCI, V137, P982, DOI 10.1111/j.1749-6632.1966.tb50211.x; WILSON C, 1993, NEUROCHEM RES, V18, P743, DOI 10.1007/BF00966768; WOODRUFF G, 1991, REV PHARM, V31, P469; ZUZEL KA, 1985, NEUROSCIENCE, V15, P149, DOI 10.1016/0306-4522(85)90129-0	50	141	147	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1996	380	6573					403	409		10.1038/380403a0	http://dx.doi.org/10.1038/380403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602240				2022-12-24	WOS:A1996UD59000051
J	Levin, JE; Miller, JP				Levin, JE; Miller, JP			Broadband neural encoding in the cricket cercal sensory system enhanced by stochastic resonance	NATURE			English	Article							PRIMARY INTERNEURONS; INFORMATION; REPRESENTATION	Sensory systems are often required to detect a small amplitude signal embedded in broadband background noise. Traditionally, ambient noise is regarded as detrimental to encoding accuracy. Recently, however, a phenomenon known as stochastic resonance has been described in which, for systems with a nonlinear threshold, increasing the input noise level can actually improve the output signal-to-noise ratio over a limited range of signal and noise strengths. Previous theoretical and experimental studies of stochastic resonance in physica(1-7) and biological(6-10) systems have dealt exclusively with single-frequency sine stimuli embedded in a broadband noise background. In the past year it has been shown in a theoretical and modelling study that stochastic resonance can be observed with broadband signals(11,12). Here we demonstrate that broadband stochastic resonance is manifest in the peripheral layers of neural processing in a simple sensory system, and that it plays a role over a wide range of biologically relevant stimulus parameters. Further, we quantify the functional significance of the phenomenon within the context of signal processing, using information theory.			Levin, JE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BIALEK W, 1993, PHYSICA A, V200, P581, DOI 10.1016/0378-4371(93)90563-J; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1991, J THEOR BIOL, V152, P531, DOI 10.1016/S0022-5193(05)80396-0; CAMHI JM, 1978, J COMP PHYSIOL, V128, P203, DOI 10.1007/BF00656853; COLLINS JJ, 1995, NATURE, V376, P236, DOI 10.1038/376236a0; COLLINS JJ, 1995, PHYS REV E, V52, pR3321, DOI 10.1103/PhysRevE.52.R3321; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; FAUUVE S, 1993, J POHYS LETT A, V97, P5; GNATZY W, 1990, J COMP PHYSIOL A, V167, P551, DOI 10.1007/BF00190826; KANOU M, 1984, J COMP PHYSIOL, V154, P357, DOI 10.1007/BF00605235; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; Shannon CE, 1949, MATH THEORY COMMUNIC, P64; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; THEUNISSEN FE, IN OPRESS J NEUROPHY; THEUNISSEN FE, 1993, THESIS U CALIFORNIA; TOBIAS M, 1979, J COMP PHYSIOL, V129, P51, DOI 10.1007/BF00679911; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; ZHOU T, 1990, PHYS REV A, V41, P4255, DOI 10.1103/PhysRevA.41.4255	23	599	615	2	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					165	168		10.1038/380165a0	http://dx.doi.org/10.1038/380165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600392				2022-12-24	WOS:A1996TZ97800053
J	DeRobertis, EM; Sasai, Y				DeRobertis, EM; Sasai, Y			A common plan for dorsoventral patterning in Bilateria	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; XENOPUS MESODERM; MELANOGASTER; INDUCTION; NOGGIN; STAGE	Functional studies seem now to confirm, as first suggested by E. Geoffroy Saint-Hilaire in 1822, that there was an inversion of the dorsoventral axis during animal evolution. A conserved system of extracellular signals provides positional information for the allocation of embryonic cells to specific tissue types both in Drosophila and vertebrates; the ventral region of Drosophila is homologous to the dorsal side of the vertebrate. Developmental studies are now revealing some of the characteristics of the ancestral animal that gave rise to the arthropod and mammalian lineages, for which we propose the name Urbilateria.			DeRobertis, EM (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869				Appel Toby A., 1987, CUVIER GEOFFROY DEBA; ARENDT D, 1994, NATURE, V371, P26, DOI 10.1038/371026a0; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CLEMENT JH, 1995, MECH DEVELOP, V52, P357, DOI 10.1016/0925-4773(95)00413-U; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DALE L, 1992, DEVELOPMENT, V115, P573; De Robertis E.M., 1994, P11; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; Haeckel E., 1874, Q J MICROSCOPIC SCI, V14, P142; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAWLEY SHB, 1995, GENE DEV, V9, P2913; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HOGEN BLM, 1995, NATURE, V376, P210; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JEFFERIES RPS, 1995, NATURE, V374, P22, DOI 10.1038/374022a0; JONES CM, 1995, CURR BIOL, V5, P574, DOI 10.1016/S0960-9822(95)00112-6; JONES CM, 1992, DEVELOPMENT, V115, P639; LACALLI TC, 1995, NATURE, V373, P110, DOI 10.1038/373110c0; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUBLERJUNG K, 1994, ROUX ARCH DEV BIOL, V203, P357, DOI 10.1007/BF00188683; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PETERSON KJ, 1995, NATURE, V373, P111, DOI 10.1038/373111a0; PHILIPPE H, 1994, DEVELOPMENT, P15; PREOBRAZHENSKII AA, 1985, DOKL AKAD NAUK SSSR+, V284, P1489; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1989, DEV BIOL, V134, P263, DOI 10.1016/0012-1606(89)90096-1; SCHIMDT JE, 1995, DEV BIOL, V169, P37; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; SUZUKI A, 1995, GROWTH DIFFERENT, V35, P581; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WILLMER CH, 1990, INVERTEBRATE RELATIO; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMADA, 1995, J CELL BIOL, V130, P217; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; ZUKER CS, 1994, SCIENCE, V265, P742, DOI 10.1126/science.8047881; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	57	555	568	4	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					37	40		10.1038/380037a0	http://dx.doi.org/10.1038/380037a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598900				2022-12-24	WOS:A1996TY87700047
J	Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R				Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R			Inhibition of monoamine oxidase B in the brains of smokers	NATURE			English	Article							L-DEPRENYL; PARKINSONS-DISEASE; CIGARETTE SMOKERS; TOBACCO-SMOKE; NEUROTOXICITY; STRIATUM; RATS	THE massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking(1). Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders(2) and is associated with a decreased risk of Parkinson's disease(3), Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine(4), as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species 5, We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.	SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fowler, JS (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.							BERLIN I, 1995, CLIN PHARMACOL THER, V58, P444, DOI 10.1016/0009-9236(95)90058-6; BERRY MD, 1994, PROG NEUROBIOL, V42, P375, DOI 10.1016/0301-0082(94)90081-7; BOULTON AA, 1988, LANCET, V1, P114; CARR LA, 1991, LIFE SCI, V48, P1173, DOI 10.1016/0024-3205(91)90455-K; CARR LA, 1990, NEUROPHARMACOLOGY, V29, P311, DOI 10.1016/0028-3908(90)90019-N; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DLUZEN DE, 1991, J NEURAL TRANSM-GEN, V85, P145, DOI 10.1007/BF01244706; Dougherty E. R., 1992, INTRO MORPHOLOGICAL; FOWLER JS, 1994, SYNAPSE, V18, P86, DOI 10.1002/syn.890180203; FOWLER JS, 1995, J NUCL MED, V36, P1255; FOWLER JS, 1988, J NEUROCHEM, V51, P1524, DOI 10.1111/j.1471-4159.1988.tb01121.x; Henningfield Jack E., 1995, P1715; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JOSSAN SS, 1987, BIOGENIC AMINES, V4, P371; KNOLL J, 1994, LIFE SCI, V54, P1047, DOI 10.1016/0024-3205(94)00415-3; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; NORMAN TR, 1987, PSYCHIAT RES, V20, P199, DOI 10.1016/0165-1781(87)90079-5; ORELAND L, 1981, LIFE SCI, V29, P2511, DOI 10.1016/0024-3205(81)90706-2; PATERSON IA, 1991, J PHARMACOL EXP THER, V258, P1019; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pavlin R, 1993, FARM VESTN, V44, P185; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RIEDERER P, 1986, J NEUROCHEM, V46, P1359, DOI 10.1111/j.1471-4159.1986.tb01747.x; STAPLETON JM, 1993, NIDA RES MONOGR, V132, P106; TARIOT PN, 1987, PSYCHOPHARMACOLOGY, V91, P489, DOI 10.1007/BF00216016; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; WANG GJ, 1994, J NUCL MED, V35, P1457; YAMASHITA K, 1988, GERONTOLOGY, V34, P199, DOI 10.1159/000212953; YONG VW, 1986, J NEUROL SCI, V72, P265, DOI 10.1016/0022-510X(86)90014-6; YU PH, 1987, LIFE SCI, V41, P675, DOI 10.1016/0024-3205(87)90446-2	31	519	538	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					733	736		10.1038/379733a0	http://dx.doi.org/10.1038/379733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602220				2022-12-24	WOS:A1996TW56700054
J	Bounameaux, H; Hicklin, L; Desmarais, S				Bounameaux, H; Hicklin, L; Desmarais, S			Seasonal variation in deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Bounameaux, H (corresponding author), UNIV HOSP GENEVA, DEPT INTERNAL MED, DIV ANGIOL & HAEMOSTASIS, CH-1211 GENEVA 4, SWITZERLAND.							COOKE EA, 1995, BRIT MED J, V310, P129, DOI 10.1136/bmj.310.6972.129b; GALLERANI M, 1992, EUR HEART J, V13, P661, DOI 10.1093/oxfordjournals.eurheartj.a060232; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; WROBLEWSKI BM, 1992, CLIN ORTHOP RELAT R, P222	5	55	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	1996	312	7026					284	285						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611784				2022-12-24	WOS:A1996TU50700022
J	Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL				Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL			The progression from hypertension to congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DYSFUNCTION; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; UNITED-STATES; FRAMINGHAM; MORTALITY; DISEASE; POPULATION; PREVALENCE	Objectives.-To study the relative and population-attributable risks of hypertension for the development of congestive heart failure (CHF), to assess the time course of progression from hypertension to CHF, and to identify risk factors that contribute to the development of overt heart failure in hypertensive subjects. Design.-Inception cohort study. Setting.-General community. Participants.-Original Framingham Heart Study and Framingham Offspring Study participants aged 40 to 89 years and free of CHF. To reflect more contemporary experience, the starting point of this study was January 1, 1970. Exposure Measures.-Hypertension (blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or current use of medications for treatment of high blood pressure) and other potential CHF risk factors were assessed at periodic clinic examinations. Outcome Measure.-The development of CHF. Results.-A total of 5143 eligible subjects contributed 72 422 person-years of observation. During up to 20.1 years of follow-up (mean, 14.1 years), there were 392 new cases of heart failure; in 91% (357/392), hypertension antedated the development of heart failure. Adjusting for age and heart failure risk factors in proportional hazards regression models, the hazard for developing heart failure in hypertensive compared with normotensive subjects was about 2-fold in men and 3-fold in women. Multivariable analyses revealed that hypertension had a high population-attributable risk for CHF, accounting for 39% of cases in men and 59% in women. Among hypertensive subjects, myocardial infarction, diabetes, left ventricular hypertrophy, and valvular heart disease were predictive of increased risk for CHF in both sexes. Survival following the onset of hypertensive CHF was bleak; only 24% of men and 31% of women survived 5 years. Conclusions.-Hypertension was the most common risk factor for CHF, and it contributed a large proportion of heart failure cases in this population-based sample. Preventive strategies directed toward earlier and more aggressive blood pressure control are likely to offer the greatest promise for reducing the incidence of CHF and its associated mortality.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Levy, D (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1007; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cox DR, 1984, ANAL SURVIVAL DATA, P48; Cutler Jeffrey A., 1995, P253; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; ERIKSSON H, 1988, ACTA MED SCAND, V223, P197; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; Furberg C D, 1986, Adv Cardiol, V34, P124; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GLYNN JR, 1993, LANCET, V342, P530, DOI 10.1016/0140-6736(93)91651-2; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; KANNEL W, 1988, FRAMINGHAM STUDY, P5; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1987, AM J CARDIOL, V60, pI85; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; *SAS I INC, 1992, P229 SAS I INC, P433; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1027; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; Vasan RS, 1996, ARCH INTERN MED, V156, P146, DOI 10.1001/archinte.156.2.146; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; VASAN RS, 1995, CIRCULATION S1, V92, P665; WACKERS FJ, 1976, BRIT HEART J, V38, P906; WONG WF, 1989, AM J CARDIOL, V63, P1526, DOI 10.1016/0002-9149(89)90022-2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1989, HYPERTENSION, V0013; 1994, MMWR-MORBID MORTAL W, V43, P77	55	1426	1489	3	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1557	1562		10.1001/jama.275.20.1557	http://dx.doi.org/10.1001/jama.275.20.1557			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622246				2022-12-24	WOS:A1996UL02900027
J	Staessen, JA; Roels, H; Fagard, R				Staessen, JA; Roels, H; Fagard, R			Lead exposure and conventional and ambulatory blood pressure - A prospective population study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; RENAL-FUNCTION; UNITED-STATES; HYPERTENSION; ASSOCIATION; FRAMINGHAM; ALCOHOL; HEALTH; TRIALS	Objective.-To evaluate in a prospective fashion the association between low-level lead exposure and blood pressure. Design.-Prospective cohort study. Setting.-General population. Participants.-A random population sample (N=728; 49% men; age range, 20-82 years) was studied in Belgium for 1985 through 1989 and reexamined for 1991 through 1995. Mean Outcome Measures.-At baseline and follow-up, blood pressure was measured by conventional sphygmomanometry (15 total readings) and at followup also by 24-hour ambulatory monitoring. Lead exposure was estimated from blood lead and zinc protoporphyrin concentrations. Multivariate analyses controlled for sex, age, body mass index, smoking and drinking habits, physical activity, exposure at work, social class, menopausal status, use of medications (antihypertensive medication, oral contraceptives, hormonal replacement therapy), hematocrit or hemoglobin, serum total calcium concentration, 24-hour urinary sodium and potassium excretion, and gamma-glutamyltransferase activity. Results.-At baseline, mean (SD) systolic/diastolic conventional blood pressure was 130 (17)/77 (9) mm Hg. The mean blood lead concentration was 0.42 mu mol/L (8.7 mu g/dL), and the mean zinc protoporphyrin concentration was 1.0 mu g per gram of hemoglobin. Over the 5.2-year median follow-up, the mean blood lead concentration dropped by 32% (0.14 mu mol/L [2.9 mu g/dL]) (P<.001). Small but significant (P<.01) changes occurred in systolic (-1.5 mm Hg) and diastolic (+1.7 mm Hg) conventional blood pressure and in zinc protoporphyrin concentration (+0.5 mu g per gram of hemoglobin). Over the follow-up period, no consistent associations emerged between the changes in conventional blood pressure and in blood lead or zinc protoporphyrin concentrations. In addition, after adjustment for sex, age, and body mass index, blood lead and zinc protoporphyrin concentrations at baseline did not predict the development of hypertension in 47 patients (risk ratio for doubling of the initial lead concentration, 1.2; 95% confidence interval, 0.7-2.0). In a time-integrated analysis in which each person was characterized by all available measurements, conventional blood pressure did not correlate with blood lead or zinc protoporphyrin concentrations in a consistent manner. Similarly, the mean (SD) 24-hour blood pressure at follow-up (119 [11]/71 [8] mm Hg; N=684) did not show a consistent relationship with blood lead or zinc protoporphyrin concentrations at baseline or at follow-up. Conclusions.-Lead exposure at the intensity studied (<1.45 mu mol/L [<30 mu g/dL]) was not consistently associated with increased conventional or 24-hour blood pressure in the general population or with increased risk of hypertension. These findings argue against the hypothesis that current lead exposure levels are associated with excess cardiovascular morbidity and mortality caused by hypertension.	UNIV LOUVAIN, DEPT MOL & CARDIOVASC RES, HYPERTENS & CARDIOVASC REHABIL UNIT, LOUVAIN, BELGIUM; UNIV LOUVAIN, IND TOXICOL & OCCUPAT MED UNIT, BRUSSELS, BELGIUM	Universite Catholique Louvain			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; Astrand PO., 1986, TXB WORK PHYSL PHYSL, P486; CHABANEL A, 1995, HYPERTENSION PATHOPH, V1, P365; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; COATE D, 1989, J HEALTH ECON, V8, P173, DOI 10.1016/0167-6296(89)90002-7; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONWAY J, 1988, J HYPERTENS, V6, P111; COOPER WC, 1985, SCAND J WORK ENV HEA, V11, P331, DOI 10.5271/sjweh.2215; ELLIOTT P, 1988, BRIT MED J, V297, P319; GARTSIDE PS, 1988, ENVIRON HEALTH PERSP, V78, P31, DOI 10.2307/3430495; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HARLAN WR, 1984, AM J EPIDEMIOL, V120, P17, DOI 10.1093/oxfordjournals.aje.a113870; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LOCKETT CJ, 1987, B ENVIRON CONTAM TOX, V38, P975, DOI 10.1007/BF01609083; Machin D, 1987, STAT TABLES DESIGN C, P89; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MANCIA G, 1983, LANCET, V2, P695; MCARDLE WD, 1991, EXERCISE PHYSL ENERG, P804; MOLLER L, 1992, AM J EPIDEMIOL, V136, P1091, DOI 10.1093/oxfordjournals.aje.a116574; NERI LC, 1988, ENVIRON HEALTH PERSP, V78, P123, DOI 10.2307/3430512; OBRIEN E, 1991, J HUM HYPERTENS, V5, P223; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; OLSEN NB, 1981, DAN MED BULL, V28, P168; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; Pickering TG., 1991, AMBULATORY MONITORIN; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; RABINOWITZ M, 1987, HYPERTENSION, V10, P447, DOI 10.1161/01.HYP.10.4.447; SCHMID RW, 1957, ANAL CHEM, V29, P264, DOI 10.1021/ac60122a026; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SIEGEL S, 1988, NONPARAMETRIC STAT B, P73; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1991, J HUM HYPERTENS, V5, P355; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1984, ACTA CARDIOL, V39, P55; Staessen J A, 1994, J Cardiovasc Risk, V1, P87; Staessen J.A., 1993, J HYPERTENS S2, V11, pS35; STAESSEN JA, 1995, J HUM HYPERTENS, V9, P303; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; Thijs L, 1992, HIGH BLOOD PRESSURE, V1, P17; *US EPA, 1986, US EPA PUBL, P1; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; YAMADA Y, 1991, HYPERTENSION, V18, P819, DOI 10.1161/01.HYP.18.6.819; 1990, J HYPERTENS       S6, V8, pS135	53	59	62	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1563	1570		10.1001/jama.275.20.1563	http://dx.doi.org/10.1001/jama.275.20.1563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622247				2022-12-24	WOS:A1996UL02900028
J	Thompson, D; Oster, G				Thompson, D; Oster, G			Use of terfenadine and contraindicated drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSEQUENCES	Objective.-To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling. Design.-Retrospective review of computerized pharmacy claims. Setting.-A large health insurer in New England. Patients.-Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994. Main Outcome Measures.-Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as (''same-day dispensing'') or had therapy days that overlapped those of (''overlapping use'') a prescription for terfenadine. Results.-Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84%, from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. Conclusions.-Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics and imidazole antifungals continues to occur.	POLICY ANAL INC,BROOKLINE,MA 02146	Policy Analysis Inc			Thompson, David/E-2431-2018	Thompson, David/0000-0001-8518-6307				[Anonymous], 1992, Med Lett Drugs Ther, V34, P9; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; CRANE JK, 1993, AM J MED, V95, P445, DOI 10.1016/0002-9343(93)90317-I; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HONIG PK, 1993, J CLIN PHARMACOL, V33, P1201, DOI 10.1002/j.1552-4604.1993.tb03920.x; *IMS AM LTD, 1995, 1995 NAT PRESCR AUD; MASHETER HC, 1993, CLIN REV ALLERG, V11, P5; *MM DOW INC, 1990, IMP DRUG WARN; *MM DOW INC, 1992, IMP DRUG WARN; *MM DOW INC, 1993, SELD PROD LAB; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; NIGHTINGALE SL, 1992, JAMA-J AM MED ASSOC, V268, P705, DOI 10.1001/jama.268.6.705; PECK CC, 1993, JAMA-J AM MED ASSOC, V269, P1550, DOI 10.1001/jama.269.12.1550; Pulmonary-Allergy Drugs Advisory Committee, 1990, P PULM ALL DRUGS ADV; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1535	16	88	88	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1339	1341		10.1001/jama.275.17.1339	http://dx.doi.org/10.1001/jama.275.17.1339			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614120				2022-12-24	WOS:A1996UG61200031
J	Enari, M; Talanian, RV; Wong, WW; Nagata, S				Enari, M; Talanian, RV; Wong, WW; Nagata, S			Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis	NATURE			English	Article								BINDING of Fas ligand or an agonistic anti-Fas antibody induces apoptosis in Fas-bearing cells(1). The interleukin-1 beta-converting enzyme (ICE) is a cysteine protease(2) that is involved in apoptosis induced by various stimuli, including Fas-mediated apoptosis(3-8). Several ICE homologues have been identified, and these are subdivided into three groups (ICE-, CPP32- and Ich-1-like proteases)(9-18). We show here that specific inhibitors of ICE- or CPP32-like proteases can inhibit Fas-mediated apoptosis. Transient ICE-like activity was found in the cytosolic fraction of Fas-activated cells, whereas ICE-dependent, CPP32-like activity gradually accumulated in the cytosol. Cell lysates from mouse lymphoma supplemented with either recombinant ICE or CPP32 induced apoptosis of nuclei. The CPP32 inhibitor inhibited ICE- or CPP32-induced apoptosis in the cell-free system, whereas the ICE-inhibitor only inhibited ICE-induced apoptosis. Cell extracts from thymocytes from ICE-null mice induced apoptosis in the cell-free system when it was supplemented with CPP32. These results indicate that Fas sequentially activates ICE- and CPP32-like proteases, and that downstream CPP32, together with a component(s) in the cytoplasm, causes apoptosis of nuclei.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; BASF BIORES CORP,WORCESTER,MA 01605; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	BASF; Osaka University			Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMBERY N, 1995, PERSP DRUG DISC DES, V2, P389; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TWARI M, 1995, CELL, V81, P801; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7	30	953	979	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					723	726		10.1038/380723a0	http://dx.doi.org/10.1038/380723a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614469				2022-12-24	WOS:A1996UG82700055
J	Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK				Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK			Neutrophil rolling altered by inhibition of L-selectin shedding in vitro	NATURE			English	Article							ADHESION MOLECULE-1; CHEMOTACTIC FACTORS; ENDOTHELIAL-CELLS; PRECURSOR; INFLAMMATION; CLEAVAGE; PROTEIN; INVIVO; ALPHA	THE L-selectin adhesion molecule is involved in guiding leukocytes to sites of inflammation(1). L-selectin is cleaved by an unusual proteolytic activity at a membrane-proximal site resulting in rapid shedding from the cell surface(2-7). Although it has been demonstrated that L-selectin mediates, in part, the early event of leukocyte rolling under hydrodynamic flows(8-10), the contribution of shedding to L-selectin function has remained unknown. Here we show that hydroxamic acid-based metalloprotease inhibitors block L-selectin downregulation from the cell surface of stimulated neutrophils, without affecting Mac-1 mobilization or general neutrophil activation, and inhibit cleavage of L-selectin in a cell-free system. Unexpectedly, the hydroxamic acid-based inhibitors reduced neutrophil rolling velocity under hydrodynamic flow, resulting in increased neutrophil accumulation. These results suggest that L-selectin is cleaved in seconds-much faster than previously suspected-during the process of rolling under hydrodynamic flow, and that shedding of L-selectin may contribute significantly to the velocity of leukocyte rolling, L-selectin shedding during rolling interactions may be physiologically important for limiting leukocyte aggregation and accumulation at sites of inflammation.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,RIDGEFIELD,CT 06877; KHEPRI PHARMACEUT INC,S SAN FRANCISCO,CA 94080; UNIV LOUISVILLE,DEPT CHEM,LOUISVILLE,KY 40292; UNIV LOUISVILLE,DEPT BIOCHEM,LOUISVILLE,KY 40292	Boehringer Ingelheim; Boehringer Ingelheim; University of Louisville; University of Louisville								ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; HAMANN A, 1988, J IMMUNOL, V140, P737; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LEY K, 1991, BLOOD, V77, P2553; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SIMON SI, 1992, J IMMUNOL, V149, P2765; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPATOLA AF, 1992, PEPTIDES CHEM BIOL, P820; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	32	260	269	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					720	723		10.1038/380720a0	http://dx.doi.org/10.1038/380720a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614468				2022-12-24	WOS:A1996UG82700054
J	Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R				Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R			Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2	NATURE			English	Article							BINDING; LIBRARY; LIGANDS	A NETWORK of interacting proteins controls the activity of cyclin-dependent kinase 2 (Cdk2) (refs 1, 2) and governs the entry of higher eukaryotic cells into S phase. Analysis of this and other genetic regulatory networks would be facilitated by intracellular reagents that recognize specific targets and inhibit specific network connections. We report here the expression of a combinatorial library of constrained 20-residue peptides displayed by the active-site loop of Escherichia coli thioredoxin, and the use of a two-hybrid system to select those that bind human Cdk2. These peptide aptamers were designed to mimic the recognition function of the complementarity-determining regions of immunoglobulins. The aptamers recognized different epitopes on the Cdk2 surface with equilibrium dissociation constant in the nanomolar range; those tested inhibited Cdk2 activity. Our results show that peptide aptamers bear some analogies with monoclonal antibodies, with the advantages that they are isolated together with their coding genes, that their small sizes should allow their structures to be solved, and that they are designated to function inside cells.	MASSACHUSETTS GEN HOSP, DEPT BIOL MOLEC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; GENET INST INC, CAMBRIDGE, MA 02142 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Colas, Pierre/0000-0001-7436-3718				Ausubel F.M., 1987, CURRENT PROTOCOLS MO; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KATO J, 1993, GENE DEV, V7, P331; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MCCONNELL SJ, 1994, GENE, V151, P115, DOI 10.1016/0378-1119(94)90640-8; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; REYMOND A, 1995, ONCOGENE, V11, P1173; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	26	336	410	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					548	550		10.1038/380548a0	http://dx.doi.org/10.1038/380548a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606778				2022-12-24	WOS:A1996UE66300056
J	Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC				Duchosal, MA; Rothermel, AL; McConahey, PJ; Dixon, FJ; Altieri, DC			In vivo immunosuppression by targeting a novel protease receptor	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; B-CELL LYMPHOMAS; PBL-SCID MICE; LYMPHOPROLIFERATIVE DISEASE; T-CELLS; ACTIVATION; PATHOGENESIS; GENERATION; MECHANISM	MEMBRANE receptors for blood proteases govern the clotting(1) and fibrinolytic(2) cascades, regulate signal transduction(3,4), and control the growth of mesenchymal cells(5,6). Despite their importance in the development of vascular injury(7), it is unclear whether these mechanisms participate in the generation of an immune response. Here we report that targeting a factor Xa receptor, designated effector cell protease receptor-1 (EPR-1), with antisense oligonucleotide or with a monoclonal antibody (mAb 2E1)(8) inhibited CD3/T-cell receptor-dependent lymphocyte proliferation. Immunosuppression was mediated by abolishing cytokine production and down-modulating membrane expression of the interleukin (IL)-2 receptor. In vivo administration of mAb 2E1 to severe-combined-immunodeficient mice injected with human peripheral blood leukocytes suppressed production of human immunoglobulin, abolished graft-versus-host disease, and protected these xenochimaeric mice from Epstein-Barr-virus-induced human lymphoproliferative disease. These observations indicate a new role for protease receptors in the regulation of the immune response, and identify a potential target for therapeutic immunosuppression in humans.	RW JOHNSON PHARMACEUT RES INST, RARITAN, NJ 08869 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; YALE UNIV, BOYER CTR MOLEC MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Yale University	Duchosal, MA (corresponding author), CHU VAUDOIS, DEPT INTERNAL MED, DIV HAEMATOL, CH-1011 LAUSANNE, SWITZERLAND.							ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; DUCHOSAL MA, 1992, AM J PATHOL, V141, P1097; DUCHOSAL MA, 1992, NATURE, V355, P258, DOI 10.1038/355258a0; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; JANEWAY CA, 1993, CURR OPIN IMMUNOL, V5, P313, DOI 10.1016/0952-7915(93)90048-W; JENKINS MK, 1993, CURR OPIN IMMUNOL, V5, P361, DOI 10.1016/0952-7915(93)90054-V; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MOSIER DE, 1989, NATURE, V338, P211, DOI 10.1038/338211b0; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1991, NATURE, V353, P509, DOI 10.1038/353509c0; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; OKANO M, 1990, AM J PATHOL, V137, P517; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PICCHIO GR, 1992, CANCER RES, V52, P2468; PIRRUCCELLO SJ, 1992, AM J PATHOL, V140, P1187; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN BL, 1991, J IMMUNOL, V147, P2493; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER C, 1987, EUR J IMMUNOL, V17, P873, DOI 10.1002/eji.1830170622	28	26	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 28	1996	380	6572					352	356		10.1038/380352a0	http://dx.doi.org/10.1038/380352a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598931				2022-12-24	WOS:A1996UC37900062
J	Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P				Mengaud, J; Ohayon, H; Gounon, P; Mege, RM; Cossart, P			E-cadherin is the receptor for internalin, a surface protein required for entry of L-monocytogenes into epithelial cells	CELL			English	Article							CULTURED MAMMALIAN-CELLS; GRAM-POSITIVE COCCI; ADHESION MOLECULES; LISTERIA-MONOCYTOGENES; MEDIATED-IMMUNITY; INVASIN PROTEIN; IDENTIFICATION; UVOMORULIN; BACTERIA; DOMAIN	We report the first identification of a cellular receptor mediating entry of a gram-positive bacterium into nonphagocytotic cells. By an affinity chromatography approach, we identified E-cadherin as the ligand for internalin, an L. monocytogenes protein essential for entry into epithelial cells. Expression of the chicken homolog of E-cadherin (L-CAM) in transfected fibroblasts dramatically increases entry of L. monocytogenes and promotes that of a recombinant L. innocua strain expressing internalin but does not promote entry of the wild-type noninvasive L. innocua or that of an internalin-deficient mutant of L. monocytogenes. Furthermore, L-CAM-specific antibodies block internalin-mediated entry. In contrast to Salmonella, Listeria enters cells by a mechanism of induced phagocytosis occurring without membrane ruffling. This work reveals a novel type of heterophilic interactions for E-cadherin.	INST PASTEUR, UNITE INTERACT BACTERIES CELLULES, F-75724 PARIS 15, FRANCE; INST PASTEUR, STN CENT MICROSCOPIE ELECT, F-75724 PARIS 15, FRANCE; INSERM, U440, F-75005 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mege, Rene Marc/M-9569-2013	Mege, Rene-Marc/0000-0001-8128-5543				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; BRAY DF, 1993, MICROSC RES TECHNIQ, V26, P489, DOI 10.1002/jemt.1070260603; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; DRAMSI S, 1993, MOL MICROBIOL, V9, P931, DOI 10.1111/j.1365-2958.1993.tb01223.x; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; Finlay B B, 1994, Curr Top Microbiol Immunol, V192, P163; FINLAY BB, 1991, J CELL SCI, V99, P283; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1985, J EXP MED, V161, P1384, DOI 10.1084/jem.161.6.1384; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GAILLARD JL, 1994, METHOD ENZYMOL, V236, P551; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAPLAN G, 1977, SCAND J IMMUNOL, V6, P797, DOI 10.1111/j.1365-3083.1977.tb02153.x; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEPAY DA, 1985, J EXP MED, V161, P1503, DOI 10.1084/jem.161.6.1503; MACDONALD TT, 1980, INFECT IMMUN, V28, P516; MARCO AJ, 1992, J COMP PATHOL, V107, P1, DOI 10.1016/0021-9975(92)90090-H; MASON I, 1994, CURR BIOL, V4, P1158, DOI 10.1016/S0960-9822(00)00263-3; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILLER VL, 1994, INVASION GENES YERSI, P213; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Parsot C, 1994, Curr Top Microbiol Immunol, V192, P217; RACZ P, 1972, LAB INVEST, V26, P694; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P89, DOI 10.1016/S0962-8924(00)88956-4; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG P, 1994, MOL BIOL CELL, V5, P455, DOI 10.1091/mbc.5.4.455; TEMMGROVE CJ, 1994, J CELL SCI, V107, P2951; VELGE P, 1994, MICROB PATHOGENESIS, V17, P37, DOI 10.1006/mpat.1994.1050; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WILLEMS J, 1995, FEBS LETT, V363, P289, DOI 10.1016/0014-5793(95)00334-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	63	667	687	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					923	932		10.1016/S0092-8674(00)81070-3	http://dx.doi.org/10.1016/S0092-8674(00)81070-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601315	Bronze			2022-12-24	WOS:A1996UC38100013
J	Crossley, PH; Martinez, S; Martin, GR				Crossley, PH; Martinez, S; Martin, GR			Midbrain development induced by FGF8 in the chick embryo	NATURE			English	Article							EXPRESSION PATTERNS; INT-1 PROTOONCOGENE; MOUSE-BRAIN; HOMEO BOX; EN-2; PHENOTYPE; REGION; WNT-1; GENES	Vertebrate midbrain development depends on an organizing centre located at the isthmus, a constriction in the embryonic mid/hindbrain region-(1-3,28). Isthmic tissue grafts transform chick caudal forebrain into an ectopic midbrain that is the mirror image of the normal midbrain(4). Here we report that FGF8 protein has the same midbrain-inducing and polarizing effect as isthmic tissue. Moreover, FGF8 induces ectopic expression in the forebrain of genes normally expressed in the isthmus, suggesting that the ectopic midbrain forms under the influence of signals from a new 'isthmus-like' organizing centre induced in the forebrain. Because Fgf8 itself is expressed in the isthmus, our results identify FGF8 as an important signalling molecule in normal midbrain development.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV ALICANTE,INST NEUROSCI,ALACANT,SPAIN; UNIV MURCIA,FAC MED,DEPT MORPHOL SCI,E-30001 MURCIA,SPAIN	University of California System; University of California San Francisco; Universitat d'Alacant; University of Murcia	Crossley, PH (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926				ANG SL, 1993, DEVELOPMENT, V118, P139; BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BALLYCUIF L, 1994, DEVELOPMENT, V120, P3379; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; GARDNER CA, 1992, DEV DYNAM, V193, P370, DOI 10.1002/aja.1001930410; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; MARIN F, 1994, DEV BIOL, V163, P19, DOI 10.1006/dbio.1994.1120; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUBENSTEIN J, 1995, SCIENCE, V266, P578; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; WILKINSON D, 1992, IN SITU HYBRIDISATIO; WURST W, 1994, DEVELOPMENT, V120, P2065	28	597	604	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 7	1996	380	6569					66	68		10.1038/380066a0	http://dx.doi.org/10.1038/380066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598907				2022-12-24	WOS:A1996TY87700057
J	Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M				Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M			Nuclear magnetic resonance imaging with hyperpolarised helium-3	LANCET			English	Article								Background Magnetic resonance imaging (MRI) relies on magnetisation of hydrogen nuclei (protons) of water molecules in tissue as source of the signal. This technique has been valuable for studying tissues that contain significant amounts of water, but biological settings with low proton content, notably the lungs, are difficult to image. We report use of spin-polarised helium-3 for lung MRI. Methods A volunteer inhaled hyperpolarised He-3 to fill the lungs, which were imaged with a conventional MRI detector assembly. The nuclear spin polarisation of helium, and other noble gases, can be greatly enhanced by laser optical pumping and is about 10(5) times larger than the polarisation of water protons, This enormous gain in polarisation easily overcomes the loss in signal due to the lower density of the gas. Findings The in-vivo experiment was done in a whole-body MRI scanner. The He-3 image showed clear demarcation of the lung against diaphragm, heart, chest wall, and blood vessels (which gave no signal). The signal intensity within the air spaces was greatest in lung regions that are preferentially ventilated in the supine position; less well ventilated areas, such as the apices, showed a weaker signal. Interpretation MRI with hyperpolarised He-3 gas could be an alternative to established nuclear medicine methods, The ability to image air spaces offers the possibility of investigating physiological and pathophysiological processes in pulmonary ventilation and differences in its regional distribution.	UNIV MAINZ,INST PHYS,D-55099 MAINZ,GERMANY; UNIV MAINZ,KLIN POLIKLIN RADIOL,D-55099 MAINZ,GERMANY; ECOLE NORMALE SUPER,F-75231 PARIS,FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM,FORSCH SCHWERPUNKT RADIOL DIAGNOST & THERAPIE,HEIDELBERG,GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Helmholtz Association; German Cancer Research Center (DKFZ)								ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; AMINOFF CG, 1989, REV PHYS APPL, V24, P827, DOI 10.1051/rphysap:01989002408082700; BECKER J, 1994, NUCL INSTRUM METH A, V346, P45, DOI 10.1016/0168-9002(94)90687-4; ECKERT G, 1992, NUCL INSTRUM METH A, V320, P53, DOI 10.1016/0168-9002(92)90769-Z; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HEIL W, 1995, PHYS LETT A, V201, P337, DOI 10.1016/0375-9601(95)00243-V; HEIL W, IN PRESS J NEUTRON R; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; SAAM B, 1995, PHYS REV A, V52, P862, DOI 10.1103/PhysRevA.52.862; WEST JB, 1971, LANCET, V1, P839; WEST JB, 1972, J APPL PHYSIOL, V32, P332, DOI 10.1152/jappl.1972.32.3.332	11	168	175	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1297	1299		10.1016/S0140-6736(96)90940-X	http://dx.doi.org/10.1016/S0140-6736(96)90940-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622506				2022-12-24	WOS:A1996UK75800011
J	Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA				Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA			Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; PRIMARY HIV-1 INFECTION; BIOLOGICAL PHENOTYPE; SYNDROME AIDS; CLONAL POOLS; POPULATIONS; TRANSMISSION; PROGRESSION; SEQUENCES; DIVERSITY	The rate of progression to disease varies considerably among individuals infected with human immunodeficiency virus-type 1 (HIV-1). Analyses of semiannual blood samples obtained from six infected men showed that a rapid rate of CD4 T cell loss was associated with relative evolutionary stasis of the HIV-1 quasispecies virus population. More moderate rates of CD4 T cell loss correlated with genetic evolution within three of four subjects. Consistent with selection by the immune constraints of these subjects, amino acid changes were apparent within the appropriate epitopes of human leukocyte antigen class I-restricted cytotoxic T lymphocytes. Thus, the evolutionary dynamics exhibited by the HIV-1 quasispecies virus populations under natural selection are compatible with adaptive evolution.	LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA; AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; ROCKEFELLER UNIV, NEW YORK, NY 10016 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Rockefeller University	Wolinsky, SM (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Korber, Bette/0000-0002-2026-5757; Wolinsky, Steven/0000-0002-9625-6697; Furtado, Manohar/0000-0001-6016-1357	NIAID NIH HHS [AI45218, AI35522, AI32535] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035522, R01AI035522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1995, J VIROL, V69, P1001, DOI 10.1128/JVI.69.2.1001-1012.1995; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASJO B, 1986, LANCET, V2, P660; AUTRAN B, 1996, 10 C CEUT GARD, P118; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BUCHBINDER S, 1994, AIDS, V8, P393; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELATORRE JC, 1990, J VIROL, V64, P664, DOI 10.1128/JVI.64.2.664-671.1990; DELWART E, UNPUB; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; Eigen M., 1988, RNA GENETICS, V3, P211; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; Felsenstein J, 1993, PHYLIP PHYLOGENY INT; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; Ganeshan S., UNPUB; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GRASSBERGER P, 1983, PHYS LETT A, V97, P227, DOI 10.1016/0375-9601(83)90753-3; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HENIKOFF S, 1991, NEW BIOL, V3, P1148; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; IVERSEN AKN, 1995, J VIROL, V69, P5743, DOI 10.1128/JVI.69.9.5743-5753.1995; JOHNSON RP, 1993, J VIROL, V67, P438, DOI 10.1128/JVI.67.1.438-445.1993; KELT I, 1994, J INFECT DIS, V169, P1236; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; KORBER BTM, 1995, NATURE, V378, P242, DOI 10.1038/378242a0; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, UNPUB; KUIKEN CL, 1992, J VIROL, V66, P4622, DOI 10.1128/JVI.66.7.4622-4627.1992; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANDE R, 1985, P NATL ACAD SCI USA, V82, P7641, DOI 10.1073/pnas.82.22.7641; LEARMONT J, 1993, LANCET, V341, P113; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MULLINS J, 1994, 9 C CENT GENT GARD, P77; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; Myers G, 1994, HUMAN RETROVIRUSES A; NEWMAN CM, 1985, NATURE, V315, P400, DOI 10.1038/315400a0; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, 1995, NATURE, V375, P534; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; Renyi A., 1970, PROBABILITY THEORY; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SAAG MS, 1991, J EXP MED, V172, P1055; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SCHRAGER LK, 1994, AIDS, V8, P895; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; STEINHAUER DA, 1989, J VIROL, V63, P2063, DOI 10.1128/JVI.63.5.2063-2071.1989; STEINHAUER DA, 1989, J VIROL, V63, P2072, DOI 10.1128/JVI.63.5.2072-2080.1989; SWOFFEND D, 1988, THESIS U ILLINOIS UR; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY S, UNPUB; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; WOLINSKY SM, 1994, 9 C CENT GENT GARD, P95; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; WRIGHT S, 1977, EVOLUTION GENETICS P, V1; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	94	496	513	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					537	542		10.1126/science.272.5261.537	http://dx.doi.org/10.1126/science.272.5261.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614801				2022-12-24	WOS:A1996UG82600041
J	Presti, JC				Presti, JC			Estrogen therapy for prostate carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CANCER				Presti, JC (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT UROL,SAN FRANCISCO,CA 94143, USA.							BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; HENRIKSSON P, 1986, BRIT MED J, V293, P413, DOI 10.1136/bmj.293.6544.413; JOHANSSON JE, 1991, J UROLOGY, V145, P519, DOI 10.1016/S0022-5347(17)38385-4; 1984, NEW ENGL J MED, V311, P1281	4	5	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1153	1153		10.1001/jama.275.15.1153	http://dx.doi.org/10.1001/jama.275.15.1153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609673				2022-12-24	WOS:A1996UE62500010
J	Becker, L; Poreda, RJ; Bada, JL				Becker, L; Poreda, RJ; Bada, JL			Extraterrestrial helium trapped in fullerenes in the sudbury impact structure	SCIENCE			English	Article							ION-MOLECULE REACTIONS; CIRCUMSTELLAR CHEMISTRY; ALLENDE METEORITE; ORGANIC-MOLECULES; INTERSTELLAR; CARBON; PARTICLES; DELIVERY; ORIGINS; GASES	Fullerenes (C-60 and C-70) in the Sudbury impact structure contain trapped helium with a He-3/He-4 ratio of 5.5 x 10(-4) to 5.9 x 10(-4). The He-3/He-4 ratio exceeds the accepted solar wind value by 20 to 30 percent and is higher by an order of magnitude than the maximum reported mantle value, Terrestrial nuclear reactions or cosmic-ray bombardment are not sufficient to generate such a high ratio. The He-3/He-4 ratios in the Sudbury fullerenes are similar to those found in meteorites and in some interplanetary dust particles. The implication is that the helium within the C-60 molecules at Sudbury is of extraterrestrial origin.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093; UNIV ROCHESTER,DEPT EARTH & ENVIRONM SCI,ROCHESTER,NY 14627	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Rochester	Becker, L (corresponding author), NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035, USA.							ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; ANDERS E, 1975, SCIENCE, V190, P1262, DOI 10.1126/science.190.4221.1262; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BECKER L, 1994, NATURE, V372, P507, DOI 10.1038/372507a0; BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; BLACK DC, 1969, EARTH PLANET SC LETT, V6, P395, DOI 10.1016/0012-821X(69)90190-3; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; HARE JP, 1992, ACCOUNTS CHEM RES, V25, P106, DOI 10.1021/ar00015a002; HEYMANN D, 1986, J GEOPHYS RES, V91, P135; JIMENEZVASQUEZ HA, IN PRESS J CHEM PHYS; JIMENEZVAZQUEZ HA, 1994, CHEM PHYS LETT, V229, P111, DOI 10.1016/0009-2614(94)01028-5; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO H, 1988, SCIENCE, V242, P1139, DOI 10.1126/science.242.4882.1139; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P38; LAL D, 1989, EARTH PLANET SC LETT, V96, P1, DOI 10.1016/0012-821X(89)90118-0; LEWIS RS, 1976, METEORITICS, V11, P320; MAMYRIN BA, 1984, HELIUM ISOTOPESNATUR; MATSUDA JI, 1980, GEOCHIM COSMOCHIM AC, V44, P1861, DOI 10.1016/0016-7037(80)90235-5; NIEMEYER S, 1981, P LUNAR PLANET SCI, V12, P1177; NIER AO, 1992, METEORITICS, V27, P166, DOI 10.1111/j.1945-5100.1992.tb00744.x; NIER AO, 1990, GEOCHIM COSMOCHIM AC, V54, P173, DOI 10.1016/0016-7037(90)90205-Y; OTT U, 1981, GEOCHIM COSMOCHIM AC, V45, P1751, DOI 10.1016/0016-7037(81)90009-0; OZIMA M, 1984, NATURE, V311, P449; Ozima M., 1983, NOBLE GAS GEOCHEMIST; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P662; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; RISON W, 1983, EARTH PLANET SC LETT, V66, P367; ROBL TL, 1993, ORG GEOCHEM, V20, P249, DOI 10.1016/0146-6380(93)90042-A; SAUNDERS M, 1993, SCIENCE, V259, P1428, DOI 10.1126/science.259.5100.1428; Saunders M, 1996, SCIENCE, V271, P1693, DOI 10.1126/science.271.5256.1693; SMALLEY RE, 1991, J PHYS CHEM-US, V95, P7564; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SWART PK, 1983, SCIENCE, V220, P406, DOI 10.1126/science.220.4595.406; SWINDLE TD, 1988, METEORITES EARLY SOL, P535; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; WEISKE T, 1991, CHEM PHYS LETT, V193, P97; ZINNER E, 1995, METEORITICS, V30, P209, DOI 10.1111/j.1945-5100.1995.tb01115.x; ZINNER E, 1990, LUNAR PLANET SCI, V21, P1379	45	78	84	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					249	252		10.1126/science.272.5259.249	http://dx.doi.org/10.1126/science.272.5259.249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602508	Green Published			2022-12-24	WOS:A1996UE72900036
J	Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR				Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR			A neural basis for lexical retrieval	NATURE			English	Article							BRAIN; SYSTEMS; ORGANIZATION; RECOGNITION; LANGUAGE; APHASIA; ANATOMY; SPEECH; NOUNS; VERBS	Two parallel studies using positron emission tomography, one conducted in neurological patients with brain lesions, the other in normal individuals, indicate that the normal process of retrieving words that denote concrete entities depends in part on multiple regions of the left cerebral hemisphere, located outside the classic language areas. Moreover, anatomically separable regions tend to process words for distinct kinds of items.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, POSITRON EMISS TOMOG IMAGING CTR, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of Iowa; University of Iowa; Salk Institute			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1992, NEW ENGL J MED, V326, P531, DOI 10.1056/NEJM199202203260806; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1992, SCI AM, V267, P89; DAMASIO AR, 1990, S QUANTITATIVE BIOL, V55, P1039; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAMASIO H, 1993, INT CONGR SER, V1030, P465; DANIELE A, 1994, NEUROPSYCHOLOGIA, V32, P1325, DOI 10.1016/0028-3932(94)00066-2; DEHAENE S, 1995, NEUROREPORT, V6, P2153, DOI 10.1097/00001756-199511000-00014; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; GOODGLASS H, 1986, CORTEX, V22, P87, DOI 10.1016/S0010-9452(86)80034-X; GRABOWSKI TJ, IN PRESS HUM BRAIN M; GRABOWSKI TJ, 1995, HUM BRAIN MAPP, V2, P123, DOI DOI 10.1002/HBM.460020302; HART J, 1992, NATURE, V359, P60, DOI 10.1038/359060a0; HART J, 1985, NATURE, V316, P439, DOI 10.1038/316439a0; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HICHWA RD, 1995, CHEMISTS' VIEWS OF IMAGING CENTERS, P401; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; HILLIS AE, 1995, J COGNITIVE NEUROSCI, V7, P396, DOI 10.1162/jocn.1995.7.3.396; Kosslyn S. M., 1994, IMAGE BRAIN; LEVELT WJM, 1992, COGNITION, V42, P1, DOI 10.1016/0010-0277(92)90038-J; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MCKENNA P, 1994, NEUROPSYCHOL REHABIL, V4, P255; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; Ono M, 1990, ATLAS CEREBRAL SULCI; Perani D., 1995, Society for Neuroscience Abstracts, V21, P1498; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Smith EE, 1981, CATEGORIES CONCEPTS; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; TRANEL D, 1995, J COGNITIVE NEUROSCI, V7, P425, DOI 10.1162/jocn.1995.7.4.425; Tranel D., 1995, Society for Neuroscience Abstracts, V21, P1497; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WORSLEY KJ, 1994, ADV APPL PROBAB, V26, P13, DOI 10.2307/1427576	49	1092	1111	1	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	1996	380	6574					499	505		10.1038/380499a0	http://dx.doi.org/10.1038/380499a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606767				2022-12-24	WOS:A1996UE66300041
J	Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS				Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS			Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INCIPIENT NEPHROPATHY; DENSITY-LIPOPROTEIN; BLOOD-PRESSURE; RISK-FACTORS; MICROALBUMINURIA; MORTALITY; MELLITUS; HYPERTENSION; PREVALENCE; NIDDM	Objective-To examine whether slightly elevated urinary albumin excretion precedes development of atherosclerotic vascular disease in patients with insulin dependent diabetes independently of conventional atherogenic risk factors and of diabetic nephropathy. Design-Cohort study with 11 year follow up. Setting-Diabetes centre in Denmark. Subjects-259 patients aged 19-51 with insulin dependent diabetes of 6-34 years' duration and without atherosclerotic vascular disease or diabetic nephropathy at baseline. Main outcome measures-Baseline variables: urinary albumin excretion, blood pressure, smoking habits, and serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor. End point: atherosclerotic vascular disease assessed by death certificates, mailed questionnaires, and hospital records. Results-Thirty patients developed atherosclerotic vascular disease during follow up of 2457 person years. Elevated urinary albumin excretion was significantly predictive of atherosclerotic vascular disease (hazard ratio 1.06 (95% confidence interval 1.02 to 1.18) per 5 mg increase in 24 hour urinary albumin excretion, P=0.002). Predictive effect was independent of age; sex; blood pressure; smoking; serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor; level of haemoglobin A(1c); insulin dose; duration of diabetes; and diabetic nephropathy (hazard ratio 1.04 (1.01 to 1.08) per 5 mg increase in 24 hour urinary albumin excretion, P=0.03). Conclusion-Slightly elevated urinary albumin excretion independently predicted atherosclerotic vascular disease in patients with insulin dependent diabetes.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center				Mathiesen, elisabeth/0000-0003-3279-0863; Feldt-Rasmussen, Bo/0000-0002-8267-3027				BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BRIT MED J, V294, P1561; CASTELLO M, 1979, NATURE, V281, P677; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CROOK MA, 1994, DIABETES CARE, V17, P305, DOI 10.2337/diacare.17.4.305; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DECKERT T, 1991, CARDIOVASCULAR RISK, V1, P154; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1987, DIABETOLOGIA, V30, P610; INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143; Jarrett R J, 1984, Diabet Med, V1, P17; JARRETT RJ, 1989, DIABETES METAB REV, V5, P547, DOI 10.1002/dmr.5610050702; JENSEN G, 1983, ACTA MED SCAND S682, V214, P1; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1989, BRIT MED J, V298, P27, DOI 10.1136/bmj.298.6665.27-a; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, SCAND J CLIN LAB INV, V49, P589, DOI 10.3109/00365518909089140; JENSEN T, 1989, LANCET, V1, P461; JENSEN T, 1989, NEW ENGL J MED, V321, P1572, DOI 10.1056/NEJM198912073212304; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; NORGAARD K, 1990, DIABETOLOGIA, V33, P407, DOI 10.1007/BF00404089; OREKHOV AN, 1991, ATHEROSCLEROSIS, V86, P153, DOI 10.1016/0021-9150(91)90211-K; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P546; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHMITZ A, 1988, DIABETIC MED, V5, P1126; SCHNITZER JE, 1992, AM J PHYSIOL, V32, pH48; SCHROLL M, 1982, DAN MED BULL, V29, P213; SIMPSON H, 1993, BRIT J BIOMED SCI, V50, P164; SVENDSEN PA, 1980, DIABETOLOGIA, V19, P130, DOI 10.1007/BF00421859; TELMER S, 1984, ACTA MED SCAND, V215, P63; Torffvit Ole, 1993, Journal of Diabetes and its Complications, V7, P49, DOI 10.1016/1056-8727(93)90024-S; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YOKOYAMA H, 1995, J INTERN MED, V237, P519, DOI 10.1111/j.1365-2796.1995.tb00878.x; YUDKIN JS, 1988, LANCET, V2, P530	46	156	159	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					871	874						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611873				2022-12-24	WOS:A1996UE37100017
J	Gomi, H; Kawato, M				Gomi, H; Kawato, M			Equilibrium-point control hypothesis examined by measured arm stiffness during multijoint movement	SCIENCE			English	Article							HUMAN ELBOW JOINT; TRAJECTORY FORMATION; VOLUNTARY MOVEMENTS; POSTURE; MODEL; COORDINATION; MAINTENANCE; CEREBELLUM; POSITION	For the last 20 years, it has been hypothesized that well-coordinated, multijoint movements are executed without complex computation by the brain, with the use of springlike muscle properties and peripheral neural feedback loops. However, it has been technically and conceptually difficult to examine this ''equilibrium-point control'' hypothesis directly in physiological or behavioral experiments. A high-performance manipulandum was developed and used here to measure human arm stiffness, the magnitude of which during multijoint movement is important for this hypothesis. Here, the equilibrium-point trajectory was estimated from the measured stiffness, the actual trajectory, and the generated torque. Its velocity profile differed from that of the actual trajectory. These results argue against the hypothesis that the brain sends as a motor command only an equilibrium-point trajectory similar to the actual trajectory.	ATR HUMAN INFORMAT PROC RES LABS, SEIKA, KYOTO, JAPAN		Gomi, H (corresponding author), NIPPON TELEGRAPH & TEL PUBL CORP, BASIC RES LABS, INFORMAT SCI RES LAB, WAKAMIYA 3-1, ATSUGI, KANAGAWA, JAPAN.		Gomi, Hiroaki/C-5269-2013; Gomi, Hiroaki/AEL-2645-2022	Gomi, Hiroaki/0000-0003-3541-2251				ABEND W, 1982, BRAIN, V105, P331, DOI 10.1093/brain/105.2.331; BENNETT DJ, 1992, EXP BRAIN RES, V88, P433, DOI 10.1007/BF02259118; BENNETT DJ, 1993, EXP BRAIN RES, V95, P488; BIZZI E, 1976, J NEUROPHYSIOL, V39, P435, DOI 10.1152/jn.1976.39.2.435; BIZZI E, 1984, J NEUROSCI, V4, P2738; DOLAN JM, 1993, IEEE T SYST MAN CYB, V23, P698, DOI 10.1109/21.256543; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P565; FELDMAN AG, 1986, J MOTOR BEHAV, V18, P17; FLANAGAN JR, 1993, J MOTOR BEHAV, V25, P140, DOI 10.1080/00222895.1993.9942045; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; FLASH T, 1987, BIOL CYBERN, V57, P257, DOI 10.1007/BF00338819; FLASH T, 1990, EXP BRAIN RES, V82, P315; GOMI H, 1992, P 14 IEEE ENG MED BI, V4, P1628; GOMI H, 1995, ISRL954 NTT BAS RES; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; HOGAN N, 1984, J NEUROSCI, V4, P2745; HOLLERBACH JM, 1989, ROBOTICS SCI, P378; KATAYAMA M, 1993, BIOL CYBERN, V69, P353, DOI 10.1007/BF01185407; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; KAWATO M, 1992, ATTENTION PERFORM, V14, P821; KELSO JAS, 1979, SCIENCE, V203, P1029, DOI 10.1126/science.424729; LACQUANITI F, 1993, J NEUROPHYSIOL, V69, P1443, DOI 10.1152/jn.1993.69.5.1443; MCINTYRE J, 1993, J MOTOR BEHAV, V25, P193, DOI 10.1080/00222895.1993.9942049; MORASSO P, 1981, EXP BRAIN RES, V42, P223; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; NICHOLS TR, 1976, J NEUROPHYSIOL, V39, P119, DOI 10.1152/jn.1976.39.1.119; Paul R.P., 1981, ROBOT MANIPULATORS M; POLIT A, 1979, J NEUROPHYSIOL, V42, P183, DOI 10.1152/jn.1979.42.1.183; SCHWEIGHOFER N, 1995, THESIS SO CALIFORNIA; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; TSUJI T, 1995, BIOL CYBERN, V72, P475, DOI 10.1007/BF00199890; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; WITNERS JM, 1990, MULTIPLE MUSCLE SYST, P69; 1993, J MOT BEHAV, V25; 1992, BEHAV BRAIN SCI, V15	36	342	347	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					117	120		10.1126/science.272.5258.117	http://dx.doi.org/10.1126/science.272.5258.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UD597	8600521				2022-12-24	WOS:A1996UD59700053
J	vanGent, DC; Ramsden, DA; Gellert, M				vanGent, DC; Ramsden, DA; Gellert, M			The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination	CELL			English	Article							MOUSE THYMOCYTES; SIGNALS; DNA	V(D)J recombination requires a pair of signal sequences with spacer lengths of 12 and 23 base pairs. Cleavage by the RAG1 and RAG2 proteins was previously shown to demand only a single signal sequence. Here, we establish conditions where 12- and 23-spacer signal sequences are both necessary for cleavage. Coupled cutting at both sites requires only the RAG1 and RAG2 proteins, but depends on the metal ion. In Mn2+, a single signal sequence supports efficient double strand cleavage, but cutting in Mg2+ requires two signal sequences and is best with the canonical 12/23 pair. Thus, the RAG proteins determine both aspects of the specificity of V(D)J recombination, the recognition of a single signal sequence and the correct 12/23 coupling in a pair of signals.			vanGent, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,NIH,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748				BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RAMSDEN DA, 1996, IN PRESS EMBO J; Roberts R, 1993, NUCLEASES, P35; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	18	239	240	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					107	113		10.1016/S0092-8674(00)81086-7	http://dx.doi.org/10.1016/S0092-8674(00)81086-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620529	Bronze			2022-12-24	WOS:A1996UE55900013
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy with autologous bone marrow stem-cell rescue in lung cancer	LANCET			English	Editorial Material							THERAPY; CARCINOMA; SUPPORT		NARGIS DUTT MEM CANC HOSP,BARSHI,INDIA; CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), TATA MEM HOSP,DEPT MED ONCOL,BARSHI,INDIA.							BRUGGER W, 1995, SEMIN ONCOL, V22, P3; CANON JL, 1988, EUR J CANCER CLIN ON, V24, P147, DOI 10.1016/0277-5379(88)90245-3; ELIAS A, 1995, HIGH DOSE CANC THERA, P824; ELIAS AD, 1993, CHEST, V103, pS433, DOI 10.1378/chest.103.4.433S; LEONARD RCF, 1990, CANCER RES, V50, P6545; MARANGOLO M, 1989, BONE MARROW TRANSPL, V4, P405; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; SPITZER G, 1986, J CLIN ONCOL, V4, P4, DOI 10.1200/JCO.1986.4.1.4; STAHEL RA, 1985, J CLIN ONCOL, V3, P455, DOI 10.1200/JCO.1985.3.4.455; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					847	848		10.1016/S0140-6736(96)91341-0	http://dx.doi.org/10.1016/S0140-6736(96)91341-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622387				2022-12-24	WOS:A1996UC45000005
J	Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B				Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B			Low blood pressure and dementia in elderly people: The Kungsholmen project	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; POPULATION SURVEY; SENILE DEMENTIA; FLOW; DISORDER; GLUCOSE; SCALE; AGE	Objective-To examine the relation between blood pressure and dementia in elderly people. Design-Cross sectional, population based study. Setting-Kungsholmen district of Stockholm, Sweden. Subjects-1642 subjects aged 75-101 years. Main outcome measures-Prevalence and adjusted odds ratio of dementia by blood pressure. Results-People with systolic pressure less than or equal to 140 mmHg were more often diagnosed as demented than those with systolic pressure >140 mmHg: odds ratios (95% confidence interval) adjusted for age, sex, and education were 2.98 (2.17 to 4.08) for all dementias, 2.91 (1.93 to 4.38) for Alzheimer's disease, 2.00 (1.09 to 3.65) for vascular dementia, and 5.07 (2.65 to 9.70) for other dementias. Similar results were seen in subjects with diastolic pressure less than or equal to 75 mmHg compared with those with higher diastolic pressure. When severity and duration of dementia were taken into account, only moderate and severe dementia were found to be significantly related to relatively low blood pressure, and the association was stronger in subjects with longer disease duration. Use of hypotensive drugs and comorbidity with cardiovascular disease did not modify the results for all dementias, Alzheimer's disease, and other dementias but slightly reduced the association between vascular dementia and diastolic blood pressure. Conclusions-Both systolic and diastolic blood pressure were inversely related to prevalence of dementia in elderly people. We think that relatively low blood pressure is probably a complication of the dementia process, particularly Alzheimer's disease, although it is possible that low blood pressure may predispose a subpopulation to developing dementia.	KAROLINSKA INST,DEPT GERIATR MED,S-11382 STOCKHOLM,SWEDEN	Karolinska Institutet	Guo, ZC (corresponding author), STOCKHOLM GERONTOL RES CTR,DALAGATAN 9-11,S-11382 STOCKHOLM,SWEDEN.		Viitanen, Matti/AAY-5163-2020	Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; [Anonymous], 1990, GUID ATC CLASS; ARONSON MK, 1993, ALZHEIMERS DIS ADV C, P55; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BROWN WD, 1991, ALZ DIS ASSOC DIS, V5, P131, DOI 10.1097/00002093-199100520-00010; BUCHT G, 1983, ACTA MED SCAND, V213, P387; BURKE WJ, 1994, J AUTONOM NERV SYST, V48, P65, DOI 10.1016/0165-1838(94)90160-0; ELMSTAHL S, 1992, AGE AGEING, V21, P301, DOI 10.1093/ageing/21.4.301; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORETTE F, 1991, AM J MED, V90, pS14, DOI 10.1016/0002-9343(91)90430-6; FORSELL Y, 1992, ACTA PSYCHIAT SCAND, V86, P49, DOI 10.1111/j.1600-0447.1992.tb03225.x; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FRATIGLIONI L, 1992, ARCH NEUROL-CHICAGO, V49, P927, DOI 10.1001/archneur.1992.00530330049015; FRATIGLIONI L, 1992, NEUROEPIDEMIOLOGY, V11, P29, DOI 10.1159/000110958; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HARDY J, 1985, NEUROCHEM INT, V7, P545, DOI 10.1016/0197-0186(85)90050-6; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; OBRIEN JT, 1992, J NEUROL NEUROSUR PS, V55, P1182, DOI 10.1136/jnnp.55.12.1182; OBRIEN MD, 1994, DEMENTIA, V5, P133, DOI 10.1159/000106710; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; *SPSS, 1994, SPSS ADV STAT 6 1; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; SULKAVA R, 1987, ACTA NEUROL SCAND, V76, P123, DOI 10.1111/j.1600-0404.1987.tb03555.x; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	26	233	239	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					805	808		10.1136/bmj.312.7034.805	http://dx.doi.org/10.1136/bmj.312.7034.805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608286	Green Published			2022-12-24	WOS:A1996UD37800021
J	Nightingale, SL				Nightingale, SL			First product available for preventing serious RSV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-24	WOS:A1996UA56300009
J	Goldberg, J; Nairn, AC; Kuriyan, J				Goldberg, J; Nairn, AC; Kuriyan, J			Structural basis for the autoinhibition of calcium calmodulin-dependent protein kinase I	CELL			English	Article							LIGHT CHAIN KINASE; CATALYTIC SUBUNIT; INTRASTERIC REGULATION; INHIBITOR PEPTIDE; CRYSTAL-STRUCTURE; BINDING; COMPLEX; RECOGNITION; REFINEMENT; SEQUENCE	The crystal structure of calcium/calmodulin-dependent protein kinase I has been determined in the autoinhibited form. The C-terminal regulatory region of the enzyme forms a helix-loop-helix segment that extends across the two domains of the catalytic core, making multiple inhibitory interactions. Elements of the first regulatory alpha helix and the loop interfere with the binding site for peptide substrates, while the loop and the second helix interact with the ATP-binding domain to induce conformational changes that obstruct the nucleotide binding pocket. lane part of the calmodulin recognition element protrudes away from the catalytic domain and is potentially available for an initial interaction with calmodulin. The structure provides a view of an intact calmodulin target and suggests that substantial structural changes will accompany kinase activation by calmodulin binding to the regulatory region.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University	Goldberg, J (corresponding author), HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Nairn, Angus/0000-0002-7075-0195				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRAGG WL, 1954, ACTA CRYSTALLOGR, V7, P409, DOI 10.1107/S0365110X54001235; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRUNER SM, 1994, CURR OPIN STRUC BIOL, V4, P765, DOI 10.1016/S0959-440X(94)90177-5; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KEMP BE, 1994, STRUCTURAL ASPECTS P, P30; KEMP BE, 1991, PSEUDOSUBSTRATE BASE; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NALM AC, 1987, J BIOL CHEM, V262, P7273; NALM AC, 1994, SEMIN CANCER BIOL, V5, P295; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; PARKER PJ, 1994, PROTEIN KINASES, P68; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICKERSGILL RW, 1987, ACTA CRYSTALLOGR A, V43, P502, DOI 10.1107/S0108767387099112; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; WILSON AJC, 1949, ACTA CRYSTALLOGR, V2, P318, DOI 10.1107/S0365110X49000813; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	69	265	273	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					875	887		10.1016/S0092-8674(00)81066-1	http://dx.doi.org/10.1016/S0092-8674(00)81066-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601311	Bronze			2022-12-24	WOS:A1996UC38100009
J	Spiller, RC				Spiller, RC			Cholesterol, fibre, and bile acids	LANCET			English	Editorial Material							DIETARY FIBER; LIPIDS; SERUM; MEN				Spiller, RC (corresponding author), UNIV HOSP,QUEENS MED CTR,DEPT THERAPEUT,NOTTINGHAM,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; EVERSON GT, 1992, J LIPID RES, V33, P1183; GELISSEN IC, 1995, BRIT J NUTR, V74, P221, DOI 10.1079/BJN19950125; JENKINS DJA, 1975, LANCET, V1, P1116, DOI 10.1016/S0140-6736(75)92503-9; KESANIEMI YA, 1990, AM J CLIN NUTR, V51, P1007, DOI 10.1093/ajcn/51.6.1007; MIETTINEN TA, 1987, AM J CLIN NUTR, V45, P1237, DOI 10.1093/ajcn/45.5.1237; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; TOPPING DL, 1991, NUTR REV, V49, P195, DOI 10.1111/j.1753-4887.1991.tb03021.x; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316	9	12	12	2	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					415	416		10.1016/S0140-6736(96)90005-7	http://dx.doi.org/10.1016/S0140-6736(96)90005-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618479				2022-12-24	WOS:A1996TV72200005
J	Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S				Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S			A Late Neanderthal associated with Upper Palaeolithic artefacts	NATURE			English	Article								THE French site of Arcy-sur-Cure is a key locality in documenting the Middle-Upper Palaeolithic transition in Europe. Reliable attribution of the fragmentary hominid fossils associated with its early Upper Palaeolithic Chatelperronian industry has not been possible. Here we report the first conclusive identification of one of these fossils as Neanderthal on the basis of newly discovered derived features of the bony labyrinth. Dated at about thirty-four thousand years (34 kyr) ago, the fossil is representative of the youngest known Neanderthal populations, and its archaeological context indicates that these hominids used a rich bone industry as well as personal ornaments. The evidence supports the hypothesis of a long term coexistence with technocultural interactions between the first modern humans and the last Neanderthals in Europe. However, the complete absence of the derived Neanderthal traits in labyrinths of modern Upper Palaeolithic specimens from western Europe argues against phylogenetic continuity between the two populations in this region.	UNIV NANCY 1, DEPT ANAT, F-54505 VANDOEUVRE LES NANCY, FRANCE; UNIV UTRECHT HOSP, DEPT DIAGNOST RADIOL, 3584 CX UTRECHT, NETHERLANDS; INST PALEONTOL HUMAINE, F-75013 PARIS, FRANCE; MUSEE HOMME PARIS, LAB ANTHROPOL, F-75116 PARIS, FRANCE; UCL, DEPT ANAT & DEV BIOL, EVOLUT ANAT UNIT, LONDON WC1E 6JJ, ENGLAND	Universite de Lorraine; Utrecht University; Utrecht University Medical Center; Museum National d'Histoire Naturelle (MNHN); University of London; University College London			Spoor, Fred/C-1718-2008; Condemi, Silvana/ABE-2701-2021	Condemi, Silvana/0000-0002-6516-0879				BISCHOFF JL, 1994, J ARCHAEOL SCI, V21, P541, DOI 10.1006/jasc.1994.1053; BISCHOFF JL, 1989, J ARCHAEOL SCI, V16, P553; Cabrera-Valdes V., 1989, J ARCHAEOL SCI, V16, P577, DOI [10.1016/0305-4403(89)90023-X, DOI 10.1016/0305-4403(89)90023-X]; CLARK GA, 1989, HUMAN REVOLUTION, P621; DEMARS PY, 1989, ERAUL LIEGE, V34, P29; Girard M., 1990, PALEOLITHIQUE MOYEN, V3, P295; HARROLD FB, 1989, HUMAN REVOLUTION, P677; Hedges R.E., 1994, ARCHAEOMETRY, V36, P337, DOI DOI 10.1111/J.1475-4754.1994.TB00975.X; HOWELL FC, 1994, INTERD CONT, P253; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; Leroi-Gourhan A., 1958, ANN PALEONTOL, V44, P87; Leroyer C, 1983, B SOC PREHIST FRANC, V80, P41; LEROYER C, 1988, ERAUL LIEGE, V35, P103; LEUJEUNE M, 1987, ART MOBILIER PALEOLI, V4; LEVEQUE F, 1980, CR ACAD SCI D NAT, V291, P187; MAFFIER D, 1990, PALEOLITHIQUE MOYEN, P329; MELLARS PA, 1992, PHILOS T ROY SOC B, V337, P225, DOI 10.1098/rstb.1992.0100; MERCIER N, 1991, NATURE, V351, P735; Pelegrin J., 1995, CAHIERS QUATERNAIRE, V20, P297; RAK Y, 1994, SPECIES SPECIES CONC, P523; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; Spoor C.E, 1993, COMP MORPHOLOGY PHYL; SPOOR CF, 1994, COUR FORSCH SENCKENB, V171, P251; SPOOR CF, 1995, J ANAT, V186, P271; SPOOR F, 1994, NATURE, V369, P645, DOI 10.1038/369645a0; Straus L.G., 1993, EVOLUTIONARY ANTHR, V2, P195; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; TABORIN Y, 1990, PALEOLITHIQUE MOYEN, P335; VANVARK GN, 1984, MULTIVARIATE STATIST, P323; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0	30	259	270	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					224	226		10.1038/381224a0	http://dx.doi.org/10.1038/381224a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UL249	8622762				2022-12-24	WOS:A1996UL24900050
J	Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C				Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C			Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; COMPLICATION; ATHEROMAS; PLAQUE	Background. Atherosclerotic disease of the aortic arch is found in 60 percent of patients 60 years of age or older who have had brain infarction. The aim of this study was to determine whether atherosclerotic plaques in the aortic arch are a risk factor for recurrent brain infarction and for vascular events in general (i.e., brain infarction, myocardial infarction, peripheral embolism, and death from vascular causes). Methods. For a period of two to four years, we followed a cohort of 331 patients 60 years of age or older who were consecutively admitted to the hospital with brain infarction (a total of 788 person-years of follow-up). All patients underwent transesophageal echocardiography to determine whether atherosclerotic plaques were present in the aortic arch proximal to the ostium of the left subclavian artery. The patients were divided into three groups according to the thickness of the wall of the aortic arch (<1 mm, 1 to 3.9 mm, and greater than or equal to 4 mm). Results. The incidence of recurrent brain infarction was 11.9 per 100 person-years in patients with an aortic-wall thickness of greater than or equal to 4 mm, as compared with 3.5 per 100 person-years in patients with a wall thickness of 1 to 3.9 mm and 2.8 per 100 person-years in patients with a wall thickness of <1 mm (P<0.001). The overall incidence of vascular events was 26.0, 9.1, and 5.9 per 100 person-years of follow-up in the respective groups (P<0.001). After adjustment for the presence of carotid stenosis, atrial fibrillation, peripheral arterial disease, and other risk factors, aortic plaques greater than or equal to 4 mm thick (including the thickness of the aortic wall) were found to be independent predictors of recurrent brain infarction (relative risk, 3.8; 95 percent confidence interval, 1.8 to 7.8; P=0.0012) and of all vascular events (relative risk, 3.5; 95 percent confidence interval, 2.1 to 5.9; P<0.001). Conclusions. Atherosclerotic plaques greater than or equal to 4 mm thick in the aortic arch are significant predictors of recurrent brain infarction and other vascular events. (C) 1996, Massachusetts Medical Society.			Amarenco, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/L-6344-2019; Tzourio, christophe/B-4015-2009; VERCUEIL, Laurent/AAN-2941-2021	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; VERCUEIL, Laurent/0000-0003-3323-0091; Moulin, thierry/0000-0002-6639-8117				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; DAVILAROMAN VG, 1994, STROKE, V25, P2010, DOI 10.1161/01.STR.25.10.2010; DIXON WJ, 1992, BMDP STATISTICAL SOF; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; JONES EF, 1995, STROKE, V26, P218; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; *SAS I, 1989, SAS US GUID, V1; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1994, J AM COLL CARDIOL, V23, P1085, DOI 10.1016/0735-1097(94)90595-9; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1993, LANCET, V342, P1255; 1994, BRIT MED J, V308, P1540; 1972, NEW ENGL J MED, V286, P1146	36	457	466	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1216	1221						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606716				2022-12-24	WOS:A1996UJ05400002
J	Hubbard, R; Lewontin, RC				Hubbard, R; Lewontin, RC			Pitfalls of genetic testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATTITUDES				Hubbard, R (corresponding author), HARVARD UNIV,CAMBRIDGE,MA 02138, USA.							BABUL R, 1993, JAMA-J AM MED ASSOC, V270, P2321, DOI 10.1001/jama.270.19.2321; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KOLATA G, 1996, NY TIMES        0401, pA15; KOLATA G, 1996, NY TIMES        0617, pA1; PAPERMASTER DS, 1995, NAT MED, V1, P874, DOI 10.1038/nm0995-874; Seachrist Lisa, 1995, Sci News, V148, P394, DOI 10.2307/4018302; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P93; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P50; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P74; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P104; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P64; WERTZ DC, 1992, AM J HUM GENET, V50, P1077; 1993, NEW ENGL J MED, V329, P1308	17	84	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1192	1194		10.1056/NEJM199605023341812	http://dx.doi.org/10.1056/NEJM199605023341812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602190				2022-12-24	WOS:A1996UG83100012
J	Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM				Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM			Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; E CONSUMPTION; ATHEROSCLEROSIS; RISK; QUESTIONNAIRE; PROGRESSION; POPULATION; RABBIT; MEN	Background. The role of dietary antioxidant vitamins in preventing coronary heart disease has aroused considerable interest because of the knowledge that oxidative modification of low-density lipoprotein may promote atherosclerosis. Methods. We studied 34,486 postmenopausal women with no cardiovascular disease who in early 1986 completed a questionnaire that assessed, among other factors, their intake of vitamins A, E, and C from food sources and supplements. During approximately seven years of follow-up (ending December 31, 1992), 242 of the women died of coronary heart disease. Results. In analyses adjusted for age and dietary energy intake, vitamin E consumption appeared to be inversely associated with the risk of death from coronary heart disease, This association was particularly striking in the subgroup of 21,809 women who did not consume vitamin supplements (relative risks from lowest to highest quintile of vitamin E intake, 1.0, 0.68, 0.71, 0.42, and 0.42; P for trend=0.008), After adjustment for possible confounding variables, this inverse association remained (relative risks from lowest to highest quintile, 1.0, 0.70, 0.76, 0.32, and 0.38; P for trend=0.004). There was little evidence that the intake of vitamin E from supplements was associated with a decreased risk of death from coronary heart disease, but the effects of high-dose supplementation and the duration of supplement use could not be definitively addressed, Intake of vitamins A and C did not appear to be associated with the risk of death from coronary heart disease. Conclusions. These results suggest that in postmenopausal women the intake of vitamin E from food is inversely associated with the risk of death from coronary heart disease and that such women can lower their risk without using vitamin supplements. By contrast, the intake of vitamins A and C was not associated with lower risks of dying from coronary disease. (C) 1996, Massachusetis Medical Society.	UNIV MIAMI, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA	University of Miami; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Wake Forest Baptist Medical Center	Kushi, LH (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Kushi, Lawrence/0000-0001-9136-1175	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; BEATON GH, 1994, AM J CLIN NUTR, V59, p253S, DOI 10.1093/ajcn/59.1.253S; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MEYER F, 1994, CIRCULATION, V89, P932; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; Prineas R J, 1993, Ann Epidemiol, V3, P35, DOI 10.1016/1047-2797(93)90007-Q; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WHITE AD, IN PRESS J CLIN EPID; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	30	696	721	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1156	1162		10.1056/NEJM199605023341803	http://dx.doi.org/10.1056/NEJM199605023341803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602181				2022-12-24	WOS:A1996UG83100003
J	Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE				Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE			Structure and mutational analysis of Rab GDP-dissociation inhibitor	NATURE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; GTP-BINDING PROTEIN; CHOROIDEREMIA GENE; CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; GERANYLGERANYL TRANSFERASE; PURIFICATION; RESOLUTION; SUBSTRATE; HOMOLOG	The crystal structure of the bovine alpha-isoform of Rab GDP-dissociation inhibitor (GDI), which functions in vesicle-membrane transport to recycle and regulate Rab GTPases, has been determined to a resolution of 1.81 Angstrom. GDI is constructed of two main structural units, a large complex multisheet domain I and a smaller alpha-helical domain II. The structural organization of domain I is surprisingly closely related to FAD-containing monooxygenases and oxidases. Sequence-conserved regions common to GDI and the choroideraemia gene product, which delivers Rab to catalytic subunits of Rab geranylgeranyltransferase II, are clustered on one face of the molecule. The two most sequence-conserved regions, which form a compact structure at the apex of GDI, are shown by site-directed mutagenesis to play a critical role in the binding of Rab proteins.	SCRIPPS RES INST, DEPT MOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, THESIS YALE U; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEKKER LV, 1991, J NEUROCHEM, V54, P205; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; FUREY W, 1990, AM CRYSTALLOGR ASS 4; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee D.E., 1993, PRACTICAL PROTEIN CR, P1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHALK IJ, 1994, J MOL BIOL, V244, P469, DOI 10.1006/jmbi.1994.1744; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOTT K, 1993, J BIOL CHEM, V268, P6097; STURA EA, 1994, ACTA CRYSTALLOGR D, V50, P448, DOI 10.1107/S0907444994001794; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1041, DOI 10.1093/hmg/3.7.1041; VANDENHURK JAJM, 1992, AM J HUM GENET, V50, P1195; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON AL, 1993, J BIOL CHEM, V268, P14561	52	141	144	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					42	48		10.1038/381042a0	http://dx.doi.org/10.1038/381042a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609986				2022-12-24	WOS:A1996UJ05300048
J	Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L				Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L			Breast feeding and hypertrophic pyloric stenosis: Population based case-control study	BRITISH MEDICAL JOURNAL			English	Article									SANTOBONO PAEDIAT HOSP,NAPLES,ITALY		Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							DODGE JA, 1975, ARCH DIS CHILD, V50, P171, DOI 10.1136/adc.50.3.171; JEDD MB, 1986, AM J DIS CHILD, V142, P334; MARCHINI G, 1994, ACTA PAEDIATR, V83, P374, DOI 10.1111/j.1651-2227.1994.tb18122.x; SPENCE MA, 1978, GENETIC EPIDEMIOLOGY, P331; WEBB AR, 1983, ARCH DIS CHILD, V58, P586, DOI 10.1136/adc.58.8.586	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					745	746						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605461	Green Published			2022-12-24	WOS:A1996UC16600027
J	Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA				Gilks, CF; Ojoo, SA; Ojoo, JC; Brindle, RJ; Paul, J; Batchelor, BIF; Kimari, JN; Newnham, R; Bwayo, J; Plummer, FA; Warrell, DA			Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya	LANCET			English	Article							BACTEREMIA; DIAGNOSIS; PNEUMONIA; SINUSITIS; ADULTS	Background HIV infection is a major risk factor for pneumococcal disease in industrialised countries. Although both are common infections in sub-Saharan Africa, few studies have investigated the importance of this interaction. We have followed up a cohort of female sex-workers in Nairobi and report here on the extent of invasive pneumococcal disease. Methods A well-established cohort of low-class female sex-workers, based around a community clinic, was followed up from October, 1989, to September, 1992. 587 participants were HIV positive and 132 remained HIV negative. Set protocols were used to investigate common presentations. Cases were identified clinically and radiographically. and other pathogens were identified clinically and radiographically. Streptococcus pneumoniae and other pathogens were diagnosed by culture. Findings Seventy-nine episodes of invasive pneumococcal disease were seen in the 587 HIV-positive women compared with one episode in the 132 seronegative women (relative risk 17.8, 95% CI 2.5 to 126.5). In seropositive women the incidence rate was 42.5 per 1000 person-years and the recurrence rate was 264 per 1000 person-years. By serotyping, most recurrent events were re-infection. A wide spectrum of HIV-related pneumococcal disease was seen: only 56% of cases were pneumonia; sinusitis was seen in 30% of cases, and occult bacteraemia, a novel adult presentation, in 11%. Despite forty-two bacteraemic episodes, no deaths were attributable to Strep pneumoniae. At first presentation the mean CD4 cell count was 302/mu L (SD 191) and was 171/mu L (105) for recurrent episodes. During acute Strep pneumoniae infection the CD4 cell count was reversibly suppressed (mean fall in sixteen episodes, 105/mu L [123]). The neutrophil response to acute infection was blunted and was correlated with CD4 count (r=0.50, 95% CI 0.29 to 0.66). Strep pneumoniae caused more disease, at an earlier stage of HIV immunosuppression, than Mycobacterium tuberculosis or non-typhi salmonellae. Interpretation Our study highlights the importance of the pneumococcus as an early but readily treatable complication of HIV infection in sub-Saharan Africa.	KENYA GOVT MED RES CTR,CLIN RES CTR,NAIROBI,KENYA; KENYA GOVT MED RES CTR,CTR MICROBIOL RES,NAIROBI,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV WINNIPEG,WINNIPEG,MB R3B 2E9,CANADA; UNIV OXFORD,CTR TROP MED,OXFORD,ENGLAND	Kenya Medical Research Institute; Kenya Medical Research Institute; University of Nairobi; University of Winnipeg; University of Oxford			Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADERAYE G, 1994, TUBERCLE LUNG DIS, V75, P308, DOI 10.1016/0962-8479(94)90138-4; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AUSTRIAN R, 1986, SA MED J, V77, P46; BARNES DJ, 1988, AUST NZ J MED, V18, P754, DOI 10.1111/j.1445-5994.1988.tb00174.x; BARRETTC.E, 1971, AM REV RESPIR DIS, V103, P845; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GILKS C, 1993, 9 INT C AIDS BERL; GILKS CF, 1993, LANCET, V342, P1037, DOI 10.1016/0140-6736(93)92885-W; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GODOFSKY EW, 1992, AM J MED, V93, P163, DOI 10.1016/0002-9343(92)90046-E; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JORDENS JZ, 1995, J INFECT DIS, V172, P983, DOI 10.1093/infdis/172.4.983; KELL CM, 1993, INFECT IMMUN, V61, P4382, DOI 10.1128/IAI.61.10.4382-4391.1993; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; MIENTJES GHC, 1993, BRIT MED J, V306, P371, DOI 10.1136/bmj.306.6874.371; NUNN P, 1993, TUBERC LUND DIS, V7, P273; PALLANGYO K, 1992, AIDS, V6, P971, DOI 10.1097/00002030-199209000-00010; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SIMANI P, 1992, 8 INT C AIDS AMST; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; SPITALNY KC, 1982, JOHNS HOPKINS MED J, V150, P35; TAELMAN H, 1990, 5 INT C AIDS AFR KIN; TAELMAN H, 1992, 8 INT C AIDS AMST; TEKLU B, 1984, PRINCIPLES MED AFRIC, P761; VONREYN CF, 1993, J CLIN MICROBIOL, V31, P3247; WALLACE JM, 1993, AM REV RESPIR DIS, V148, P1523, DOI 10.1164/ajrccm/148.6_Pt_1.1523; *WHO, 1994, WHOGPATCOSEF944; 1987, MMWR-MORBID M      S, V36, pS1; 1992, MMWR-MORBID MORTAL W, V41, P1	31	163	163	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					718	723		10.1016/S0140-6736(96)90076-8	http://dx.doi.org/10.1016/S0140-6736(96)90076-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602001				2022-12-24	WOS:A1996TZ98200009
J	Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES				Dietrich, WF; Miller, J; Steen, R; Merchant, MA; DamronBoles, D; Husain, Z; Dredge, R; Daly, MJ; Ingalls, KA; OConnor, TJ; Evans, CA; DeAngelis, MM; Levinson, DM; Kruglyak, L; Goodman, N; Copeland, NG; Jenkins, NA; Hawkins, TL; Stein, L; Page, DC; Lander, ES			A comprehensive genetic map of the mouse genome	NATURE			English	Article							LINKAGE MAP	The availability of dense genetic linkage maps of mammalian genomes makes feasible a wide range of studies, including positional cloning of monogenic traits, genetic dissection of polygenic traits, construction of genome-wide physical maps, rapid marker-assisted construction of congenic strains, and evolutionary comparisons(1,2). We have been engaged for the past five years in a concerted effort to produce a dense genetic map of the laboratory mouse(3-6). Here we present the final report of this project. The map contains 7,377 genetic markers, consisting of 6,580 highly informative simple sequence length polymorphisms integrated with 797 restriction fragment length polymorphisms in mouse genes. The average spacing between markers is about 0.2 centimorgans or 400 kilobases.	WHITEHEAD INST BIOMED RES, WHITEHEAD MIT CTR GENOME RES, CAMBRIDGE, MA 02142 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			DeAngelis, e/J-7863-2015; Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752; Merchant, Mark/0000-0003-0690-8581				BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; BUCHBERG AM, 1989, GENETICS, V122, P153; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIETRICH WF, 1992, GENETIC MAPS 1992; EVANS E, 1994, GENETIC VARIANTS STR; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOB HJ, 1995, NAT GENET, V9, P63, DOI 10.1038/ng0195-63; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2; MILLER JC, 1994, GENETIC VARIANTS STR; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	19	738	778	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					149	152		10.1038/380149a0	http://dx.doi.org/10.1038/380149a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600386				2022-12-24	WOS:A1996TZ97800047
J	Sheldon, TA; Raffle, A; Watt, I				Sheldon, TA; Raffle, A; Watt, I			Controversies in management - Department of health shoots itself in the hip - Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing	BRITISH MEDICAL JOURNAL			English	Article									AVON HLTH,BRISTOL BS2 8EE,AVON,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DIRECTORATE CLIN RADIOL,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary	Sheldon, TA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Sheldon, Trevor Andrew/0000-0002-7479-5913				BARLOW DM, 1994, ADVISORY GROUP OSTEO; Calman K, 1994, J Med Screen, V1, P101; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chalmers I, 1995, SYSTEMATIC REV; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EVANS NJB, 1995, REV DEPT HLTH ARRANG; PECKHAM M, 1993, RES HLTH; Sox H. C., 1989, ASSESSMENT DIAGNOSTI; TORGERSON DJ, 1995, EUR J OBSTET GYN R B, V59, P57, DOI 10.1016/0028-2243(94)02002-V; 1995, MEASUREMENT BONE DEN	10	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					296	297						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611790				2022-12-24	WOS:A1996TU50700030
J	Verheugt, FWA				Verheugt, FWA			Primary angioplasty for acute myocardial infarction: Is the balloon half full or half empty?	LANCET			English	Editorial Material							IMMEDIATE ANGIOPLASTY				Verheugt, FWA (corresponding author), UNIV NIJMEGEN HOSP, DEPT CARDIOL, 6500 HB NIJMEGEN, NETHERLANDS.		Verheugt, F.W.A./H-8105-2014					AHMAD T, 1995, AM J CARDIOL, V76, P77, DOI 10.1016/S0002-9149(99)80807-8; Elizaga J., 1993, European Heart Journal, V14, P118; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grinfeld Liliana, 1996, Journal of the American College of Cardiology, V27, p222A; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ribichini Flavio, 1996, Journal of the American College of Cardiology, V27, p221A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1996	347	9011					1276	1277		10.1016/S0140-6736(96)90933-2	http://dx.doi.org/10.1016/S0140-6736(96)90933-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622499	Green Submitted			2022-12-24	WOS:A1996UK75800004
J	Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC				Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC			C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ACUTE PHASE; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; LIPIDS; SERUM; INFECTION; DISEASE	Objective-To test the hypothesis that minor chronic insults such as smoking, chronic bronchitis, and two persistent bacterial infections may be associated with increases in C reactive protein concentration within the normal range and that variations in the C reactive protein concentration in turn may be associated with levels of cardiovascular risk factors and chronic coronary heart disease. Design-Population based cross sectional study. Setting-General practices in Merton, Sutton, and Wandsworth. Subjects-A random sample of 388 men aged 50-69 years from general practice registers. 612 men were invited to attend and 413 attended, of whom 25 non-white men were excluded. The first 303 of the remaining 388 men had full risk factor profiles determined. Interventions-Measurements of serum C reactive protein concentrations by in house enzyme linked immunosorbent assay (ELISA); other determinations by standard methods. Coronary heart disease was sought by the Rose angina questionnaire and Minnesota coded electrocardiograms. Main outcome measures-Serum C reactive protein concentrations, cardiovascular risk factor levels, and the presence of coronary heart disease. Results-Increasing age, smoking, symptoms of chronic bronchitis, Helicobacter pylori and Chlamydia pneumoniae infections, and body mass index were all associated with raised concentrations of C reactive protein. C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. C Reactive protein concentration was negatively associated with high density lipoprotein cholesterol concentration. There was a weaker positive relation with low density lipoprotein cholesterol concentration and no relation with apolipoprotein A I value. C Reactive protein concentration was also strongly associated with coronary heart disease. Conclusion-The body's response to inflammation may play an important part in influencing the progression of atherosclerosis. The association of C reactive protein concentration with coronary heart disease needs testing in prospective studies.			Mendall, MA (corresponding author), ST GEORGES MED SCH,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND.							AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALVAREZ C, 1986, CLIN CHEM, V32, P142; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; CABANA VG, 1989, J LIPID RES, V30, P39; COOMBES EJ, 1980, J TRAUMA, V20, P971, DOI 10.1097/00005373-198011000-00012; DEBEER FC, 1982, J IMMUNOL METHODS, V50, P299, DOI 10.1016/0022-1759(82)90168-5; FAHIEWILSON M, 1987, CLIN CHIM ACTA, V167, P197, DOI 10.1016/0009-8981(87)90372-X; FEINGOLD KR, 1992, DIABETES, V41, P97, DOI 10.2337/diab.41.2.S97; GAULDIE J, 1989, ANN NY ACAD SCI, V557, P46; HELDENBERG D, 1980, ATHEROSCLEROSIS, V35, P433, DOI 10.1016/0021-9150(80)90184-7; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KAHN C, 1995, SCIENCE, V373, P384; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MENDALL MA, 1994, BRIT HEART J, V71, P437; NAITO H K, 1987, Comprehensive Therapy, V13, P43; PALOSUO T, 1986, ACTA MED SCAND, V220, P175; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	27	709	740	1	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1061	1065						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616412				2022-12-24	WOS:A1996UH81600023
J	May, EW; Craig, NL				May, EW; Craig, NL			Switching from cut-and-paste to replicative Tn7 transposition	SCIENCE			English	Article							BACTERIOPHAGE-MU; MICROSCOPIC ANALYSIS; MECHANISM; DNA; RECOMBINATION; INTERMEDIATE; INSERTION; PROTEIN; COINTEGRATION; PURIFICATION	The bacterial transposon Tn7 usually moves through a cut-and-paste mechanism whereby the transposon is excised from a donor site and joined to a target site io form a simple insertion. The transposon was converted to a replicative element that generated plasmid fusions in vitro and cointegrate products in vivo. This switch was a consequence of the separation of 5'- and 3'-end processing reactions of Tn7 transposition as demonstrated by the consequences of a single amino acid alteration in an element-encoded protein essential for normal cut-and-paste transposition. The mutation specifically blocked cleavage of the 5' strand at each transposon end without disturbing the breakage and joining or! the 3' strand, producing a fusion (the Shapiro Intermediate) that resulted in replicative transposition. The ability of Tn7 recombination products to serve as substrates for both the limited gap repair required to complete cut-and-paste transposition and the extensive DNA replication involved in cointegrate formation suggests a remarkable plasticity in Tn7's recruitment of host repair and replication functions.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								ARCISZEWSKA LK, 1991, J BIOL CHEM, V266, P21736; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; Berg D. E., 1989, MOBILE DNA; BIEL SW, 1984, GENETICS, V108, P319; BIERY M, UNPUB; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1989, MOBILE DNA, P211; CRAIG NL, 1995, CURR TOP MICROBIOL I, V204, P27; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; DERBYSHIRE KM, 1986, CELL, V47, P325, DOI 10.1016/0092-8674(86)90586-6; GALAS DJ, 1989, MOBILE DNA, P109; GARY P, IN PRESS J MOL BIOL; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; MAY E, UNPUB; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; OHTSUBO E, 1980, COLD SPRING HARB SYM, V45, P283, DOI 10.1101/SQB.1981.045.01.041; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SARNOVSKY R, UNPUB; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHARPE PL, 1992, NUCLEIC ACIDS RES, V20, P2525; SHERRATT D, 1989, MOBILE DNA, P163; STELLWAGEN A, UNPUB; SURETTE MG, 1987, CELL, V49, P254; TANG Y, 1991, NUCLEIC ACIDS RES, V19, P3395, DOI 10.1093/nar/19.12.3395; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; WEINERT TA, 1983, SCIENCE, V222, P755, DOI 10.1126/science.6314502	39	84	87	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					401	404		10.1126/science.272.5260.401	http://dx.doi.org/10.1126/science.272.5260.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602527				2022-12-24	WOS:A1996UG25200044
J	Bamji, AN				Bamji, AN			Brain injury rehabilitation: Jaw jaw not war war	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					916	917						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611911				2022-12-24	WOS:A1996UE37100071
J	Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD				Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD			Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR ARRHYTHMIAS; RECOVERY	Objective-To determine whether QTc dispersion, which is easily obtained from a standard electrocardiogram, can predict those patients with peripheral vascular disease who will subsequently suffer a cardiac death, despite having no cardiac symptoms or signs. Design-Patients with peripheral vascular disease were followed up for five years after they had had coronary angiography, radionuclide ventriculography, and their QTc dispersion calculated from their 12 lead electrocardiogram. Subjects-49 such patients were then divided into three groups: survivors (34), cardiac death (12), and non-cardiac death (3). Main outcome measure-Survival. Results-The mean (SD; range) ejection fractions were similar in all three groups: survivors 45.9 (11.0; 27.0-52.0), cardiac death 44.0 (7.90; 28.5-59.0), and non-cardiac death 45.3 (4.55; 39.0-50.0). QTc dispersion was significantly prolonged in the cardiac death group compared with in the survivors (86.3 (23.9; 41.0-139) v 56.5 (25.4; 25.0-164); P=0.002). A QTc dispersion greater than or equal to 60 ms had a 92% sensitivity and 81% specificity in predicting cardiac death. QTc dispersion in patients with diffuse coronary artery disease was significantly (P<0.05) greater than in those with no disease or disease affecting one, two, or three vessels. Conclusions-There is a strong link between QTc dispersion and cardiac death in patients with peripheral vascular disease. QTc dispersion may therefore be a cheap and non-invasive way of assessing the risk of cardiac death in patients with peripheral vascular disease.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CARDIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee			Darbar, Dawood/C-9079-2015	Darbar, Dawood/0000-0002-4103-5977; Struthers, Allan/0000-0002-2926-2528				BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; DAVEY P, 1994, BRIT HEART J, V71, P268; HIGHAM P, 1994, BRIT HEART J, V71, P508; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; LEE HS, 1994, BR HEART J S5, V71, P98; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; MORENO FL, 1994, CIRCULATION, V90, P94, DOI 10.1161/01.CIR.90.1.94; MURRAY A, 1994, BRIT HEART J, V71, P386; Potratz J., 1993, European Heart Journal, V14, P254; PYE M, 1994, BRIT HEART J, V71, P511; PYE MP, 1992, CARDIOVASC RES, V26, P740, DOI 10.1093/cvr/26.8.740; STOLETNIY LN, 1994, J AM COLL CARDIOL, pA178; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUNUS A, 1994, J AM COLL CARDIOL, pA179	18	78	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					874	878						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611874				2022-12-24	WOS:A1996UE37100018
J	Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW				Taylor, IK; Hill, AA; Hayes, M; Rhodes, CG; OShaughnessy, KM; OConnor, BJ; Jones, HA; Hughes, JMB; Jones, T; Pride, NB; Fuller, RW			Imaging allergen-invoked airway inflammation in atopic asthma with [F-18]-fluorodeoxyglucose and positron emission tomography	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE; GLUCOSE-UTILIZATION; LOBAR PNEUMONIA; CHALLENGE; LUNG; METABOLISM; DENSITY; HUMANS	Background Airway inflammation is a feature of asthma and can be quantified invasively with bronchial lavage and endobronchial histology. Inflammatory foci can be imaged non-invasively with positron emission tomography (PET) and [F-18]-fluorodeoxyglucose ((18)FDG) to quantify glucose uptake in activated granulocytes. We used this technique to study airway inflammation in asthma. Methods Nine men with mild atopic asthma were studied. In five, we studied the effect of bronchoscopic segmental allergen challenge on (18)FDG uptake. Allergen was instilled into the posterior segment of the right upper lobe; a similar volume (20 mL) of isotonic saline was instilled into the posterior segment of the left upper lobe. At 1-32 h after instillation, PET with (18)FDG was done. In the other four patients, we administered aerosolised allergen. Findings (18)FDG uptake was increased four-fold in the right compared with the left upper lobe (geometric mean of ratios 4.30, 95% Cl 2.39-7.72, p=0.002). Aerosolised administration of allergen did not significantly increase (18)FDG uptake. Interpretation These data show that local allergen-invoked airway inflammation can be visualised with (18)FDG and PET in asthma. The cellular localisation of the (18)FDG signal remains to be determined.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT RESP MED,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CLIN PHARMACOL,LONDON W12,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CYCLOTRON UNIT,LONDON W12,ENGLAND; GLAXO RES & DEV,GREENFORD,MIDDX,ENGLAND	Imperial College London; Imperial College London; Imperial College London; GlaxoSmithKline				Hill, Anthony/0000-0002-7605-9274				BRUDIN LH, 1994, EUR J NUCL MED, V21, P297, DOI 10.1007/BF00947964; DECHATELET LR, 1977, BLOOD, V50, P525; DUPUIS R, 1992, J ALLERGY CLIN IMMUN, V89, P850, DOI 10.1016/0091-6749(92)90441-4; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; HASLETT C, 1989, AM REV RESPIR DIS, V140, P756, DOI 10.1164/ajrccm/140.3.756; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; JONES HA, 1994, AM J RESP CRIT CARE, V149, P1635, DOI 10.1164/ajrccm.149.6.7516252; JONES HA, 1995, AM J RESP CRIT CARE, V151, pA343; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; NOLOP KB, 1987, CANCER, V60, P2682, DOI 10.1002/1097-0142(19871201)60:11<2682::AID-CNCR2820601118>3.0.CO;2-H; PANTIN CF, 1988, AM REV RESPIR DIS, V138, P1234, DOI 10.1164/ajrccm/138.5.1234; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; REISS M, 1978, J CLIN INVEST, V61, P480, DOI 10.1172/JCI108959; RHODES CG, 1981, J COMPUT ASSIST TOMO, V5, P783, DOI 10.1097/00004728-198112000-00001; ROBB R A, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P9; SAVERYMUTTU SH, 1985, THORAX, V40, P925, DOI 10.1136/thx.40.12.925; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; UEKI J, 1993, J APPL PHYSIOL, V75, P559, DOI 10.1152/jappl.1993.75.2.559; WASHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797; WOLLMER P, 1982, LANCET, V2, P1361	23	59	61	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 6	1996	347	9006					937	940		10.1016/S0140-6736(96)91416-6	http://dx.doi.org/10.1016/S0140-6736(96)91416-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD591	8598758				2022-12-24	WOS:A1996UD59100011
J	Heichman, KA; Roberts, JM				Heichman, KA; Roberts, JM			The yeast CDC16 and CDC27 genes restrict DNA replication to once per cell cycle	CELL			English	Article							POLE BODY DUPLICATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; BUDDING YEAST; ASPERGILLUS-NIDULANS; NUCLEAR DIVISION; LICENSING FACTOR; MITOSIS; ANAPHASE; MUTANTS	CDC16 and CDC27 were identified as genes in S. cerevisiae necessary to limit DNA replication to once per cell cycle. A screen for mutants that overreplicated their DNA uncovered new conditional alleles that cause accumulation of up to 8C DNA. DNA overreplication involves all chromosomes and does not require passage through mitosis or another START. It occurs within a single cell cycle and can cause arrest at the MEC1 checkpoint. Remarkably, CIb2-Cdc28 activity remains elevated in the overreplicating cells. These observations distinguish CDC16 and CDC27 from other mutants that accumulate extra DNA after completing an aberrent mitosis, or skipping mitosis altogether, and entering a second, inappropriate G1 and S phase. CDC16 and CDC27 may contribute to replication control by targeted proteolysis of an S phase initiator.			Heichman, KA (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.							ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; CREANOR J, 1990, J CELL SCI, V96, P435; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUBERMAN JA, 1995, NATURE, V375, P360, DOI 10.1038/375360a0; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLYCE HR, 1973, EXP CELL RES, V82, P47, DOI 10.1016/0014-4827(73)90243-7; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; ODONNELL KL, 1991, J CELL SCI, V99, P711; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	53	78	80	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					39	48		10.1016/S0092-8674(00)81080-6	http://dx.doi.org/10.1016/S0092-8674(00)81080-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620535	Bronze			2022-12-24	WOS:A1996UE55900007
J	Konig, P; Giraldo, R; Chapman, L; Rhodes, D				Konig, P; Giraldo, R; Chapman, L; Rhodes, D			The crystal structure of the DNA-binding domain of yeast RAP1 in complex with telomeric DNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANTENNAPEDIA HOMEODOMAIN; PROTEIN; SILENCER; LENGTH; TRANSCRIPTION; RESOLUTION; SEQUENCES; STABILITY; ERRORS	Telomeres, the nucleoprotein complexes at the ends of eukaryotic chromosomes, are essential for chromosome stability. In the yeast S. cerevisiae, telomeric DNA is bound in a sequence-specific manner by RAP1, a multifunctional protein also involved in transcriptional regulation. Here we report the crystal structure of the DNA-binding domain of RAP1 in complex with a telomeric DNA site at 2.25 Angstrom resolution. The protein contains two similar domains that bind DNA in a tandem orientation, recognizing a tandemly repeated DNA sequence. The domains are structurally related to the homeodomain and the proto-oncogene Myb, but show novel features in their DNA-binding mode. A structured linker between the domains and a long C-terminal tail contribute to the binding specificity. This structure provides insight into the recognition of the conserved telomeric DNA sequences by a protein.	CSIC,CTR INVEST BIOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Konig, P (corresponding author), MRC,MOLEC BIOL LAB,LONDON W1N 4AL,ENGLAND.		Giraldo, Rafael/P-3289-2014	Giraldo, Rafael/0000-0002-5358-7488				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; FREEMAN K, 1995, GENETICS, V141, P1253; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENRY YAL, 1990, NUCLEIC ACIDS RES, V18, P2617, DOI 10.1093/nar/18.9.2617; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P110; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TSANG JSH, 1990, NUCLEIC ACIDS RES, V18, P7331, DOI 10.1093/nar/18.24.7331; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035; ZAKIAN AV, 1995, SCIENCE, V270, P1601	64	251	254	4	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					125	136		10.1016/S0092-8674(00)81088-0	http://dx.doi.org/10.1016/S0092-8674(00)81088-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620531	Bronze			2022-12-24	WOS:A1996UE55900015
J	Scanziani, M; Malenka, RC; Nicoll, RA				Scanziani, M; Malenka, RC; Nicoll, RA			Role of intercellular interactions in heterosynaptic long-term depression	NATURE			English	Article							SYNAPTIC PLASTICITY; AREA CA1; HIPPOCAMPUS; POTENTIATION; RECEPTORS; INDUCTION; RAT; STIMULATION	BIDIRECTIONAL control of synaptic strength is thought to be important for the development of neuronal circuits and information storage. The demonstration of homosynaptic long-term depression(1) greatly enhances the usefulness of the synapse as a mnemonic device, but theoreticians have also seen the need for heterosynaptic decreases in synaptic efficacy, both in neuronal development(2-4) and information storage(5). Indeed, induction of long-term potentiation in one population of synapses can be associated with a modest depression at neighbouring inactive synapses in the same population of cells(6-10). Here we report that in the CA1 region of the hippocampus this heterosynaptic long-term depression has the property that its sites of induction and expression occur in different populations of cells and thus requires the spread of a signal between neurons. Such a mechanism ensures a widespread distribution of this form of plasticity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scanziani, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHRISTIE BR, 1994, HIPPOCAMPUS, V4, P127, DOI 10.1002/hipo.450040203; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DESMOND NL, 1991, BRAIN RES, V552, P93, DOI 10.1016/0006-8993(91)90664-H; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MANZONI OJ, 1994, SCIENCE, V265, P2098, DOI 10.1126/science.7916485; MARTIN KAC, 1988, Q J EXP PHYSIOL CMS, V73, P637, DOI 10.1113/expphysiol.1988.sp003190; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHREURS BG, 1993, BRAIN RES, V631, P235, DOI 10.1016/0006-8993(93)91540-9; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	27	89	90	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					446	450		10.1038/380446a0	http://dx.doi.org/10.1038/380446a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602244				2022-12-24	WOS:A1996UD59000064
J	Green, AR				Green, AR			Pathogenesis of polycythaemia vera	LANCET			English	Editorial Material							POLYCYTHEMIA-VERA; ERYTHROPOIETIN				Green, AR (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE,ENGLAND.			Green, Anthony/0000-0002-9795-0218				ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Aldred M. A., 1995, American Journal of Human Genetics, V57, pA255; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1992, BLOOD, V80, P891; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; FISHER MJ, 1994, BLOOD, V84, P1982; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; KRALOVICS R, 1995, BLOOD, V86, P733; KRALOVICS R, 1995, BLOOD, V86, P270; NUNEZ C, 1994, BLOOD, V85, P635; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	15	20	20	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					844	845		10.1016/S0140-6736(96)91338-0	http://dx.doi.org/10.1016/S0140-6736(96)91338-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622384				2022-12-24	WOS:A1996UC45000002
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			A role for stereoscopic depth cues in the rapid visual stabilization of the eyes	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; DEPENDENCE	PRIMATES have visual tracking systems that help stabilize the eyes on the surroundings by responding to retinal image motion at ultra-short latencies(1,2). However, as the observer moves through the environment, the image motion on the retina depends on the three-dimensional structure of the scene(3,4). We report here that the very earliest of these tracking responses is elicited only by objects moving in the immediate vicinity of the plane of fixation: objects nearer or farther are ignored. This selectivity is achieved by means of a stereoscopic depth mechanism which uses the fact that the two eyes have differing viewpoints, so only objects in the plane of fixation have images that occupy corresponding positions on the two retinae. Such behaviour is readily explained by the known binocular properties of some motion-selective neurons in the visual cortex(5). Some (stereoanomalous) subjects showed highly specific tracking deficits as though lacking one subtype of these neurons.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BUSETTINI C, 1991, J NEUROPHYSIOL, V66, P865, DOI 10.1152/jn.1991.66.3.865; BUSETTINI C, 1994, CONTEMPORARY OCULAR MOTOR AND VESTIBULAR RESEARCH: A TRIBUTE TO DAVID A. ROBINSON, P312; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; Gibson J. J., 1950, PERCEPTION VISUAL WO; HOWARD IP, 1989, EXP BRAIN RES, V78, P309; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; MILES FA, 1992, HEAD NECK SENSORY MO, P471; MILES FA, 1991, REPRESENTATIONS VISI, P185; MORGAN MJ, 1995, NATURE, V378, P380, DOI 10.1038/378380a0; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193	11	46	46	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					342	345		10.1038/380342a0	http://dx.doi.org/10.1038/380342a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598928				2022-12-24	WOS:A1996UC37900059
J	Hein, HO; Suadicani, P; Gyntelberg, F				Hein, HO; Suadicani, P; Gyntelberg, F			Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: Six year follow up in the Copenhagen male study	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; MEN	Objectives-To investigate the interplay between use of alcohol, concentration of low density lipoprotein cholesterol, and risk of ischaemic heart disease. Design-Prospective study with controlling for several relevant confounders, including concentrations of other lipid fractions. Setting-Copenhagen male study, Denmark. Subjects-2826 men aged 53-74 years without overt ischaemic heart disease. Main outcome measure-Incidence of ischaemic heart disease during a six year follow up period. Results-172 men (6.1%) had a first ischaemic heart disease event. There was an overall inverse association between alcohol intake and risk of ischaemic heart disease. The association was highly dependent on concentration of low density lipoprotein cholesterol. In men with a high concentration (greater than or equal to 5.25 mmol/l) cumulative incidence rates of ischaemic heart disease were 16.4% for abstainers, 8.7% for those who drank 1-21 beverages a week, and 4.4% for those who drank 22 or more beverages a week. With abstainers as reference and after adjust ment for confounders, corresponding relative risks (95% confidence interval) were 0.4 (0.2 to 1.0; P<0.05) and 0.2 (0.1 to 0.8; P<0.01). In men with a concentration <3.63 mmol/l use of alcohol was not associated with risk. The attributable risk (95% confidence interval) of ischaemic heart disease among men with concentrations greater than or equal to 3.63 mmol/l who abstained from drinking alcohol was 43% (10% to 64%). Conclusions-In middle aged and elderly men the inverse association between alcohol consumption and risk of ischaemic heart disease is highly dependent on the concentration of low density lipoprotein cholesterol. These results support the suggestion that use of alcohol may in part explain the French paradox.			Hein, HO (corresponding author), STATE UNIV HOSP,RIGSHOSP 7122,EPIDEMIOL RES UNIT,DK-2200 COPENHAGEN N,DENMARK.							BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTELLI WP, 1977, LANCET, V2, P153; CASTELLI WP, 1984, AM J MED, V76, P2; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; FOLSOM AR, 1955, EUR HEART J SA, V16, P21; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; GYNTELBERG F, 1975, DAN MED BULL, V22, P81; HEIN HO, 1992, J INTERN MED, V232, P481, DOI 10.1111/j.1365-2796.1992.tb00620.x; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; NORUSIS MJ, 1988, SPSS PC PLUS BASE MA; NORUSIS MJ, 1988, SPSS PC PLUS ADV STA; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Rose G, 1982, CARDIOVASCULAR SURVE; ROSE GA, 1964, LANCET, V1, P296; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; Stahler F, 1977, Med Lab (Stuttg), V30, P29; SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Svalastoga Kaare, 1959, PRESTIGE CLASS MOBIL; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1960, BRIT MED J, V2, P1665	34	98	99	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					736	741						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605458	Green Published			2022-12-24	WOS:A1996UC16600024
J	vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD				vanderSchouw, YT; vanderGraaf, Y; Steyerberg, EW; Eijkemans, MJC; Banga, JD			Age at menopause as a risk factor for cardiovascular mortality	LANCET			English	Article							CORONARY HEART-DISEASE; WOMEN; ESTROGEN	Background Although an association of occurrence of menopause and subsequent oestrogen deficiency with increased cardiovascular disease has been postulated, studies on this association have not shown convincing results. We investigated whether age at menopause is associated with cardiovascular mortality risk. Methods We studied a cohort of 12 115 postmenopausal women living in Utrecht, Netherlands, aged 50-65 years at enrolment in a breast cancer screening project. During follow-up of up to 20 years the women attended screening rounds at which we asked questions on menopausal status, age at menopause, medication use, cardiovascular risk factors, and ovarian function. Deaths were ascertained from the patient's family physicians. Life-table analysis and Cox regression analysis were used to investigate the association between age at menopause and cardiovascular mortality. All analyses were adjusted for biological age. Findings 824 women died of cardiovascular causes. 1459 women had left the study area. The risk of cardiovascular mortality was higher for women with early menopauses than for those with late menopauses. The age-adjusted hazard ratio of age at menopause was 0.982 (95% CI 0.968-0.996, p=0.01)-ie, for each year's delay in the menopause the cardiovascular mortality risk decreased by 2%. The extra risk of early menopause seemed to decrease with biological age (p for interaction 0.07); at biological age 60 the reduction of the annual hazard was 3%, but at age 80 there was no reduction. Adjustment for known cardiovascular risk factors and indicators of ovarian function did not significantly alter the risk estimate. Interpretation These results support the hypothesis that longer exposure to endogenous oestrogens protects against cardiovascular diseases. The effect of an early menopause may be more important at younger biological ages.	ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, CTR CLIN DECIS SCI, ROTTERDAM, NETHERLANDS; ACAD HOSP, DEPT INTERNAL MED, UTRECHT, NETHERLANDS	Erasmus University Rotterdam	vanderSchouw, YT (corresponding author), UNIV UTRECHT, DEPT EPIDEMIOL, POB 80035, 3508 TA UTRECHT, NETHERLANDS.		Eijkemans, Marinus J/D-8214-2013; van der Schouw, Yvonne T./F-8327-2014; Steyerberg, Ewout/C-1509-2018	van der Schouw, Yvonne T./0000-0002-4605-435X; Steyerberg, Ewout/0000-0002-7787-0122				BARRETTCONNOR E, 1995, BRIT MED J, V311, P1193, DOI 10.1136/bmj.311.7014.1193; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BENGTSSON C, 1973, ACTA MED SCAND S, V89, P75; BRAMBILLA DJ, 1989, J CLIN EPIDEMIOL, V42, P1031, DOI 10.1016/0895-4356(89)90044-9; BRESLOW NE, 1987, STAT METHODS CANCER, V2, P195; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; CORRAO JM, 1990, CARDIOLOGY, V77, P8, DOI 10.1159/000174649; DENTONKELAAR I, 1994, BRIT J CANCER, V69, P352, DOI 10.1038/bjc.1994.64; DEWAARD F, 1984, J CHRON DIS, V47, P41; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; LUOTO R, 1994, AM J EPIDEMIOL, V139, P64, DOI 10.1093/oxfordjournals.aje.a116936; Midgette A S, 1990, Epidemiology, V1, P474, DOI 10.1097/00001648-199011000-00010; PARRISH HM, 1967, AM J OBSTET GYNECOL, V99, P155; RIVIN AU, 1954, CIRCULATION, V9, P533, DOI 10.1161/01.CIR.9.4.533; ROBINSON RW, 1959, ARCH INTERN MED, V104, P908, DOI 10.1001/archinte.1959.00270120064010; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STANFORD JL, 1987, J CHRON DIS, V40, P995, DOI 10.1016/0021-9681(87)90113-5; TRACY RE, 1966, J CHRON DIS, V19, P1245, DOI 10.1016/0021-9681(66)90022-1; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; WUEST JH, 1953, CIRCULATION, V7, P801, DOI 10.1161/01.CIR.7.6.801	27	481	486	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 16	1996	347	9003					714	718		10.1016/S0140-6736(96)90075-6	http://dx.doi.org/10.1016/S0140-6736(96)90075-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602000	Green Submitted			2022-12-24	WOS:A1996TZ98200008
J	Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD				Perelson, AS; Neumann, AU; Markowitz, M; Leonard, JM; Ho, DD			HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1	A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t(1/2) = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t(1/2) = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time-defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles-is 2.6 days, These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.	AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories			Yang, Chen/G-1379-2010; Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002	NCRR NIH HHS [RR06555] Funding Source: Medline; NIAID NIH HHS [N01 AI45218, AI27742] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, N01AI045218] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAO YZ, 1995, AIDS RES HUM RETROV, V11, P353, DOI 10.1089/aid.1995.11.353; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; NATHANSON N, 1966, AM J EPIDEMIOL, V85, P494; NOWAK MA, 1995, NATURE, V375, P193, DOI 10.1038/375193a0; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Winslow D L, 1995, AIDS, V9 Suppl A, pS183	15	2627	2722	6	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1582	1586		10.1126/science.271.5255.1582	http://dx.doi.org/10.1126/science.271.5255.1582			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599114				2022-12-24	WOS:A1996TZ98300041
J	Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK				Wang, TW; Danielson, PD; Li, BY; Shah, PC; Kim, SD; Donahoe, PK			The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PROTEIN FARNESYLTRANSFERASE; II RECEPTOR; P21RAS; CLONING; RECOGNITION; EXPRESSION; ACTIVATION	The alpha subunit of p21(RAS) farnesyltransferase (FNTA), which is also shared by geranylgeranyltransferase, was isolated as a specific cytoplasmic interactor of the transforming growth factor-beta (TGF-beta) and activin type I receptors with the use of the yeast two-hybrid system. FNTA interacts specifically with ligand-free TGF-beta type I receptor but is phosphorylated and released upon ligand binding. Furthermore, the release is dependent on the kinase activity of the TGF-beta type II receptor. Thus, the growth inhibitory and differentiative pathways activated by TGF-beta and activin involve novel mechanisms of serine-threonine receptor phosphorylation-dependent release of cytoplasmic interactors and regulation of the activation of small G proteins, such as p21(RAS).			Wang, TW (corresponding author), MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114, USA.				NICHD NIH HHS [R01 HD3081, R01 HD32112, HD28138] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112, P30HD028138] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES DA, 1993, GENOMICS, V18, P105, DOI 10.1006/geno.1993.1432; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WANG TW, UNPUB; WARANA JL, 1994, MOL CELL BIOL, V14, P944; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	34	109	111	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1120	1122		10.1126/science.271.5252.1120	http://dx.doi.org/10.1126/science.271.5252.1120			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599089				2022-12-24	WOS:A1996TW70100039
J	Patz, JA; Epstein, PR; Burke, TA; Balbus, JM				Patz, JA; Epstein, PR; Burke, TA; Balbus, JM			Global climate change and emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AEDES-AEGYPTI DIPTERA; SUB-SAHARAN AFRICA; CONTACT HYPERSENSITIVITY; SCHISTOSOMA-HAEMATOBIUM; ULTRAVIOLET-IRRADIATION; IMMUNE-SYSTEM; UV-RADIATION; SEA-LEVEL; TEMPERATURE; SUPPRESSION	Climatic factors influence the emergence and reemergence of infectious diseases, in addition to multiple human, biological, and ecological determinants. Climatologists have identified upward trends in global temperatures and now estimate an unprecedented rise of 2.0 degrees C by the year 2100. Of major concern is that these changes can affect the introduction and dissemination of many serious infectious diseases. The incidence of mosquito-borne diseases, including malaria, dengue, and viral encephalitides, are among those diseases most sensitive to climate. Climate change would directly affect disease transmission by shifting the vector's geographic range and increasing reproductive and biting rates and by shortening the pathogen incubation period. Climate-related increases in sea surface temperature and sea level can lead to higher incidence of water-borne infectious and toxin-related illnesses, such as cholera and shellfish poisoning. Human migration and damage to health infrastructures from the projected increase in climate variability could indirectly contribute to disease transmission. Human susceptibility to infections might be further compounded by malnutrition due to climate stress on agriculture and potential alterations in the human immune system caused by increased flux of ultraviolet radiation. Analyzing the role of climate in the emergence of human infectious diseases will require interdisciplinary cooperation among physicians, climatologists, biologists, and social scientists. Increased disease surveillance; integrated modeling, and use of geographically based data systems wilt afford more anticipatory measures by the medical community. Understanding the linkages between climatological and ecological change as determinants of disease emergence and redistribution will ultimately help optimize preventive strategies.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DIV ENVIRONM & OCCUPAT MED,WASHINGTON,DC 20052	Johns Hopkins University; Harvard University; Harvard Medical School; George Washington University	Patz, JA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; ANDERSON DM, 1992, HARMFUL ALGAE NEWS, V2, P4; [Anonymous], 1995, ECOSYST HEALLTH; [Anonymous], 1993, BRUCE CHWATTS ESSENT; [Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; [Anonymous], 1991, MALARIA OBSTACLES OP; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARNOLA JM, 1994, TRENDS 93 COMPENDIUM, V65; Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BOWEN SG, 1980, ST LOUIS ENCEPHALITI; Brown A. W. A., 1983, Integrated mosquito control methodologies. Volume 1. Experience and components from conventional chemical control, P161; BRUCE JP, 1994, B AM METEOROL SOC, V75, P1831, DOI 10.1175/1520-0477(1994)075<1831:NDRAGC>2.0.CO;2; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CESTARI TF, 1995, J INVEST DERMATOL, V105, P8, DOI 10.1111/1523-1747.ep12312309; CHANDLER AC, 1945, AM J TROP MED, V25, P145; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; CRUZ PD, 1988, PHOTODERMATOLOGY, V5, P151; DAYNES RA, 1990, GLOBAL ATMOSPHERIC C; DEFABO EC, 1983, J EXP MED, V157, P84; DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; DOBSON A, 1992, GLOBAL WARMING BIOL; EPSTEIN PR, 1995, AM J PUBLIC HEALTH, V85, P168, DOI 10.2105/AJPH.85.2.168; EPSTEIN PR, 1994, DIS EVOLUTION GLOBAL, P423; Figueroa M, 1982, Bull Pan Am Health Organ, V16, P130; FLAVIN C, 1994, WORLD WATCH, V7, P10; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GIANNINI MS, 1990, GLOBAL ATMOSPHERIC C; GILLETT JD, 1974, EFFECTS METEOROLOGIC, P79; Glantz M.H., 1991, TELECONNECTIONS LINK; GLASS GE, 1993, APPLICATIONS GIS TEC; GREENWOOD BM, 1984, LANCET, V1, P1339; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Haile D.G., 1989, POTENTIAL EFFECTS GL; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HALSTEAD SB, 1988, HDB VIRAL RICKETTSIA, P85; Halstead Scott B., 1993, Tropical Medicine, V35, P137; HARDY JL, 1988, ARBOVIRUSES EPIDEMIO, V1; HERRERABASTO E, 1992, AM J TROP MED HYG, V46, P649, DOI 10.4269/ajtmh.1992.46.649; HERSEY P, 1983, J IMMUNOL, V31, P171; Houghton J.T., 1990, CLIMATE CHANGE IPCC; Houghton J.T., 1992, CLIMATE CHANGE 1992; HUQ A, 1990, APPL ENVIRON MICROB, V56, P2370, DOI 10.1128/AEM.56.8.2370-2373.1990; JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O; JETTEN TH, 1994, CHANGE, V18, P10; KARL TR, 1993, B AM METEOROL SOC, V74, P1007, DOI 10.1175/1520-0477(1993)074<1007:ANPORG>2.0.CO;2; KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0; Karl TR, 1995, CONSEQUENCES, V1, P3; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; KRIPKE ML, 1986, J INVEST DERMATOL, V86, P543, DOI 10.1111/1523-1747.ep12355000; KRIPKE ML, 1992, EFFECTS HUMAN HLTH U; LARCOM LL, 1990, J NATL CANCER I, V82, P1361, DOI 10.1093/jnci/82.16.1361; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECTIONS; Lembeye G., 1992, HARMFUL ALGAE NEWS, V2, P1; LEVINS R, 1994, AM SCI, V82, P52; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MACDONALD G, 1954, TROPICAL DIS B, V50, P871; MACDONALD W W, 1956, Ann Trop Med Parasitol, V50, P399; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; MARTENS WJM, 1994, GLOBAL DYNAMICS SUST, V3; MARTENS WJM, 1995, GLOBO REPORT SERIES, V10; MASKELL K, 1993, LANCET, V342, P1027, DOI 10.1016/0140-6736(93)92883-U; Matsuoka Y., 1995, J GLOBAL ENV ENG, V1, P43; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; MEARNS LO, 1993, DROUGHT ASSESSMENT M, P109; Mills D., 1995, PUBLICATIONS CLIMATO, V48, P1; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; MONATH TP, 1987, AM J TROP MED HYG, V37, pS40, DOI 10.4269/ajtmh.1987.37.40S; MONATH TP, 1990, PRINCIPLES PRACTICE; MOORE PS, 1992, CLIN INFECT DIS, V14, P515, DOI 10.1093/clinids/14.2.515; MORISON WL, 1989, PHOTOCHEM PHOTOBIOL, V50, P515, DOI 10.1111/j.1751-1097.1989.tb05557.x; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nicholls N., 1991, TELECONNECTIONS LINK, P493; NODEN BH, IN PRESS PARASITOLOG; NOONAN FP, 1981, PHOTOCHEM PHOTOBIOL, V34, P683, DOI 10.1111/j.1751-1097.1981.tb09425.x; PANT CP, 1973, J MED ENTOMOL, V10, P219, DOI 10.1093/jmedent/10.2.219; PARRILLA G, 1994, NATURE, V369, P204; PARRY ML, 1993, LANCET, V342, P1345, DOI 10.1016/0140-6736(93)92251-N; PATZ JA, 1995, WORLD RESOURCE REV, V7, P104; PATZ JA, IN PRESS CLIMATE RES; RAPER SCB, 1995, RISING SEA LEVEL SUB; REEVES WC, 1994, J MED ENTOMOL, V31, P323, DOI 10.1093/jmedent/31.3.323; REISEN WK, 1993, J MED ENTOMOL, V30, P151, DOI 10.1093/jmedent/30.1.151; REITER P, 1988, ARBOVIRUSES EPIDEMIO, P245; ROGERS DJ, 1991, NATURE, V351, P739, DOI 10.1038/351739a0; ROGERS DJ, 1993, LANCET, V342, P1282, DOI 10.1016/0140-6736(93)92367-3; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; RUEDA LM, 1990, J MED ENTOMOL, V27, P892, DOI 10.1093/jmedent/27.5.892; Schneider S.H., 1990, GLOBAL WARMING ARE W; SCOTT TW, 1993, J MED ENTOMOL, V30, P922, DOI 10.1093/jmedent/30.5.922; SHIFF CJ, 1979, T ROY SOC TROP MED H, V73, P375, DOI 10.1016/0035-9203(79)90157-3; SHIFF CJ, 1975, INT J PARASITOL, V5, P119; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Shope R.E., 1990, GLOBAL ATMOSPHERIC C; SHOPE RE, 1980, YALE J BIOL MED, V53, P93; STONE R, 1993, SCIENCE, V262, P833, DOI 10.1126/science.8235603; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TAYLOR P, 1986, T ROY SOC TROP MED H, V80, P12, DOI 10.1016/0035-9203(86)90185-9; TESTER P, 1991, HLTH ENV DIGEST, V5, P4; Titus J. G., 1995, PROBABILITY SEA LEVE; TRENT DW, 1983, VIROLOGY, V128, P271, DOI 10.1016/0042-6822(83)90255-6; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; VANDERLEUN JC, 1991, ENV EFFECTS OZONE DE; WASHINO RK, 1994, AM J TROP MED HYG, V50, P134, DOI 10.4269/ajtmh.1994.50.134; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; WENZEL RP, 1994, NEW ENGL J MED, V330, P1004, DOI 10.1056/NEJM199404073301410; WHETTON PH, 1993, CLIMATIC CHANGE, V25, P289, DOI 10.1007/BF01098378; WIGLEY TML, 1992, NATURE, V357, P293, DOI 10.1038/357293a0; WJMcG Tegart, 1990, CLIMATE CHANGE IPCC, DOI Australian Government Publishing Service; WOLFF K, 1983, J INVEST DERMATOL, V80, pS17, DOI 10.1111/1523-1747.ep12536750; ZULUETA J, 1980, T R SOC TROP MED HYG, V74, P624; 1985, 10 YEARS ONCHOCERCIA; 1992, 9404 SCRIPPS I OC RE; 1989, MMWR-MORBID MORTAL W, V38, P440; 1994, RAD FORCING CLIMATE; 1990, POTENTIAL HLTH EFFEC; 1994, DENGUE DENGUE HEMORR, P98; IN PRESS CLIMATE CHA; 1991, 1991 ENSO CLIM CHANG	128	419	450	9	328	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					217	223		10.1001/jama.275.3.217	http://dx.doi.org/10.1001/jama.275.3.217			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604175				2022-12-24	WOS:A1996TP28200030
J	Rice, WR				Rice, WR			Sexually antagonistic male adaptation triggered by experimental arrest of female evolution	NATURE			English	Article								EACH sex is part of the environment of the other sex. This may lead to perpetual coevolution between the sexes, when adaptation by one sex reduces fitness of the other. Indirect evidence comes from experiments with Drosophila melanogaster indicating that seminal fluid reduces the competitive ability of sperm from other males, thereby increasing male fitness(1,2). It also reduces a female's propensity to remate and increases her egg-laying rate(3). In contrast to these benefits to males, seminal fluid has substantial toxic side effects in females, with increasing quantity leading to decreasing female survival(4,5). Here I show that when female D. melanogaster are experimentally prevented from coevolving with males, males rapidly adapt to the static female phenotype. This male adaptation leads to a reduction in female survivorship, which is mediated by an increased rate of remating and increased toxicity of seminal fluid.			Rice, WR (corresponding author), UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064, USA.							BARTON NH, 1995, GENETICS, V140, P821; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; CHARLESWORTH D, 1993, GENET RES, V61, P1289; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; MANNING JT, 1984, ACTA BIOTHEOR, V33, P219, DOI 10.1007/BF00048429; Muller H., 1942, BIOL S, V6, P71; ORR HA, 1995, GENETICS, V139, P1805; Palopoli M.F., 1994, ANNU REV GENET, V27, P283, DOI 10.1146/annurev.ge.28.120194.001435; PECK JR, 1994, GENETICS, V137, P597; RICE WR, 1994, TRENDS ECOL EVOL, V9, P235, DOI 10.1016/0169-5347(94)90258-5; RICE WR, 1993, EVOLUTION, V47, P1637, DOI 10.1111/j.1558-5646.1993.tb01257.x; van Valen L., 1973, EVOL THEOR, V1, P1, DOI DOI 10.1038/344864A0	17	767	776	0	173	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					232	234		10.1038/381232a0	http://dx.doi.org/10.1038/381232a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622764				2022-12-24	WOS:A1996UL24900053
J	Surks, MI; DeFesi, CR				Surks, MI; DeFesi, CR			Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine - A paradox resolved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM PHENYTOIN; EPILEPTIC PATIENTS; ANTICONVULSANT DRUGS; EQUILIBRIUM DIALYSIS; FUNCTION TESTS; FREE-THYROXINE; DIPHENYLHYDANTOIN; TRIIODOTHYRONINE; BINDING; 5,5'-DIPHENYLHYDANTOIN	Objective.-To address the paradox that phenytoin- and carbamazepine-treated patients have decreased serum free thyroxine (T-4) and triiodothyronine (T-3) concentrations but appear clinically euthyroid and have normal serum thyroid-stimulating hormone (TSH) concentrations. Design.-In vitro studies comparing measurements of total and free T-4 and T-3 by ultrafiltration assay (undiluted serum) and a commercial free T-4 estimate kit in control serum samples or serum samples containing added therapeutic levels of phenytoin or carbamazepine. These measurements were made in serum samples diluted 1:5 with either identical serum or phosphate buffer, pH 7.4, and in serum samples from patients with seizure disorders who were treated with phenytoin or carbamazepine. Setting.-A 650-bed teaching hospital. Patients.-Selected patients (n=19) who were in good health except for seizure disorder, with stable anticonvulsant drug levels in the upper half of the therapeutic range, and were not taking any other drugs that could affect thyroid parameters. Main Outcome Measure.-Serum concentrations of free T-4 and free T-3 in patients taking phenytoin or carbamazepine vs normal controls. Results-Addition of phenytoin or carbamazepine to normal human serum in vitro resulted in a significant increase in free T-4 fraction and free T-4 (P<.001). In patients taking phenytoin or carbamazepine, serum total T-4 decreased significantly to 60% and 74%, respectively, of the control serum concentration (P<.001 for both phenytoin and carbamazepine); free T-4 fraction (by ultrafiltration assay) increased 65% and 44%, respectively (P<.001 for phenytoin, P<.01 for carbamazepine); and free T-4 remained unchanged. Free T-4 concentration measured by a commercial kit (1.5 serum dilution) was significantly lower than the control concentration in both phenytoin- and carbamazepine-treated patients. Serum free T-3 and serum TSH were also normal in phenytoin- and carbamazepine-treated patients. Conclusions.-Therapeutic levels of phenytoin and carbamazepine displace T-4 and T-3 from serum binding proteins. When added to serum, the drugs effect an increase in free hormone fractions and free T-4 and T-3. In drug-treated patients, increased free T-4 and free T-3 fractions offset the significant decrease in serum T-4 and T-3, resulting in normal free T-4 and free T-3 concentrations. Since currently available clinical tests will continue to show decreased free T-4 concentrations in patients taking phenytoin or carbamazepine, clinicians should rely on serum TSH measurements to confirm the euthyroid status of these patients.	ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Surks, MI (corresponding author), MONTEFIORE MED CTR, DEPT MED & PATHOL, DIV ENDOCRINOL & METAB, 111 E 210TH ST, BRONX, NY 10467 USA.							BENTSEN KD, 1983, ACTA NEUROL SCAND, V67, P235, DOI 10.1111/j.1600-0404.1983.tb04569.x; BLACKSHEAR JL, 1983, ANN INTERN MED, V99, P341, DOI 10.7326/0003-4819-99-3-341; CAVALIERI RR, 1979, METABOLISM, V28, P1161, DOI 10.1016/0026-0495(79)90156-2; CHIN W, 1968, J CLIN ENDOCR METAB, V28, P181, DOI 10.1210/jcem-28-2-181; CONNELL JMC, 1984, EUR J CLIN PHARMACOL, V26, P453, DOI 10.1007/BF00542140; EKINS R, 1990, ENDOCR REV, V11, P5, DOI 10.1210/edrv-11-1-5; FICHSEL H, 1978, EPILEPSIA, V19, P323, DOI 10.1111/j.1528-1157.1978.tb04498.x; FRANKLYN JA, 1985, J ENDOCRINOL, V104, P201, DOI 10.1677/joe.0.1040201; FRANKLYN JA, 1984, EUR J CLIN PHARMACOL, V26, P633, DOI 10.1007/BF00543499; HANSEN JM, 1974, J CLIN ENDOCR METAB, V39, P785, DOI 10.1210/jcem-39-4-785; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HERMAN R, 1991, BIOL PSYCHIAT, V29, P779, DOI 10.1016/0006-3223(91)90197-T; HEYMA P, 1977, CLIN ENDOCRINOL, V6, P369, DOI 10.1111/j.1365-2265.1977.tb02023.x; ISOJARVI JIT, 1990, ARCH NEUROL-CHICAGO, V47, P670, DOI 10.1001/archneur.1990.00530060082023; ISOJARVI JIT, 1993, J NEUROL NEUROSUR PS, V56, P710, DOI 10.1136/jnnp.56.6.710; ISOJARVI JIT, 1989, ARCH NEUROL-CHICAGO, V46, P1175, DOI 10.1001/archneur.1989.00520470029021; LARSEN PR, 1970, J CLIN INVEST, V49, P1266, DOI 10.1172/JCI106339; LIEWENDAHL K, 1976, SCAND J CLIN LAB INV, V36, P141, DOI 10.3109/00365517609055240; LIEWENDAHL K, 1978, CLIN ENDOCRINOL, V8, P185, DOI 10.1111/j.1365-2265.1978.tb01493.x; LIEWENDAHL K, 1985, CLIN CHEM, V31, P1993; LIM CF, 1988, J CLIN ENDOCR METAB, V67, P682, DOI 10.1210/jcem-67-4-682; MANN DN, 1983, ENDOCRINOLOGY, V112, P1723, DOI 10.1210/endo-112-5-1723; OPPENHEIMER J, 1961, J CLIN ENDOCR METAB, V21, P252, DOI 10.1210/jcem-21-3-252; OPPENHEIMER JH, 1962, ENDOCRINOLOGY, V71, P496, DOI 10.1210/endo-71-3-496; ROOTWELT K, 1978, SCAND J CLIN LAB INV, V38, P731, DOI 10.3109/00365517809104880; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; Snedecor G.W., 1967, STAT METHODS; STJERNHOLM MR, 1975, CLIN CHEM, V21, P1388; SURKS MI, 1988, J CLIN ENDOCR METAB, V67, P1031, DOI 10.1210/jcem-67-5-1031; YEO PPB, 1978, BRIT MED J, V1, P1581, DOI 10.1136/bmj.1.6127.1581	30	70	72	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1495	1498		10.1001/jama.275.19.1495	http://dx.doi.org/10.1001/jama.275.19.1495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622224				2022-12-24	WOS:A1996UJ93700033
J	Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R				Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R			Prognostic implications of monosomy 3 in uveal melanoma	LANCET			English	Article							ENUCLEATION; CHROMOSOME-3	Background A high proportion of patients with uveal melanoma die of metastatic disease. In a subgroup of uveal melanomas there is the loss of one chromosome 3, To assess the prognostic implications of this genetic anomaly, we studied 54 patients for a median of 3 . 4 years. Methods 180 patients underwent primary enucleation for malignant uveal melanoma at the Ophthalmology Department of the Universitatskiinikum Essen between 1987 and 1993. Tumour material was available for chromosome analysis and DNA preparation from 69 of these patients (for logistic reasons unlikely, we believe, to introduce bias), 15 patients were excluded from our study: nine because the methods for assessment of monosomy 3 were unsuccessful; five because of insufficient information about their relapse status; one because histopathological data were incomplete. Of the 54 remaining patients, the tumours of 16 were assessed for copy number of chromosome 3 by karyotype analysis, of 30 by comparative genomic hybridisation, and of eight by both techniques. Clinical status was assessed by contact with family doctor or a clinical check up. Statistical analysis was by the log-rank test and Cox proportional-hazard regression. Findings The tumours of 30 patients had monosomy 3. 17 (57%) of these patients relapsed with metastatic disease, and the 3-year relapse-free survival rate was 50%. By contrast, of the 24 patients whose tumours had retained both chromosomes 3, none developed metastatic disease, In univariate analysis monosomy 3 was the most significant (p<0 . 0001) predictor of poor prognosis in uveal melanoma, followed by tumour location (p<0 . 0007) and tumour diameter (p<0 . 0021). Histopathological subtype, age, sex, extrascleral growth, and tumour thickness had no additional predictive value. Interpretation In uveal melanoma, monosomy 3 is a significant predictor of both relapse-free and overall survival.	UNIV KLINIKUM ESSEN,INNERE KLIN & POLIKLIN,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST MED INFORMAT BIOMETRIE & EPIDEMIOL,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST HUMAN GENET,D-45122 ESSEN,GERMANY; FREE UNIV BERLIN,AUGENKLIN & POLIKLIN,UNIV KLINIKUM BENJAMIN FRANKLIN,W-1000 BERLIN,GERMANY	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ALBERT DM, 1992, SURV OPHTHALMOL, V36, P429, DOI 10.1016/S0039-6257(05)80024-4; COLEMAN K, 1993, BRIT J OPHTHALMOL, V77, P688, DOI 10.1136/bjo.77.11.688; DIENERWEST M, 1992, ARCH OPHTHALMOL-CHIC, V110, P245, DOI 10.1001/archopht.1992.01080140101036; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FOLBERG R, 1993, OPHTHALMOLOGY, V100, P1389; GORDON KB, 1994, CANCER RES, V54, P4764; HORSMAN DE, 1993, CANCER, V71, P811, DOI 10.1002/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F; HORSTHEMKE B, 1992, GENE CHROMOSOME CANC, V4, P217, DOI 10.1002/gcc.2870040305; JENSEN OA, 1982, ACTA OPHTHALMOL, V60, P161; MCLEAN IW, 1982, HUM PATHOL, V13, P123; MCLEAN IW, 1995, OPHTHALMOLOGY, V102, P1060; PRESCHER G, 1992, LANCET, V339, P691, DOI 10.1016/0140-6736(92)90861-V; PRESCHER G, 1990, J NATL CANCER I, V82, P1765, DOI 10.1093/jnci/82.22.1765; RUMMELT V, 1995, OPHTHALMOLOGY, V102, P844, DOI 10.1016/S0161-6420(95)30947-5; SEDDON JM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1894; SHIELDS JA, 1993, CANCER, V72, P2067, DOI 10.1002/1097-0142(19931001)72:7<2067::AID-CNCR2820720702>3.0.CO;2-0; SISLEY K, 1990, GENE CHROMOSOME CANC, V2, P205, DOI 10.1002/gcc.2870020307; Soulen M C, 1994, Oncology (Williston Park), V8, P77; SPEICHER MR, 1994, CANCER RES, V54, P3817	19	540	549	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1222	1225						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622452				2022-12-24	WOS:A1996UJ59700011
J	Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP				Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP			Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease	LANCET			English	Article							PRIMARY SCLEROSING CHOLANGITIS; PRIMERS PCR-SSP; ULCERATIVE-COLITIS; CROHNS-DISEASE; HLA; LINKAGE	Background Despite strong evidence implicating immune dysfunction and genetic predisposition in the pathogenesis of the chronic inflammatory bower diseases Crohn's disease and ulcerative colitis, the importance of the genes of the major histocompatibility complex remains uncertain, We have investigated the contribution of HLA DRB1 and DQB genes by the strategies of non-parametric linkage analysis (affected sibling pair method) as well as association study. The relation between genotype and phenotype was examined in detail. Methods For linkage analysis 74 families in whom two or more siblings had inflammatory bowel disease were studied. A total of 83 affected sibling pairs were involved: in 42 pairs both siblings had Crohn's disease; in 29 both had ulcerative colitis; in 12 one sibling had Crohn's disease, the other ulcerative colitis. for the association study there were 175 patients with ulcerative colitis, 173 with Crohn's disease, and 472 controls. Details of sex, age of onset, disease extent, and family history were analysed. 24 patients with ulcerative colitis and 92 with Crohn's disease required surgery for refractory disease, HLA DRB1 and DQB1 gene-typing was performed by polymerase chain reaction with sequence-specific primers. Findings in ulcerative colitis, the sharing of alleles among affected sibling pairs provided evidence for linkage with DRB1 locus (p=0 . 017, chi(2)=5 . 32). Of 29 affected sibling pairs studied, only one pair shared no DRB1 DQB haplotypes. 15 shared two DRB DQB haplotypes. In contrast, no linkage was noted for Crohn's disease (42 sibling pairs; p=0 . 30, chi 2=0 . 16) or for inflammatory bowel disease overall (83 sibling pairs, p=0 . 16, chi(2)=2 . 28), In the association study the rare DRB1*103 (8 . 3% vs 3 . 2% in controls) and DRB1*12 (8 . 6% vs 2 . 1% in controls) alleles were associated with ulcerative colitis (p=0 . 0074, chi(2)=7 . 22, odds ratio OR=2 . 9 [95% CI 1 . 3-6-4] and p=0 . 0056, chi(2)=12 . 63, OR=4 . 33 [1 . 8-11 . 0] respectively). No association with alleles representing DR2 (p=0 . 55, chi(2)=0 . 34) was noted, No overall association was seen in Crohn's disease, In ulcerative colitis, the frequency of DRB1*0301 DQB*0201 (DR3 DQ2) was reduced in females (9 . 8% vs 26 . 3% in controls, p=0 . 037, chi(2)=8 . 39 OR=0 . 34 (0 . 15-0 . 71]), particularly in those with distal disease (2 . 3%, p=0 . 001 vs controls, chi(2)=11 . 35, OR=0 . 07 [0 . 00-0 . 39]). In both males and females, the DR3 DQ2 haplotype was predictive of extensive ulcerative colitis (32 . 9% vs 10 . 7% in distal disease, p<0 . 01, chi(2)=10 . 94, OR 4 . 09 [1 . 70-10 . 6]) but not of need for surgery (p=0 . 93, chi(2)=0 . 01), Interpretation These data provide strong evidence for genetic heterogeneity in inflammatory bower disease. Genes of the major histocompatibility complex are implicated as important inherited determinants of susceptibility to ulcerative colitis and may also influence the pattern of disease. In Crohn's disease, important susceptibility genes are likely to exist outside the HLA region.	OXFORD RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD,ENGLAND; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics			JULIER, Cécile/M-9824-2017	JULIER, Cécile/0000-0002-1538-0240	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAKURA H, 1982, GASTROENTEROLOGY, V82, P413; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BRIGGS DC, 1991, LANCET, V338, P661, DOI 10.1016/0140-6736(91)91235-M; BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R; BUNCE M, IN PRESS TISSUE ANTI; CHAPMAN RW, 1991, GUT, V32, P1433, DOI 10.1136/gut.32.12.1433; DUERR RH, 1995, GASTROENTEROLOGY, V108, P423, DOI 10.1016/0016-5085(95)90069-1; FARMER RG, 1985, GASTROENTEROLOGY, V88, P1818, DOI 10.1016/0016-5085(85)90006-X; FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217; HASHIMOTO M, 1994, TISSUE ANTIGENS, V44, P166, DOI 10.1111/j.1399-0039.1994.tb02375.x; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; MCCONNELL RB, 1992, GENETIC BASIS COMMON, P326; MERRETT M, 1992, Gastroenterology, V102, pA935; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAOM IS, 1994, GUT, V35, pS30; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; REIJONEN H, 1994, TISSUE ANTIGENS, V43, P1, DOI 10.1111/j.1399-0039.1994.tb02289.x; RISCH N, 1987, AM J HUM GENET, V40, P1; ROITBERGTAMBUR A, 1994, TISSUE ANTIGENS, V43, P219, DOI 10.1111/j.1399-0039.1994.tb02328.x; ROTTER JI, 1984, CLIN GENET, V26, P529; SATSANGI J, 1994, GUT, V35, P696, DOI 10.1136/gut.35.5.696; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WASSMUTH R, 1994, EUR J GASTROEN HEPAT, V6, P405; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	29	319	334	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1212	1217		10.1016/S0140-6736(96)90734-5	http://dx.doi.org/10.1016/S0140-6736(96)90734-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622450				2022-12-24	WOS:A1996UJ59700009
J	Svoboda, K; Tank, DW; Denk, W				Svoboda, K; Tank, DW; Denk, W			Direct measurement of coupling between dendritic spines and shafts	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERIAL ELECTRON-MICROSCOPY; BIOPHYSICAL CHARACTERISTICS; FLUORESCENCE MICROSCOPY; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PURKINJE-CELLS; CALCIUM; VARIABILITY; AMPLITUDE	Characterization of the diffusional and electrotonic coupling of spines to the dendritic shaft is crucial to understanding neuronal integration and synaptic plasticity. Two-photon photobleaching and photorelease of fluorescein dextran were used to generate concentration gradients between spines and shafts in rat CAI pyramidal neurons. Diffusional reequilibration was monitored with two-photon fluorescence imaging. The time course of reequilibration was exponential, with time constants in the range of 20 to 100 milliseconds, demonstrating chemical compartmentalization on such time scales. These values imply that electrical spine neck resistances are unlikely to exceed 150 megohms and more likely range from 4 to 50 megohms.	AT&T BELL LABS,LUCENT TECHNOL,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; Baudry M., 1994, LONG TERM POTENTIATI, V2; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Berg, 2018, RANDOM WALKS BIOL; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN TH, 1992, SINGLE NEURON COMPUT, P81; CAUCHETEUXSILBERZAN I, 1993, BIOPHYS J, V64, pA109; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; DENK W, UNPUB; Denk Winfried, 1995, P445; FROMHERZ P, 1994, P NATL ACAD SCI USA, V91, P4604, DOI 10.1073/pnas.91.10.4604; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1992, J NEUROSCI, V12, P2685; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HOLMES WR, 1990, BRAIN RES, V519, P338, DOI 10.1016/0006-8993(90)90098-V; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LANNI F, 1985, J CELL BIOL, V100, P1091, DOI 10.1083/jcb.100.4.1091; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALENKA RC, 1994, LONG TERM POTENTIATI, V2, P121; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Peters A, 1991, FINE STRUCTURE NERVO; PETROZZINO JJ, 1995, NEURON, V14, P1223, DOI 10.1016/0896-6273(95)90269-4; POPOV S, 1992, J NEUROSCI, V12, P77; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; SEJNOWSKI TJ, 1992, SINGLE NEURON COMPUT, P117; SVOBODA K, UNPUB; Tank DW, 1995, J NEUROSCI, V15, P7940; WILSON CJ, 1984, J NEUROSCI, V4, P281; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	43	386	395	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					716	719		10.1126/science.272.5262.716	http://dx.doi.org/10.1126/science.272.5262.716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614831				2022-12-24	WOS:A1996UJ05100049
J	Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW				Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW			Structure of Bordetella pertussis virulence factor P.69 pertactin	NATURE			English	Article							PROTEIN; IDENTIFICATION; MOTIF	A NEW generation of whooping-cough vaccines contain P.69 pertactin, a surface-exposed domain of an outer membrane protein expressed by the virulent bacterium Bordetella pertussis(1-3). This protein is a virulence factor that mediates adhesion to target mammalian cells, a reaction that is in part mediated by an RGD sequence, The X-ray crystal structure of P.69 pertactin has been determined to 2.5 Angstrom. The protein fold consists of a 16-stranded parallel beta-helix with a V-shaped cross-section, and is the largest beta-helix known to date, Several between-strand weakly conserved amino-acid repeats form internal and external ladders, The structure appears as a helix from which several loops protrude, which contain sequence motifs associated with the biological activity of the protein. One particular (GGXXP)(5) sequence is located directly after the RGD motif, and may mediate interaction with epithelial cells. The carboxy-terminal region of P.69 pertactin incorporates a (PQP)(5) motif loop containing the major immunoprotective epitope.	UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UCL, CRUCIFORM PROJECT, LONDON W1P 9LN, ENGLAND; GLAXO WELLCOME RES LABS, DEPT CELL BIOL, BECKENHAM BR3 385, KENT, ENGLAND	University of Glasgow; University of London; University College London; GlaxoSmithKline; Wellcome Research Laboratories					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BRUNGRE AT, 1988, X PLOR REFERENCE MAN; CHARLES I, 1994, MICROBIOL-SGM, V140, P3301, DOI 10.1099/13500872-140-12-3301; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHARLES IG, 1991, EUR J IMMUNOL, V21, P1147, DOI 10.1002/eji.1830210509; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EMSLEY P, 1994, J MOL BIOL, V235, P772, DOI 10.1006/jmbi.1994.1029; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HYNES RO, 1987, CELL, V48, P547; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; MAKOFF AJ, 1990, BIO-TECHNOL, V8, P1030, DOI 10.1038/nbt1190-1030; MONTARAZ JA, 1985, INFECT IMMUN, V47, P744, DOI 10.1128/IAI.47.3.744-751.1985; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; OTWINOWSKI Z, 1992, DATA COLLECTION PROC, P56; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; 1988, LANCET, V8592, P955	28	254	271	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					90	92		10.1038/381090a0	http://dx.doi.org/10.1038/381090a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609998				2022-12-24	WOS:A1996UJ05300064
J	Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ				Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ			Delayed tuberculin reactivity in persons of Indochinese origin: Implications for preventive therapy	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculin test; tuberculosis; Vietnam; ethnic groups; lymphocyte transformation	SKIN-TEST; LYMPHOCYTE-RESPONSES; SUPPRESSION; REACTORS	Objectives: To 1) study a variant delayed reaction to tuberculin testing as a way to enhance screening for tuberculosis among high-risk persons and 2) correlate the delayed reaction with lymphocyte blastogenesis. Design: Cross-sectional study. Setting: 2 public health department clinics in North Carolina. Participants: 121 adults who had recently emigrated from Vietnam to North Carolina and who were ethnic Vietnamese and ethnic Dega, a minority population group from the central highlands region of Vietnam. Measurements: Medical history, physical examination, laboratory evaluation, and standard purified protein derivative (PPD) testing (Mantoux method). Skin test results were read at 72 hours and again at 6 days. Variant reactivity was defined as induration of less than 10 mm at 72 hours that, when reassessed at 6 days, had increased in size to 10 mm or greater. Persons with negative (n = 54) and variant (n = 32) PPD results also had booster testing at 10 to 12 weeks. Serum samples were obtained from 57 participants for lymphocyte blastogenesis studies. Results: 26% of participants had variant tuberculin reactivity. Variant reactivity was strongly associated with booster positivity: Sixty-five percent of persons with variant PPD results had booster positivity compared with 16% of persons with negative PPD results (P < 0.001). The lymphocyte blastogenesis response of persons with variant PPD results was between the response of persons with negative PPD results and that of persons with positive PPD results. Conclusions: Variant reactivity in this high-risk group was a predictor of booster positivity. Together with the blastogenic response pattern, this association strongly-suggests that variant reactivity has a high positive predictive value for tuberculous infection. Clinicians should incorporate these findings into their approach for choosing candidates for preventive therapy.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, SCH MED, DEPT RADIOL, CHAPEL HILL, NC 27599 USA; UNIV ALABAMA, DEPT MED, DIV PREVENT MED, BIRMINGHAM, AL 35205 USA	Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham	Robertson, JM (corresponding author), UNIV NEW MEXICO, DEPT MED, SCH MED, ACC 5TH FLOOR, 2211 LOMAS NE, ALBUQUERQUE, NM 87131 USA.			Ellner, Jerrold/0000-0001-6150-0082				*AM SOC HLTH SYST, 1995, AHFS DRUG INF, P1722; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BURTT DS, 1992, EVALUATING ALTERNATI; ELLNER JJ, 1979, CELL IMMUNOL, V45, P213, DOI 10.1016/0008-8749(79)90379-4; HAVLIR DV, 1991, CHEST, V99, P1172, DOI 10.1378/chest.99.5.1172; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231; KLEINHENZ ME, 1983, J LAB CLIN MED, V102, P751; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MCANULTY JM, 1995, ARCH INTERN MED, V155, P713, DOI 10.1001/archinte.155.7.713; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; *STAT CORP, 1993, STAT VERS 3 1; *US BUR CENS, 1995, STAT ABSTR US, P11; *USD, 1990, EPI INFO VERS 5 0 WO; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; Wenzel M, 1991, Nurse Pract, V16, P25; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P961; 1993, MMWR-MORBID MORTAL W, V42, P628	26	12	13	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					779	+		10.7326/0003-4819-124-9-199605010-00001	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610946				2022-12-24	WOS:A1996UG25400001
J	Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H				Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H			Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4	NATURE			English	Article							SEX-DETERMINING REGION; CELL DEVELOPMENT; BONE-MARROW; GENE; PROTEIN; FAMILY	A STRIKING example of the relationship between regulation of transcription and phenotype is the central role of the Y-chromo somal gene Sry in mammalian sex determination(1,2). Sry is the founding member of a large family of so-called Sox genes(1,3). During murine embryogenesis, the transcriptional activator Sox-4 is expressed at several sites, hut in adult mice expression is restricted to immature B and T lymphocytes(4). Using targeted genedisruption, we have found that Sox-4(-/-) embryos succumb to circulatory failure at day E14. This was a result of impaired development of the endocardial ridges (a specific site of Sox-4 expression) into the semilunar valves and the outlet portion of the muscular ventricular septum. The observed range of septation defects is known as 'common arterial trunk' in man. We studied haemopoiesis in lethally irradiated mice reconstituted with Sox-4(-/-) fetal liver cells acid found that a specific block occurred in B-cell development at the pro-B cell stage. In line with this, the frequency and proliferative capacity of IL-7-responsive B cell progenitors in fetal liver were severely decreased in vitro.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,TRANSGEN MOUSE FACIL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT ANAT & EMBRYOL,1105 A2 AMSTERDAM,NETHERLANDS; INST PASTEUR,UNITE BIOL MOL GENE,F-75024 PARIS 15,FRANCE	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamers, Wouter H./D-2965-2012; Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Cumano, Ana/0000-0002-4578-959X				ANGELINI P, 1974, EUR J CARDIOL, V2, P11; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VANMIEROP LHS, 1969, CIBA COLLECTION MEDI, V5, P112; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VONDEWETERING M, 1993, EMBO J, V12, P3847; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	30	375	382	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					711	714		10.1038/380711a0	http://dx.doi.org/10.1038/380711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614465				2022-12-24	WOS:A1996UG82700051
J	Nightingale, SL				Nightingale, SL			New cancer therapy initiatives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-24	WOS:A1996UF47800009
J	Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK				Ball, JM; Tian, P; Zeng, CQY; Morris, AP; Estes, MK			Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein	SCIENCE			English	Article							HEAT-STABLE ENTEROTOXIN; ESCHERICHIA-COLI; GUANYLATE-CYCLASE; MURINE ROTAVIRUS; GNOTOBIOTIC PIGS; PATHOGENESIS; INFECTION; MICE; SITES; SEQUENCE	The rotavirus nonstructural glycoprotein NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope as subviral particles bud into the endoplasmic reticulum. NSP4 also causes an increase in intracellular calcium in insect cells. Purified NSP4 or a peptide corresponding to NSP4 residues 114 to 135 induced diarrhea in young (6 to 10 days old) CD1 mice. This disease response was age-dependent, dose-dependent, and specific. Electrophysiologic data from intestinal mucosa showed that the NSP4 114-135 peptide potentiates chloride secretion by a calcium-dependent signaling pathway. Diarrhea is induced when NSP4, acting as a viral enterotoxin, triggers a signal transduction pathway.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT INTEGRAT BIOL,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston					NIDDK NIH HHS [DK 30144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030144, R56DK030144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL JM, 1994, J IMMUNOL METHODS, V171, P37, DOI 10.1016/0022-1759(94)90226-7; BOTH GW, 1983, J VIROL, V48, P335, DOI 10.1128/JVI.48.2.335-339.1983; BURGESS MN, 1978, INFECT IMMUN, V21, P526, DOI 10.1128/IAI.21.2.526-531.1978; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CARPINO LA, 1970, J AM CHEM SOC, V92, P5748, DOI 10.1021/ja00722a043; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLINS J, 1988, J PEDIATR GASTR NUTR, V7, P264, DOI 10.1097/00005176-198803000-00017; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; ESTES MK, 1983, CURR TOP MICROBIOL, V105, P123; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GIANNELLA RA, 1983, AM J PHYSIOL, V245, pG492, DOI 10.1152/ajpgi.1983.245.4.G492; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; GRAHAM DY, 1984, DIGEST DIS SCI, V29, P1028, DOI 10.1007/BF01311255; Greenberg H B, 1994, Curr Top Microbiol Immunol, V185, P255; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; HALVORSRUD J, 1980, SCAND J INFECT DIS, V12, P161, DOI 10.3109/inf.1980.12.issue-3.01; HOLZEL H, 1980, J INFECTION, V2, P33, DOI 10.1016/S0163-4453(80)91750-8; HOSHINO Y, 1995, VIROLOGY, V209, P274, DOI 10.1006/viro.1995.1255; JIANG X, 1990, Science (Washington D C), V250, P1580; JOHNSON GP, 1986, ANAL CHEM, V58, P1084; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAPIKIAN AC, 1996, VIROLOGY, pCH55; KRAUSE WJ, 1990, CELL TISSUE RES, V260, P387, DOI 10.1007/BF00318641; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LITTLE LM, 1982, INFECT IMMUN, V38, P755, DOI 10.1128/IAI.38.2.755-763.1982; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MCADARAGH JP, 1980, AM J VET RES, V41, P1572; MEBUS CA, 1976, AM J DIG DIS, V21, P592, DOI 10.1007/BF01464768; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; NOVITSKY TJ, 1984, OCEANUS, V27, P13; OSBORNE MP, 1988, J PEDIATR GASTR NUTR, V7, P236, DOI 10.1097/00005176-198803000-00014; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; RAMIG RF, 1988, MICROB PATHOGENESIS, V4, P189, DOI 10.1016/0882-4010(88)90069-1; REED L. J., 1938, AMER JOUR HYG, V27, P493; SAIF LJ, IN PRESS P SAPP INT; SEARS CL, 1995, INFECTIONS GASTROINT, pCH44; STARKEY WG, 1986, J GEN VIROL, V67, P2625, DOI 10.1099/0022-1317-67-12-2625; THEIL KW, 1978, AM J VET RES, V39, P213; TIAN P, 1995, J VIROL, V69, P5763, DOI 10.1128/JVI.69.9.5763-5772.1995; TIAN P, 1994, J VIROL, V68, P251, DOI 10.1128/JVI.68.1.251-257.1994; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; ZENG CQY, IN PRESS J VIROL; [No title captured]	45	479	509	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					101	104		10.1126/science.272.5258.101	http://dx.doi.org/10.1126/science.272.5258.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600515				2022-12-24	WOS:A1996UD59700047
J	Seiwert, SD; Heidmann, S; Stuart, K				Seiwert, SD; Heidmann, S; Stuart, K			Direct visualization of uridylate deletion in vitro suggests a mechanism for kinetoplastid RNA editing	CELL			English	Article							MITOCHONDRIAL EXTRACTS; LEISHMANIA-TARENTOLAE; MESSENGER-RNAS; MOLECULES; INVITRO; SITES	Deletion of uridylates from the 3'-most editing site of synthetic ATPase 6 pre-mRNA can be visualized directly by coincubation of a radiolabeled substrate RNA and a synthetic gRNA in 20S fractions of T. brucei mitochondrial lysates. Substrate RNA cleavage is gRNA directed and occurs 3' to the uridylates to be deleted. U residues appear to be sequentially removed from the 3' end of the 5' cleavage product prior to religation of the two pre-mRNA halves. gRNA/mRNA chimeric molecules are also produced. Time course experiments indicate that chimeras appear after cleavage intermediates and edited product. Furthermore, a mutant gRNA promotes formation of edited product but not detectable chimeras. Our results suggest a model for kinetoplastid RNA editing in which chimeric molecules are nonproductive end products of editing and not intermediates that serve as a repository for deleted U's.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Seiwert, SD (corresponding author), SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109, USA.				NIGMS NIH HHS [GM42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTS GJ, 1993, EMBO J, V12, P1523, DOI 10.1002/j.1460-2075.1993.tb05796.x; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1996, MOL CELL BIOL, V16; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1991, CELL, V67, P637; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RILEY GR, 1995, NUCLEIC ACIDS RES, V23, P708, DOI 10.1093/nar/23.4.708; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SIMPSON AM, 1992, J BIOL CHEM, V267, P6782; SIMPSON L, 1995, CELL, V81, P837, DOI 10.1016/0092-8674(95)90003-9; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; WHITE TC, 1987, NUCLEIC ACIDS RES, V15, P3276	33	177	179	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					831	841		10.1016/S0092-8674(00)81062-4	http://dx.doi.org/10.1016/S0092-8674(00)81062-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601307	Bronze			2022-12-24	WOS:A1996UC38100005
J	Grimm, S; Pflugfelder, GO				Grimm, S; Pflugfelder, GO			Control of the gene optomotor-blind in Drosophila wing development by decapentaplegic and wingless	SCIENCE			English	Article							SEGMENT-POLARITY GENE; PATTERN-FORMATION; IMAGINAL DISKS; BETA HOMOLOG; MELANOGASTER; EXPRESSION; MUTATIONS; TRANSCRIPT; DIRECTS; SYSTEM	Diffusible factors of several protein families control appendage outgrowth and patterning in both insects and vertebrates. In Drosophila wing development, the gene decapentaplegic (dpp) is expressed along the anteroposterior compartment boundary. Early wingless (wg) expression is involved in setting up the dorsoventral boundary. Interaction between dpp- and wg-expressing cells promotes appendage outgrowth. Here, it is shown that optomotor-blind (omb) expression is required for distal wing development and is controlled by both dpp and wg. Ectopic omb expression can lead to the growth of additional wings. Thus, omb is essential for wing development and is controlled by two signaling pathways.	UNIV WURZBURG,THEODOR BOVERI INST,BIOZENTRUM,LEHRSTUHL GENET,D-97074 WURZBURG,GERMANY	University of Wurzburg			Pflugfelder, Gert/ABG-9562-2021					BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BALLES J, UNPUB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BAUSENWEIN B, 1994, GENE DEV, V8, P2137; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; BOWNES M, 1981, DIFFERENTIATION, V18, P89, DOI 10.1111/j.1432-0436.1981.tb01108.x; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BRYANT PJ, 1993, SCIENCE, V259, P471, DOI 10.1126/science.8424169; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; BURATOVICH MA, 1995, DEV BIOL, V168, P452, DOI 10.1006/dbio.1995.1094; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; CUNLIFFE V, 1994, EMBO J, V13, P349, DOI 10.1002/j.1460-2075.1994.tb06268.x; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GELBART WM, 1989, DEVELOPMENT, V107, P65; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1994, BIOESSAYS, V16, P627, DOI 10.1002/bies.950160906; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PFLUGFELDER GO, 1995, COMP BIOCHEM PHYS A, V110, P185, DOI 10.1016/0300-9629(94)00159-Q; PFLUGFELDER GO, 1992, P NATL ACAD SCI USA, V89, P1199, DOI 10.1073/pnas.89.4.1199; POECK B, 1993, DEVELOPMENT, V117, P1017; POECK B, 1993, MOL GEN GENET, V238, P325, DOI 10.1007/BF00291990; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; SMITH JC, 1991, CELL, V67, P1; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; SUN YH, 1995, GENETICS, V141, P1075; TABATA T, 1995, DEVELOPMENT, V121, P3359; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	188	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 15	1996	271	5255					1601	1604		10.1126/science.271.5255.1601	http://dx.doi.org/10.1126/science.271.5255.1601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599120				2022-12-24	WOS:A1996TZ98300047
J	Euling, S; Ambros, V				Euling, S; Ambros, V			Heterochronic genes control cell cycle progress and developmental competence of C-elegans vulva precursor cells	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ENCODES; EXPRESSION; LINEAGES; FATES; MUTANTS; LIN-14; LOCUS; IDENTIFICATION; PROLIFERATION	Heterochronic genes control the timing of vulval development in the C. elegans hermaphrodite. lin-14 or lin-28 loss-of-function mutations cause the vulval precursor cells (VPCs) to enter S phase and to divide one larval stage earlier than in the wild type. A precocious vulva is formed by essentially normal cell lineage patterns, governed by the same intercellular signals as in the wild type. Mutations that prevent the normal developmental down-regulation of lin-14 activity delay or block VPC division and prevent vulval differentiation. A genetic pathway that includes lin-4, lin-14, and lin-28 controls when VPCs complete G1 and also controls when VPCs acquire the competence to respond to the intercellular patterning signals and express vulval fates.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	Euling, S (corresponding author), DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034028] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON D, 1987, DEV BIOL, V63, P165; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1981, CELL, V24, P56; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CLARK SG, 1994, GENETICS, V137, P987; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EULING S, 1993, THESIS HARVARD U CAM; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL RJ, 1993, DEVELOPMENT S, V119, P9; HORVITZ HR, 1980, GENETICS, V96, P435; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; Kornberg A., 1992, DNA REPLICATION; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; LIU ZC, 1995, DEVELOPMENT, V121, P2471; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROUGVIE AE, 1995, DEVELOPMENT, V121, P2491; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Sokal R. R, 1981, BIOMETRY; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TUCK S, 1995, GENE DEV, V9, P347; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WILKINSON HA, 1995, GENETICS, V141, P513; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	57	86	94	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					667	676		10.1016/S0092-8674(00)81045-4	http://dx.doi.org/10.1016/S0092-8674(00)81045-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625405	Bronze			2022-12-24	WOS:A1996TZ99000005
J	Wetzel, FT				Wetzel, FT			Surgery for herniated vertebral disks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Wetzel, FT (corresponding author), UNIV CHICAGO,DEPT SURG,SECT ORTHOPAED SURG & REHABIL MED,CHICAGO,IL 60637, USA.							BODEN SD, 1990, ORTHOP T, V14, P66; BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013; Mixter W.J., 1934, NEW ENGL J MED, V211, P210, DOI [10.1056/NEJM193408022110506, DOI 10.1056/NEJM193408022110506]; MORRIS EW, 1986, SPINE, V11, P436, DOI 10.1097/00007632-198606000-00007; MORRIS J, 1988, ORTHOPEDICS, V11, P1483; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; WILLIAMS RW, 1986, SPINE, V11, P851, DOI 10.1097/00007632-198610000-00023	8	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606464				2022-12-24	WOS:A1996TV56900011
J	Neal, KR; Scott, HM; Slack, RCB; Logan, RFA				Neal, KR; Scott, HM; Slack, RCB; Logan, RFA			Omeprazole as a risk factor for campylobacter gastroenteritis: Case-control study	BRITISH MEDICAL JOURNAL			English	Article									NOTTINGHAM HLTH AUTHOR,NOTTINGHAM NG1 6GN,ENGLAND		Neal, KR (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; GLYNN JR, 1992, EPIDEMIOL INFECT, V109, P371, DOI 10.1017/S0950268800050366; NEAL KR, 1994, BRIT MED J, V308, P176; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; 1993, INTERIM REPORT CAMPY	5	111	111	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 17	1996	312	7028					414	415						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW564	8601113				2022-12-24	WOS:A1996TW56400022
J	[Anonymous]				[Anonymous]			Reductionists lay claim to the mind	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					97	97						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610018				2022-12-24	WOS:A1996UK13900001
J	Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD				Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD			Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries	BRITISH MEDICAL JOURNAL			English	Article									UNIV PITTSBURGH,INST CANC,MOL CARCINOGENESIS PROGRAM,PITTSBURGH,PA 15238; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; INST EXPT & CLIN MED,DEPT EPIDEMIOL & BIOSTAT,TALLINN,ESTONIA; LATVIA CANC REGISTRY,RIGA,LATVIA; LITHUANIAN CHERNOBYL MED CTR,VILNIUS,LITHUANIA; LITHUANIAN CANC REGISTRY,MITHUANIAN ONCOL CTR,VILNIUS,LITHUANIA; FINNISH CTR RADIAT & NUCL SAFETY,HELSINKI,FINLAND; FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND; NCI,EXTRAMURAL PROGRAMS BRANCH,BETHESDA,MD 20892; NCI,RADIAT EPIDEMIOL BRANCH,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; National Cancer Institute - Lithuania; Radiation & Nuclear Safety Authority (STUK); Finnish Cancer Registry; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bigbee, WL (corresponding author), UNIV PITTSBURGH,CTR ENVIRONM & OCCUPAT HLTH & TOXICOL,GRAD SCH PUBL HLTH,PITTSBURGH,PA 15238, USA.		Auvinen, Anssi/AAL-2111-2020; Auvinen, Anssi/AAD-9311-2020; Rahu, Mati/A-9981-2008	Auvinen, Anssi/0000-0003-1125-4818; 	NCI NIH HHS [N01-CP-50520] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; JENSEN RH, IN PRESS CYTOMETRY; LANGLOIS RG, 1993, RADIAT RES, V136, P111, DOI 10.2307/3578647; STRAUME T, 1991, HEALTH PHYS, V60, P71, DOI 10.1097/00004032-199101000-00011; *UN SCI COMM EFF A, 1988, SOURC EFF RISK ION R	5	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1078	1079						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616416				2022-12-24	WOS:A1996UH81600027
J	Danziger, R				Danziger, R			An epidemic like any other? Rights and responsibilities in HIV prevention	BRITISH MEDICAL JOURNAL			English	Article								Throughout the 1980s and into the 1990s, HIV prevention has been closely associated with the protection of individual human rights. Traditional public health measures such as compulsory testing and isolation have largely been rejected as ineffective in public health terms and inappropriate in the context of human rights protection. HIV prevention has been based instead chiefly on elective measures -information, education, counselling, and voluntary testing. In the past five years there have been important clinical, epidemiological, and social developments in the AIDS epidemic. These changes, combined with a growing recognition of possible weaknesses inherent in a strictly voluntarist approach to HIV prevention, may herald a new approach to AIDS control which places more weight on social responsibility in the context of HIV prevention.			Danziger, R (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							Bayer Ronald, 1992, ADIS IND DEMOCRACIES, P1; BERRIDGE V, 1992, AIDS MAKING CHRONIC, P299; CHRYSTIE IL, 1995, BRIT MED J, V311, P928, DOI 10.1136/bmj.311.7010.928; CLARKE A, 1994, SOC SCI MED, V39, P591, DOI 10.1016/0277-9536(94)90102-3; DILLNER L, 1995, BRIT MED J, V311, P827, DOI 10.1136/bmj.311.7009.827; ETZIONI A, 1993, TIME MAGAZINE    DEC, V13, P60; JOSEPH SC, 1992, DRAGON GATES ONCE FU, P82; MINKOFF H, 1995, JAMA-J AM MED ASSOC, V274, P1165, DOI 10.1001/jama.274.14.1165; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SCHEPERHUGHES N, 1994, SOC SCI MED, V39, P991, DOI 10.1016/0277-9536(94)90210-0; SIGNORILE M, 1995, GUARDIAN        0301; *UN COMM HUM RIGHT, 1993, DISCR HIV INF PEOPL; VEEKEN H, 1995, BRIT MED J, V311, P935; WILFERT CM, 1994, CLIN INFECT DIS, V19, P664, DOI 10.1093/clinids/19.4.664	14	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1083	1084						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616419				2022-12-24	WOS:A1996UH81600031
J	Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR				Pirkle, JL; Flegal, KM; Bernert, JT; Brody, DJ; Etzel, RA; Maurer, KR			Exposure of the US population to environmental tobacco smoke - The Third National Health and Nutrition Examination Survey, 1988 to 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCOTTISH HEART HEALTH; PASSIVE SMOKING; NONSMOKING WOMEN; URINARY COTININE; DIETARY NICOTINE; SERUM COTININE; LUNG-CANCER; BODY-FLUIDS; SALIVA	Objective.-To estimate the extent of exposure of the US population to environmental tobacco smoke and the contribution of the home and workplace environment to environmental tobacco smoke exposure. Design.-Nationally representative cross-sectional survey including questionnaire information from persons aged 2 months and older (n=16818) and measurements of serum cotinine (a metabolite of nicotine) from persons aged 4 years and older (n=10642). Setting/Participants.-Participants in the Third National Health and Nutrition Examination Survey, October 25, 1988, to October 21, 1991. Results.-Of US children aged 2 months to 11 years, 43% lived in a home with at least 1 smoker, and 37% of adult non-tobacco users lived in a home with at least 1 smoker or reported environmental tobacco smoke exposure at work. Serum cotinine levels indicated more widespread exposure to nicotine. Of non-tobacco users, 87.9% had detectable levels of serum cotinine, Both the number of smokers in the household and the hours exposed at work were significantly and independently associated (P<.001, multiple regression t test) with increased serum cotinine levels. Serum cotinine levels of children, non-Hispanic blacks, and males indicated that these groups had higher exposure to environmental tobacco smoke. Dietary variables showed no consistent association with serum cotinine levels, and dietary contribution to serum cotinine level, if any, appeared to be extremely small. Conclusions.-The high proportion of the population with detectable serum cotinine levels indicates widespread exposure to environmental tobacco smoke in the US population, Both the home and workplace environments significantly contribute to environmental tobacco smoke exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Pirkle, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,MAILSTOP F20,ATLANTA,GA 30341, USA.		Etzel, Ruth A./N-5700-2019	Etzel, Ruth A./0000-0002-5236-3976; Flegal, Katherine/0000-0002-0838-469X				BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; BENOWITZ NL, 1995, CLIN PHARMACOL THER, V57, P159; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; CASTRO A, 1986, BIOCHEM ARCH, V2, P91; CUMMINGS KM, 1990, ARCH ENVIRON HEALTH, V45, P74, DOI 10.1080/00039896.1990.9935929; CUMMINGS SR, 1988, AM J PUBLIC HEALTH, V78, P574, DOI 10.2105/AJPH.78.5.574; DAVIS RA, 1991, FOOD CHEM TOXICOL, V29, P821, DOI 10.1016/0278-6915(91)90109-K; DOMINO EF, 1993, NEW ENGL J MED, V329, P437, DOI 10.1056/NEJM199308053290619; EMMONS KM, 1994, PREV MED, V23, P35, DOI 10.1006/pmed.1994.1005; ETZEL RA, 1990, PREV MED, V19, P190, DOI 10.1016/0091-7435(90)90020-K; EZZATI TM, 1992, VITAL HLTH STAT, V113; FLEGAL KM, 1987, DIABETES, V36, P523; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HINDS WC, 1975, NEW ENGL J MED, V292, P844, DOI 10.1056/NEJM197504172921606; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; JARVIS MJ, 1994, BRIT MED J, V308, P62; JENKINS PL, 1992, ATMOS ENVIRON A-GEN, V26, P2141, DOI 10.1016/0960-1686(92)90402-7; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; MURAMATSU M, 1984, ENVIRON RES, V35, P218, DOI 10.1016/0013-9351(84)90130-0; National Research Council Committee on Passive Smoking, 1986, ENV TOB SMOK MEAS EX; OVERPECK MD, 1991, ADV DATA VITAL HLTH, V202; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; REPACE JL, 1994, BRIT MED J, V308, P61, DOI 10.1136/bmj.308.6920.61c; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SAS Institute Inc., 1990, SAS LANG REF VERS 6; SHAH BV, 1991, SUDAAN USERS MANUAL; SHEEN SJ, 1988, J FOOD SCI, V53, P1572, DOI 10.1111/j.1365-2621.1988.tb09328.x; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; TAYLOR JK, 1987, QUALITY CONTROL CHEM; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; *US DEPT HHS, 1986, PUBL PHS; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; WALL MA, 1988, AM J PUBLIC HEALTH, V78, P699, DOI 10.2105/AJPH.78.6.699; WATTS RR, 1990, ENVIRON HEALTH PERSP, V84, P173, DOI 10.2307/3430719; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P88, DOI 10.1016/0091-7435(92)90008-6; 1992, EPA600690006F OFF AI; 1994, VITAL HLTH STAT, V1	50	510	517	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1233	1240						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601954				2022-12-24	WOS:A1996UF47800026
J	Coggon, D; Winter, P; Martyn, C; Inskip, H				Coggon, D; Winter, P; Martyn, C; Inskip, H			Contrasting epidemiology of aortic aneurysm and peripheral vascular disease in England and Wales	BRITISH MEDICAL JOURNAL			English	Article											Coggon, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BEGNTSSON H, 1992, EUR J SURG, V158, P19; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; MARMOT M, 1992, CORONARY HEART DIS E, P3; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; VANLAARHOVEN CJHM, 1993, EUR J VASCULAR SURG, V7, P386, DOI 10.1016/S0950-821X(05)80254-3	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					948	948						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616309				2022-12-24	WOS:A1996UF65900021
J	Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E				Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E			Rho1p, a yeast protein at the interface between cell polarization and morphogenesis	SCIENCE			English	Article							RAS SUPERFAMILY GENES; SACCHAROMYCES-CEREVISIAE; BETA-(1->3)GLUCAN SYNTHETASE; WALL; BIOSYNTHESIS; GROWTH; DEFECT; GTP	The enzyme that catalyzes the synthesis of the major structural component of the yeast cell wall, beta(1-->3)-D-glucan synthase (also known as 1,3-beta-glucan synthase), requires a guanosine triphosphate (GTP) binding protein for activity. The GTP binding protein was identified as Rho1p. The rho1 mutants were defective in GTP stimulation of glucan synthase, and the defect was corrected by addition of purified or recombinant Rho1p. A protein missing in purified preparations from a rho1 strain was identified as Rho1p. Rho1p also regulates protein kinase C, which controls a mitogen-activated protein kinase cascade. Experiments with a dominant positive PKC1 gene showed that the two effects of Rho1p are independent of each other. The colocalization of Rho1p with actin patches at the site of bud emergence and the role of Rho1p in cell wall synthesis emphasize the importance of Rho1p in polarized growth and morphogenesis.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University; University of Texas System; University of Texas Austin			chan, cherry/GQY-4591-2022; Drgonova, Jana/B-2903-2008; Chen, Guang-Chao/P-1262-2019	Chen, Guang-Chao/0000-0002-4980-4718; Drgonova, Jana/0000-0002-4623-8466				CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, UNPUB; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DOUGLAS CM, 1994, P NATL ACAD SCI USA, V91, P12907, DOI 10.1073/pnas.91.26.12907; DRGONOVA J, UNPUB; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KANG MS, 1986, P NATL ACAD SCI USA, V83, P5808, DOI 10.1073/pnas.83.16.5808; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOL PC, 1994, J BIOL CHEM, V269, P31267; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	24	301	316	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					277	279		10.1126/science.272.5259.277	http://dx.doi.org/10.1126/science.272.5259.277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602514				2022-12-24	WOS:A1996UE72900044
J	Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W				Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W			Role of reticular activation in the modulation of intracortical synchronization	SCIENCE			English	Article							CAT VISUAL-CORTEX; OSCILLATORY NEURONAL RESPONSES; CROSS-CORRELATION; CONNECTIONS; MONKEY; HZ	During aroused states of the brain, electroencephalographic activity is characterized by fast, irregular fluctuations of low amplitude, which are thought to reflect desynchronization of neuronal activity. This phenomenon seems at odds with the proposal that synchronization of cortical responses may play an important role in the processing of sensory signals. Here, activation of the mesencephalic reticular formation (MRF), an effective way to ''desynchronize the electroencephalogram,'' was shown to facilitate oscillatory activity in the gamma frequency range and to enhance the stimulus-specific synchronization of neuronal spike responses in the visual cortex of cats.			Munk, MHJ (corresponding author), MAX PLANCK INST HIRNFORSCH,ABT NEUROPHYSIOL,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		Singer, Wolf/D-6874-2012; Roelfsema, Pieter/J-6903-2013; König, Peter/ABB-2380-2020; Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012	Roelfsema, Pieter/0000-0002-1625-0034; König, Peter/0000-0003-3654-5267; Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466				Abeles M., 1982, LOCAL CORTICAL CIRCU; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; COPE TC, 1987, J PHYSIOL-LONDON, V390, P161, DOI 10.1113/jphysiol.1987.sp016692; ECKHORN R, 1993, NEUROREPORT, V4, P243, DOI 10.1097/00001756-199303000-00004; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL A K, 1992, Current Biology, V2, P332, DOI 10.1016/0960-9822(92)90898-K; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; GRAY C M, 1987, Neuroscience, V22, pS434; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; KONIG P, 1995, P NATL ACAD SCI USA, V92, P290, DOI 10.1073/pnas.92.1.290; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; KREITER AK, IN PRESS J NEUROSCI; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Munk MHJ, 1995, J NEUROPHYSIOL, V74, P2401, DOI 10.1152/jn.1995.74.6.2401; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; Nowak LG, 1995, J NEUROPHYSIOL, V74, P2379, DOI 10.1152/jn.1995.74.6.2379; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SINGER W, 1990, BRAIN CHOLINERGIC SY, P314; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396	30	344	347	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					271	274		10.1126/science.272.5259.271	http://dx.doi.org/10.1126/science.272.5259.271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602512				2022-12-24	WOS:A1996UE72900042
J	Nightingale, SL				Nightingale, SL			Nicorette gum approved for over-the-counter marketing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1996	275	12					902	902						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UA563	8598604				2022-12-24	WOS:A1996UA56300010
J	Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH				Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH			Endothelium and inelastic arteries: An early marker of vascular dysfunction in noninsulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		UNIV WALES COLL MED,DIABET RES UNIT,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED STAT & COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	Goodfellow, J (corresponding author), UNIV WALES COLL MED,CARDIOVASC SCI RES GRP,CARDIFF CF4 4XN,S GLAM,WALES.							COATES PA, 1993, DIABETES, V42, P1635, DOI 10.2337/diabetes.42.11.1635; OROURKE MF, 1989, J HUM HYPERTEN, V10, P47; RAMSEY MW, 1995, CIRCULATION, V92, P3212, DOI 10.1161/01.CIR.92.11.3212; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	4	116	117	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					744	745						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605460				2022-12-24	WOS:A1996UC16600026
J	SelaHerman, S; Scharschmidt, BF				SelaHerman, S; Scharschmidt, BF			Choledochal cyst, a disease for all ages	LANCET			English	Editorial Material									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SelaHerman, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.							Chaudhary A, 1996, BRIT J SURG, V83, P186, DOI 10.1046/j.1365-2168.1996.02042.x; IWAI N, 1992, ANN SURG, V215, P27, DOI 10.1097/00000658-199201000-00003; LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007; STAIN SC, 1995, ANN SURG, V222, P128, DOI 10.1097/00000658-199508000-00004; Stringer MD, 1995, ARCH DIS CHILD, V73, P528, DOI 10.1136/adc.73.6.528	5	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					779	779		10.1016/S0140-6736(96)90864-8	http://dx.doi.org/10.1016/S0140-6736(96)90864-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622330				2022-12-24	WOS:A1996UB15300005
J	Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM				Ramirez, AJ; Graham, J; Richards, MA; Cull, A; Gregory, WM			Mental health of hospital consultants: The effects of stress and satisfaction at work	LANCET			English	Article								Background Burnout and psychiatric morbidity among gastroenterologists, surgeons, radiologists, and oncologists in the UK have been estimated by means of a questionnaire-based survey. The relationship between consultants' mental health and their job stress and satisfaction, as well as their job and demographic characteristics, were also examined. Methods Psychiatric morbidity was estimated using the 12-item General Health Questionnaire. The three components of burnout-emotional exhaustion, depersonalisation, and low personal accomplishment-were assessed using the Maslach Burnout Inventory. Job stress and satisfaction were measured using study-specific questions. Findings Of 1133 consultants, 882 (78%) returned questionnaires. The estimated prevalence of psychiatric morbidity was 27%, with no significant differences between the four specialist groups. Radiologists reported the highest level of burnout in terms of low personal accomplishment. Job satisfaction significantly protected consultants' mental health against job stress. Three sources of stress were associated with both burnout and psychiatric morbidity: feeling overloaded, and its effect on home life; feeling poorly managed and resourced; and dealing with patients' suffering. Burnout was also associated with low satisfaction in three domains: relationships with patients, relatives, and staff; professional status/esteem; intellectual stimulation. In addition, being aged 55 years or less and being single were independent risk factors for burnout. Burnout was also more prevalent among consultants who felt insufficiently trained in communication and management skills. Interpretation Consultants' mental health is likely to be protected against the high demands of medical practice by maintaining or enhancing job satisfaction, and by providing training in communication and management skills.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Edinburgh								BANKS MH, 1980, J OCCUP PSYCHOL, V53, P187, DOI 10.1111/j.2044-8325.1980.tb00024.x; BLENKIN H, 1995, BRIT MED J, V310, P534, DOI 10.1136/bmj.310.6978.534; *BMA, 1992, STRESS MED PROF; *BMA, 1993, MORB MORT MED PROF; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; Charlton J., 1993, POPULATION TRENDS, V71, P34; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; FREUDENBERGER HJ, 1974, J SOC ISSUES, V30, P159, DOI 10.1111/j.1540-4560.1974.tb00706.x; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; Maslach C., 1996, BURNOUT INVENTORY MA; SILVEY S, 1970, STAT INFERENCE, P108; SIMON R, 1986, ANN INTERN MED, V105, P49; 1994, LANCET, V344, P1583	14	613	629	1	112	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					724	728		10.1016/S0140-6736(96)90077-X	http://dx.doi.org/10.1016/S0140-6736(96)90077-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ982	8602002	Bronze			2022-12-24	WOS:A1996TZ98200010
J	Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L				Biver, N; Rauer, H; Despois, D; Moreno, R; Paubert, G; BockeleeMorvan, D; Colom, P; Crovisier, J; Gerard, E; Jorda, L			Substantial outgassing of CO from comet Hale-Bopp at large heliocentric distance	NATURE			English	Article								When comet C/1995 O1 (Hale-Bopp) was discovered(1), at a distance of seven astronomical units from the Sun, it was more than one hundred times brighter than comet Halley at the same distance. A comet's brightness is derived from the reflection of sunlight from dust grains driven away from the nucleus by the sublimation of volatile ices. Near the Sun, sublimation of water ice (a main constituent of comet nuclei) is the source of cometary activity; but at its current heliocentric distance, Hale-Bopp is too cold for this process to operate. Other comets have shown activity at large distances(2), and in the case of comet Schwassmann-Wachmann 1, carbon monoxide has been detected in quantities sufficient to generate its observed coma(3,4). Here we report the detection of CO emission from Hale-Bopp, at levels indicating a very large rate of outgassing. Several other volatile species were searched for, but not detected. Sublimation of CO therefore appears to be responsible for the present activity of this comet, and we anticipate that future observations will reveal the onset of sublimation of other volatile species as the comet continues its present journey towards the Sun.	OBSERV BORDEAUX, F-33270 FLOIRAC, FRANCE; IRAM, E-18012 GRANADA, SPAIN		Biver, N (corresponding author), OBSERV PARIS, F-92195 MEUDON, FRANCE.		Jorda, Laurent/AAA-1718-2021					AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; AHEARN MF, 1995, 6244 IAU; BOCKELEEMORVAN D, 1990, ASTRON ASTROPHYS, V238, P382; BOCKELEEMORVAN D, 1994, ASTRON ASTROPHYS, V287, P647; COLOM P, 1992, ASTRON ASTROPHYS, V264, P710; CROVISIER J, 1995, ICARUS, V115, P213, DOI 10.1006/icar.1995.1091; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1994, IAU SYMP, P313; DAVIES J, 1995, 6225 IAU; DESPOIS D, IN PRESS PLANET SPAC; Fitzsimmons A, 1996, MON NOT R ASTRON SOC, V278, pL37, DOI 10.1093/mnras/278.2.L37; FULLE M, 1992, NATURE, V359, P42, DOI 10.1038/359042a0; HALE A, 1995, 6187 IAU; HUEBNER WF, 1992, WORKSH ACT DIST COM; Jewitt D., 1990, Astrophysical Journal, V351, P277, DOI 10.1086/168463; KIDGER M, 1995, 6240 IAU; MATTHEWS HE, 1995, 6234 IAU; RAUER H, 1995, 6236 IAU; SENAY MC, 1994, NATURE, V371, P229, DOI 10.1038/371229a0; WILD W, 1995, 30M MANUAL HDB IRAM; WOMACK M, 1995, 6276 IAU	21	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	1996	380	6570					137	139		10.1038/380137a0	http://dx.doi.org/10.1038/380137a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600385				2022-12-24	WOS:A1996TZ97800042
J	Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA				Chao, DM; Gadbois, EL; Murray, PJ; Anderson, SF; Sonu, MS; Parvin, JD; Young, RA			A mammalian SRB protein associated with an RNA polymerase II holoenzyme	NATURE			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTION; PURIFICATION; YEAST; CTD	A large multisubunit complex containing RNA polymerase II, general transcription factors and SRB regulatory proteins initiates transcription of class II genes in yeast cells(1-4). The SRB proteins are a hallmark of this RNA polymerase II holoenzyme as they are found only in this complex, where they contribute to the response to regulators(4-8). We have now isolated a human homologue of the yeast SRB7 gene and used antibodies against human SRB7 protein to purify and characterize a mammalian RNA polymerase II holoenzyme containing the general transcription factors TFIIE and TFIIH. This holoenzyme is more responsive to transcriptional activators than core RNA polymerase II when assayed in the presence of coactivators.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; BRIGHAM & WOMENS HOSP, DIV MOLEC ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chao, DM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Young, Richard A/F-6495-2012; Murray, Peter J/K-4725-2018; Parvin, Jeffrey D/C-8955-2009	Young, Richard A/0000-0001-8855-8647; Murray, Peter J/0000-0001-6329-9802; Chao, David/0000-0001-9198-337X				BASSET DE, 1995, TRENDS GENET, V11, P372, DOI 10.1016/S0168-9525(00)89109-X; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; DRAPKIN R, 1994, TRENDS BIOCHEM SCI, V19, P504, DOI 10.1016/0968-0004(94)90139-2; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLESKE AJ, IN PRESS METH ENZYM; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069	27	130	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					82	85		10.1038/380082a0	http://dx.doi.org/10.1038/380082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598913				2022-12-24	WOS:A1996TY87700062
J	Beale, J				Beale, J			Reconsidering an attenuated vaccine for AIDS	LANCET			English	Editorial Material																		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BEALE J, 1995, LANCET, V345, P1318, DOI 10.1016/S0140-6736(95)92532-5; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; HILLEMAN MR, 1995, NAT MED, V1, P1126, DOI 10.1038/nm1195-1126; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; RUD EW, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P217; SABIN AB, 1993, NATURE, V362, P212, DOI 10.1038/362212a0	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					344	345		10.1016/S0140-6736(96)90532-2	http://dx.doi.org/10.1016/S0140-6736(96)90532-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598696				2022-12-24	WOS:A1996TU69500004
J	Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM				Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM			Dimeric inhibin a as a marker for Down's syndrome in early pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SERUM ALPHA-FETOPROTEIN; CHROMOSOMALLY ABNORMAL PREGNANCIES; MATERNAL SERUM; UNCONJUGATED ESTRIOL; IMMUNOREACTIVE INHIBIN; RISK; AGE; CHORIOGONADOTROPIN; TRISOMY-18	Background. In screening for Down's syndrome in the second trimester of pregnancy, the concentrations of alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and intact human chorionic gonadotropin in maternal serum are widely used markers. We investigated a new marker, dimeric inhibin A, and compared its predictive value with that of the established markers. Methods. Serum samples were obtained at 7 to 18 weeks of gestation from 58 women whose fetuses were known to be affected by Down's syndrome, 32 whose fetuses were affected by trisomy 18, and 438 whose fetuses were normal, and the samples were analyzed for each marker. Individual serum concentrations of each marker were converted to multiples of the median value at the appropriate length of gestation in the women with normal pregnancies, and rates of detection of Down's syndrome by screening for inhibin A in various combinations with the other markers were estimated by multivariate analysis. Results. In the women with fetuses affected by Down's syndrome, the serum inhibin A concentrations were 2.06 times the median value in the women with normal pregnancies (P<0.001). This compared with 2.00 times the median for the beta subunit of human chorionic gonadotropin, 1.82 times the median for intact human chorionic gonadotropin, and 0.72 times the median for alphafetoprotein. The serum concentrations of inhibin A in the women with fetuses affected by Down's syndrome did not appear to be significantly elevated above normal until the end of the first trimester and were not significantly different from normal in the women with fetuses affected by trisomy 18 (P=0.17). The rate of detection of Down's syndrome was 53 percent and the false positive rate was 5 percent when alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and maternal age were used together as predictors. The detection rate increased to 75 percent when inhibin A was added (P=0.002). Conclusions. In the second trimester of pregnancy, measuring inhibin A in maternal serum, in combination with measurements of alpha-fetoprotein and the beta subunit of human chorionic gonadotropin, significantly improved the rate of detection of Down's syndrome. (C) 1996, Massachusetts Medical Society.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; MRC,CTR REPROD BIOL,REPROD BIOL UNIT,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; OXFORD BROOKES UNIV,SCH BIOL & MOLEC SCI,OXFORD,ENGLAND; NTD LABS,HUNTINGTON STN,NEW YORK,NY	University of Edinburgh; Oxford Brookes University	Aitken, DA (corresponding author), DUNCAN GUTHRIE INST MED GENET,GLASGOW G3 8SJ,LANARK,SCOTLAND.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233				AITKEN DA, 1993, PRENATAL DIAG, V13, P681, DOI 10.1002/pd.1970130804; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; BROCK DJH, 1990, PRENATAL DIAG, V10, P245, DOI 10.1002/pd.1970100406; Canick J. A., 1994, American Journal of Human Genetics, V55, pA9; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; Crossley J A, 1994, J Med Screen, V1, P180; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1994, PRENATAL DIAG, V14, P387, DOI 10.1002/pd.1970140508; CUCKLE HS, 1995, PRENATAL DIAG, V15, P385, DOI 10.1002/pd.1970150416; GOODBURN SF, 1994, PRENATAL DIAG, V14, P391, DOI 10.1002/pd.1970140509; GRAHAM GW, 1992, PRENATAL DIAG, V12, P505, DOI 10.1002/pd.1970120605; GROOME N, 1993, J IMMUNOL METHODS, V165, P167, DOI 10.1016/0022-1759(93)90342-5; GROOME NP, 1994, CLIN ENDOCRINOL, V40, P717, DOI 10.1111/j.1365-2265.1994.tb02504.x; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; MACINTOSH MCM, 1993, PRENATAL DIAG, V13, P563, DOI 10.1002/pd.1970130705; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MACRI JN, 1994, PRENATAL DIAG, V14, P97, DOI 10.1002/pd.1970140204; MCLACHLAN RI, 1987, CLIN ENDOCRINOL, V27, P663, DOI 10.1111/j.1365-2265.1987.tb02949.x; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; QU JP, 1991, J CLIN ENDOCR METAB, V72, P862, DOI 10.1210/jcem-72-4-862; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; ROBERTSON DM, 1995, J ENDOCRINOL, V144, P261, DOI 10.1677/joe.0.1440261; SCHNEYER AL, 1990, J CLIN ENDOCR METAB, V70, P1208, DOI 10.1210/jcem-70-4-1208; SPENCER K, 1994, ANN CLIN BIOCHEM, V31, P447, DOI 10.1177/000456329403100504; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1993, BRIT MED J, V307, P1455, DOI 10.1136/bmj.307.6917.1455; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P219, DOI 10.1177/000456329303000226; TOVANABUTRA S, 1993, CLIN ENDOCRINOL, V38, P101, DOI 10.1111/j.1365-2265.1993.tb00979.x; VANLITH JMM, 1994, OBSTET GYNECOL, V83, P661; VANLITH JMM, 1992, PRENATAL DIAG, V12, P801, DOI 10.1002/pd.1970121005; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1988, BRIT J OBSTET GYNAEC, V95, P334, DOI 10.1111/j.1471-0528.1988.tb06602.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALLACE EM, 1994, CLIN ENDOCRINOL, V41, P483, DOI 10.1111/j.1365-2265.1994.tb02579.x; WALLACE EM, 1995, PRENATAL DIAG, V15, P359, DOI 10.1002/pd.1970150410; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	45	132	135	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1231	1236		10.1056/NEJM199605093341904	http://dx.doi.org/10.1056/NEJM199605093341904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606718				2022-12-24	WOS:A1996UJ05400004
J	Malonek, D; Grinvald, A				Malonek, D; Grinvald, A			Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: Implications for functional brain mapping	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; HUMAN VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; SENSORY STIMULATION; HIPPOCAMPAL SLICES; INTRINSIC SIGNALS; NEURAL ACTIVITY; STRIATE CORTEX; ARCHITECTURE; ORGANIZATION	Modern neuroimaging techniques use signals originating from microcirculation to map brain function. In this study, activity-dependent changes in oxyhemoglobin, deoxyhemoglobin, and light scattering were characterized by an imaging spectroscopy approach that offers high spatial, temporal, and spectral resolution. Sensory stimulation of cortical columns initiates tissue hypoxia and vascular responses that occur within the first 3 seconds and are highly localized to individual cortical columns. However, the later phase of the vascular response is less localized, spreading over distances of 3 to 5 millimeters.			Malonek, D (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL.							BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1968, NATURE, V218, P438, DOI 10.1038/218438a0; DIRNAGL U, COMMUNICATION; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINRICH U, 1987, PFLUG ARCH EUR J PHY, V409, P152, DOI 10.1007/BF00584764; HENNIG T, 1994, MAGNET RESON MED, V31, P85, DOI 10.1002/mrm.1910310115; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; JOBSIS FF, 1977, J APPL PHYSIOL, V43, P858; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; KUSCHINSKY W, 1992, CEREBROVAS BRAIN MET, V4, P261; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MENON RS, 1994, P SOC MAGN RES, V1, P68; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OLESEN J, 1971, BRAIN, V94, P635, DOI 10.1093/brain/94.4.635; RAICHLE ME, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0494-58; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; RISBERG J, 1973, BRAIN, V96, P737, DOI 10.1093/brain/96.4.737; Roy C S, 1890, J Physiol, V11, P85; SALZBERG BM, 1983, NATURE, V306, P36, DOI 10.1038/306036a0; Silver I A, 1978, Ciba Found Symp, P49; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TASAKI I, 1968, P NATL ACAD SCI USA, V61, P883, DOI 10.1073/pnas.61.3.883; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Turner R, 1994, P SOC MAGN RESON, V1, P430; WATANABE M, 1994, J CEREBR BLOOD F MET, V14, P75, DOI 10.1038/jcbfm.1994.12; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	44	849	858	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					551	554		10.1126/science.272.5261.551	http://dx.doi.org/10.1126/science.272.5261.551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614805				2022-12-24	WOS:A1996UG82600045
J	Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ				Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ			Prevention and reversal of renal allograft rejection by antibody against CD45RB	NATURE			English	Article								REJECTION continues to be the single largest impediment to successful organ transplantation(1). Antilymphocyte globulin, which contains antibodies that react with the leukocyte common antigen known as CD45 (refs 2-6), has proved to be one of the most effective agents for preventing rejection. We have shown earlier that a monoclonal antibody directed against the RB isoform of CD45 substantially inhibits the alloreactivity of human CD4(+) lymphocytes in vitro(7). Here we investigate whether CD45RB could be an appropriate target for preventing renal allograft rejection in mice. Mice treated with two injections of a monoclonal antibody (MB23G2) (ref. 8) raised against CD45RB protein all survived and had normal renal function. Furthermore, this antibody reversed acute rejection when therapy was delayed until day 4, and the mice survived for their natural lifespan. The immunosuppression achieved may find application in the prevention and treatment of transplant rejection in man.	UNIV WESTERN ONTARIO,FAC MED,DEPT MED,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT SURG,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT PATHOL,LONDON,ON N6A 5A5,CANADA; UNIV GRONINGEN,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Groningen	Lazarovits, AI (corresponding author), JOHN P ROBARTS RES INST,LONDON HLTH SCI CTR,MULTIORGAN TRANSPLANT SERV,UNIV CAMPUS,LONDON,ON N6A 5A5,CANADA.		Jevnikar, Anthony M./G-3309-2011; Poppema, Sibrand/D-1204-2012					BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BONNEFOYBERARD N, 1991, TRANSPLANTATION, V51, P669, DOI 10.1097/00007890-199103000-00024; FABRE JW, 1977, TRANSPLANTATION, V23, P349, DOI 10.1097/00007890-197704000-00009; FABRE JW, 1980, TRANSPLANTATION, V30, P167, DOI 10.1097/00007890-198009000-00003; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; IBRAHIM S, 1995, TRANSPLANTATION, V59, P724, DOI 10.1097/00007890-199503150-00015; LAZAROVITS AI, 1992, TRANSPLANTATION, V54, P724, DOI 10.1097/00007890-199210000-00030; LAZAROVITS AI, 1994, J IMMUNOL, V153, P3956; LAZAROVITS AI, 1993, J IMMUNOL, V150, P5163; QUAN D, 1994, TRANSPLANTATION, V58, P808, DOI 10.1097/00007890-199410150-00011; REBELLATO LM, 1994, TRANSPLANTATION, V57, P685, DOI 10.1097/00007890-199403150-00010; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WARR GW, 1976, IMMUNOCHEMISTRY, V13, P753, DOI 10.1016/0019-2791(76)90196-8; ZHANG Z, 1995, MICROSURG, V16, P103, DOI 10.1002/micr.1920160212	15	135	149	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					717	720		10.1038/380717a0	http://dx.doi.org/10.1038/380717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614467				2022-12-24	WOS:A1996UG82700053
J	Wang, Y; Reen, DJ; Puri, P				Wang, Y; Reen, DJ; Puri, P			Is a histologically normal appendix following emergency appendicectomy always normal?	LANCET			English	Article								Background Appendixes removed from patients with suspected appendicitis often appear normal on histological examination. We examined appendix specimens for expression of abnormal amounts of cytokines, an indicator of an inflammatory response. Methods Tumour necrosis factor alpha (TNF alpha) and interleukin-2 (IL-2) expression was measured by in-situ hybridisation in ten specimens from patients with acute appendicitis, 12 normal appendix specimens removed from patients undergoing elective abdominal surgery, and 31 appendix specimens from patients with a clinical diagnosis of appendicitis but an appendix histologically classified as normal. Cytokine-specific RNA antisense probes were prepared by in-vitro transcription and digoxigenin (DIG) labelled. In-situ hybridisation was done on 5 mu m paraffin sections. Tissue sections hybridised by sense probes acted as negative control for each cytokine. Following hybridisation, the probes were detected by alkaline phosphatase labelled anti-DIG monoclonal antibody and visualised by nitroblue tetrazolium staining. Findings All histologically proven acute appendicitis specimens demonstrated intense cellular TNF alpha mRNA expression in germinal centres and moderate levels of expression throughout the mucosa. IL-2 mRNA was strongly expressed in the lamina propria and only moderately expressed in germinal centres. Normal appendixes all showed almost complete absence of TNF alpha and IL-2 mRNA expression. Seven of the 31 histologically classified normal appendix specimens from patients with a clinical diagnosis of appendicitis demonstrated TNF alpha and IL-2 mRNA expression similar to acute appendicitis specimens in germinal centres, submucosa, and lamina propria layers. Interpretation TNF alpha and IL-2 mRNA expression is sensitive marker of inflammation in appendicitis. A substantial proportion of histologically normal appendixes showed clear evidence of an inflammatory response in the form of increased cytokine expression.	OUR LADYS HOSP SICK CHILDREN,CHILDRENS RES CTR,CRUMLIN 12,DUBLIN,IRELAND	Our Ladys Children Hospital Crumlin								BRAEGGER CP, 1994, ANN ALLERGY, V72, P135; COMMINIELLO C, 1994, ANGIOLOGY, V45, P1015; DAHLSTROM JE, 1994, AUST NZ J SURG, V64, P692, DOI 10.1111/j.1445-2197.1994.tb02059.x; DISEBASTIANO P, 1995, DIGEST DIS SCI, V40, P366, DOI 10.1007/BF02065423; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; FINE G, 1995, ANDERSONS PATHOLOGY, P1055; GURBINDO C, 1993, J PEDIATR GASTR NUTR, V17, P247, DOI 10.1097/00005176-199310000-00003; KARTTUNEN R, 1995, GUT, V36, P341, DOI 10.1136/gut.36.3.341; KONTAKOU M, 1994, GUT, V35, P1037, DOI 10.1136/gut.35.8.1037; Levine J.D., 1994, TXB PAIN, P45; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MAHUMMUD N, 1995, EUR J GASTROEN HEPAT, V7, P215; PARDUE ML, 1983, NUCLEIC ACID HYBRIDI, P179; PURI P, 1995, PEDIATR SURG INT, V10, P61; SHER ME, 1995, AM J SURG, V169, P133, DOI 10.1016/S0002-9610(99)80121-4; SIEGEL MJ, 1995, PEDIATR SURG INT, V10, P62; TSUJI M, 1993, J PEDIATR GASTR NUTR, V16, P43, DOI 10.1097/00005176-199301000-00008; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0	18	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1076	1079		10.1016/S0140-6736(96)90279-2	http://dx.doi.org/10.1016/S0140-6736(96)90279-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602058				2022-12-24	WOS:A1996UG04200012
J	Alvarez, FJ; DelRio, MC				Alvarez, FJ; DelRio, MC			Alcohol and driving	LANCET			English	Editorial Material											Alvarez, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/X-2294-2019; Alvarez, F. Javier/E-7204-2016	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				BIECHELER MB, 1995, 9403CN0130 EURICPALD; *DIR GEN TRANSP CO, 1995, VII3921995 DIR GEN T; DUNBAR JA, 1987, BRIT MED J, V295, P1458, DOI 10.1136/bmj.295.6611.1458; *EUR TRANSP SAF CO, 1995, RED TRAFF INJ RES AL; GUPPY A, 1994, BRIT MED J, V308, P1056; POLEN M R, 1988, Journal of the American Medical Association, V259, P77; WELLSPARKER E, 1995, ADDICTION, V90, P907, DOI 10.1046/j.1360-0443.1995.9079074.x; 1995, 9403CN01 EURICPALDT	8	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					985	986						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606608				2022-12-24	WOS:A1996UF38000004
J	Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I				Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I			Prenatal diagnosis of Batten's disease	LANCET			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS	Background Batten's disease is the most common progressive encephalopathy of childhood in Western countries. The major mutation is a 1 kb deletion, which is carried by 81% of Batten's disease patients. We report on the use of direct gene analysis in the prenatal diagnosis of this disease. Methods and findings A Finnish woman with a son with Batten's disease came for genetic counselling for her current pregnancy. Electron microscopy of a chorionic villus sample gave suggestive findings. We used PCR to look for the intragenic microsatellite marker D16S298; 96% of Finnish Batten's disease patients carry allele 6 at this marker. The fetus and the affected son both carried the same high-risk genotype, 6/6. Both were homozygous for the 1 kb deletion. The pregnancy was terminated. Electron microscopy of the fetus showed typical Batten's disease changes. Interpretation We have successfully used direct gene analysis in the prenatal diagnosis of Batten's disease.	NATL PUBL HLTH INST, LAB HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UCL, SCH MED, RAYNE INST, DEPT PAEDIAT, LONDON, ENGLAND; UNIV HELSINKI, CHILDRENS HOSP, HELSINKI, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN GENET, TAMPERE, FINLAND	Finland National Institute for Health & Welfare; University of London; King's College London; University College London; UCL Medical School; University of Helsinki; Tampere University; Tampere University Hospital			Jarvela, Irma E/L-5836-2013; Mitchison, Hannah M./C-1891-2008; Mole, Sara/C-2024-2008	Jarvela, Irma E/0000-0002-1770-6187; Mole, Sara/0000-0003-4385-4957; Munroe, Patricia/0000-0002-4176-2947; Mitchison, Hannah/0000-0002-3163-6293	NINDS NIH HHS [NS28722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARPENTER S, 1977, BRAIN, V100, P137, DOI 10.1093/brain/100.1.137; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; LAKE BD, 1995, 41 ANN M PAED PATH S; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; MITCHISON HM, 1994, GENOMICS, V22, P465, DOI 10.1006/geno.1994.1412; MITCHISON HM, 1995, AM J HUM GENET, V56, P654; RAPOLA J, 1990, PRENATAL DIAG, V10, P553, DOI 10.1002/pd.1970100902; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X	9	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1014	1015		10.1016/S0140-6736(96)90148-8	http://dx.doi.org/10.1016/S0140-6736(96)90148-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606564				2022-12-24	WOS:A1996UF38000013
J	Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM				Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM			Haem iron intake in 12-36 month old children depleted in iron: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY ANEMIA; INFANTS; RISK; MILK	Objective-To compare the intakes of haem and non-haem iron in iron depleted and iron replete children. Design-Case-control study. Setting-Early Childhood Centres and a long day care centre in Sydney, Australia. Subjects-Children aged 12-36 months depleted in iron and controls matched for age and sex. Mean outcome measures-Iron status by using plasma ferritin concentration. A three day weighed dietary intake record completed by the parents. Risk factors for iron deficiency assessed by questionnaire. Results-Fifty six iron depleted and 68 iron replete children participated. The average daily intake of haem iron was significantly lower in the iron depleted group (t=2.392, P=0.018); there was a tendency towards a lower average daily intake of non-haem iron (t=1 724, P=0.086) and vitamin C (t=1.921, P=0.057) for iron depleted children. Low intake of haem iron (<0 71 mg/day) was significantly associated with iron depletion with an odds ratio of 3.0 (P=0.005). The proportion of iron depleted children who were given whole cows' milk before 12 months of age was almost double that of iron replete children; multivariate analysis showed that both haem iron intake and age of introduction of cows' milk were independently associated with iron depletion. Conclusions-The results of this study show that, in young children in developed countries, a lower haem iron intake is a major risk factor for iron depletion; the introduction of whole cows' milk before 12 months is further confirmed as a risk factor. Parental education on nutrition should now focus on these two aspects of nutrition for infants and young children.	ROYAL PRINCE ALFRED HOSP, CENT SYDNEY AREA HLTH SERV, COMMUNITY HLTH SERV, CAMPERDOWN, NSW 2050, AUSTRALIA; AUSTRALIAN NATL UNIV, NATL CTR EPIDEMIOL & POPULAT HLTH, CANBERRA, ACT, AUSTRALIA	University of Sydney; Australian National University	Mira, M (corresponding author), CENT SYDNEY AREA HLTH SERV, DIV GEN PRACTICE, BALMAIN, NSW 2041, AUSTRALIA.		Ranmuthugala, Geetha/P-5041-2019; Ranmuthugala, Geetha/F-5938-2012	Ranmuthugala, Geetha/0000-0002-4893-5775; Ranmuthugala, Geetha/0000-0002-4893-5775				BJORNRASMUSSEN E, 1974, J CLIN INVEST, V53, P237; CALVO EB, 1992, PEDIATRICS, V90, P375; DALLMAN P, 1989, AM J CLIN NUTR, V50, P575; DALLMAN PR, 1980, AM J CLIN NUTR, V33, P86, DOI 10.1093/ajcn/33.1.86; Dean A. G., 1990, EPI INFO VERSION 5 W; FRIEL JK, 1990, CAN MED ASSOC J, V143, P733; GEBSKI V, 1992, STAT PACKAGE INTERAC; HALLBERG L, 1984, AM J CLIN NUTR, V39, P577, DOI 10.1093/ajcn/39.4.577; HERCBERG S, 1987, NUTR REP INT, V35, P307; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MACPHAIL AP, 1989, ACTA PAEDIATR SCAND, P114; MILLS AF, 1990, ARCH DIS CHILD, V65, P428, DOI 10.1136/adc.65.4.428; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; *NAT HLTH MED RES, 1991, NH MRC REC DIET INT; OSKI FA, 1983, PEDIATRICS, V71, P877; SIIMES MA, 1984, J PEDIATR-US, V104, P196, DOI 10.1016/S0022-3476(84)80991-9; TUNNESSEN WW, 1987, J PEDIATR-US, V111, P813, DOI 10.1016/S0022-3476(87)80193-2; VAZQUEZSEOANE P, 1985, NEW ENGL J MED, V313, P1239, DOI 10.1056/NEJM198511073131936; WALTER T, 1989, PEDIATRICS, V84, P7; *XYR, 1989, DIET 1 VERS 3 00; [No title captured]	21	33	33	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1996	312	7035					881	883						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611876	Green Published			2022-12-24	WOS:A1996UE37100021
J	Pascher, T; Chesick, JP; Winkler, JR; Gray, HB				Pascher, T; Chesick, JP; Winkler, JR; Gray, HB			Protein folding triggered by electron transfer	SCIENCE			English	Article							THERMODYNAMICS; HYDRATION	Rapid photochemical electron injection into unfolded ferricytochrome c titrated with 2.3 to 4.6 M guanidine hydrochloride (GuHCl) at pH 7 and 40 degrees C produced unfolded ferrocytochrome, which then converted to the folded protein. Two folding phases were observed: a fast process with a time constant of 40 microseconds (4.6 M GuHCl), and a slower phase with a rate constant of 90 +/- 20 per second (2.3 M GuHCl). The activation free energy for the slow step varied linearly with GuHCl concentration; the rate constant, extrapolated to aqueous solution, was 7600 per second, Electron-transfer methods can bridge the nanosecond to millisecond measurement time gap for protein folding.	CALTECH, BECKMAN INST, PASADENA, CA 91125 USA; HAVERFORD COLL, HAVERFORD, PA 19041 USA	California Institute of Technology; Haverford College								BABUL J, 1971, BIOPOLYMERS, V10, P2359, DOI 10.1002/bip.360101125; BABUL J, 1972, BIOCHEMISTRY-US, V11, P1195, DOI 10.1021/bi00757a013; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BALDWIN RL, 1994, BIOESSAYS, V16, P207, DOI 10.1002/bies.950160312; BALLEW RM, IN PRESS P NATL ACAD; BEALS JM, 1991, BIOCHEMISTRY-US, V30, P7680, DOI 10.1021/bi00245a004; BERTRAND P, 1995, BIOCHEMISTRY-US, V34, P11071, DOI 10.1021/bi00035a012; BIXLER J, 1992, J AM CHEM SOC, V114, P6938, DOI 10.1021/ja00043a062; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; CHEN BL, 1992, BIOCHEMISTRY-US, V31, P1464, DOI 10.1021/bi00120a025; CHEN LXQ, 1987, CHEM PHYS LETT, V139, P55, DOI 10.1016/0009-2614(87)80150-1; COHEN DS, 1995, J AM CHEM SOC, V117, P1675, DOI 10.1021/ja00111a001; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; FERSHT AR, 1995, CURR OPIN STRUC BIOL, V5, P79, DOI 10.1016/0959-440X(95)80012-P; GUTIN AM, 1995, P NATL ACAD SCI USA, V92, P1282, DOI 10.1073/pnas.92.5.1282; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; KARPLUS M, 1994, PROTEIN SCI, V3, P650; KUWAJIMA K, 1987, FEBS LETT, V221, P115, DOI 10.1016/0014-5793(87)80363-0; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLENDON G, 1978, J BIOL CHEM, V253, P4004; NOTLING B, 1995, P NATL ACAD SCI USA, V92, P10668; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; PHILLIPS CM, 1995, P NATL ACAD SCI USA, V92, P7292, DOI 10.1073/pnas.92.16.7292; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SANTUCCI R, 1988, J AM CHEM SOC, V110, P8536, DOI 10.1021/ja00233a035; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sutin N, 1978, ADV CHEM SER, V168, P1; TANIGUCHI VT, 1980, PURE APPL CHEM, V52, P2275, DOI 10.1351/pac198052102275; WOODRUFF WH, 1994, BIOPHYS J, V66, pA397; YEE EL, 1979, J AM CHEM SOC, V101, P1131, DOI 10.1021/ja00499a013	32	317	318	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 15	1996	271	5255					1558	1560		10.1126/science.271.5255.1558	http://dx.doi.org/10.1126/science.271.5255.1558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ983	8599112				2022-12-24	WOS:A1996TZ98300033
J	Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M				Thomas, T; Thomas, G; McLendon, C; Sutton, T; Mullan, M			beta-Amyloid-mediated vasoactivity and vascular endothelial damage	NATURE			English	Article							ALZHEIMERS-DISEASE; PROTEIN	Deposits of beta-amyloid are apparent in ageing and Alzheimer's disease(1), but the role of this peptide in neurodegeneration is unclear(2). The free-radical theory of ageing may also account for Alzheimer-type degeneration and consequently links between free-radical generation and beta-amyloid have been sought(3). We demonstrate here that beta-amyloid interacts with endothelial cells on blood vessels to produce an excess of superoxide radicals, with attendant alterations in endothelial structure and function. The superoxide radical can scavenge endothelium-derived relaxing factor and produce potent oxidizing agents, which can cause lipid peroxidation and other degenerative changes(4). The alterations in vascular tone and endothelial damage are prevented by the oxygen-radical-scavenging enzyme superoxide dismutase. These observations suggest a normal vasoactive role for beta-amyloid as well as a mechanism by which beta-amyloid may play a role in vascular abnormalities and neurodegeneration mediated by free radicals.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,TAMPA,FL 33613	State University System of Florida; University of South Florida	Thomas, T (corresponding author), UNIV S FLORIDA,ROSKAMP LABS,INST PSYCHIAT RES,TAMPA,FL 33613, USA.			Mullan, Michael/0000-0002-1473-7527				BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1992, JAP J PHARM S2, V58, P185; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; Scholz W, 1938, Z GESAMTE NEUROL PSY, V162, P694, DOI 10.1007/BF02890989; TOMIMOTO H, 1994, J CEREB BLOOD FLOW M, V14, P563; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	14	625	648	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					168	171		10.1038/380168a0	http://dx.doi.org/10.1038/380168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600393				2022-12-24	WOS:A1996TZ97800054
J	Weliky, M; Bosking, WH; Fitzpatrick, D				Weliky, M; Bosking, WH; Fitzpatrick, D			A systematic map of direction preference in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; ISO-ORIENTATION DOMAINS; FUNCTIONAL ARCHITECTURE; ORGANIZATION; SELECTIVITY; GEOMETRY; COLUMNS; AREA-18	NEURONS in the primary visual cortex respond selectively to the orientation of edges and their direction of motion. Orientation preference is mapped in a systematic fashion across the cortical surface, such that neurons in adjacent columns have similar but slightly shifted preferred orientations(1-7), Microelectrode studies have suggested that direction preference is also arranged in a systematic fashion(8-10), but exactly how this response property is mapped remains unclear. Here we show by optical imaging(4-5) of intrinsic signals(6-7,11-14) in ferret cortical area 17 that there is a mosaic-like map of direction preference, This map consists of numerous regions within which direction preference changes in a slow, continuous fashion, These regions are separated by winding boundaries (fractures) across which direction preference shifts abruptly, often by 180 degrees, Comparison of direction and orientation preference maps shows that these fractures subdivide iso-orientation domains into regions selective for opposite directions of motion.			Weliky, M (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.							BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BLASDEL GG, 1992, J NEUROSCI, V12, P3115, DOI 10.1523/JNEUROSCI.12-08-03115.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; FITZPATRICK D, 1994, J SOC NEUR ABSTR, V20, P837; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; MALONEK D, 1994, P ROY SOC B-BIOL SCI, V258, P109, DOI 10.1098/rspb.1994.0150; PAYNE BR, 1981, BRAIN RES, V211, P445, DOI 10.1016/0006-8993(81)90971-9; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TOLHURST DJ, 1981, EXP BRAIN RES, V44, P340; WELIKY M, 1994, J NEUROSCI, V14, P7291; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	17	194	194	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					725	728		10.1038/379725a0	http://dx.doi.org/10.1038/379725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602218				2022-12-24	WOS:A1996TW56700052
J	Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH				Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH			Inositol trisphosphate and cyclic ADP-ribose-mediated release of Ca2+ from single isolated pancreatic zymogen granules	CELL			English	Article							EXOCRINE PANCREAS; ACINAR-CELLS; SUBCELLULAR-DISTRIBUTION; ENDOPLASMIC-RETICULUM; PROTEIN-SYNTHESIS; CALCIUM; SECRETION; OSCILLATIONS; THAPSIGARGIN; INHIBITION	In pancreatic acinar cells low (physiological) agonist concentrations evoke cytosolic Ca2+ spikes specifically in the apical secretory pole that contains a high density of secretory (zymogen) granules (ZGs). Inositol 1,4,5-trisphosphate (IP3) is believed to release Ca2+ from the endoplasmic reticulum, but we have now tested whether the Ca2+-releasing messengers IP3 and cyclic ADP-ribose (cADPr) can liberate Ca2+ from ZGs. In experiments on single isolated ZGs, we show using confocal microscopy that IP3 and cADPr evoke a marked decrease in the free intragranular Ca2+ concentration. Using a novel high resolution method, we have measured changes in the Ca2+ concentration in the vicinity of an isolated ZG and show that IP3 and cADPr cause rapid Ca2+ release from the granule, explaining the agonist-evoked cytosolic Ca2+ rise in the secretory pole.	UNIV LIVERPOOL,PHYSIOL LAB,MRC SECRETORY CONTROL,RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Gerasimenko, Oleg/A-6622-2010; Petersen, Ole H/E-8708-2010; Gerasimenko, Julia/A-7688-2010; Belan, Pavel/AAV-3522-2021	Gerasimenko, Oleg/0000-0003-2573-8258; Belan, Pavel/0000-0001-5429-3716; Gerasimenko, Julia/0000-0002-2262-2543; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEMENTE F, 1975, J CELL BIOL, V65, P88, DOI 10.1083/jcb.65.1.88; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V415, P29, DOI 10.1007/BF00373138; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gorelick Frederick S., 1994, P1353; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASAI H, 1995, CIBA F SYMP, V188, P104; Kern Horst F., 1993, P9; MARTY A, 1991, J MEMBRANE BIOL, V124, P189, DOI 10.1007/BF01994353; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; NAKAGAKI I, 1984, PFLUG ARCH EUR J PHY, V401, P340, DOI 10.1007/BF00584333; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROGERS J, 1987, BIOCHIM BIOPHYS ACTA, V897, P217, DOI 10.1016/0005-2736(87)90418-4; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; WILCOX RA, 1994, J BIOL CHEM, V269, P26815; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	40	207	217	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					473	480		10.1016/S0092-8674(00)81292-1	http://dx.doi.org/10.1016/S0092-8674(00)81292-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608601	Bronze			2022-12-24	WOS:A1996TV70800016
J	Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E				Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E			Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS; CYTOKINES; GROWTH; CELLS	Background. Sequences of a novel herpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), have been identified in Kaposi's sarcoma tissue, but it is not known whether the virus is transmitted by sexual contact. Methods. Using the polymerase chain reaction (PCR), we searched for KSHV DNA sequences in ejaculates from 43 healthy men and tissue from the urogenital tract or prostate of 100 immunocompetent adults. Results. In an unblinded analysis, we identified KSHV DNA sequences in 2 of 20 tissue specimens from the urinary tract (10 percent; 15 men and 5 women), 3 of 46 specimens from the female genital tract (6.5 percent), 4 of 18 specimens from the glans or foreskin (22 percent), 7 of 16 specimens from the prostate (44 percent), and 30 of 33 ejaculates (91 percent), By contrast, such sequences were present in 1 of 18 samples of normal skin (5.5 percent) and 1 of 14 samples of peripheral-blood mononuclear cells (PBMCs; 7.1 percent), Ejaculates and PBMC samples from each of 10 study subjects were analyzed in a blinded, coded fashion, along with PBMCs and biopsy specimens of normal skin from 4 and 8 other patients, respectively. This analysis confirmed the presence of KSHV DNA sequences in semen, Viral DNA was not found in the sperm heads but was present in the fraction of the ejaculates that contained urothelial and other types of cells. Point mutations were found in PCR products amplified from both prostate tissue and sperm samples. Conclusions. KSHV infects a large proportion of healthy adults and is probably transmitted by sexual contact. (C) 1996, Massachusetts Medical Society.	ST ANNA HOSP,LAB ANAL,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna	Monini, P (corresponding author), UNIV FERRARA,INST MICROBIOL,VIA L BORSARI 46,I-44100 FERRARA,ITALY.		Monini, Paolo/K-1429-2016	Monini, Paolo/0000-0002-4941-6854				BARILLARI G, 1992, J IMMUNOL, V149, P3727; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BROOKS JJ, 1986, LANCET, V2, P1309; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COUTURIER E, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92685-B; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KYO S, 1994, J INFECT DIS, V170, P682, DOI 10.1093/infdis/170.3.682; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; REAL FX, 1985, NEW ENGL J MED, V313, P1659; ROIZMAN B, 1995, NEW ENGL J MED, V332, P1227, DOI 10.1056/NEJM199505043321810; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; VONBEROLDINGEN CH, 1989, PCR TECHNOLOGY PRINC, P209	18	217	225	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1168	1172		10.1056/NEJM199605023341805	http://dx.doi.org/10.1056/NEJM199605023341805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602183	Bronze			2022-12-24	WOS:A1996UG83100005
J	Geli, MI; Riezman, H				Geli, MI; Riezman, H			Role of type I myosins in receptor-mediated endocytosis in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; ACTIN; CELLS	Type I myosins are thought to drive actin-dependent membrane motility, but the direct demonstration in vivo of their involvement in specific cellular processes has been difficult. Deletion of the genes MYO3 and MYO5, which encode the yeast type I myosins, almost abolished growth. A double-deleted mutant complemented with a MYO5 temperature-sensitive allele (myo5-1) showed a strong defect in the internalization step of receptor-mediated endocytosis, whereas the secretory pathway remained apparently unaffected. Thus, myosin I activity is required for a budding event in endocytosis but not for several other aspects of membrane traffic.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel			Geli, Maria Isabel/L-3246-2014	Geli, Maria Isabel/0000-0002-3452-6700; Riezman, Howard/0000-0003-4680-9422				BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DULIC V, 1991, METHOD ENZYMOL, V194, P697; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HICKE L, UNPUB; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; 1988, GENE, V74, P527	28	219	225	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					533	535		10.1126/science.272.5261.533	http://dx.doi.org/10.1126/science.272.5261.533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614799				2022-12-24	WOS:A1996UG82600039
J	Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B				Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B			Accurate processing of a eukaryotic precursor ribosomal RNA by ribonuclease MRP in vitro	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; U1 SNRNA; SUBSTRATE; INVITRO; CONTAINS; MUTANT; GENE	Very few of the enzymes required for eukaryotic precursor ribosomal RNA (pre-rRNA) processing have been identified, Ribonuclease (RNase) MRP was characterized as a nuclease that cleaves mitochondrial replication primers, but it is predominantly nucleolar, Previous genetic evidence revealed that this ribonucleoprotein is required, directly or indirectly, for cleavage of the yeast pre-rRNA in vivo at site A(3). Here, an in vitro processing system that accurately reproduces this cleavage is described. Biochemical purification and the use of extracts depleted of the MRP RNA demonstrate that endonucleolytic cleavage of the pre-rRNA is directly mediated by RNase MRP, This establishes a role for RNase MRP in the nucleolus.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; Seraphin, Bertrand/0000-0002-5168-1921; Allmang, Christine/0000-0001-8883-0874				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDAHL L, 1992, NUCLEIC ACIDS RES, V20, P295, DOI 10.1093/nar/20.2.295; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; LYGEROU Z, UNPUB; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; POTUSCHAK T, 1993, NUCLEIC ACIDS RES, V21, P3239, DOI 10.1093/nar/21.14.3239; Sambrook J., 1989, MOL CLONING; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; TRANGUCH AJ, 1994, BIOCHEMISTRY-US, V33, P1778, DOI 10.1021/bi00173a022; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; YIP MT, 1989, J BIOL CHEM, V264, P4045	29	211	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					268	270		10.1126/science.272.5259.268	http://dx.doi.org/10.1126/science.272.5259.268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602511				2022-12-24	WOS:A1996UE72900041
J	Wan, Y; Kurosaki, T; Huang, XY				Wan, Y; Kurosaki, T; Huang, XY			Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors	NATURE			English	Article							GENE-PRODUCT; PHOSPHORYLATES; FIBROBLASTS; CLONING; RAS	THE mitogen-activated protein kinase (MAPK) signalling cascade is a prominent cellular pathway used by many growth factors, hormones and neurotransmitters to regulate physiological responses(1,2). Although activation of the MAPK pathway by receptors with tyrosine kinase activity is well defined(3), the mechanism used by heterotrimeric G-protein-coupled receptors to activate this pathway is less clear. Here we show that in cells deficient in the Src-related tyrosine kinase Lyn, stimulation of MAPK kinase and MAPK by G(q)-coupled mi muscarinic acetylcholine receptors (mAChR) is blocked, whereas G(i)-coupled m2 mAChR-mediated stimulation is unaffected. In cells deficient in the tyrosine kinase SyK, both m(1) and m2 mAChRs failed to stimulate MAPK kinase and MAPK. This result indicates that Syk is essential for the G(i)-coupled pathway and that Lyn and Syk are necessary for the G(q)-coupled pathway.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; WYETH AYERST RES,DEPT ONCOL & IMMUNOL,PEARL RIVER,NY 10965	Cornell University; Pfizer								ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	27	264	268	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					541	544		10.1038/380541a0	http://dx.doi.org/10.1038/380541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606776				2022-12-24	WOS:A1996UE66300054
J	Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M				Davis, AW; Roote, J; Morley, T; Sawamura, K; Herrmann, S; Ashburner, M			Rescue of hybrid sterility in crosses between D-melanogaster and D-simulans	NATURE			English	Article							TRANSPOSABLE ELEMENT MARINER; DROSOPHILA-MELANOGASTER; SPECIES COMPLEX; LETHAL SYSTEMS; GENETIC-BASIS; SUBGROUP	The genetic analysis of reproductive isolation between species of Drosophila has now reached the resolution necessary(1,2) to start answering one of the fundamental questions of evolution: what is the genetic basis of species differences? (ref. 3). A. H. Sturtevant, one of the founders of Drosophila genetics, was fascinated by this question(4) and thought he had found a way to analyse it when he realized that 'Drosophila melanogaster' was actually two species: D. melanogaster and D. simulans(5). By passing genes between these two species he hoped to investigate their genetic differences directly. No doubt he was disappointed to find that the D. melanogaster/D. simulans hybridization resulted only in unisexual sterile hybrids(6), a disappointment appreciated all the more by modern evolutionary biologists. Seventy-five years after Sturtevant's description of D. melanogaster/D. simulans hybrid sterility, we have discovered a strain of D. simulans that produces fertile female hybrids in crosses with D. melanogaster. Our discovery promises to bring the enormous resolution of D. melanogaster genetics to the study of reproductive isolation and species differences.			Davis, AW (corresponding author), UNIV CAMBRIDGE,DEPT GENET,DOWNING ST,CAMBRIDGE CB2 3EH,ENGLAND.							ASHBURNER M, 1989, DROSOPHILA LABORATOR; CACCONE A, 1988, GENETICS, V118, P671; COYNE JA, 1983, EVOLUTION, V37, P1101, DOI 10.1111/j.1558-5646.1983.tb00225.x; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; Dobzhansky T., 1937, GENETICS ORIGIN SPEC; GARZA D, 1991, GENETICS, V128, P303; HEY J, 1993, MOL BIOL EVOL, V10, P804; HUTTER P, 1990, GENETICS, V124, P909; HUTTER P, 1987, NATURE, V327, P331, DOI 10.1038/327331a0; JEFFS PS, 1994, MOL BIOL EVOL, V11, P287; LEMEUNIER F, 1976, PROC R SOC SER B-BIO, V193, P275, DOI 10.1098/rspb.1976.0046; LEMEUNIER F, 1984, GENET BIOL DROSOPHIL, P147; MARUYAMA K, 1991, GENETICS, V128, P319; MULLER HJ, 1940, NATURE, V146, P1969; PEREZ DE, 1995, GENETICS, V140, P201; PONTECORVO G, 1943, P R SOC EDINB B, V61, P385; PROVINE WB, 1991, GENETICS, V129, P1; Sambrook J., 1989, MOL CLONING LAB MANU; SAWAMURA K, 1993, GENETICA, V88, P175, DOI 10.1007/BF02424474; SAWAMURA K, 1993, GENETICS, V133, P307; SAWAMURA K, 1993, GENETICS, V133, P299; Sturtevant A. H., 1919, Psyche Boston, V26, DOI 10.1155/1919/97402; Sturtevant AH, 1920, GENETICS, V5, P488; WATANABE TK, 1979, JPN J GENET, V54, P325, DOI 10.1266/jjg.54.325; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435	25	78	79	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					157	159		10.1038/380157a0	http://dx.doi.org/10.1038/380157a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600389				2022-12-24	WOS:A1996TZ97800050
J	Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M				Zeng, HK; Qian, ZW; Myers, MP; Rosbash, M			A light-entrainment mechanism for the Drosophila circadian clock	NATURE			English	Article							MESSENGER-RNA LEVELS; PERIOD; GENE; MELANOGASTER; MUTANTS; PRODUCT; PROTEIN	Biochemical studies indicate that the Drosophila timeless protein (Tim) is a stoichiometric partner of the period protein (Per) in fly head extracts. A Per-Tim heterodimeric complex explains the reciprocal autoregulation of the proteins on transcription. The complex is under clock control, and many circadian features of the Tim cycle resemble those of the Per cycle. However, Tim is rapidly degraded in the early morning or in response to light, releasing Per from the complex. The Per-Tim complex is a functional unit of the Drosophila circadian clock, and Tim degradation may be the initial response of the clock to light.	BRANDEIS UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,WALTHAM,MA 02254; BRANDEIS UNIV,TECHNOL CTR BIOL TIMING,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NATL SCI FDN SCI,NEW YORK,NY 10021; ROCKEFELLER UNIV,TECHNOL CTR BIOL TIMING,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Brandeis University; Howard Hughes Medical Institute; Brandeis University; Brandeis University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University								CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JACKSON FR, 1986, NATURE, V320, P185, DOI 10.1038/320185a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAY SA, 1995, CELL, V83, P361, DOI 10.1016/0092-8674(95)90113-2; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LOROS J, 1995, NEUROSCIENCES, V7, P3; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; ROSBASH M, 1995, CURR OPIN GENET DEV, V5, P662, DOI 10.1016/0959-437X(95)80037-9; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	34	390	396	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					129	135		10.1038/380129a0	http://dx.doi.org/10.1038/380129a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600384				2022-12-24	WOS:A1996TZ97800041
J	Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D				Banner, DW; DArcy, A; Chene, C; Winkler, FK; Guha, A; Konigsberg, WH; Nemerson, Y; Kirchhofer, D			The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor	NATURE			English	Article							EGF-LIKE DOMAIN; HUMAN FACTOR-IX; ACTIVE-SITE; FACTOR-X; CALCIUM-BINDING; CA2+ ION; RESOLUTION; SURFACE; LOCALIZATION; FLUORESCENCE	Blood coagulation is initiated when tissue factor binds to coagulation factor VIIa to give an enzymatically active complex which then activates factors IX and X, leading too thrombin generation and clot formation. We have determined the crystal structure at 2.0-Angstrom resolution of active-site-inhibited factor VIIa complexed with the cleaved extracellular domain of tissue factor. In the complex, factor VIIa adopts an extended conformation. This structure provides a basis for understanding many molecular aspects of the initiation of coagulation.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yale University	Banner, DW (corresponding author), F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1991, J BIOL CHEM, V266, P20085; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; GIBBS CS, 1994, BIOCHEMISTRY-US, V33, P14003, DOI 10.1021/bi00251a007; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KIRCHHOFER D, 1995, PROTEINS, V22, P419, DOI 10.1002/prot.340220412; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEMERSON Y, 1988, BLOOD, V71, P1; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TUDDENHAM EGD, 1995, THROMB HAEMOSTASIS, V74, P313; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	51	665	698	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 7	1996	380	6569					41	46		10.1038/380041a0	http://dx.doi.org/10.1038/380041a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TY877	8598903				2022-12-24	WOS:A1996TY87700048
J	Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG				Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG			The tomato Cf-2 disease resistance locus comprises two functional genes encoding leucine-rich repeat proteins	CELL			English	Article							CLADOSPORIUM-FULVUM; CLONING; KINASE	In plants, resistance to pathogens is frequently determined by dominant resistance genes, whose products are proposed to recognize pathogen-encoded avirulence gene (Avr) products. The tomato resistance locus Cf-2 was isolated by positional cloning and found to contain two almost identical genes, each conferring resistance to isolates of tomato leaf mould (C. fulvum) expressing the corresponding Avr2 gene. The two Cf-2 genes encode protein products that differ from each other by only three amino acids and contain 38 leucine-rich repeat (LRR) motifs. Of the LRRs, 20 show extremely conserved alternating repeats. The C-terminus of Cf-2 carries regions of pronounced homology to the protein encoded by the unlinked Cf-9 gene. We suggest that this conserved region interacts with other proteins involved in activating plant defense mechanisms.	JOHN INNES CTR,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Jones, Jonathan DG/J-5129-2012; Jones, David A/C-9507-2009	Jones, Jonathan DG/0000-0002-4953-261X; Jones, David A/0000-0001-8809-5822				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHFIELD T, 1994, MOL PLANT MICROBE IN, V7, P645, DOI 10.1094/MPMI-7-0645; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; CARROLL BJ, 1995, GENETICS, V139, P407; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON MS, 1995, MOL PLANT MICROBE IN, V8, P200, DOI 10.1094/MPMI-8-0200; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; Flor H. H., 1946, JOUR AGRIC RES, V73, P335; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, MOL PLANT MICROBE IN, V7, P58, DOI 10.1094/MPMI-7-0058; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JONES JDG, 1994, CURR BIOL, V4, P749, DOI 10.1016/S0960-9822(00)00168-8; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MAY MJ, 1996, IN PRESS PLANT PHYSL; MINDRINOS M, 1994, CELL, V78, P1069; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; OLIVER RP, 1993, MOL PLANT MICROBE IN, V6, P521, DOI 10.1094/MPMI-6-521; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J., 1989, MOL CLONING LAB MANU; SCONFIEDL S, 1992, PLANT CELL, V4, P573; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Stevens MA, 1988, THE TOMATO CROP, P35; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VERAESTRELLA R, 1992, PLANT PHYSIOL, V99, P1208, DOI 10.1104/pp.99.3.1208; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1994, PLANT MOL BIOL, V26, P1599, DOI 10.1007/BF00016492; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	44	448	504	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					451	459		10.1016/S0092-8674(00)81290-8	http://dx.doi.org/10.1016/S0092-8674(00)81290-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608599	Bronze			2022-12-24	WOS:A1996TV70800014
J	Jernigan, DB; Cetron, MS; Breiman, RF				Jernigan, DB; Cetron, MS; Breiman, RF			Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP) - A strategy from the DRSP Working Group	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; PENICILLIN-RESISTANT; MICRODILUTION SYSTEM; MENINGITIS; FAILURE; SUSCEPTIBILITY; PNEUMOCOCCI; MEDIA	Emergence of drug-resistant Streptococcus pneumoniae (DRSP) presents a challenge to the medical and public health communities since the magnitude of the problem is not known, the clinical impact of DRSP infections is not well described, national vaccination rates are low, and antimicrobial drugs are often used excessively and inappropriately. To address the problem of DRSP, a working group sponsored by Centers for Disease Control and Prevention was formed in June 1994 consisting of public health practitioners, health care providers, and clinical laboratorians representing state and federal agencies and various professional organizations. Through periodic open meetings, the working group has developed a strategy for surveillance, investigation, prevention, and control of infections due to DRSP, The strategy focuses on (1) implementing an electronic laboratory-based surveillance (ELBS) system for reporting invasive DRSP infections and providing clinically relevant feedback to clinicians, (2) identifying risk factors and outcomes of DRSP infection, (3) increasing pneumococcal vaccination, and (4) promoting judicious antimicrobial drug use. Data received through ELBS will be used to make timely estimates of the community-specific prevalence of drug-resistant pneumococci. National, regional, and local trends will be made available to health care providers and clinicians to promote optimal antimicrobial drug use and increased vaccination in targeted areas. Once in operation, the ELBS network will be adaptable to other diseases, improving the comprehensiveness and timeliness of public health surveillance. The intended outcome of the strategy is to reduce complications of DRSP infection, such as long-ten sequelae of infection, health care expenditures, morbidity, and mortality.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARROLL K, 1991, J CLIN MICROBIOL, V29, P2651, DOI 10.1128/JCM.29.11.2651-2652.1991; CHANDY CJ, 1994, CLIN INFECT DIS, V18, P188; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; FEDSON DS, 1994, VACCINES, P543; GARRETT L, 1994, COMING PLAGUE, P411; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JERNIGAN DB, 1995, 35TH INT C ANT AG CH; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P2448, DOI 10.1128/JCM.32.10.2448-2459.1994; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; RADETSKY MS, 1981, LANCET, V2, P771; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SHANHOLTZER CJ, 1986, AM J CLIN PATHOL, V85, P626, DOI 10.1093/ajcp/85.5.626; Shlaes D, 1991, ASM NEWS, V57, P455; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; Tilghman RC, 1937, ARCH INTERN MED, V59, P602, DOI 10.1001/archinte.1937.00170200044004; 1995, MMWR-MORBID MORTAL W, V44, P513; 1995, MMWR-MORBID MORTAL W, V44, P506; 1994, MMWR-MORBID MORTAL W, V43, P216; 1995, MMWR-MORBID MORTAL W, V44, P737; 1994, PERFORMANCE STAND S5; 1992, EMERGING INFECTIONS, P92; 1994, PERFORMANCE STANDARD, P14; 1990, DHHS PHS9150213 PUBL; 1994, TIME            0912, V144, P62; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P223	36	156	158	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					206	209		10.1001/jama.275.3.206	http://dx.doi.org/10.1001/jama.275.3.206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604173				2022-12-24	WOS:A1996TP28200028
J	Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS				Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS			Localization of dopamine D4 receptors in GABAergic neurons of the primate brain	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; SLEEP; METABOLITES; INHIBITION; CA1	DOPAMINE receptors are the principal targets of drugs used in the treatment of schizophrenia(1). Among the five mammalian dopamine-receptor subtypes, the D4 subtype is of particular interest because of its high affinity for the atypical neuroleptic clozapine(1-3). Interest in clozapine stems from its effectiveness in reducing positive and negative symptoms in acutely psychotic and treatment-resistant schizophrenic patients,without eliciting extrapyramidal side effects(4). We have produced a subtype-specific antibody against the D4 receptor and localized it within specific cellular elements and synaptic circuits of the central nervous system. The D4-receptor antibody labelled GABAergic neurons in the cerebral cortex, hippocampus, thalamic reticular nucleus, globus pallidus and the substantia nigra (pars reticulata). Labelling was also observed in a subset of cortical pyramidal cells. Our findings suggest that clozapine's beneficial effects in schizophrenia may be achieved, in part, through D4-mediated GABA modulation, possibly implicating disinhibition of excitatory transmission in intrinsic cortical, thalamocortical and extrapyramidal pathways.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; UPJOHN PHARMACIA CELL BIOL,KALAMAZOO,MI 49001	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Levenson, Robert/0000-0002-0936-8421				ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	389	403	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					245	248		10.1038/381245a0	http://dx.doi.org/10.1038/381245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622768				2022-12-24	WOS:A1996UL24900057
J	Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH				Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH			Triggering myocardial infarction by sexual activity - Low absolute risk and prevention by regular physical exertion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the relative risks of nonfatal myocardial infarction (MI) triggered by sexual activity among the general population and in patients with prior coronary heart disease. Design.-Relative risks and effect modification were calculated by the case-crossover method, a new epidemiologic technique designed to quantify the transient change in risk following exposure to a potential disease trigger. Setting/Participants.-A total of 1774 patients with MI were interviewed in 45 hospitals throughout the United States. Data were gathered on potential triggers of MI occurring immediately prior to the event and during the previous year. Results are presented for the 858 patients who were sexually active in the year prior to the MI, with attention to the 273 patients who had coronary artery disease prior to their index MI, and the effect of regular exertion on risk. Main Outcome Measure.-The relative risk of nonfatal MI following sexual activity. Results.-Of the 858 patients, 79 (9%) reported sexual activity in the 24 hours preceding MI, and 27 (3%) reported sexual activity in the 2 hours preceding onset of symptoms of MI. The relative risk of MI occurring in the 2 hours after sexual activity was 2.5 (95% confidence interval [CI], 1.7-3.7). The relative risk of triggering onset of MI among patients with a history of prior angina (2.1 [95% CI, 0.8-5.8]) or prior MI (2.9 [95% CI, 1.3-6.5) was not greater than that observed in those without prior cardiac disease. Sexual activity was a likely contributor to the onset of MI in only 0.9% of cases and regular exertion was associated with decreasing risk. Conclusions.-Sexual activity can trigger the onset of MI, However, the relative risk is low, and since the absolute hourly risk of MI is extremely low, the absolute risk increase caused by sexual activity also is extremely low (1 chance in a million for a healthy individual). Moreover, the relative risk is not increased in patients with a prior history of cardiac disease and regular exercise appears to prevent triggering, These findings should be useful for counseling patients and decreasing the fear of sexual activity that often prevents complete rehabilitation from cardiovascular disease.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Muller, JE (corresponding author), DEACONESS HOSP,DIV CARDIOVASC,INST PREVENT CARDIOVASC DIS,DEPT MED,1 AUTUMN ST,5TH FLOOR,BOSTON,MA 02215, USA.			Mittleman, Murray/0000-0001-9788-7274	NHLBI NIH HHS [HL41016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 1995, 1995 STAT SUPPL HEAR; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1993, AM HEART J, V121, P293; ESLER M, 1995, J CLIN ENDOCR METAB, V80, P435, DOI 10.1210/jc.80.2.435; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HELLERSTEIN HK, 1970, ARCH INTERN MED, V125, P987, DOI 10.1001/archinte.125.6.987; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; NALBANTGIL I, 1976, AM HEART J, V91, P405, DOI 10.1016/S0002-8703(76)80235-9; PAPADOPOULOS C, 1980, ARCH INTERN MED, V140, P38, DOI 10.1001/archinte.140.1.38; PAPADOPOULOS C, 1986, CHEST, V90, P681, DOI 10.1378/chest.90.5.681; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROTHMAN KJ, 1981, AM J EPIDEMIOL, V114, P253, DOI 10.1093/oxfordjournals.aje.a113189; STEIN RA, 1977, CIRCULATION, V55, P738, DOI 10.1161/01.CIR.55.5.738; TARDIF GS, 1989, ARCH PHYS MED REHAB, V70, P763; TRIMBLE GX, 1970, MED ASPECTS HUM SEX, V5, P64; UENO M, 1963, JPN J LEGAL MED, V17, P330; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396	23	281	293	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1405	1409		10.1001/jama.275.18.1405	http://dx.doi.org/10.1001/jama.275.18.1405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618365				2022-12-24	WOS:A1996UJ30300025
J	Foulkes, NS; Duval, G; SassoneCorsi, P				Foulkes, NS; Duval, G; SassoneCorsi, P			Adaptive inducibility of CREM as transcriptional memory of circadian rhythms	NATURE			English	Article							PINEAL N-ACETYLTRANSFERASE; BETA-ADRENERGIC-RECEPTOR; GLAND; SPERMATOGENESIS; EXPRESSION; REPRESSOR; DIRECTS; SWITCH	THE CREM gene(1-4) encodes the transcriptional repressor ICER(3,5), which has been implicated in the molecular mechanisms controlling circadian rhythms in mammals(4-6). ICER is rhythmically expressed in the pineal gland, with peak levels occurring at night(5). ICER levels are regulated by light by means of the suprachiasmatic nucleus (SCN); transcription is induced during darkness by adrenergic input to the pineal gland from the SCN, which activates the ICER promoter using cyclic AMP and the transcriptional activator CREB. This induction is transient because ICER represses its own transcription(3), Here we show that the response of the CREM gene to adrenergic stimulation is determined by night length, Depending on the photoperiod of the prior entraining cycles, the CREM gene is either subsensitive or supersensitive to induction. This differential responsiveness is controlled by the changing balance between positive (CREB) and negative (ICER) transcriptional regulators. Thus, the transcriptional response of the CREM gene is determined by the memory of past photoperiods.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen, Heiko T./A-5770-2008; Foulkes, Nicholas S/K-7003-2013	Jansen, Heiko T./0000-0003-0178-396X; Foulkes, Nicholas S/0000-0002-1794-9891				ARMSTRONG A, 1995, MOL CELL BIOL, V15, P1826; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DEGUCHI T, 1973, P NATL ACAD SCI USA, V70, P2411, DOI 10.1073/pnas.70.8.2411; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; ILLNEROVA H, 1985, J PINEAL RES, V2, P67, DOI 10.1111/j.1600-079X.1985.tb00628.x; ILLNEROVA H, 1988, PINEAL RES REV, V6, P173; ILNEROVA H, 1986, CIRCADIAN RHYTHMS MA, P1; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; ROMERO JA, 1974, SCIENCE, V184, P1091, DOI 10.1126/science.184.4141.1091; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P1661, DOI 10.1073/pnas.72.5.1661; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SASSONECORSI PA, 1995, REV CELL DEV BIOL, V11, P355; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEHLE JH, 1995, MOL ENDOCRINOL, V9, P706, DOI 10.1210/me.9.6.706; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; SUMIOVA A, 1995, P NATL ACAD SCI USA, V92, P7754; TAKAHASHI JS, 1994, CURR BIOL, V4, P165, DOI 10.1016/S0960-9822(94)00040-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	85	85	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					83	85		10.1038/381083a0	http://dx.doi.org/10.1038/381083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609995				2022-12-24	WOS:A1996UJ05300062
J	Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR				Warner, KE; Fulton, GA; Nicolas, P; Grimes, DR			Employment implications of declining tobacco product sales for the regional economies of the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine whether declines in tobacco product sales significantly reduce employment in the United States, as the tobacco industry claims. Design.-Computer simulation of the economies of the Southeast Tobacco region and 8 nontobacco regions of the United States, with domestic tobacco expenditures eliminated or reduced and the equivalent spending redistributed, according to consumers' normal spending patterns, We compared these results with baseline forecasts of the regional economies that include normal tobacco expenditures. Main Outcome Measure.-Number of jobs. Results.-Had there been no spending on tobacco products in the United States in 1993, the Southeast Tobacco region would have had 303 000 fewer jobs. Collectively, however, the 8 nontobacco regions would have gained enough employment to completely offset losses in the Southeast Tobacco region, with every nontobacco region gaining jobs. By the year 2000, the absence of tobacco spending would mean a loss of 222 000 jobs in the Southeast Tobacco region, but a gain of 355 000 throughout the rest of the country. In the more realistic scenario of doubling the downward trend in tobacco consumption, the Southeast Tobacco region would lose 6300 jobs in 1993 (0.03% of regional employment) and 36 600 jobs by 2000 (0.2%). The 8 nontobacco regions would gain 6400 jobs in 1993 and 56 300 jobs in 2000, with each of the nontobacco regions gaining employment in every year. Conclusions.-Contrary to the tobacco industry's claims, reductions in spending on tobacco products will boost employment in every one of the 8 nontobacco regions and will not diminish employment in the Southeast Tobacco region by as much as the industry estimates. The primary concern about tobacco should be the enormity of its toll on health and not its impact on employment.	UNIV MICHIGAN,INST LABOR & IND RELAT,ANN ARBOR,MI; UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Warner, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH MANAGEMENT & POLICY,109 S OBSERV,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776				ALLEN RC, 1993, FALSE DILEMMA IMPACT; Bartlett J. C., 1994, Morbidity and Mortality Weekly Report, V43, P469; Buck D, 1995, TOBACCO AND JOBS; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; KOOP CE, 1984, JM JON LECT ANN M AM; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; *TOB I, 1995, TAX BURD TOB HIST CO, V29; *TOB MERCH ASS, 1995, TOB CONTR NAT EC; Treyz G. I., 1993, REGIONAL EC MODELING; TREYZ GI, 1992, INT REGIONAL SCI REV, V14, P221, DOI 10.1177/016001769201400301; *U MI, 1994, EC OUTL 1995; *U PA, 1979, STUD TOB IND EC CONT; *US BUR CENS, 1992, GEOGR AR SER 1992 CE; *US BUR EC AN, 1995, STAT PERS INC 1929 9; *US BUR LAB STAT, 1993, AM WORKF 1992 2005; WARNER KE, 1994, JAMA-J AM MED ASSOC, V271, P771, DOI 10.1001/jama.271.10.771; WARNER KE, 1987, JAMA-J AM MED ASSOC, V258, P2080, DOI 10.1001/jama.258.15.2080; 1986, ROCHESTER CITY  1016, V1, P6; 1985, EC IMPACT TOBACCO IN, V1, pV3; 1990, EC IMPACT TOBACCO IN; 1992, EC IMPACT TOBACCO IN; 1993, MON LABOR REV, V11, P3	22	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1241	1246		10.1001/jama.275.16.1241	http://dx.doi.org/10.1001/jama.275.16.1241			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601955				2022-12-24	WOS:A1996UF47800027
J	Miyazaki, T; Dierich, A; Benoist, C; Mathis, D				Miyazaki, T; Dierich, A; Benoist, C; Mathis, D			Independent modes of natural killing distinguished in mice lacking Lag3	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; KILLER-CELLS; T-CELLS; ANTIGEN RECOGNITION; GENE-COMPLEX; MOUSE NKR-P1; NK CLONES; EXPRESSION; SPECIFICITY; LY-49	The LAG3 protein has several features in common with CD4, suggesting that it may be important in controlling T cell reactivity. However, mice with a Lag3 null mutation have now been shown to exhibit a defect in the natural killer cell, rather than the T cell, compartment. Killing of certain tumor targets by natural killer cells from these mice was inhibited or even abolished, whereas lysis of cells displaying major histocompatibility complex class I disparities remained intact. It appears that LAG3 is a receptor or coreceptor that defines different modes of natural killing.	CU STRASBOURG,STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Miyazaki, T (corresponding author), ULP,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,FRANCE.							BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BYRNE BC, 1988, NUCLEIC ACIDS RES, V16, P4165, DOI 10.1093/nar/16.19.9342; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DENNERT G, 1988, J IMMUNOL, V140, P2472; GIORDA R, 1991, J IMMUNOL, V147, P1701; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; KARLHOFER FM, 1995, J EXP MED, V181, P1785, DOI 10.1084/jem.181.5.1785; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P7; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MIYAZAKI T, IN PRESS INT IMMUNOL; Miyazaki T., UNPUB; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; PIONTEK GE, 1985, J IMMUNOL, V135, P4281; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; RYAN JC, 1995, J EXP MED, V181, P1911, DOI 10.1084/jem.181.5.1911; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SENTMAN CL, 1994, J IMMUNOL, V153, P5482; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; STONEMAN ER, 1995, J EXP MED, V182, P305, DOI 10.1084/jem.182.2.305; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; TRIEBEL F, 1995, EUR J IMMUNOL, V25, P2718; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZAJAC AJ, 1995, INT IMMUNOL, V7, P1545, DOI 10.1093/intimm/7.10.1545; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228	45	121	130	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					405	408		10.1126/science.272.5260.405	http://dx.doi.org/10.1126/science.272.5260.405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602528				2022-12-24	WOS:A1996UG25200045
J	Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE				Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE			Ca2+/S100 regulation of giant protein kinases	NATURE			English	Article							CALCIUM-BINDING; PEPTIDE COMPLEX; CALMODULIN; ELEGANS	Protein phosphorylation by protein kinases plays a central regulatory role in cellular processes and these kinases are themselves tightly regulated(1). One common mechanism of regulation involves Ca2+-binding proteins (CaBP) such as calmodulin (CaM)(2). Here we report a Ca2+-effector mechanism for protein kinase activation by demonstrating the specific and >1,000-fold activation of the myosin-associated giant protein kinase twitchin by Ca2+/S100A1(2). S100A1(2) is a member of a large CaBP family that is implicated in various cellular processes, including cell growth, differentiation and motility, but whose molecular actions are largely unknown(3). The S100A1(2)-binding site is a part of the autoregulatory sequence positioned in the active site that is responsible for intrasteric autoinhibition of twitchin kinase; the mechanism of autoinhibition based on the crystal structures of two twitchin kinase fragments is described elsewhere(4). Ca2+/S100 represents a likely physiological activator for the entire family of giant protein kinases involved in muscle contractions and cytoskeletal structure(2,5-9).	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	St. Vincent's Institute of Medical Research; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Emory University			Kemp, Bruce/G-9602-2019; Kobe, Bostjan/D-1292-2009; Kemp, Bruce E/L-2633-2014; Parker, Michael W/F-9069-2013	Kemp, Bruce/0000-0001-6735-5082; Kobe, Bostjan/0000-0001-9413-9166; Kemp, Bruce E/0000-0001-6735-5082; Parker, Michael W/0000-0002-3101-1138				AYMESOUTHGATE A, 1995, J CELL BIOL, V128, P393, DOI 10.1083/jcb.128.3.393; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATO K, 1986, J NEUROCHEM, V46, P15555; KEMP BE, 1994, PROTEIN KINASES, P30; KOBE B, UNPUB NATURE STRUCTB; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEI JY, 1994, J BIOL CHEM, V269, P21078; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOR WE, 1993, SCIENCE, V262, P17185; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAYLOR SS, 1994, PROTEIN KINASES, P1; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	119	121	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					636	639		10.1038/380636a0	http://dx.doi.org/10.1038/380636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602266				2022-12-24	WOS:A1996UF74100049
J	Smith, CB; Betz, WJ				Smith, CB; Betz, WJ			Simultaneous independent measurement of endocytosis and exocytosis	NATURE			English	Article							BOVINE CHROMAFFIN CELLS; CAPACITANCE MEASUREMENTS; SECRETION	STUDIES of membrane traffic between the cytoplasm and surface of a cell suggest that membrane internalization is tightly coupled to secretion. Studies using the capacitance technique show that endocytosis can follow evoked exocytosis within a second or less(1-3). The capacitance technique, however, measures only the net change in cell surface area, and thus separating exocytosis from endocytosis requires that the two events do not overlap in time. This condition is probably met with small, brief stimuli(1-5), but during prolonged stimulation it is more likely that exocytosis and endocytosis occur simultaneously(6). We used FM1-43 fluorescence, which provides a cumulative measure of exocytosis, independent of endocytosis, in combination with capacitance monitoring to track unidirectional movements of membrane simultaneously and in real time in bovine adrenal chromaffin cells. We confirm that, with relatively small stimuli, exocytosis ceases before endocytosis begins (no overlap). In contrast, during prolonged stimulation, the onset of endocytosis is delayed by 2-3 min, but then the rate of endocytosis quickly grows to equal that of exocytosis. The delayed onset of endocytosis may be an emergency defence against catastrophic cell swelling.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,PROGRAM NEUROSCI,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GREER MA, 1992, HORMONE METAB RES, V24; GRINVALD A, 1982, BIOPHYS J, V39, P301, DOI 10.1016/S0006-3495(82)84520-7; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HARTMANN J, 1995, J PHYSIOL-LONDON, V483, P201, DOI 10.1113/jphysiol.1995.sp020578; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENKEL AW, IN PRESS P NATL ACAD; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRASZEWSKI K, 1995, NEUROSCIENCE, V15, P4328; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OBERHAUSER AF, 1995, BIOPHYS J, V69, P451, DOI 10.1016/S0006-3495(95)79918-0; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0	30	202	204	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					531	534		10.1038/380531a0	http://dx.doi.org/10.1038/380531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606773				2022-12-24	WOS:A1996UE66300051
J	Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK				Xie, XL; Kokubo, T; Cohen, SL; Mirza, UA; Hoffmann, A; Chait, BT; Roeder, RG; Nakatani, Y; Burley, SK			Structural similarity between TAFs and the heterotetrameric core of the histone octamer	NATURE			English	Article							TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; CRYSTAL-STRUCTURE; NUCLEOSOME; RESOLUTION; INITIATION; INTERACTS; DOMAIN; DNA	A complex of two TFIID TATA hox-binding protein-associated factors (TAF(II)s) is described at 2.0 Angstrom resolution. The amino-terminal portions of dTAF(II)42 and dTAF(II)62 from Drosophila adopt the canonical histone fold, consisting of two short alpha-helices flanking a long central alpha-helix. Like histones H3 and H4, dTAF(II)42 and dTAF(II)62 form an intimate heterodimer by extensive hydrophobic contacts between the paired molecules. In solution and in the crystalline state, the dTAF(II)42/dTAF(II)62 complex exists as a heterotetramer, resembling the (H3/H4), heterotetrameric core of the histone octamer, suggesting that TFIID contains a histone octamer-like substructure.	ROCKEFELLER UNIV,LAB MOLEC BIOPHYS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY & GASEOUS ION CHEM LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; NICHHD,NIH,BETHESDA,MD 20892	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Burley, Stephen K./0000-0002-2487-9713				ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURLEY SK, IN PRESS A REV BIOCH, V65; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DARCY A, 1994, ACTA CRYSTALLOGR D, V50, P469, DOI 10.1107/S0907444993014362; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; KARANTZA V, IN PRESS BIOCHEMISTR, V35; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KLUG A, 1980, NATURE, V287, P509, DOI 10.1038/287509a0; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATTMAN E, 1982, SCIENCE, V216, P1016, DOI 10.1126/science.7079748; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	50	226	231	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 28	1996	380	6572					316	322		10.1038/380316a0	http://dx.doi.org/10.1038/380316a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UC379	8598927				2022-12-24	WOS:A1996UC37900050
J	Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP				Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP			Breast feeding and tonsillectomy	BRITISH MEDICAL JOURNAL			English	Article											Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							BISSET AF, 1994, BRIT MED J, V308, P1129, DOI 10.1136/bmj.308.6937.1129; BRODSKY L, 1989, PEDIATR CLIN N AM, V36, P1551; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; MAW AR, 1986, ARCH DIS CHILD, V61, P421, DOI 10.1136/adc.61.5.421; PISACANE A, 1995, BRIT MED J, V310, P836, DOI 10.1136/bmj.310.6983.836	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					746	747						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605462	Green Published			2022-12-24	WOS:A1996UC16600028
J	Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P				Deng, CX; WynshawBoris, A; Zhou, F; Kuo, A; Leder, P			Fibroblast growth factor receptor 3 is a negative regulator of bone growth	CELL			English	Article							EXPRESSION PATTERN; MOUSE; FAMILY; MUTATION; PROTEINS; ORGANOGENESIS; DISRUPTION; CARTILAGE; ONCOGENE; MEMBER	Endochondral ossification is a major mode of bone formation that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate. Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis. In light of these mouse results, certain human disorders, such as achondroplasia, can be interpreted as gain-of-function mutations that activate the fundamentally negative growth control exerted by the FGFR-3 kinase.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute			deng, chuxia/N-6713-2016		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01393] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHITAYAT D, 1995, AM J MED GENET, V55, P147, DOI 10.1002/ajmg.1320550203; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GILBERT SF, 1994, DEV BIOL; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKUSICK VA, 1973, J MED GENET, V10, P11, DOI 10.1136/jmg.10.1.11; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORIOLI I, 1979, J MED GENET, V23, P328; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STARK KL, 1991, DEVELOPMENT, V113, P641; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	43	852	885	1	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					911	921		10.1016/S0092-8674(00)81069-7	http://dx.doi.org/10.1016/S0092-8674(00)81069-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601314	Bronze			2022-12-24	WOS:A1996UC38100012
J	Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS				Muslin, AJ; Tanner, JW; Allen, PM; Shaw, AS			Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine	CELL			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; KINASE-C; PHOSPHORYLATION; TYROSINE; RAF-1; IDENTIFICATION; PURIFICATION; MATURATION; TECHNOLOGY	The highly conserved and ubiquitously expressed 14-3-3 family of proteins bind to a variety of proteins involved in signal transduction and cell cycle regulation. The nature and specificity of 14-3-3 binding is, however, not known. Here we show that 14-3-3 is a specific phosphoserine-binding protein. Using a panel of phosphorylated peptides based on Raf-1, we have defined the 14-3-3 binding motif and show that most of the known 14-3-3 binding proteins contain the motif. Peptides containing the motif could disrupt 14-3-3 complexes and inhibit maturation of Xenopus laevis oocytes. These results suggest that the interactions of 14-3-3 with signaling proteins are critical for the activation of signaling proteins. Our findings also suggest novel roles for serine/threonine phosphorylation in the assembly of protein-protein complexes.	WASHINGTON UNIV, SCH MED, DEPT PHYSIOL & CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Muslin, AJ (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV CARDIOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.			Shaw, Andrey/0000-0001-5685-0272	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34094] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LORENZ RG, 1989, J EXP MED, V170, P203, DOI 10.1084/jem.170.1.203; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723	44	1183	1221	1	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	1996	84	6					889	897		10.1016/S0092-8674(00)81067-3	http://dx.doi.org/10.1016/S0092-8674(00)81067-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601312	Bronze			2022-12-24	WOS:A1996UC38100010
J	Berg, JM; Shi, YG				Berg, JM; Shi, YG			The galvanization of biology: A growing appreciation for the roles of zinc	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; FINGER DNA RECOGNITION; ACID BINDING-PROTEIN; NUCLEOCAPSID PROTEIN; CRYSTAL-STRUCTURE; GLUCOCORTICOID RECEPTOR; DEPENDENT STRUCTURE; IRON-METABOLISM; METAL-BINDING; 5S RNA	Zinc ions are key structural components of a large number of proteins. The binding of zinc stabilizes the folded conformations of domains so that they may facilitate interactions between the proteins and other macromolecules such as DNA. The modular nature of some of these zinc-containing proteins has allowed the rational design of site-specific DNA binding proteins. The ability of zinc to be bound specifically within a range of tetrahedral sites appears to be responsible for the evolution of the wide range of zinc-stabilized structural domains now known to exist. The lack of redox activity for the zinc ion and its binding and exchange kinetics also may be important in the use of zinc for specific functional roles.			Berg, JM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA.		Berg, Jeremy/GRY-6706-2022	Berg, Jeremy/0000-0002-2444-8139; Berg, Jeremy/0000-0003-3022-0963; Shi, Yigong/0000-0003-2030-168X				ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EIGEN M, 1963, PURE APPL CHEM, V6, P105; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figgis BN., 1966, INTRO LIGAND FIELDS; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HANAS JS, 1983, J BIOL CHEM, V258, P4120; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; HU HM, 1994, J BIOL CHEM, V269, P30069; HUANG RC, 1993, P NATL ACAD SCI USA, V90, P11806, DOI 10.1073/pnas.90.24.11806; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; Keilin D, 1940, BIOCHEM J, V34, P1163, DOI 10.1042/bj0341163; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORIUCHI H, 1994, VIROLOGY, V205, P238, DOI 10.1006/viro.1994.1639; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RG, 1969, SURVERY PROGR CHEM, V1, pCH1; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; Raulin J., 1869, ANN SCI NAT BOT BIOL, V11, P93; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; ROBERTS WJ, 1989, BIOCHEMISTRY-US, V28, P10043, DOI 10.1021/bi00452a024; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	81	1617	1741	6	280	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1081	1085		10.1126/science.271.5252.1081	http://dx.doi.org/10.1126/science.271.5252.1081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599083				2022-12-24	WOS:A1996TW70100028
J	Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D				Festenstein, R; Tolaini, M; Corbella, P; Mamalaki, C; Parrington, J; Fox, M; Miliou, A; Jones, M; Kioussis, D			Locus control region function and heterochromatin-induced position effect variegation	SCIENCE			English	Article							HUMAN CD2 GENE; TRANSGENIC MICE; GLOBIN GENE; MONOCLONAL-ANTIBODIES; DEPENDENT EXPRESSION; FAR UPSTREAM; HIGH-LEVEL; DROSOPHILA; BOUNDARIES; SEQUENCES	Human CD2 locus control region (LCR) sequences are shown here to be essential for establishing an open chromatin configuration. Transgenic mice carrying an hCD2 minigene attached only to the 3' CD2 transcriptional enhancer exhibited variegated expression when the transgene integrated in the centromere. In contrast, mice carrying a transgene with additional 3' sequences showed no variegation even when the latter integrated in centromeric positions. This result suggests that LCRs operate by ensuring an open chromatin configuration and that a short region, with no enhancer activity, functions in the establishment, maintenance, or both of an open chromatin domain.	UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, GALTON LAB, LONDON NW1 2HE, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PATHOL, OXFORD OX3 9DU, ENGLAND	University of London; University College London; University of Oxford	Festenstein, R (corresponding author), NATL INST MED RES, DIV MOLEC IMMUNOL, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.				Telethon [TGT95000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CARSON S, 1993, NUCLEIC ACIDS RES, V21, P2065, DOI 10.1093/nar/21.9.2065; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DIAZ P, 1994, IMMUNITY, V1, P207, DOI 10.1016/1074-7613(94)90099-X; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; ELLIOTT JI, 1995, EMBO J, V14, P575, DOI 10.1002/j.1460-2075.1995.tb07033.x; FESTENSTEIN R, UNPUB; GHARIB B, 1993, ANN HUM GENET, V57, P9, DOI 10.1111/j.1469-1809.1993.tb00882.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; KARPEN GH, 1992, GENETICS, V132, P737; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORETTA A, 1986, EUR J IMMUNOL, V16, P1427, DOI 10.1002/eji.1830161118; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PARRINGTON J, UNPUB; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRAVTCHEVA DD, 1994, J EXP ZOOL, V268, P452, DOI 10.1002/jez.1402680606; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANOPOULOU E, 1990, THESIS U LONDON; VERBI W, 1982, EUR J IMMUNOL, V12, P81, DOI 10.1002/eji.1830120115; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819	39	303	313	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 23	1996	271	5252					1123	1125		10.1126/science.271.5252.1123	http://dx.doi.org/10.1126/science.271.5252.1123			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599090				2022-12-24	WOS:A1996TW70100040
J	Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI				Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI			Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPRESSION; LOCUS; GENE	Objective.-To characterize the presence and behavior of the dystrophinopathic myocardial damage in female carriers of a gene defect at the Xp21 locus of the X chromosome that causes Duchenne and Becker muscular dystrophies (DMD and BMD). Design.-Cohort study from April 1, 1985, to April 30, 1995, with cardiologic follow-up performed yearly for a minimum of 3 to a maximum of 10 years. Setting.-Counseling center for genetic muscular disorders, Patients.-A total of 197 women and girls aged 5 to 60 years ascertained to be carriers of the DMD (n=152) or BMD (n=45) gene. Main Outcome Measures.-Cardiac status at yearly examinations as determined by 12-lead electrocardiogram (ECG), 24-hour ambulatory ECG, M-mode and 2-dimensional echocardiography, and carotid pulse tracing. Myocardial scintigram was performed on each individual at least twice during the study, Immunohistochemical analysis of dystrophin from myocardium and/or skeletal muscle biopsy was performed in 12 carriers. Results.-Preclinical or clinically evident myocardial involvement was found in 166 cases (84.3%), without significant differences in percentage and behavior between DMD and BMD carriers. Its occurrence increased significantly with age, from 54.5% (18 cases) in carriers aged between 5 and 16 years to 90.2% (148 cases) in carriers older than 16 years. Dystrophin anomalies were detected at the membrane level of the myocardial fibers in all endomyocardial biopsy specimens. Conclusions.-Genetic anomalies can be considered the primary cause of myocardial damage in carriers of dystrophinopathic myopathies; myocardial damage shows the same behavior already described in DMD and BMD patients and progresses from preclinical to dilated cardiomyopathy, passing through stages of myocardial hypertrophy or dysrhythmias.	UNIV NAPLES 2,DEPT INTERNAL & EXPT MED,CARDIOMYOL & GENET SECT,NAPLES,ITALY; UNIV NAPLES 2,INST GEN PATHOL & ONCOL,NAPLES,ITALY; UNIV NAPLES,ENVIRONM PATHOL INTERUNIV CTR,NAPLES,ITALY; UNIV NAPLES,INTERDEPT CTR GENET IMMUNOL & CARDIOVASC DIS,NAPLES,ITALY	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Naples Federico II; University of Naples Federico II			Nigro, Vincenzo/AAB-2274-2022; POLITANO, LUISA/AAK-6885-2020	Nigro, Vincenzo/0000-0002-3378-5006	Telethon [287] Funding Source: Medline	Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BRAUNWALD E, 1994, HEART DISEASE TXB CA; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; COMI LI, 1993, ACTA CARDIOMIOL, V1, P117; COMI LI, 1991, ACTA CARDIOMIOL, V3, P35; DEVISSER M, 1992, MUSCLE NERVE, V15, P591, DOI 10.1002/mus.880150510; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; EMERY AH, 1990, PRINCIPLES PRACTICE; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; ISHIKAWA Y, 1995, SEMIN NEUROL, V15, P93, DOI 10.1055/s-2008-1041013; KAMAKURA K, 1990, J NEUROL, V237, P483, DOI 10.1007/BF00314767; LANE RJM, 1980, NEUROLOGY, V30, P497, DOI 10.1212/WNL.30.5.497; LIMONGELLI FM, 1982, CARDIOMYOLOGY, V1, P105; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NIGRO G, 1983, MUSCLE NERVE, V6, P253, DOI 10.1002/mus.880060403; NIGRO G, 1995, MUSCLE NERVE, V18, P283, DOI 10.1002/mus.880180304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; NIGRO G, 1994, NEUROMUSCULAR DISORD, V4, P371, DOI 10.1016/0960-8966(94)90073-6; NIGRO G, 1995, ANN NY ACAD SCI, V752, P108, DOI 10.1111/j.1749-6632.1995.tb17412.x; NIGRO G, 1976, P 7 EUR C CARD AMST, P421; Nigro G., 1984, CARDIOMYOLOGY, V3, P45; NIGRO V, 1994, HUM MOL GENET, V3, P1907, DOI 10.1093/hmg/3.10.1907; NIGRO V, 1992, HUM MOL GENET, V1, P517, DOI 10.1093/hmg/1.7.517; PERLOFF JK, 1992, J CARDIOVASC ELECTR, V3, P394, DOI 10.1111/j.1540-8167.1992.tb00982.x; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; Politano L, 1986, CARDIOMYOLOGY, V5, P139; POLITANO L, 1993, 5EME C NAT MAL NEUR; SALZER HR, 1984, CARDIOMYOLOGY, V3, P23; STEARE SE, 1992, BRIT HEART J, V68, P304; TOWBIN JA, 1990, PEDIATR RES, V27, pA25; WIEGAND V, 1984, Z KARDIOL, V73, P188	34	147	150	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1335	1338		10.1001/jama.275.17.1335	http://dx.doi.org/10.1001/jama.275.17.1335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614119				2022-12-24	WOS:A1996UG61200030
J	Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ				Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ			Human minisatellite mutation rate after the Chernobyl accident	NATURE			English	Article							IONIZING-RADIATION; HUMAN DNA; CHILDREN; LENGTH; LOCI	Germline mutation at human minisatellite loci has been studied among children horn in heavily polluted areas of the Mogilev district of Belarus after the Chernobyl accident and in a control population. The frequency of mutation was found to be twice as high in the exposed families as in the control group. Mutation rate in the Mogilev families was correlated with the level of caesium-137 surface contamination, consistent with radiation induction of germline mutation.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, LEICS, ENGLAND; RES INST RADIAT MED, MOGILYOV 212004, BELARUS	University of Leicester			Dubrova, Yuri/ABA-7148-2020	Neil, David/0000-0002-9994-9536; Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOCHKOV NP, 1993, VESTN ROS AKAD MED+, P51; CROMPTON NEA, 1990, RADIAT RES, V124, P300, DOI 10.2307/3577843; DROSDOVITCH VV, 1989, PROGNOSIS DOSES EXPO; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FAN YF, 1995, NT J RAD BIOL, V68, P177; GIVER CR, 1995, CARCINOGENESIS, V16, P267, DOI 10.1093/carcin/16.2.267; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1991, AM J HUM GENET, V48, P824; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KENIGSBERG YE, 1994, CHERNOBYL DISASTER M, P18; KIEFER J, 1988, RADIAT RES, V113, P71, DOI 10.2307/3577181; KODAIRA M, 1995, AM J HUM GENET, V57, P1275; LAZJUK GI, 1993, CHERNOBYL PAPERS, V1, P385; LAZYUK GI, 1994, GENETIKA+, V30, P1268; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LUNING KG, 1971, MUTAT RES, V12, P291, DOI 10.1016/0027-5107(71)90017-0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NEEL JV, 1988, AM J HUM GENET, V42, P663; NEEL JV, 1990, AM J HUM GENET, V46, P1053; NEEL JV, 1980, P 14 INT C GEN MIR, V1, P235; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; ORLOV MY, 1992, ATOM ENERGY+, V72, P334, DOI 10.1007/BF00760881; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	31	315	337	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					683	686		10.1038/380683a0	http://dx.doi.org/10.1038/380683a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614461				2022-12-24	WOS:A1996UG82700040
J	Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T				Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T			Essential role of the posterior morphogen nanos for germline development in Drosophila	NATURE			English	Article							POLE CELL-FORMATION; MATERNAL GENE; BODY PATTERN; EMBRYO; PLASM; SEGMENTATION; ANTERIOR; OSKAR; ANTEROPOSTERIOR; MELANOGASTER	IN many animal groups, factors required for germline formation are localized in germ plasm(1), a region of the egg cytoplasm, In Drosophila embryos, germ plasm is located in the posterior pole region and is inherited in pole cells, the germline progenitors. Transplantation experiments have demonstrated that germ plasm contains factors that can form germline(2-4), and germ plasm also directs abdomen formation(5). Genetic analysis has shown that a common mechanism directs the localization of the abdomen and germline-forming factors to the posterior pole(6-12). The critical factor for abdomen formation is the nanos (nos) protein (nanos)(13-15). Here we show that nos is also essential for germline formation in Drosophila; pole cells lacking nanos activity fail to migrate into the gonads, and so do not become functional germ cells. In such pole cells, gene expression, which normally initiates within the gonad, begins prematurely during pole cell migration. Premature activation of genes in germline precursors may mean that these cells fail to develop normally. A function for nos protein in Drosophila germline formation is compatible with observations of its association with germ plasm in other animals(16-18).	UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	Kobayashi, S (corresponding author), UNIV TSUKUBA, INST BIOL SCI, GENE EXPT CTR, TSUKUBA, IBARAKI 305, JAPAN.		Yamada, Masashi/AAI-1059-2020; Yamada, Masashi/AAQ-1314-2021	Yamada, Masashi/0000-0002-8660-1653; Asaoka, Miho/0000-0001-5591-8626				BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CURTIS D, 1995, DEVELOPMENT, V121, P1899; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KOBAYASHI S, 1993, BIOTECH HISTOCHEM, V68, P237, DOI 10.3109/10520299309104704; KOBAYASHI S, 1993, DEVELOPMENT, V117, P885; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	239	251	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					708	711		10.1038/380708a0	http://dx.doi.org/10.1038/380708a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614464				2022-12-24	WOS:A1996UG82700050
J	Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G				Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G			A follow up study of depression in the carers of dementia sufferers	BRITISH MEDICAL JOURNAL			English	Article									YARDLEY GREEN HOSP,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; REASIDE CLIN,BIRMINGHAM B45 9BE,W MIDLANDS,ENGLAND; FRENCHAY HOSP,BRISTOL BS16 1LE,AVON,ENGLAND		Ballard, CG (corresponding author), NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				BALLARD CG, 1995, INT J GERIATR PSYCH, V10, P477, DOI 10.1002/gps.930100607; COOPE B, 1995, INT J GERIATR PSYCH, V10, P237, DOI 10.1002/gps.930100310; COSTELLO CG, 1990, BR J PSYCH, V157, P612; MORRIS RG, 1988, BRIT J PSYCHIAT, V153, P147, DOI 10.1192/bjp.153.2.147; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583	5	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					947	947						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616308				2022-12-24	WOS:A1996UF65900020
J	CastroAlamancos, MA; Connors, BW				CastroAlamancos, MA; Connors, BW			Short-term plasticity of a thalamocortical pathway dynamically modulated by behavioral state	SCIENCE			English	Article							AUGMENTING RESPONSES; NEURONS; CAT; RAT; NEOCORTEX; CORTEX; NOREPINEPHRINE; POTENTIALS	The neocortex receives information about the environment and the rest of the brain through pathways from the thalamus. These pathways have frequency-dependent properties that can strongly influence their effect on the neocortex. In 1943 Morison and Dempsey described "augmenting responses," a form of short-term plasticity in some thalamocortical pathways that is triggered by 8- to 15-hertz activation. Results from anesthetized rats showed that the augmenting response is initiated by pyramidal cells in layer V. The augmenting response was also observed in awake, unrestrained animals and was found to be dynamically modulated by their behavioral state.			CastroAlamancos, MA (corresponding author), BROWN UNIV, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157; Castro-Alamancos, Manuel/0000-0002-2916-9585	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025983] Funding Source: NIH RePORTER; NIMH NIH HHS [MH19118] Funding Source: Medline; NINDS NIH HHS [NS25983] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGMON A, 1992, J NEUROSCI, V12, P319; ASTONJONES G, 1981, J NEUROSCI, V1, P876; CASTROALAMANCOS MA, 1993, NEUROSCIENCE, V52, P637, DOI 10.1016/0306-4522(93)90412-9; CastroAlamancos MA, 1996, J NEUROSCI, V16, P2767; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Cooper J.R., 1991, BIOCH BASIS NEUROPHA; Dempsey EW, 1943, AM J PHYSIOL, V138, P0283, DOI 10.1152/ajplegacy.1943.138.2.283; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; GLENN LL, 1982, NEUROSCIENCE, V7, P1861, DOI 10.1016/0306-4522(82)90003-3; HERKENHAM M, 1980, SCIENCE, V207, P532, DOI 10.1126/science.7352263; Herkenham M., 1986, CEREB CORTEX, V5, P403; JONES EG, 1986, CEREBRAL CORTEX, V5; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; MORIN D, 1981, BRAIN RES, V205, P49, DOI 10.1016/0006-8993(81)90719-8; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Paxinos G., 2004, J CHEM INF MODEL, V5th; PURPURA DP, 1964, J NEUROPHYSIOL, V27, P117, DOI 10.1152/jn.1964.27.2.117; SASAKI K, 1970, Experimental Neurology, V26, P369, DOI 10.1016/0014-4886(70)90133-0; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; SOMOGYI P, 1990, NEURAL MECHANISMS VI, P35; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P26, DOI 10.1152/jn.1961.24.1.26; STERIADE M, 1969, J NEUROPHYSIOL, V32, P251, DOI 10.1152/jn.1969.32.2.251; STERIADE M, 1981, BRAIN RES, V205, P67, DOI 10.1016/0006-8993(81)90720-4; Steriade M., 1990, THALAMIC OSCILLATION; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WANG Z, 1993, J NEUROSCI, V13, P2199; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	31	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					274	277		10.1126/science.272.5259.274	http://dx.doi.org/10.1126/science.272.5259.274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602513				2022-12-24	WOS:A1996UE72900043
J	Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A				Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A			Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; STEM-CELLS; MICE; ANGIOGENESIS; EXPRESSION; GENE; VASCULOGENESIS; RECEPTOR	THE endothelial cell-specific vascular endothelial growth factor (VEGF)(1-5) and its cellular receptors Flt-1 (refs 6,7) and Flk-1 (refs 8,9) have been implicated in the formation of the embryonic vasculature. This is suggested by their colocalized expression during embryogenesis(10,11) and the impaired vessel formation in Flk-1 (ref. 12) and Flt-1 (ref. 13) deficient embryos. However, because Flt-1 also binds placental growth factor(14,15), a VEGF homologue, the precise role of VEGF was unknown. Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF(+/-)) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES)(16,17), and more impaired in homozygous VEGF-deficient (VEGF(-/-)) T-ES embryos, resulting in death at mid-gestation. Similar phenotypes were observed in F-1-VEGF(+/-) embryos, generated by germline transmission. We believe that this heterozygous lethal phenotype, which differs from the homozygous lethality in VEGF-receptor-deficient embryos, is unprecedented for a targeted autosomal gene inactivation, and is indicative of a tight dose-dependent regulation of embryonic vessel development by VEGF.	MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, ABT MOL ZELLBIOL, BAD NAUHEIM, GERMANY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A1, CANADA	Max Planck Society; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Carmeliet, P (corresponding author), CATHOLIC UNIV LEUVEN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM.		Nagy, Andras/G-6465-2013; Breier, Georg/E-3580-2016; Carmeliet, Peter/AAQ-5140-2020	Nagy, Andras/0000-0003-4311-0413; Breier, Georg/0000-0002-9467-780X; Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9276; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAGY A, 1994, GENE TARGETING PRACT, P147; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	28	3150	3324	2	147	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					435	439		10.1038/380435a0	http://dx.doi.org/10.1038/380435a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602241				2022-12-24	WOS:A1996UD59000061
J	Sawatari, A; Callaway, EM				Sawatari, A; Callaway, EM			Convergence of magno- and parvocellular pathways in layer 4B of macaque primary visual cortex	NATURE			English	Article							SLICES; PARALLEL	EARLY visual processing is characterized by two independent parallel pathways: the magnocellular stream, which carries information useful for motion analysis, and the parvocellular stream, which carries information useful for analyses of shape and colour(1-3). Although increasing anatomical and physiological evidence indicates some degree of convergence of the two streams, the pathway through layer 4B of primary visual cortex (V1) and on to higher cortical areas is usually considered to carry only magnocellular input(1-3). This is inferred from anatomical descriptions of local circuitry in V1, and functional studies of area MT, which receives input from layer 4B(4-7). We have directly measured the sources of local functional input to individual layer 4B neurons by combining intracellular recording and biocytin labelling with laser-scanning photostimulations(8-10). We found that most layer 4B neurons receive strong input from both magnocellular-stream-recipient layer 4C alpha neurons and parvocellular-stream-recipient layer 4C beta neurons. Thus higher cortical areas that receive input either directly or indirectly from layer 4B are likely to be more strongly influenced by the parvocellular pathway than previously believed.			Sawatari, A (corresponding author), SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Callaway, Edward/D-4336-2011	Callaway, Edward/0000-0002-6366-5267				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Van Essen D. C., 1994, COGNITIVE NEUROSCIEN; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; YOSHIOKA T, 1994, VISUAL NEUROSCI, V11, P467, DOI 10.1017/S0952523800002406	15	129	133	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					442	446		10.1038/380442a0	http://dx.doi.org/10.1038/380442a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602243				2022-12-24	WOS:A1996UD59000063
J	Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T				Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T			Direct observation of single kinesin molecules moving along microtubules	NATURE			English	Article							HEAVY-CHAIN; MOVEMENT; DOMAIN; MOTOR; EXPRESSION	KINESIN is a two-headed motor protein that powers organelle transport along microtubules(1). Many ATP molecules are hydrolysed by kinesin for each diffusional encounter with the microtubule(2,3). Here we report the development of a new assay in which the processive movement of individual fluorescently labelled kinesin molecules along a microtubule can be visualized directly; this observation is achieved by low-background total internal reflection fluorescence microscopy(4) in the absence of attachment of the motor to a cargo (for example, an organelle or bead). The average distance travelled after a binding encounter with a microtubule is 600 nm, which reflects a similar to 1% probability of detachment per mechanical cycle, Surprisingly, processive movement could still be observed at salt concentrations as high as 0.3 M NaCl. Truncated kinesin molecules having only a single motor domain do not show detectable processive movement, which is consistent with a model in which kinesin's two force-generating heads operate by a hand-over-hand mechanism.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Osaka University	Vale, RD (corresponding author), RES DEV CORP JAPAN,ERATO,YANAGIDA BIOMOTRON PROJECT,SENBA HIGASHI 2-4-14,MINO,OSAKA 562,JAPAN.		Funatsu, Takashi/Q-1404-2015; Yanagida, Toshio/D-1919-2009	Funatsu, Takashi/0000-0002-9656-8308; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895, P01 AR042895-040005] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1994, J BIOL CHEM, V269, P23769; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	579	617	0	108	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					451	453		10.1038/380451a0	http://dx.doi.org/10.1038/380451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602245	Green Accepted			2022-12-24	WOS:A1996UD59000065
J	Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P				Nantel, F; Monaco, L; Foulkes, NS; Masquilier, D; LeMeur, M; Henriksen, K; Dierich, A; Parvinen, M; SassoneCorsi, P			Spermiogenesis deficiency and germ-cell apoptosis in CREM-mutant mice	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; MOUSE PROTAMINE-1; PROTEIN; SPERMATOGENESIS; TRANSCRIPTION; EXPRESSION; ACTIVATOR; DIRECTS; SWITCH; GENES	Spermiogenesis is a complex process by which postmeiotic male germ cells differentiate into mature spermatozoa. This process involves remarkable structural and biochemical changes including nuclear DNA compaction and acrosome formation(1,2). Transcriptional activator CREM (cyclic AMP-responsive element modulator) is highly expressed in postmeiotic cells(3-5), and CREM may be responsible for the activation of several haploid germ cell-specific genes involved in the structuring of the spermatozoon(5-7). The specific role of CREM in spermiogenesis was addressed using CREM-mutant mice generated by homologous recombination. Analysis of the seminiferous epithelium in mutant male mice reveals postmeiotic arrest at the first step of spermiogenesis. Late spermatids are completely absent, and there is a significant increase in apoptotic germ cells. We show that CREM deficiency results in the lack of postmeiotic cell-specific gene expression. The complete lack of spermatozoa in the mutant mice is reminiscent of cases of human infertility.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; TURKU UNIV,DEPT ANAT,SF-20520 TURKU,FINLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Turku			Foulkes, Nicholas S/K-7003-2013; Monaco, Lucia/A-4031-2010	Foulkes, Nicholas S/0000-0002-1794-9891; 				BABA T, 1994, J BIOL CHEM, V269, P10133; CHAGANTI RSK, 1979, AM J HUM GENET, V31, P634; CHEVRIER P, 1988, EMBO J, V7, P29; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; HENRIKSEN K, 1995, INT J ANDROL, V18, P256, DOI 10.1111/ijan.1995.18.5.256; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KISTLER MK, 1994, BIOL REPROD, V51, P1322, DOI 10.1095/biolreprod51.6.1322; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; LALLI E, 1994, J BIOL CHEM, V269, P17356; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MICIC M, 1992, HUM REPROD, V7, P1118, DOI 10.1093/oxfordjournals.humrep.a137804; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; PARVINEN M, 1981, HISTOCHEMISTRY, V71, P567, DOI 10.1007/BF00508382; PARVINEN M, 1982, ENDOCR REV, V3, P404, DOI 10.1210/edrv-3-4-404; PEREY B, 1961, AM J ANAT, V108, P47, DOI 10.1002/aja.1001080105; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Rubin M R, 1991, DNA Seq, V1, P329, DOI 10.3109/10425179109020787; Santen R. J., 1987, ENDOCRINOL METAB, P821; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418	30	477	494	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 14	1996	380	6570					159	162		10.1038/380159a0	http://dx.doi.org/10.1038/380159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TZ978	8600390				2022-12-24	WOS:A1996TZ97800051
J	Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA				Johnson, AE; Gordon, C; Hobbs, FDR; Bacon, PA			Undiagnosed systemic lupus erythematosus in the community	LANCET			English	Article							POPULATION	Background Systemic lupus erythematosus (SLE) produces a wide range of symptoms, some of them mild; therefore it may be underdiagnosed. In a pilot study we tested the ability of a screening questionnaire to identify undiagnosed cases in the community. Methods A 10-item questionnaire was mailed to 3500 women aged 18-65 randomly selected from a general practice list in Birmingham, UK. A random sample of 300 non-respondents were sent two further mailings, Women returning the questionnaire with three positive answers were to attend for an antinuclear antibody (ANA) test; and those testing positive were to be referred to a rheumatologist for standard clinical assessment. Findings 1153 (30%) of the women responded, and 307 of these gave three or more positive answers on the questionnaire, The survey disclosed three women with previously undiagnosed SLE; and, in addition, it picked up all four of the women whose SLE had been diagnosed previously. Interpretation The prevalence of SLE revealed by this survey in Birmingham women is 200/100 000 (95% confidence interval 80 to 412), whereas the prevalence of diagnosed SLE in this age group is 54/100 000 (95% CI 47-62). Thus, a substantial number of undiagnosed cases exist, and further work needs to focus on the prevalence in different ethnic groups and the benefits of early diagnosis and treatment.	UNIV BIRMINGHAM,FAC MED & DENT,DEPT RHEUMATOL,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,FAC MED & DENT,DEPT GEN PRACTICE,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham				hobbs, richard/0000-0001-7976-7172; Gordon, Caroline/0000-0002-1244-6443				Balarajan R, 1991, Health Trends, V23, P90; CHANG NC, 1983, J RHEUMATOL, V10, P41; CHOU CT, 1986, J RHEUMATOL, V13, P806; HAYNES RB, 1988, CAN MED ASSOC J, V124, P703; HOCHBERG MC, 1983, CLIN EXP RHEUMATOL, V1, P67; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; JOHNSON AE, 1993, BRIT J RHEUMATOL, V32, P30; LIANG MH, 1980, ARTHRITIS RHEUM-US, V23, P153, DOI 10.1002/art.1780230204; MCINNES PM, 1994, ARTHRITIS RHEUM, V37, P1000, DOI 10.1002/art.1780370704; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	10	45	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 10	1996	347	8998					367	369		10.1016/S0140-6736(96)90539-5	http://dx.doi.org/10.1016/S0140-6736(96)90539-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU695	8598703				2022-12-24	WOS:A1996TU69500011
J	Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E				Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E			Neglected aspects of false positive findings of mammography in breast cancer screening: Analysis of false positive cases from the Stockholm trial	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; MORTALITY; WOMEN	Objectives-To examine the implications of false positive results of mammography in terms of the time lag from screening and complete mammography to the point when women with false positive results are declared free of cancer; the extra examinations, biopsies, and check ups required; and the cost of these extra procedures. Design-Review of women with false positive results from the Stockholm mammography screening trial. Setting-Department of Oncology, South Hospital, Stockholm. Subjects-352 and 150 women with false positive results of mammography from the first and second screening rounds of the Stockholm trial. Main outcome measures-Extra examinations and investigations required and the cost of these procedures. Results-The 352 women from the first screening round made 1112 visits to the physician and had 397 fine needle aspiration biopsies, 187 mammograms, and 90 surgical biopsies before being declared free of cancer. After six months 64% of the women (219/342) were declared cancer free. The 150 women in the second round made 427 visits to the physician and had 145 fine needle aspiration biopsies, 70 mammograms, and 28 surgical biopsies, and after six months 73% (107/147) were declared cancer free. The follow up costs of the false positive screening results were Kr2.54m (pound 250 000) in the first round and Kr0.85m (pound 84 000) in the second round. Women under 50 accounted for about 41% of these costs. Conclusions-The examinations and investigations carried out after false positive mammography-especially in women under 50-and the cost of these procedures are a neglected but substantial problem.	SODER SJUKHUSET,STOCKHOLM,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED,STOCKHOLM,SWEDEN	Sodersjukhuset Hospital; Karolinska Institutet								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1981, RADIOLOGY, V138, P59, DOI 10.1148/radiology.138.1.7455098; BROWN ML, 1992, J GERONTOL, V47, P51; BROWN ML, 1992, CANCER-AM CANCER SOC, V69, P1963, DOI 10.1002/1097-0142(19920401)69:7+<1963::AID-CNCR2820691717>3.0.CO;2-0; COCKBURN J, 1992, SOC SCI MED, V34, P1129, DOI 10.1016/0277-9536(92)90286-Y; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEVITT JE, 1989, LANCET, V2, P1257; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; Erichsen G G, 1990, Nord Med, V105, P64; FENTIMAN IS, 1988, LANCET, V1, P1041; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; FRISELL J, 1989, BREAST CANCER RES TR, V13, P79, DOI 10.1007/BF01806553; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; KOPANS DB, 1987, AJR AM J ROENTGENOL, V150, P785; Lerman C E, 1993, Oncology (Williston Park), V7, P67; LIDBRINK EK, 1994, ACTA ONCOL, V33, P353, DOI 10.3109/02841869409098428; MCLELLAND R, 1992, RADIOL CLIN N AM, V30, P235; MILLER AB, 1993, AM J PREV MED, V9, P175, DOI 10.1016/S0749-3797(18)30734-7; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; NIELSEN M, 1984, CANCER, V43, P107; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OKUBO I, 1991, CANCER, V67, P2021, DOI 10.1002/1097-0142(19910415)67:8<2021::AID-CNCR2820670802>3.0.CO;2-L; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; Skrabanek P, 1991, Int J Technol Assess Health Care, V7, P633; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Van Der Maas PJ, 1989, INT J CANCER, V43, P1055, DOI 10.1002/ijc.2910430617; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, MAMMOGRAFISCREENING, V3, P1	33	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					273	276						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611781				2022-12-24	WOS:A1996TU50700019
J	Annas, GJ; Caplan, A; Elias, S				Annas, GJ; Caplan, A; Elias, S			The politics of human-embryo research - Avoiding ethical gridlock	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118; UNIV PENN,CTR BIOETH,PHILADELPHIA,PA 19104; BAYLOR COLL MED,HOUSTON,TX 77030	Boston University; University of Pennsylvania; Pennsylvania Medicine; Baylor College of Medicine	Annas, GJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; CAMPBELL CS, 1995, HASTINGS CENT REP, V25, P44, DOI 10.2307/3562495; CARSON SA, 1995, CONTEMP OBSTET GYNEC, V40, P71; CHARO A, 1995, STANFORD LAW POLICY, V6, P2; COREA G, 1985, MOTHER MACHINE, P178; COWLEY G, 1995, NEWSWEEK        0612, P66; HEALY BP, 1995, J WOMENS HLTH, V4, P609; MORGAN D, 1995, WASH POST       1103, pA1; National Institute of Health, 1994, REP HUM EMBR RES PAN; NIEBUHR G, 1996, NY TIMES        0417, pA19; Purdum Todd S, 1996, N Y Times Web, pB10; ROBERTSON JA, 1995, HASTINGS CENT REP, V25, P37, DOI 10.2307/3562492; Schwartz John, 1994, WASH POST       0803	13	47	47	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1329	1332		10.1056/NEJM199605163342012	http://dx.doi.org/10.1056/NEJM199605163342012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK880	8609955	Green Published			2022-12-24	WOS:A1996UK88000012
J	Williams, PT				Williams, PT			High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; DISTANCE RUNNERS; ALCOHOL INTAKE; UNITED-STATES; FOLLOW-UP; WOMEN; EXERCISE; PREMENOPAUSAL; SUBFRACTIONS	Background. Official guidelines from the Centers for Disease Control and Prevention assert that the majority of health benefits from physical activity are obtained by walking 2 miles (3.2 km) briskly most days of the week (the energy equivalent of running 8 to 12 km per week). The objective of our study was to examine the dose-response relation in women between risk factors for coronary heart disease, particularly the concentration of high-density lipoprotein (HDL) cholesterol, and vigorous exercise at levels that exceed the official guidelines. Methods. The number of kilometers run per week reported by 1837 female recreational runners in a national cross-sectional survey was compared with medical data provided by the women's physicians. Results. In these cross-sectional data, plasma HDL cholesterol concentrations were higher by an average (+/-SE) of 0.133+/-0.020 mg per deciliter (0.003+/-0.0005 mmol per liter) for every additional kilometer run per week, an amount nearly identical with that previously reported for men (0.136+/-0.006 mg per deciliter [0.004+/-0.0002 mmol per liter] per kilometer per week). Among women who ran less than 48 km per week, mean plasma HDL concentrations were significantly higher with each 16-km increment in distance. Women who ran more than 64 km per week had significantly higher mean concentrations of HDL cholesterol than did women who ran less than 48 km per week. They were also significantly more likely to have HDL cholesterol concentrations greater than 100, 90, or 80 mg per deciliter (2.6, 2.3, or 2.1 mmol per liter) than were women running less than 64 km per week. HDL cholesterol concentrations increased significantly in relation to the number of kilometers run per week in premenopausal women who were not using oral contraceptives and in postmenopausal women, whether they were receiving estrogen-replacement therapy or not. Conclusions. Substantial increases in HDL cholesterol concentrations were found in women who exercised at levels exceeding current guidelines; higher HDL cholesterol concentrations could provide added health benefits to these women.			Williams, PT (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BLDG 934,BERKELEY,CA 94720, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL045652, R01HL045652, R03HL055640] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45652, HL-55640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, GUID EX TEST PRESCR; BLUMENTHAL JA, 1991, ARTERIOSCLER THROMB, V11, P912, DOI 10.1161/01.ATV.11.4.912; BROWNELL KD, 1982, CIRCULATION, V65, P477, DOI 10.1161/01.CIR.65.3.477; BRUNNER D, 1987, AM J CARDIOL, V59, P1271, DOI 10.1016/0002-9149(87)90903-9; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; FULLER WA, 1987, MEASUREMENT ERROR MO, P4; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; HARTING GH, 1984, EXP AGING RES, V10, P13, DOI 10.1080/03610738408258535; HARTUNG GH, 1986, AM J CARDIOL, V58, P148, DOI 10.1016/0002-9149(86)90259-6; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KAISERAUER S, 1989, MED SCI SPORT EXER, V21, P120; KRUMMEL D, 1993, P SOC EXP BIOL MED, V204, P123; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LaRosa J C, 1992, Womens Health Issues, V2, P102, DOI 10.1016/S1049-3867(05)80278-6; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LINDHEIM SR, 1994, OBSTET GYNECOL, V83, P167; LOKEY EA, 1989, INT J SPORTS MED, V10, P424, DOI 10.1055/s-2007-1024937; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Miller RG, 1986, ANOVA BASICS APPL ST; MOORE CE, 1983, METABOLISM, V32, P189, DOI 10.1016/0026-0495(83)90228-7; MORGAN DW, 1986, PHYSICIAN SPORTSMED, V14, P166, DOI 10.1080/00913847.1986.11709017; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PODL TR, 1994, METABOLISM, V43, P808, DOI 10.1016/0026-0495(94)90258-5; RAINVILLE S, 1984, INT J SPORTS MED, V5, P137, DOI 10.1055/s-2008-1025895; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SEIDELL JC, 1990, INT J EPIDEMIOL, V19, P303, DOI 10.1093/ije/19.2.303; STAMFORD BA, 1984, METABOLISM, V33, P585, DOI 10.1016/0026-0495(84)90053-2; SUTER E, 1992, J SPORT MED PHYS FIT, V32, P400; UPTON SJ, 1984, MED SCI SPORT EXER, V16, P67; WILLIAMS PT, 1982, JAMA-J AM MED ASSOC, V247, P2674, DOI 10.1001/jama.247.19.2674; WILLIAMS PT, 1992, ARTERIOSCLER THROMB, V12, P332, DOI 10.1161/01.ATV.12.3.332; WILLIAMS PT, 1993, ATHEROSCLEROSIS, V98, P251, DOI 10.1016/0021-9150(93)90134-G; WILLIAMS PT, 1994, METABOLISM, V43, P917, DOI 10.1016/0026-0495(94)90277-1; WILLIAMS PT, 1995, JAMA-J AM MED ASSOC, V274, P533, DOI 10.1001/jama.1995.03530070031016; WILLIAMS PT, 1994, CIRCULATION, V90, P471; Wood P D, 1977, Ann N Y Acad Sci, V301, P748, DOI 10.1111/j.1749-6632.1977.tb38244.x; 1995, MMWR-MORBID MORTAL W, V44, P105; 1995, MMWR-MORBID MORTAL W, V44, P113	41	129	131	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1298	1303		10.1056/NEJM199605163342004	http://dx.doi.org/10.1056/NEJM199605163342004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609947				2022-12-24	WOS:A1996UK88000004
J	Ames, R				Ames, R			Angioplasty for renal artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ATHEROSCLEROTIC RENOVASCULAR DISEASE; PULMONARY-EDEMA; HYPERTENSION; INSUFFICIENCY; CAPTOPRIL; FAILURE				Ames, R (corresponding author), ST LUKES ROOSEVELT HOSP, DEPT MED, NEW YORK, NY 10025 USA.							DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DIAMOND JR, 1993, AM J KIDNEY DIS, V21, P328, DOI 10.1016/S0272-6386(12)80756-6; GRIM CE, 1981, ANN INTERN MED, V95, P439, DOI 10.7326/0003-4819-95-4-439; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; MISSOURIS CG, 1993, LANCET, V341, P1521, DOI 10.1016/0140-6736(93)90645-W; MIYAMORI I, 1988, AM J HYPERTENS, V1, P359, DOI 10.1093/ajh/1.4.359; *NIH NAT I DIAB DI, 1991, US REN DAT SYST 1991, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; PICKERING TG, 1987, CIRCULATION, V76, P274; Pickering Thomas G., 1995, P2039; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RIBSTEIN J, 1988, AM J HYPERTENS, V1, P239, DOI 10.1093/ajh/1.3.239; RIMMER JM, 1993, ANN INTERN MED, V118, P712, DOI 10.7326/0003-4819-118-9-199305010-00010; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; TOLLEFSON DFJ, 1991, J VASC SURG, V14, P327; TOTO RD, 1991, ANN INTERN MED, V115, P513, DOI 10.7326/0003-4819-115-7-513	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1476	1476		10.1001/jama.275.19.1476	http://dx.doi.org/10.1001/jama.275.19.1476			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622210				2022-12-24	WOS:A1996UJ93700016
J	Davis, GL				Davis, GL			Hepatitis C virus infection among health care workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK-FACTORS; PERSONNEL				Davis, GL (corresponding author), UNIV FLORIDA,COLL MED,SECT HEPATOBILIARY DIS,GAINESVILLE,FL 32611, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; COOPER BW, 1992, INFECT CONT HOSP EP, V13, P82, DOI 10.1086/646477; DAVIS GL, 1994, GASTROENTEROL CLIN N, V23, P603; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; HOFMANN H, 1990, INFECTION, V18, P286, DOI 10.1007/BF01647006; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MANIAN FA, 1992, ANN INTERN MED, V116, P345; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1016/0270-9139(92)90001-P; SCHIFF ER, 1992, HEPATOLOGY, V16, P1300	11	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1474	1474		10.1001/jama.275.19.1474	http://dx.doi.org/10.1001/jama.275.19.1474			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622209				2022-12-24	WOS:A1996UJ93700015
J	Lifson, AR				Lifson, AR			Mosquitoes, models, and dengue	LANCET			English	Editorial Material											Lifson, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Horton R, 1996, LANCET, V347, P134, DOI 10.1016/S0140-6736(96)90333-5; LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; LLOYD LS, 1994, AM J TROP MED HYG, V50, P401, DOI 10.4269/ajtmh.1994.50.401; Organizacion Mundial de la Salud (OMS), 1995, DENGUE DENGUE HEMORR, V548; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; 1994, WKLY EPIDEMIOL REV, V69, P177	12	51	56	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1201	1202		10.1016/S0140-6736(96)90730-8	http://dx.doi.org/10.1016/S0140-6736(96)90730-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622446				2022-12-24	WOS:A1996UJ59700005
J	GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG				GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG			A mouse model of familial hypertrophic cardiomyopathy	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; MYOSIN HEAVY-CHAIN	A mouse model of familial hypertrophic cardiomyopathy (FHC) was generated by the introduction of an Arg(403)-->Gln mutation into the alpha cardiac myosin heavy chain (Mwc) gene. Homozygous alpha MHC(403/403) mice died 7 days after birth, and sedentary heterozygous alpha MHC(403/+) mice survived for 1 year. Cardiac histopathology and dysfunction in the alpha MHC(403/+) mice resembled human FHC. Cardiac dysfunction preceded histopathologic changes, and myocyte disarray, hypertrophy, and fibrosis increased with age. Young male alpha MHC(403/+) mice showed more evidence of disease than did their female counterparts. Preliminary results suggested that exercise capacity may have been compromised in the alpha MHC(403/+) mice. This mouse model may help to define the natural history of FHC.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute								CHRISTE M, UNPUB; CHRISTE ME, 1994, AM J PHYSIOL-HEART C, V267, pH2050, DOI 10.1152/ajpheart.1994.267.5.H2050; GEISTERFERLOWRA.AA, UNPUB; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEIS JH, 1994, CURRENT PROTOCOLS MO, pCH5; WYNNE J, 1992, HEART DISEASE TXB CA, P1394; ZHANG W, 1996, J EXP MED, V183, P1	18	411	424	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					731	734		10.1126/science.272.5262.731	http://dx.doi.org/10.1126/science.272.5262.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614836				2022-12-24	WOS:A1996UJ05100054
J	Shah, NM; Groves, AK; Anderson, DJ				Shah, NM; Groves, AK; Anderson, DJ			Alternative neural crest cell fates are instructively promoted by TGF beta superfamily members	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; ACHAETE-SCUTE HOMOLOG-1; SMOOTH-MUSCLE CELL; CLONAL ANALYSIS; GROWTH-FACTORS; NEURONAL DIFFERENTIATION; NERVOUS-SYSTEM; MOUSE EMBRYO; LINEAGE; COMMITMENT	How growth factors influence the fate of multipotent progenitor cells is not well understood. Most hematopoietic growth factors act selectively as survival factors, rather than instructively as lineage determination signals. In the neural crest, neuregulin instructively promotes gliogenesis, but how alternative fates are determined is unclear. We demonstrate that bone morphogenic protein 2 (BMP2) induces the basic-helix-loop-helix protein MASH1 and neurogenesis in neural crest stem cells. In vivo, MASH1(+) cells are located near sites of BMPS mRNA expression. Some smooth muscle differentiation is also observed in BMP2. A related factor, transforming growth factor beta 1 (TGF beta 1), exclusively promotes smooth muscle differentiation. Like neuregulin, BMP2 and TGF beta 1 act instructively rather than selectively. The neural crest and hematopoietic systems may therefore utilize growth factors in different ways to generate cellular diversity.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute				Groves, Andrew/0000-0002-0784-7998	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BRONNERFRASER M, 1993, CURR OPIN GENET DEV, V3, P641, DOI 10.1016/0959-437X(93)90101-T; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIS CB, 1994, CURR OPIN IMMUNOL, V6, P266, DOI 10.1016/0952-7915(94)90100-7; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DICKSON MC, 1993, DEVELOPMENT, V117, P625; DUPIN E, 1995, DEV BIOL, V168, P529, DOI 10.1006/dbio.1995.1100; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Horstadius S., 1950, NEURAL CREST; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; ITO K, 1993, DEV BIOL, V156, P191, DOI 10.1006/dbio.1993.1069; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KIRBY ML, 1987, PEDIATR RES, V21, P219, DOI 10.1203/00006450-198703000-00001; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KRANTZ SB, 1991, BLOOD, V77, P419; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MILLAN FA, 1991, DEVELOPMENT, V111, P131; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; OGAWA M, 1993, BLOOD, V81, P2844; OWENS GK, 1995, PHYSIOL REV, V75, P487; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Sieber-Blum M., 1990, Comments on Developmental Neurobiology, V1, P225; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; SIMPSON P, 1995, NEURON, V15, P739, DOI 10.1016/0896-6273(95)90163-9; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STERN CD, 1991, DEVELOPMENT, V113, P207; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	74	675	707	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					331	343		10.1016/S0092-8674(00)81112-5	http://dx.doi.org/10.1016/S0092-8674(00)81112-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616889	Bronze			2022-12-24	WOS:A1996UK14000007
J	Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D				Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D			A human RNA polymerase II complex associated with SRB and DNA-repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENE	WE report here the isolation of a human RNA polymerase II complex containing a subset of the basal transcription factors and the human homologues of the yeast SRB (for suppressors of RNA polymerase B) proteins(1-3). The complex contains transcriptional coactivators and increases the activation of transcription, In addition, some components of the RNA polymerase II complex participate in DNA repair.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; STANFORD UNIV,DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CHEM,PALO ALTO,CA 94304; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT BIOCHEM,BERKELEY,CA 94720	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERARD M, 1991, J BIOL CHEM, V266, P20940; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HWANG PI, 1995, FASEB J, V9, pA1398; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LESSMILLER SP, 1995, SCIENCE, V267, P1183; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OSSIPOW, 1995, CELL, V83, P137; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THOMPSON GM, 1995, P NATL ACAD SCI USA, V92, P4587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0	31	306	314	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					86	89		10.1038/381086a0	http://dx.doi.org/10.1038/381086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609996				2022-12-24	WOS:A1996UJ05300063
J	Arno, PS; Brandt, AM; Gostin, LO; Morgan, J				Arno, PS; Brandt, AM; Gostin, LO; Morgan, J			Tobacco industry strategies to oppose federal regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH		HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115; GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC	Harvard University; Harvard Medical School; Georgetown University	Arno, PS (corresponding author), YESHIVA UNIV,ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; CALIFANO JA, 1994, JAMA-J AM MED ASSOC, V272, P1217; CARTER B, 1995, NY TIMES        1111, pA39; Carter Bill, 1995, NY TIMES        1109, pA1; *CDCP, 1996, CDCP PUBL; COHEN SE, 1964, ADVERTISING AGE, V35, P82; COHEN SE, 1964, ADVERTISING AGE, V35, P1; COLLINS G, 1995, NY TIMES        0218, pD4; FEDER BJ, 1996, NY TIMES        0107; FRANKEL A, 1995, AM LAWYER        JUL, P68; FRITSCHLER AL, 1969, SMOKING POLITICS POL; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V272, P1176, DOI 10.1001/jama.272.15.1176; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Goodin R. E., 1989, NO SMOKING ETHICAL I; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P904, DOI 10.1001/jama.269.7.904; GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; HOVENKAMP H, 1995, YALE J REGUL, V12, P549; JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; KENT C, 1995, AM MED NEWS     0911, P2; KENT C, 1996, AM MED NEWS, V39, P3; MOORE S, 1994, JAMA-J AM MED ASSOC, V272, P1171, DOI 10.1001/jama.272.15.1171; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; NEWBERGER MB, 1963, SMOKE SCREEN TOBACCO; POSNER RA, 1971, BELL J ECON, V2, P22, DOI 10.2307/3003161; Quirk PJ, 1981, IND INFLUENCE FEDERA; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P28; SHEPARD AC, 1995, AM JOURNALISM REV, V17, P47; SHEPARD AM, 1965, AM JOURNALISM REV, V17, P30; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; *TOB I, 1990, ITS LAW TOB PROD RET; *TOB I, 1993, TAX BURD TOB; *US DEPT HHS, 1994, PREV TOB US AM YOUNG; *US DEPT HHS, 1995, PUBL PHS; *US DEPT HHS, 1988, HLTH CONS SMOK NIC A; *US DHEW, 1964, US PHS PUBL, V1103; Warner K, 1995, TOB CONTROL, V4, P180; WATERHOUSE P, 1992, EC IMPACT TOBACCO IN; 1994, MMWR-MORBID MORTAL W, V43, P925; 1964, FED REGISTER, V29, P530; 1984, TIMES           0409, P91; 1995, CANT KICK HABIT TOBA; PUBL L, V8992; 1965, CONSUM REP, V30, P488; 1995, FED REG         1016, V60, P41313	45	22	23	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1258	1262		10.1001/jama.275.16.1258	http://dx.doi.org/10.1001/jama.275.16.1258			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF478	8601958				2022-12-24	WOS:A1996UF47800030
J	Nightingale, SL				Nightingale, SL			Important new safety information for tramadol hydrochloride	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	1996	275	16					1224	1224		10.1001/jama.275.16.1224	http://dx.doi.org/10.1001/jama.275.16.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF478	8601942				2022-12-24	WOS:A1996UF47800008
J	Simske, JS; Kaech, SM; Harp, SA; Kim, SK				Simske, JS; Kaech, SM; Harp, SA; Kim, SK			LET-23 receptor localization by the cell junction protein LIN-7 during C-elegans vulval induction	CELL			English	Article							TUMOR SUPPRESSOR GENE; NEMATODE CAENORHABDITIS-ELEGANS; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; GUANYLATE KINASE; TYROSINE KINASE; DROSOPHILA; EXPRESSION; ENCODES; DISKS	In C. elegans, the anchor cell signal induces Pn.p cells to form the vulva by activating a conserved receptor tyrosine kinase pathway. lin-2 and lin-7 mutants exhibit a vulvaless phenotype similar to the phenotype observed when this signaling pathway is defective. We have found that LIN-7 is a cell junction-associated protein that binds to the LET-23 receptor tyrosine kinase. LET-23 is also localized to the cell junctions, and both LIN-2 and LIN-7 are required for this localization. LET-23 overexpression rescues the lin-2 or lin-7 vulvaless phenotype, suggesting that increased receptor density can compensate for mislocalization. These results suggest that proper localization of LET-23 receptor to the Pn.p cell junctions is required for signaling activity.			Simske, JS (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043977] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM043977-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FEHON R, 1994, DEVELOPMENT, V103, P545; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1980, GENETICS, V96, P435; Hoskins R, 1996, DEVELOPMENT, V122, P97; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOGA M, 1995, DEVELOPMENT, V121, P2655; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook JFE, 1989, MOL CLONING LAB MANU; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wood WB, 1988, NEMATODE CAENORHABDI; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V	46	227	240	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					195	204		10.1016/S0092-8674(00)81096-X	http://dx.doi.org/10.1016/S0092-8674(00)81096-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612272	Bronze			2022-12-24	WOS:A1996UG25500008
J	NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM				NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM			A candidate gene for the mouse mutation tubby	NATURE			English	Article							PHOSPHODIESTERASE	A MUTATION in the tub gene causes maturity-onset obesity, insulin resistance(1), and sensory (d)eficits(2,3). In contrast to the rapid juvenile-onset weight gain seen in diabetes (db) and obese (ob) mice, obesity in tubby mice develops gradually, and strongly resembles the late-onset obesity seen in the human population. Excessive deposition of adipose tissue eventually leads to a twofold increase of body weight. Tubby mice also suffer retinal degeneration and neurosensory hearing loss(2,3). The tripartite character of the tubby phenotype shows striking similarity to human obesity syndromes, such as Alstrom(4) and Bardet-Biedl(5). Here we report the identification of a G --> T transversion in a candidate gene that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. This alteration is predicted to replate the 44-carboxy-terminal amino acids with a 20-amino-acid sequence not found in the wild-type protein. Additionally, a second, prematurely truncated transcript with the unspliced intron is observed in testis messenger RNA and a 2-3-fold increase in brain mRNA is observed in tubby mice compared to B6. The phenotypic features of tubby mice may be the result of cellular apoptosis triggered by expression of the mutated tub gene.	JACKSON LAB,BAR HARBOR,ME 04609; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037	Jackson Laboratory								ALSTROM C H, 1959, Acta Psychiatr Neurol Scand Suppl, V129, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRAY GA, 1995, OBES RES, V3, P383, DOI 10.1002/j.1550-8528.1995.tb00164.x; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LOVETT M, 1994, CURRENT PROTOCOLS HU; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NORTH MA, 1993, MAMM GENOME, V4, P466, DOI 10.1007/BF00364779; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066	20	271	285	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					534	538		10.1038/380534a0	http://dx.doi.org/10.1038/380534a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606774				2022-12-24	WOS:A1996UE66300052
J	Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB				Burns, JW; SiadatPajouh, M; Krishnaney, AA; Greenberg, HB			Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity	SCIENCE			English	Article							INTESTINAL M-CELLS; RHESUS ROTAVIRUS; IMMUNOGLOBULIN-A; INFECTION; RESPONSES; DIARRHEA; PROTEINS; DEFENSE; VIRUS; MODEL	Rotaviruses are the leading cause of severe gastroenteritis and dehydrating diarrhea in young children and animals worldwide. A murine model and ''backpack tumor'' transplantatio n were used to determine the protective effect of anti bod ies against VP4 (an outer capsid viral protein) and VP6 (a major inner capsid viral protein). Only two non-neutralizing immunoglobulin A (IgA) antibodies to VP6 were capable of preventing primary and resolving chronic murine rotavirus infections. These antibodies were not active, however, when presented directly to the luminal side of the intestinal tract. These findings support the hypothesis that in vivo intracellular viral inactivation by secretory IgA during transcytosis is a mechanism of host defense against rotavirus infection.	STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; VET ADM, PALO ALTO HLTH CARE SYST, PALO ALTO, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Burns, JW (corresponding author), STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB SURGE BLDG, ROOM P304, STANFORD, CA 94305 USA.			greenberg, harry/0000-0002-2128-9080	NIAID NIH HHS [R37AI21362] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burns JK., UNPUB; BURNS JW, 1988, J VIROL, V62, P2164, DOI 10.1128/JVI.62.6.2164-2172.1988; BURNS JW, 1995, VIROLOGY, V207, P143, DOI 10.1006/viro.1995.1060; CHIBA S, 1986, LANCET, V2, P417; CHILDERS NK, 1989, ANNU REV MICROBIOL, V43, P503, DOI 10.1146/annurev.mi.43.100189.002443; DHARAKUL T, 1990, J VIROL, V64, P4375, DOI 10.1128/JVI.64.9.4375-4382.1990; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FENG NG, 1994, J VIROL, V68, P7766, DOI 10.1128/JVI.68.12.7766-7773.1994; GLASS RI, 1994, SCIENCE, V265, P1389, DOI 10.1126/science.8073280; HERRMANN JE, IN PRESS ARCH VIROL; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; MACKOW ER, 1988, VIROLOGY, V165, P511, DOI 10.1016/0042-6822(88)90595-8; MACKOW ER, 1988, P NATL ACAD SCI USA, V85, P645, DOI 10.1073/pnas.85.3.645; MATSON DO, 1993, J INFECT DIS, V167, P577, DOI 10.1093/infdis/167.3.577; MATSUI SM, 1989, ADV VIRUS RES, V36, P181; MAZANEC MB, 1992, P NATL ACAD SCI USA, V89, P6901, DOI 10.1073/pnas.89.15.6901; MAZANEC MB, 1995, J VIROL, V69, P1339, DOI 10.1128/JVI.69.2.1339-1343.1995; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; McGhee J R, 1990, Infect Dis Clin North Am, V4, P315; MCNEAL MM, 1995, VIROLOGY, V211, P474, DOI 10.1006/viro.1995.1429; OFFIT PA, 1986, J VIROL, V58, P700, DOI 10.1128/JVI.58.2.700-703.1986; PADILLANORIEGA L, 1992, J CLIN MICROBIOL, V30, P1392, DOI 10.1128/JCM.30.6.1392-1397.1992; SHAW RD, 1986, VIROLOGY, V155, P434, DOI 10.1016/0042-6822(86)90205-9; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WARD RL, 1990, J VIROL, V64, P5070, DOI 10.1128/JVI.64.10.5070-5075.1990; WARD RL, 1992, J INFECT DIS, V166, P1251, DOI 10.1093/infdis/166.6.1251; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	29	399	428	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 5	1996	272	5258					104	107		10.1126/science.272.5258.104	http://dx.doi.org/10.1126/science.272.5258.104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600516				2022-12-24	WOS:A1996UD59700048
J	Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM				Frankel, SS; Wenig, BM; Burke, AP; Mannan, P; Thompson, LDR; Abbondanzo, SL; Nelson, AM; Pope, M; Steinman, RM			Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid	SCIENCE			English	Article							EPIDERMAL LANGERHANS CELLS; LYMPH-NODES; INFECTED PATIENTS; VIRUS; EXPRESSION; AIDS; LYMPHADENOPATHY; DISEASE; RNA; RESERVOIRS	Human immunodeficiency virus-type 1 (HIV-1) replicates actively in infected individuals, yet cells with intracellular depots of viral protein are observed only infrequently. Many cells expressing the HIV-1 Gag protein were detected at the surface of the nasopharyngeal tonsil or adenoid. This infected mucosal surface contained T cells and dendritic cells, two cell types that together support HIV-1 replication in culture. The infected cells were multinucleated syncytia and expressed the S100 and p55 dendritic cell markers. Eleven of the 13 specimens analyzed were from donors who did not have symptoms of acquired immunodeficiency syndrome (AIDS). The interaction of dendritic cells and T cells in mucosa may support HIV-1 replication, even in subclinical stages of infection.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,DIV AIDS,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT OTOLARYNG & ENDOCRINE PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT CARDIOVASC PATHOL,WASHINGTON,DC 20306; ARMED FORCES INST PATHOL,DEPT HEMATOL & LYMPHAT PATHOL,WASHINGTON,DC 20306	Rockefeller University; United States Department of Defense; United States Department of Defense; United States Department of Defense; United States Department of Defense			Steinman, Ralph/F-7729-2012; Thompson, Lester D. R./J-8404-2016	Thompson, Lester D. R./0000-0003-3714-1432	NIAID NIH HHS [AI24775] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1984, LANCET, V2, P370; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAWCETT DW, 1986, TXB HIST; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FRANKEL S, UNPUB; GIANNETTI A, 1993, J ACQ IMMUN DEF SYND, V6, P329; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KALTER DC, 1991, J IMMUNOL, V146, P3396; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; KLEIN J, 1990, IMMUNOLOGY, P52; Mosialos G, 1996, AM J PATHOL, V148, P593; MULLER H, 1993, RES VIROLOGY, V144, P59, DOI 10.1016/S0923-2516(06)80013-0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POPE M, 1995, J INVEST DERMATOL, V104, P11, DOI 10.1111/1523-1747.ep12613452; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; RACZ KT, 1988, AIDS, V2, P299; RACZ KT, 1985, LANCET, V1, P105; RUCO LP, 1995, J PATHOL, V176, P391, DOI 10.1002/path.1711760410; SCHUURMAN HJ, 1988, AM J PATHOL, V133, P516; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; TAKAHASHI K, 1984, AM J PATHOL, V116, P497; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISER B, 1990, P NATL ACAD SCI USA, V87, P3997, DOI 10.1073/pnas.87.10.3997	29	269	270	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 5	1996	272	5258					115	117		10.1126/science.272.5258.115	http://dx.doi.org/10.1126/science.272.5258.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD597	8600520				2022-12-24	WOS:A1996UD59700052
J	Chen, ZJ; Parent, L; Maniatis, T				Chen, ZJ; Parent, L; Maniatis, T			Site-specific phosphorylation of I kappa B alpha by a novel ubiquitination-dependent protein kinase activity	CELL			English	Article							DEGRADATION; ACTIVATION; LIGASE	Signal-induced activation of the transcription factor NF-kappa B requires specific phosphorylation of the inhibitor I kappa B alpha and its subsequent proteolytic degradation. Phosphorylation of serine residues 32 and 36 targets I kappa B alpha to the ubiquitin (Ub)-proteasome pathway. Here we report the identification of a large, multisubunit kinase (molecular mass similar to 700 kDa) that phosphorylates I kappa B alpha at S32 and S36. Remarkably, the activity of this kinase requires the Uh-activating enzyme (E1), a specific Ub carrier protein (E2) of the Ubc4/Ubc5 family, and Ub. We also show that a ubiquitination event in the kinase complex is a prerequisite for specific phosphorylation of I kappa B alpha. Thus, ubiquitination serves a novel regulatory function that does not involve proteolysis.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University	Chen, ZJ (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BROOKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clechanover A., 1994, CELL, V79, P13; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MENON SD, 1993, J BIOL CHEM, V268, P26805; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	48	851	889	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 22	1996	84	6					853	862		10.1016/S0092-8674(00)81064-8	http://dx.doi.org/10.1016/S0092-8674(00)81064-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UC381	8601309	Bronze			2022-12-24	WOS:A1996UC38100007
J	Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC				Faham, S; Hileman, RE; Fromm, JR; Linhardt, RJ; Rees, DC			Heparin structure and interactions with basic fibroblast growth factor	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; MITOGENIC ACTIVITY; FACTOR FAMILY; BINDING; RECEPTOR; OLIGOSACCHARIDES; REFINEMENT; RESOLUTION; AFFINITY; CELLS	Crystal structures of heparin-derived tetra- and hexasaccharides complexed with basic fibroblast growth factor (bFGF) were determined at resolutions of 1.9 and 2.2 angstroms, respectively. The heparin structure may be approximated as a helical polymer with a disaccharide rotation of 174 degrees and a translation of 8.6 angstroms along the helix axis. Both molecules bound similarly to a region of the bFGF surface containing residues asparagine-28, arginine-121, lysine-126, and glutamine-135; the hexasaccharide also interacted with an additional binding site formed by lysine-27, asparagine-102, and lysine-136. No significant conformational change in bFGF occurred upon heparin oligosaccharide binding, which suggests that heparin primarily serves to juxtapose components of the FGF signal transduction pathway.	CALTECH,DIV CHEM & CHEM ENGN 14775CH,PASADENA,CA 91125; UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242	California Institute of Technology; University of Iowa					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045162, T32GM008346, R37GM045162, R01GM038060] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45162, GM38060, T32 GM08346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGO H, 1991, J BIOCHEM-TOKYO, V110, P360, DOI 10.1093/oxfordjournals.jbchem.a123586; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DA, 1989, HEPARIN; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lindahl, 1989, HEPARIN CHEM BIOL PR, P51; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stoddart J.F., 1971, STEREOCHEMISTRY CARB; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WALKER A, 1994, J BIOL CHEM, V269, P931; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	708	728	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 23	1996	271	5252					1116	1120		10.1126/science.271.5252.1116	http://dx.doi.org/10.1126/science.271.5252.1116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW701	8599088				2022-12-24	WOS:A1996TW70100038
